- Jul 2023
-
www.biorxiv.org www.biorxiv.org
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
In the manuscript by Gala et al, the authors perform meta-analysis of transcriptomic datasets from different studies focused on synaptically-associated mammalian glial cells. Based on a detailed analysis, the authors predict 1700 localized transcripts and attempted to identify the local transcriptome in glial cells conserved in Drosophila and mammals. This kind of data mining is informative, and can predict the top candidates relatively well, however, the study suffers from lack of depth and a careful assessment comparing across the different datasets. The main concerns have been listed below and suggestions for a more detailed an careful assessment of the data.<br /> 1. The authors have pooled data from different studies across different type of glial cells performed from in vitro to in vivo. While pooling datasets may reveal common transcripts enriched in processes, this may not be the best approach considering these are completely different types of glial cells with distinct function in neuronal physiology.<br /> 2. It is important to note the limitations of the study. For example, DeSeq2 is biased for highly expressed transcripts. How robust was the prediction for low abundance transcripts?<br /> 3. The authors identify 1,700 transcripts that they classify as "predicted to be present" in the projections of the Drosophila PNS glia. This was based on the comparison to all the mammalian glial transcripts. Since the authors have access to a transcriptomic study from Perisynaptic Schwann cells (PSCs), the nonmyelinating glia associated with the NMJ isolated from mice; it would be more convincing to then validate the extent of overlap between Drosophila peripheral glial with the mammalian PSCs. This may reveal conserved features of localized transcripts in the PNS, particularly associated with the NMJ function.<br /> 4. Fig 2: What is the extent of overlap between the translating fractions versus the localized fraction? It will be informative to perform the functional annotation of the translating glial transcripts as identified from Fig 1D.<br /> 5. "We conclude predicted group of 1,700 are highly likely to be peripherally localized in Drosophila cytoplasmic glial projections". To validate their predictions, the authors test some of these candidates in only one glial cell type. It might be worthy to extend this for other differentially expressed genes localized in another glial type as well.<br /> 6. Figure 5: The authors perform KD of candidate transcripts to test the effect on synapse formation. However, these are KD with RNAi that spans across the entire cell. To make the claim about the importance of "target" RNA localization in glia stronger, ideally, they should disrupt the enrichment specifically in the glial protusions and test the impact on bouton formation. Do these three RNAs have any putative localization elements?<br /> 7. RNA localization in oligodendrocytes has been well studied and characterized. The authors should cite and discuss those papers (PMID: 18442491; PMID: 9281585).
Significance
In the manuscript by Gala et al, the authors perform meta-analysis of transcriptomic datasets from different studies focused on synaptically-associated mammalian glial cells. Based on a detailed analysis, the authors predict 1700 localized transcripts and attempted to identify the local transcriptome in glial cells conserved in Drosophila and mammals. This kind of data mining is informative, and can predict the top candidates relatively well, however, the study suffers from lack of depth and a careful assessment comparing across the different datasets and the biological significance.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary:
The manuscript by Gala et al. describes efforts to systematically identify candidate localizing mRNAs within glial cells of the Drosophila larval nervous system. They address this issue with an interesting and novel approach that involves compiling candidate localized transcripts from available mammalian cell datasets and cross-referencing a list of mRNAs from homologous Drosophila genes with a small number of candidates for mRNA localization in Drosophila glia cells that this team identified in a previous study (which they have now validated further). The results provide compelling evidence that their pipeline has predictive power. The authors then go on to perform functional analysis of a small number of validated localizing transcripts and provide evidence that several of these genes are functionally important in glia, including in processes related to synaptic plasticity. These observations raise the possibility that the localization process is functionally important but this was not tested directly (doing so would require a separate long-term study).
The manuscript is well written and the figures are of high quality. Methodological details are provided, as is quantification where appropriate. However, some points are not yet sufficiently strongly supported by the data yet and the justification for some aspects of the workflow needs clarifying.
Major points:
- The authors analyse the 1700 shortlisted genes for Gene Ontology and associations with austism spectrum disorder, leading to interesting results. However, it is not clear to what extent the enrichments they observe are driven by their presumptive localization or if the associations are driven to a significant extent by the presence of these genes in the selected cell types in the Fly Cell Atlas. One way to address this would be to perform the GO and SFARI analysis on genes that are expressed in the same cells in the Fly Cell Atlas but were not shortlisted from the mammalian cell datasets - the results could then be compared to those obtained with the 1700 localized transcripts.
- Although the authors attempt to justify its inclusion, I'm not convinced why it was important to use the whole cell transcriptome of perisynaptic Schwann cells as part of the selection process for localizing transcripts. Including this dataset may reduce the power of the pipeline by including mRNAs that are not localized to protrusions. How many of the shortlisted 1700 genes, and how many of the 11 glial localized mRNAs in Table 5, would be lost if the whole cell transcriptome were excluded. More generally, what is the distribution of the 11 validated localizing transcripts in each dataset in Table 4? This information might be valuable for determining which dataset(s), if any, has the best predictive power in this context.
- Did the authors check if any of the RNAi constructs are reducing levels of the target mRNA or protein? Doing so would strengthen the confidence in these important results significantly. In any case, the authors should also mention the caveat of potential off-target effects of RNAi.
- Methods: what is the justification for assuming that if the RNAi cross caused embryonic or larval lethality then the 'next most suitable' RNAi line is reporting on a phenotype specific to the gene. If the authors want to claim the effect is associated with different degrees of knockdown they should show this experimentally. An alternative explanation is that the line used for phenotypic analysis in glia is associated with an off-target effect.
Minor points:
- It would be helpful to have in the Introduction (rather than the Results, as is currently the case) an operational definition of mRNA localization in the context of the study. And is it known whether or not localization in protrusions is the norm in mammalian glia or the Drosophila larval glia? I ask because it may be that almost all mRNAs diffuse into the protrusion, so this is not a selective process. One interesting approach to test this idea might be to test if the 1700 shortlisted transcripts have a significant underrepresentation of 'housekeeping' functions.
- Introduction: 'Asymmetric mRNA localization is likely to be as important in glia, as it is in neurons,...'. Remove commas
Significance
Whilst glial mRNA localization has been reported in other systems, this study is significant as it paves the way for functional and mechanistic dissection of this process in a genetically tractable model system that involves physiologically relevant neuron-glia interactions. The successful results of the data mining approach may also encourage others to address other problems in this manner. The study would be more impactful if additional hits from the 1700 transcripts were validated for glial localization but the findings in the current manuscript are still important. The advance is more methodological than conceptual. The work will appeal to cell biology and systems biology audiences.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
The study of mRNA localization in glia has been largely overlooked in comparison to neurons. However, glia are also polarized cells with long cytoplasmic processes that play important roles in neural function. In this manuscript, Gala and Lee et al attempt to fill in this missing void in the literature. They first use a meta-analysis of existing, cross-species, transcriptomic data to identify a set of 1,700 transcripts that are likely to be localized to the periphery of glia in Drosophila. They then used this list of transcripts to predict which mammalian glial transcripts are also likely to be localized. They're analysis suggests that a large proportion of the mammalian glial transcripts are predicted to be localized to the periphery of glia, and that these transcripts are enriched for functions involved in membrane trafficking, cytoskeleton regulation, local translation, and cell-cell communication. A connection with cross-cellular communication (ie glia-glia, glia-neuron, glia-muscle) at the neuromuscular junction, prompting the authors to assess if some of these transcripts play a role in plasticity of at the NMJ. Using siRNA driver lines, that loss of some of their assessed transcripts prevent new synapse formation- suggestive of a role for mRNA localization and local protein synthesis in driving synaptic plasticity. These findings suggest that mRNA localization is a widespread phenomenon in glia, and that it plays an equally important role as the more widely studied neuronal mRNA localization.
Key Points
- 1,700 transcripts are predicted to be localized to the periphery of PNS glia in Drosophila at the NMJ.
- A large proportion of the mammalian glial transcripts are predicted to be localized to the periphery of glia.
- Localized transcripts are enriched for functions involved in membrane trafficking, cytoskeleton regulation, local translation, and cell-cell communication.
- Localized glial transcripts may function in synaptic plasticity.
Major comments
Overall, the work presented within manuscript is well reasoned and supports the points the authors generally are trying to make. The work as is, does fall a little on the light side, resting on almost exclusive bioinformatic analysis with some limited validation. The presented work itself (Figures 1-4) does not need significant adjustments prior to publication, in my view, with only a few points to address. However, the work in Figure 5- doesn't really support the claims the authors make on its own, and would require some additional experiments or at the very least discussion of the caveats to its current form.
- Localized glia transcripts, are they "glial/CNS/PNS" significant or are they similar to other known datasets of protrusion transcriptomes? The authors compared their 4801 "total" localized to a local transcriptome dataset from the Chekulaeva lab finding that a significant fraction are localized in both. As the authors note, this is in good agreement with a recent paper from the Talifarro lab showing conservation of localization of mRNAs across different cell types. What the authors haven't done here, is further test this by looking at other non-neuronal projection transcriptomic datasets (for example Mardakheh Developmental Cell 2015, among others). If the predicted glia-localized processes are similar to non-neuronal processes transcriptomes, this would further strengthen this claim and rule out some level of CNS/PNS derived linage driving the similarities between glia and neuronal localized transcripts.
- The presentation/discussion around Figure 3 is a bit weaker than other parts of the manuscript, and it doesn't really contribute to the story in its current form. Notably there is no discussion about the significance of glia in neurological disorders until the very end of the manuscript (page 21), meaning when its first brought up.. it just sits there as a one off side point. The authors might consider strengthening/tightening up the discussion here, if they really want to keep it as a solo main figure rather than integrating it somewhere else/putting it into supplemental. In my view, Figures 2 & 3 should be merged into something a bit more streamlined.
- Why aren't there more examples of different mRNAs in Figure 4? Seems a waste to kick them all to supplemental.
- The plasticity experiments, while creative, I think need to be approached far more cautiously in their interpretation. Given that the siRNAs will completely deplete these mRNAs- it really needs to be stressed any/all of the effects seen could just be the result of "defective" or "altered" states in this glial population- which has spill over effects on plasticity in at the NMJ. Without directly visualizing if these mRNAs are locally translated in these processes and assessing if their translation is modulated by their plasticity paradigm, all these experiments can say is that these RNAs are needed in glia to modulate ghost bouton formation in axons. This represents the weakest part of this manuscript, and the part that I feel does not actually backup the claims currently being made. Without any experiments to A. quantify how much of these transcripts are localized vs in the cell body of these glia, B. visualize/quantify the translation of these mRNAs during baseline and during plasticity; the authors cannot use these data to claim that localized mRNAs are required for synaptic plasticity.
Minor points:
- The use of blue/green or blue/green/magenta is difficult to resolve in some places. Swapping blue for cyan would greatly aid in visualizing their data.
- Make the colouring/formatting of the tables more consistent, its distracting when its constantly changing (also there is no need for a blue background.. just use a basic white table).
Significance
This work would be well received within the field, being at a time where increasing focus on mRNA localization and local protein synthesis are major players in glia along with the more widely studied neurons. Additionally, that mRNAs localized in glia are relevant to neurological disorders also comes at a time where increasingly, especially in neurodegenerative disorders, glia are believed to be drivers of the diseases as well- suggesting that dysregulation of local protein synthesis in glia may play a role. The major weakness of this work is that being largely bioinformatic (from existing datasets), a lot of this is speculative and no conclusive data is shown to demonstrate how/that this glia population is utilizing mRNA localization in protrusions to fuel local protein synthesis for a specific purpose (ie synaptic plasticity).
This work would be of interested to those broadly interested in glial biology and mRNA localization.
The reviewers background is in RNA localization and local protein synthesis in neurons.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary:
The authors characterized 4 proteins from P. falciparum via cellular (co-)localization, endocytosis, parasite growth, and artemisinin resistance assays. These proteins have been identified as candidates for Kelch13 compartment and a possible role in endocytosis in their previously work with quantitative BioID for potential proximity to K13 and Eps15 (Birnbaum et al. 2020). In the current work, additional 6 proteins were not confirmed as being associated to the K13 compartment. This experimental work was complemented by an in-silico analysis of protein domains based on AlphaFold algorithm. For this protein structure evaluation all proteins were chosen, which were experimentally confirmed to be linked to the K13 compartment in the current publication and previous work. With the work 3 novel proteins linked to artemisinin resistance or endocytosis could be functionally described (KIC12, MCA2, and MyoF) and a number of hypotheses were generated.
Major comments:
The quality of the presented work is solid, the experimental design is adequate, and methods are presented clearly. The publication contains a lot of results both presented in text and in the figures and it is not always straight forward for the reader to follow the descriptions due to many details presented and a lack of context for some of these experiments.
Specific suggestions for consideration by the authors to improve the manuscript.
Abstract: - R 31: Mention how the 4 proteins were identified as candidates, you need to refer to previous work to clarify this - R38: "Second group of proteins" is confusing - different from the 4 mentioned above? Significance to endocytosis unclear. Please unify terminology in the manuscript, see also comment below on proxiome - Abstract can only be understood after reading the full publication
Results: Table 1 is missing from the submitted materials Consider to shorten and stratify the result section to focus on the significant data Unclear how the localization and functionalization assays might be impaired by the fusion proteins Significance of ART resistance assay is not clear, in presence of strong growth effects due to inactivation or truncation of genes/proteins
MCA Stratify results, order by significance of findings, it appears to be described in chronological order, improve readability/flow, eg ART resistance if mentioned in r138, but only reported in r183ff MyoF R195 to 197 - consider moving to discussion as it is distracting here Term proxiome is introduced above, but not used in result section - suggest to unify language, eg r195 uses "K13 compartment DiQ-BioIDs" instead, which is not very convenient for the reader What is the enrichment factor? Please provide for this and the following proteins, eg in Table 1 R225 to 243 - overall significance of the growth experiments with mislocaliser is not clear, consider removing from manuscript or explain relevance more clearly KIC11/KIC12 Enrichment factor?
Referees cross-commenting
I would like to applaud reviewer #1 for a great, very thorough review and lots of detailed suggestions. I agree with the conclusions mentioned in the significance evaluation from reviewer #1 and #2: the work presented does not contain novel methods and the scope is rather narrow with the current results. (I am working on clinical studies with novel antimalarial agents)
Significance
On the one hand side, the authors have wrapped up some of the remaining protein candidates of the K13 compartment and could verify 4 of 10 proteins. The work is of interest for the scientific community working on endocytosis and malaria drug resistance mechanisms. Overall, the conclusions and findings from the previous work, Birnbaum et al. 2020, could be confirmed and extended mainly using the methods previously described. On the other hand, the authors made use of progress in protein structure predictions and identified domains linking the K13 compartment proteins to putative functions. The overlaid protein folds of the newly identified domains in figure 5 look convincing, but I can't comment on the technical details or cut-off used for this in-silico analysis.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
In a previous publication the Spielmann lab identified the molecular mechanism of ART resistance in P. falciparum by connecting reduced levels of the protein K13 to decreased endocytosis (uptake of hemoglobin from the RBC cytosol), which results in reduced ART susceptibility. Using quantitative BioID the authors further identified proteins belonging to a K13 compartment, highlighting an unusual endocytosis mechanism.
In the present manuscript the authors follow up on this work and closely examine ten more proteins of the K13/Eps15-related "proxiome". They successfully link MCA2 to ART resistance in vitro, while the proteins MyoF and KIC12 are involved in endocytosis but do not confer in vitro ART resistance when impaired. They further characterize one candidate (KIC11) that partially colocalizes with K13 in trophozoites but to a lesser degree in schizonts. Growth assays suggest an important function for KIC11 in late stages of the intraerythrocytic developmental cycle. Five analyzed proteins however do not colocalize with the K13 compartment, while a sixth was refractory to endogenous tagging.
Using AlphaFold predictions of the KIC protein structures the author identify domains in most constituents of the K13 compartment, highlighting vesicle trafficking-related features that were not identified on primary sequence level before. The combination of functional data together with structure predictions leads them to propose a refinement of the K13 compartment as being divided into proteins participating in endocytosis and proteins that have an unknown function.
Major comments:
- Table 1 is missing
- Lines 117-123: Given the total list of uncharacterized candidates encompasses 13 proteins, can the author gives the reason why only the top 10 and not all 13 were characterized in this study?
- Line 174: 20% of observed MCA2 foci show no overlap with K13 and 21% only partially overlap, can the author confirm that the observed MCA2 foci in schizonts are the ones that co-localize with K13. (Addition of a schizont stage image in Fig 1C would be sufficient).
- The localization and observed phenotype of KIC11 is interesting but unfortunately the authors do not explore it further. Does KIC11 localize with markers of e.g. the secretory organelles (micronemes or rhoptries) in schizonts and could therefore be involved in RBC invasion? Can the author distinguish if KIC11 is involved in RBC invasion or in establishment of the ring-stage parasite?
Minor comments:
- Table S1: Please add the criterion for the order of proteins (abundance in "proxiome"?) in the table as a separate column. I would also suggest adding a new column that highlights the 10 proteins investigated in this study as I found the color-coding slightly confusing.
- 154-155: There is a discrepancy between the text and Fig1C regarding the % of partial overlapping and non overlapping foci.
- The y-axis label is missing in Fig 3E
- Fig 4I left graph, the superscript 2 is missing in μm2
- Did the author colocalize KIC11 in schizonts with other proteins found in the K13 compartment group of proteins not involved in endocytosis/ART resistance? This may help to further subgroup these proteins.
- As a general comment: to make the beautiful IFAs more accessible to a broader readership, I would encourage the authors to switch the color-coding to green/magenta/blue or an equivalent color system or add grayscale images.
Significance
Characterizing the molecular components involved in Plasmodium endocytosis will not only reveal interesting biology in these highly adapted parasites, but will more importantly lead to a better understanding and potentially open new avenues for intervention of ART resistance. The here presented manuscript is a carefully executed follow-up on previous work done in Dr. Spielmann's lab focusing on the K13 compartment. The authors use established assays to characterize novel components and reveal three new players in endocytosis with one mediating ART resistance in vitro. The proposition that parts of the K13 compartment have a function other than endocytosis is interesting, but will have to await more data from future studies. Taken together this manuscript adds significantly to our understanding of endocytosis in P. falciparum.
This work is of interest for cell and molecular biologists working on Apicomplexa, but especially for the Plasmodium community.
I am a cell and molecular biologist working on Toxoplasma gondii
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
With the emergence and spread of resistance to Artemisinin (ART), a key component of current frontline malaria combination therapies, there is a growing effort to understand the mechanisms that lead to ART resistance. Previous work has shown that ART resistant parasites harbour mutations in the Kelch13 protein, which in turn leads to reduced endocytosis of host haemoglobin. The digestion of haemoglobin is thought to be critical for the activation of the artemisinin endoperoxide bridge, leading to the production of free radicals and parasite death. However, the mechanisms by which the parasites endocytose host cell haemoglobin remain poorly understood.
Previous work by the authors identified several proteins in the proximity of K13 using proximity-based labelling (BioID) (Birnbaum et al. 2020). The authors then went on to characterise several of these proteins, showing that when proteins including EPS15, AP2mu, UBP1 and KIC7 are disrupted, this leads to ART resistance and defects in endocytosis leading to the hypothesis that these two processes are inextricably linked.
In this manuscript, Schmidt et al. set themselves the task of characterising more K13 component candidates identified in their previous work (Birnbaum et al. 2020) that were not previously validated or characterised. They chose 10 candidates and investigated their localisations, and colocalisation with K13, and their involvement in endocytosis and in vitro ART resistance, 2 processes mediated by K13 and some members of the K13 compartments
The authors show that of their 10 candidates, only 4 can be co-localised with K13. Then, using a combination of targeted gene disruption (TGD) as well as knock sideways (KS), they characterised these 4 proteins found in the K13 compartment. They show that MyoF and KIC12 are involved in endocytosis and are important for parasite growth, however their disruption does not lead to a change in ART sensitivity. The authors also confirm the findings of their previous publication (Birnbaum et al. 2020), using a slightly different TGD, that MCA2 is involved in ART resistance, however they did not check whether its disruption impacts haemoglobin uptake. They also show that KIC11 is not involved in mediating haemoglobin uptake or ART resistance. To finish, the authors used AlphaFold to identify new domains in the proteins of the K13 compartment. This led them to the conclusion that vesicle trafficking domains are enriched in proteins of the K13 compartment involved in endocytosis and in vitro ART resistance.
The majority of the experiments conducted by the authors are performed to a good standard in biological and technical replicates, with the correct controls. Their findings provide confirmation that their 4 candidate genes seem to be important for parasite growth, and show that some of their candidates are involved in endocytosis. While the KD and KS approaches employed by the authors to study their candidate genes each have their own advantages and can be excellent tools for studying a large sets or genes, this manuscript highlights the many limitations of these approaches. For example, the large tag used for the KS approach can mislocalise proteins or disrupt their function (as is the case for MyoF), resulting in spurious results, or indeed the inability to generate the tagged line (as is the case for MCA2). The KS approach also makes the results of a protein with a dual localisation, like KIC12, extremely difficult to interpret.
Moreover, the manuscript is disjointed at times, with the authors choosing to conduct certain experiments for only a subset of genes, but not for others. For example, considering that the aim of this paper was to identify more proteins involved in ART resistance and endocytosis, it is confusing why the authors do not perform the endocytosis assays for all their selected proteins, and why they do not do this for the proteins they identify in their domain search. There is significant room for improvement for this manuscript, and a generally interesting question. But in it's current format, other than confirming that MCA2 is involved in ART resistance (which was already known from the Birnbaum paper), the authors do not further expand our understanding of the link between ART resistance and endocytosis in this manuscript.
Major Comments
line 31: please change defined to characterised - defined suggests that novel proteins were identified in this study, which is not the case.
line 37: please change 'second' to "another". As explained further below, the authors identified 3 classes of proteins (confer ART resistance + involved in HCCU, involved in HCCU only, or involved in neither).
Line 40: You define KIC11 as essential but according to your data some parasites are still alive and replicating 2 cycles after induction of the knock sideways. Please consider changing "essential" to "important for asexual parasite growth"
Line 40: please change 'second group' to 'this group'
line 41: state here that despite it being essential, it is unknown what it is involved in.
Line 50: the authors should state here that there is actually a reversal in this trend over the last few years.
Line 54: please separate out the references for each of the two statements made in this line (a: that ART resistance is widespread in SEA, and b: that ART resistance is now in Africa) Reference 14 also seems to reference ART resistance in Amazonia - which is not covered by the statement made by the authors (in which case the authors should state ART is now present in Africa and South America). The authors should also reference PMID: 34279219 for their statement that ART resistance is now found in Africa (albeit a different mutation to the one found in SEA).
Line 65: it is also worth mentioning here that there are other mutations in proteins other than K13, such as AP2mu and UBP1 (PMID: 24994911;24270944) that can lead to ART resistance.
Line 80, 86: ref 43 is misused. Reference 43 refers to Maurer's clefts trafficking which takes place in the erythrocyte cytosol and is not involved in haemoglobin uptake as far as I know. Please replace ref 43 with one showing the role of actin in haemoglobin uptake.
Line 98: the authors state here that they 'identified' further candidates from the K13 proxiome. This suggests that they identified new proteins in this paper, when in fact the list was already generated in ref 26. All they did was characterise proteins from that list that were not previously characterised. The authors should therefore remove identified from this statement.
Line 107-108: it is not clear from this sentence why these proteins were left out of the initial analysis in Ref 26. A sentence here explaining this would be valuable for the reader.
Line 117-123: The authors say that PF3D7_0204300, PF3D7_1117900 and PF3D7_1016200 were not studied because they were not in the top 10 hits. However, the current organisation of Supplementary Table 1 shows all 3 proteins among the top 10 hits (MyoF, KIC12, UIS14 and 0907200 being after them). I think the authors should reorganise their table. It is also unclear according to what the proteins in the table are ranked. Could the authors indicate the metric used for the ranking?
Line 129-141: Can the authors be clearer with their explanations of the identification of mutation Y1344Stop? One dataset (ref 61) shows that 52% of African parasites have a mutation in MCA2 in position 1344 leading to a STOP codon. But another dataset (ref 62) shows that the next base is also mutated, reverting the stop codon. That should have been seen in the first dataset as well. Could the authors please clarify.
Line 147: the authors say that MCA2 is expressed throughout the intraerythrocytic cycle as shown by live cell imaging. In Birnbaum et al 2020 fig 4I, the authors show that MCA2 is mainly expressed between 4 and 16hpi. But in Figure 1B of this manuscript there is a clear multiplication of MCA2 signal between trophozoite and schizont. How do the authors explain this discrepancy? Could expression of the truncated MCA2 be different than the full length? This cannot be assessed as expression and localisation of the full-length HA tag MCA2 is not shown in Schizonts. MCA2 expression seems also different for the MCA2TGD-GFP with no expression in rings.
Line 158: would it not have been more useful for the authors to have episomally expressed MCA2-3xHA in their MCA2Y1344STOP-GFPENDO line to make sure that the truncated protein is indeed going to the correct compartment? The experiments done by the authors suggests that the MCA2Y1344STOP goes to the right location but does not really confirm it.
Line 191: it is stated that MCA2 confers resistance independently of the MCA domain, however in both the MCA2-TGD and MCA2Y1344STOP-GFPENDO parasites, the MCA domain is deleted, and for both parasites, there is resistance (albeit to a lower level in the MCA2Y1344STOP-GFPENDO line). Therefore, how can the authors state that the ART resistance is independent of the MCA domain? This statement should be that resistance is dependent on the loss of the MCA domain.
Line 192: Why did the authors not check if MCA2 is involved in endocytosis? They state later on in the manuscript that they did not do endocytosis assays with TGD lines, however if the authors include the correct controls, this could be easily done. It would also be really interesting to see whether endocytosis gets progressively worse going from WT to MCA2Y1344STOP to MAC2TGD. This experiment (as well as doing endocytosis assays for KIC4 and KIC5 TGD lines) would drastically increase the impact of this study. These experiments would not take more than 3 weeks to perform, and would not require the generation of new lines.
The authors should consider re-organising the MCA2 section, first showing that the 3xHA tagged line colocalises with K13, then performing the new truncation.
Line 197: Once again ref 43 is not correct to illustrate that actin/myosin is involved in endocytosis
Line 202: the authors state that MyoF localises near the food vacuole from ring stage/trophs onwards. However, how can this statement be made in schizonts based on these images (Fig. 2A), where it doesn't look like MyoF is anywhere near the FV? This statement can only be made for schizonts if co-localised with a FV marker (which is done in Fig. 2B), however, based on the number of MyoF foci, it appears that this was not done for schizonts. Please either remove the statement that MyoF is near the food vacuole from trophs onwards (because it is only seen near the FV up until trophs) or show the data in Fig. 2B of schizonts to substantiate these claims.
Line 204-206: what does this statement bring to the paper? Is it to show that it is the real localisation of MyoF because 2 tag cell line show the same localisation? I don't think this is needed, especially as later in the manuscript an HA-tag MyoF line is used and show similar localisation.
Line 212: The overlap of K13 with MyoF in Fig 2C 3rd panel (1st trophozoite panel) is not obvious, especially as the MyoF signal seems inexistant. I would advise the authors to replace with a better image. Also, why are there no images of schizonts shown in Figure 2C?
Line 217: the spatial association of MyoF with K13 is very different when it is tagged with GFP and when it is tagged with 3xHA. The way the authors word it here, it seems that there is agreement with the two datasets, when this is not in fact the case (59% overlap for MyoF-GFP and only 16% overlap with MyoF-3xHA). These data suggest that the GFP and the multiple FKBP tags are doing something to the protein and therefore maybe the ensuing results using this line should not be trusted or be taken with a pinch of salt.
Line 219: the authors state here that they could not detect MyoF-GFP in rings, when in Figure 2C they show MyoF-GFP in rings, and also show that they could detect MyoF in Sup Fig. 3B with the 3xHA tagged line. Is this a labelling mistake in Figure 2C? If the authors could indeed not see MoyF-GFP in rings, this statement should have been made when Figure 2A was presented, and not so late in the manuscript, which causes confusion. Line 237: Showing a DNA marker (DAPI, Hoescht) for Figure 2E, and subsequent figures using mislocalisation to the nucleus, would help the reader assess efficiency of the mislocalisation.
Line 254-256: authors should show the results of the bloating assay for parental 3D7 parasites (+ and - rapalog) to see whether the MyoF line - rapalog has increased baseline bloating. This applies to all subsequent FV bloating assays.
Line 254-257: The authors say that because fewer parasites show a bloated food vacuole upon inactivation of MyoF it means that less hemoglobin reached the food vacuole. I understand the authors statement, however, shouldn't they look at the size of the food vacuole, instead of the number of parasites with bloated FV, to make such a statement? This has been done for KIC12 so why not doing it for MyoF?
Line 259-261: these results would be difficult to interpret namely because the authors have dying parasites, which is exacerbated with the protein being knocked sideways. The authors should mention the pitfalls their knock sideways and tagging design here.<br /> Line 260-261: RSA is an assay relying on measuring parasite growth 1 cycle after a challenge with ART for 6 hours.
Line 261-263: the authors sate that MyoF has a function in endocytosis but at a different step compared to K13 compartment proteins. I am not sure what they mean here. Can this be clarified? Do the authors mean that it is involved in endocytosis but not in ART resistance? If so, this is a very difficult statement to make since the parasites are dying. Is there any evidence of point mutations in MyoF in the field?
Line 298: the authors state that there is no growth defect in the first cycle when rapalog is added to the KIC11 line, however based on Figure 3D, there is evidently a 25% reduction in growth compared to - rapalog at day 1 post treatment, and a 60% reduction by day 2, which is still within the 1st growth cycle. The authors should either revise their statement or provide an explanation for these findings. The authors should also explain why their Giemsa data in Fig. 3E is not in accordance with their FACS data.
Line 301: KIC11 could also be important very early for establishment of the ring stage for example for establishment of the PV. Also, was mislocalisation assessed in rapalog-treated parasites at 72 hours or in cycle 3?
Line 311: the authors should change the sentence from 'not related to endocytosis' to 'not related to endocytosis or ART resistance'.
Line 323-325: Authors say that a nuclear GFP signal can be observed in early schizonts for KIC12. According to the pictures provided in Figure 4A and Figure S5A it is not very obvious. Also faint cytoplasmic GFP signal could only be background as we can see that exposure is higher for schizont pictures
Line 326-328: The authors say that kic12 transcriptional profile indicate mRNA levels peak (no s at peak) in merozoites. Should they show live cell imaging of merozoites then? Because from the Figure 4A schizont pictures where schizonts are almost fully segmented no signal can be observed. Line 347: The authors state that using the Lyn mislocaliser the nuclear pool of KIC12 is inactivated by mislocalisation to the PPM. This tends to suggest that only the nuclear pool of KIC12 is mislocalised. How is it possible that only the nuclear pool is mislocalised? Line 368-369: Effect was also only partial for MyoF. Why didn't you measure the same metrics for MyoF? Line 379: you don't know if all proteins acting later in endocytosis will have an increased number of vesicles as a phenotype
Line 413-414: The authors state that no growth defect was observed upon KS of 1365800. Is growth alone enough to say that there is no impact on endocytosis?
Line 432: in this section, the authors state that KIC4 and KIC5 seem to have domains that may suggest these proteins are involved in endocytosis, based on the alpha fold data that is publicly available. Considering the authors have TGD-SLI versions of these lines (Birnbaum et al. 2020) and have already confirmed in this previous publication that they confer resistance to ART; it would make sense to look at endocytosis for these genes. This would be a relatively simple and straightforward experiment, taking no longer than two to three weeks, and would require no additional reagents or line generation. Doing these experiments would add a lot more weight to this final section. The authors later state that KIC4 and 5 are TGD lines, so not the best for endocytosis assays. It is unclear why this would be difficult to do if an adequate control is contained in the experiment (such as parental 3D7). It explains why they did not perform the MCA2 endocytosis assays further up, but in my opinion, an attempt at doing these assays is important and would significantly increase the impact of this paper.
Line 490-493: the authors state that the K13 compartment proteins fall in two groups, some that are involved in ART resistance AND endocytosis, and some that have different functions. However, in this manuscript the authors have demonstrated 3 flavours that K13 compartment proteins can come in: • Some that confer ART resistance and are involved in HCCU (MCA2) • Some that are involved in HCCU but not ART resistance (MyoF & KIC12) • Some that are involved in neither (KIC11) The authors should therefore revise this statement.
Line 508: the authors state that they expanded the repertoire of K13 compartments, when in fact they functionally analysed them - they did not do another BioID to identify more candidates.
Line 570-572: has anyone ever tested whether CytoD or JAS treatment in rings, is sufficient to mediate ART resistance? Something similar to what was done in PMID 21709259 with protease inhibitors. If not this would be a pretty interesting experiment for the authors to do that could shed more light on the MyoF data. It would take maybe 2 weeks to do and not require the generation of any new lines. This would clarify whether other Myosins other than MyoF are involved in endocytosis, as is suggested by previous publications (PMID: 17944961).
Line 608: inhibitors targeting the metacaspase domain of MCA2 may inadvertently inactivate other essential parts of the protein. They authors should acknowledge this possibility in the text.
Line 624-625: the authors state that MyoF is 'lowly expressed in rings' - indeed this is the case in their MyoF-2xFKBP-GFP-2xFKBP line which the authors established has defects due to the tag, but it appears from their MyoF-3xHA tagged line that it is expressed in rings. The authors should therefore revise their statement, and be careful of making claims based on their defective line and using fluorescence imaging as their only metric. If they do want to make the statement that it is not there in rings, they should also do a western blot, which is much more sensitive since it amplifies the signal compared to an image of one parasite.
Line 635: arguably this is the 3rd variety and not the 2nd (the authors already mentioned 2 types - ones that are involved in HCCU AND ART and those involved in HCCU only). See comment for line 490-493 above.
Line 785: Bloated food vacuole assay/E64 hemoglobin uptake assay method specify that a concentration of 33mM E64protease inhibitor was used. However, in reference 44, cited in the manuscript, a concentration of 33µM E64 was used. Please confirmed if this is just a typo or if 1000x E64 concentration was used which renders the experiment invalid.
Line 788: it is unclear from this section what is considered a bloated food vacuole - is there an area above which the FV is considered bloated? Do the authors do these measurements manually or use an addon in FIJI/ImageJ? What is the cutoff for if a FV is bloated? Please clarify. Additionally, for the representative images + rapalog for Figures 2H and 4H, it would be useful to see where the authors delineate the FV (add a white circle showing what is actually measured).
Line 863-864: this sentence seems to be out of place.
Line 875: the authors state that there is a light blue wedge, when the circle consists of grey and black wedges. Please revise this.
Line 1059-1061: it is unclear whether the individual growth curves are different clones or whether they are just the same experiment repeated? If it is the latter, then why are they not combined, as is traditionally done?
Line 919-924: the authors mention a blue and red line, but there is only a black line in figure 3D. Moreover, the experiment of using the LYN mislocaliser was only done for KIC12 according to the manuscript. Additionally, the y axis of the figure states relative growth day 4[%] compared to rapalog, but then on the x axis there are several days. In the text it says there is no growth defect until the second cycle, but from this graph it appears the growth defect is evident as early as 1 day post rapalog treatment. Can the authors please clarify and correct the issues pointed out.
Figure 1 panel B & C: the label of the figure where the signal from MCA2Y1344STOP-GFP is shown with the DAPI signal overlayed is deceptive since it suggests that this is the signal of full length MCA2. Please change the label of this panel from MAC2/DAPI to MCA2Y1344STOP/DAPI. The same is true for Panel C for the image labeled MCA2/K13 - please change this to MCA2Y1344STOP/K13.
Figure 2B: what stages are these parasites? Please state this in the figure. Based on the MyoF pattern, it looks like rings in the upper panel and trophs in the bottom pannel. Why were schizonts not shown?
Figure 2D&F: it is not very meaningful when growth assays are shown as a final bar after 4 days of growth. It is much more useful and informative to see a growth curve instead (as is shown in the supplementary), since it shows if the defect is apparent in the first growth cycle or later. With the way the data is currently shown, this is not apparent. I would advise the authors to switch the graph in 2F out of a combined graph of all the biological replicates growth curves for S3D - showing error bars.
Figure 3: why were the calculation of FV area, parasite area and FV/parasite area only done for KIC12 and not done for MyoF? It would be interesting to see if any of these values are different for MyoF - whether the parasites are smaller in area and therefore FV smaller. Please present them Figure 2. Images should be already available and would not require further experiments to be done, only the analysis.
Figure 3B: why is there no spatial association assessment for KIC11 and K13 as was done for the MCA2 and MyoF? The authors should show a pie chart showing the degree of association here as was done for the other proteins.
Figure 3D: The y axis of the figure states relative growth day 4[%] compared to rapalog, but then on the x axis the experiment takes place over several days. Is this a typo in the y axis? Additionally, the authors state in line 287-290 that the growth defect upon addition of rapalog is only seen in the second cycle, but from this graph it appears the growth defect is already evident 1 day post rapalog addition. The figure legend also does not make sense for this figure since it mentions a blue and a red line, when there is only a black line present. The legend also mentions the LYN mislocaliser which was used for KIC12 not KIC 11 (see above).
Figure 3E: the colour for Control and Rapalog 4 hpi are very similar and very hard to discern. Please choose an alternative colour or add a pattern to one of the samples. The y axis is also missing a label. Is this supposed to be parasitemia (%)?
Figure 4A: the ring shown in this figure does not appear to be a ring (it is far too large and appears to have multiple nuclei?). Do the authors have any other representative images to show instead?
Figure 4B: why is there no spatial association assessment for KIC12 and K13 as was done for the MCA2 and MyoF? The authors should show a pie chart showing the degree of association here as was done for the other proteins. This should be done for the different life cycle stages considering the changing localisation of KIC12.
Figures 4C&E: it is extremely important to show the DNA stain in both these samples considering that a portion of KIC12 is in the nucleus! Please add the DAPI signal for these figures (as for all other figures!).
Figure 4E: this figure should be presented before 4D (considering the line being presented in 4E is used in an experiment in 4D). The authors should switch the order of these two.
It is unclear why in many of the fluorescence images the authors do not show the DAPI signal - particularly when colocalising with K13 and when doing the knock sideways experiments. Please add these images to the figures - I would assume they have already been taken, so would simply involved adding the images to the panel.
Throughout the manuscript, there is no western blot confirming the correct size of their modified proteins. This should be provided.
None of the figures are appropriate for individuals with colour blindness, limiting their accessibility to the paper. Please change the colour schemes for all fluorescent images using magenta/green or an alternative colour combination appropriate for colourblind individuals.
Minor Comments
line 29: remove 'are'.
Line 29: the text says "HCCU is critical for parasite survival but is poorly understood, with the K13 compartment proteins are among the few proteins so far functionally linked to this process." The sentence should be: 'HCCU is critical for parasite survival but is poorly understood, with the K13 compartment proteins among the few proteins so far functionally linked to this process."
line 44: remove 'the'
Line 48: consider mentioning here that malaria is caused by the parasite Plasmodium - otherwise the first mention of parasite in line 52 is confusing for the non-specialist reader.
Line 49: estimated malaria-related death and case numbers are from the 2021 WHO World malaria report. You cite the 2020 WHO World malaria report.
Line 53: please insert the word 'have' between now and also.
Line 54: please change 'was linked' to is linked
Line 72: I would specify that free heme is toxic to the parasite. Especially as you mention that hemozoin is nontoxic. Sentence would be "where digestion results in the generation of free heme, toxic to the parasite, which is further converted into nontoxic hemozoin"
Line 90: authors should either say "in previous works" or "in a previous work"
Line 91: "We designated these proteins as K13 interaction candidates (KICs)"
Line 95: please change 'rate' to number
Line 109: Please include a coma before (ii).
Line 112: as shown by Rudlaff et al in the paper you are citing, PPP8 is actually associated with the basal complex. You can say that "(ii) were either linked or had been shown to localise to the inner membrane complex (IMC) or the basal complex (PF3D7...).
Line 114: Protein PF3D7_1141300 is called APR1 in the manuscript but ARP1 in Supplementary Table 1. Please correct.
Line 131: please define SNP - this is the first use of the acronym.
Line 133-134: South-East Asia instead of "South Asia"
Line 135: please explain what TGD is - it is referred to over and over again in the manuscript without ever being explained.
Line 145: change 'Western blot' to western blot - only Southern blot is capitalised since it is named after an individual, while the other techniques are not.
Line 152: add "the" between 'and spatial'
Line 158: please define SLI as selected linked integration, since it is the first use of the acronym.
Line 178: introduce a coma after protein. Sentence should be "Proliferation assays with the MCAY1344STOP-GFPendo parasites which express a larger portion of this protein, yet still lacking the MCA domain (Figure 1), indicated no growth ...
Line 195: the authors could mention that MyoF was previously called MyoC in the Birnbaum 2020 paper. I wanted to check back in the Birnbaum 2020 paper and could not find MyoF
Line 200: "Expression and localisation of the fusion protein was analysed by fluorescent microscopy". Why expression was not analysed also by western Blot same as for MCA2?
Line 204: I could not find any mention of MyoF (Pf3D7_1329100) in reference 65. Please remove reference 65 if not correct. Also reference 66 looks at Plasmodium chabaudii transcriptomes so I would specify that "This expression pattern is in agreement with the transcriptional profile of its Plasmodium chabaudii orthologue"
Line 208: Please indicate a reference for P40 being a marker of the food vacuole
Line 220-224: The authors should consider changing to " Taken together these results show that MyoF is in foci that are mainly close to K13 and, at times, overlapping, indicating that MyoF is found in a regular close spatial association with the K13 compartment."
Line 255: In Figure 2H, and subsequent figures showing bloated FV assay, I would delineate the food vacuole with dashed line as in Birnbaum et al. 2020 to help the reader understanding where the food vacuole is.
Line 265-266: Here the title says that KIC11 is a K13 compartment associated protein, but the title of Figure 3 says KIC11 is a K13 compartment protein. I noticed that you make the difference between K13 compartment protein et K13 compartment associated protein for MyoF for example which is not clearly associated with the K13 compartment. Which one is it for KIC11?
Line 309-310: indicate a reference for your statement "which is in contrast to previously characterised essential K13 compartment proteins".
Line 377: Figure 4I, please correct 1st panel Y axis legend
Line 404: replace "dispensability" with dispensable
Line 416: can the authors provide any speculation as to why they observed these proteins as hits in the BioID experiments?
Line 451: Where the "97% of proteins containing these domains also contain an Adaptin_N domain and function in vesicle adaptor complexes as subunit " come from. Do you have a reference?
Line 465-467: the same could be said for KIC4 as it also has a VHS domain.
Line 477-479: Can be rephrased to "However, we found this protein as being likely dispensable for intra-erythrocytic parasite development and no colocalisation with K13 could be demonstrated, suggesting a limited role for PF3D7_1365800 in endocytosis. Or something like that. Makes it clearer.
Line 535: Have AP-2 or AP-2 been shown to be at the K13 compartment?
Line 569: reference 43 is wrong
Line 746: typo "ot" instead of or.
Line 801: method for Domain Identification using AlphaFold specify that RMSDs of under 5Å over more than 60 amino acids are listed in the results. However, there is a typo in Figure 5B for KIC5 where it says "RMSD 4.0 Å over 8 aa". Please correct.
Line 856: In Figure 1E, please use the same Y axis legend as in Figure 2D "relative growth at day 4 [%] compared with 3D7"
Figure S1: Some PCR gels check for integration are presented as 5', 3' and ori whereas other gels are presented as ori, 5' and 3'. This is confusing. Figure S1: Why was the expression of only MCA2 was verified by Western blot? What about the other proteins?
Line 493: Considering KIC11 was not involved in HCCU or ART resistance it might be worth mentioning in this section that it is of note that there are no domains detected that would be involved in endocytosis.
Line 503-506: is it wise to generate more drugs that target a pathway that is already highly susceptible to mutations? The authors should add a statement explaining how this might be avoided.
Throughout, scale bars are stated in the figure legends at the end of the legend. This is a slightly confusing format. The authors should consider stating the scale bar for each sub-legend where a fluorescence image is taken.
Referees cross-commenting
After reading reviewer 2 and 3's comments, I think there are significant overlaps in the key points raised in terms of questions about fusion proteins and their potential partial mis-localisation, better descripton of results and target selection. Overall I think we agree that the work has potential, but in its current form does not represent a major advance. It would be immensely helpful if the manuscript would be carefully edited for a better flow and linear description of results.
Significance
The authors set out to test whether other proteins that are in the vicinity of K13 are involved in mediating ART resistance and endocytosis. This is an interesting question. However, other than MCA2 which was already known to be involved in mediating ART resistance (and was not tested for its involvement in endocytosis), none of their candidate proteins seem to be involved in mediating both these functions. The authors show that the other proteins tested appear important for parasite growth, with KIC12 and MyoF involved in mediating endocytosis. While these findings are novel, the KS approach used by the authors casts some doubt over the findings, and would mean that these findings would have to be re-tested with a more reliable approach, such as the GlmS system or generating a conditional knockout using the DiCre system. Despite not advancing our understanding of ART resistance, or identifying further players involved in this process, this manuscripts provides two candidates that are involved in mediating endocytosis and a further candidate that appears to be important for parasite growth. Further work on these proteins will be required to understand their exact roles. As stated above, there is currently limited interest for these results (limited to researchers working on endocytosis in apicomplexan parasites and possibly the wider endocytosis field from an evolutionary perspective), however with further work, this could increase the impact and interest of this work substantially.
The authors do not describe any novel methods/approaches within this work.
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer 1
In this manuscript Pho et al., characterize the effects of actin confinement versus acto-myosin contractility on nuclear deformation and nuclear envelope (NE) rupture/blebs. They use both genetic and pharmacological perturbations that impact nuclear shape and integrity such as chromatin decompaction and genetic deletion of nucleo-skeleton components (LaminA and LaminB). First, the authors show that modulation of acto-myosin contractility does not affect nuclear height (a proxy for the effects of actin confinement on the nucleus). This finding allowed them to study the effects of acto-myosin contractility on nuclear shape and integrity independently of actin-mediated nuclear confinement. Using fibroblasts expressing a NLS-GFP construct to assess nuclear shape and integrity, the authors show that increased acto-myosin contractility by treatment with Rho activator (CN03) leads to nuclear blebs and NE rupture events (curiously, they show that in LaminA-/- fibroblasts the NE rupture events were not bleb-based and were not affected by CN03). With these results, authors conclude that actin contraction is a major determinant of bleb-based NE rupture, independently of actin confinement. Next, since many studies have associated loss of nucleo-cytoplasmic compartmentalization with increased DNA damage, the authors addressed the occurrence of DNA damage foci in several contexts/perturbations. They find that increased NE rupture frequency by CN03 treatment does not lead to increased DNA damage. Based on the sole finding, authors then claim that DNA damage is mostly associated with abnormal shaped nuclei instead of ruptured nuclei. The data presented is overall convincing and well controlled but a more in-depth characterization of the DNA damage events in VPA-treated cells, LaminB-/- and LaminA-/- cells is needed to support the claim that DNA damage is not associated with NE events in their system. More details below.
We thank the reviewer for careful consideration of our work. We are happy that the reviewer found, “__The data presented is overall convincing and well controlled…”. __While the author appears positive on the paper as a whole, what follows is the Reviewer’s largest concern with the paper.
“ a more in-depth characterization of the DNA damage events…is needed to support the claim that DNA damage is not associated with NE events in their system.” We appreciate the Reviewer’s feedback and agree that this one statement was an overstatement. To address this concern,
1) We removed this disagreeable/unsupported conclusion,
2) We replaced it with more measured statement supported by the data (red text highlights changes to the original manuscript),
3) because we have removed the unsupported conclusion, we prefer not to carry out the suggested experiments because they constitute a completely new study beyond the scope of this manuscript.
Major points 1,2,3 all focus on the removed unsupported conclusion. They outline numerous new experiments which we feel constitute a new study and separate manuscript and thus beyond the scope of the current manuscript. Instead, we tone down or conclusions clearly labeled by red text.
__
__
__ __
__Major comments:____
1-In fig. 4, increased NE rupture frequency by CN03 treatment did not lead to an increase in gH2AX foci, so authors claim that DNA damage is not associated with NE events. However, the increase observed in NE rupture frequency is rather very subtle (from 1.5 to 3 in WT cells; from 2.5 to 4 in VPA treated ells and from 2 to 2.5 in LaminB-/- cells) so I wonder if such a minor increase might be sufficient to cause an increase in DNA damage foci. Moreover, DNA damage events are repaired within minutes and the analysis throughout this manuscript is made on snapshots. Therefore it becomes difficult to draw any conclusion regarding the absence of a link between NE rupture and DNA damage. To assess DNA damage events in a quantitative manner and show that abnormal shape (as opposed to NE rupture) is the main driver of DNA damage, authors should perform live cell imaging of cells co-expressing a DNA damage marker and a NE rupture marker to track DNA damage events following NE rupture.__
The reviewer raises concerns that we have too strongly stated a conclusion of nuclear rupture affects DNA damage less than shape. Overall, we understand this concern and have revised the text to remove this conclusion and in general tone down our conclusion from this data. We agree with the reviewers point that doubling the frequency either might not be sufficient to increase DNA damage OR a single rupture is sufficient to increase DNA damage. We now state: “ DNA damage measured by γH2AX foci did not significantly increase upon CN03 activation of actin contraction, suggesting that the slight yet significant increase in nuclear blebbing, rupture, and rupture frequency from CN03 did not have a significant impact on DNA damage (Figure 4, C and B).
We prefer not to. The reviewer’s request for live cell nuclear rupture and DNA damage data is now beyond the scope of the paper because we have revised the manuscript by removing this conclusion. A full analysis of live cell DNA damage analysis in conjunction with nuclear rupture for bleb-based, non-bleb-based normal circularity, and non-bleb-based normal circularity across 4 conditions (WT, VPA, LMNB1-/-, and LMNA-/-) is a paper in and of itself.
2-Fig. 4C: to show that frequency of NE rupture is less important than abnormal nuclear shape for DNA damage appearance, authors need to quantify gH2AX in normal x blebbed x abnormal nuclei in each one of the conditions (untreated, CN03 and Y27). But again, this analysis must be complemented by live cell imaging experiments to track DNA damage foci appearance (or not?) following NE rupture events.
We prefer not to Similar to point (1) we have removed this disagreeable conclusion and revised the manuscript. Further extensive studies of DNA damage for nuclear rupture and shape, while interesting, are beyond the scope of the current manuscript.
We now clearly state this in the Discussion section: “Our data in wild type, VPA, and LMNB1-/- cannot decouple the roles of nuclear shape and ruptures, which are intertwined, causing increased DNA damage (Figure 4). However, we provide novel data that actin contraction is necessary for the behaviors of nuclear blebbing, rupture, and increased DNA damage, independent of changes in actin confinement.
__ 3- Since VPA treatment increases both the percentage of bleb-based NE rupture and NE rupture frequency in LaminA-/- cells, authors should show that gH2AX foci in this sample remain unaltered to further support their claim that frequency of NE rupture is less important than abnormal nuclear shape.__
We prefer not to Similar to points (1) and (2) we have revised the manuscript to remove this disagreeable conclusion. Instead, Figure 6 is focused on the interesting phenomena where LMINA-/- nuclei display abnormal nuclear shape and majority non-bleb-based nuclear ruptures. To determine if LMNA-/- nuclei have the capacity to increase nuclear blebbing and bleb-based ruptures, we treated with VPA, which causes both. LMNA-/- with VPA shows that these calls lacking both lamin A and C can form blebs and increase in bleb-based ruptures.
__ 4-Does methylstat treatment rescue LaminB-/- phenotypes (blebs, ruptures, ...)?__
We do not see how this relates to a specific change to the manuscript but instead is a direct question of interest.
The reviewer would like us to clarify how our past work rescued Lamin B1 null (LMNB1-/-) phenotype which we cited in the original manuscript as a supporting point (top of page 16).
“This new data agrees with our previous data showing that increased heterochromatin levels via histone demethylase inhibition by methylstat treatment (Stephens et al., 2018) and mechanotransduction (Stephens et al., 2019a) rescues nuclear shape in LMNB1-/- nuclei.”
In our previous publication we showed that methylstat, which increases heterochromatin levels, can suppress nuclear blebbing in LMNB1-/- (Stephens 2018 MBoC). In another manuscript we increased heterochromatin levels via a mechantransduction pathway. This resulted in decreased nuclear blebbing, ruptures, and DNA damage (Stephens 2019 MBoC). However, this manuscript goes on to show that loss of facultative heterochromatin alone via GSK126 can recapitulate the LMNB1-/- which shows loss of facultative heterochromatin (Figure 5).
__ 5-Auhors mention throughout the manuscript the "actin confinement" component (actin cables localized at the top of the nucleus-not convincingly shown in fig. 2C). Some studies have reported the occurrence of perinuclear actin caps that surround the entire nucleus (DOI: 10.1038/s41467-018-04404-4; DOI: 10.1038/srep40953; DOI: 10.1038/ncb3387). Can the authors investigate the existence of such perinuclear actin ring on the LaminB-/-, LaminA-/- and VPA-treated cells? Could this ring affect NE rupture and shape? Also, if these perinuclear actin rings can be observed, what would they look like in CN03- and Y27-treated cells?__
The reviewer is requesting that we address possible changes to actin perinuclear cap and surrounding structure. We plan to address this concern by closer analysis of our current data and gather more data if needed.
__ Minor comments:__
We will address all the minor comments during revision.__
1-Please mention/discuss CytoD treatment in main text (Fig 2C).__
We plan to add text to address this concern.
__ 2-Can the authors comment on why CN03 treatment on VPA cells does not cause changes in blebs or NE rupture (fig. 3A, B)?__
We plan to comment on this point.
__ 3-I'd move fig. 2B to supplement.__
We prefer to keep this material in the main manuscript Figures as it supports a major support of the title and major conlcusion.
__ 4-In my opinion schematics on figs. 1A, 2A, 3E are confusing and do not add anything to the manuscript.__
We prefer to keep this material in the manuscript.
__ 5-There is something missing on the following sentence, please revise it: "We hypothesized that LMNA-/- nuclei do not show bleb-based behaviors because this perturbation cannot, due to reported disrupted nuclear-actin connections (Broers et al., 2004; Vahabikashi et al., 2022)."__
We have revised this sentence to read: “We hypothesized that LMNA-/- nuclei do not show bleb-based behaviors because of the reported disruption of nuclear-actin connections (Broers et al., 2004; Vahabikashi et al., 2022).”
__ 6-Can the authors explain in the Discussion why there is a decrease in gH2AX foci in VPA-treated cells and LaminA-/- cells upon CN03 treatment?__
We do not have an explanation at this time.
Significance
Nuclear deformation is a common event observed in homeostasis and disease and both extra-cellular physical cues and different cellular components play critical roles in nuclear morphology and integrity. It is well known that the actin cytoskeleton exerts a wide range of forces on the nucleus and causes nuclear deformation (via LINC complex) as cells migrate, grow or spread within complex microenvironments. The contribution of mutations of nucleo-skeleton components to nuclear abnormalities and rupture are well described. Additionally, more recently, the contribution of the actin cytoskeleton to nuclear integrity and morphology has also been characterized. However, the role played by actin contraction on nuclear shape and integrity, independently of actin confinement (exerted by the actin cables localized at the top of the nucleus), remain elusive. In this manuscript Pho et al., address this question using cells expressing NLS-GFP to detect nuclear rupture events and potential nuclear deformations. There is no real conceptual advance in this study but there is a novel finding as it shows that acto-myosin contraction affects nuclear integrity and morphology independently of dorsal actin cables (actin confinement). Moreover, the experiments were performed on flat 2D surfaces, a distant scenario from the 3D in vivo landscapes. As a classic cell biology study this manuscript has the potential to be of interest to basic researchers in the field of cell migration, crosstalk of nucleo-skeleton/cytoskeleton and nuclear mechano-sensing.
We appreciate that Reviewer states
- “role played by actin contraction on nuclear shape and integrity, independently of actin confinement (exerted by the actin cables localized at the top of the nucleus), remain elusive.”
- “In this manuscript Pho et al., address this question…” and “[our manuscript] is a novel finding as it shows that acto-myosin contraction affects nuclear integrity and morphology independently of dorsal actin cables (actin confinement).” Thus our manuscript provides a novel finding of interest to the cell biology community
While individually, chromatin decompaction via VPA, lamin B1 knockout (LMNB1-/-), and lamin A/C knockout (LMNA-/-) have been well-studied, there is no other publication that directly compares them and furthermore decouples the role of actin contraction from confinement.
__ __
Reviewer 2
The authentication of cell lines was not clear. The origin of the cell lines used was not clear. Were they immortalized? Did they examine primary MEFs? The authors did not seem to be aware of convincing data showing that Lamin B1 increases nuclear dispensability, whereas lamin B1 deficiency has the opposite effect.
Cell lines have been previously published multiple times, but originated from Shimi et al. 2011. We have revised the text to clarify that these are immortalized MEFs used in many previous studies cited in the main manuscript and the materials and methods, and not primary MEFs.
“ MEFs were immortalized with SV40 large T antigen by retroviral transduction of the gene encoding the SV40 large T antigen as previously described (Shimi et al., 2011, 2015).”
We also included citations to (Vahabikashi et al., PNAS 2022) which has recently compared many lamin knockouts and knockdowns.
The reviewer makes an unclear statement about lamin B1 levels and “dispensability” but provides no citations. As cited in the original manuscript lamin B1 null nuclei are one of the most studied models of nuclear blebbing and rupture (Vagas et al., Nucleus 2012; Hatch et al., JCB 2016; Young et al., MBoC 2020). __
The paper reads like a rough draft. Nomenclature inappropriate.__
The nomenclature used in this manuscript follows previous publications in the field including for chromatin notation (VPA, Stephens et al., 2017 and all previous manuscripts using this drug), lamin KOs (LMNB1-/- and LMNA-/-, Shimi et al. 2011.), and actin contraction and confinement are field appropriate.
We will revise the text to clarify nomenclature.
Significance
The impact of actin on blebs and nuclear shape is well established. The implications of these findings for distinct roles of the nuclear lamin proteins were not clear. The impact of the interventions on nuclear stiffness was not measured.
We agree with the reviewer that the impact of actin on nuclear shape is well established. However, the differential roles of actin contraction vs. confinement are not clear, as we state in the intro of the original manuscript. We believe our paper shows for the first time the separate role of actin contraction from actin confinement, where actin contraction is modulated, and we find that actin confinement measured by nuclear height remains the same. Reviewer #1 agrees that our data separating the roles of actin contraction and confinement is a novel finding (See Reviewer #1 Significance above).
The reviewer states that the distinct roles of lamins are not clear. We use different lamin knockout mutants as phenotypes of nuclear blebbing (LMNB1-/-, along side VPA) and abnormal nuclear shape measured as decreased nuclear circularity with no change in nuclear blebbing (LMNA-/-). These two different phenotypes of nuclear blebbing and abnormal shape also coincide with bleb-based nuclear ruptures and non-bleb-based nuclear ruptures, respectively (Figure 1). We do not examine the full role of lamins in this manuscript, as it is well beyond the scope of this work.
As cited in the original manuscript, interventions on chromatin (VPA) and lamins (LMNB1-/- and LMNA-/-) have been previously published and thus were not the focus. Nuclear stiffness measurement of perturbation of chromatin compaction via VPA has been published numerous times by our lab (Stephens et al., 2017,2018, 2019 MBoC; Berg et al., 2022 biorxiv) and others (Hobson et al., 2020 MBoC, Shimanoto et al., 2017). Nuclear stiffness in LMNB1-/- and LMNA-/- has been published in (Vahabikashi et al., PNAS 2022). We also have previously shown that depolymerization of actin does not impact nuclear stiffness (Stephens et al., 2017 MBoC), which would suggest that changes in actin contraction would not influence nuclear stiffness. This is supported by the fact that changes in actin contraction to not alter actin confinement pushing down on the nucleus resisting it (force balance) in all conditions except VPA Y27632 (Figure 2).
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #4
Evidence, reproducibility and clarity
This article examines the cellular processes that predispose cells to nuclear blebbing and DNA damage in response to lamin and chromatin perturbations. The authors show key differences in these two types of perturbation and demonstrate a role for actin contractility. The experiments are well controlled and the data analysis generally rigorous. However, prior to acceptance, a number of issues must be fixed to improve the manuscript. I do not know the field sufficiently well to judge the novelty of the data.
Major issues:
- page 7, bottom: The authors state that measuring nuclear height gives an indication of confinement and force balance. But, if the nuclear mechanical properties have changed, then the nuclear height could change without any change in contractility. So, the authors would need to also verify that the level of contractility hasn't changed and that the mechanical properties haven't changed to really confirm that the cell height is a good measure of confinement. The level of contractility can be assessed by staining for pMLC. The nuclear mechanical properties may have been measured by others.
- In general, are the changes in contractility resulting from drug treatments sufficiently large to deform the nucleus? Can the authors show a time course of nuclear height in response to a treatment for WT for example? This would allow to link contractility to nuclear height.
- Page 9: The authors do not find any change in nuclear shape. Can they measure shape pre/post treatment on the same cells? It could be that the effect is lost in variability unless you do paired measurements?
- Page 11: the authors find nuclear ruptures unchanged in LMA -/- even when there is no contractility. They then state: "We hypothesized that LMNA-/- nuclei do not show bleb-based behaviors because this perturbation cannot, due to reported disrupted nuclear-actin connections". I do not understand this sentence.
- To characterise actin contractility better, it would be good to present images of the actin cables in each condition and pre/post treatments. This would allow to visually assess whether the morphology of the F-actin cytoskeleton has changed. This is one of the main topics of the study and as such it should be examined.
- On all bar charts, the authors should indicate: the number of independent experiments, the number of cells examined.
- I find the diagrams on Fig 1A, 2A etc do not help to illustrate what the authors think is happening. Can they redraw them in a more informative way?
- The abstract, introduction, and discussion are overly long and lack focus. These should be rewritten succinctly.
Minor issues:
- page 4: inhibitors of Rho-kinase will also modulate actin polymerisation indirectly through the action on Lim-kinase and cofilin.
- page 5, second paragraph: the authors should state that they are measuring the frequency of ruptures. At first, I thought this might be a mechanical strain.
- Page 7: In general, it may be useful to discuss the temporal evolution of the c/n and the circularity side by side. The change in circularity over time could be an indicator of mechanical strain, while the c/n would report on any transient loss of integrity of the nuclear membrane.
- Fig 1B: it would be nice to present the time course of the c/n as well.
- Fig S1: it might be interesting to characterise the dynamics/amplitude of the c/n for the different conditions. There doesn't appear to be any difference between the nuclear blebbing rupture and the non blebbing rupture. This suggests that the two phenomena (nuclear blebbing and nuclear rupture) are independent: i.e. rupture is not causally linked to blebbing.
Significance
This article examines the cellular processes that predispose cells to nuclear blebbing and DNA damage in response to lamin and chromatin perturbations. The authors show key differences in these two types of perturbation and demonstrate a role for actin contractility. The experiments are well controlled and the data analysis generally rigorous. However, prior to acceptance, a number of issues must be fixed to improve the manuscript. I do not know the field sufficiently well to judge the novelty of the data.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary: In this manuscript, the authors set out to compare the contributions of chromatin and both A- and B-type lamins to the maintenance of nuclear shape and NE integrity, while also observing how actin contraction or confinement individually contribute to changes in nuclear shape and integrity. To do this, they used mouse embryonic fibroblasts (MEFs) expressing an NLS-GFP as a readout of nuclear shape and rupture, while perturbing chromatin compaction (using the HDAC inhibitor VPA) or using MEF lines devoid of A-type (LMNA -/-) or B-type (LMNB1 -/-) lamins, while simultaneously decreasing or increasing actin-mediating tensile forces but maintaining actin compressive forces by observing nuclear height. They found that increased actin contraction causes a higher instance of bleb-based nuclear shape changes and ruptures in WT and LMB1-/- cells, as well as cells with chromatin decompaction, but actin contraction did not impact the nuclear morphology or prevalence of bleb-based ruptures with a loss of LMNA. The authors also show that loss of LmnB1 causes chromatin decompaction phenotype, and loss of Lamin A/C creates and increase in bleb-based nuclear ruptures, but only under conditions of chromatin decompaction with VPA.
Major critiques:
- Fig 2B- The authors use γMLC2 as a readout for actin contractility when CN03 and Y27632 is applied. While this method has been used previously as a readout for actin contractility, it would be more convincing if the authors included at least another technique to verify and increase or decrease in actin contractility in some of their conditions (e.g. traction force microscopy).
- Fig 2C- the authors suggest that the shape changes and blebbing are not due to actin confinement on the nucleus, because nuclear height does not change. This is an large assumption made from only a small amount of data, considering that there could be increased confinement on the nucleus during actin contractility, yet it is too small to be measured by the side imaging technique described in the paper. The manuscript would benefit greatly from more experiments that could show that the blebs are being made even when there is no confinement.
Minor critiques:
- Fig 2B- the statistical significance asterisks above the MLC2 relative fluorescence graph do not seem to be aligned appropriately with the bars, and it is difficult to know which asterisk belongs to which bar. Same is true for the nuclear height graph. The "vs. WT" box above the nuclear height graph is also confusing in that it is hard to see which statistical
Significance
The manuscript creates value in the field, in that the major findings of the relationship between lamins, chromatin, and actin and their respective impacts on nuclear shape and rupture are in agreement with findings from previous studies and therefore bolsters the current model on NE mechanics. The novelty in the paper comes from the reported finding that actin contraction and not confinement is what controls nuclear blebbing and ruptures, although this evidence seems to be limited to a single method (nuclear height measurements) presented in Fig 2 and Fig S3A. In contrast to the author's suggestions, it is possible that during actin contractility, actin cables running over the nucleus could be confining the nucleus to height changes that are too subtle to be measured using a confocal microscope, and there are forces acting on to top of the nucleus that could contribute to the blebbing phenotype observed. In my opinion, the conclusions drawn by the authors in this matter rely too few evidence.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
The authentication of cell lines was not clear. The origin of the cell lines used was not clear. Were they immortalized? Did they examine primary MEFs? The authors did not seem to be aware of convincing data showing that Lamin B1 increases nuclear dispensability, whereas lamin B1 deficiency has the opposite effect.
The paper reads like a rough draft. Nomenclature inappropriate.
Significance
The impact of actin on blebs and nuclear shape is well established. The implications of these findings for distinct roles of the nuclear lamin proteins were not clear. The impact of the interventions on nuclear stiffness was not measured.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
In this manuscript Pho et al., characterize the effects of actin confinement versus acto-myosin contractility on nuclear deformation and nuclear envelope (NE) rupture/blebs. They use both genetic and pharmacological perturbations that impact nuclear shape and integrity such as chromatin decompaction and genetic deletion of nucleo-skeleton components (LaminA and LaminB). First, the authors show that modulation of acto-myosin contractility does not affect nuclear height (a proxy for the effects of actin confinement on the nucleus). This finding allowed them to study the effects of acto-myosin contractility on nuclear shape and integrity independently of actin-mediated nuclear confinement. Using fibroblasts expressing a NLS-GFP construct to assess nuclear shape and integrity, the authors show that increased acto-myosin contractility by treatment with Rho activator (CN03) leads to nuclear blebs and NE rupture events (curiously, they show that in LaminA-/- fibroblasts the NE rupture events were not bleb-based and were not affected by CN03). With these results, authors conclude that actin contraction is a major determinant of bleb-based NE rupture, independently of actin confinement. Next, since many studies have associated loss of nucleo-cytoplasmic compartmentalization with increased DNA damage, the authors addressed the occurrence of DNA damage foci in several contexts/perturbations. They find that increased NE rupture frequency by CN03 treatment does not lead to increased DNA damage. Based on the sole finding, authors then claim that DNA damage is mostly associated with abnormal shaped nuclei instead of ruptured nuclei. The data presented is overall convincing and well controlled but a more in-depth characterization of the DNA damage events in VPA-treated cells, LaminB-/- and LaminA-/- cells is needed to support the claim that DNA damage is not associated with NE events in their system. More details below.
Major comments:
- In fig. 4, increased NE rupture frequency by CN03 treatment did not lead to an increase in gH2AX foci, so authors claim that DNA damage is not associated with NE events. However, the increase observed in NE rupture frequency is rather very subtle (from 1.5 to 3 in WT cells; from 2.5 to 4 in VPA treated ells and from 2 to 2.5 in LaminB-/- cells) so I wonder if such a minor increase might be sufficient to cause an increase in DNA damage foci. Moreover, DNA damage events are repaired within minutes and the analysis throughout this manuscript is made on snapshots. Therefore it becomes difficult to draw any conclusion regarding the absence of a link between NE rupture and DNA damage. To assess DNA damage events in a quantitative manner and show that abnormal shape (as opposed to NE rupture) is the main driver of DNA damage, authors should perform live cell imaging of cells co-expressing a DNA damage marker and a NE rupture marker to track DNA damage events following NE rupture.
- Fig. 4C: to show that frequency of NE rupture is less important than abnormal nuclear shape for DNA damage appearance, authors need to quantify gH2AX in normal x blebbed x abnormal nuclei in each one of the conditions (untreated, CN03 and Y27). But again, this analysis must be complemented by live cell imaging experiments to track DNA damage foci appearance (or not?) following NE rupture events.
- Since VPA treatment increases both the percentage of bleb-based NE rupture and NE rupture frequency in LaminA-/- cells, authors should show that gH2AX foci in this sample remain unaltered to further support their claim that frequency of NE rupture is less important than abnormal nuclear shape.
- Does methylstat treatment rescue LaminB-/- phenotypes (blebs, ruptures, ...)?
- Auhors mention throughout the manuscript the "actin confinement" component (actin cables localized at the top of the nucleus-not convincingly shown in fig. 2C). Some studies have reported the occurrence of perinuclear actin caps that surround the entire nucleus (DOI: 10.1038/s41467-018-04404-4; DOI: 10.1038/srep40953; DOI: 10.1038/ncb3387). Can the authors investigate the existence of such perinuclear actin ring on the LaminB-/-, LaminA-/- and VPA-treated cells? Could this ring affect NE rupture and shape? Also, if these perinuclear actin rings can be observed, what would they look like in CN03- and Y27-treated cells?
Minor comments:
- Please mention/discuss CytoD treatment in main text (Fig 2C).
- Can the authors comment on why CN03 treatment on VPA cells does not cause changes in blebs or NE rupture (fig. 3A, B)?
- I'd move fig. 2B to supplement.
- In my opinion schematics on figs. 1A, 2A, 3E are confusing and do not add anything to the manuscript.
- There is something missing on the following sentence, please revise it: "We hypothesized that LMNA-/- nuclei do not show bleb-based behaviors because this perturbation cannot, due to reported disrupted nuclear-actin connections (Broers et al., 2004; Vahabikashi et al., 2022)."
- Can the authors explain in the Discussion why there is a decrease in gH2AX foci in VPA-treated cells and LaminA-/- cells upon CN03 treatment?
Significance
Nuclear deformation is a common event observed in homeostasis and disease and both extra-cellular physical cues and different cellular components play critical roles in nuclear morphology and integrity. It is well known that the actin cytoskeleton exerts a wide range of forces on the nucleus and causes nuclear deformation (via LINC complex) as cells migrate, grow or spread within complex microenvironments. The contribution of mutations of nucleo-skeleton components to nuclear abnormalities and rupture are well described. Additionally, more recently, the contribution of the actin cytoskeleton to nuclear integrity and morphology has also been characterized. However, the role played by actin contraction on nuclear shape and integrity, independently of actin confinement (exerted by the actin cables localized at the top of the nucleus), remain elusive. In this manuscript Pho et al., address this question using cells expressing NLS-GFP to detect nuclear rupture events and potential nuclear deformations. There is no real conceptual advance in this study but there is a novel finding as it shows that acto-myosin contraction affects nuclear integrity and morphology independently of dorsal actin cables (actin confinement). Moreover, the experiments were performed on flat 2D surfaces, a distant scenario from the 3D in vivo landscapes. As a classic cell biology study this manuscript has the potential to be of interest to basic researchers in the field of cell migration, crosstalk of nucleo-skeleton/cytoskeleton and nuclear mechano-sensing.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We would like to first thank the reviewers for their patience with us given the delays in the generation of our revised manuscript. In addition to a maternity leave taken by Dr. Goyon, we took the reviewers comments very seriously and generated significant amounts of new data to address the insightful comments and suggestions of all three reviewers. The manuscript now has 9 figures, with 7 supplemental figures and 3 tables.
Our point-by-point rebuttal is below, but the major new additions are:
- Full analysis of bile acid species in the feces (to complement the liver and serum analysis provided in first submission). We also performed FDG-glucose PET analysis of the mice, which revealed significant alterations in proliferation in the gut in young MAPL KO mice. We did this in response to the concerns raised by reviewers 1 and 3 about the effects of the gut on bile acid regulation, and we discuss our findings below in response to reviewers, and within the revised manuscript.
- Our initial submission reported an Illumina approach for transcriptomics in livers of male wt and KO mice. We now completed RNAseq analysis on both male and female (littermate) control and MAPL KO mice at 3 months old. This validated what we had seen in the Illumina arrays, but allowed us a deeper look into transcriptional and sex specific changes that we present in response to review and within the revised manuscript. We have also expanded our feed/fast cycle analysis of the dynamic changes in gene expression of bile acid related pathways to further document the disruption in the feedback cycles regulating bile acid synthesis in liver.
- We have developed assays using primary hepatocytes from +/-MAPL mice for a better analysis of cell autonomous functions and bile acid secretion. This complements the tail-vein rescue experiments we had presented in initial submission.
Reviewer #1 (Evidence, reproducibility and clarity (Required)):__
In this study, the authors have investigated the impact of permanently silencing the expression of the mitochondrial anchored protein ligase (MAPL) in mice on bile acid (BA) metabolism through the alteration of ABCD3 SUMOylation. This ABC pump mediates the uptake of C27-BAs by peroxisomes and hence determines the shortening of the BA sidechain. In addition, other aspects of general metabolism have also been investigated. The study is highly relevant and contains valuable information__.
AUTHORS: We sincerely thank the reviewer for their supportive comments on the value of our work.
Major points
R1: 1) Sidechain shortening is essential for the synthesis of primary C24 BAs. This study suggests that the entrance of C27 BAs in peroxisomes, which depends on ABCD3 activity, is reduced by MAPL-dependent ABCD3 SUMOylation. Thus, knocking out MAPL in mice results in enhanced BA accumulation in serum and liver, presumably by facilitated uptake of C27 by the peroxisomes and stimulation of de novo synthesis of primary BA. Indeed, a decreased C27/C24 BA ratio was found. However, the results suggest that Cyp7a1 is not the main checkpoint for the control of BA synthesis or that Fxr/Fgf15/Cyp7a1 pathway is also affected by MAPL manipulation because Cyp7a1 expression, which could be expected to be downregulated in response to enhanced BA levels, is not affected in MAPL knockout. Moreover, no change in Fgf15 was found (Suppl. Fig. 2C, 2D, 2G). The authors must discuss these surprising findings.
AUTHORS: We entirely agree with the reviewer that the lack of feedback to downregulate bile acid synthesis through the canonical pathways was very unusual and is one of the novel aspects of our study. While the circulating bile was significantly elevated, this was not sensed by the pathways in the gut or liver to downregulate CYP7A1 through the activation of bile receptors FXR/FGF15. We have rewritten a great deal of the manuscript to be clearer about this, as we also feel the MAPL KO presents us a very unique model of bile acid dysregulation with many unexpected observations. In revision we completed an analysis of ~40 bile acid species within the feces to understand what may be happening in the gut. Interestingly, bile acid levels were decreased in feces, in contrast to the elevations seen in gut and liver (New Fig3). This prompted us to consider a block in bile acid delivery to the gut, or cholestasis. However, such a pathology is generally lethal, yet MAPL KO mice live past 2 years. Histological analysis (presented in New Fig 3) did not reveal any obstructions, necrosis or pathology in the bile canaliculi. Bomb calorimetry of the feces showed equivalent calories in KO mice (New Fig3), suggesting that digestion of food was fully intact, something that would have been altered if bile was absent. Lastly, the secondary bile acids that are generated by the microbiome were elevated in serum and liver, indicative of the successful transit of these bile species through the gut. Therefore, we conclude that the bile does reach the gut, yet appears to be significantly reabsorbed back into circulation without alerting the bile sensing pathways to secrete more FGF15. Ultimately, we have not answered the initial question, since we do not know yet how MAPL is required, directly or indirectly, for bile acid feedback loops. But we realize now that this will take significant effort to resolve mechanistically, something we will continue to work on in the next stage of our project.
R1: 2) The authors discussed that the alternative acidic pathway is responsible for these changes, but Cyp27a1 was, in fact, moderately downregulated in MAPL knockout mice.
AUTHORS: We apologize for the confusion. Yes, Cyp27A1 is moderately downregulated in MAPL KO mice, seen now within RNAseq analysis (New Fig 2C) and the western blots (Fig 3C) which we meant to say could reflect a specific feedback loop to inhibit bile acid synthesis from the acidic pathway, rather than through canonical, FXR/FGF15 mediated changes in Cyp7A1. We considered that very little is known about the regulation of the acidic pathway, and perhaps MAPL effects on bile acid metabolism may be more dominant in this loop. However, clearly it remains unresolved how the elevated bile, even in liver, goes undetected by FXR to downregulate Cyp7A1. We have tried to approach our results and discussion in a more systematic way to make these points clearer.
R1: 3) Serum BAs may reflect a higher BA pool. Nevertheless, this has not been assayed. Enhanced flow of C27-BA precursors into peroxisomes is consistent with increased C24-BA production and reduced intrahepatic concentration of C27-BA in MAPL knockout mice (Suppl. Table 2). However, it is not explained why C27-BA serum concentrations were increased in these animals (Suppl. Table 2 and Suppl. Fig. 2B).
AUTHORS: We thank the reviewer for pointing that out. We added quantification in the feces of the bile acid species (New Fig2C). Surprisingly we found decreased levels of C27 and C24 bile acids. We are speculating that some of the increased bile acid levels in the serum are due to increased synthesis/flux through the hepatocyte peroxisomes and some due to reabsorption.
R1: 4) C27-BAs have been described as more toxic species than most C24-BAs. In the liver of MAPL knockout mice, C27-BAs levels were decreased (Suppl. Table 2). Other toxic species such as DCA and CDCA were not markedly changed. Muricholic acids and ursodeoxycholic acid, which were increased, are believed to be non-toxic or even hepatoprotective. Therefore, the relationship between changes in BA homeostasis and liver carcinogenesis should be better justified.
AUTHORS: We apologize for generalizing too much in assigning elevated bile acid species as potential drivers/contributors of tumorogenesis. We have made note in the text of the reviewers points, including references to the protective nature of some bile species. We cannot yet pinpoint the precise cause of cellular transformation but have tried to balance the discussion around potential changes in 1) proliferative signaling cascades potentially linked to bile signaling, 2) ER stress, which has been linked to tumorogenesis, and 3) the protection against cell death pathways seen in MAPL KO cells.
R1: 5) SUMOylation may affect transporters which may simulate certain cholestasis with retention in serum of BAs. Expression levels of basolateral Ntcp, Oatps, and canalicular Bsep are required to better understand BA homeostasis. Besides, biliary secretion in MAPL knockout mice would give relevant information on what is actually happening in the biliary function of these animals.
AUTHORS: We thank the reviewer for an excellent point. To get a better view of the transcriptional changes of the transporters highlighted here, but also of all genes in liver, we completed RNAseq analysis. This showed no change in the mRNA levels of the transporters highlighted, so we performed qRT-PCR analysis from livers during a feed/fast experiment to determine whether the dynamic behavior of expression may be altered upon MAPL loss (New Fig 4). Importantly, we found that the transporters expression was unchanged (except for one of the Oatp which would limit hepatocyte reabsorption). We also added bile secretion from primary hepatocytes reproducing the phenotype. This reinforces our point that MAPL loss affect primarily bile acid flux through the peroxisome and that is enough to have increased bile acid in the serum. Lastly, to test whether bile was successfully transiting into the gut we completed the bile acid analysis of feces, along with bomb calorimetry, PET analysis and histology of the gut, all of which indicate that bile flux to the gut is intact.
__Reviewer #1 (Significance (Required)):
The study is relevant and original.__
AUTHORS: We thank the reviewer for appreciating the strengths of our study.
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
The present manuscript described novel interacting partners of a mitochondrial/peroxisomal Sumoylation ligase MAPL and describes the phenotype of a newly generated MAPL KO mouse model.
Major comments:
R2: The authors describe in the introduction that MAPL has multiple functions, including a role in mitophagy,mitochondrial division, inflammation and cell death. New is a role in regulation of peroxisomal bile salt handling. Also the role in hepatic cell proliferation in vivo has not been demonstrated before. The individual findings are generally convincing. However, the relation between the large number of observations is not clear. The authors postulate that multiple aspects of the MAPL KO mice are related to direct effects on PMP70/ABCD3 sumoylation and/or to effects on bile salts. This connection is highly speculative and mechanistically underexplored. As MAPL function was already implicated in many processes unrelated to bile salts/ABCD3, alternative explanations are likely.
AUTHORS: We appreciate these critical comments, and agree that MAPL has distinct substrates that play important roles in multiple aspects of mitochondrial (and now peroxisomal) signaling, survival and metabolism. This certainly makes it difficult to assign a given substrate to a broad set of pathologies in a KO mouse model. Our lab has been working on MAPL for over 15 years, and a major question has been the physiological function of MAPL in vivo. Our report that the primary phenotypes appear in liver, that effects global metabolism (lean phenotype, insulin sensitivity), proliferation and cancer provide the first evidence of the importance of MAPL in metabolism. Our BioID approach to identify MAPL partners led us to ABCD3, the peroxisomal bile acid transporter, in addition to the identification of established proteins of the mitochondrial and peroxisomal fission machineries. Furthermore, we provide critical new evidence that MAPLs primary role is not to regulate the degradation of its substrate partners, since they were not stabilized upon inhibition of the proteasome. We confirmed the interaction and SUMOylation of ABCD3 from liver tissue using multiple approaches (BioID, co-IP, SIM beads, glycerol gradients), therefore we do not consider the interaction between the two proteins as speculative. We agree that more will need to be done to develop structure/functional analysis of the SUMOylated bile acid transporter. Important to this study, functional data in vivo demonstrates major increases in bile acid production in liver and (new to the revision) primary hepatocytes, consistent with a role for MAPL mediated SUMOylation to gate ABCD3, the only primary bile acid transporter in peroxisomes. We have attempted to position our findings within the context of MAPL function in other pathways and broadened our discussion in terms of all mechanisms and phenotypes.
In this revised manuscript we expanded our analysis into the gut, given the important role of the gut in bile acid homeostasis. In searching for an explanation for the disruption in FXR/FGF15 responsiveness, we observed a striking proliferative phenotype in the duodenum. The limited proliferation in duodenum is consistent with previous work showing that bile acids can promote proliferation through a number of mechanisms, from the signaling of TGR5 bile receptors to YAP activation. It may also reflect cell autonomous functions of MAPL in enterocytes responsible for the suppression of proliferation, however the limitation of the proliferative phenotype to the top section of the gut does suggest a link to bile. We have included these data, along with a full bile acid analysis of feces, in the revised manuscript given the essential role of the gut as a driver of the feedback loop for bile acid homeostasis. We hope the reviewer will now be convinced that our work places MAPL as a key metabolic regulator offering a new animal model that highlights some very unusual bile acid phenotypes, and a model of spontaneous hepatocellular carcinoma. These are unexpected phenoptypes for a MAPL KO animal given all previous work into MAPL/MUL1.
R2: Similarly, the metabolic consequences of bile salt signalling (the authors postulate this may occur via TGR5) versus effects of the ER-stress/FGF21 pathway remain unclear.
AUTHORS: It is not entirely clear to us which metabolic consequences the reviewer refers to in this concern, so hopefully we will answer the question as intended. Assuming the reviewer refers to the lean, insulin sensitive phenotype of MAPL KO mice, we understand there remains some speculation in the relationship between the bile acids or FGF21 as drivers of the insulin sensitivity. The phenotype mimics FGF21 overexpression, as this hepatokine has been long linked to leanness and insulin sensitivity in mice. The curious finding was in our tail vein rescue experiments, even empty adenovirus induced ER stress, so we could not test if MAPL expression would rescue CHOP expression. Yet we had a full restoration of both FGF21 and circulating bile. This indicates that the ER stress is not the main driver of FGF21 expression (or bile secretion) in this system. Given the direct interactions we observed between MAPL and the bile acid transporter, we hypothesized that the rescue of MAPL would return the gating function of ABCD3, and perhaps that the bile acids themselves were driving FGF21 expression. This is consistent with a 2018 study demonstrating that FGF21 signaling resulted in the downregulation of bile acid synthesis (PMID: 29615519), a potential feedback loop to explain the downregulation of many bile acid enzymes seen in our RNAseq analysis. We have been more careful to state the limitations and outstanding questions in the study. It will take many additional mouse crosses, knock-in models carrying mutations in ABCD3, and many other experiments to resolve this question fully. We sincerely hope the reviewer can agree that the observations are robust and well controlled, and will open new avenues of research in the future.
R2: The title and discussion is too speculative in my opinion, in particular the claim linking ABCD3 activity to all the metabolic effects observed in the MAPL KO.
AUTHORS: We have changed the title of the manuscript to better reflect the global consequences of MAPL loss and the novelty of our findings overall.
- Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.
R2: Experimental support for an altered role of ABCD3 activity as CAUSAL for the observed phenotype is essential
AUTHORS: We argue that our data has established the MAPL-dependent SUMOylation of ABCD3 in vivo using the SIM-bead pull down, our BioID identified this transporter as the top partner of MAPL, validated with immunoprecipitation from liver in floxed and MAPLKO mice, and we observe biochemical alterations in the oligomeric state of ABCD3. Identifying the SUMO sites and generating CRISPR KI mice to confirm effects on bile acid flux would represent another year (at least) of work. We strongly believe that our study provides a number of very important new insights into bile acid metabolism with phenotypes that have not been seen before (as explained by Rev1). We understand that this will be a final documentation of the structure/function relationship between MAPL and ABCD3, but we have established this interaction and substrate/enzyme pairing between a newly identified bile acid transporter (for which very little work has been done anywhere), and an evolutionarily conserved SUMO E3 ligase.
- Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.
R2: As Sumoylation sites can be predicted to some level, an MAPL-insensitive ABCD3 protein could be made and used to link effects of ABCD3 sumoylation to MAPL and consequences of MAPL deficiency. Minimally, data linking the modest effects on ABCD3 activity (for example by PMP70 knockdown in vivo) on the observed phenotype of MAPL KO is required to support the currents aims.
AUTHORS: Knocking down ABCD3/PMP70 would be possible with tail vein injection. However, the loss of ABCD3 would give the opposite phenotype, where bile acid production would be lost, as already documented in Ferdinandusse et al 2015 (PMID: __25168382). ABCD3 is the only known bile acid transporter in peroxisomes so we do not agree that our phenotypes are so obviously explained by another mechanism, nor why the reviewer considers the effects on bile acid to be “modest”? We suggest, based on established paradigms for the SUMOylation of ion transporters, that the SUMOylation would gate the transporter to inhibit it. We agree this is a next step, but it is beyond the scope of this manuscript. __
- Are the data and the methods presented in such a way that they can be reproduced? Yes
- Are the experiments adequately replicated and statistical analysis adequate? Yes.
R2: However, the initial and main finding of the manuscript, the identification of ABCD3 as MAPL interacting partner is plotted somewhat vague. Seems like data is from a single experiment, while the method section suggests otherwise
AUTHORS: We have repeated these experiments (BioID, co-IP, SIM bead experiments) numerous times from multiple mouse livers and cell lines. We have ensured the numbers are in the methods and legends. We would also submit that the interaction with ABCD3 is not, in fact, the main finding of the manuscript. The entire characterization of the mouse pathology, ending in the spontaneous development of hepatocellular carcinoma, will be of high interest to researchers in the fields of metabolism, liver biology and cancer, MAPL/MUL1 function, and insulin sensitivity. The BioID and interactomics was (to us) also very important for the things it did NOT find, for example, the substrates others consider to be regulated by MUL1 ubiquitination. Our experiments with MG132 clearly show that the candidate substrates identified in BioID are not targeted for degradation, including Mfn2 and others. MAPL loss did not lead to changes in mitochondrial or peroxisome mass, nor did it significantly alter the gene expression of these proteins (new RNAseq analysis). While some of these aspects represent negative data, it is an important, in vivo demonstration that MAPL is not a key player in mitochondrial quality control. In this sense, the entire study is highly unexpected, with such clear phenotypes in global metabolism, bile acid and liver specific effects, proliferation and cancer.
Minor comments:
R2: Abstract states: "BioID revealed the peroxisomal bile acid transporter ABCD3 as a primary MAPL interacting partner, which we show is SUMOylated in a MAPL-dependent manner." The method aspect of this sentence is too unclear as it assumes all readers know what BioID entails.
AUTHORS: We apologize for the confusion and have clarified that sentence.
R2: The abstract also states that increased bile salt secretion is occurring. No experimental data supporting increased hepatocellular bile salt secretion is provided, only increased serum levels, which is not the same.
AUTHORS: We thank the reviewer for pushing us to examine bile acid secretion from primary hepatocytes isolated from MAPL KO or littermate control mice. This took us some time since the MAPL KO hepatocytes didn’t seed as well as control cells, but we adapted our protocols and the cells adhered well. These experiments showed that MAPL KO hepatocytes produce 2-3X more bile acids than wild type hepatocytes over a 48 hours culture period. Therefore we have confirmed that the hepatocytes are producing more bile.
R2: How was FGF15 measured? The methods section is unclear about this, and the legends indicates this was measured by ELISA. Earlier paper suggests that FGF15 is not easily detectable and controls for the elisa should thus be included (PMID: 26039452).
AUTHORS: We quantified FGF15 by ELISA using established protocols without any difficulty, and have included all standards and controls in the excel sheets. The paper cited is from 2015, which is nearly 10 years ago so it appears that these tools have improved.
R2: Figure 1D; last lane with the duplo of the rescue with the mutant MAPL seems missing, only single value is plotted.
AUTHORS: The quantification presents n=3 biological replicates, the figure is a representative immunoblot of the 3 replicates, where only one mutant MAPL rescue is loaded. We clarified that in the legend.
Reviewer #2 (Significance (Required)):
- Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.
R2: The individual findings/observation are very interesting. However, as the causal link and relative contribution of the multitude of processes affected in the MAPL KO remains unclear current impact is limited.
AUTHORS: We respectfully disagree with the reviewer that the impact is limited by the fact that we are studying an E3 ligase with multiple substrates. Clearly we understand that MAPL has functions at mitochondria regulating DRP1 and other processes, as we have worked on MAPL for over years. The novelty and importance of this study is that it is the first full characterization of a MAPL KO mouse that presents with very unexpected phenotypes that will be used to advance the field in multiple ways. The identification of ABCD3 as a substrate represents the first in peroxisomes to be examined, and very little is known about the regulation of these transporters. Even if there are additional functions of MAPL at play in liver (which I’m sure there are), linking it to bile acid flux, is a novel finding.
- Place the work in the context of the existing literature (provide references, where appropriate).
R2: A highly related manuscript recently appeared: mitochondrial ubiquitin ligase MARCH5 is a dual-organelle locating protein that interacts with several peroxisomal proteins. Peroxisomal MARCH5 is required for mTOR inhibition-induced pexophagy by binding and ubiquitinating PMP70 (J Cell Biol. 2022 Jan 3; 221(1): e202103156.) This is not discussed at all. However, it supports that better scientific insight into regulation of peroxisomal processes, including the activity of ABCD3/PMP70 is very relevant to the field.
AUTHORS: We apologize for omitting the study of MARCH5 in our manuscript. The reviewer is correct that this highlights the unique function of MAPL in the regulation of the transporter through SUMOylation. MAPL loss does not alter the turnover or expression of ABCD3/PMP70 (or peroxisomes for that matter), which is the opposite of MARCH5.
- State what audience might be interested in and influenced by the reported findings. An audience interesting in peroxisomal function and/or bile salt signalling/toxicity
- Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate. R2: bile salt signalling; transport
AUTHORS: We understand that the reviewer focused on the first figure (of 9), and perhaps did not appreciate the unique findings we have made in characterizing a very novel bile acid phenotype where the feedback loops are interrupted. The links to cancer were also not mentioned by the reviewer, something we also feel strongly about since it is consistent with the roles of MAPL in cell death pathways. The establishment of a novel animal model of HCC is of value to the community.
Reviewer #3 (Evidence, reproducibility and clarity (Required)):
R3: In the manuscript „SUMOylation of ABCD3 restricts bile acid synthesis and regulates metabolic homeostasis", the authors showed that MAPL has a critical role in regulation of bile acid synthesis and loss of MAPL leads to changes in metabolism and development of liver cancer. The findings are of certain interest, However, before publication of the manuscript several shortcomings have to be clarified.
AUTHORS: We thank the reviewer for recognizing that the identification of MAPL as having a critical role in metabolism, bile acid signaling and cancer is of importance to the field.
Major Comments: R3: Since levels of muricholic acid is drastically increased, the authors should investigate Cyp2c70 expression since this enzyme is responsible for muricholic acid synthesis. Is there are direct regulatory effect of MAPL on Cyp2c70?
AUTHORS: We thank the reviewer for the suggestion, we measured Cyp2c70 and found no change in MAPL KO livers, as seen in our new RNAseq analysis and qRT-PCR (New Fig4).
R3: Does MAPL directly regulate the changes on cyp enzymes or is the regulation indirect via acting on the nuclear receptors known to regulate bile acid synthesis such as FXR, CAR, PXR. Please provide data on that.
AUTHORS: We completed RNAseq analysis from livers of control and MAPLKO mice to generate a more complete picture of precise transcriptional changes in all genes. We also looked specifically at FXR, LXR, PXR and PPARa target genes using qRT-PCR approaches from livers in feed/fasting experiments to examine dynamic changes in expression. Most were unchanged and responded normally, with the exception of some PPARs target genes that were increased, supporting the metabolism necessary to handle high levels of bile acid flux.
R3: The authors show that Cyp4a14 is increased due to loss of MAPL. Cyp4a14 is also a downstream target of PPARa. The authors should provide data on PPARa signalling in MAPLKO mice, especially on beta oxidation. This may explain why MAPL KO mice are lean.
AUTHORS: See previous response
R3: The authors did not investigate bile duct proliferation and activation of cholangiocytes, features which often occur in the context of changes in bile acid homeostasis. Do MAPL. KO mice show increased ductular proiliferation and reactive cholangiocyte phenotype? Please provide data such as expression and staining of CK19, KI67, OPN, VCAM • EGR1 and EGFR are key regulators in HCC and are known to be regulated by bile acids. The authors should investigate whether these key regulators may play a role in development of HCC in MAPL KO mice.
AUTHORS: We thank the reviewer for these suggestions. We have the Ki67 data included in Figure 8. It shows increased hepatocyte proliferation but not cholangiocytes. Moreover our histology stainings do not support any change in canicular structure. We also measured the EGF receptor activation in our model and found no change (Supplemental Figure 3). We also tried to find other indication of inflammation (as suggested), in our RNAseq dataset, we can find some known inflammatory signals like SPP1/Osteopontin, VCAM1, CCL2, CD68 being increased. However, the pathway analyses did not reveal any increased inflammatory status, which is also supported by absence of immune cell infiltration. It is possible that some immune or inflammation remodeling is happening but not at a large scale and not following the canonical inflammatory liver diseases.
Reviewer #3 (Significance (Required)):
R3: The finding that loss of MAPL is involved in regulation of bile acid synthesis is of certain interest for the field of cholestatic liver and bile duct injuries. MAPL KO mice might be an interesting model to study potential therapeutics for these diseases. Furthermore, the fact that MAPL KO mice develop spontaneous HCC is also of particular interest, since such models are quite rare.
AUTHORS: We thank the reviewer for finding our work ‘of particular interest’
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
In the manuscript „SUMOylation of ABCD3 restricts bile acid synthesis and regulates metabolic homeostasis", the authors showed that MAPL has a critical role in regulation of bile acid synthesis and loss of MAPL leads to changes in metabolism and development of liver cancer. The findings are of certain interest, However, before publication of the manuscript several short cummings have to be claryfied.
Major Comments:
- Since levels of muricholic acid is drastically increased, the authors should investigate Cyp2c70 expression since this enzyme is responsible for muricholic acid synthesis. Is zhere are direct regulatory effect of MAPL on Cyp2c70?
- Does MAPL directly regulate the changes on cyp enzymes or is the regulation indirect via acting on the nuclear receptors known to regulate bile acid synthesis such as FXR, CAR, PXR. Please provide data on that.
- The authors show that Cyp4a14 is increased due to loss of MAPL. Cyp4a14 is also a downstream target of PPARa. The authors should provide data on PPARa signalling in MAPL KO mice, especially on beta oxidation. This may explain why MAPL KO mice are lean.
- The authors did not investigate bile duct proliferation and activation of cholangiocytes, features which often occur in the context of changes in bile acid homeostasis. Do MAPL. KO mice show increased ductular proiliferation and reactive cholangiocyte phenotype? Please provide data such as expression and staining of CK19, KI67, OPN, VCAM
- EGR1 and EGFR are key regulators in HCC and are known to be regulated by bile acids. The authors should investigate whether these key regulators may play a role in development of HCC in MAPL KO mice.
Significance
The finding that loss of MAPL is involved in regulation of bile acid synthsesis is of certain interest for the field of cholestatic liver and bile duct injuries. MAPL KO mice might be an interesting model to study potential therapeutics for these diseases. Furthermore, the fact that MAPL KO mice develop spontaneous HCC is also of particular interest, since such models are quite rare.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary:
Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate).
The present manuscript described novel interacting partners of a mitochondrial/peroxisomal Sumoylation ligase MAPL and describes the phenotype of a newly generated MAPL KO mouse model.
Major comments:
- Are the key conclusions convincing?
The authors describe in the introduction that MAPL has multiple functions, including a role in mitophagy,mitochondrial division, inflammation and cell death. New is a role in regulation of peroxisomal bile salt handling. Also the role in hepatic cell proliferation in vivo has not been demonstrated before. The individual findings are generally convincing. However, the relation between the large number of observations is not clear. The authors postulate that multiple aspects of the MAPL KO mice are related to direct effects on PMP70/ABCD3 sumoylation and/or to effects on bile salts. This connection is highly speculative and mechanistically underexplored. As MAPL function was already implicated in many processes unrelated to bile salts/ABCD3, alternative explanations are likely. Similarly, the metabolic consequences of bile salt signalling (the authors postulate this may occur via TGR5) versus effects of the ER-stress/FGF21 pathway remain unclear. - Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?
Yes, the title and discussion is too speculative in my opinion, in particular the claim linking ABCD3 activity to all the metabolic effects observed in the MAPL KO. - Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.
Experimental support for an altered role of ABCD3 activity as CAUSAL for the observed phenotype is essential - Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.
As Sumoylation sites can be predicted to some level, an MAPL-insensitive ABCD3 protein could be made and used to link effects of ABCD3 sumoylation to MAPL and consequences of MAPL deficiency. Minimally, data linking the modest effects on ABCD3 activity (for example by PMP70 knockdown in vivo) on the observed phenotype of MAPL KO is required to support the currents aims. - Are the data and the methods presented in such a way that they can be reproduced? Yes - Are the experiments adequately replicated and statistical analysis adequate?
Yes. However, the initial and main finding of the manuscript, the identification of ABCD3 as MAPL interacting partner is plotted somewhat vague. Seems like data is from a single experiment, while the method section suggests otherwise
Minor comments:
- Specific experimental issues that are easily addressable.
- Are prior studies referenced appropriately?
- Are the text and figures clear and accurate?
Abstract states: "BioID revealed the peroxisomal bile acid transporter ABCD3 as a primary MAPL interacting partner, which we show is SUMOylated in a MAPL-dependent manner." The method aspect of this sentence is too unclear as it assumes all readers know what BioID entails. The abstract also states that increased bile salt secretion is occurring. No experimental data supporting increased hepatocellular bile salt secretion is provided, only increased serum levels, which is not the same.
How was FGF15 measured? The methods section is unclear about this, and the legends indicates this was measured by ELISA. Earlier paper suggests that FGF15 is not easily detectable and controls for the elisa should thus be included (PMID: 26039452). Figure 1D; last lane with the duplo of the rescue with the mutant MAPL seems missing, only single value is plotted. - Do you have suggestions that would help the authors improve the presentation of their data and conclusions?
no
Significance
- Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.
The individual findings/observation are very interesting. However, as the causal link and relative contribution of the multitude of processes affected in the MAPL KO remains unclear current impact is limited. - Place the work in the context of the existing literature (provide references, where appropriate).
A highly related manuscript recently appeared: mitochondrial ubiquitin ligase MARCH5 is a dual-organelle locating protein that interacts with several peroxisomal proteins. Peroxisomal MARCH5 is required for mTOR inhibition-induced pexophagy by binding and ubiquitinating PMP70 (J Cell Biol. 2022 Jan 3; 221(1): e202103156.) This is not discussed at all. However, it supports that better scientific insight into regulation of peroxisomal processes, including the activity of ABCD3/PMP70 is very relevant to the field. - State what audience might be interested in and influenced by the reported findings.
An audience interesting in peroxisomal function and/or bile salt signalling/toxicity - Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.
bile salt signalling; transport
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
In this study, the authors have investigated the impact of permanently silencing the expression of the mitochondrial anchored protein ligase (MAPL) in mice on bile acid (BA) metabolism through the alteration of ABCD3 SUMOylation. This ABC pump mediates the uptake of C27-BAs by peroxisomes and hence determines the shortening of the BA sidechain. In addition, other aspects of general metabolism have also been investigated. The study is highly relevant and contains valuable information.
Major points
- Sidechain shortening is essential for the synthesis of primary C24 BAs. This study suggests that the entrance of C27 BAs in peroxisomes, which depends on ABCD3 activity, is reduced by MAPL-dependent ABCD3 SUMOylation. Thus, knocking out MAPL in mice results in enhanced BA accumulation in serum and liver, presumably by facilitated uptake of C27 by the peroxisomes and stimulation of de novo synthesis of primary BA. Indeed, a decreased C27/C24 BA ratio was found. However, the results suggest that Cyp7a1 is not the main checkpoint for the control of BA synthesis or that Fxr/Fgf15/Cyp7a1 pathway is also affected by MAPL manipulation because Cyp7a1 expression, which could be expected to be downregulated in response to enhanced BA levels, is not affected in MAPL knockout. Moreover, no change in Fgf15 was found (Suppl. Fig. 2C, 2D, 2G). The authors must discuss these surprising findings.
- The authors discussed that the alternative acidic pathway is responsible for these changes, but Cyp27a1 was, in fact, moderately downregulated in MAPL knockout mice.
- Serum BAs may reflect a higher BA pool. Nevertheless, this has not been assayed. Enhanced flow of C27-BA precursors into peroxisomes is consistent with increased C24-BA production and reduced intrahepatic concentration of C27-BA in MAPL knockout mice (Suppl. Table 2). However, it is not explained why C27-BA serum concentrations were increased in these animals (Suppl. Table 2 and Suppl. Fig. 2B).
- C27-BAs have been described as more toxic species than most C24-BAs. In the liver of MAPL knockout mice, C27-BAs levels were decreased (Suppl. Table 2). Other toxic species such as DCA and CDCA were not markedly changed. Muricholic acids and ursodeoxycholic acid, which were increased, are believed to be non-toxic or even hepatoprotective. Therefore, the relationship between changes in BA homeostasis and liver carcinogenesis should be better justified.
- SUMOylation may affect transporters which may simulate certain cholestasis with retention in serum of BAs. Expression levels of basolateral Ntcp, Oatps, and canalicular Bsep are required to better understand BA homeostasis. Besides, biliary secretion in MAPL knockout mice would give relevant information on what is actually happening in the biliary function of these animals.
Significance
The study is relevant and original.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
If you wish to submit a preliminary revision with a revision plan, please use our "Revision Plan" template. It is important to use the appropriate template to clearly inform the editors of your intentions.]
1. General Statements
We were naturally pleased to read the enthusiasm coming from both reviewers. Both mentioned that an extension to experimentation in cells would increase the impact of the study, even though both recognize that the biophysical and biochemical experiments constitute a study that is significant and interesting to a broad readership.
2. Point-by-point description of the revisions
Reviewer #1 (Evidence, reproducibility and clarity (Required)):
This manuscript by Bryan et al., describes the use of Hydrogen/Deuterium-exchange Mass Spectrometry (HXMS) as a powerful tool to identify key amino acid residues and associated interactions driving liquid-liquid demixing. They have particularly focused on the Chromosomal Passenger Complex (CPC), an important regulator of chromosome segregation, which has recently been shown to undergo liquid-liquid demixing in vitro. Their work presented here allowed them to identify a few key electrostatic interactions as molecular determinants driving the liquid-liquid demixing of the CPC. Their work also shows that crystal packing information of protein molecules, where available, can provide valuable insight into likely factors driving liquid-liquid demixing.
Major comments:
[#1] A previous study by Trivedi et al., NCB 2019 identified an unstructured region in Borealin (aa residues 139-160) as the main region driving the phase separation of CPC. Interestingly, this region only shows a moderate reduction in HX upon liquid-liquid demixing. But no experiments or discussions related to this observation are presented in the current version of the manuscript.
In the Trivedi et al. paper, the authors were careful to state that the region of borealin between 139-160 contributed to phase separation, but there was clearly a remaining propensity to phase separate in vitro in the mutant. Thus, it is fully expected that there should be other regions in the complex that contribute to phase separation. It was satisfying that this region was independently identified in the hydrogen-deuterium exchange experiments and we suggest that a “moderate” reduction is consistent with a protein condensate having liquid properties. Since this region was already characterized we have focused our work in this paper to the new region identified by the hydrogen-deuterium exchange experiments.
[#2] In the absence of cellular data on if and how these mutations (within the triple-helical bundle region) affect CPC's ability to phase separate in cells, the implication of this work is very limited - One can't say for sure these are interactions driving phase separation of CPC in a cellular environment. In the absence of any cellular data with the mutants described here, much of the discussion on the possible roles of CPC phase separation in cells does not appear relevant to this manuscript. I would suggest that the authors focus mainly on highlighting the power of using HXMS as a tool to characterise the molecular determinants of liquid-liquid demixing at a relatively high resolution.
We have now added cellular data in the form of one of the key experiments used to explore CPC liquid-liquid demixing utilizing the Cry2 optogenetic system for inducible dimerization. The results of testing WT Borealin versus the mutant we identified is defective in droplet formation are shown in the all new Fig. 6. Some relation of our overall findings, encompassing observations made with purified components and now in cells, to the cellular function of the CPC is pertinent. In light of the reviewer comments, we have also reduced this aspect in the discussion (see the substantial edits on pg. 12).
Minor comments:
[#3] The authors should ensure that the introduction cites relevant literature thoroughly. For example, where the potential role of Borealin residues 139-160 in conferring phase separation properties to the CPC is mentioned, the authors failed to cite Abad et al., 2019, which showed the contribution of the same Borealin region in conferring nucleosome binding ability to the CPC.
We have made this particular change on pg. 4 and also have gone through to ensure we are appropriately citing relevant literature.
Reviewer #1 (Significance (Required)):
This is a highly relevant and significant work, particularly considering the rapidly growing list of examples for Phase separation of proteins/protein assemblies and their potential biological roles (in spite of ongoing debates in the field about the cellular relevance of several phase separation claims). The data presented in this manuscript are solid and convincingly establish HXMS as a useful tool to characterise molecular interactions driving liquid-liquid demixing. Considering its applicability to characterise wide-ranging protein assemblies implicated in phase separation, this work will be of interest to a broad readership.
We thank the reviewer for the strong praise of the significance of our study.
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
In this manuscript, using the technique of hydrogen/deuterium-exchange mass spectrometry (HXMS), the authors have tried to gain insights into the structure of the chromosomal passenger complex (CPC) within the phase separated chromatin body, known to regulate chromosome segregation in mitosis. The CPC phase separated compartment comprises three regulatory and targeting subunits, INCENP, Survivin, and Borealin, forming a three-helix bundle hetero-trimer. By measuring changes in the polypeptide backbone dynamics of this trimeric INCENP/Survivin/Borealin complex, in the liquid-liquid de-mixed state in comparison to its soluble state, using HXMS measurements, the paper puts forward high-resolution structural details of the phase separated CPC. Using a step-wise mutagenesis approach in conjunction with the information from HXMS measurements and previous crystallographic data, this work also identifies distinct regions/interfaces within this complex harboring crucial salt bridges, which directly contribute toward the liquid-liquid demixing of the CPC. Comments: 1) "The three non-catalytic subunits of the CPC (INCENP1-58, Borealin, and Survivin) form soluble homotrimers that have a propensity to undergo liquid-liquid phase separation.8 " Do the authors mean the hetero-trimeric CPC?
Yes, we meant heterotrimers. It is now corrected.
2) For better clarity, the authors can indicate the residue numbers of each of the components INCENP, Survivin, and Borealin in the CPC trimeric helix-bundle crystallographic structure in Fig 1.
These are included on the revised Figure 1A.
3) "In the condition we identified, 90% +/- 5% of the ISB protein was found within the rapidly sedimenting droplet population (Fig. 1C)." The authors should include the time-point corresponding to the gel shown in Fig 1C.
This information is now directly labeled in Fig. 1C.
4) Prior to the HXMS experiments on the phase-separated ISB protein complex, were the samples subjected to sedimentation to separate the dispersed from the condensed droplet phase? Since several time points after formation of phase-separated ISB complex have been characterized to compare and contrast between the dispersed and the droplet phase, the authors can consider performing a time-dependent sedimentation assay to ascertain the fraction of the ISB complex in the droplet phase.
The HXMS experiments were not performed on sedimented samples, so this complication in our HX workflow is not necessary. We note that the sedimentation that we include in our study (Figs. 1C, 5E, and S6), involves centrifugation for 10 minutes, and that length of time presents a substantial design challenge to our HX experimentation. We considered it at the outset of our study, but, in the end, our study was facilitated by our finding early on that this separation step was unnecessary. Further, we note that we report statistically significant differences at the earliest HX timepoints in the areas prominently protected from HX upon droplet formation (10 and 100 s; see Fig. 1C for an example). Indeed, we do not observe broadening of our HXMS spectra (examples shown for all timepoints, Fig. 2B,F) that would be expected if there were a large degree of mixed states (i.e. a large population of molecules in the free protein state and a large population of molecules in the droplet state) each having different HXMS rates. One can imagine that this sort of envelope broadening behavior (“EX1-like”) could be observed in other samples where there are multiple substantially populated states of a protein present at a particular timepoint, but this is not what we observe in the experiments we performed in this study.
5) "At the 100 s timepoint, the most prominent differences between the soluble and droplet state were located within the three-helix bundle of the ISB, with long stretches in two subunits (INCENP and Borealin) and a small region at the N-terminal portion of the impacted a-helix in Survivin (Fig. 1F)" According to Fig 1F, at the 100 s time-point, there is also another small region in Survivin (approximately residues 12-20) that exhibits slower exchange rates in the droplet state. Can the authors comment on whether this region undergoes any conformational change or if it exhibits homotypic interactions retarding the hydrogen/deuterium exchange rates in the droplet phase?
Our general approach in the Black lab over the past decade-plus of HXMS has been to restrict our conclusions whenever practical to do so to the consensus behavior. This permits multiple partially overlapping peptides to be used to generate confidence in the changes that drive our conclusions. The reviewer carefully recognizes the behavior of a single peptide (in 2 different charge states) that might have actual changes relative to some of the longer peptides that it partially overlaps with, and smaller changes can yield larger percentage changes on small peptides. We have chosen to not include this single peptide in the text describing our main conclusions from the work to be consistent with our longstanding strategy for rigorous interpretation of HXMS data. Our conclusion is that this region of not substantially changed upon droplet formation.
6) The authors mention that: "By the latest timepoint, 3000 s, there was some diminution in the number of droplets which may indicate the start of a transition of the droplets to a more solid state (i.e., gel-like)." As a result of this time points beyond 3000 s have not been used for comparing Hydrogen/Deuterium exchange rates in the condensed droplet phase with the soluble state. Can the authors comment on what happens to the nature of these specific interactions between the components of the CPC in the 'gel-like state'? A combination of both non-specific weak interactions as well as strong site-specific interactions between macromolecular components has been widely known to contribute towards the formation of several phase-separated compartments. It will be interesting to know the perspective of the authors on what sort of interactions get populated within these compartments to give rise to a more solid gel-like state. At this later time points, do the droplets exhibit reversibility under higher ionic strength conditions? Do the authors have some data to show how the material property of these droplets evolve as a function of time?
We offered the idea of a transition to a more solid state to the reader because it was a reasonable conclusion, although challenging to prove (something the Stukenberg lab is actively working on, though, see our response to point #9, below). The vast majority of our conclusions in the paper, and essentially all of what we emphasize are the important ones, are based on earlier timepoints where this is not an issue. Thus, we find an extended study of the late-developing features in our droplets something more appropriate for separate studies outside the scope of the current one.
7) "Examination of the entire time course shows that during intermediate levels of HX (i.e., between 100-1000 s), this region takes about three times as long to undergo the same amount of exchange when the ISB is in the droplet state relative to when it's in the free protein state (Figs. 2B, C and Supplemental Fig. 2). Upon droplet formation, HX protection within Borealin is primarily located in the interacting a-helix and is less pronounced at any given peptide when compared to INCENP peptides (Fig. 2E). Nonetheless, similar to INCENP peptides, it still takes about twice as long to achieve the same level of deuteration for this region of Borealin in the droplet state as compared to the free state." How do the hydrogen/deuterium exchange rates and extent of deuteration in the N-terminal part (residues 98-142) of the Survivin polypeptide chain, constituting the three-helix bundle core, evolve as a function of time? Also, how do the exchange rates for peptides in this region compare with those of the other protein subunits Borealin and INCENP and what inference can be drawn from these differences?
The peptides from a.a. 98-142 of Survivin exhibit HX protection through the timecourse (and before and after droplet formation) consistent with a folded a-helix (and comparable to the overall HX behavior of the other helices in the 3-helix bundle of the ISB)(Fig. S2). There is subtly slower HX in the droplet state for this region at later timepoints for this portion of Survivin (Fig. S4), and this is explicitly highlighted in the Results section on pg. 6.
8) The authors mention that mutating either all the glutamate residues or combinations of these residues on the acidic patch on the INCENP subunit, to positively charged residues, causes a decrease in the propensity of phase separation, as formation of salt bridges with Borealin subunit from adjacent hetero-trimeric complexes appears to be the major driving force for phase separation. Can the authors elaborate on how the reduction in the phase separation propensity of these salt-bridge inhibiting mutants might be directly affecting the subsequent localization of the CPC to the inner centromeres? Can the authors supplement their existing in vitro data with further in vivo characterization of CPC recruitment or localization to the centromeres, for each of the constructs exhibiting reduced propensity of phase separation?
As we state in the introduction, the recruitment to centromeres requires established ‘conventional’ targeting via the specific histone marks to which we refer. We also cite the correlations demonstrated between prior mutations in Borealin (impacting aa 139-160) that both disrupt phase separation in vitro and reduce CPC levels at the centromere. In our revision, we have added what we feel are the most critical cell-based experiments to relate to our HX studies in the new Fig. 6. We are preparing for future studies to study mutants arising from our HX studies, and our plans are to pursue gene replacement approaches that will rigorously test the impact on the mitotic function of the CPC. In the process of these future studies, the impact on localization will be measured, too. As others in the field are investigating the correlations between observations made with purified components and those made in the cell, and where there are nuances at play in how the actual experiments are conducted, we are certain our cell-based studies will extend far beyond the timeframe appropriate for our HX-focused study. Rigorous cell-based studies of mitotic functions are what is needed, however, and we have made our plans with that in mind.
9) It might be really interesting for the authors to look at the recent preprint from Hedtfeld et al. 2023 Molecular Cell, (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4472737). In this preprint they have recombinantly purified a stoichiometric trimer (referred to as CPC-TARGWT) comprising full length survivin, borealin, and a 1-350 residue fragment of INCENP (instead of 1-58 used in this study) and have tried to assess if any correlation exists between the in-vitro phase behaviour of CPC-TARGWT mutants and their corresponding recruitment to the inner centromere, to form a phase separated compartment. Targeting residues in the BIR domain of Survivin involved in interactions with the N-terminus of the Histone H3, Shugosin 1 or in the recognition of H3T3phos, and substituting them with Alanine or completely deleting C-terminal domain of Borealin (a region implicated in CPC dimerization and centromere recruitment), was found to result in poor centromere localization, although the in vitro phase separation properties of these constructs were found to be indistinguishable, suggesting no evident correlation between the two phenomena. Thus it might be a useful piece of data to correlate the phase separation propensities of the ISB complex variants used in this current study with the extents of their in vivo recruitment to the inner centromere. This maybe beyond the scope of the paper, but it would be good to comment on this.
For the correlation studies, please refer to our response to point #8, above. From our reading of the June 2023 preprint that the reviewer mentions, the main concern raised by the authors is questioning whether the region first identified in the Trivedi et al paper in Borealin (aa 139-160) has a role in phase separation. As the reviewer noted, Hedtfeld et al report using a complex that includes more of the INCENP protein than used in the Trivedi et al study, complicating the direct comparison between studies. Using the data in figure 5E of the Hedtfeld et al preprint, the authors suggest that the condensate formation of their version of the Borealin mutant D139-160 in vitro complex has similar phase separation properties as the wild type. However, we note that in our inspection of these data we see numerous differences. The mutant forms rounder, and larger condensates than WT and have reduced concentration of protein (less bright intensity). Finally only the WT protein has a “grape bunch” morphology. We note that unpublished data in the Stukenberg lab show these same differences can represent a defect in liquid demixing properties of a version of the purified CPC. While it is intuitive that larger condensates represent more phase separation, the unpublished data mentioned above suggests the opposite is true for the CPC. In particular, the data from the Stukenberg lab suggest the size of a droplet is mostly governed by the amount of droplet fusion in the first minutes after dilution and thus is limited by relatively rapid hardening of the complex. We note that in the course of discussions with the corresponding author of the preprint mentioned by the reviewer we did apprise them of the unpublished observations mentioned, above, in case they saw fit to include in their ongoing studies what would seem to be critical measurements (e.g. measuring circularity, droplet size, droplet intensity, and FRAP) to assess our suspicion that their construct contains a portion of INCENP that can accelerate condensate formation. If true, the Hedtfeld et al data are fully consistent with the Borealin mutant D139-160 having a significant condensate formation potential than the WT protein.
10[A]) "Our data also provide an important clue about the previously identified region on Borealin that is required for liquid-demixing in vitro and proper CPC assembly in cells 8. Specifically, our data (Fig. 1F, Supplementary Figs. 2, 4A) suggest this region of Borealin adopts secondary structure that undergoes additional HX protection in the liquid-liquid demixed state" This data fits perfectly with previous studies from Trivedi et al. (2019), which states that deletion of the Borealin 139-160 fragment obliterates its phase separation in vitro and also reduces the accumulation of CPC at the centromere. On the contrary, in the recent preprint from Hedtfeld et al. 2023 Molecular Cell, they have shown that the phase separation behaviour of their reconstituted CPC-TARGWT harboring the Borealin 139-160 deletion mutant was found to be indistinguishable from the WT. Can the authors comment on what might be the reason for this difference? Is it possible that this central Borealin region is involved in interactions with the additional fragment of INCENP subunit used in the helical bundle reconstitution, or with other centromere component proteins, whereby the deletion of region is causing inefficient recruitment to the inner centromere? This can be elaborated in the discussion section of the manuscript.
This is discussed in the response to #9, above. Through this format (the Review Commons procedure for public posting of author responses before submission of the study to a journal), our comments herein will be made public for those with the most interest in comparing our data to what is has been posted on preprint servers. We think that is the most appropriate for now, with more to surely come when the aforementioned results from the Stukenberg lab are posted/published and, hopefully when there is more information about the nature of the droplets reported in the Hedtfeld et al., study.
10 [B]) It is also well known that in addition to these electrostatic interactions, the core of the ISB helical bundle is formed by an extensive network of hydrophobic interactions. Have the authors ever looked into how perturbing any of these intra-trimeric complex hydrophobic interactions affect their ability to phase separate and perform their subsequent function?
We think there is some confusion, here. The electrostatics we focus on are between heterotrimers rather than within them. We certainly would predict that disrupting the hydrophobic surface that generates a stable heterotrimer would, in turn, disrupt individual heterotrimers. Our study assumes a stable heterotrimer as a starting point, so we view this type of perturbation as unrelated to our conclusions.
11) The phase separated CPC compartment is known to enrich several other inner centromere proteins such as the Histone H3, Sgo1, the histone H3T3phos, among others. Have the authors tried to increase the complexity of the reconstituted CPC scaffold by incorporating more components to look into whether that changes any of the interaction interfaces between the ISB trimeric complexes within the condensed phase? Can this CPC compartment be reconstituted using a bottom-up approach?
We are glad that our studies with a reductionist biochemical reconstitution approach have inspired the questions that require increased complexity. They are now warranted based on the advance we have made in the present study, and hopefully will form the basis for future, separate studies.
Overall, this paper brings forward a useful technique to probe the conformational landscape of proteins in the condensed droplet phase and compare it with its dispersed phase. This paper serves as an interesting read showing how specific salt-bridge interactions between multiple stoichiometric protein complexes can be the driving force for phase separation.
Reviewer #2 (Significance (Required)):
In this manuscript, using the technique of hydrogen/deuterium-exchange mass spectrometry (HXMS), the authors have tried to gain insights into the structure of the chromosomal passenger complex (CPC) within the phase separated chromatin body, known to regulate chromosome segregation in mitosis. The CPC phase separated compartment comprises three regulatory and targeting subunits, INCENP, Survivin, and Borealin, forming a three-helix bundle hetero-trimer. By measuring changes in the polypeptide backbone dynamics of this trimeric INCENP/Survivin/Borealin complex, in the liquid-liquid de-mixed state in comparison to its soluble state, using HXMS measurements, the paper puts forward high-resolution structural details of the phase separated CPC. Using a step-wise mutagenesis approach in conjunction with the information from HXMS measurements and previous crystallographic data, this work also identifies distinct regions/interfaces within this complex harboring crucial salt bridges, which directly contribute toward the liquid-liquid demixing of the CPC.
Overall, this paper brings forward a useful technique to probe the conformational landscape of proteins in the condensed droplet phase and compare it with its dispersed phase. This paper serves as an interesting read showing how specific salt-bridge interactions between multiple stoichiometric protein complexes can be the driving force for phase separation
We thank the reviewer for the positive comments on the significance of our study.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Structural Basis for the Phase Separation of the Chromosome Passenger Complex Nikaela W. Bryan, Ewa Niedzialkowska, Leland Mayne, P. Todd Stukenberg, and Ben E. Black# Reviewer Comments Manuscript Number: RC-2023-02017
In this manuscript, using the technique of hydrogen/deuterium-exchange mass spectrometry (HXMS), the authors have tried to gain insights into the structure of the chromosomal passenger complex (CPC) within the phase separated chromatin body, known to regulate chromosome segregation in mitosis. The CPC phase separated compartment comprises three regulatory and targeting subunits, INCENP, Survivin, and Borealin, forming a three-helix bundle hetero-trimer. By measuring changes in the polypeptide backbone dynamics of this trimeric INCENP/Survivin/Borealin complex, in the liquid-liquid de-mixed state in comparison to its soluble state, using HXMS measurements, the paper puts forward high-resolution structural details of the phase separated CPC. Using a step-wise mutagenesis approach in conjunction with the information from HXMS measurements and previous crystallographic data, this work also identifies distinct regions/interfaces within this complex harboring crucial salt bridges, which directly contribute toward the liquid-liquid demixing of the CPC.
Comments: 1. "The three non-catalytic subunits of the CPC (INCENP1-58, Borealin, and Survivin) form soluble homotrimers that have a propensity to undergo liquid-liquid phase separation.8 " Do the authors mean the hetero-trimeric CPC? 2. For better clarity, the authors can indicate the residue numbers of each of the components INCENP, Survivin, and Borealin in the CPC trimeric helix-bundle crystallographic structure in Fig 1. 3. "In the condition we identified, 90% +/- 5% of the ISB protein was found within the rapidly sedimenting droplet population (Fig. 1C)." The authors should include the time-point corresponding to the gel shown in Fig 1C. 4. Prior to the HXMS experiments on the phase-separated ISB protein complex, were the samples subjected to sedimentation to separate the dispersed from the condensed droplet phase? Since several time points after formation of phase-separated ISB complex have been characterized to compare and contrast between the dispersed and the droplet phase, the authors can consider performing a time-dependent sedimentation assay to ascertain the fraction of the ISB complex in the droplet phase. 5. "At the 100 s timepoint, the most prominent differences between the soluble and droplet state were located within the three-helix bundle of the ISB, with long stretches in two subunits (INCENP and Borealin) and a small region at the N-terminal portion of the impacted a-helix in Survivin (Fig. 1F)" According to Fig 1F, at the 100 s time-point, there is also another small region in Survivin (approximately residues 12-20) that exhibits slower exchange rates in the droplet state. Can the authors comment on whether this region undergoes any conformational change or if it exhibits homotypic interactions retarding the hydrogen/deuterium exchange rates in the droplet phase? 6. The authors mention that: "By the latest timepoint, 3000 s, there was some diminution in the number of droplets which may indicate the start of a transition of the droplets to a more solid state (i.e., gel-like)." As a result of this time points beyond 3000 s have not been used for comparing Hydrogen/Deuterium exchange rates in the condensed droplet phase with the soluble state. Can the authors comment on what happens to the nature of these specific interactions between the components of the CPC in the 'gel-like state'? A combination of both non-specific weak interactions as well as strong site-specific interactions between macromolecular components has been widely known to contribute towards the formation of several phase-separated compartments. It will be interesting to know the perspective of the authors on what sort of interactions get populated within these compartments to give rise to a more solid gel-like state. At this later time points, do the droplets exhibit reversibility under higher ionic strength conditions? Do the authors have some data to show how the material property of these droplets evolve as a function of time? 7. "Examination of the entire time course shows that during intermediate levels of HX (i.e., between 100-1000 s), this region takes about three times as long to undergo the same amount of exchange when the ISB is in the droplet state relative to when it's in the free protein state (Figs. 2B, C and Supplemental Fig. 2). Upon droplet formation, HX protection within Borealin is primarily located in the interacting a-helix and is less pronounced at any given peptide when compared to INCENP peptides (Fig. 2E). Nonetheless, similar to INCENP peptides, it still takes about twice as long to achieve the same level of deuteration for this region of Borealin in the droplet state as compared to the free state." How do the hydrogen/deuterium exchange rates and extent of deuteration in the N-terminal part (residues 98-142) of the Survivin polypeptide chain, constituting the three-helix bundle core, evolve as a function of time? Also, how do the exchange rates for peptides in this region compare with those of the other protein subunits Borealin and INCENP and what inference can be drawn from these differences? 8. The authors mention that mutating either all the glutamate residues or combinations of these residues on the acidic patch on the INCENP subunit, to positively charged residues, causes a decrease in the propensity of phase separation, as formation of salt bridges with Borealin subunit from adjacent hetero-trimeric complexes appears to be the major driving force for phase separation. Can the authors elaborate on how the reduction in the phase separation propensity of these salt-bridge inhibiting mutants might be directly affecting the subsequent localization of the CPC to the inner centromeres? Can the authors supplement their existing in vitro data with further in vivo characterization of CPC recruitment or localization to the centromeres, for each of the constructs exhibiting reduced propensity of phase separation? 9. It might be really interesting for the authors to look at the recent preprint from Hedtfeld et al. 2023 Molecular Cell, (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4472737). In this preprint they have recombinantly purified a stoichiometric trimer (referred to as CPC-TARGWT) comprising full length survivin, borealin, and a 1-350 residue fragment of INCENP (instead of 1-58 used in this study) and have tried to assess if any correlation exists between the in-vitro phase behaviour of CPC-TARGWT mutants and their corresponding recruitment to the inner centromere, to form a phase separated compartment. Targeting residues in the BIR domain of Survivin involved in interactions with the N-terminus of the Histone H3, Shugosin 1 or in the recognition of H3T3phos, and substituting them with Alanine or completely deleting C-terminal domain of Borealin (a region implicated in CPC dimerization and centromere recruitment), was found to result in poor centromere localization, although the in vitro phase separation properties of these constructs were found to be indistinguishable, suggesting no evident correlation between the two phenomena. Thus it might be a useful piece of data to correlate the phase separation propensities of the ISB complex variants used in this current study with the extents of their in vivo recruitment to the inner centromere. This maybe beyond the scope of the paper, but it would be good to comment on this. 10. "Our data also provide an important clue about the previously identified region on Borealin that is required for liquid-demixing in vitro and proper CPC assembly in cells 8. Specifically, our data (Fig. 1F, Supplementary Figs. 2, 4A) suggest this region of Borealin adopts secondary structure that undergoes additional HX protection in the liquid-liquid demixed state" This data fits perfectly with previous studies from Trivedi et al. (2019), which states that deletion of the Borealin 139-160 fragment obliterates its phase separation in vitro and also reduces the accumulation of CPC at the centromere. On the contrary, in the recent preprint from Hedtfeld et al. 2023 Molecular Cell, they have shown that the phase separation behaviour of their reconstituted CPC-TARGWT harboring the Borealin 139-160 deletion mutant was found to be indistinguishable from the WT. Can the authors comment on what might be the reason for this difference? Is it possible that this central Borealin region is involved in interactions with the additional fragment of INCENP subunit used in the helical bundle reconstitution, or with other centromere component proteins, whereby the deletion of region is causing inefficient recruitment to the inner centromere? This can be elaborated in the discussion section of the manuscript. 10. It is also well known that in addition to these electrostatic interactions, the core of the ISB helical bundle is formed by an extensive network of hydrophobic interactions. Have the authors ever looked into how perturbing any of these intra-trimeric complex hydrophobic interactions affect their ability to phase separate and perform their subsequent function? 11. The phase separated CPC compartment is known to enrich several other inner centromere proteins such as the Histone H3, Sgo1, the histone H3T3phos, among others. Have the authors tried to increase the complexity of the reconstituted CPC scaffold by incorporating more components to look into whether that changes any of the interaction interfaces between the ISB trimeric complexes within the condensed phase? Can this CPC compartment be reconstituted using a bottom-up approach?
Overall, this paper brings forward a useful technique to probe the conformational landscape of proteins in the condensed droplet phase and compare it with its dispersed phase. This paper serves as an interesting read showing how specific salt-bridge interactions between multiple stoichiometric protein complexes can be the driving force for phase separation.
Significance
In this manuscript, using the technique of hydrogen/deuterium-exchange mass spectrometry (HXMS), the authors have tried to gain insights into the structure of the chromosomal passenger complex (CPC) within the phase separated chromatin body, known to regulate chromosome segregation in mitosis. The CPC phase separated compartment comprises three regulatory and targeting subunits, INCENP, Survivin, and Borealin, forming a three-helix bundle hetero-trimer. By measuring changes in the polypeptide backbone dynamics of this trimeric INCENP/Survivin/Borealin complex, in the liquid-liquid de-mixed state in comparison to its soluble state, using HXMS measurements, the paper puts forward high-resolution structural details of the phase separated CPC. Using a step-wise mutagenesis approach in conjunction with the information from HXMS measurements and previous crystallographic data, this work also identifies distinct regions/interfaces within this complex harboring crucial salt bridges, which directly contribute toward the liquid-liquid demixing of the CPC.
Overall, this paper brings forward a useful technique to probe the conformational landscape of proteins in the condensed droplet phase and compare it with its dispersed phase. This paper serves as an interesting read showing how specific salt-bridge interactions between multiple stoichiometric protein complexes can be the driving force for phase separation
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
This manuscript by Bryan et al., describes the use of Hydrogen/Deuterium-exchange Mass Spectrometry (HXMS) as a powerful tool to identify key amino acid residues and associated interactions driving liquid-liquid demixing. They have particularly focused on the Chromosomal Passenger Complex (CPC), an important regulator of chromosome segregation, which has recently been shown to undergo liquid-liquid demixing in vitro. Their work presented here allowed them to identify a few key electrostatic interactions as molecular determinants driving the liquid-liquid demixing of the CPC. Their work also shows that crystal packing information of protein molecules, where available, can provide valuable insight into likely factors driving liquid-liquid demixing.
Major comments:
A previous study by Trivedi et al., NCB 2019 identified an unstructured region in Borealin (aa residues 139-160) as the main region driving the phase separation of CPC. Interestingly, this region only shows a moderate reduction in HX upon liquid-liquid demixing. But no experiments or discussions related to this observation are presented in the current version of the manuscript.
In the absence of cellular data on if and how these mutations (within the triple-helical bundle region) affect CPC's ability to phase separate in cells, the implication of this work is very limited - One can't say for sure these are interactions driving phase separation of CPC in a cellular environment.
In the absence of any cellular data with the mutants described here, much of the discussion on the possible roles of CPC phase separation in cells does not appear relevant to this manuscript. I would suggest that the authors focus mainly on highlighting the power of using HXMS as a tool to characterise the molecular determinants of liquid-liquid demixing at a relatively high resolution.
Minor comments:
The authors should ensure that the introduction cites relevant literature thoroughly. For example, where the potential role of Borealin residues 139-160 in conferring phase separation properties to the CPC is mentioned, the authors failed to cite Abad et al., 2019, which showed the contribution of the same Borealin region in conferring nucleosome binding ability to the CPC.
Significance
This is a highly relevant and significant work, particularly considering the rapidly growing list of examples for Phase separation of proteins/protein assemblies and their potential biological roles (in spite of ongoing debates in the field about the cellular relevance of several phase separation claims). The data presented in this manuscript are solid and convincingly establish HXMS as a useful tool to characterise molecular interactions driving liquid-liquid demixing. Considering its applicability to characterise wide-ranging protein assemblies implicated in phase separation, this work will be of interest to a broad readership.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1 (Evidence, reproducibility and clarity (Required)):
Centrioles are small cylindrical structures with roles in cell division, motility, and signaling. Typically, centrioles are highly stable structures which can persist for many cell generations. However, in some cells, such as the female germ line of many species, centrioles are programmed for elimination. This process is essential for maintaining centriole number from one generation to the next in sexually reproducing organisms, yet in nearly all species the molecular mechanisms underlying how centrioles are eliminated is unknown. The current study utilizes the nematode C. elegans to explore how centriole architecture changes during the elimination program in the female germ line. Using a suite of light microscopy techniques, the authors provide a stunning visual perspective of how centrioles are disassembled during oogenesis and show that removal of the central tube component SAS-1, a key regulator of centriole stability, is an early event in elimination. I have no major objections to the work and enthusiastically endorse its publication with the following minor revisions.
Page 9 line 200: In the pcmd-1 mutant, the authors state that centriolar foci devoid of nuclei are present in rachis, but they do not mention in the text that there are also nuclei that lack centriole foci in early pachytene. This is mentioned in the figure legend, but I felt it was important enough to mention in the text.
As per the reviewer’s suggestion, we will provide this information in the main text as well.
Page 9 line 211. The authors found that in the absence of dynein heavy or light chain that centrioles remain associated with the nuclear envelope (rather than moving to the periphery). To me this was striking as dynein depletion in the embryo results in the opposite phenotype with centrioles losing attachment to the nuclear envelope and moving to the cell periphery (Gonczy et al. 1999 JCB 147:135). It might be worth pointing this out somewhere in the manuscript and speculating about the reasons for this difference.
We will expand the Discussion section to better explain the difference of dynein’s involvement in the oocyte versus the embryo.
Page 11 line 277: The authors state that elimination timing is not affected by the loss of SPD-5. This is a small but important point. It really is the absence of PCMD-1 and not SPD-5, as SPD-5 is still present in the cell. An alternative would be to say "in the absence of PCM" or "in absence of a pericentriolar accumulation of SAS-5".
Fully agreed, we will modify the text accordingly.
Figure 4D: Why does loss of PCMD-1 result in a delay in oocyte maturation as judged by RME-2 accumulation? This is not mentioned in the paper. Is this a general response to a loss of PCM or is this specific to a loss of PCMD-1?
We realize that we were not sufficiently clear in explaining that RME-2 accumulation reflects the maturation state of oocytes. In the revised manuscript, we will clarify this point further and mention that a mild developmental delay (such as in pcmd-1(t3421ts) mutant animals) can impact the number of maturing oocytes present in the proximal gonad, and thereby lead to a slight shift in RME‑2::GFP distribution. See also related minor comment 2 of reviewer 2, and major comment 1 of reviewer 3.
Figure 7 E and F. The authors measure the tubulin and SAS-4 intensity in wild-type and sas-1(t1521) embryos and conclude that microtubules and SAS-4 signals decay faster in the sas-1 mutant than in the control. To me, this is convinceingly the case with microtubules in panel E but I am not so sure this is the case with SAS-4 as shown in panel F. The differences in SAS-4 levels are much smaller between mutant and control. Could the authors provide statistical analysis to show how significant the differences are?
We will provide the requested statistical analysis (which indeed shows significance).
Page 15 line 363. I think this sentence should be reworded to: "Finally, we demonstrate that the central tube protein SAS-1 is the first of the factors analyzed here to leave centrioles..."
In response to this suggestion and to the related comment of reviewer 2 (see below), we will rephrase this sentence to read “among the centriolar components analyzed to date, SAS-1 is the first to depart”.
Reviewer #1 (Significance (Required)):
The work contained in this manuscript represents a fundemental step forward in understanding the process of centriole elimination. The authors have carefully described the stepwise disassembly of the centriole including changes in the architechure during oogenesis. They have identified loss of the centriole stability factor SAS-1, as an early event in the elimination program and have found that in a sas-1 mutant, the centriole disassembles prematurely. They have also shown that loss of SAS-1 is followed by expansion of the centriole and ultimately loss of structural integrity. This work should be of interest to a broad range of scientists including those interested in centrosome dynamics, germ line development, and more generally cell biologists.
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
Summary In this manuscript Pierron et al. explore the mechanisms of centriole elimination during oogenesis in C. elegans. Centriole elimination is a common feature of oogenesis in many species, but it is relatively poorly understood and understudied. Here, the authors characterise the kinetics with which several key centriole and centrosome proteins are lost during this process in living worms, and they correlate this with an EM and expansion microscopy (U-Ex-STED) analyses of fixed tissues. They conclude that centriole elimination begins with the loss of SAS-1 from the central region of the centrioles, which correlates with the widening of the structure and the loss of the centriole MTs. A remnant structure containing several core centriole proteins remains, however, and this often ultimately detaches from the nuclear envelope and moves towards the plasma membrane in a MT-motor-dependent fashion before it dissipates (although detachment from the nucleus does not seem to be required for the eventual elimination of this residual structure). Intriguingly, centriole loss in this system does not appear to require the down-regulation of PLK activity, which is in contrast to the situation in Drosophila oogenesis.
The manuscript is generally well written and the data is of a high quality and is logically and clearly presented. Although the ultimate mechanisms regulating centriole elimination remain obscure (i.e. what triggers the loss of SAS-1, and how is this regulated?), the data presented here will be of significant interest to the centriole/centrosome field and I am supportive of publication. I have a few points that the authors should consider prior to publication.
Major comment:
In the EM shown in Figure 5F the authors claim that the central tube of the centriole is disrupted, but the other elements (inner tube, MTs and paddlewheel) are not. I don't think this is as clear cut as the authors claim-at least from comparing the images of the one normal centriole (5E) and one centriole that is starting to be eliminated (5F). It seems much harder to distinguish the MTs and the inner tube in the image in 5F. Perhaps this is obvious to the authors as they have compared many more images, but I think they need to find some way of showing this more convincingly (a montage of multiple centrioles)?
We understand that Figure 5F alone may have left the reviewer wondering whether the central tube is truly the first element to be disrupted during centriole elimination. We plan on strengthening this point by providing additional EM images as a Supplemental Figure.
This same issue is compounded in Figure 6D where, using a different technique (U-Ex-STED), the authors claim that the centriolar distribution of SAS-1 is gradually disrupted as centriole elimination proceeds. It does look like the amount of SAS-1 has decreased from early prophase to late pachytene, but the central tube it stains doesn't look particularly disrupted and, if anything, the MTs look more disrupted (and also possibly of lower intensity, perhaps explaining why the ratio of SAS-1/tubulin doesn't change very much over these stages, as shown in Figure 6G).
As the reviewer correctly noticed, there is some variability in central tube removal during oogenesis. In some cases, such as in the centriole on the right of the late pachytene panel in Fig. 6D, SAS-1 signal intensity diminishes uniformly, without apparent holes in the central tube. By contrast, in other cases, such as in the centriole on the left of the late pachytene panel, SAS-1 signal intensity diminution is accompanied by a loss of central tube continuity. We will clarify the writing and qualify our findings on this important point in the revised manuscript.
These points are important, as throughout the manuscript the authors assume it as a fact that SAS-1 leaves the centriole early (which is clear), and that this leads to the specific loss of the central tube (which, at least on the basis of this data, is not so clear).
As mentioned above, we will make certain that the results linking SAS-1 departure and central tube loss are explained in a clear and balanced manner in the revised manuscript.
Minor comments:
- The authors state that the kinetics of GFP-SAS-7 or SAS-4 loss were not altered in pcmd-1 mutants (Figure 4A-C; Figure S3E,F). This doesn't look correct to me, as both proteins seem to stay brighter for longer in the mutant embryos (and this is quite easy to see on the quantification graph for SAS-7 in Figure 4C). It looks similar for SAS-4 from the pictures shown in Figure S3E,F, although this data is not quantified (and is there any reason why this data is not quantified?).
As mentioned in response to reviewers 1 and 3, we will mention in the revised manuscript that a mild developmental delay can impact the number of maturing oocytes present in the proximal gonad, thereby leading to this slight shift in GFP::SAS-7 and GFP::SAS-4 persistence.
- The authors state that they demonstrate that SAS-1 is the first component to leave the disassembling centrioles. I would rephrase as they can't know this for sure (i.e. there could be some untested component that leaves earlier).
In response to this suggestion and to the related comment of reviewer 1 (see above), we will rephrase this sentence to read “among the centriolar components analyzed to date, SAS-1 is the first to depart”.
In the latter part of the Discussion the authors state that SAS-1 is critical for centriole elimination. I would rephrase, as this seems to suggest it is required for centriole elimination, which is not the case. It might also be worth discussing that the elimination machinery clearly seems to target SAS-1 early on, but we don't yet know what this machinery is or how it is regulated.
We thank the reviewer for raising this important point, which we will implement in the Discussion accordingly.
Reviewer #2 (Significance (Required)):
The manuscript is generally well written and the data is of a high quality and is logically and clearly presented. Although the ultimate mechanisms regulating centriole elimination remain obscure (i.e. what triggers the loss of SAS-1, and how is this regulated?), the data presented here will be of significant interest to the centriole/centrosome field and I am supportive of publication. I have a few points that the authors should consider prior to publication.
Reviewer #3 (Evidence, reproducibility and clarity (Required)):
Pierron et al. uses C. elegans oocytes to tackle a fundamental, yet heavily under-studied question in developmental biology: how are centrioles are eliminated during gamete formation/maturation? The paper's main conclusion is that SAS-1 (a key protein that make up the central tube in C. elegans centrioles) plays a critical part to regulate the timing of centriole elimination. I congratulate the authors on all the experiments related to SAS-1 part of their story, as they are done meticulously and in unprecedented detail (particularly all the fascinating EM and expansion microscopy data!).
The paper also concludes that the Polo-like kinase family does not have a central role in this process, in stark contrast to a previous report demonstrating their importance for centriole elimination in Drosophila oogenesis (Pimenta-Marques et al. 2016 Science). Unfortunately, I am less convinced about this part of the paper, and half of my major comments below relate to the experiments/analyses in this regard. I was similarly not very enthusiastic about a part of story that I didn't find very relevant to the main point of the paper: half of the centrioles detach from the nucleus and translocate to plasma membrane prior to their elimination. I find the observations here quite epiphenomenal and lacking a direct/mechanistic relevance to either the PLK or SAS-1 part of the story. In my view, the authors should consider taking this part out.
Regarding this last suggestion: we think that even if the movement of centrioles remnant is not essential for final removal, an account of this process provides important information about cellular dynamics during oocyte maturation. We note also that the two other reviewers did not raise this point, but leave the final decision to the editor.
Overall, the piece is well written and organized, however it suffers from several shortcomings that preclude it from publication in its current form. I list my criticisms and suggestions below.
Major comments:
- The authors state firmly at several places in the text that PCM components do not contribute to the timing of centriole elimination (e.g., lines 420-421), particularly given their experiments with Polo kinase paralogs. In my view, the data speaks otherwise. The centriole elimination process appears strikingly premature when SPD5__1__ (another PCM component) is overexpressed with the fluorescent transgene (Figure 1I). The opposite is also true - when another PCM component, PCMD-1, is knockdown by a temperature sensitive allele, the centriole elimination process is severely delayed 2 (Figure 4C). Even more extremely in the epistatic Polo mutant conditions (Fig. S3B), the centrioles do not appear to be eliminated at all__3__ (though the authors prefer to interpret this result differently in line 260-263, which could be flawed per my second comment below). How do the authors explain all these intriguing results? (underlining and numbering added above to clarify our responses point by point hereafter)
1 > We respectfully disagree, since our quantifications show clearly that the SAS-7 signal disappears with an analogous timing in the line expressing RFP::SPD-5 (Fig. 1J) when compared to the other lines (Fig. 1D, 1F and 1H). The image shown currently for RFP::SPD-5 (Fig. 1I) is somewhat of an outlier compared to the others (Fig. 1C, 1E and 1G), and we will therefore provide a more representative specimen in the revised manuscript to avoid confusion.
2 > As mentioned also in response to reviewers 1 and 2, we realize that we were not sufficiently clear in explaining that RME-2 accumulation reflects the maturation state of oocytes. In the revised manuscript, we will clarify this point and mention that a mild developmental delay (such as in pcmd-1(t3421ts) mutant animals) can impact the number of maturing oocytes present in the proximal gonad, and thereby lead to a slight shift in RME‑2::GFP distribution (as opposed to representing a delay in centriole elimination in pcmd-1(t3421ts) mutant animals).
3 > We used plk-1(or683ts); plk-2(ok1936) double mutants to further test whether there might be premature elimination in this strong reduction-of-function condition compared to RNAi-mediated depletion. Although centriolar foci appear to remain for a longer time, these gonads are extremely disorganized, so that our conclusion regarding PLK-1 and PLK-2 are based primarily on the combined data shown in Fig. 3 and Fig. S3, which do not exhibit premature centriole elimination. We will rectify the writing to clarify these points.
Also, I believe these claims (on the PCM components and their role in centriole elimination) will benefit from more nuanced statements. For instance, although Plk paralogs may not be necessary for the centriole elimination process, some other centrosome components clearly are. Paradoxically, the effects observed here (when disrupting or promoting PCM formation) has the totally opposite effects observed in Pimenta-Marques et al. 2016 Science. The 2016 piece claimed that the loss of PCM renders centrioles more vulnerable to losing their stability (which makes sense). How do the authors interpret their own results (i.e. that a disturbed PCM leads to slower centriole elimination, and vice versa)?
As suggested by the reviewer, we will consider toning down claims regarding the role of PCM components in centriole elimination. Moreover, we will expand the section in the Discussion comparing our results with the published work of Pimenta-Marques et al. in Drosophila. This being written, as mentioned above, our findings do not suggest that removing the PCM (in pcmd-1(t3421ts) mutant animals) alters centriole elimination timing in C. elegans.
I invite the authors to more carefully tread these nuances throughout their manuscript, which otherwise may cast major doubt on their claims.
See point above.
- When investigating the role of Polo-like kinases, the authors assume that centriole elimination must follow (or correlate with) the dynamics of RME-2 (as a proxy for oocyte maturation). What guarantees that the centriole elimination process has to follow oocyte maturation? As far as I could tell, there is no direct evidence presented in the paper about this point. Do the authors have direct data (or reference to another work) that this trend must hold true at all times? I can readily see several places in the paper where this correlation doesn't appear to hold (e.g., in Fig. 4D the centriole elimination precedes the oocyte maturation under pcmd-1 condition).
We will provide further data supporting the view that oocyte maturation and centriole elimination are correlated, whereby premature oocyte maturation mutants, such as let-60(ga89ts) and kin-18(ok395), exhibit precocious elimination.
To correctly interpret their results on the epistatic Polo mutants, the authors could examine centriole elimination timing with mutants that can pre-maturely trigger or delay oocyte maturation (and do so without affecting the centriole biology itself).
See above point.
- Lines 155-159 on the dimness of the SAS-6 signal make me worried about how successfully the transgenes were generated. Could the authors comment on, or perhaps extend in detail in the Methods section, through what assays the transgenes were validated? For example, did the authors try to rescue a SAS-6-/- with a SAS-6::GFP transgene? I would like to see further support for their validities.
We will explicitly explain in the Material and Methods section that the SAS-6::GFP transgene indeed rescues the sas-6 null phenotype.
If the authors can demonstrate the validity of their transgenes more reliably, could they possibly comment on the bunch of seemingly random SAS-6::GFP foci in Fig. 1G?
We will comment on the presence of small SAS-6::GFP foci in the most mature oocytes, which correspond to potential precursors of centriolar elements later assembled in the embryo.
- Starting from line 204, the authors use the percentage of oocytes with detached centrioles (from the nucleus) as a proxy for movement to plasma membrane. This can be very confounding in my view (due to erroneous detachments etc.). As the authors explicitly state that the detachment is a process followed by a directed movement (with a defined velocity) towards the plasma membrane, this calls for a much better measurement in general. The authors should directly measure how far the centrioles are from the closest plasma membrane region in each condition they are examining (and should do this as a function of the "time progression" in different oocytes as they get closer to fertilization).
As mentioned above, we think that an account of the movement of centriole remnants provides important information about cellular dynamics during oocyte maturation. However, given that this movement is not essential for the elimination of such remnants, it appears that providing additional complex 3D analysis as suggested by the reviewer will not benefit the present manuscript.
Do the authors observe any propensity in sas1(t1521ts) oocytes as to where the centrioles are being degraded more prominently in the cytoplasm (i.e., when attached to the nucleus vs. when near the plasma membrane)? They could perform analyses à la their assessments in Fig. S2 and see whether they can extract some more information about this. In other words, I am wondering whether SAS-1 regulates the centriole elimination process more prominently at near the nucleus or near the plasma membrane.
Centriole elimination occurs during pachytene in sas-1(t1521) mutant animals, when nuclei are packed in the gonad and surrounded by little cytoplasm. Therefore, even if foci were to detach from nuclei at this stage, we would not be able to quantify it with certainty. We will discuss these points in the revised manuscript.
I ask this because the section about "centrioles moving to plasma membrane" appears epiphenomenal and rather random (i.e., the chances of a centriole moving to plasma membrane appears 50-50 under some control conditions - see control RNAi in Fig. 2G for example). Could the authors explore their existing data more closely (like suggested above), to see whether they could find intriguing correlations that tells us a little more about whether the centriole elimination at these two places are achieved differently? Otherwise, I frankly do not think this section contributes significantly to the essence of the story.
We apologize for the confusion our writing seems to have generated. The chances of moving to the plasma membrane are not 50-50. The actual figure is 78.7% (reported as ~80% in the manuscript, line 187), and stems from the live imaging experiments where every travelling event can be monitored. By contrast, the analysis of fixed specimens is an underestimate as it provides only a snapshot of a dynamic process. We will expand the writing in the revised manuscript to clarify this point.
Finally, the statements about a deterministic function for the plasma membrane re-localization should be toned down, because unlike what the authors claim in the paper (that ~80% of the centrioles move to plasma membrane), the control data (in Fig. 2B) clearly demonstrates that this number is more like ~60% (hence close to its chances being 50-50).
Please see response just above.
The paper carefully quantifies most of the data (for which I sincerely congratulate the authors!), however the experiments in Fig. S3 fall short of this. It would be nice if the authors could do the same here for completion.
We will provide quantifications for Fig. S3E and S3F. However, due to the high disorganization of plk-1(or683ts); plk-2(ok1936) gonads, the presence of centriolar foci relative to oocyte position cannot be quantified accurately in this case.
Minor comments:
- Sentence in lines 110-113 is too long and perturbs the flow. This should be shortened or be broken into better clauses. Perhaps the following way? "Prior analysis of centriole elimination in C. elegans oogenesis uncovered that this process takes place during diplotene..."
The text will be modified accordingly.
What are the orange arrowheads in the figure panels? They are not stated explicitly in the figure legends. My prediction was that they point to regions where centrioles are in another plane (though the overview is depicted from a different slice in the stack). Is this right? Either way, it will be useful to over-guide the reader on these orange arrowheads.
The meaning of the orange arrowheads is explained in lines 520-521.
If I am not wrong, the data/graph in Figures S2G and 2E are essentially the same (i.e., the data are duplicated). I couldn't find any statement in the figure legends indicating this. This should be added.
Apologies about this oversight -the reviewer is correct and we will make a mention of this redundancy in the legend of Fig. S2.
Some may consider the discussion on C2CD3 a little far-fetched, as this protein localizes to the distal end of centrioles (completely unlike SAS-1). Also, unlike the C. elegans centrioles, mammal centrioles do not contain a discernible central tube, casting doubt on the possibility of speculations made in the Discussion section. I suggest to remove out this paragraph, and instead to explicitly state whether the SAS-1 dependent mechanism could be applicable to other species is unclear.
We will nuance these thoughts, further stressing their speculative nature, but intend to maintain them in some form as they provide a potential parallel that will be of interest to the human cell biology community.
Could the authors add in their Discussion section some comment/thought on what the remaining GFP::SAS-7 pool (line 300-302) might possibly be? Curiously, there doesn't seem to be any structure associated with it in their EM tomograms, so it would be helpful to guide the reader further on this interesting finding.
Although we would love to comment on this further, the remaining GFP::SAS-7 foci lack ultrastructural organization and do not exhibit recognizable electron densities. That this is the case will be stated explicitly in the revised manuscript.
Reviewer #3 (Significance (Required)):
General Assessment: This paper's strength is in its rigorous cell biology approaches to tackle a fundamental developmental biology problem. However, some of their conclusions are too firm while not being well-supported by the data, so the paper requires major revision before its publication.
Advance: Discovery of a new molecular player in the centriole elimination process in worm oocytes, which can pave the way for future discoveries of centriole elimination mechanisms in other species. It is not yet clear whether the results will be broadly applicable, as some of the findings presented are in stark contrast to previous studies published on centriole elimination processes in Drosophila oocytes (e.g., Pimenta-Marques et al. 2016 Science). However, as summarized in the above section, these conclusions require further experimental evidence/support.
Audience: Centriole elimination mechanisms are not widely studied, so I am not entirely sure whether this piece will be of immediate interest to the broad cell biology community. It will certainly be of general interest to several groups studying centriole elimination mechanisms, as well as developmental biologists trying to understand the oocyte maturation process.
My expertise: Molecular and cellular mechanisms of cytoplasmic organization in development
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Pierron et al. uses C. elegans oocytes to tackle a fundamental, yet heavily under-studied question in developmental biology: how are centrioles are eliminated during gamete formation/maturation? The paper's main conclusion is that SAS-1 (a key protein that make up the central tube in C. elegans centrioles) plays a critical part to regulate the timing of centriole elimination. I congratulate the authors on all the experiments related to SAS-1 part of their story, as they are done meticulously and in unprecedented detail (particularly all the fascinating EM and expansion microscopy data!).
The paper also concludes that the Polo-like kinase family does not have a central role in this process, in stark contrast to a previous report demonstrating their importance for centriole elimination in Drosophila oogenesis (Pimenta-Marques et al. 2016 Science). Unfortunately, I am less convinced about this part of the paper, and half of my major comments below relate to the experiments/analyses in this regard. I was similarly not very enthusiastic about a part of story that I didn't find very relevant to the main point of the paper: half of the centrioles detach from the nucleus and translocate to plasma membrane prior to their elimination. I find the observations here quite epiphenomenal and lacking a direct/mechanistic relevance to either the PLK or SAS-1 part of the story. In my view, the authors should consider taking this part out.
Overall, the piece is well written and organized, however it suffers from several shortcomings that preclude it from publication in its current form. I list my criticisms and suggestions below.
Major comments:
- The authors state firmly at several places in the text that PCM components do not contribute to the timing of centriole elimination (e.g., lines 420-421), particularly given their experiments with Polo kinase paralogs. In my view, the data speaks otherwise. The centriole elimination process appears strikingly premature when SPD5 (another PCM component) is overexpressed with the fluorescent transgene (Figure 1I). The opposite is also true - when another PCM component, PCMD-1, is knockdown by a temperature sensitive allele, the centriole elimination process is severely delayed (Figure 4C). Even more extremely in the epistatic Polo mutant conditions (Fig. S3B), the centrioles do not appear to be eliminated at all (though the authors prefer to interpret this result differently in line 260-263, which could be flawed per my second comment below). How do the authors explain all these intriguing results?
Also, I believe these claims (on the PCM components and their role in centriole elimination) will benefit from more nuanced statements. For instance, although Plk paralogs may not be necessary for the centriole elimination process, some other centrosome components clearly are. Paradoxically, the effects observed here (when disrupting or promoting PCM formation) has the totally opposite effects observed in Pimenta-Marques et al. 2016 Science. The 2016 piece claimed that the loss of PCM renders centrioles more vulnerable to losing their stability (which makes sense). How do the authors interpret their own results (i.e. that a disturbed PCM leads to slower centriole elimination, and vice versa)?
I invite the authors to more carefully tread these nuances throughout their manuscript, which otherwise may cast major doubt on their claims. 2. When investigating the role of Polo-like kinases, the authors assume that centriole elimination must follow (or correlate with) the dynamics of RME-2 (as a proxy for oocyte maturation). What guarantees that the centriole elimination process has to follow oocyte maturation? As far as I could tell, there is no direct evidence presented in the paper about this point. Do the authors have direct data (or reference to another work) that this trend must hold true at all times? I can readily see several places in the paper where this correlation doesn't appear to hold (e.g., in Fig. 4D the centriole elimination precedes the oocyte maturation under pcmd-1 condition).
To correctly interpret their results on the epistatic Polo mutants, the authors could examine centriole elimination timing with mutants that can pre-maturely trigger or delay oocyte maturation (and do so without affecting the centriole biology itself). <br /> 3. Lines 155-159 on the dimness of the SAS-6 signal make me worried about how successfully the transgenes were generated. Could the authors comment on, or perhaps extend in detail in the Methods section, through what assays the transgenes were validated? For example, did the authors try to rescue a SAS-6-/- with a SAS-6::GFP transgene? I would like to see further support for their validities.
If the authors can demonstrate the validity of their transgenes more reliably, could they possibly comment on the bunch of seemingly random SAS-6::GFP foci in Fig. 1G? 4. Starting from line 204, the authors use the percentage of oocytes with detached centrioles (from the nucleus) as a proxy for movement to plasma membrane. This can be very confounding in my view (due to erroneous detachments etc.). As the authors explicitly state that the detachment is a process followed by a directed movement (with a defined velocity) towards the plasma membrane, this calls for a much better measurement in general. The authors should directly measure how far the centrioles are from the closest plasma membrane region in each condition they are examining (and should do this as a function of the "time progression" in different oocytes as they get closer to fertilization).<br /> 5. Do the authors observe any propensity in sas1(t1521ts) oocytes as to where the centrioles are being degraded more prominently in the cytoplasm (i.e., when attached to the nucleus vs. when near the plasma membrane)? They could perform analyses à la their assessments in Fig. S2 and see whether they can extract some more information about this. In other words, I am wondering whether SAS-1 regulates the centriole elimination process more prominently at near the nucleus or near the plasma membrane.
I ask this because the section about "centrioles moving to plasma membrane" appears epiphenomenal and rather random (i.e., the chances of a centriole moving to plasma membrane appears 50-50 under some control conditions - see control RNAi in Fig. 2G for example). Could the authors explore their existing data more closely (like suggested above), to see whether they could find intriguing correlations that tells us a little more about whether the centriole elimination at these two places are achieved differently? Otherwise, I frankly do not think this section contributes significantly to the essence of the story.
Finally, the statements about a deterministic function for the plasma membrane re-localization should be toned down, because unlike what the authors claim in the paper (that ~80% of the centrioles move to plasma membrane), the control data (in Fig. 2B) clearly demonstrates that this number is more like ~60% (hence close to its chances being 50-50). 6. The paper carefully quantifies most of the data (for which I sincerely congratulate the authors!), however the experiments in Fig. S3 fall short of this. It would be nice if the authors could do the same here for completion.
Minor comments:
- Sentence in lines 110-113 is too long and perturbs the flow. This should be shortened or be broken into better clauses. Perhaps the following way? "Prior analysis of centriole elimination in C. elegans oogenesis uncovered that this process takes place during diplotene..."
- What are the orange arrowheads in the figure panels? They are not stated explicitly in the figure legends. My prediction was that they point to regions where centrioles are in another plane (though the overview is depicted from a different slice in the stack). Is this right? Either way, it will be useful to over-guide the reader on these orange arrowheads.
- If I am not wrong, the data/graph in Figures S2G and 2E are essentially the same (i.e., the data are duplicated). I couldn't find any statement in the figure legends indicating this. This should be added.
- Some may consider the discussion on C2CD3 a little far-fetched, as this protein localizes to the distal end of centrioles (completely unlike SAS-1). Also, unlike the C. elegans centrioles, mammal centrioles do not contain a discernible central tube, casting doubt on the possibility of speculations made in the Discussion section. I suggest to remove out this paragraph, and instead to explicitly state whether the SAS-1 dependent mechanism could be applicable to other species is unclear.
- Could the authors add in their Discussion section some comment/thought on what the remaining GFP::SAS-7 pool (line 300-302) might possibly be? Curiously, there doesn't seem to be any structure associated with it in their EM tomograms, so it would be helpful to guide the reader further on this interesting finding.
Significance
General Assessment: This paper's strength is in its rigorous cell biology approaches to tackle a fundamental developmental biology problem. However, some of their conclusions are too firm while not being well-supported by the data, so the paper requires major revision before its publication.
Advance: Discovery of a new molecular player in the centriole elimination process in worm oocytes, which can pave the way for future discoveries of centriole elimination mechanisms in other species. It is not yet clear whether the results will be broadly applicable, as some of the findings presented are in stark contrast to previous studies published on centriole elimination processes in Drosophila oocytes (e.g., Pimenta-Marques et al. 2016 Science). However, as summarized in the above section, these conclusions require further experimental evidence/support.
Audience: Centriole elimination mechanisms are not widely studied, so I am not entirely sure whether this piece will be of immediate interest to the broad cell biology community. It will certainly be of general interest to several groups studying centriole elimination mechanisms, as well as developmental biologists trying to understand the oocyte maturation process.
My expertise: Molecular and cellular mechanisms of cytoplasmic organization in development
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary
In this manuscript Pierron et al. explore the mechanisms of centriole elimination during oogenesis in C. elegans. Centriole elimination is a common feature of oogenesis in many species, but it is relatively poorly understood and understudied. Here, the authors characterise the kinetics with which several key centriole and centrosome proteins are lost during this process in living worms, and they correlate this with an EM and expansion microscopy (U-Ex-STED) analyses of fixed tissues. They conclude that centriole elimination begins with the loss of SAS-1 from the central region of the centrioles, which correlates with the widening of the structure and the loss of the centriole MTs. A remnant structure containing several core centriole proteins remains, however, and this often ultimately detaches from the nuclear envelope and moves towards the plasma membrane in a MT-motor-dependent fashion before it dissipates (although detachment from the nucleus does not seem to be required for the eventual elimination of this residual structure). Intriguingly, centriole loss in this system does not appear to require the down-regulation of PLK activity, which is in contrast to the situation in Drosophila oogenesis.
The manuscript is generally well written and the data is of a high quality and is logically and clearly presented. Although the ultimate mechanisms regulating centriole elimination remain obscure (i.e. what triggers the loss of SAS-1, and how is this regulated?), the data presented here will be of significant interest to the centriole/centrosome field and I am supportive of publication. I have a few points that the authors should consider prior to publication.
Major comment:
In the EM shown in Figure 5F the authors claim that the central tube of the centriole is disrupted, but the other elements (inner tube, MTs and paddlewheel) are not. I don't think this is as clear cut as the authors claim-at least from comparing the images of the one normal centriole (5E) and one centriole that is starting to be eliminated (5F). It seems much harder to distinguish the MTs and the inner tube in the image in 5F. Perhaps this is obvious to the authors as they have compared many more images, but I think they need to find some way of showing this more convincingly (a montage of multiple centrioles)?
This same issue is compounded in Figure 6D where, using a different technique (U-Ex-STED), the authors claim that the centriolar distribution of SAS-1 is gradually disrupted as centriole elimination proceeds. It does look like the amount of SAS-1 has decreased from early prophase to late pachytene, but the central tube it stains doesn't look particularly disrupted and, if anything, the MTs look more disrupted (and also possibly of lower intensity, perhaps explaining why the ratio of SAS-1/tubulin doesn't change very much over these stages, as shown in Figure 6G).
These points are important, as throughout the manuscript the authors assume it as a fact that SAS-1 leaves the centriole early (which is clear), and that this leads to the specific loss of the central tube (which, at least on the basis of this data, is not so clear).
Minor comments:
- The authors state that the kinetics of GFP-SAS-7 or SAS-4 loss were not altered in pcmd-1 mutants (Figure 4A-C; Figure S3E,F). This doesn't look correct to me, as both proteins seem to stay brighter for longer in the mutant embryos (and this is quite easy to see on the quantification graph for SAS-7 in Figure 4C). It looks similar for SAS-4 from the pictures shown in Figure S3E,F, although this data is not quantified (and is there any reason why this data is not quantified?).
- The authors state that they demonstrate that SAS-1 is the first component to leave the disassembling centrioles. I would rephrase as they can't know this for sure (i.e. there could be some untested component that leaves earlier).
- In the latter part of the Discussion the authors state that SAS-1 is critical for centriole elimination. I would rephrase, as this seems to suggest it is required for centriole elimination, which is not the case. It might also be worth discussing that the elimination machinery clearly seems to target SAS-1 early on, but we don't yet know what this machinery is or how it is regulated.
Significance
The manuscript is generally well written and the data is of a high quality and is logically and clearly presented. Although the ultimate mechanisms regulating centriole elimination remain obscure (i.e. what triggers the loss of SAS-1, and how is this regulated?), the data presented here will be of significant interest to the centriole/centrosome field and I am supportive of publication. I have a few points that the authors should consider prior to publication.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Centrioles are small cylindrical structures with roles in cell division, motility, and signaling. Typically, centrioles are highly stable structures which can persist for many cell generations. However, in some cells, such as the female germ line of many species, centrioles are programmed for elimination. This process is essential for maintaining centriole number from one generation to the next in sexually reproducing organisms, yet in nearly all species the molecular mechanisms underlying how centrioles are eliminated is unknown. The current study utilizes the nematode C. elegans to explore how centriole architecture changes during the elimination program in the female germ line. Using a suite of light microscopy techniques, the authors provide a stunning visual perspective of how centrioles are disassembled during oogenesis and show that removal of the central tube component SAS-1, a key regulator of centriole stability, is an early event in elimination. I have no major objections to the work and enthusiastically endorse its publication with the following minor revisions.
Page 9 line 200: In the pcmd-1 mutant, the authors state that centriolar foci devoid of nuclei are present in rachis, but they do not mention in the text that there are also nuclei that lack centriole foci in early pachytene. This is mentioned in the figure legend, but I felt it was important enough to mention in the text.
Page 9 line 211. The authors found that in the absence of dynein heavy or light chain that centrioles remain associated with the nuclear envelope (rather than moving to the periphery). To me this was striking as dynein depletion in the embryo results in the opposite phenotype with centrioles losing attachment to the nuclear envelope and moving to the cell periphery (Gonczy et al. 1999 JCB 147:135). It might be worth pointing this out somewhere in the manuscript and speculating about the reasons for this difference.
Page 11 line 277: The authors state that elimination timing is not affected by the loss of SPD-5. This is a small but important point. It really is the absence of PCMD-1 and not SPD-5, as SPD-5 is still present in the cell. An alternative would be to say "in the absence of PCM" or "in absence of a pericentriolar accumulation of SAS-5".
Figure 4D: Why does loss of PCMD-1 result in a delay in oocyte maturation as judged by RME-2 accumulation? This is not mentioned in the paper. Is this a general response to a loss of PCM or is this specific to a loss of PCMD-1?
Figure 7 E and F. The authors measure the tubulin and SAS-4 intensity in wild-type and sas-1(t1521) embryos and conclude that microtubules and SAS-4 signals decay faster in the sas-1 mutant than in the control. To me, this is convinceingly the case with microtubules in panel E but I am not so sure this is the case with SAS-4 as shown in panel F. The differences in SAS-4 levels are much smaller between mutant and control. Could the authors provide statistical analysis to show how significant the differences are?
Page 15 line 363. I think this sentence should be reworded to: "Finally, we demonstrate that the central tube protein SAS-1 is the first of the factors analyzed here to leave centrioles..."
Significance
The work contained in this manuscript represents a fundemental step forward in understanding the process of centriole elimination. The authors have carefully described the stepwise disassembly of the centriole including changes in the architechure during oogenesis. They have identified loss of the centriole stability factor SAS-1, as an early event in the elimination program and have found that in a sas-1 mutant, the centriole disassembles prematurely. They have also shown that loss of SAS-1 is followed by expansion of the centriole and ultimately loss of structural integrity. This work should be of interest to a broad range of scientists including those interested in centrosome dynamics, germ line development, and more generally cell biologists.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
To simplify the reading of our answers, we have numbered the questions of the reviewers. Similarly, to make the identification of the changes easier, we have written the changes in the manuscript in blue, orange and green when they were asked by reviewer 1, 2 or 3 respectively.
__Reviewer #1 __
Major comments:
-
One issue concerns the conclusion that microglial TNFa signaling shapes slow waves during NREM sleep (e.g., title; lines 148, 175-176; 180; 222-223; 288) on the basis of the data shown in Fig. 4b-d. Slow waves normally consist of two components, The amount of changes reported in the study might indeed seem small if the role of microglia was to gate slow-wave-sleep itself. In contrast, the effects we report are in the upper range of the modulations reported for NREM sleep slow-waves: depletion of microglial TNFα yielded a ~17 % decrease (relative to controls) in maximal slope (fig 4d); while sleep deprivation or physiological sleep-wake cycle have been associated with similar changes in the slope of slow-waves:
-
6% increase after sleep deprivation and 17% increase after SOM-IN optogenetic stimulation (Funk et al. 2017, ref 17);
- 15% above or below average in early and late sleep (Vyazovskiy et al. 2007, ref 79);
- Daily fluctuation of the slow-wave slope is smaller that 15% (Hubbard et al. 2020, ref 50). Noteworthy, as noticed by this reviewer, slow saves consist of slow oscillations and delta waves. We also measured the slope and duration of slow oscillations and delta waves and found significant differences in both between control and micTNFα-KO mice. (see response to Reviewer 2 point 8).
The change in delta peak reported here following microglial TNFα depletion reveals a pre-eminence of slower waves (“d1” waves 0.75-1.75Hz), over the faster waves (“d2” waves 2.5-3.5Hz) the latter being the main form of oscillations potentiated by sleep need (Hubbard et al. 2020; ref 50). Similarly, enhanced SW-slope and short SW-period is associated with high sleep need (Hubbard et al. 2020; ref 50) and we found that microglial TNFα depletion reduces SW slope and enhances SW duration. Together, these results suggest a role of microglial TNFα in modulating delta oscillations in response to sleep need, which gives further support to our recent publication on the role of microglia in the expression of sleep need and sleep homeostasis (Pinto et al 2023; ref 80). Accordingly, we have now replaced in the figure 4 the panel 4b with the value of the peak of delta (whose significance is less clear) with the ratio of power in the two delta bands which has a clearer interpretation in light of the work cited above. Figure 4b and the text were changed accordingly (line 161 of the results and line 277 in the discussion). Similarly, microglia may contribute to changes in SWA related to memory consolidation following intense recruitment of cortical circuits (Huber et al. 2004, ref 83). This is now more clearly stated in the text (line 292).
We do not claim to have demonstrated that the change in slow oscillations fully explains the loss of memory consolidation, but instead we report the convergent findings that TNFa depletion in microglia produces alterations in sleep slow oscillations of the order of magnitude of sleep-need induced effects, and disrupts memory consolidation known to be sleep-dependent.
VGAT was used to identify GABAergic synapses in conjunction with GABAA receptors. Of various GABAergic interneurons, somatostatin (SOM)-containing GABAergic interneurons are known to be crucial for generating slow waves during NREM sleep through their axon terminals that target and concentrate in L1 (e.g., Funk et al., 2017, ref. 17). However, not all GABAA receptors in L1 would be associated with the inputs from SOM-containing GABA interneurons. For example, there are parvalbumin-containing GABA interneurons and their activation has been reported to DECREASE slow waves (Funk et al. 2017). This is relevant and should be discussed in relation to the results.
Answer: As pointed out by the reviewer, we do acknowledge that not all GABAergic synapses in L1 are associated to inputs of SOM+ interneurons. Other than the axonal projections of SOM+ interneurons, axons of the inhibitory neuronal types neurogliaform cells and canopy cells can be found in L1. This does not seem to be the case for PV+ interneurons whose somata is not located in L1 and lack projections to L1 (Schuman et al. 2021 - ref 19). We have now acknowledged and discussed this in the discussion:
Line 285: “In this study we show that L1 inhibitory synapses are modulated by microglia in a sleep-dependent manner. Our data favor the possibility that the microglia-targeted GABAergic synapses arise from SOM-IN. However, inhibition on L1 also originates local axonal arbors of neurogliaform and canopy cells and the identity of the microglia-regulated presynaptic terminals remains to be established.”
To follow up on the above, (1) it is unclear why NeuN was used to delineate cell bodies (Fig. 1e). In fact, SOM-containing GABA neurons (see above) have been shown to inhibit pyramidal neurons through presynaptic inhibition of excitatory inputs as well as postsynaptic inhibition of dendrites, but not cell bodies, of pyramidal neurons (see Funk et al. 2017 for references). Some discussion along this line would be useful and potentially important. (2) In addition, it would have been interesting to add an immunolabel for SOM to identify SOM-containing axon terminals associated with VGAT (Figs 1, 2), and this could be done for parvalbumin (see above) terminals as well; however, this analysis is optional and not required.
Answer:
- The rationale for analyzing GABAergic synapses in L5 was to assess whether the daily change in synaptic GABAAR observed in L1 had some degree of regional specificity or was rather a widespread event throughout the cortical layers. In this regard, NeuN was used to delineate cell bodies in order to assess changes in synaptic GABAARs at somatic synapses, known to be targeted by parvalbumin inhibitory neurons. In addition to the quantification provided in figure 1e, we also analyzed synaptic GABAARs at non-somatic VGAT clusters in L5 and observed no ZT6/ZT18 difference (data not shown).
- We do agree with this reviewer that looking selectively at GABAAR located at somatostatin pre-terminals would be extremely interesting. Accordingly, we have now tried to quantify the synaptic GABAR facing SOM positive presynaptic boutons identified in mice expressing tdTomato in SOM interneurons (figure S3). However, GABAAR immunostaining requires using an antigen retrieval method (see below) that, in our hands, bleaches tdTomato fluorescence. Our attempt to retrieve the lost SOM-tdTomato signal by IHC with RFP antibodies was unsuccessful (see below) suggesting that the structure of tdTomato is altered, thereby preventing such quantification.
Quantification of changes in synaptic GABAARs at synapses targeted by SOM interneurons (SOM-IN) is not technically possible. Top, Confocal images of adult brain cortical layer 1 show signal of GABAARγ2, gephyrin and VGAT obtained with different protocols for tissue processing (fresh-frozen, perfusion with paraformaldehyde and perfusion with paraformaldehyde followed by decloaking chamber-based heat-induced epitope retrieval). Visualization of bona-fide gephyrin+VGAT+ synapses and synaptic GABAAR clusters was only possible by epitope retrieval. Bottom, Confocal images of mice expressing tdTomato in SOM-IN (SOMCre/+R26tdTom/+) show expected signal revealing SOM-tdTomato+ presynaptic boutons after perfusion. When the protocol for epitope retrieval is used, SOM-tdTomato+ signal is lost, which could not be retrieved by IHC with 3 different antibodies (source and catalog number are indicated).
Minor comments:
It appears that n's are not consistently reported. Please check.
Answer: We have now:
-added n’s in the legend of figure 4.
-corrected a typo in the legend of figure 5 (line 664: “(f-i) n= 11” instead of “(f, g) n= 11”).
-in the legend of figure S2, we have added “g. Mean intensity…b-g, n= 53-60 FOVs from 5 mice per group”.
The Y-axis does not start from zero in some graphs. Although this might be a matter of preference, it can be misleading.
Answer: The Y-axis that did not start from zero have now been explicitly signaled (figure 4b, d; figure 5b, d, e)
In the supplementary information PDF, under Immunohistochemistry (IHC): "In direct IHC" in the first line of the paragraph should be "Indirect IHC".
Answer: this is corrected. The sentence now starts by “Cryostat sections…”. Also, “Table 2 – Antibodies and IHC method used” has been corrected accordingly.
__Reviewer #2 __
Major Comments:
1) (1) There are several instances where the authors state the experiments occurred "across the 24 h light/dark cycle" (Lines 42, 139), "during the sleep/wake cycle" (Lines 87, 242, 248), or "during sleep" (Lines 155, 220, 254). These statements are imprecise and can lead to erroneous interpretations of the data. For molecular studies, data were collected at a light period timepoint (Zeitgeber Time (ZT) 6) and a dark period timepoint (ZT18). While I appreciate the comparisons of the light and dark phases, 2 timepoints are not sufficient to claim that phenomena were tested across the light-dark cycle. More importantly, though, it is not accurate to claim outcomes from data collected during ZT6 occurred "during sleep" (or ZT18 outcomes occurred during wake). Although mice sleep more in the light period vs. the dark period, they are polyphasic sleepers and thus can be awake at ZT6 and asleep at ZT18. Therefore, statements should be edited for accuracy to instead state that phenomena were observed at ZT6/ZT18 or light/dark periods. (2) In addition, any figures (e.g., Figure S1) using x-axis labels of "W" and "S" should be relabeled as "ZT18" and "ZT6," respectively.
Answer : (1) We agree with this reviewer and we have consistently corrected these imprecise wordings.
(2) We have relabeled the figure S1 and replaced “W” and “S” by “ZT18” and “ZT6” respectively.
2) The authors claim that microglial TNFα plays a role in sleep-dependent memory consolidation (Title and Lines 20, 22, 178, 198, 224, 276, 288) based on a series of experiments using tests previously shown to have a sleep-dependent consolidation component. However, the authors did not assess sleep-dependent consolidation in the micTNFα-KO and the tCtl mice, and thus this conclusion cannot be drawn. This is because the experimental paradigms did not include sleep deprivation. Claims that outcomes are sleep-dependent need to be shown as absent/impaired after sleep deprivation especially in mutant (and control) lines that have not been previously tested in this context. As such, claims of sleep-dependent memory consolidation (including in the title) should be removed OR new experiments including sleep deprivation should be included.
Answer: Previous studies have shown that in the learning tasks that we have used, memory consolidation is lost in sleep-deprived animals (refs 53 to 55). Our current study indicates that memory consolidation is also lost in micTNFα-KO mice. Thus, we believe it would not be informative to perform sleep-deprivation in micTNFα-KO as requested by this reviewer since the outcomes (loss of memory consolidation) cannot be additive. However, we acknowledge that even though microglial TNFα depletion impacts slow waves that are known to play a causal role in consolidating the memory during sleep (refs 51 and 52), it cannot be excluded that TNFα depletion impairs memory consolidation by a non-sleep dependent pathway. Therefore, we have modified the title of the study to prevent misleading interpretations:
New title: “Microglial TNFα controls synaptic GABAARs, sleep slow waves and memory consolidation”
We have changed wording (lines 225 and 643). We have further added a cautionary note in the discussion:
Line 299 : “We now show that mice lacking microglial TNFα display impaired memory consolidation when tested in a complex rotator motor learning task or in the floor-texture recognition (FTR) task. In these two tasks, memory consolidation is sleep-dependent. This suggests a possible involvement of microglial TNFα in the sleep processes that promote memory consolidation, while leaving open the possibility of a non-sleep-dependent mechanism.”.
We are now more cautious in our conclusion and write (line 313) “This work demonstrates that microglia tune slow waves and support memory consolidation probably by acting during sleep”
3) (1) "This shows that P2RX7 and microglial TNFα drive daily fluctuations in CaMKII Thr286-phosphorylation and are required for sleep-dependent GABAAR synaptic upregulation in L1 during the light phase" (Lines 144 - 146). Similar to the above comment, it cannot be definitively concluded the P2X7R or microglial TNFα are required for sleep-dependent GABAAR synaptic upregulation because sleep deprivation studies were not conducted in the P2rx7-KO or micTNFα-KO mice. (2) Furthermore, there is no analysis (or citation) of P2rx7-KO mice sleep-wake expression nor has the micTNFα-KO sleep data been presented at this point to make any determinations on how (possibly perturbed) sleep-wake expression in these mice could affect the stated outcomes.
Answer:
(1) As discussed in our previous answer, both sleep deprivation (fig 1d) and inactivation of TNFα or P2RX7 (fig 3) completely prevent the synaptic GABAAR accumulation and CaMKII phosphorylation at ZT6. Performing sleep deprivation on micTNFα-KO and P2RX7 KO is thus not expected to exert an effect since the outcomes (loss of synaptic accumulation and phosphorylation of CaMKII at ZT6) cannot be additive. We actually conducted sleep deprivation studies in micTNFα-KO as suggested by this reviewer (see below). As expected however, sleep deprivation (SD6) has no further effect on GABAAR accumulation and CaMKII phosphorylation on micTNFα-KOs when compared to ZT6.
Impact of sleep deprivation on synaptic GABAAR and CaMKII phosphorylation in micTNFα-KO mouse brain. In complement to figure 3, SD prevents that increased accumulation of synaptic GABAARγ2 (left) and CaMKII phosphorylation (right) in tCTR, but has no effect in micTNFα-KO (green).
left: Mean intensity of GABAARγ2 clusters at gephyrin+VGAT+ synapses normalized to ZT18. n= 48 to 65 FOVs from 4-5 mice per group.
Right: Mean intensity of Thr286-phosphorylated CaMKII signal in L1 normalized to ZT18. n= 37 to 50 FOVs from 4-5 mice per group.
(2) Please note that analysis of sleep structure of micTNF-KO mice is shown in figure 4, which reveals “that microglial TNFα has limited effects on sleep-wake patterns as shown by the lack of major alterations in the amounts of wake, NREM and REM sleep between micTNFα-KO and tCTL mice along a light/dark cycle (fig. 4a).” (line 158). Similarly, analysis of baseline sleep-wake structure in P2RX7-KO mice revealed no abnormalities (Krueger et al 2010, ref 45). This has now been discussed in the text (lines 143).
4) There are some details regarding data analysis that are lacking:
-
How were bouts defined for each arousal state? Answer: We have now defined the bouts in the Materials and Methods (section : “Sleep recording and analysis”) : “Bouts were defined as consecutive 10-s epochs of similar vigilance state and could be as short as one epoch.”
-
(1) It seems more details are needed for EEG spectra analysis. From what values was the median derived and over what time period? How was each spectral bin normalized and over what time period? (2) What data (i.e., from what time period and duration) are shown in Figure 4b? Same question for Figure 4c-d? Were these time periods the same for controls and mutants given that NREM SWA changes across the light-dark cycle? Answer:
(1) The spectrum of bouts of 2.56s (512 points at 200Hz) was computed by FFT and the spectrum corresponds to the median of the FFT of all bouts. This information is now in the material and methods section “Spectral analysis”.
(2) The graphs reported in the text correspond to the 24h time period for both tCTL and micTNFα-KO mice. This has now been clearly indicated in figure 4 legend and in the material and methods section “Slow-wave analysis”.
- How was NREM delta power normalized and analyzed and over what time period? Answer: Normalization corresponds to the division for each animal of the spectrum by the total power of the spectrum. Data reported correspond to the 24h time period.
5) Claims that GABAAR enrichment at synapses is sleep-dependent is based primarily on the data presented in Figure 1d reporting no increase in cortical GABAAR after sleep deprivation. A previous study (not cited) showed sleep deprivation increased GABAAR expression in CaMKIIα+ neurons in barrel cortex (Del Cid-Pellitero et al., Front Syst Neurosci, 2017). It would be helpful if the authors cited and discussed this study.
Answer: Indeed, Del Cid-Pellitero et al. show that GABAARs located around the soma of layer 5 neurons are increased upon sleep deprivation. Importantly, they used brain tissue collected after perfusion with paraformaldehyde without antigen retrieval. This protocol was shown to result in uniform surface labeling of GABAARs without staining the pool of receptors clustered at synapses (Gasser et al. 2006 Nature Protocols, PMID: 17487173). In this study we performed antigen retrieval that allows visualization of synaptic GABAARs (see figure 1). We and them are thus labelling different pools of GABAARs: synaptic vs. membrane at the soma level (comprising both synaptic and extrasynaptic). On the other hand, as we did not observe a difference in synaptic GABAARs at the soma level in L5 between ZT6 and ZT18, we did not assess sleep-dependency by performing sleep deprivation in this cortical layer. Together, we do not interpret their results as conflicting to our findings, but rather that different sleep- and wake-dependent mechanism exist to regulate the abundance of GABAARs at the subcellular level. We have now cited this work and include a brief discussion:
Line 58: “Sleep deprivation has previously been shown to increase GABAARs located around excitatory somas60. This suggests that the expression of GABAARs are differentially regulated depending on their subcellular localization”.
6) Some sentences/conclusions are overstatements:
- "...discarding the possibility that lack of synaptic GABAARs enrichment upon PLX3397 treatment results from perturbed sleep during the light phase" (Lines 68 - 69). Only sleep time is reported to make this claim, but bout frequency, bout duration, and EEG spectra could be perturbed with this manipulation. This claim should be edited for accuracy or additional data (e.g., bout and spectral analysis) should be presented. In addition, Line 68 should be edited to state that "...microglia depletion does not alter sleep time during the light phase..." unless additional analyses are provided. Answer: We have now added the bout analysis in microglia depleted mice in extended table 2.
"TNFα, which is mostly if not exclusively produced by microglia in the brain..." (Lines 93 -94). Although microglia are a major source of TNFα, there is evidence other brain cell types also release TNFα. In addition, the citation provided does not support this exclusivity claim.
Answer: The reference 29 (Zeisel et al., reference 28 in the previous version) is a single cell transcriptomic study. The data are available online: http://mousebrain.org/adolescent/genesearch.html and show that TNFα mRNA is only detected in microglia. We are not aware of evidence showing that other brain cell types release TNFα. To our knowledge there is no brain RNA seq repository that shows TNFα expression in other brain cell-types e.g :
- https://celltypes.brain-map.org/rnaseq/mouse_ctx-hpf_smart-seq;
- http://biogps.org/#goto=genereport&id=21926
- http://www.brainrnaseq.org/
- "We thus anticipate that microglial TNFα may control REM by acting at the basal forebrain..." (Line 163). This statement is based on a cited study that reported REMS suppression (and increased NREMS time) after TNFα injection in the subarachnoid space of the basal forebrain. It is unclear to me why this statement is included when ICV and IV TNFα administration also reduce REMS (Shoham et al, Am J Physiol, 1987). Given these data and this statement is not being tested, it does not seem like it needs to be included. It should also be noted a previously reported (but not cited) global TNFα KO mouse (Szentirmai and Kapás, Brain Behav Immun, 2019) also showed increased REMS and REMS bouts, but this seemed to be a dark period phenotype (NREMS and Wake time, bout frequency, and bout duration were unaffected). This is an interesting detail to at least include in the second paragraph of the Discussion. Answer: To comply with this comment, we have now removed the sentence “We thus anticipate…” (line 163, now 160), and we have modified the second paragraph of the discussion so as to include the dark-period specificity described in Szentirmai and Kapás that we now cite.
7) It is unclear to me why the authors believe ATP in these studies has a neuronal origin (Lines 106, 132, 218) when other cell types also release ATP. Is this because of NMDA treatment? If so, NMDA receptors are also expressed on other cell types like astrocytes (Verkhratsky and Chvátal, Neurochemical Research, 2020). Answer: We do not believe and we did not write that ATP has a neuronal origin. Indeed, we wrote:
-line 104: “We next identified the signaling pathway between neuron and microglia”.
-line 130: “ATP released downstream neuronal activity activates microglial P2RX7”
-line 218: “…microglia sense neuronal activity through an ATP/P2RX7 signaling pathway”.
However, to rule out any misinterpretation, we have now added a sentence that explicitly recall the possible involvement of other cell types:
Line 132 “Noteworthy, our results do not exclude the possible involvement of other cell types acting between neurons and microglia”
8) Because the authors rationalize investigating memory consolidation based on micTNFα-KO changes in NREM SWA, I am curious if the authors considered parsing NREM SWA into slow oscillations and delta waves as Vaidyanathan et al (eLife, 2021) did. The reason for this is because slow oscillations are shown to be associated with memory consolidation, but delta waves are associated with weakening memories.
Answer: The parsing between delta waves and slow oscillations (SO) in the Vaidyanathan et al. article is based on a quantile separation of the size of the events (the top 15% of events are called SO while the rest may qualify as delta waves events; this is quite different from our definition which is based on deviations larger than 3 times the estimated standard deviation of slow fluctuations during Wake); it is worth noting that applying the definition from Vaidyanathan et al. to compare groups may introduce a bias in the interpretation if the rate of slow waves is modified between groups of animals. We have performed the parsing of slow events according to Vaidyanathan et al. and found similar changes for Slow Oscillations as using our definition (wider and “slower” SO). The same effect was observed in delta waves, suggesting that microglial TNFα affects both types of slow waves similarly. __ __
9) For the complex wheel task, micTNFα-KO mice seem to start and end with better performance compared to tCTL on S1 (although it is not clear if this difference was statistically evaluated). Would the conclusions from this experiment change if data were normalized to account for the apparent better starting performance? Answer: Despite a trend for a better performance of micTNFα-KO at S1, no significant difference in the mean performance was found between controls and micTNFα-KO mice at S1. We show below the mean performance at S1 and S2 for controls and micTNFα-KO mice. Moreover, learning within each session (both at S1 and S2) is not altered in micTNFα-KO (figure 5c) revealing that the ability to learn is not affected in microglia TNF-KO mice neither in S1 nor in S2 suggesting that memory impairment across sessions is not the result of saturation of learning capacity.
Mean performance in the two sessions (S1 and S2) of the complex wheel learning task in control and micTNFα-KO as measured by the mean time on the complex wheel (in seconds) of all trials in each session. ***p Nevertheless, we acknowledge that the apparent better starting performance could lead to misinterpretation of the results, and so as suggested by this reviewer, we normalized the data to the average of the last 3 trials in session 1 and computed using the normalized values the performance improvement (figure 5d) and consolidation (figure 5e). The same results were obtained. We thus interpret that the differences in memory consolidation between S1 and S2 (fig 5d, e) do not stem from changes in baseline performance.
Results on the complex wheel task following normalization to performance in S1. For each mouse, latency to fall off the complex wheel in each S1 and S2 trials was normalized to the average of the last 3 trials in S1. The normalized values were used to plot the graphs as in figure 5:
Left, latency to fall in S1 and S2;
middle, performance improvement;
right, consolidation of motor learning.
We have now modified figure 5 accordingly.
10) Many of the molecular studies emphasized a layer-specific effect in L1 vs. L5. It would be helpful if the authors could link (at least in the Discussion) this cortical-layer specificity with reported microglial TNFα effects on sleep parameters and memory consolidation.
Answer: According to this comment, we have now proposed a mechanism for the L1 vs L5 specificity in the discussion:
Line 254: “The layer 1 vs layer 5 specificity may arise from the molecular difference of GABAergic synapses across the somato-dendritic arbour as proposed. Alternatively, but not exclusively, it may result from a differential expression of TNF-R1 along the cortical layers and/or from layer-specific behavior of microglia”.
We hope that it will help understand our hypothesis of a link between microglial TNFα effect on upper layer synapses with the effect on sleep parameters and memory consolidation that are proposed from line 277 onwards.
Minor Comments:
1) For the experiments investigating TNF receptor (TNFR) involvement (fig. S5), it would have been interesting to see the response to human recombinant TNFα which interacts with TNFR1 but not TNFR2 whereas mouse recombinant TNFα interacts with both receptors (Lewis et al, PNAS, 1991).
Answer: The differential effect of human and mouse TNFα was not known by us. We do agree with this reviewer that the proposed experiment would have been interesting and would further confirm the data shown in Supp fig 5b showing an involvement of TNFR1 but not of TNFR2.
2) "Synapse plasticity in the sleeping brain likely supports crucial functions of sleep" (Line 33). I believe it is more accurate to instead state sleep supports synapse plasticity. The sentences immediately following also provide examples of sleep/wake mediating plasticity.
Answer: We have now replaced the sentence in line 29 for “Sleep drives plasticity of excitatory synapses”.
3) "Moreover, microglia depletion also abolished the reduction of synaptic AMPA receptor subunit GluA2 at ZT6 (fig. S1)..." (Lines 70 -71). The data in this figure shows an increase GluA2, but the data cited showed decreased excitatory transmission. This discrepancy is not discussed.
Answer: We agree with this reviewer that the we did not discuss the increased GluA2 at synapses upon microglial depletion. However, we believe that this aspect is beyond the scope of this study and although showing the data seemed important, we believed that discussing these data might lose the reader. We have now rephrased this sentence so as not to mislead the reader (line 68):
“Moreover, microglia depletion also reversed the reduction of synaptic AMPA receptor subunit GluA2 at ZT6”
4) If you normalize within treatment (e.g., PLX, SAP, minoc, 4-OHT, apy, PPADS, A74, PSB) rather than to controls (e.g., normalize PLX-iLTP to PLX-bsl instead of CTL-bsl) in Figures 2b-f, 3b-c, do you get the same results? Similarly, if you normalize PLX treatment to CTL ZT18 in Figure 1c-d, do you get the same general outcome?
Answer: As requested by this reviewer, we have normalized to treatment rather than to control for all the experiments shown in figure 2b-f. The graph below with this normalization shows that the same results are obtained.
Concerning figures 1c-d and 3b-c, the normalization suggested cannot be performed because CTL and PLX treated mice or mutant mice were not processed for immunohistochemistry simultaneously, and so intensity values are not comparable.
5) Is there a significance marker missing in Figure 2g for bls vs. BzATP?
Answer: The significance marker it is not missing. Even though the individual experiments performed consistently show an increase in CaMKII T286 phosphorylation with BzATP treatment, the difference does not reach statistical significance between bsl and BzATP using a nested one-way ANOVA followed by Sidak’s multiple comparison test (p=0.09). There was however a typo in the legend of figure 2g about the statistical test used, which has been corrected (lines 611).
6) It is unclear if the fig. 5a callout is the correct one at Line 143. If it is correct, then it is confusing (to me) in the way it is currently associated with the text.
Answer: at line 143 (now 142), the callout is fig S5a (supplementary figure 5a that confirms TNFα depletion) and not 5a.
7) There is a missing reference in Line 279 after "NOR."
Answer: we have now added the reference.
__Reviewer #3 __
Summary: This paper tries top address how microglia-related TNFa modulate the REM sleep and motor behavior consolidation, using layer I gabaergic synapse enhancement (possible by SOM interneurons).
The methods and results are solid/convincing and easily to be followed and they seem logically for the conclusion which they state.
However there are major issues which need to be addressed before formal submission.
Reviewer #3 (Significance (Required)):
These works have serious limitations to be addressed before submitting to formal journals.
(1) The in vivo sleep experiments with micTNFa-KO (fig. 4 and extended table S1, Fig S8 a/b) indicate that layer I GABAergic synapse potentiation modulates the start of down-state of slow-waves, which supposes to affect the NREM sleep. Controversially, NREM sleep is not affected (with SW down state duration increased in KO mice) and only REM sleep is influenced. This is opposite to the literature that GABAergic synapses in the cortex or thalamus determine the power of slow-waves and The fast transition to down state suggests that cortical neurons should be less active for REM sleep compared with NREM sleep.
Answer This reviewer pointed out that in extended table 1, micTNFα-KO mice spent more time in REM sleep over 24 hours. However, we believe that this increase is marginally significant because there was no parallel decrease in the time spent in Wake or NREM sleep. Accordingly, the mean duration of REM sleep is not affected (extended table 1) and when measuring the amount of REM sleep in 2-hour bins, figure 4a shows no difference between micTNFα-KO and tCTL mice. Additionally, figure 4 shows that there is no change in the electrophysiological features of REM sleep. On the other hand, the electrophysiological parameters of NREM sleep, such as the duration and slope of slow waves, are affected, as pointed out by this reviewer. Therefore, we do not view our findings as controversial. While we have not tested this hypothesis, we do not exclude that the lack of synaptic plasticity observed in micTNFα-KO mice is linked to the prolonged REM sleep.
(2) REM sleep can consolidate motor learning. However, the data (Fig. 5) do not consistently support this, although the authors cite the literature to support their results with complex motor learning.
Answer: In line with the comment of this reviewer, Li et al. 2017 (ref 13) study showed that REM sleep deprivation impairs the performance improvement in a motor learning tasks. However, and as noticed by this reviewer, the amount of REM sleep is increased in micTNFα-KO and we are not aware of any study that has shown the consequences of increased REM sleep on motor learning consolidation. The floor-texture recognition task that we have used to show an alteration of consolidation in micTNFα-KO was shown to be NREM sleep-dependent (Miyamoto et al 2016, ref 54).
(3) NMDA-iLTP needs to be further addressed since NMDA with CNQX in oganotypic slices supposes not be able to activate NMDARs that need co-activation of AMPARs to depolarize to remove the Mg-blockade before NMDAR activation in neurons. To further strengthen this result, ACh should be co-applied with NMDA (if not AMPA) since only REM sleep is enhanced in this study indicating that ACh should be involved to activate neurons during rem sleep, more relevant to REM sleep enhancement.
Answer: we followed the iLTP protocol in culture described by Petrini et al. (reference 26) and verified an increase in GABAAR accumulation at synapses. Furthermore, in preliminary experiments (not shown), we found that this effect depended on CaMKII, as previously reported by Chiu et al. who used NMDA only on acute slices (reference 27). These findings indicate that the application of NMDA+CNQX on organotypic slices replicates the synaptic effects observed in primary cultures (in which NMDA+CNQX is used) and acute slices (only NMDA). While investigating a novel protocol of synaptic plasticity using Ach and its possible connection to REM sleep is intriguing, we believe it would be more appropriate to explore this in a separate study.
-
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary: This paper tries top address how microglia-related TNFa modulate the REM sleep and motor behavior consolidation, using layer I gabaergic synapse enhancement (possible by SOM interneurons).
The methods and results are solid/convincing and easily to be followed and they seem logically for the conclusion which they state.
However there are major issues which need to be addressed before formal submission.
Significance
These works have serious limitations to be addressed before submitting to formal journals.
- The in vivo sleep experiments with micTNFa-KO (fig. 4 and extended table S1, Fig S8 a/b) indicate that layer I GABAergic synapse potentiation modulates the start of down-state of slow-waves, which supposes to affect the NREM sleep. Controversially, NREM sleep is not affected (with SW down state duration increased in KO mice) and only REM sleep is influenced. This is opposite to the literature that GABAergic synapses in the cortex or thalamus determine the power of slow-waves and The fast transition to down state suggests that cortical neurons should be less active for REM sleep compared with NREM sleep.
- REM sleep can consolidate motor learning. However, the data (Fig. 5) do not consistently support this, although the authors cite the literature to support their results with complex motor learning.
- NMDA-iLTP needs to be further addressed since NMDA with CNQX in oganotypic slices supposes not be able to activate NMDARs that need co-activation of AMPARs to depolarize to remove the Mg-blockade before NMDAR activation in neurons. To further strengthen this result, ACh should be co-applied with NMDA (if not AMPA) since only REM sleep is enhanced in this study indicating that ACh should be involved to activate neurons during rem sleep, more relevant to REM sleep enhancement.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary:
Pinto et al. sought to determine the role of microglia in sleep and plasticity. Using a combination of in vivo experiments in mice and organotypic slices, they report a molecular circuit whereby microglia respond to ATP via the purinergic receptor P2X7R to release tumor necrosis factor α (TNFα). TNFα then acts in its soluble form at TNF receptor 1 (TNRF1) to increase synaptic enrichment of GABAA receptors (GABAAR) in layer 1 (L1) of cortex (but not L5) during the light phase. These results suggest that microglial TNFα mediates cortical inhibitory synapses in a layer- and time-of-day-specific manner. The authors also showed selectively disrupting microglia TNFα alters slow wave activity (SWA) during non-rapid eye movement sleep (NREMS) and impairs memory consolidation.
Major Comments:
The authors performed several well-designed and controlled studies to uncover microglia regulation of GABAAR enrichment at synapses during the light period uncovering a nicely presented molecular circuit that included upstream and downstream mechanisms. They also nicely probed this circuit in vivo with a conditional, microglial-specific depletion of TNFα to determine the role of microglial TNFα in sleep and memory consolidation. Although the experiments were well done, the authors made some conclusions that cannot be determined by the experiments presented in this manuscript. Specifically, there are several claims that some of the phenomena occurred "during sleep" or are "sleep-dependent" when the experiments were not designed to test these claims. I provide more detailed comments below:
- There are several instances where the authors state the experiments occurred "across the 24 h light/dark cycle" (Lines 42, 139), "during the sleep/wake cycle" (Lines 87, 242, 248), or "during sleep" (Lines 155, 220, 254). These statements are imprecise and can lead to erroneous interpretations of the data. For molecular studies, data were collected at a light period timepoint (Zeitgeber Time (ZT) 6) and a dark period timepoint (ZT18). While I appreciate the comparisons of the light and dark phases, 2 timepoints are not sufficient to claim that phenomena were tested across the light-dark cycle. More importantly, though, it is not accurate to claim outcomes from data collected during ZT6 occurred "during sleep" (or ZT18 outcomes occurred during wake). Although mice sleep more in the light period vs. the dark period, they are polyphasic sleepers and thus can be awake at ZT6 and asleep at ZT18. Therefore, statements should be edited for accuracy to instead state that phenomena were observed at ZT6/ZT18 or light/dark periods. In addition, any figures (e.g., Figure S1) using x-axis labels of "W" and "S" should be relabeled as "ZT18" and "ZT6," respectively.
- The authors claim that microglial TNFα plays a role in sleep-dependent memory consolidation (Title and Lines 20, 22, 178, 198, 224, 276, 288) based on a series of experiments using tests previously shown to have a sleep-dependent consolidation component. However, the authors did not assess sleep-dependent consolidation in the micTNFα-KO and the tCtl mice, and thus this conclusion cannot be drawn. This is because the experimental paradigms did not include sleep deprivation. Claims that outcomes are sleep-dependent need to be shown as absent/impaired after sleep deprivation especially in mutant (and control) lines that have not been previously tested in this context. As such, claims of sleep-dependent memory consolidation (including in the title) should be removed OR new experiments including sleep deprivation should be included.
- "This shows that P2RX7 and microglial TNFα drive daily fluctuations in CaMKII Thr286-phosphorylation and are required for sleep-dependent GABAAR synaptic upregulation in L1 during the light phase" (Lines 144 - 146). Similar to the above comment, it cannot be definitively concluded the P2X7R or microglial TNFα are required for sleep-dependent GABAAR synaptic upregulation because sleep deprivation studies were not conducted in the P2rx7-KO or micTNFα-KO mice. Furthermore, there is no analysis (or citation) of P2rx7-KO mice sleep-wake expression nor has the micTNFα-KO sleep data been presented at this point to make any determinations on how (possibly perturbed) sleep-wake expression in these mice could affect the stated outcomes.
- There are some details regarding data analysis that are lacking:
- a. How were bouts defined for each arousal state?
- b. It seems more details are needed for EEG spectra analysis. From what values was the median derived and over what time period? How was each spectral bin normalized and over what time period? What data (i.e., from what time period and duration) are shown in Figure 4b? Same question for Figure 4c-d? Were these time periods the same for controls and mutants given that NREM SWA changes across the light-dark cycle?
- c. How was NREM delta power normalized and analyzed and over what time period?
- Claims that GABAAR enrichment at synapses is sleep-dependent is based primarily on the data presented in Figure 1d reporting no increase in cortical GABAAR after sleep deprivation. A previous study (not cited) showed sleep deprivation increased GABAAR expression in CaMKIIα+ neurons in barrel cortex (Del Cid-Pellitero et al., Front Syst Neurosci, 2017). It would be helpful if the authors cited and discussed this study.
- Some sentences/conclusions are overstatements:
- a. "...discarding the possibility that lack of synaptic GABAARs enrichment upon PLX3397 treatment results from perturbed sleep during the light phase" (Lines 68 - 69). Only sleep time is reported to make this claim, but bout frequency, bout duration, and EEG spectra could be perturbed with this manipulation. This claim should be edited for accuracy or additional data (e.g., bout and spectral analysis) should be presented. In addition, Line 68 should be edited to state that "...microglia depletion does not alter sleep time during the light phase..." unless additional analyses are provided.
- b. "TNFα, which is mostly if not exclusively produced by microglia in the brain..." (Lines 93 -94). Although microglia are a major source of TNFα, there is evidence other brain cell types also release TNFα. In addition, the citation provided does not support this exclusivity claim.
- c. "We thus anticipate that microglial TNFα may control REM by acting at the basal forebrain..." (Line 163). This statement is based on a cited study that reported REMS suppression (and increased NREMS time) after TNFα injection in the subarachnoid space of the basal forebrain. It is unclear to me why this statement is included when ICV and IV TNFα administration also reduce REMS (Shoham et al, Am J Physiol, 1987). Given these data and this statement is not being tested, it does not seem like it needs to be included. It should also be noted a previously reported (but not cited) global TNFα KO mouse (Szentirmai and Kapás, Brain Behav Immun, 2019) also showed increased REMS and REMS bouts, but this seemed to be a dark period phenotype (NREMS and Wake time, bout frequency, and bout duration were unaffected). This is an interesting detail to at least include in the second paragraph of the Discussion.
- It is unclear to me why the authors believe ATP in these studies has a neuronal origin (Lines 106, 132, 218) when other cell types also release ATP. Is this because of NMDA treatment? If so, NMDA receptors are also expressed on other cell types like astrocytes (Verkhratsky and Chvátal, Neurochemical Research, 2020).
- Because the authors rationalize investigating memory consolidation based on micTNFα-KO changes in NREM SWA, I am curious if the authors considered parsing NREM SWA into slow oscillations and delta waves as Vaidyanathan et al (eLife, 2021) did. The reason for this is because slow oscillations are shown to be associated with memory consolidation, but delta waves are associated with weakening memories.
- For the complex wheel task, micTNFα-KO mice seem to start and end with better performance compared to tCTL on S1 (although it is not clear if this difference was statistically evaluated). Would the conclusions from this experiment change if data were normalized to account for the apparent better starting performance?
- Many of the molecular studies emphasized a layer-specific effect in L1 vs. L5. It would be helpful if the authors could link (at least in the Discussion) this cortical-layer specificity with reported microglial TNFα effects on sleep parameters and memory consolidation.
Minor Comments:
- For the experiments investigating TNF receptor (TNFR) involvement (fig. S5), it would have been interesting to see the response to human recombinant TNFα which interacts with TNFR1 but not TNFR2 whereas mouse recombinant TNFα interacts with both receptors (Lewis et al, PNAS, 1991).
- "Synapse plasticity in the sleeping brain likely supports crucial functions of sleep" (Line 33). I believe it is more accurate to instead state sleep supports synapse plasticity. The sentences immediately following also provide examples of sleep/wake mediating plasticity.
- "Moreover, microglia depletion also abolished the reduction of synaptic AMPA receptor subunit GluA2 at ZT6 (fig. S1)..." (Lines 70 -71). The data in this figure shows an increase GluA2, but the data cited showed decreased excitatory transmission. This discrepancy is not discussed.
- If you normalize within treatment (e.g., PLX, SAP, minoc, 4-OHT, apy, PPADS, A74, PSB) rather than to controls (e.g., normalize PLX-iLTP to PLX-bsl instead of CTL-bsl) in Figures 2b-f, 3b-c, do you get the same results? Similarly, if you normalize PLX treatment to CTL ZT18 in Figure 1c-d, do you get the same general outcome?
- Is there a significance marker missing in Figure 2g for bls vs. BzATP?
- It is unclear if the fig. 5a callout is the correct one at Line 143. If it is correct, then it is confusing (to me) in the way it is currently associated with the text.
- There is a missing reference in Line 279 after "NOR."
Significance
The role of non-neuronal cells in sleep and sleep-related processes like learning and memory is relatively unexplored and this is especially true of microglia. The authors present a nicely done series of rigorous experiments that reveal a microglial-centric molecular circuit of inhibitory synaptic modulation that differs between the light and dark periods and plays a role in NREM slow wave activity and memory consolidation. However, most of the claims of sleep dependency of the reported phenomena have not been directly tested in this manuscript and thus await additional experiments or re-framing of the stated conclusions. Re-framing these conclusions without claims of sleep dependency still provides very interesting and informative data about the mechanistic role of microglia in inhibitory synapse plasticity and memory consolidation that may be of interest to researchers interested in learning and memory, synaptic plasticity, and sleep.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary:
Using both in vivo and ex vivo approaches in mice, the authors showed that microglia in layer 1 (L1) of the frontal cortex modulate the level of GABAA receptors at L1 GABAergic synapses depending on the light/dark phase and, more specifically, sleep/wake state (high during sleep). This was shown to be mediated through purinergic signaling via microglial P2RX7 receptors followed by microglial release of TNFa then CaMKIIa phosphorylation in neurons. Microglia-selective TNFa-KO mice showed normal sleep/wake cycles except for an increase in REM sleep amount, but cortical EEG slow waves during NREM sleep, a measure of sleep propensity, were slower in the delta range (1-4 Hz), but without any change in delta power. These animals also showed deficits in memory consolidation in two out of three memory tasks used.
Major comments:
- The paper is clearly written and easy to follow, with virtually no typos or editorial errors. Both the introduction and discussion are informative and well-referenced.
- The experiments are generally carefully designed including appropriate controls and comparison groups (e.g., L1 vs. L5; GABAAR vs. AMPAR; PLX vs. saporin vs. minocycline). The results are presented appropriately and often in detail including supplementary figures and tables.
- One issue concerns the conclusion that microglial TNFa signaling shapes slow waves during NREM sleep (e.g., title; lines 148, 175-176; 180; 222-223; 288) on the basis of the data shown in Fig. 4b-d. Slow waves normally consist of two components, < 1Hz (slow oscillations) and 1-4 Hz (delta waves), and Fig. 4b shows a modest slowing in delta range (from ~2.2 Hz to ~1.7 Hz, from reading the graph for means). Importantly, there was no change in the spectral density in delta range. In the opinion of this reviewer, this is a modest effect and its significance and impact remain to be investigated. Arguably, the effects on memory consolidation could have been a result of microglial TNFa gene deletion elsewhere in the brain of these KO mice. Modification of the claim on slow waves should be considered.
- VGAT was used to identify GABAergic synapses in conjunction with GABAA receptors. Of various GABAergic interneurons, somatostatin (SOM)-containing GABAergic interneurons are known to be crucial for generating slow waves during NREM sleep through their axon terminals that target and concentrate in L1 (e.g., Funk et al., 2017, ref. 17). However, not all GABAA receptors in L1 would be associated with the inputs from SOM-containing GABA interneurons. For example, there are parvalbumin-containing GABA interneurons and their activation has been reported to DECREASE slow waves (Funk et al. 2017). This is relevant and should be discussed in relation to the results.
- To follow up on the above, it is unclear why NeuN was used to delineate cell bodies (Fig. 1e). In fact, SOM-containing GABA neurons (see above) have been shown to inhibit pyramidal neurons through presynaptic inhibition of excitatory inputs as well as postsynaptic inhibition of dendrites, but not cell bodies, of pyramidal neurons (see Funk et al. 2017 for references). Some discussion along this line would be useful and potentially important. In addition, it would have been interesting to add an immunolabel for SOM to identify SOM-containing axon terminals associated with VGAT (Figs 1, 2), and this could be done for parvalbumin (see above) terminals as well; however, this analysis is optional and not required.
Minor comments:
- It appears that n's are not consistently reported. Please check.
- The Y-axis does not start from zero in some graphs. Although this might be a matter of preference, it can be misleading.
- In the supplementary information PDF, under Immunohistochemistry (IHC): "In direct IHC" in the first line of the paragraph should be "Indirect IHC".
Significance
There is increasing evidence for and interest in the role of microglia in modulating synapses and neuronal circuits underlying various behaviors including sleep. However, the role of cortical microglia in sleep or NREM slow waves (a measure of sleep propensity or sleep need) is unclear. GABAergic synapses in cortical L1 are known to play an important role in NREM slow waves. Thus, the evidence that microglial P2X7-TNFa signaling enriches synaptic GABAA receptors selectively in L1 (not in L5) and during sleep is important and novel.
On the other hand, in this reviewer's opinion, the effect of microglia-selective TNFa gene deletion on slow waves during NREM sleep seems modest (minor slowing but no change in power) and it is also unclear whether the effects on memory consolidation in two out of three tasks were due to the observed change in slow waves, or other alterations that are likely in these KO mice.
The reviewer's expertise: sleep neurobiology. Familiar with microglia and much of the techniques, but not ex vivo techniques.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1
Further work required on divergence to address the observed level of gene flow between wild and crop populations and the lack of admixed/hybrid genomes.
- Authors should plot Fst and Dxy along the main scaffolds. It would permit to see whether there is huge peaks of divergence and differentiation between the two populations.
We will measure Dxy across the genome and plot against Fst in the larger contigs. Check for similarities and differences in these two measures and their relationship with effector locations. Relate results to effectors as well as broader demography as highlighted by the network.
Virulence can be mediated at the expression level by effector silencing and the reviewer suggests looking for premature stop codons, deletion of an exons, or mutations in the promoter region.
We will run SNPeff to annotate and classify the severity of variants. We will relate that to potential roles in silencing in effectors relative to non-effector genes.
Simulations would provide stronger support for conclusions.
Absolutely. Simulations are important to validate our conclusions and improve our hypotheses as to the levels of selection, rates of gene flow and/or boom and bust. Our simulation would look at:
- The strength of balancing selection required to preserve diversity in pathogen virulence genes.
- The strength and direction of selection required to partition that diversity to produce increased Fst we observe at virulence genes.
- The impact of differential rates of recombination in the wild and crop populations
- The impact of clonality in the crop population at multiple levels:
- On divergence between populations and levels of inbreeding (Fis)
- On boom-and-bust dynamics and the frequency of successive invasions
To parameterise this model, we would need to estimate the rate of recombination using linkage decay across a near/pseudo chromosomal assembly. Our assembly isn’t contiguous enough to estimate recombination rates for our populations. Given the parameter space we must investigate, combined with unknowns, we feel that the investment required to design and test such a model is significant, including requiring a new (long read, phased) genome assembly. This is our aim but without that data now, we feel that a simulation would not be strong enough to get through the rigor of peer review. We are happy to add a discussion of the importance these next steps to validate our conclusions, in the Discussion section.
Figure 2 network suggests strong divergence between populations, and this needs further exploration because divergence and the locus level is very low.
- The reviewer requests a PCA
- (Reviewer #2 missed the Machine Learning in the supplementary which also speaks to this work).
Reorder Figure 2 to reduce confusion. Reduce the content in Figure 2 to include only the map, the network, and the admixture plot. Add a new Figure 3 which would include a larger PCA and the supplementary data which uses Machine Learning to attempt to partition individuals into clusters/populations.
Authors should also look for how many effector genes are non-expressed in cultivated population face to wild population.
The reviewer’s suggestion of analysis of premature stop codons etc will be done using SNPeff.
Run Selscan (ZA Szpiech and RD Hernandez (2014) or similar to look at indicators of selection.
It is feasible to run selection scan software, although this would be heavily caveated because these methods often do not account for clonal expansion in a single population.
Address Minor Comments
Reviewer #2
- Effector candidates were not evaluated/characterized in any form.
- Authors should compare pathogen features to other related species and try to contrast what stands out, especially the effectors' diversity
The reviewer referred to a statement in which we suggest that it is difficult to functionally annotate effectors (“According to the authors, it is difficult to functionally annotate these genes in general”). This statement was not intended to suggest that we did not annotate them, only that, because effectors are quickly evolving, fewer of them tend to receive an annotation, as compared to non-effector genes. In fact, we use shared annotations to refer to the presence of shared effector annotations in other rust species.
Details of cross species functional annotation were included in Supporting Information 01. They included annotation using AHRD, UniProt (Swss-Prot and TrEMBL) blast and InterProScan. AHRD uses a database of unbiased ground truth set of high-quality protein annotations with minimal redundancy to assign GO annotations. UniProt is the world’s leading high-quality protein sequence and functional information. It contains more than 190 million sequences with which to assign functional annotations to proteins. InterProScan was used to assign proteins into families as well as predict domains. All these methods utilise cross species information to assign gene/domain function and ontology (GO), the output from these is included for each gene along with that gene’s population genetic signature (Supporting Information 08).
In the results section we did highlight effector functional annotations and conservation among the Pucciniales (e.g. Rust Transferred Protein, Alpha-amylase, CSEP-06 and PriA, among others). We will clarify that statement to reflect our efforts in that area and throughout.
Where exactly the machine learning was used?
It’s in the supplement. Accounting for this comment as well as Reviewer 1 & 2 about the complexity of Figure 2 we plan to bring those results into the main document. This would allow us to unpack genetic diversity and differentiation as a separate figure from the map and network.
Address Minor Comments
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary: In the present study, using beet (Beta vulgaris) - rust (Uromyces beticola) as a model system, the authors set out to assess how crop pathogens evolve to evade resistance using wild reservoirs. They tested whether 1) the genes necessary to success in wild and crop environments are more genetically differentiated between pathogen populations and 2) the rate of clonal to sexual reproduction is higher in crop pathogen populations. Using freshly obtained 42 pathogen isolates from both crop and wild beets across the east of England, the authors assessed the genetic variation among virulent genes(effectors) between wild and crop pathogens. They found evidence for higher signals of diversity and differentiation in effectors and significant differences in reproductive rates between the wild and crop pathogen populations. They highlight that these findings can be used to identify candidate genes for pathogen survival in crops and develop methods to circumvent crop pathogen resistance. Additionally, they developed a new DNA peel extraction protocol for pathogens and produced a new annotation of Uromyces beticola genome annotation.
Major comments:
- The study design and the methodologies are appropriately explained and the statistical analyses are strong enough to draw the conclusions presented in the manuscript. The results are adequately explained and the inferences drawn from them are satisfactory.
- The putative effectors (virulent genes) were identified based on the assumption that gene products secreted outside of the fungal cell and into the host are host interaction genes, potentially facilitating infection. However, these candidates were not evaluated/characterized in any form. According to the authors, it is difficult to functionally annotate these genes in general. However, I believe at least the predicted functionality can be checked with published adequately annotated genomes of related species. This comparison is lacking in the analysis. Not having confirmed the functionality of at least some of the effectors undermines the finding that the study reflects the actual genetic differentiation in infectious genes.
- Similarly, comparisons of current findings to a related species/system are missing. Authors should compare pathogen features to other related species and try to contrast what stands out, especially the effectors' diversity.
- Although the authors claim that machine learning was utilized in the manuscript, where exactly the machine learning was used is not clear. The models used in the analyses are already implemented in the software packages and methods described in the manuscript. I did not see any machine learning method being applied to improve the analysis either. If it is actually used, it would be beneficial to highlight for what and where it was used and how it improved specific analyses.
Minor comments:
- Lines 184 - 186: Can the lack of admixture and gene low among these wild isolates also explain this observation? what about the levels of FIS in these isolates? Clonality in these populations may have a significant impact on the genetic diversity in these populations.
- lines 216-220: Is this also reflected in the excess of heterozygosity non-effectors in these crop populations? The mutations should equally accumulate in both gene categories.
- lines 219-220: it is not clear which CDS are being referred to here; Are you talking about the correlation between the CDSs of wild and crops or effectors and non-effectors?
- Figure 1: I suggest separating F & G from the rest
- Figure 3: D. Unless this is a noe to one window comparison of pi, this plot does not necessarily show a correlation. Please explain how the windows were treated in this comparison.
- Figure 4: A. I would expect a relatively high correlation between the FST and pi in effectors. Does this include both wild and crop effectors?
- I spotted a number of typos throughout the manuscript. So I suggest the authors pay attention to punctuation and typos.
Significance
This study presents a critical comparative analysis of crop pathogens in their wild populations. It highlights the significance of assessing the crop pathogen genetic diversity against their wild background/relatives to identify how crop pathogens evolve to evade crop resistance. And in turn, it will help us to improve our crop varieties to be better resistant to pathogens in this era of ever-increasing demand for crop production.
Further, the present study also provides a new methodology with an annotated genome of beet pathogen Uromyces beticola to identify candidate crop resistance genes in other related pathogens. The scientific community will also benefit from the protocol they developed to extract pathogens from host peels.
Therefore, I believe this work will reach a wide audience in genetics, genomics, agriculture, crop development, and landscape genomics.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary:
This study presents a pathosystem beet/Uromyces beticola in order to understand how reservoirs can play a role in ermergence of new virulences. To do this, the authors sample cultivated beets and wild beets in England and resequence 42 genomes of U beticola found on these two beet species (24 from sugar beet hosts and 18 from coastal places on wild beet hosts). The authors use population genomics tools to explore population structure and compare diversities of the two populations found. Indeed they found a population of U beticola exclusively living on wild beets, and a population infecting both sugar and wild beets. They compare genes encoding for effectors (important in interactions with hosts) with genes encoding for other proteins. They found that genes encoding for effectors are more diverse in wild compartiment than genes encoding for other types of proteins. In general, the wild compartiment is more diverse than the cultivated one. The authors draw conclusions about the role of reservoir of wild population for emergence of new virulence in the cultivated population. At last, as the authors found excess of heterozygosity in the cultivated population, they conclude about clonal reproduction in this population.
Major comments:
- Are the claims and the conclusions supported by the data or do they require additional experiments or analyses to support them?
Although the paper is well written and the population genomics studies were well done, the analyses are still preliminary and hence conclusions are not accurate. Indeed, in Fig2 authors show a tree representing the clear divergence between strains found in sugar beets and the ones found in wild beets (excepted for five isolates found in wild beets but belonging to the cultivated clade). Despite the fact that this apparent divergence is supported by other analyses, the authors do not conclude about the lack of gene flow between theses two populations. Indeed, the gene flow occurred there would have been admixed genomes and no clearcut delineations between the two populations. In other word, they authors have not found hybrids in their sampling. In general, divergence is not really studied in this paper. The comparison between genes encoding for effectors and the ones encoding for other genes is very interesting. However, the authors just forget that sometimes virulence is acquired by effector silencing. Indeed an effector that is no more expressed can not be recognised by host, and then resistance can be overcome. The authors should look for effectors that are no more expressed (with stop codon for example, deletion of an exon, or mutated in the promoter region) in crop population. They could find other good candidates for adaptation. In general, conclusions are badly supported. The authors should use simulations for their model validation. This study strongly deserves it. I will detail this in the following. - Please request additional experiments only if they are essential for the conclusions. Alternatively, ask the authors to qualify their claims as preliminary or speculative, or to remove them altogether. - First validate your assumations with models simulated. If the authors assume that population infecting cultivated beets come from population infecting wild beets, they should be able to confirm this hypothesis by simulations. For instance, authors could use ABC method in order to check the posterior probability of such a model. - Authors should use divergence statistics in order to check whether there is divergence or not on their data. For example, use Dxy in order to check the degree of divergence between wild and cultivated population. As for evidence in Figure 2, there is a strong divergence between the two populations. It could be interesting to check whether there is gene flow or not between these two populations. - Authors should also look for how many effector genes are non expressed in cultivated population face to wild population. - Authors should plot Fst and Dxy along the main scaffolds. It would permit to see whether there is huge peaks of divergence and differentiation between the two populations. - Are the data and the methods presented in such a way that they can be reproduced?
Yes, the data can be reproduced as well as the analyses. - Are the experiments adequately replicated and statistical analysis adequate?
Both experiments and statistics are adequate.
Minor comments:
- Specific experimental issues that are easily addressable.
Yes they are - Are prior studies referenced appropriately?
Yes they are - Are the text and figures clear and accurate?
Figure 2 is somewhat hard to understand. There is too much data here. - Do you have suggestions that would help the authors improve the presentation of their data and conclusions?
I would prefer a PCA plot, just showing strains plotted along the first axis and showing that there is no hybrid.
Referee Cross-commenting
Hello everyone I just start the comment session by providing a few points that I think to be important to be treated in a future version of the paper. 1- Characterize the relationships between wild and agricultural populations. As shown on figure 2, the tree presented clearly indicates divergence between wild and agricultural strains. A PCA would be interesting to be plotted, as it may indicate that there is no hybrid between populations. In a general manner, statistics like Dxy or Da as well as Fst should be plotted along the genome. 2- The scenario should be validated using simulations and tested against a null hypothesis. 3- Virulence can be acquired through effector losing function. Thus, variations like occurrence of codon stop, delection in ORF, or mutations altering the promoter region should be checked.
Significance
Provide contextual information to readers (editors and researchers) about the novelty of the study, its value for the field and the communities that might be interested.
The following aspects are important:
- General assessment: provide a summary of the strengths and limitations of the study. What are the strongest and most important aspects? What aspects of the study should be improved or could be developed? This study is interesting in showing the crucial role of wild compartiment as a reservoir of virulence. However, as the data are well produced, their analysis suffer from several flaws. As divergence is not analysed, and only differentiation is shown. In addition, the model proposed is not validated by simulation, not even tested by ABC. In order to be more conclusive, selection should be tested. Fst variance is not a good predictor of selection. I would recommend to use Selscan (ZA Szpiech and RD Hernandez (2014) ) in order to test for selection on genomic data. It would give real clues for selection acting on cultivated population.
- Audience: describe the type of audience ("specialized", "broad", "basic research", "translational/clinical", etc...) that will be interested or influenced by this research; how will this research be used by others; will it be of interest beyond the specific field? This paper is of a broad audience as it treats of large problematic of evolution of plant pathogen.
- Please define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.
I am a population genomicist working on evolution of pathogens.
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We would like to thank reviewers for their insightful comments.
Overall, there were two major concerns/suggestions:
-
Applicability to humans of the increase of BTC in non-alcoholic steatohepatitis (NASH) and mechanisms of downregulation of BTC by omega-3. We now analyzed __3 __additional human gene expression datasets and show that BTC not only is increased in human NASH (as we have already shown for liver cancer meta-analysis), but is also decreased in livers of patients who received omega-3.
-
One of the reviewers suggested investigating a potential mechanism of how BTC is regulated by omega3 fatty acids. Although a complete answer to this question would require entirely new studies to be done, we still performed additional investigation that was possible within a reasonable timeframe. We found that transcription factor FOXO3 (well-known inhibitor of carcinogenesis) is a highly probable mediator of the DHA inhibitory effect on BTC.
See all details of items 1 and 2 as well as answers to other (less critical concerns) below after each specific question.
Reviewer #1 (Evidence, reproducibility and clarity (Required)):
This work by Padiadpu and colleagues investigate the mechanism by which pufa of the n-3 series (mostly DHA) may influence NAFLD progression using systems biology analysis and multiple omics analysis. The work is interesting and may provide a novel view of the topic. However, there are a number of issues the authors may wish to consider in order to improve their manuscript.
Major issues: Clarity: Since the authors refer to previously published experiments, they must refer to this work in the figure legends and improve the clarity of such legends. Here are a list of issues that must be fixed:
Fig.1: First panel is not clear. What does the table tell the reader? What are the effects of the different diets on NAFLD?
All the transcriptomic data are newly generated from the samples of previously published studies. The table shows the number of features changed by DHA and/or EPA in each of the -omics and phenotypic data used in the analysis.
I understand that the results are published elsewhere, but the authors must provide information regarding the NAFLD/ NASH scores.
We now added a supplementary table 1a showing the scores.
Fig.4: Why is there sometimes a DHA diet, sometimes DHA and EPA. Legend is not clear. What does WD + Mean? I guess it is olive oil... But the legend must be improved.
We added details in the legend for more clarity. Specifically, WD+O means WD + olive oil added as a control for WD+DHA, WD+EPA. As described in the 2nd paragraph of results, when both EPA and DHA had a similar and significant effects in reversing WD effect, it was defined as “EPA&DHA category” of parameters. When only WD+DHA or WD+EPA were significantly changed vs WD+O, those were assigned as “DHA category” or “EPA category”, respectively.
One issue the authors may consider trying to fix is the specificity of the effect of DHA on BTC.
Is it really specific? It seems to me that EPA has more or less the same effect. If the effect is DHA-specific, than make this clearer through the text.
Although BTC expression was reduced by both DHA and EPA comparing to WD, DHA had a statistically significant stronger effect than EPA (Fig. 3D).
Another issue the authors may wish to investigate is the relationship between W3 consumption and BTC expression in studies performed by other labs (if available on Gene expression omnibus?).
Thanks for the suggestion. We used publicly available data of human and mouse studies that showed significant increase in liver BTC gene expression in NASH in multiple datasets while a human trial with Omega 3 treatment for one year showed its significant reduction (Figures 3F - human data, S3G-mouse data).
Finally, a key issue would be to identify the mechanism by which DHA inhibits BTC expression? How does this happen? could such inhibition be induced by other fatty acids of the W3 series? I understand that this is not easy to address but it would significantly strengthen the manuscript.
Thanks to your question we investigated and found at least one of potential mechanisms contributing to how “DHA inhibits BTC expression”. See details in the answer to next question. As for “other fatty acids” while we agree this is important question, it is outside of the scope of the current study but will be investigated in future studies.
Moreover, it might be possible to identify the set of genes highly co-regulated with BTC expression and to investigate the possible transcription factors at play in the control of such gene set.
We really appreciate this question as our efforts in this direction provided one potential mechanism. A direct screen of transcription factor (TF) motifs in genes co-regulated with BTC did not provide any clear results. Therefore, we implemented a combination of network analysis and screen for motifs in BTC gene with the in vivo and in vitro treatment results and found FOXO3 as a candidate TF regulated by DHA upstream of BTC.
See details of the analysis and results in a new Supplementary Figure S6 and corresponding text located at the end of the results.
Minor: the authors use the term "beneficial" transcriptome alterations by DHA.
I do not think it is correct to use "beneficial".
We agree and removed the word "beneficial”.
Reviewer #1 (Significance (Required)):
Strength: This paper uses new approaches to investigate the relationship between W3 consumption and liver gene expression and its relevance to chronic metabolic liver diseases.
The experiments and data set used to perform systems biology are from an excellent lab (the authors lab) who has published a lot of important and reproducible discoveries in the field of regulation of gene expression by dietary fatty acids.
The work has high translational relevance in medicine / hepatology / metabolism.
I am not a qualified reviewer to assess the systems biology that has been done.
Limitation: The mechanistic link between DHA consumption and BTC expression is not very clear. The specificity of this effect could also be tested (DHA vs other W3 and/or W6).
Although BTC expression was reduced by both DHA and EPA comparing to WD, DHA had a significantly stronger effect than EPA (Fig. 3D). Other omega fatty acids were not tested but it can be done in future studies.
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
The authors files a manuscript describing the impact of the suppression of betacellulin as a key mechanism to counteract fibrosis and inflammation in NASH by modulating fatty acids in WD-fed mice.
Major Comments: (i) No histological analysis was presented and indeed this is of clinical relevance for NASH since diagnosis is still based on biopsy.
While histological evaluation was presented in the originally published papers (PMID: 28422962, 23303872), it is now provided in Supplementary Table S1a.
(ii) Human comparative analysis: is done with HCC not with NASH patients.
This cancer-related dataset is most likely obtained from different etiologies.
I would suggest comparing these mouse datasets with GSE48452 (human NAFLD-NASH spectra).
Thanks for this important question. We now analyzed available human data of NASH and show significant increase of BTC expression in two datasets while a human trial with omega-3 treatment for one year showed its significant reduction of BTC expression (Figure 3F) resembling our observations in mice.
(iii) to compare the inflammation and fibrosis (also lipid metabolism), one can compare these mouse datasets with GSE222576 and cite this preprint (https://doi.org/10.21203/rs.3.rs-2009380/v1)
Using the suggested dataset (of a chemically induced liver fibrosis), we first observed that Btc gene expression was significantly increased over 10 weeks of the model and now included this result in Fig. S3G.
We also queried the 66 genes from the network modules described by the authors to check their changes in our NASH model. We observed that 28 genes were differentially expressed in NASH with 14 of them belonging to the module that authors named as “Pathways in Cancer”. Other genes were from the lipid metabolism (4 genes), immunity (2) and inflammation (2 genes). In addition, we observed that several genes we found regulated by omega-3 and changed in this fibrosis model contained other inflammatory genes such as classical macrophage genes (Mmp12, Lgals3, Cd68, Trem2), fibrosis (Col4a1, Col27a1, Itga2b, Itga8) and lipid metabolism (Scd2, Lpl, Soat1). Of note, the preprint has been published and we now cite the corresponding article.
Minor comments:
(i) The heatmap in Figure 1B and another heatmap should show all mice not the average to see the variability
The supplementary figure with all the individual mouse data as another heatmap is added to show the variability and similarity (Figure S1D).
Reviewer #2 (Significance (Required)): The authors files a manuscript describing the impact of the suppression of betacellulin as a key mechanism to counteract fibrosis and inflammation in NASH by modulating fatty acids.
This is well designed experiment, and the results are of interest to hepatologists and should be indeed published after consideration of the following points
Strength is multiOMICs approach.
Weakness is human applicability.
We improved human applicability by investigating 3 additional human datasets of NASH (Fig. 3F) and finding consistent changes in BTC expression closely resembling our observations in mouse NASH model, including one trial with omega-3 treatment of patients for one year showing significant reduction in BTC gene expression.
-
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
The authors files a manuscript describing the impact of the suppression of betacellulin as a key mechanism to counteract fibrosis and inflammation in NASH by modulating fatty acids in WD-fed mice.
Major Comments:
- (i) No histological analysis was presented and indeed this is of clinical relevance for NASH since diagnosis is still based on biopsy.
- (ii) Human comparative analysis: is done with HCC not with NASH patients. This cancer-related dataset is most likely obtained from different etiologies. I would suggest comparing these mouse datasets with GSE48452 (human NAFLD-NASH spectra).
- (iii) to compare the inflammation and fibrosis (also lipid metabolism), one can compare these mouse datasets with GSE222576 and cite this preprint (https://doi.org/10.21203/rs.3.rs-2009380/v1)
Minor comments:
- (i) The heatmap in Figure 1B and another heatmap should show all mice not the average to see the variability
Significance
The authors files a manuscript describing the impact of the suppression of betacellulin as a key mechanism to counteract fibrosis and inflammation in NASH by modulating fatty acids. This is well designed experiment and the results are of interest to hepatologists and should be indeed published after consideration of the following points
Strength is multiOMICs approach
Weakness is human applicability
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
This work by Padiadpu and colleagues investigate the mechanism by which pufa of the n-3 series (mostly DHA) may influence NAFLD progression using systems biology analysis and multiple omics analysis.
The work is interesting and may provide a novel view of the topic.
However, there are a number of issues the authors may wish to consider in order to improve their manuscript.
Major issues:
Clarity:
Since the authors refer to previously published experiments they must refer to this work in the figure legends and improve the clarity of such legends. Here are a list of issues that must be fixed: Fig.1 : Firts panel is not clear. What does the table tell the reader? What are the effects of the different diets on NAFLD? I understand that the results are published elsewhere, but the authors must provide information regarding the NAFLD/ NASH scores. Fig.4: Why is there sometimes a DHA diet, sometimes DHA and EPA. Legend is not clear. What does WD + Mean? I guess it is olive oil... But the legend must be improved.
One issue the authors may consider trying to fix is the specificity of the effect of DHA on BTC. Is it really specific? It seems to me that EPA has more or less the same effect. If the effect is DHA-specific, than make this clearer through the text. In this current version of the manusript, the authors alternatively use the term DHA or W3. Related to this issue, it would be nice to know what the composition of the WD is? More specifically, it would be important to know whether it might be W3 deficient.
Another issue the authors may wish to investigate is the relationship between W3 consumption and BTC expression in studies performed by other labs (if available on Gene expression omnibus?).
Finally, a key issue would be to identify the mechanism by which DHA inhibits BTC expression? How does this happen? could such inhibition be induced by other fatty acids of the W3 series? I understand that this is not easy to address but it would significantly strengthen the manuscript. Moreover, it might be possible to identify the set of genes highly co-regulated with BTC expression and to investigate the possible transcription factors at play in the control of such gene set.
Minor: the authors use the term "beneficial" transcriptome alterations by DHA. I do not think it is correct to use "beneficial".
Significance
Strenght:
This paper uses new approaches to investigate the relationship between W3 consumption and liver gene expression and its relevance to chronic metabolic liver diseases. The experiments and data set used to perform systems biology are from and excellent lab (the authors lab) who has published a lot of important and reproducible discoveries in the field of regulation of gene expression by dietary fatty acids.
Limitation:
The mechanistic link between DHA consumption and BTC expression is not very clear. The specificity of this effect could also be tested (DHA vs other W3 and/or W6).
The work has high translational relevance in medicine / hepatology / metabolism.
I am not a qualified reviewer to assess the systems biology that has been done.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Manuscript number: RC-2023-01919
Corresponding author(s): Fumio, Matsuzaki and Quan, Wu.
[The “revision plan” should delineate the revisions that authors intend to carry out in response to the points raised by the referees. It also provides the authors with the opportunity to explain their view of the paper and of the referee reports.
The document is important for the editors of affiliate journals when they make a first decision on the transferred manuscript. It will also be useful to readers of the reprint and help them to obtain a balanced view of the paper.
If you wish to submit a full revision, please use our "Full Revision" template. It is important to use the appropriate template to clearly inform the editors of your intentions.]
General Statements [optional]
This section is optional. Insert here any general statements you wish to make about the goal of the study or about the reviews.
We thank two reviewers very much for their comments. Their comments greatly contribute to our revision plan. Reviewer 1 fairly evaluated our data and provided us constructive and supportive comments. We incorporated responses to Reviewer 1’s comments to our revision plan, in which we made some novel analyses and discussions according to Reviewer1’s comments. Reviewer 2 also provided us very helpful comments, which are based on his/her careful reading of our manuscript, especially from the viewpoints of a ferret specialist. These comments help us to improve our manuscript very much, whereas some of the reviewer 2’s requests appear beyond the scope of our paper and against the policy of Review Comments; the standard policy of the review for Review Commons is “do not add new pipeline of experiments” such as adding additional replicates for scRNAseq. We have made revision plans (section 2) according to the order of comments given by reviewer 1 and then next by reviewer 2, considering all the statements of the two reviewers on balance; there are 6 comments from reviewer 1, and 25 comments from reviewer 2. In the section 2, we selected revision plans that we have reflected to the preliminary revision of our manuscript.
Finally, we would like to note our fundamental interest; we are studying the cortical development of ferrets as a model of brain development to understand what mechanisms are conserved or species-specific during brain size expansion in the mammalian evolution, which, of course, includes humans. It would be great if the ferret model can be a tool used to study tRG cell biology, contributing to understanding the human cortical development.
For this purpose, it’s been critical to create series of single cell transcriptomes along cortical development. A comparison between humans and ferrets, focused in this paper, is the first attempt, because human data of single cell transcriptomes have been extraordinary enriched. These attempts of comparisons between ferrets and humans will provide valuable information about which mechanism is shared and which is not shared for the cortical development in the gyrencephalic mammals. To represent the usefulness of our approach, we chose finding of tRG in ferrets as a symbolic example, and analyzed its origin and fates.
Description of the planned revisions
Insert here a point-by-point reply that explains what revisions, additional experimentations and analyses are planned to address the points raised by the referees.
Reviewer #1 (Evidence, reproducibility and clarity (Required)):
Summary: Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate).
In this manuscript, the authors conduct a series of single-cell transcriptomic analyses and imaging assays in the developing ferret cortex suggesting that (1) ferrets harbor a radial glia (RG) subtype similar to the truncated radial glia (tRG) described previously in humans that may have the potential to (2) produce ependymal and astrogenic lineages which (3) can also be found in the developing human cortex. These findings appear to be an important step in the validation and development of the ferret model towards a tool that can be used to study tRG cell biology, a feat currently difficult due to the inaccessibility of a genetically tractable source of tRG for molecular and cell biology experiments.
Major comments:
- Are the key conclusions convincing?
I found the key conclusions described above and in the authors' abstract convincing. I found the identification of a distinct, tRG-like cell type from the authors' single-cell transcriptomic analysis of the ferret cortex compelling, particularly because (1) the expression of the previously utilized tRG marker gene CRYAB is specific to the tRG-like cluster and (2) the tRG-like cluster marker genes (including CRYAB) are relatively unique to the tRG-like cluster. I found this strengthened by their morphological analyses showing the tRG-characteristic apical endfoot and short basal process in these CRYAB+ cells in the ferret cortex. I found the combination of imaging and bioinformatic analyses showing the increase in FOXJ1 co-expression in CRYAB+ cells to compellingly suggest that CRYAB+ cells can produce FOXJ1+ ependymal cells, and similarly with the authors' analyses to suggest that tRG-like cells can also contribute to SPARCL1+ astrocyte cells. I found that the cluster score analyses compelling suggest that the tRG-like cells in the ferret dataset correlate with the tRG cells annotated in a separate, human developing cortical dataset. I also appreciated the comparison of astroglial, ependymal, and uncommited ferret tRG sub populations from the pseudo time analysis with the clusters generated from the integrated ferret-human dataset in Fig. 7.
- Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?
- Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.
- Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.
1-1. The weakest claim in the paper is lines 202: "...tRG cells are formed by apical asymmetric division(s) from unique apical IPC". From my understanding, the main evidence that the tRG parent cells shown in Fig. 3 are not tRGs are the data from Fig. 2E-G showing the low amounts of CRYAB+ cells co-expressing KI67, TBR2, or OLIG2 in P5 and P10. Especially given that these timepoints are after those used in Fig. 3, I believe further evidence is needed to confirm the cell type identity of tRG parent cells in Fig. 3. Such experiments (isolating IPCs from ferret cortex and growing in vitro to determine progeny cells) may be outside of the scope of this paper, in which case I believe the text can be strengthened with either (1) presenting the data from the cited Tsunekawa et al, in preparation that would suggest this claim or (2) rephrasing these claims to omit the mention of IPCs.
We thank the reviewer for the suggestion to revise the definition of tRG parent cells in lines 194-204. This issue is also pointed out by the reviewer 2.
Revision plan:
- We revise the term “IPC” as “mitotic sibling of vRG” and stated that these cells might be tRG (CRYAB+) or non-tRG (CRYAB-) intermediate progenitors. By the term of “intermediate progenitors”, we did not intend to refer to TBR2+ neurogenic IPCs, but rather to an intermediate state of progenitors, in a general sense, with a similar morphology as tRG. To avoid any confusions on this terminology, we revised our manuscript by replacing “IPC” with “a sibling of vRG”.
- We delete all statements relevant to Tsunekawa et al. data from the manuscript. We regret that we are not able to include Tsunekawa et al. data because we are planning to submit this data as a separate manuscript, which describes that in ferrets, vRG frequently (30% of apical division) generate non-Tbr2-positive mitotic sibling cells bearing a short basal process during the entire neurogenesis. This study includes a large volume of data with human ones and largely concerns stages that are earlier than that of tRG formation. It is, therefore, not appropriate to combine these data with those described in this manuscript.
- As also pointed by reviewer 2, we cannot exclude the possibility that the mitotic sibling cells of vRG with a short basal process (IPC in the previous version of the manuscript) are also CRYAB positive tRG. To clarify the identity and variety of vRG sibling cells at tRG-generating stage, we are examining the sibling pairs of vRG by immunostaining for a mitotic marker Ki67 and CRYAB during P0-P5 after incorporating EGFP by electroporation to label vRG lineages. We will increase the sample size for a quantification and statistical analyses of this newly provided data to incorporate in our fully revised manuscript.
1-2. I also believe the claim in Line 365-366 is overstated: "We found that ferret (and presumably also human) tRG cells differentiate into ependymal cells and astrogenic cells." While I believe the transcriptomic comparisons suggest the presence of uncommitted tRG in both the ferret and human datasets, I would appreciate further analyses to confirm the prevalence of astroglial and ependymal tRG in the humans and/or functional analyses before claiming that human tRG cells make ependymal and astrogenic cells. I appreciate the authors' note that "GW25 is...the latest stages experimentally available" (line 376-377), but their comparative approaches could be applied to existing datasets of the human cortex (Herring et al., 2022, PMID: 36318921) that span later developmental ages. Identifying the presence of astroglial and ependymal tRGs in this and/or similar datasets would provide more convincing evidence of the tRGs' developmental potential. If this computational analysis is outside the scope of the paper, I believe paring the certainty of these claims (especially lines 379 - 383) and recognizing the need for further functional analyses would negate the need for deeper mechanistic validation.
We agree with the Reviewer 1 that identifying the presence of astroglial and ependymal tRGs in datasets spanning later developmental stages would provide convincing evidence for the potential of human tRG.
Revision plan:
- We compared our ferret dataset to the human postnatal dataset recommended by the Reviewer 1 (Herring et al., 2022). As a conclusion of our analyses shown below, we found that Herring et al., (2022) dataset was not favorable for a comparative analysis with our ferret dataset regarding the fates of human tRG, because Herring’s human dataset was derived from the prefrontal cortex; This human dataset does not include neither tRG cell population nor ependymal clusters. We have also elaborated our discussion after analyzing Herring et al. dataset in the discussion.
- We, therefore, pare down our claim in lines 365-366, by removing “(and presumably human)” to state that “Our pseudotime trajectory analyses and immunohistochemistry analyses strongly suggested that…”.
- We also tone down the statements as for the discussion of the relationship between human and ferrets regarding the tRG progeny fates (originally lines from 372 to the end) also elaborated our discussion after analyzing Herring et al. dataset in the same paragraph.
We will describe the details of our analysis of Herring et al. (2022) below.
As mentioned above, Herring’s human dataset was derived from the prefrontal cortex, and that it did not include a specific subtype defined as tRG nor other HES1-expressing progenitor clusters such as RG in the original cluster annotation. We, therefore, re-clustered the raw dataset from GW22 (the earliest stage available) up to 10-months after birth by using Seurat pipeline with default parameters (B), and found a CRYAB-expressing population in the original “Astrocyte_GFAP” subtype among astrocyte clusters (A), which distribute in the most of collected stages, from late development through the adulthood. We then examined this dataset to find out whether tRG or its progenies are present.
After reclustering, CRYAB-expressing cells (with more than 1 raw count) represented 0.15% of the dataset and were grouped as a part of cluster 44, which was mostly derived from postnatal stages (among which 4-months was the most enriched one; C). Several astrocyte markers, such as SPARCL1, HOPX, CLU, and GJA1, as well as CRYAB, were enriched in the cluster 44 as revealed by FindMarkers (Methods). FOXJ1 expression was nearly absent overall in this dataset, indicating the absence of the ependymal cell population, a tRG-descendant cell types in ferrets (C).
To evaluate the similarity between cluster 44 and tRG or astroglial tRG, we next integrated Herring dataset with our ferret subset (about 15,000 cells) and the human GW25 subset from Bhaduri et al. (2021) of approx. 3,000 cells, both of which contained only progenitor cells. As we have done in Figure 7 of our original manuscript; we have removed cells other than progenitors, astrocytes and oligodendrocytes, such as neurons, microglia, endothelial cells. This resulted in about 20,000 cells in Herring dataset.
This integration (D) reveals that Herring’s cluster 44 is closely located to Bhaduri’s human and our ferret tRG clusters on UMAP, but does not overlap with these tRG clusters. This result further suggested that tRG population might be lacking or very rare in this neuron- and glia-dominated dataset, which might be due to the sampling method that targeted the enrichment of neuronal layers (Herring et al., 2022). It is also possible that this fragmented information on astrocyte and ependymal lineages could be due to the regional and/or temporal difference of samples between two human datasets.
1-3. I believe the most significant advance for this paper is the potential to use ferret tRG cells to model those of the human brain. However to support this claim (see Lines 83-84), I believe a comparison of the ferret tRG cells with existing cortical organoid datasets (Bhaduri et al., 2020, PMID: 31996853) would be helpful. If cortical organoids currently lack the presence of tRG cell types, that would strengthen the importance of the ferret model and the findings of this paper - otherwise, I feel that the use of the ferret model needs to be justified in light of the greater accesibility and genetic tractability of the cortical organoid system.
We absolutely agree that human organoids are good models to study human brain development.
Revision plan:
According to the suggestion of reviewer 1, we analyzed two cortical organoid datasets (Bhaduri et al., 2020; Herring et al., 2022) to examine whether different tRG populations are present in organoids. Our analyses led us to conclude that tRG-like populations seem to be lacking in available organoid datasets; organoids can have CRYAB-expressing astrocyte-like cells in single-cell transcriptome datasets, but the presence of tRG-like cells seem to be unstable and dependent of lines and protocols how organoids are generated. A further assessment on tRGs’ cellular features is required on organoids by immunostaining experiments. In the light of this analysis, we elaborated our discussion by describing observations shown below. Below is our analysis of organoid data.
Bhaduri dataset contained organoids generated from 4 different lines, which showed a variability in terms of cell distribution on UMAP while overall temporal and differentiation axes were recapitulated (A). While keeping the original cluster annotations except for YH10 line, we performed reclustering. CRYAB was expressed in clusters 26 and 30 enriched in YH10 line, and cluster 29 enriched in 13234 line (B).
To confirm the identity of these clusters, we integrated organoid dataset with the dataset of primary tissues from the same paper (Bhaduri et al., 2020; C).
As a result of the integration, tRG cells from the primary tissue were not overlapped with organoid-derived CRYAB-expressing cells, although a part of CRYAB-expressing organoid cells were localized in the integrated cluster 16 where primary tRG resided (D). Other cell types that were included in the integrated cluster 16 were “lateRG”, “vRG”, “oRG” from primary tissue dataset, and “glycolyticRG” from organoid dataset. We found that CRYAB-expressing organoid clusters 26 and 30 overlapped with “oRG/astrocyte” clusters of primary tissues.
Furthermore, we have analyzed another organoid dataset in stages including 5-months, 9-months and 12-months (Herring et al., 2022; E), but found no clusters that specifically expressed CRYAB (F).
1-4. I found the total number of tRG-like cells in the ferret dataset quite small (162), but I understand the difficulty with isolating and sequencing rare cell types from primary tissue sources. I believe most of the transcriptomic analyses were conducted with this low n in consideration, but this caveat is even more reason to pare down the wording for the weaker claims mentioned above.
We thank the Reviewer for appreciating the difficulties associated with isolating and sequencing rare cell types. We were able to identify a total of 409 tRG cells (in tRG-like cluster) after merging all timepoints of sequencing, (Figure 1C, S3C) as stated in line 162 of the original manuscript. However, to perform pseudotime analyses, we subset our dataset using 6,000 cells in total (excluding neuron and non-progenitor clusters; Methods), which included 162 tRG cells. Pseudotime analysis transcriptomically distinguished tRG into 3 subgroups (Figure 4E). Remaining 247 tRG cells also appear to distribute similarly into these subgroups rather than forming a distinct subregion within tRG cluster (right panel in figure below). Furthermore, we conducted extensive immunohistochemical analyses of tRG-like cells, and we found that both the morphology and gene/protein expression were consistent with the notion that “tRG-like” cluster in our ferret dataset represents tRG defined in humans (Nowakowski et al., 2016).
Revision plan:
As for human dataset, we agree that the population of committed tRG was minor. Thus, we pared down our statements regarding the fates of tRG as mentioned in other comments, both in the Results and Discussion.
- Are prior studies referenced appropriately?
1-5. I found it interesting that tRGs persist and even expand in number in postnatal timepoints (Fig. 2C). I'd be interested to know if this is in line with what is known in human developing cortex. If so, it would strengthen the conclusion that ferret tRGs can model that of humans - and if not, this would either be an important finding regarding tRG function or an important caveat in the use of ferret tRGs to model the cell type in humans.
We thank the Reviewer for bringing up this issue. This is an important issue because we wanted in this study to use the ferret as a good model for the complex brain development in gyrencephalic animals, in general, to know what characteristics are shared or not, across gyrencephalic species (such as the presence of the OSVZ vs. the temporal scale).
Revision plan:
Our study demonstrated the presence of tRG cells up to P10 by immunohistochemistry and scRNA-seq. P5~P10 is the stage where neurogenesis became dominated by gliogenesis in the dorsal cortex in ferrets, although its timing is delayed in the visual cortex. On the other hand, Nowakowski et al. (2016) originally identified and defined CRYAB-expressing tRG, based on morphology and gene expression on human primary tissues during mid-neurogenic stages, while cortical neurogenesis is mostly declined in human postnatal stages. We have failed to find literatures or textbooks describing the presence of CRYAB-expressing tRG, while an ependymal layer was detected in the postnatal human cortices (Honig et al., 1996; preprint Nascimento et al., 2022). At the moment, the lack of information thus makes it difficult to compare the relationship of birth timing with the period of tRG persistence between ferrets and humans. In the revised manuscript, the “Discussion” will include this argument as well as the following difference between humans and ferrets in the RG scaffold.
Besides birth timing, Nowakowski et al. also reported that radial glia scaffold spanning from the VZ to the pial surface undergoes a transformation during neurogenic stages; tRG becomes the major RG population in the VZ, disconnecting VZ and OSVZ. In contrast, we did not find a discontinuous scaffold stage over the course of ferret neurogenesis. Instead, we still detected CRYAB-negative vRG with an apical attachment and a basal process extending beyond the OSVZ during stages where the peak of tRG expansion is achieved (such as P5 in Figure 2A, S3A). This appears to be a prominent difference between human and ferret corticogenesis.
- Are the text and figures clear and accurate? Yes
- Do you have suggestions that would help the authors improve the presentation of their data and conclusions?
1-6. For Fig. 2A, I would find it helpful to compare the morphology of GFP+/CRYAB+ cells vs GFP+/CRYAB- cells, with the hypothesis that GFP+/CRYAB- cells will have elongated basal processes. I believe this could be done by finding GFP+/CRYAB- cells in the raw images obtained to generate Fig. 2A (or similar), and showing those cells in an adjacent panel. This side-by-side comparison could provide more support that the CRYAB+ cells from the single-cell analyses are indeed specifically linked to tRG-like morphology.
Revision plan:
We prepared the images for GFP+/CRYAB- vRG cells in an adjacent panel in Figure 2A as recommended by the reviewer (below). To better distinguish the morphology of an isolated vRG cell from other labelled cells, we sparsely labeled RG cells with EGFP at P3 by electroporation (Methods), and fixed the samples two days later (right panel). We highlighted the morphology (cell body and basal fiber) of a CRYAB- GFP+ vRG and that of a neighboring CRYAB+ GFP- tRG on the same panel to clarify that vRG did not express CRYAB.
Reviewer #1 (Significance (Required)):
This paper primarily presents a technical advance in the field, showing that tRG cells that can model those found in the developing human cortex are found in the developing ferret cortex.
- Place the work in the context of the existing literature (provide references, where appropriate).
- State what audience might be interested in and influenced by the reported findings.
Several studies in the human and macaque brain have identified the presence of tRGs (deAzevedo et al., 2003; Nowakowski et al., 2016), but understanding the molecular functions and development of these cells - and many human-specific cell types in the brain - is difficult due to the lack of tractable models of human neurodevelopment. Ferrets, given their layered cortices, may be a potential model system for these cell types, but further analyses to determine their transcriptomic similarity to the developing human cortex and their ability to recapitulate human cell types are required in order to evaluate their use as a model system. By generating a useful resource in the ferret single-cell transcriptomic atlas, this study provides evidence that - at least for the tRG subtypes - ferrets may be useful in dissecting the generation and functional importance of tRG cells. With the caveat that a direct comparison with the use of cortical organoids to study tRG is lacking in this paper (see above), I believe this work can provide useful insight into the field's current search for model systems to functionally interrogate human-specific aspects of cortical development.
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
2-1. In this report, Bilgic and colleagues study the diversity of progenitor cell types in the developing ferret cerebral cortex, a valuable in vivo model to understand cortex expansion and folding, as in primates including human. Using a single-cell transcriptomics approach, they describe a diversity of progenitor cell types and their interrelation by transcriptomic trajectories, which are conserved but biased as development progresses. Most interestingly, they identify in ferret a type of cell only identified in human before, tRG, which they then characterize throughoutly by transcriptomics. They also identify these cells in histological sections, and via time-lapse videomicroscopy they characterize their cell type of origin. They also provide indirect evidence that tRG may be the source of ependymal cells in the ventricle of the mature cerebral cortex, as well as astroglial progenitor cells. Finally, they extend their analyses to identify oRG in ferret based on previous human single cell data, concluding that they have in ferret a quite different transcriptomic profile than in human.
We would like to thank the reviewer for carefully reading our manuscript and providing us with valuable feedback. However, we would like to clarify that there might have been a misunderstanding regarding our conclusion about the identification of oRG-like cells in ferrets.
Our study did not conclude that we have identified oRG cells in ferrets with “a quite different transcriptomic profile than in human”. Instead, our findings indicate that unlike oRG cells in human, ferret oRG-like cells did not exhibit specificity for human oRG markers (such as HOPX and CLU) that would enable us to distinguish them from other late RG cells in ferrets. Despite this, oRG score derived from human oRG marker expression showed higher values in predicted ferret oRG-like cells compared to other ferret RG cells, reflecting a similarity of the transcriptome profile between human oRG and ferret oRG-like cells (Figure 7H-I). We will carefully describe our methodology to reach this conclusion in response to reviewer 2’s comment regarding how we determined ferret oRG in a later comment.
Major issues:
2-2. The authors must provide evidence that the cortical area they are examining will give rise to Somatosensory cortex. Their sampling area appears more like Cingulate cortex, while somatosensory may be a bit more lateral. The cingulate cortex is a very unique region, with some unique characteristics including lamination and connectivity. It would be important to provide some justification as to why they chose this particular part of the cerebral cortex, and keep this into consideration when discussing the general value of their findings.
The reviewer 2 seems to misunderstand that we took cortical strips shown in Figure S1A as samples for scRNA seq. If our description in the main text is confusing, that would be our fault.
In Figure S1A of the original manuscript, we showed the cropped images of the medial part to emphasize the distinguishment of different germinal layers (VZ/iSVZ/oSVZ) and their temporal changes in ferret cortices.
Revision Plan. To avoid such a misleading, we inserted the dotty lines in the revised Figure S1A to demarcate the tissue parts for scRNAseq, which correspond to almost all lateral cortices, mainly including the somatosensory area 1 and 2 with surrounding areas. We accordingly added the following sentence in the legend, “The approximate boundaries of dorsal cortex area used for scRNA sequencing are highlighted with dotty line segments in the dorsal cortex hemisphere above each strip.”.
We also show actual sampling for single-cell transcriptomics below. As our sampling was not restricted to the somatosensory cortex, we have revised “somatosensory cortex” as “dorsal cortex” in Lines 131 and 1191 of our manuscript.
2-3. It seems that the single cell datasets were collected from only 1 replica at each developmental stage. Current best practice sets the inclusion of several biological replicates. Whereas this represents multiplying the workload (and costs) and re-doing many of the analyses, it is currently highly valued. On the other hand, the authors already have their analysis pipelines defined, and so the time involved should be much shorter than before.
We disagree with the reviewer 2’s comment. We would like to clarify that we collected brain tissues in two different ways for the same set of developmental stages; one brain tissue by removing cortical plate (T); another independent brain tissue at the same developmental stage by sorting GFP-labelled lineage from neural progenitors that were electroporated at embryonic stages (AG, Methods). Both manipulations of samples aimed to increase progenitor cell populations in scRNAseq. Therefore, we have two sets of samples of the same temporal series, each prepared in a totally different way. All cell types were present in both methods of collection shown as Supplementary Figure 2E’ (below left) that separates samples by different preparations at each stage (by modifying Supplementary Figure 2E; below right). We believe that the biological replica (n=2) in this manuscript would be sufficiently reliable, judged by its reproducibility.
Here, we also cite several examples of papers important in the field of single-cell or bulk transcriptomics of brain tissue, where only a single replicate or pair (replica) was taken for experiments on mice, humans and ferrets:
mice: Ogrodnik et al., 2021 PMID: 33470505, Hochgerner et al., 2018 PMID: 29335606, Joglekar et al., 2021 PMID: 33469025;
human: Herring et al., 2022 PMID: 36318921, Polioudakis et al., 2019 PMID: 31303374, Mayer et al., 2019 PMID: 30770253, Fietz et al., 2012 PMID: 22753484;
macaque: Schmitz et al., 2022 PMID: 35322231;
ferret: Johnson et al., 2018 PMID: 29643508.
2-4. Single cell QC methods are incomplete as described in Methods. It is key to consider the relative abundance of mitochondrial RNAs when assessing the integrity and validity of cells, and thus a key criterion to select the cells for clustering analysis. The criteria for the selected choice of clustering resolution is also missing.
The reviewer pointed out an important criterion, the abundance of mitochondria.
Revision Plan:
We have now added the mitochondrial QC metrics in the new Figure S2A, and revised the legends as follows: “Violin plots showing the number of genes, mRNAs and the percentage of mitochondrial genes per cell in each sample and time point”. We have computed the percentage of mitochondrial genes for each cell type and found that the majority of cells in each cell type had a value less than 5% while the content value in some cells distributed along the range between 0% and 10%, up to a maximum of 28% (Figure S2A). Despite this, we have decided to include all cells that had less than 30% of mitochondrial genes in our analysis based on the percentage of reads mapped on mitochondrial genome for the following reasons:
- The percentage of mitochondrial indicates respiratory activity, rather than apoptosis and the percentage of mitochondrial quite depends on the tissue type and species. For example, in human case, such percentage range from 5%~30% (Mercer et al., 2011 Cell; The human mitochondrial transcriptome).
- Unfortunately, unlike human and mouse brains, there is no reference to show the percentage of mitochondrial in ferret brains. Therefore, the suitable way is to keep all of these cells.
- These cells showing high percentage of mitochondrial genes are not clustered as an apoptosis cluster in UMAP, instead, these cells are observed in most of clusters (below). Therefore, we believed that these cells are not apoptotic cells and include these cells in further analysis.
https://www.dropbox.com/scl/fi/4kp3fczxzo6x4fx8hqt8m/reviewer2_4_1.pdf?rlkey=ypojzbuwgelt51qlf56g883s9&dl=0 4. After all, we have obtained similar clustering overall after filtering cells with a higher percentage for mitochondrial genes; we set the threshold to 10%. This filtering resulted in 28,686 cells in our dataset. We then performed our workflow from the normalization step with the same settings that we applied to our original ferret dataset (Methods). Below, we show the results comparing newly generated clusters in this filtered subset on UMAP (left), and the original clusters shown in Figure 1B (right). 26 clusters were obtained in both conditions, and both major cell types and subtypes were conserved after filtering.
Clustering resolution: Our choice of the resolution was based on avoiding over- or under-clustering of ferret cells. After trying several resolution values, including 0.6, 0.8, 1.0 and 1.2, we have decided to use the resolution of 0.8 as the separation of cell types was the most reasonable among other resolutions that we have tried, in a similar way to actual known cell types. For example, the resolution of 0.6 did not distinguish “tRG” cells from “late_RG1” cells, as well as “early_RG” subtypes which were distinctly enriched with different cell cycle markers (Figure S2D). On the other hand, the resolution of 1.2 resulted in an over-clustering of IPC, OPC, DL neurons and microglia.
2-5. When first describing tRGs (line 171), orthogonal views of the image z-stacks must be shown to demonstrate the full morphology of these cells. The basal process might have been cut during tissue sectioning. The same applies to images in Fig. 2C, 2D, S3A.
Revision plan:
We focused on Figure 2A and S3A (2D is a histogram) to show the full morphology of CRYAB+ tRG, because Figure 2A is the initial presentation of tRG in this paper, and Fig. 2A and Fig.S3A images are taken on a 200-micrometer thick section, originally aiming to indicate that CRYAB-positive fiber is short, spanning nearly along the VZ and the SVZ. We made 3D-reconstructions of those images, which are rather better than orthogonal projections, in order to show that CRYAB+ fibers are shorter than those of vRG (terminating at positions around the upper boundary of the SVZ) and that the short basal processes are not due to the cut of long radial fibers during tissue sectioning.
We will show these 3D-reconstruction below. Please download movie files from the following URLs to look at them clearly.
Figure 2A
https://www.dropbox.com/s/qocve596c5xhtlc/%E2%98%85fig2A-Ver02.mp4?dl=0
Figure S3A
https://www.dropbox.com/s/v8gqwfi1r8ff5n5/%E2%98%85figS3A-P0%20movie-ver2.mp4?dl=0
2-6. In Figure 3, the authors perform time-lapse imaging to visualize and characterize the cells and lineage that give rise to tRGs. While very nice and a technical challenge that must be properly acknowledged, they unfortunately only obtained a total of three examples, which is clearly insufficient to reach any meaningful conclusion on this respect. These conclusions, while fascinating, are based only on 3 cell divisions. If this is to be taken as a strong argument for the conclusions of the study, the authors must obtain. If the authors want to make a solid statement out of this experimental approach, they must obtain a sufficient amount of additional data, which will depend on the variability of the results they find.
We thank the reviewer for appreciating our time-lapse imaging data as very nice and a technical challenge. The number of time-lapse imaging that could follow the cell fates was from “4” samples instead of 3. It is indeed very infrequent and difficult to obtain a complete set of consecutive divisions from vRG, followed by histochemical examinations (fixation, cryo-sectioning and immunostaining of slices). This is because some of EGFP-labeled cells are frequently indistinguishable from each other by overlapping within a clone or with cells in other clones. Therefore, we decided to take a different way to clarify the pathways from vRG and its variety to generate tRG at the tRG-generating stage.
Revision plan:
Increasing the number of time-lapse image series will be extremely inefficient because of the reasons described above, perhaps taking a long time such as 3-5 months according to our breeding schedule of ferrets. Therefore, we take an alternative way to clarify the division patterns from vRG to generate tRG, especially focusing on the identity and variety of vRG sibling cells at the tRG-generating stage; we are examining the sibling pair of vRG and/or precursor of tRG to see what kind of cell the vRGs actually generate at their mitosis. For this purpose, we electroporate ferret cortices with the EGFP-expressing plasmid approximately one cell cycle prior to fixation (E38 or P0). We then stain ferret cortices for a mitotic marker Ki67 and tRG marker CRYAB and other markers during the tRG-generating state (P0-P5), assuming the cell cycle length of vRG and IPC as approximately 33h~45h based on our own consecutive EdU labeling experiments and time-lapse imaging.
2-7. Still regarding the time-lapse results presented in Figure 3, it is unclear why after first division the authors identify the blue cell as IPC, when it has the exact features of tRG: apical process anchored in VZ surface + short basal process. This is applicable to all three examples shown. For example, the authors describe: "the mother IPC of tRG also possessed both an apical endfoot and a short basal fiber (Fig. 3D)". Why is this identified as IPC, when it looks exactly like vRG, NOT as an IPC? The interpretation of IPCs being the mother cells to tRGs must be changed, to those being vRGs. Or else, more convincing data must be provided.
In fact, their analyses in Fig 4A contradict their interpretation on tRG mother cells, showing that the transcriptomic trajectory leading to tRGs does not inlcude Eomes+ cells, accumulated in the neurogenic state 2. At the end of this section, the authors indicate: "our data suggest that tRG cells are formed by apical asymmetric division(s) from unique apical IPC with a short basal fiber (Tsunekawa et al, in preparation).". Being as important as this point is, if there is solid supporting data the authors must include it in this study.
We appreciate the reviewer 2’s question about “why is this identified as IPC, when it looks exactly like vRG, NOT as an IPC?”
Revision plan.
- We are confident that this blue-labeled cells in Figure 3A and D are not vRG but mitotic sibling cell (of vRG) with a short basal fiber (that we named IPC in the initial manuscript). We now made the morphological features of these cells clearly visible by constructing 3D-views of the images with different snapshot images (we show below and in the preliminary revision as a supplementary movie). In addition, it divides once as time-lapse imaging revealed, hence this cell is still mitotic, instead of a postmitotic cell. Therefore, we used the term that is generally used for this type of cells, namely, intermediate progenitor cells (IPC), by which we did not intend to refer to TBR2+ neurogenic IPC. We plan to include these revised images into our fully revised manuscript.
- We agree the reviewer 2 on the point that this blue-labeled cell may express CRYAB (the next comment of reviewer 2 essentially claims the same point), as we also wrote this possibility in line 204-207 of the original manuscript. It could not be technically possible at the moment to examine CRYAB expression in a cell emerging only in the course of time-lapse imaging. If we could label vRG with a transgenic or knock-in fluorescence marker, which mimics CRYAB gene expression, we could have figured out whether blue cells (the mitotic vRG sibling cells) express the CRYAB gene. Indeed, we tried to knock the EGFP gene in the CRYAB gene many times over a year, but have so far failed. Given that tRG is defined as the cell type expressing CRYAB with a short basal fiber at late-neurogenic stage, irrespective of its mitotic activity, this blue labeled vRG sibling cell in Fig. 3A (and/or Fig. 3D) might express CRYAB, hence can be a “mitotic tRG” (although its possibility seems to be low as shown in Fig. 2E). To avoid any possible misleading, we have changed the term of these cells to a “mitotic vRG sibling cell (or mitotic tRG parental cell) with a short basal process”, and add a comment that “this cell might be mitotic tRG with CRYAB expression”.
- As for the TBR2 expression, we do not know these cells that appeared in the course of time-lapse imaging express TBR2 or not. As shown in Fig. 2F, 10% (P10) to 30 % (P5) of CRYAB+ cells express TBR2. On the other hand, “intermediate progenitors” do not necessarily express TBR2 in general. Therefore, we disagree on the reviewer 2’s comment “their analyses in Fig 4A contradict their interpretation on tRG’s parent cells”, but “our analyses in Fig 4A is compatible with our interpretation on tRG’s parent cells in time-lapse imaging”, and that is “a mitotic vRG sibling (or mitotic tRG parental cell) with a short basal fiber divides to produce CRYAB+ tRG at the end of timelapse imaging”. However, to avoid any overstatements or misunderstanding on this issue, we have revised related text as described above.
- We are not able to include the data taken by Tsunekawa et al.. This is because we are going to submit a separate paper, which includes a large volume of data with human ones in collaboration with another group and largely concerns stages that are earlier than that of tRG formation. It is, therefore, not practical to combine these data with those described in this manuscript. Therefore, we remove all descriptions related with Tsunekawa et al.
Below we show snapshot images and 3D-reconstructions for Figure 3A and 3D. Please download movie files from the following URLs to view at them at the highest resolution.
@Figure 3A:
1)A time lapse movie (20 min interval) showing images around time 40:00 at which vRG underwent the second division.
https://www.dropbox.com/s/znx3bboxefhj0jt/%E2%98%85Fig_3A%20movies%20around%2040%20h.mp4?dl=0
2)Snapshot images for time 40:00
https://www.dropbox.com/s/6y25mk4jhwqy6v7/%E2%98%85E38-fig3A-sRG-2.png?dl=0
3) 3D-reconstruction images at the same time point (40:00)
4) The entire time-lapse movies of time 0:00-84:00; The mitotic sibling cell of the vRG is indicated by a white arrow.
https://www.dropbox.com/s/ywua95f8fmohsmc/%E2%98%85Fig3A-arrow-time.mp4?dl=0
@Figure 3D:
A revised time-lapse snapshots of Figure 3D.
The assignment of the cell has corrected to the right one for the same mitotic cell because cell body position at the first two time points were misassigned in the original manuscript (at the following time points, there is no change).
Snapshot image at time point of 06:20; https://www.dropbox.com/s/hn3v6ao1qkhnfjh/%E2%98%85Fig3D%20sRG%20at%200620.png?dl=0
Rotating movie of 3D-reconstruction at time point of 06:40:
2-8. Alternative interpretation of time-lapse images (lines 196-197): maybe a tRG can generate one tRG CRYAB+, and one IPC CRYAB-.
We agree with reviewer 2 that there is an alternative interpretation of cell identity appearing in time-lapse imaging of Fig. 3. In line 196-197, we wrote that “These mother IPC underwent an asymmetric division to generate a non-CRYAB expressing cell and a CRYAB__+ tRG”. As pointed by reviewer 2 here and in the previous comment, we cannot exclude the possibility that this vRG sibling cell may be a mitotic tRG (see our response to the previous reviewer 2 comment). If so, what we observed in Fig. 3A and D could be interpreted as a mitotic tRG, and generate one CRYAB+ tRG and one CRYAB- climbing cell. However, as we haven’t confirmed or stated whether this parent cell was a mitotic tRG, we also did not examine the identity of this sister cell of CRYAB+ tRG. It can be an IPC or nascent neuron or even an astroglial progenitor cell. From our data, we cannot say anything about the identity of the CRYAB-negative sister cell other than that this cell is CRYAB-negative, migrating upward. That is why we did not mention about the identity of this CRYAB-negative sister cell of tRG other than that the sister cell of tRG is CRYAB-negative.
Revision plan. We changed the term of IPC to “a mitotic vRG sibling cell” and describe the possibility that “This mitotic vRG sibling cell (or mitotic tRG parental cell) can be a mitotic tRG if this cell express CRYAB, and its apical division generates one tRG and one CRYAB-negative climbing cell with an unknown identity, replacing the description of line 196-197.
2-9. Arrows in Fig 5E are shifted between the top and bottom panels. There is no obvious evidence of mitosis visible. This should be unequivocally labeled with anti-PH3 antibodies.
We thank reviewer 2 for pointing our careless mistake.
Revision plan. We have corrected the shifted position of arrows in Figure 5E. We have removed “mitosis” in the title of Figure 5E since the initial manuscript did not include descriptions on mitosis in the text.
2-10. Line 277: “Transcriptomic trajectories were homologous across the two species”. What does this refer to? What are these trajectories? Pseudotime? Is this statistically tested?
The meaning of the term “Transcriptomic trajectories” was not clear.
Revision plan. We revised our description in this part as “Temporal patterns and variety of neural progenitors during the cortical development were similar to each other between humans and ferrets at the single cell transcriptome level”.
2-11. When comparing tRG cells between ferret and human, the authors indicate a remarkable similarity between the two species as represented by CRYAB, EGR1, and CYR61 expression. As shown in Fig 6E, EGR1 and CYR61 are not expressed selectively in human tRG as they clearly are in ferret tRG. Hence, this argument is not valid.
In lines 291-292, we mention that “tRG cells also showed a remarkable similarity between the two species (Fig. 6C, 6D), as represented by CRYAB, EGR1, and CYR61 expression (Fig. 6E)”. Here, what we wanted to claim is that the same combination of gene expression (CRYAB, EGR1, and CYR61) is characteristically at relatively high levels in both ferrets and human tRG. As the reviewer 2 claimed, CRYAB and CYR61 genes are highly selective for ferret tRG among mid-late RG types, while the expression of EGR1 and CYR1 are just relatively enriched in tRG than in other cell types in human RG (except for highly selective CRYAB). Irrespective of the difference in their relative enrichment in tRG between humans and ferrets, one can still state that the combination of these marker expression at higher levels is shared in these two species”. We were not able to find which part in the manuscript was the reviewer referring to for the claimed argument (“EGR1 and CYR61 are expressed selectively in human tRG”).
Revision plan. To clarify our statement, we changed this sentence into “tRG cells also showed a remarkable similarity between the two species (Fig. 6C, 6D), as represented by a high level of expression for the combination of CRYAB, EGR1, and CYR61 (Fig. 6E)”
2-12. In the last part, the authors try to identify oRG-like cells in ferret by comparison with their transcriptomes identified in human. For this, they decide to call ferret oRG-like cells those that are near human oRGs in the integrated UMAP, as identified in a previous human study. What was the criterion for this? How much near is "near"? The fact that the selected cells have higher oRG scores is expected and obvious, as these cells were selected precisely based on their proximity in the UMAP. Even more importantly, the identification of oRGs in the human study is not unambiguous. Therefore, the correlate in ferret cells is also non-conclusive as to the identity of such cells.
We apologize for a confusion caused by insufficient explanations for our methodology. We want to clarify that we did not find " ferret oRG-like cells as those near human oRGs in the integrated UMAP." Rather, we try to identify oRG-like cells in ferrets based on the hypothesis that, when comparing ferret and human datasets, oRG-like cells in ferrets would exhibit a higher degree of similarity to human oRG cells than to other cell types. This hypothesis was supported by our observations of other clusters such as tRG, later RG, and IPC (Figure 6 C and D).
To identify oRG-like cells in ferrets, we utilized the mutual nearest neighbor (MNN) method to determine the similarity between cells from different species (Stuart et al., 2019 PMID: 31178118). For example, when attempting to identify the human cell that was most similar to a given ferret cell (F), we calculated the distance between cell F and all the cells in the human dataset in the high dimensional expression space. This allowed us to identify a human cell (H) that exhibited the smallest distance to cell F. Subsequently, we computed the distance between cell H and all the cells in the ferret dataset. If cell F had the smallest distance to cell H in the human dataset, we considered cells H and F as a pair of mutual nearest neighbors.
Using this method, we can find all pair of mutual nearest neighbors in two datasets. We then find these pairs that one is human oRG and define the other is oRG-like in ferret. However, upon further investigation of the characteristics of these cells, we would not find any specific markers (such as HOPX and CLU in human oRG) that would enable us to distinguish them from other later RG cells in ferrets.
Accordingly, only when our strategy to find mutual nearest neighbors is suitable, the selected cells can get higher oRG score, otherwise, the selected set of ferret cells will not show a high oRG score. Therefore, we disagree with the notion that “The fact that the selected cells have higher oRG scores is expected and obvious”.
We hope this explanation provides a clearer understanding of our methodology and the rationale behind our approach to identifying potential oRG cells in ferrets.
2-13. Discussion is surprisingly short, given the emphasis that the authors place on the importance of their findings. I would suggest extending it for a better coverage of those findings that have the greatest relevance and interest to a wider readership.
Thank reviewer 2 for his/her precious advice.
Revision plan.
We added several issues discussed in the responses to the reviewers to Discussion. Please look at our responses to comment 2-14 and 2-15 as well as the preliminary manuscript.
2-14. In Discussion, the authors state that "ferret (and presumably also human) tRG cells differentiate into ependymal cells and astrogenic cells." Again, this conclusion is purely based on transcriptomic trajectories, which must not be confused with cell lineage. This sentence must be rephrased and toned down accordingly.
We appreciate Reviewer’s comment regarding the difference between transcriptomic trajectories and cell lineage. We agree that transcriptomic trajectories do not necessarily reflect cell lineage. However, relationships along transcriptomic trajectories provides useful information about the differentiation potential of cells. Furthermore, in this study, we examined the temporal and spatial relationships between CRYAB+ tRG and FoxJ1+ ependymal cells that were predicted as tRG descendant cells by transcriptomic trajectories. We could confirm an increasing overlap of FoxJ1+cells with tRG cells along the course of post-natal development in Figure 5. We thus accessed the relationship of the two cell types by not only in silico but also in vivo analyses.
Revision plan. We disagree with the reviewer 2 as for ferrets, because we accessed the relationship of tRG and their progeny cells by not only in silico but also in vivo analyses.
On the other hand, as for progenies of human tRG, they were predicted certainly depending on the molecular relationship by comparison with ferrets without histochemical evidence, as pointed by reviewer 2, and the populations of these committed tRG are small. Therefore, we removed “(and presumably also human)” and we tone down about the progeny relationship of tRG as a prediction. We also acknowledge that further studies are needed to confirm the lineage relationships among cell types, as we discussed in the Discussion part.
2-15. In Discussion: “our cross-species analysis highlights the notable role of tRG as progenitors contributing to the formation of the ependyma and white matter”. As mentioned above, this is only based on transcriptomic trajectories, it is not demonstrated in this study. In vivo analyses of cell fate are needed to support this conclusion, and a more extensive videomicroscopy analysis is needed to confirm the cell lineage progression suggested by transcriptomes.
The statement “the notable role of tRG as progenitors contributing to the formation of the ependyma and white matter” is certainly a speculation based on our results, but not experimentally indicated yet by such as gene knockout, as the reviewer pointed out. Although we repeatedly tried to knock out the CRYAB gene in ferrets for a year, we have so far failed.
Revision plan. Taking the comments from reviewer 1 and 2 into account, we largely revised “Discussion” with a more moderate expression, by incorporating comparative analyses with other human datasets, and we also emphasize the importance of in vivo studies as the next step. We just paste the last paragraph of the preliminary revised Discussion. Please see the “Discussion” in the preliminary revision of our manuscript.
“In ferrets, genetic manipulations can be achieved through in utero or postnatal electroporation, as well as via virus-mediated transfer of DNA (Borrell, 2010; Kawasaki et al, 2012; Matsui et al, 2013; Tsunekawa et al, 2016). Thus, it is theoretically possible to disrupt the CRYAB gene in vivo in ferrets to investigate its role in tRG and their progeny, including ependymal cells, and to track the tRG lineage. If the CRYAB gene is essential to form ependymal layers, we will be able to explore how the ventricle contributes to cortical folding and expansion. Despite extensive efforts over a year, we have thus far been unsuccessful in knocking in and/or knocking out the CRYAB gene. Nevertheless, we anticipate that technical advances will surpass our expectations, both in ferret and human organoids. Taken together, these functional studies in ferrets as well as in human organoids hold promising insights into the understanding of the tRG lineage and its contribution to cortical development in the near future”.
Minor issues:
2-16. In line 59, the authors state: "cerebral carcinogenesis independently evolved to gain an additional germinal layer (outer SVZ (OSVZ);". Assuming that they mean "cerebral neurogenesis", what is the evidence for this independent evolution? Original publications demonstrating this must be cited.
Revision plan. We removed the mentioned statement from our manuscript and revised lines 58-59 as follows: “In many mammalian phylogenic states, cerebral cortex evolved to gain an additional germinal layer (Smart et al. 2002; Zecevic et al. 2005; Kriegstein et al. 2006; Reillo et al. 2011)”.
2-17. Lines 60-61, the third key publication reporting the existence of bRG must be cited together with Hansen 2010 and Fietz 2010: Reillo et al., 2011, Cerebral Cortex.
We appreciate Reviewer 2’s remark.
Revision plan. We now added these citations in lines 60-61 and in the Reference list as Reillo I, De Juan Romero C, García-Cabezas MÁ & Borrell V (2011). A role for intermediate radial glia in the tangential expansion of the mammalian cerebral cortex. Cereb Cortex 21: 1674–1694.
2-18. When introducing ferret as an interesting or important animal model, suitable original studies should be cited.
Revision plan:
For ferrets, there is a long history as experimental animals for electrophysiology similarly with cats and monkeys, but this is not a review of ferret biology. We thus added 6 additional references regarding ferret brain morphology and development listed below.
Jackson, C.A., J.D. Peduzzi, and T.L. Hickey (1989) Visual cortex development in the ferret. I. Genesis and migration of visual cortical neurons. J. Neurosci.9:1242–1253. PMID: 2703875.
Chapman B & Stryker MP (1992) Origin of orientation tuning in the visual cortex. Curr Opin Neurobiol 2: 498–501.
Chenn A., and McConnell S.K. (1995) Cleavage orientation and the asymmetric inheritance of Notch1 immunoreactivity in mammalian neurogenesis. Chenn A, et al. Cell PMID: 7664342.
Noctor SC, Scholnicoff NJ, and Juliano SL. (1997) Histogenesis of ferret somatosensory cortex. J Comp Neurol. 387(2):179-93.PMID: 9336222.
Reid CB, Tavazoie SF, Walsh CA. (1997) Clonal dispersion and evidence for asymmetric cell division in ferret cortex. Development. 1997 124(12):2441-2450. doi: 10.1242/dev.124.12.2441.PMID: 9199370
2-19. In Figure 2F-H, layer borders should be labeled. The density of CRYAB+ cells in VZ (?) at P5 seems much greater in Fig 2E,F than in Fig. 2B. Clarifying this discrepancy is important to validate the quantification of Fig 2D.
Revision plan.
Layer borders: We now labeled the approximate position of the boundary of the VZ in Figure 2E-G. We have revised the legends as follows; “The border of the VZ is shown with a white line”. For counting, we have determined borders by the distribution of DAPI, and radial glia-specific markers in our hands and determined the approximative distance of the VZ border from the ventricular surface in the antero-posterior axis where we performed the imaging in Figure 2E-G. The distance was approximately determined as 80 µm at P5 and 40 µm at P10.
Discrepancy in the intensity of CRYAB: We apologize for the unclear statement on how the images were acquired in the legends of Figure 2E-G. We now revised as follows; “Representative images taken with a 100X-objective lens are shown with MAX projection.”. In Figure 2E-G, images were taken as optical sections of 1.5 µm interval for 12 µm-thick sections. Those images were processed as MAX-projection onto the Z plane. On the other hand, In Figure 2B, we have used 20X-objective lens, instead of 100X-objective lens and did not perform any image projection procedure such as a MAX-projection and only 1 z-plane is shown. Therefore, the visual difference in the CRYAB intensity between Figure 2B and Figure 2E-G derives from whether max projection of several consecutive images was done.
2-20. Co-expression of CRYAB and FOXJ1. In Fig 5B this must be demonstrated with merged channels.
Revision plan.
We added the images with merged channels as requested and revised corresponding legends as follows: “Images with merged channels in A are shown with the same color codes, antibodies and scale bars as A.”.
2-21. Line 247: "near which nuclear line aggregates are observed more frequently (Fig. 2B)". It is very much unclear what the authors refer to. Please, define nuclear line aggregates.
Revision plan.
We will revise the cited sentence and will change the referred figure as follows: “These cells often aligned on a line parallel to the ventricular surface (Fig. 5A)”. We show these nuclear rows by arrows.
2-22. There are a number of typos along the main text and figures, which must be fully checked and corrected. For example, line 59 "cerebral carcinogenesis"; also in Figure S4, Figure 5E. Labeling of graphs in Fig 5C is wrong. The plots present the fraction of CRYAB+ cells that express FOXJ1 (FOXJ1+/CRYAB+ cells), not the reverse.
Revision plan.
We thank the Reviewer for their remarks on typos. We corrected the typos indicated by Reviewer 2. We agree with the Reviewer and also modified the title of Figure 5B as suggested by the Reviewer.
Reviewer #2 (Significance (Required)):
This manuscript is of interest for being the first ferret single-cell study, and for identifying and characterizing to a great extent a unique population of cortical progenitor cells that so far had only been observed in human. The study is presented as a resource for studies of ferret cortex development, which as such is clearly of interest to a very limited audience. A more appealing perspective might be if this study in ferret is of interest or of use to the more general community studying cortex development, or even maybe cortex evolution.
We disagree the reviewer’s view that this study is clearly of interest to a very limited audience. This study first enabled a precise comparative analysis in which we could compare rich human single cell transcriptomes and the ferret dataset of single cell transcriptomes, which were based on greatly improved genomic information (especially, gene models). This study is also first to show global temporal patterns of cortical progenitors of a carnivore species, a famous gyrencephalic mammalian model, and have been shown to be similar to a primate species at the single cell transcriptomic level. Indeed, upon uploading this manuscript in BioRxiv, many non-ferret specialists as well as specialists have inquired datasets and requested some collaborations with us. So we believe that this paper has already attract a general interest of brain scientists.
Advance: it is, so far, the first study of single cell profiling of the ferret cerebral cortex, a well established and highly valued model of gyrencephalic mammals, and a suitable best-alternative to work in primates. In addition to the technical advance, providing a new resource for work in ferret, it shows for the first time the existence of truncated Radial Glia (tRG) in a non-human cortex, and even more importantly in this model, strengthening even more its value.
This study as is presented will be of most interest to a specialized audience, those directly working with ferret. Nevertheless, it will also be of conceptual interest to the community of cortex development and evolution for the concepts that one can extract on cell type conservation.
Description of the revisions that have already been incorporated in the transferred manuscript
Please insert a point-by-point reply describing the revisions that were already carried out and included in the transferred manuscript. If no revisions have been carried out yet, please leave this section empty.
1-1. The weakest claim in the paper is lines 202: "...tRG cells are formed by apical asymmetric division(s) from unique apical IPC". From my understanding, the main evidence that the tRG parent cells shown in Fig. 3 are not tRGs are the data from Fig. 2E-G showing the low amounts of CRYAB+ cells co-expressing KI67, TBR2, or OLIG2 in P5 and P10. Especially given that these timepoints are after those used in Fig. 3, I believe further evidence is needed to confirm the cell type identity of tRG parent cells in Fig. 3. Such experiments (isolating IPCs from ferret cortex and growing in vitro to determine progeny cells) may be outside of the scope of this paper, in which case I believe the text can be strengthened with either (1) presenting the data from the cited Tsunekawa et al, in preparation that would suggest this claim or (2) rephrasing these claims to omit the mention of IPCs.
- We revise the term “IPC” as “mitotic sibling of vRG” and stated that these cells might be tRG (CRYAB+) or non-tRG (CRYAB-) intermediate progenitors. By the term of “intermediate progenitors”, we did not intend to refer to TBR2+ neurogenic IPCs, but rather to an intermediate state of progenitors, in a general sense, with a similar morphology as tRG. To avoid any confusions on this terminology, we revised our manuscript by replacing “IPC” with “a sibling of vRG”.
- We delete all statements relevant to Tsunekawa et al. data from the manuscript. We regret that we are not able to include Tsunekawa et al. data because we are planning to submit this data as a separate manuscript, which describes that in ferrets, vRG frequently (30% of apical division) generate non-Tbr2-positive mitotic sibling cells bearing a short basal process during the entire neurogenesis. This study includes a large volume of data with human ones and largely concerns stages that are earlier than that of tRG formation. It is, therefore, not appropriate to combine these data with those described in this manuscript.
1-2. I also believe the claim in Line 365-366 is overstated: "We found that ferret (and presumably also human) tRG cells differentiate into ependymal cells and astrogenic cells." While I believe the transcriptomic comparisons suggest the presence of uncommitted tRG in both the ferret and human datasets, I would appreciate further analyses to confirm the prevalence of astroglial and ependymal tRG in the humans and/or functional analyses before claiming that human tRG cells make ependymal and astrogenic cells. I appreciate the authors' note that "GW25 is...the latest stages experimentally available" (line 376-377), but their comparative approaches could be applied to existing datasets of the human cortex (Herring et al., 2022, PMID: 36318921) that span later developmental ages. Identifying the presence of astroglial and ependymal tRGs in this and/or similar datasets would provide more convincing evidence of the tRGs' developmental potential. If this computational analysis is outside the scope of the paper, I believe paring the certainty of these claims (especially lines 379 - 383) and recognizing the need for further functional analyses would negate the need for deeper mechanistic validation.
- We compared our ferret dataset to the human postnatal dataset recommended by the Reviewer 1 (Herring et al., 2022). As a conclusion of our analyses shown below, we found that Herring et al., (2022) dataset was not favorable for a comparative analysis with our ferret dataset regarding the fates of human tRG, because Herring’s human dataset was derived from the prefrontal cortex; This human dataset does not include neither tRG cell population nor ependymal clusters. We have also elaborated our discussion after analyzing Herring et al. dataset in the discussion.
- We, therefore, pare down our claim in lines 365-366, by removing “(and presumably human)” to state that “Our pseudotime trajectory analyses and immunohistochemistry analyses strongly suggested that…”.
- We also tone down the statements as for the discussion of the relationship between human and ferrets regarding the tRG progeny fates (originally lines from 372 to the end) and also elaborated our discussion after analyzing Herring et al. dataset in the same paragraph.
We will describe the details of our analysis of Herring et al. (2022) below.
As mentioned above, Herring’s human dataset was derived from the prefrontal cortex, and that it did not include a specific subtype defined as tRG nor other HES1-expressing progenitor clusters such as RG in the original cluster annotation. We, therefore, re-clustered the raw dataset from GW22 (the earliest stage available) up to 10-months after birth by using Seurat pipeline with default parameters (B), and found a CRYAB-expressing population in the original “Astrocyte_GFAP” subtype among astrocyte clusters (A), which distribute in the most of collected stages, from late development through the adulthood. We then examined this dataset to find out whether tRG or its progenies are present.
After reclustering, CRYAB-expressing cells (with more than 1 raw count) represented 0.15% of the dataset and were grouped as a part of cluster 44, which was mostly derived from postnatal stages (among which 4-months was the most enriched one; C). Several astrocyte markers, such as SPARCL1, HOPX, CLU, and GJA1, as well as CRYAB, were enriched in the cluster 44 as revealed by FindMarkers (Methods). FOXJ1 expression was nearly absent overall in this dataset, indicating the absence of the ependymal cell population, a tRG-descendant cell types in ferrets (C).
To evaluate the similarity between cluster 44 and tRG or astroglial tRG, we next integrated Herring dataset with our ferret subset (about 15,000 cells) and the human GW25 subset from Bhaduri et al. (2021) of approx. 3,000 cells, both of which contained only progenitor cells. As we have done in Figure 7 of our original manuscript; we have removed cells other than progenitors, astrocytes and oligodendrocytes, such as neurons, microglia, endothelial cells. This resulted in about 20,000 cells in Herring dataset.
This integration (D) reveals that Herring’s cluster 44 is closely located to Bhaduri’s human and our ferret tRG clusters on UMAP, but does not overlap with these tRG clusters. This result further suggested that tRG population might be lacking or very rare in this neuron- and glia-dominated dataset, which might be due to the sampling method that targeted the enrichment of neuronal layers (Herring et al., 2022). It is also possible that this fragmented information on astrocyte and ependymal lineages could be due to the regional and/or temporal difference of samples between two human datasets.
1-3. I believe the most significant advance for this paper is the potential to use ferret tRG cells to model those of the human brain. However to support this claim (see Lines 83-84), I believe a comparison of the ferret tRG cells with existing cortical organoid datasets (Bhaduri et al., 2020, PMID: 31996853) would be helpful. If cortical organoids currently lack the presence of tRG cell types, that would strengthen the importance of the ferret model and the findings of this paper - otherwise, I feel that the use of the ferret model needs to be justified in light of the greater accesibility and genetic tractability of the cortical organoid system.
According to the suggestion of reviewer 1, we analyzed two cortical organoid datasets (Bhaduri et al., 2020; Herring et al., 2022) to examine whether different tRG populations are present in organoids. Our analyses led us to conclude that tRG-like populations seem to be lacking in available organoid datasets; organoids can have CRYAB-expressing astrocyte-like cells in single-cell transcriptome datasets, but the presence of tRG-like cells seem to be unstable and dependent of lines and protocols how organoids are generated. A further assessment on tRGs’ cellular features is required on organoids by immunostaining experiments. In the light of this analysis, we elaborated our discussion by describing observations shown below. Below is our analysis of organoid data.
Bhaduri dataset contained organoids generated from 4 different lines, which showed a variability in terms of cell distribution on UMAP while overall temporal and differentiation axes were recapitulated (A). While keeping the original cluster annotations except for YH10 line, we performed reclustering. CRYAB was expressed in clusters 26 and 30 enriched in YH10 line, and cluster 29 enriched in 13234 line (B).
To confirm the identity of these clusters, we integrated organoid dataset with the dataset of primary tissues from the same paper (Bhaduri et al., 2020; C). https://www.dropbox.com/scl/fi/qnqv2e87t74uom2pg836d/reviewer1_3CD.pdf?rlkey=mv370b3dlogwvgh6ig8bdathpdl=0
As a result of the integration, tRG cells from the primary tissue were not overlapped with organoid-derived CRYAB-expressing cells, although a part of CRYAB-expressing organoid cells were localized in the integrated cluster 16 where primary tRG resided (D). Other cell types that were included in the integrated cluster 16 were “lateRG”, “vRG”, “oRG” from primary tissue dataset, and “glycolyticRG” from organoid dataset. We found that CRYAB-expressing organoid clusters 26 and 30 overlapped with “oRG/astrocyte” clusters of primary tissues.
1-4. I found the total number of tRG-like cells in the ferret dataset quite small (162), but I understand the difficulty with isolating and sequencing rare cell types from primary tissue sources. I believe most of the transcriptomic analyses were conducted with this low n in consideration, but this caveat is even more reason to pare down the wording for the weaker claims mentioned above.
As for human dataset, we agree that committed tRG was minor. Thus, we pared down our statements regarding the fates of tRG as mentioned in other comments, both in the Results and Discussion.
1-5. I found it interesting that tRGs persist and even expand in number in postnatal timepoints (Fig. 2C). I'd be interested to know if this is in line with what is known in human developing cortex. If so, it would strengthen the conclusion that ferret tRGs can model that of humans - and if not, this would either be an important finding regarding tRG function or an important caveat in the use of ferret tRGs to model the cell type in humans.
Our study demonstrated the presence of tRG cells up to P10 by immunohistochemistry and scRNA-seq. P5~P10 is the stage where neurogenesis became dominated by gliogenesis in the dorsal cortex in ferrets, although its timing is delayed in the visual cortex. On the other hand, Nowakowski et al. (2016) originally identified and defined CRYAB-expressing tRG, based on morphology and gene expression on human primary tissues during mid-neurogenic stages, while cortical neurogenesis is mostly declined in human postnatal stages. We have failed to find literatures or textbooks describing the presence of CRYAB-expressing tRG, while an ependymal layer was detected in the postnatal human cortices (Honig et al., 1996; preprint Nascimento et al., 2022). At the moment, the lack of information thus makes it difficult to compare the relationship of birth timing with the period of tRG persistence between ferrets and humans. In the revised manuscript, the “Discussion” will include this argument as well as the following difference between humans and ferrets in the RG scaffold.
Besides birth timing, Nowakowski et al. also reported that radial glia scaffold spanning from the VZ to the pial surface undergoes a transformation during neurogenic stages; tRG becomes the major RG population in the VZ, disconnecting VZ and OSVZ. In contrast, we did not find a discontinuous scaffold stage over the course of ferret neurogenesis. Instead, we still detected CRYAB-negative vRG with an apical attachment and a basal process extending beyond the OSVZ during stages where the peak of tRG expansion is achieved (such as P5 in Figure 2A, S3A). This appears to be a prominent difference between human and ferret corticogenesis.
1-6. For Fig. 2A, I would find it helpful to compare the morphology of GFP+/CRYAB+ cells vs GFP+/CRYAB- cells, with the hypothesis that GFP+/CRYAB- cells will have elongated basal processes. I believe this could be done by finding GFP+/CRYAB- cells in the raw images obtained to generate Fig. 2A (or similar), and showing those cells in an adjacent panel. This side-by-side comparison could provide more support that the CRYAB+ cells from the single-cell analyses are indeed specifically linked to tRG-like morphology.
We prepared the images for GFP+/CRYAB- vRG cells in an adjacent panel in Figure 2A as recommended by the reviewer (below). To better distinguish the morphology of an isolated vRG cell from other labelled cells, we sparsely labeled RG cells with EGFP at P3 by electroporation (Methods), and fixed the samples two days later (right panel). We highlighted the morphology (cell body and basal fiber) of a CRYAB- GFP+ vRG and that of a neighboring CRYAB+ GFP- tRG on the same panel to clarify that vRG did not express CRYAB.
2-2. The authors must provide evidence that the cortical area they are examining will give rise to Somatosensory cortex. Their sampling area appears more like Cingulate cortex, while somatosensory may be a bit more lateral. The cingulate cortex is a very unique region, with some unique characteristics including lamination and connectivity. It would be important to provide some justification as to why they chose this particular part of the cerebral cortex, and keep this into consideration when discussing the general value of their findings.
To avoid such a misleading, we inserted the dotty lines in the revised Figure S1A to demarcate the tissue parts for scRNAseq, which correspond to almost all lateral cortices, mainly including the somatosensory area 1 and 2 with surrounding areas. We accordingly added the following sentence in the legend, “The approximate boundaries of dorsal cortex area used for scRNA sequencing are highlighted with dotty line segments in the dorsal cortex hemisphere above each strip.”.
We also show actual sampling for single-cell transcriptomics below. As our sampling was not restricted to the somatosensory cortex, we have revised “somatosensory cortex” as “dorsal cortex” in Lines 131 and 1191 of our manuscript.
2-4. Single cell QC methods are incomplete as described in Methods. It is key to consider the relative abundance of mitochondrial RNAs when assessing the integrity and validity of cells, and thus a key criterion to select the cells for clustering analysis. The criteria for the selected choice of clustering resolution is also missing.
We have now added the mitochondrial QC metrics in the new Figure S2A, and revised the legends as follows: “Violin plots showing the number of genes, mRNAs and the percentage of mitochondrial genes per cell in each sample and time point”. We have computed the percentage of mitochondrial genes for each cell type and found that the majority of cells in each cell type had a value less than 5% while the content value in some cells distributed along the range between 0% and 10%, up to a maximum of 28% (Figure S2A). Despite this, we have decided to include all cells that had less than 30% of mitochondrial genes in our analysis based on the percentage of reads mapped on mitochondrial genome for the following reasons:
- The percentage of mitochondrial indicates respiratory activity, rather than apoptosis and the percentage of mitochondrial quite depends on the tissue type and species. For example, in human case, such percentage range from 5%~30% (Mercer et al., 2011 Cell; The human mitochondrial transcriptome).
- Unfortunately, unlike human and mouse brains, there is no reference to show the percentage of mitochondrial in ferret brains. Therefore, the suitable way is to keep all of these cells.
- These cells showing high percentage of mitochondrial genes are not clustered as an apoptosis cluster in UMAP, instead, these cells are observed in most of clusters (below). Therefore, we believed that these cells are not apoptotic cells and include these cells in further analysis. https://www.dropbox.com/scl/fi/4kp3fczxzo6x4fx8hqt8m/reviewer2_4_1.pdf?rlkey=ypojzbuwgelt51qlf56g883s9&dl=0
- After all, we have obtained similar clustering overall after filtering cells with a higher percentage for mitochondrial genes; we set the threshold to 10%. This filtering resulted in 28,686 cells in our dataset. We then performed our workflow from the normalization step with the same settings that we applied to our original ferret dataset (Methods). Below, we show the results comparing newly generated clusters in this filtered subset on UMAP (left), and the original clusters shown in Figure 1B (right). 26 clusters were obtained in both conditions, and both major cell types and subtypes were conserved after filtering.
Clustering resolution: Our choice of the resolution was based on avoiding over- or under-clustering of ferret cells. After trying several resolution values, including 0.6, 0.8, 1.0 and 1.2, we have decided to use the resolution of 0.8 as the separation of cell types was the most reasonable among other resolutions that we have tried, in a similar way to actual known cell types. For example, the resolution of 0.6 did not distinguish “tRG” cells from “late_RG1” cells, as well as “early_RG” subtypes which were distinctly enriched with different cell cycle markers (Figure S2D). On the other hand, the resolution of 1.2 resulted in an over-clustering of IPC, OPC, DL neurons and microglia.
2-5. When first describing tRGs (line 171), orthogonal views of the image z-stacks must be shown to demonstrate the full morphology of these cells. The basal process might have been cut during tissue sectioning. The same applies to images in Fig. 2C, 2D, S3A.
We focused on Figure 2A and S3A (2D is a histogram) to show the full morphology of CRYAB+ tRG, because Figure 2A is the initial presentation of tRG in this paper, and Fig. 2A and Fig.S3A images are taken on a 200-micrometer thick section, originally aiming to indicate that CRYAB-positive fiber is short, spanning nearly along the VZ and the SVZ. We made 3D-reconstructions of those images, which are rather better than orthogonal projections, in order to show that CRYAB+ fibers are shorter than those of vRG (terminating at positions around the upper boundary of the SVZ) and that the short basal processes are not due to the cut of long radial fibers during tissue sectioning (we show in below and in the final version as a supplementary figure and movies).
We show these 3D-reconstruction in below. Please download movie files from the following URLs to look at them clearly.
Figure 2A
https://www.dropbox.com/s/qocve596c5xhtlc/%E2%98%85fig2A-Ver02.mp4?dl=0
Figure S3A
https://www.dropbox.com/s/v8gqwfi1r8ff5n5/%E2%98%85figS3A-P0%20movie-ver2.mp4?dl=0
2-7. Still regarding the time-lapse results presented in Figure 3, it is unclear why after first division the authors identify the blue cell as IPC, when it has the exact features of tRG: apical process anchored in VZ surface + short basal process. This is applicable to all three examples shown. For example, the authors describe: "the mother IPC of tRG also possessed both an apical endfoot and a short basal fiber (Fig. 3D)". Why is this identified as IPC, when it looks exactly like vRG, NOT as an IPC? The interpretation of IPCs being the mother cells to tRGs must be changed, to those being vRGs. Or else, more convincing data must be provided.
In fact, their analyses in Fig 4A contradict their interpretation on tRG mother cells, showing that the transcriptomic trajectory leading to tRGs does not inlcude Eomes+ cells, accumulated in the neurogenic state 2. At the end of this section, the authors indicate: "our data suggest that tRG cells are formed by apical asymmetric division(s) from unique apical IPC with a short basal fiber (Tsunekawa et al, in preparation).". Being as important as this point is, if there is solid supporting data the authors must include it in this study.
- We are confident that this blue-labeled cells in Figure 3A and D are not vRG but mitotic sibling cell (of vRG) with a short basal fiber (that we named IPC in the initial manuscript). We now made the morphological features of these cells clearly visible by constructing 3D-views of the images with different snapshot images (we show below and in the final revision as a supplementary figure and movies). In addition, it divides once as time-lapse imaging revealed, hence this cell is still mitotic, instead of a postmitotic cell. Therefore, we used the term that is generally used for this type of cells, namely, intermediate progenitor cells (IPC), by which we did not intend to refer to TBR2+ neurogenic IPC. We plan to include these revised images into our fully revised manuscript.
- We agree the reviewer 2 on the point that this blue-labeled cell may express CRYAB (the next comment of reviewer 2 essentially claim the same point), as we also wrote this possibility in line 204-207 of the original manuscript. It could not be technically possible at the moment to examine CRYAB expression in a cell emerging only in the course of time-lapse imaging. If we could label vRG with a transgenic or knock-in fluorescence marker, which mimics CRYAB gene expression, we could have figured out whether blue cells the mitotic vRG sibling cells (or mitotic tRG parental cell) express the CRYAB gene. Indeed, we tried to knock the EGFP gene in the CRYAB gene many times over a year, but have so far failed. Given that tRG is defined as the cell type expressing CRYAB with a short basal fiber at late-neurogenic stage, irrespective of its mitotic activity, this blue labeled vRG sibling cell in Fig. 3A (and/or Fig. 3D) might express CRYAB, hence can be a “mitotic tRG” (although its possibility seems to be low as shown in Fig. 2E). To avoid any possible misleading, we have changed the term of these cells to a “mitotic vRG sibling cell (or mitotic tRG parental cell) with a short basal process”, and add a comment that “this cell might be mitotic tRG with CRYAB expression”.
- As for the TBR2 expression, we do not know these cells that appeared in the course of time-lapse imaging express TBR2 or not. As shown in Fig. 2F, 10% (P10) to 30 % (P5) of CRYAB+ cells express TBR2. On the other hand, “intermediate progenitors” do not necessarily express TBR2 in general. Therefore, we disagree on the reviewer 2’s comment “their analyses in Fig 4A contradict their interpretation on tRG’s parent cells”, but “our analyses in Fig 4A is compatible with our interpretation on tRG’s parent cells in time-lapse imaging”, and that is “a mitotic vRG sibling (or mitotic tRG parental cell) with a short basal fiber divides to produce CRYAB+ tRG at the end of timelapse imaging”. However, to avoid any overstatements or misunderstanding on this issue, we have revised related text as described above.
- We are not able to include the data taken by Tsunekawa et al.. This is because we are going to submit a separate paper, which includes a large volume of data with human ones in collaboration with another group and largely concerns stages that are earlier than that of tRG formation. It is, therefore, not practical to combine these data with those described in this manuscript. Therefore, we remove all descriptions related with Tsunekawa et al.
Below we show snapshot images and 3D-reconstructions for Figure 3A and 3D. Please download movie files from the following URLs to look at them clearly.
@Figure 3A:
1)A time lapse movie (20 min interval) showing images around time 40:00 at which vRG underwent the second division. https://www.dropbox.com/s/znx3bboxefhj0jt/%E2%98%85Fig_3A%20movies%20around%2040%20h.mp4?dl=0
2)Snapshot images for time 40:00
https://www.dropbox.com/s/6y25mk4jhwqy6v7/%E2%98%85E38-fig3A-sRG-2.png?dl=0
3) 3D-reconstruction images at the same time point (40:00)
4) The entire time-lapse movies of time 0:00-84:00; The mitotic sibling cell of the vRG is indicated by a white arrow.
https://www.dropbox.com/s/ywua95f8fmohsmc/%E2%98%85Fig3A-arrow-time.mp4?dl=0
@Figure 3D:
A revised time-lapse snapshots of Figure 3D.
The assignment of the cell has corrected to the right one for the same mitotic cell because cell body position at the first two time points were misassigned in the original manuscript (at the following time points, there is no change).
Snapshot image at time point of 06:20; https://www.dropbox.com/s/hn3v6ao1qkhnfjh/%E2%98%85Fig3D%20sRG%20at%200620.png?dl=0
Rotating movie of 3D-reconstruction at time point of 06:40:
2-8. Alternative interpretation of time-lapse images (lines 196-197): maybe a tRG can generate one tRG CRYAB+, and one IPC CRYAB-.
We changed the term of IPC to “a mitotic vRG (or mitotic tRG parental cell) sibling cell” and describe the possibility that “This mitotic vRG sibling cell (or mitotic tRG parental cell) can be a mitotic tRG if this cell express CRYAB, and its apical division generates one tRG and one CRYAB-negative climbing cell with an unknown identity, replacing the description of line 196-197.
2-9. Arrows in Fig 5E are shifted between the top and bottom panels. There is no obvious evidence of mitosis visible. This should be unequivocally labeled with anti-PH3 antibodies.
We have corrected the shifted position of arrows in Figure 5E. We have removed “mitosis” in the title of Figure 5E since the initial manuscript did not include descriptions on mitosis in the text.
2-10. Line 277: “Transcriptomic trajectories were homologous across the two species”. What does this refer to? What are these trajectories? Pseudotime? Is this statistically tested?
We revised our description in this part as “Temporal patterns and variety of neural progenitors during the cortical development were similar to each other between humans and ferrets at the single cell transcriptome level”.
2-11. When comparing tRG cells between ferret and human, the authors indicate a remarkable similarity between the two species as represented by CRYAB, EGR1, and CYR61 expression. As shown in Fig 6E, EGR1 and CYR61 are not expressed selectively in human tRG as they clearly are in ferret tRG. Hence, this argument is not valid.
To clarify our statement, we changed this sentence into “tRG cells also showed a remarkable similarity between the two species (Fig. 6C, 6D), as represented by a high level of expression for the combination of CRYAB, EGR1, and CYR61 (Fig. 6E)”
2-13. Discussion is surprisingly short, given the emphasis that the authors place on the importance of their findings. I would suggest extending it for a better coverage of those findings that have the greatest relevance and interest to a wider readership.
We added several issues discussed in the responses to the reviewers to Discussion. Please look at our responses to comment 2-14 and 2-15 as well as the preliminary manuscript.
2-15. In Discussion: “our cross-species analysis highlights the notable role of tRG as progenitors contributing to the formation of the ependyma and white matter”. As mentioned above, this is only based on transcriptomic trajectories, it is not demonstrated in this study. In vivo analyses of cell fate are needed to support this conclusion, and a more extensive videomicroscopy analysis is needed to confirm the cell lineage progression suggested by transcriptomes.
Taking the comments from reviewer 1 and 2 into account, we largely revised “Discussion” with a more moderate expression, by incorporating comparative analyses with other human datasets, and we also emphasize the importance of in vivo studies as the next step. We just paste the last paragraph of the preliminary revised Discussion. Please see the “Discussion” in the preliminary revision of our manuscript.
“In ferrets, genetic manipulations can be achieved through in utero or postnatal electroporation, as well as via virus-mediated transfer of DNA (Borrell, 2010; Kawasaki et al, 2012; Matsui et al, 2013; Tsunekawa et al, 2016). Thus, it is theoretically possible to disrupt the CRYAB gene in vivo in ferrets to investigate its role in tRG and their progeny, including ependymal cells, and to track the tRG lineage. If the CRYAB gene is essential to form ependymal layers, we will be able to explore how the ventricle contributes to cortical folding and expansion. Despite extensive efforts over a year, we have thus far been unsuccessful in knocking in and/or knocking out the CRYAB gene. Nevertheless, we anticipate that technical advances will surpass our expectations, both in ferret and human organoids. Taken together, these functional studies in ferrets as well as in human organoids hold promising insights into the understanding of the tRG lineage and its contribution to cortical development in the near future”.
2-16. In line 59, the authors state: "cerebral carcinogenesis independently evolved to gain an additional germinal layer (outer SVZ (OSVZ);". Assuming that they mean "cerebral neurogenesis", what is the evidence for this independent evolution? Original publications demonstrating this must be cited.
We removed the mentioned statement from our manuscript and revised lines 58-59 as follows: “In many mammalian phylogenic states, cerebral cortex evolved to gain an additional germinal layer (Smartet al. 2002; Zecevic et al. 2005; Kriegstein et al. 2006; Reillo et al. 2011)”.
2-17. Lines 60-61, the third key publication reporting the existence of bRG must be cited together with Hansen 2010 and Fietz 2010: Reillo et al., 2011, Cerebral Cortex.
We now added these citations in lines 60-61 and in the Reference list as Reillo I, De Juan Romero C, García-Cabezas MÁ & Borrell V (2011). A role for intermediate radial glia in the tangential expansion of the mammalian cerebral cortex. Cereb Cortex 21: 1674–1694.
2-18. When introducing ferret as an interesting or important animal model, suitable original studies should be cited.
For ferrets, there is a long history as experimental animals for electrophysiology similarly with cats and monkeys, but this is not a review of ferret biology. We thus added 6 additional references regarding ferret brain morphology and development listed below.
Jackson, C.A., J.D. Peduzzi, and T.L. Hickey (1989) Visual cortex development in the ferret. I. Genesis and migration of visual cortical neurons. J. Neurosci.9:1242–1253. PMID: 2703875.
Chapman B & Stryker MP (1992) Origin of orientation tuning in the visual cortex. Curr Opin Neurobiol 2: 498–501.
Chenn A., and McConnell S.K. (1995) Cleavage orientation and the asymmetric inheritance of Notch1 immunoreactivity in mammalian neurogenesis. Chenn A, et al. Cell PMID: 7664342.
Noctor SC, Scholnicoff NJ, and Juliano SL. (1997) Histogenesis of ferret somatosensory cortex. J Comp Neurol. 387(2):179-93.PMID: 9336222.
Reid CB, Tavazoie SF, Walsh CA. (1997) Clonal dispersion and evidence for asymmetric cell division in ferret cortex. Development. 1997 124(12):2441-2450. doi: 10.1242/dev.124.12.2441.PMID: 9199370
2-19. In Figure 2F-H, layer borders should be labeled. The density of CRYAB+ cells in VZ (?) at P5 seems much greater in Fig 2E,F than in Fig. 2B. Clarifying this discrepancy is important to validate the quantification of Fig 2D.
Layer borders: We now labeled the approximate position of the boundary of the VZ in Figure 2E-G. We have revised the legends as follows; “The border of the VZ is shown with a white line”. For counting, we have determined borders by the distribution of DAPI, and radial glia-specific markers in our hands and determined the approximative distance of the VZ border from the ventricular surface in the antero-posterior axis where we performed the imaging in Figure 2E-G. The distance was approximately determined as 80 µm at P5 and 40 µm at P10.
2-20. Co-expression of CRYAB and FOXJ1. In Fig 5B this must be demonstrated with merged channels.
We added the images with merged channels as requested and revised corresponding legends as follows: “Images with merged channels in A are shown with the same color codes, antibodies and scale bars as A.”.
2-21. Line 247: "near which nuclear line aggregates are observed more frequently (Fig. 2B)". It is very much unclear what the authors refer to. Please, define nuclear line aggregates.
We revise the cited sentence and will change the referred figure as follows: “These cells often aligned on a line parallel to the ventricular surface (Fig. 5A)”. We show these nuclear rows by arrows.
2-22. There are a number of typos along the main text and figures, which must be fully checked and corrected. For example, line 59 "cerebral carcinogenesis"; also in Figure S4, Figure 5E. Labeling of graphs in Fig 5C is wrong. The plots present the fraction of CRYAB+ cells that express FOXJ1 (FOXJ1+/CRYAB+ cells), not the reverse.
We thank the Reviewer for their remarks on typos. We corrected the typos indicated by Reviewer 2. We agree with the Reviewer and also modified the title of Figure 5B as suggested by the Reviewer.
Description of analyses that authors prefer not to carry out
Please include a point-by-point response explaining why some of the requested data or additional analyses might not be necessary or cannot be provided within the scope of a revision. This can be due to time or resource limitations or in case of disagreement about the necessity of such additional data given the scope of the study. Please leave empty if not applicable.
2-1. In this report, Bilgic and colleagues study the diversity of progenitor cell types in the developing ferret cerebral cortex, a valuable in vivo model to understand cortex expansion and folding, as in primates including human. Using a single-cell transcriptomics approach, they describe a diversity of progenitor cell types and their interrelation by transcriptomic trajectories, which are conserved but biased as development progresses. Most interestingly, they identify in ferret a type of cell only identified in human before, tRG, which they then characterize throughoutly by transcriptomics. They also identify these cells in histological sections, and via time-lapse videomicroscopy they characterize their cell type of origin. They also provide indirect evidence that tRG may be the source of ependymal cells in the ventricle of the mature cerebral cortex, as well as astroglial progenitor cells. Finally, they extend their analyses to identify oRG in ferret based on previous human single cell data, concluding that they have in ferret a quite different transcriptomic profile than in human.
We would like to thank the reviewer for carefully reading our manuscript and providing us with valuable feedback. However, we would like to clarify that there might have been a misunderstanding regarding our conclusion about the identification of oRG-like cells in ferrets.
Our study did not conclude that we have identified oRG cells in ferrets with “a quite different transcriptomic profile than in human”. Instead, our findings indicate that unlike oRG cells in human, ferret oRG-like cells did not exhibit specificity for human oRG markers (such as HOPX and CLU) that would enable us to distinguish them from other late RG cells in ferrets. Despite this, oRG score derived from human oRG marker expression showed higher values in predicted ferret oRG-like cells compared to other ferret RG cells, reflecting a similarity of the transcriptome profile between human oRG and ferret oRG-like cells (Figure 7H-I). We will carefully describe our methodology to reach this conclusion in response to reviewer 2’s comment regarding how we determined ferret oRG in a later comment.
2-3. It seems that the single cell datasets were collected from only 1 replica at each developmental stage. Current best practice sets the inclusion of several biological replicates. Whereas this represents multiplying the workload (and costs) and re-doing many of the analyses, it is currently highly valued. On the other hand, the authors already have their analysis pipelines defined, and so the time involved should be much shorter than before.
We disagree with the reviewer 2’s comment. We would like to clarify that we collected brain tissues in two different ways for the same set of developmental stages; one brain tissue by removing cortical plate (T); another independent brain tissue at the same developmental stage by sorting GFP-labelled lineage from neural progenitors that were electroporated at embryonic stages (AG, Methods). Both manipulations of samples aimed to increase progenitor cell populations in scRNAseq. Therefore, we have two sets of samples of the same temporal series, each prepared in a totally different way. All cell types were present in both methods of collection shown as Supplementary Figure 2E’ (section 2) that separates samples by different preparations at each stage (by modifying Supplementary Figure 2E; section 2). We believe that the biological replica (n=2) in this manuscript would be sufficiently reliable, judged by its reproducibility.
Here, we also cite several examples of papers important in the field of single-cell or bulk transcriptomics of brain tissue, where only a single replicate or pair (replica) was taken for experiments on mice, humans and ferrets:
mice: Ogrodnik et al., 2021 PMID: 33470505, Hochgerner et al., 2018 PMID: 29335606, Joglekar et al., 2021 PMID: 33469025;
human: Herring et al., 2022 PMID: 36318921, Polioudakis et al., 2019 PMID: 31303374, Mayer et al., 2019 PMID: 30770253, Fietz et al., 2012 PMID: 22753484;
macaque: Schmitz et al., 2022 PMID: 35322231;
ferret: Johnson et al., 2018 PMID: 29643508.
2-14. In Discussion, the authors state that "ferret (and presumably also human) tRG cells differentiate into ependymal cells and astrogenic cells." Again, this conclusion is purely based on transcriptomic trajectories, which must not be confused with cell lineage. This sentence must be rephrased and toned down accordingly.
We disagree with the reviewer 2 as for ferrets, because we accessed the relationship of tRG and their progeny cells by not only in silico but also in vivo analyses.
On the other hand, as for progenies of human tRG, they were predicted certainly depending on the molecular relationship by comparison with ferrets without histochemical evidence, as pointed by reviewer 2, and the populations of these committed tRG are small. Therefore, we removed “(and presumably also human)” and we tone down about the progeny relationship of tRG as a prediction. We also acknowledge that further studies are needed to confirm the lineage relationships among cell types, as we discussed in the Discussion part.
Reviewer #2 (Significance (Required)):
This manuscript is of interest for being the first ferret single-cell study, and for identifying and characterizing to a great extent a unique population of cortical progenitor cells that so far had only been observed in human. The study is presented as a resource for studies of ferret cortex development, which as such is clearly of interest to a very limited audience. A more appealing perspective might be if this study in ferret is of interest or of use to the more general community studying cortex development, or even maybe cortex evolution.
We disagree the reviewer’s view that this study is clearly of interest to a very limited audience. This study first enabled a precise comparative analysis in which we could compare rich human single cell transcriptomes and the ferret dataset of single cell transcriptomes, which were based on greatly improved genomic information (especially, gene models). This study is also first to show global temporal patterns of cortical progenitors of a carnivore species, a famous gyrencephalic mammalian model, and have been shown to be similar to a primate species at the single cell transcriptomic level. Indeed, upon uploading this manuscript in BioRxiv, many non-ferret specialists as well as specialists have inquired datasets and requested some collaborations with us. So we believe that this paper has already attract a general interest of brain scientists.
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
The authors do not wish to provide a response at this time.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary: This study by Magalhaes et al sheds light on the molecular underpinnings of the relative resistance of children to severe COVID-19. The authors found that priming of epithelial cells by resident immune cells to express tonic levels PRR receptors MDA-5 and RIG-I predisposes the epithelial cells for a faster and more robust onset of IFN-beta production upon SARS-CoV-2 infection. The study uses a combination of in vitro and ex vivo models, as well as mining of scRNA-Seq datasets from clinical specimens.
Major comments: The claims and conclusions are supported by the data and therefore no new experiments are needed.
Optional
- The use of primary cells (i.e. human airway epithelial cultures cross talking to immune cells) would make this study more compelling, although I assume that the major findings would be recapitulated in such models.
- It is not clear how the use of Yersinia enterocolitica to trigger activation of PBMC is relevant to this story. Using different (commensal) pathogens to achieve PBMC activation may yield different and more physiologically relevant results.
- The manuscripts would greatly benefit from improved structure and focus, particularly in the Abstract, Introduction and Results sections. The text is very dense, and makes it difficult for the reader to follow the flow and to distinguish important from less important information. Particularly, the introduction starts very broadly introducing COVID-19, which I think we are by now all familiar with. Directly starting with the burning question why kids get less sick with SARS-CoV-2 would capture the readers' attention better. Figure 1 a is beautiful for a review but much too dense to help the reader as a graphical abstract. In the results section, for each experiment, leading with clearly stating the rationale of the specific question, the gap in knowledge and why the gap is there, then followed by the results, then summarizing the impact of said results, would make this a much more enjoyable read and help the reader evaluate the novelty and impact better, particularly for Figures 1, 2, and 3 (but also all others). The interaction wheel graphs (Figure 4. are amazing, but are not properly explained in the text (do I read this right that in adults, all the crosstalk is basically performed by proliferating T-cells?). In all, these scientific writing issues sell an otherwise beautiful story short.
Referees cross-commenting
I agree with reviewers 1 and 2 that the use of primary cells would significantly elevate the story. However, I think this should be "optional", as I do not think it would change the findings.
Significance
General assessment:
The main strength of the study are its topic and clearly relevant question: why do kids rarely get severe COVID-19? The main novelty is the answer to this question, that immune cell-epithelial crosstalk in children elevates the tonic expression of MDA5 and RIG-I via the IRF1 axis, leading to faster onset of IFN production and signaling upon SARS-CoV-2 challenge, which ultimately mounts an antiviral response detrimental to robust SARS-CoV-2 replication. The study uses an innovative combination of in vivo and ex vivo experiments and analysis of clinical specimens.
The significant advance of this study to the field is clear to this reviewer, although it could be much better stated in the manuscript, as described at length above. The study is of great interest to the field of immunology and virology, and also has clinical and translational impact with respect to risk assessment for severe COVID-19 per age group, as well as epidemiological considerations for infection control.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
In the manuscript entitled "Enhanced airway epithelial response to SARS-CoV-2 infection in children is critically tuned by the crosstalk between immune and epithelial cells" Gonçalves Magalhães et al address the molecular interactions that result in greater antiviral responses to coronavirus infections in children versus adults. The authors have re-analyzed previously reported scRNA data from the nasal passages of healthy donors and found heightened pro-inflammatory responses in the nasal passages of children relative to the signatures in adults. Thus, the authors posit that this could result in priming of epithelial cells subsequently boosting antiviral responses to SARS-CoV-2 infection in a RIG-I and MDA5 dependent manner. Beyond the expected antiviral protection conferred by type I IFNs, the authors demonstrate type II IFN and TNF can also promote antiviral priming. Although epithelial and immune cell crosstalk has been previously demonstrated, this study proposes an age-dependent differences in the magnitude of this crosstalk. Indeed, bacterial stimulation of PBMCs derived from children resulted in greater cytokine [production and A549 priming. The article was well written, the data presented is compelling, and appropriately controlled. Importantly, the authors appropriately acknowledge the study limitations. The mechanisms that govern the increased inflammatory responsiveness of tissues derived from children remain to be addressed.
Major comments:
- Although the authors acknowledge this limitation, do primary epithelial cells respond to priming? Is there an age difference in viral detection and/or the response to priming?
- Optional: Does the deletion of IRF3 phenocopy MAVS deficiency in the context of type I IFN priming and blockade of IFN replication (Fig 2D)? Does priming induced increases in IRF1 and IRF7 and is this sufficient to overcome the loss of IRF3 (PMID: 25520509)?
Minor comments:
- Are the differences observed in MDA5 and RIG-I expression after PBMC stimulation across A549 IFNR KO cells significant?
- Figure 2C could be strengthened by the addition of total IRF3 and STAT2 immunoblot.
- Figure 3C, include tSTAT2 control.
- There is one typo on line 610. Change OSA2 to OAS2.
- Please expand the discussion to include relevant work on IFN and TNF-mediated antiviral priming (PMID: 16537619) and epithelial-immune cell crosstalk (PMID: 36563691).
Significance
Advance: This study expands upon previous work by the authors that described that children have higher expression of RLRs and in epithelial and immune cells relative to adults. The current work, provides an incremental but important advance to the previous study by demonstrating that PBMC-mediated priming of epithelial cells (A549). However, it remains to be addressed whether epithelial cells from children have increased capacity to detect SARS-CoV-2 infection or respond to priming.
Audience: This work is of interest to pediatric clinicians, virologists, immunologists, cell biologists, bioinformaticians.
Reviewer expertise: viral innate immunity; IFN regulation
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
In the manuscript entitled "Enhanced Airway Epithelial Response to SARS-CoV-2 Infection in Children is Critically Tuned by the Cross-Talk Between Immune and Epithelial Cells", the authors report a mechanism how airway epithelium of children is in a primed state to more efficiently defense SARS-CoV-2 infection. They interestingly found that the expression level of MDA5 and RIG-I are essential for this primed stage. In details, they discovered that enhanced immune-epithelial cell interactions through cytokines play a major role in the upregulation of these two RNA sensors, where IRF1 may be the most important regulator. They fully used their single cell sequencing data and established a relative convincing in vitro model to validate their hypothesis. This story is quite attractive to me since they explained the behind mechanisms for a clinical phenomenon. However, there are still some issues need to be addressed.
Major comments:
- A549 is a cancer cell line and cannot support SARS-CoV-2 replication. The authors reply on it too much. Some important experiments need to be performed in primary airway epithelial cells.
- MDA5 and RIG-I protein levels need to be detected in some important experiments such as Figure 4D, Figure 5A, Figure 5B, Figure 6B.
Minor comments:
- In figure 1B, the authors claimed that "As expected, pre-treatment alone did not trigger notable IFN-β transcription". But in my mind, pretreatment elevated IFN- β mRNA at least 5 folds compared to mock group (from 10-2.5 to 10-1.8). The authors need to make the statement more accurate.
- In figure 2A, the authors used IFNARKO cells. This should be mentioned in the manuscript.
- The statement of Figure 2C should be more accurate, "This was also confirmed at the downstream level of STAT2 activation, at which phosphorylation was still observed upon infection of RIG-I or MDA5 single KOs with SARS-CoV- 2, but was fully diminished only in the double KO cells (Fig 2C)." IRF3 phosphorylation is not downstream of STAT2. More downstream event can be shown as STAT1/STAT2/IRF9 nuclear translocation or ISGs transcription. Also, total STAT2 levels should be shown here.
- It is quite surprising that none of IRNAR, RIG-I, MDA5 affected SARS-CoV-2 replication in untreated cells.
- If we compare the mRNA induction of MDA5 and RIG-I between Figure 4D and Figure 6B, they are not in the same amplitude. There are 10 folds induction in Figure 4D while 100-300 folds in Figure 6B.
Significance
This is an interesting study with clear data. They fully used their single cell sequencing data and established a relative convincing in vitro model to validate their hypothesis. They uncovered an important mechanism why airway epithelium of children is in a primed state and more resistant to SARS-CoV-2 infection.
The limitation here is that they do not have in vivo model to support their conclusions.
Nevertheless, this manuscript is still able to answer a clinical question. Why children are much more resistant to SARS-CoV-2 infections compared to adults? It has good clinical significance. I believe that a broad audience will be interested in this story.
I study virus and cancer induced metabolic reprogramming, virus and host interaction and innate immune regulation, and mass spectrometry (metabolomics and proteomics).
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Manuscript number: RC-2023-01901
Corresponding author(s): Gavin, Sherlock
We thank the reviewers for their comments and their generally positive reviews – the reviews were constructive, and we have revised the manuscript to deal with all the requested changes and suggestions. We believe the manuscript is improved as a result, and hope that the reviewers agree that it is now suitable for publication. Below with provide a point-by-point reply that explains what revisions we have made. Reviewers’ comments are italicized, while our responses are highlighted.
- *
Reviewer #1:
- *
*It would be interesting have an idea of the global mutation rates and spectra in the diploid and haploid lineages across the conditions as well. The S. cerevisiae mutational spectrum has been shown to be dependent on the environment and genetic background to an extent but not ploidy. Ploidies differ in terms of just the frequency. How similar/ dissimilar are the overall mutational spectra here? Were there any homozygous mutations in the diploids? *
-
*
-
We have plotted the mutation types in the diploid and haploid lineages across the conditions to compare the frequencies of each type of mutation between ploidies, which is now presented as Supplemental Figure 3. The mutation types between ploidies for each of the conditions look similar. Homozygous diploids are indicated in Table 2.
*Fitness gains and losses can happen without trade-offs if neutral home mutations are non-neutral in non-home conditions. Can the authors comment on that in this context. Physico-chemically, how different are the home/ non-home environments? How do the fitness effects correlate across the environments in the absence of these adaptive mutations? It would also be useful to know the extent of fitness variance of the populations in the home and away environments, this would aid the reader better grasp the significance of fitness gains/loss. *
-
We agree that trade-offs could occur as a result of mutations that are neutral in the home condition showing trade-offs in the non-home conditions. However, in the newly added Supplemental Table 1, it is clear that most lineages have several passenger mutations, yet for lineages carrying the mutations in the same candidate beneficial mutation, they have largely similar pleiotropic profiles, suggesting that the influence of neutral mutations that arise in the home environment do not play a large role in determining fitness in other environments, at least for those tested. We have not generated strains that only contain the passenger mutations – while that would empirically test the fitness effects of the passenger mutations, it would be extremely time consuming to generate such strains, and the results would be unlikely to change our claims in the paper.
*A summary table of the pleiotropic effects would be very useful as in Bakerlee et al. 2021. *
-
We have added a summary table (Supplemental Table 3) of the pleiotropic effects as suggested. Reviewer #2
*The major conclusion of the manuscript state that "mutations in the same genes tend to produce similar pleiotropic effects", suggesting that a number of times this does not occur. For instance, the authors comment on the case of PDR3, which does not always produce 'cost-free' adaptation across environments. I believe that, to strengthen and better define their conclusion, the authors should develop a quantitative analysis of the reproducibility of pleiotropic profiles (that considers how many times genes have been found mutated). The heatmaps provided are compelling, but make it hard to generalize on how often, and to what extent, the gene mutated can predict pleiotropy across various environments. *
-
*
-
We have calculated pairwise correlations between pleiotropic profiles for mutations that arose in the same environment either in the same gene, or in different genes, and added this Supplemental Figure 10. These data show that by and large, correlations between mutations in the same gene are higher than those for different genes.
*In the concluding sentence of the discussion, it is unclear whether the authors are speculating about a role of the strength of selection in determining pleiotropy based on their results, or if that only represents a suggested hypothesis to test in future studies. *
-
We have modified the concluding sentence to clarify its meaning (it was a suggested hypothesis)
*The method used to identify putative adaptive mutations should be described in more detail. For instance, I seem to understand that only one mutation per lineage is considered 'adaptive'. However, many lineages seem to have more than one mutation. Based on what reported in the method section, the adaptive mutations have been hand-picked based on previous knowledge of selection in the environments of choice ("the list of genes was curated based on those genes' interactions with other identified genes or pathways known to be involved in the adaptation of that specific condition from previous work"). If this assumption is correct, the criteria for such a curation should be specified in more detail. *
-
We have further clarified our criteria in the text; note, there was not a requirement for there to be only a single beneficial mutation per lineage, though very few lineages had two candidate beneficial mutations.
*The term 'Pareto front' is technical and left undefined. *
-
We have clarified the meaning of Pareto front
*The section ' adaptation can be cost-free' only refer to figure 4, (with adaptive mutant lineages from populations evolved in fluconazole), while it comments extensively on mutation isolated in clotrimazole (reported in Sup. Fig10, not mentioned in the section). *
-
We thank the reviewer for noting our oversight – we have also now referenced the supplementary figure too (now Supplementary Figure 11). Reviewer #3
*It would be helpful if the authors could clearly provide information on the zygosity of the evolved mutations, as the presence of mutations in homozygous or heterozygous states can impact the results of the study. *
-
We have added zygosity information to the genotypes in the text and in Table 2, Summary of Adaptive Mutations
*Do any of the evolved lineages have multiple adaptive mutations or other potentially adaptive mutations? If so, it would be great if the authors could provide a table listing these lineages and mutations. *
-
We have added Supplemental File 1, which enumerates the adaptive and passenger mutations found in each lineage. Candidate adaptive mutations are in highlighted in red. Of the ~200 adaptive lineages, 4 have two candidate adaptive mutations, while the rest have only one.
*In the Pooling of the Isolated Clones section of the Methods, the ancestor and subject pools were mixed in different ratios for different types of pools. While not strictly necessary, it would be helpful to provide a brief explanation for this. *
-
We have added a brief explanation
*The conditions listed in Table 1 and Supplemental Figure 2 do not seem to match perfectly. *
-
We have corrected Supplemental Figure 2 such that it matches Table 1
- *
Supplementary Figure 6 demonstrates reproducible fitness estimates across lineages with the same mutations but distinct barcodes, supporting the authors' inference of adaptive mutations. However, it also appears to show no evidence of interactions among these mutations. Can the authors clarify if this is due to the absence of lineages with multiple mutations or if no observable interactions were found?
-
*
-
See response above – there are very few lineages with more than one candidate beneficial mutation. The remaining passenger mutations are thus likely neutral.
- *
*In the Pleiotropy is common, strong and variable section of the results, all three conditions were noted to have their evolved lineages tested in other conditions and presented in Supplementary Figure 5. However, due to the rapid dominance of lineages evolved in clotrimazole, there is no comparison data for them in Supplementary Figure 5. *
-
Unfortunately, we were not able to generate robust fitness remeasurements in the clotrimazole condition, due to the rapid takeover by lineages that were evolved in that condition
*In the Results section on cost-free adaptation, it would be beneficial to include any compositional differences, such as pH, between the two drugs used that could have contributed to the fitness effects of the evolved lineages in pH 7.3. *
-
We are not aware of any such differences – we did not pH any of the media other than the media with a specific pH.
*Results - Adaptation can be cost-free: While the authors did state "at least across the conditions in which we remeasured fitness" at the end of the paragraph, it may be prudent to exercise caution when stating "cost-free adaptation" as only a few conditions were tested. For instance, an all-beneficial or all-deleterious result can sometimes be obtained solely based on the chosen conditions. *
-
*
-
We have added additional caution in the text based on the reviewer’s suggestion.
- *
*Colormaps in Figure 4, Supplemental Figure 6, 10, and 11: The colors for values below -0.2 are uniform, whereas the heatmaps exhibit darker blues. *
-
*
-
We have edited the color scales on Figure 4 and Supplemental Figures 6, 10, and 11 (now Supplemental Figures 6, 11, and 12) such that the scales are uniform.
- *
*Results - Pleiotropy varies according to the mutated gene: "For example, haploid lineages adapted in glycerol/ethanol with mutations in IRA1 show the same pattern of fitness effects across conditions (Supplemental Figure 6)." I believe the authors are referring to Supplemental Figure 11. *
-
The reviewer is correct – we have fixed this reference to what is now Supplemental Figure 12
*On the topic of IRA1, IRA2, and GPB2 in the section "Pleiotropy varies according to mutated gene" in the Results: Although IRA1 mutants exhibit highly similar patterns, it is challenging to ascertain which of the two genes, GPB2 or IRA2, has a more similar pattern. *
-
*
-
We have create a new supplemental figure showing the correlation between mutations in the same gene and mutations in different genes for lineages evolved in the same condition – see response to Reviewer #1 above.
- *
Results - Pleiotropy varies according to mutated gene: From "If lineages isolated from the same home environment have similar pleiotropic profiles..." to the end of that paragraph. While it is true that "pleiotropy varies according to target genes and not environment alone," it may be premature to suggest that the environment is the "main driving force" of pleiotropy without some form of statistical analysis.
-
We did not intend to suggest that environment is the main driving force - that section was somewhat poorly worded. We have modified the wording to make that clearer.
*Discussion - line 5, paragraph 2: "For example, in glycerol/ethanol, the haploid adapted lineages have a trade off at 37{degree sign}C but the diploid adapted lineages do not (Supplemental Figure 11)." I believe the authors are referring to Supplemental Figure 6. *
-
We thank the reviewer for spotting this and have fixed the figure reference.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary
The authors present an intriguing study on the pleiotropic effects of adaptive mutations in yeast populations evolving in different environments. The study used haploid and diploid barcoded budding yeast populations to understand the pleiotropic effects of adaptive mutations in "non-home" environments where they were not selected. The findings indicate that pleiotropy is common, and most adaptive evolved lineages show fitness effects in non-home environments, which can be beneficial or deleterious. The results also highlight how ploidy influences the observed adaptive mutational spectra in different conditions. The methodology involved whole-genome sequencing and pooled fitness remeasurement assays in 12 environments with various perturbations. The study concludes that pleiotropic effects are unpredictable, but lineages with adaptive mutations in the same genes tend to show similar effects. Overall, the study provides insights into the dynamics of adaptation and the impact of pleiotropy in different environments.
Major comments
- It would be helpful if the authors could clearly provide information on the zygosity of the evolved mutations, as the presence of mutations in homozygous or heterozygous states can impact the results of the study.
- Does any of the evolved lineages have multiple adaptive mutations or other potentially adaptive mutations? If so, it would be great if the authors could provide a table listing these lineages and mutations.
Minor comments
- In the Pooling of the Isolated Clones section of the Methods, the ancestor and subject pools were mixed in different ratios for different types of pools. While not strictly necessary, it would be helpful to provide a brief explanation for this.
- The conditions listed in Table 1 and Supplemental Figure 2 do not seem to match perfectly.
- Supplementary Figure 6 demonstrates reproducible fitness estimates across lineages with the same mutations but distinct barcodes, supporting the authors' inference of adaptive mutations. However, it also appears to show no evidence of interactions among these mutations. Can the authors clarify if this is due to the absence of lineages with multiple mutations or if no observable interactions were found?
- In the Pleiotropy is common, strong and variable section of the results, all three conditions were noted to have their evolved lineages tested in other conditions and presented in Supplementary Figure 5. However, due to the rapid dominance of lineages evolved in clotrimazole, there is no comparison data for them in Supplementary Figure 5.
- In the Results section on cost-free adaptation, it would be beneficial to include any compositional differences, such as pH, between the two drugs used that could have contributed to the fitness effects of the evolved lineages in pH 7.3.
- Results - Adaptation can be cost-free: While the authors did state "at least across the conditions in which we remeasured fitness" at the end of the paragraph, it may be prudent to exercise caution when stating "cost-free adaptation" as only a few conditions were tested. For instance, an all-beneficial or all-deleterious result can sometimes be obtained solely based on the chosen conditions.
- Colormaps in Figure 4, Supplemental Figure 6, 10, and 11: The colors for values below -0.2 are uniform, whereas the heatmaps exhibit darker blues.
- Results - Pleiotropy varies according to the mutated gene: "For example, haploid lineages adapted in glycerol/ethanol with mutations in IRA1 show the same pattern of fitness effects across conditions (Supplemental Figure 6)." I believe the authors are referring to Supplemental Figure 11.
- On the topic of IRA1, IRA2, and GPB2 in the section "Pleiotropy varies according to mutated gene" in the Results: Although IRA1 mutants exhibit highly similar patterns, it is challenging to ascertain which of the two genes, GPB2 or IRA2, has a more similar pattern.
- Results - Pleiotropy varies according to mutated gene: From "If lineages isolated from the same home environment have similar pleiotropic profiles..." to the end of that paragraph. While it is true that "pleiotropy varies according to target genes and not environment alone," it may be premature to suggest that the environment is the "main driving force" of pleiotropy without some form of statistical analysis.
- Discussion - line 5, paragraph 2: "For example, in glycerol/ethanol, the haploid adapted lineages have a trade off at 37{degree sign}C but the diploid adapted lineages do not (Supplemental Figure 11)." I believe the authors are referring to Supplemental Figure 6.
Significance
General assessment:
The research is well-conducted, utilizing both haploid and diploid barcoded yeast populations, and isolating adaptive clones to determine fitness effects in non-home environments. The double-barcoding system allowed the authors to perform pooled fitness measurements of a large number of lineages coming from different home-environments in a plethora of conditions accurately and efficiently. The inclusion of a multiple evolution conditions followed by fitness measurements in a broader range of conditions allowed the authors to study the effect of environment to pleiotropy.
The low number of generations used in this study, however, could hamper the discovery of more adaptive mutations, particularly those with smaller effects, and also make the study underpowered for studying epistasis among the evolved mutations. Furthermore, while the definition of pleiotropy in this study is reasonable and practical, it also makes most, if not all, generalist mutations pleiotropic and hence it's not surprising to see pleiotropy to be so common in this study.
Advance:
This study is an extension of a few recent publications. Jerison et al. (2020) evolved 20 haploid founder replicates in 11 environments for about 700 generations and measured the fitness of evolved clones - one clone from each replicate - across these conditions. This study provides in-depth analyses of how environments affect pleiotropy and a certain level of analyses for the underlying mutations. Bakerlee et al. (2021) evolved several hundred barcoded haploid and diploid populations in a few environments for 1000 generations and traced not only the fitness changes but also the dynamics of pleiotropy longitudinally. The environments used in this study are similar to each other, and so were the results, with the exception of environments with high (37˚C) and low (21˚C) temperatures. The current study utilized their double-barcoding system to allow for testing both haploids and diploids in a broader range of conditions. Although only three of the starting environments were chosen for further analyses, these environments are more dissimilar, and the putative underlying adaptive mutations in the evolved clones were identified and more thoroughly analyzed.
The study's findings offer valuable insights into the intricate relationship between adaptation, pleiotropy, and environmental dynamics. While the complexity of pleiotropy and the multitude of factors that influence it make it challenging to comprehensively address all aspects in a single study, the results presented here contribute significantly to our understanding of this phenomenon. Nevertheless, further research of this nature is crucial to deepen our knowledge of the underlying mechanisms and to identify overarching patterns that can be applied across diverse systems. Overall, this study represents a promising step towards advancing our understanding of pleiotropy and its role in adaptive evolution.
Audience:
While the current study focuses on yeast as a model organism for evolutionary experiments, the implications of pleiotropy extend far beyond basic research. An understanding of the pleiotropic effects of mutations is crucial for comprehending the mechanisms of evolution and developing effective clinical interventions. As pleiotropy can affect disease outcomes and drug responses, the insights gained from this study can have far-reaching implications in the fields of biology and medicine. Thus, this study contributes not only to our understanding of yeast genetics but also to broader areas of research and application.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
In this manuscript, the authors address the question of pleiotropy (the multiple effects of a single mutation on different traits) of adaptive mutations occurred during evolutionary processes. To do this, they evolve populations of S.cerevisiae strains in 12 environments, they identify the major adaptive mutation occurring in a subset of them, and they use a barcoding system to address their effect on fitness in environments where they were not evolved. The study confirm a number of conclusions from previous studies, such as the frequency of positive and negative pleiotropy of evolved lines when tested in other environments. The major novelty of this work is represented by the focus on single adaptive alleles and the conclusion that mutations in the same genes tend to produce similar pleiotropic effects.
Major comments:
- The major conclusion of the manuscript state that "mutations in the same genes tend to produce similar pleiotropic effects", suggesting that a number of times this does not occur. For instance, the authors comment on the case of PDR3, which does not always produce 'cost-free' adaptation across environments. I believe that, to strengthen and better define their conclusion, the authors should develop a quantitative analysis of the reproducibility of pleiotropic profiles (that considers how many times genes have been found mutated). The heatmaps provided are compelling, but make it hard to generalize on how often, and to what extent, the gene mutated can predict pleiotropy across various environments.
- In the concluding sentence of the discussion, it is unclear whether the authors are speculating about a role of the strength of selection in determining pleiotropy based on their results, or if that only represents a suggested hypothesis to test in future studies.
- The method used to identify putative adaptive mutations should be described in more detail. For instance, I seem to understand that only one mutation per lineage is considered 'adaptive'. However, many lineages seem to have more than one mutation. Based on what reported in the method section, the adaptive mutations have been hand-picked based on previous knowledge of selection in the environments of choice ("the list of genes was curated based on those genes' interactions with other identified genes or pathways known to be involved in the adaptation of that specific condition from previous work"). If this assumption is correct, the criteria for such a curation should be specified in more detail.
Minor comments:
- The term 'Pareto front' is technical and left undefined.
- The section ' adaptation can be cost-free' only refer to figure 4, (with adaptive mutant lineages from populations evolved in fluconazole), while it comments extensively on mutation isolated in clotrimazonle (reported in Sup. Fig10, not mentioned in the section).
Referees cross-commenting
I tend to agree with reviewers 1 and 3 that, given the focus on individual mutations of this manuscript, more information about their nature is important. On top of the zygosity, I would be curious to know whether mutations predicted to inactivate the gene (frameshifts, stop codon), have different pleiotropic profiles than AA substitutions.
To answer the reviewer's 2 second major point, my understanding is that most of the lines have accumulated other mutations (marked with a '+' sign in Fig4 and FigS6,S10,S11). I suspect, however, that none of these mutations have been considered adaptive given the criteria described in the 'identifying adaptive mutations' session (e.g. mutations in coding regions appearing in more than one clone in a given condition, and with median fitness in the original home greater than 0).
Significance
The manuscript address a question (the emerge of pleiotropy during evolutionary adaptation) which has been extensively studied. However, it does it in a more comprehensive way that previously achieved, including many environments, both haploid and diploid organisms, and by focusing on single adaptive mutations. Most of the conclusions match the ones of previous studies. Perhaps the only exception is represented by the conclusion that individual genes, more than home environments, are proposed to dictate the pleiotropy profiles. However, the fact that mutations affecting the same genes often produce similar pleiotropy profiles is not necessarily unexpected. Overall, the paper is clearly written and can represent a valuable resource for a rather specialized community interested in the origin of pleiotropy during evolutionary adaptation.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary
The objective of the study was to investigate the impact of specific adaptive mutations on trade-offs and pleiotropic effects in haploid and diploid Saccharomyces cerevisiae populations. The authors identified adaptive mutations from strains evolved in three specific home conditions and then conducted fitness assays in up to 12 environments (home/non-home). They highlight that ploidy level plays a condition-specific role in shaping the adaptive mutation spectra. Adaptive mutations showed fitness effects in both home and non-home environments, which were beneficial in some cases and detrimental in others.
Major comments
It would be interesting have an idea of the global mutation rates and spectra in the diploid and haploid lineages across the conditions as well. The S. cerevisiae mutational spectra has been shown to be dependent on the environment and genetic background to an extent but not ploidy. Ploidies differ in terms of just the frequency. How similar/ dissimilar are the overall mutational spectra here? Were there any homozygous mutations in the diploids?
Fitness gains and losses can happen without trade-offs if neutral home mutations are non-neutral in non-home conditions. Can the authors comment on that in this context. Physico-chemically, how different are the home/ non-home environments? How do the fitness effects correlate across the environments in the absence of these adaptive mutations? It would also be useful to know the extent of fitness variance of the populations in the home and away environments, this would aid the reader better grasp the significance of fitness gains/loss.
Minor comments
A summary table of the pleiotropic effects would be very useful as in Bakerlee et al. 2021. Citation errors e.g. Consistent with prior work (Jerison, et al., 2021)... is either incorrect or not referenced.
Significance
The paper is well written highlighting an interesting question, the take home message is incremental at best in the context of the overall literature. In general, my suggestion would be to tone down the conclusions a bit, as the evidence isn't very clear cut .
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Point-by-Point Response (author’s replies in plain text)
Reviewer #1 (Evidence, reproducibility and clarity (Required)):
Summary: Silao et al make the intriguing observation that yeasts that are generally considered less pathogenic are unable to catabolize proline than Candida albicans. They then, in Candida albicans, construct mutants defective for the two key enzymes (Put1, Put2) required to convert proline to glutamate, which they show to be essential for proline utilization as an energy (carbon) and nitrogen source. The authors proceed to untangle the regulatory aspects of proline degradation, including the respective cellular localization of its key enzymes. They then make the important discovery that strains lacking either Put1 or Put2 suffer from a proline-dependent growth defect, which they attribute to resulting defects in mitochondrial metabolism.
The manuscript then goes on to analyze a broad range of infection models including: reconstituted human epithelial skin model, Drosophila, mouse systemic infections, organ colonization in these mice (kidney, spleen, brain, liver and histochemistry of the kidneys) as well as survival when incubated with cultured human neutrophils. Finally, they use yeast cells constitutively expressing yEmRFP (so that yeasts can be distinguished from other host cells) and coated with FITC before incubation with the host cells (which coats the wall of the original cells, but does not spread to progeny) and they go on to perform an impressive set of analyses of C. albicans growth within mouse kidneys both in vivo and ex vivo, exploiting an implanted window together with intravital imaging with a two photon microscope at different time points. The system is impressive and visualizes tissue invasion by hyphal cells beautifully. Finally, they compare the intra vital images from WT and put2-/- cells and show that, as in vitro, put2-/- cells do not form filaments and do not show extensive invasion of the kidney tissue. While the in vivo aspect of the study includes many different models, it finds defects in virulence for different subsets of put mutants and the relative importance of filamentation vs proline utilization for virulence is not conclusively resolved.
Overall, this is an important and timely manuscript, which significantly contributes to the understanding of how proline metabolism intersects with yeast fitness in the context of infections. However, there are several major concerns regarding some of the conclusions drawn from the study. In addition, some general recommendations that would improve the manuscript are provided.
Specifically, the manuscript provides a very detailed description of experiments and observations. However, in several parts it is difficult to follow and the reader needs more guidance about the logic involved in reaching conclusion. Specifically, several aspects of the paper are written for experts in Candida (yeast) metabolism. Here, explaining the rationale for some of the experiments, and providing more background information that is not obvious to a non-expert, is required.
In particular, writing a clear and measured summary sentence at the end of each paragraph and a conclusion paragraph that summarizes key findings in simple terms would help make the manuscript more digestible for readers.
In addition, the impressive microscopy and broad range of in vivo experiments is comprehensive but only adds incremental information relevant to proline metabolism-that filamentous growth in vivo and virulence is reduced in cells carrying some mutations in one or more put genes. However, this broad sweep of model systems and the development of the in vivo imagining system might have more impact in a separate paper focused on the real-time in vivo visualization of kidney invasion.
We thank Reviewer 1 for the extensive list of comments and have endeavored to adjust the manuscript to address all of the major and minor concerns. It is evident that Reviewer 1 clearly understood the significance of the work and we appreciate that the comments are presented in a positive manner intended to improve our manuscript.
Major comments:
- The main finding that impressed this reviewer is that "removing the ability to catabolize proline, in an organism that evolved to catabolize it, leads to (growth) defects". This point could be better highlighted throughout the manuscript.
Thanks for the comment. We will adjust the text to reflect this suggestion.
- The authors show that deletion strains for proline metabolism have defects that are important for in vivo pathogenicity. This is an important finding. However, as the manuscript reads now, it suggests that the main findings are that the ability to use proline in the respective host niche is key. Mechanistically, the manuscript revolves primarily around defects that arise when deleting PUT1 and/or PUT2 (i.e., an "unknown" toxicity of proline in the case of put1-/- (or put1-/- put2-/-) and the additional P5C-dependent toxicity for put2-/- mutants; see below).
Yes, the reviewer is correct in that we believe that proline catabolism is necessary to initiate and power hyphal growth, which is coupled to virulence. We have previously shown that upon phagocytosis by macrophages, the expression of Put1, Put2 and even Gdh2 are induced in phagocytized C. albicans cells, which is consistent with the analysis shown in Fig. 2D and Fig. S2B. Consequently, proline, or an amino acid that is metabolized via the proline catabolic pathway, must be present in the phagosomal compartment. However, as we now report, proline inhibits growth of cells lacking the capacity to catabolize it. Although we cannot differentiate the cause of reduced virulence in put mutants, i.e., the lack of energy due to the inability to catabolize proline vs proline toxicity, proline catabolism is clearly important and a robust indicator of virulence. As point 1, we have adjusted the text to make this clearer.
- In order to claim that catabolizing prolines promotes pathogenicity (as opposed to the alternative hypothesis that the inability to catabolize proline leads to the observed defects), additional experiments would be required. For example, the put mutants would need to be compared with mutants that significantly reduce/impair proline uptake, such as the referenced gnp2 mutant (Garbe et al 2022). While the finding that less pathogenic yeast species are unable to catabolize proline is both intriguing and important, it also remains as is presented as a loose, non-quantitative correlation that only tangentially address the question of whether "proline catabolism is key for pathogenicity".
We have in fact already shown that proline uptake is required to induce filamentation (Martínez and Ljungdahl 2003, Fig. 6). The main point of our current work, which we believe is important and of general interest, is that C. albicans is adapted to use proline as sole energy source, which reflects the environment (humans) in which it evolved. See the response to point 2. Interestingly, the differences in the expression levels of Put1 (off in the absence of proline, induced robustly by proline) and Put2 (low level of constitutive expression, induced robustly by proline) suggest that cells are primed to decrease the likelihood of becoming inhibited by P5C, i.e., the constitutive expression of Put2 is able to ameliorate the potential toxicity of P5C. Regardless, the finding that put1 and put2 mutants exhibit significantly reduced virulence in two host models provides clear support for proline catabolism being key for C. albicans pathogenicity.
- 238 onwards: The conclusion that "the primary growth inhibitory effect of proline is linked to catabolic intermediates formed by Put1 and that are metabolized further by Put2"does not appear to be fully supported by the evidence. Addition of proline to put1 mutants already reduced OD600 by ~50% (Figure 2); and is further reduced to ~10% when put2 is deleted. This implies that there are two inhibitory effects of proline, not one primary one. At the least, this option should be discussed, including why deletion of PUT1 leads to proline toxicity. The latter is not clear-is it that too much proline accumulates in the cell and this accumulation is toxic? If this is the case, the effect would be expected to be proline concentration dependent. Performing a relatively simple experiment as performed for the put2 mutant (Fig. 3 / S3F) may clarify this issue. Particularly, if the experiment would be coupled with intracellular quantification of proline.
Precisely! Proline toxicity is evident even in put1 mutants, clearly suggesting that proline, without being further catabolized, exerts a growth inhibitory effect (Fig. 3A). We traced this inhibitory effect to decreased mitochondrial respiration (Fig. 3E). There are two parameters to consider regarding the inhibitory effects of proline in put2 mutants. First, the presence of proline induces the expression of Put1 independent of Put2 (Fig. S2C), consequently, the levels of the toxic intermediate P5C increases (Fig. 3B). P5C has previously been postulated to inhibit mitochondrial respiration, which is well-aligned with our analysis (Fig. 3E; see response Point 5). We initially tested whether a proline-P5C cycle, suggested by work in mammalian cells, would play a role in proline-mediated toxicity; however, increasing cytoplasmic pools of proline by supplying high levels of glutamate (which according to work in mammalian cells should efficiently convert to cytoplasmic proline) did not occur; we did not see glutamate-enhanced Put1 expression (Fig. 2D, S2A, S2B). We agree with the reviewer with respect to the suggested experiment, and have monitored growth of put1 in media with different proline concentrations. The results are incorporated in the revised Fig. 3.
- The caption "P5C mediates a respiratory block" is misleading, as the evidence is not that compelling: Although P5C increases in put2, but not in put1 mutants, and given that both single mutants experience a proline-dependent respiratory defect (Fig. 3E), the results suggest a more complex relationship.
Previous work using pure P5C (Ref. 36; Nishimura et al) showed that it targets respiration, hence the caption “respiratory block” in the header. In mammals, PRODH (Put1) physically interacts with mitochondrial respiratory complex II in the inner mitochondrial membrane (line 89-90), while P5CDH (Put2) is in the matrix. The put1 mutation might affect basal activity of the respiratory chain resulting in lowered respiration, which may compound when proline accumulates in the mitochondria. The inhibitory mechanism remains unknown, and in going forward we have begun characterizing various GFP-tagged respiratory complex components in put1 mutants and in strains co-expressing Put1-RFP (for interaction studies). The results are out of the scope of this current work.
- The virulence assays and in vivo experiments do not present a unifying view: in Drosophila put2∆∆ is less virulent than put1∆∆, which appears similar to put3∆∆. Given that put2 mutants grow slowly, likely because of P5C inhibition, this seems logical. However, in mice, put3∆∆ remains highly virulent while put1∆∆ and put2∆∆ results for survival are mixed. Furthermore, in 4 mouse organs, put1∆∆ and put2∆∆ are not significantly different from one another but are different from wt, while put3∆∆ has no significant reduction in CFU. Kidney histology shows very little invasion by put1 and put2 and more by put3, but visually put3 appears to invade much less than the WT, and the human neutrophil experiment shows effects of put2 or put3 but not put1. This leaves the reader rather confused. It may be worth discussing the reasons for different results in different models. Is the availability of proline in each of the organisms and organs similar?
We thank the reviewer for these thoughtful observations, however, we note that all of the diverse assay systems employed provide a clear and consistent indication that the inability to completely catabolize proline significantly reduces virulence. This is well-aligned with our previous data regarding the need for proline catabolism to escape macrophages (Silao et al, 2019). The requirement for Put3 may not be very strict since the Put enzymes are still expressed in the absence of Put3 (Fig. 2D/S2A/S2B), indicating the activity of additional regulatory factors; hence, this may explain why the put3 strain behaves like wildtype in the murine model (Fig. 5B). The dispensability of Put3 in the murine model could be due to a lower neutrophil count and that murine neutrophils exhibit a lower affinity for fungal cells as compared to human blood (Machata et al., 2020, Front Immunol). The more pronounced requirement of Put3 to survive in whole human blood and when co-cultured with human neutrophils could indeed be linked to the need to rapidly derepress PUT1/PUT2 (and even other target genes) as suggested by the global RNASeq analysis that shows that proline catabolism is a core response of C. albicans during neutrophil interaction (Niemiec MJ et al., 2017, BMC Genomics). In Drosophila, a well-established model to study innate immunity, the presence of hemocytes that fulfill the equivalent functions of neutrophils and macrophages could explain the increased requirement for Put3. In summary, although it is impossible to know the precise mechanistic basis underlying the observed differences, we believe it unreasonable to expect that all mutations behave identically in each virulence model. In fact, differences considered trivial such as the use of mouse background can have profound effects on virulence. Presumably the differences we report are due to the specific nutrient composition (proline and metabolites feeding into the proline catabolic network) and physical parameters intrinsic to each model. For instance, Lionakis et al. (2013) suggested that filamentation occurs faster in the kidney compared to other organs, such as the liver/spleen, indicating the presence of kidney-specific cues that drive infections of this organ.
- The ex vivo and in vivo analysis of the dynamics of C. albicans growth in the host is visually impressive, but it distracts from the focus of the paper and the metabolic findings. Showing that put mutant cells do not form filaments in vivo (as in vitro) does not add much conceptually to the paper. Furthermore, this lovely advance in in vivo visualization is lost at the end of this paper and the authors should consider whether it might fit better in manuscript that could really highlight the in vivo visualization approach.
We appreciate this comment. Indeed, our lab is at an advanced stage of completing a manuscript focused on the use of intravital and clearing microscopy to follow the onset of an upper urinary tract infection (UTI) in a murine candidemia model. However, our ability to visualize in 3D the onset of an infection in a living host is not a trivial achievement and we were impressed that it provided a clear answer as to whether a single C. albicans cell can initiate an infection and undergo morphogenesis leading to hyphal growth. Furthermore, we tested a put2 strain, the growth of which is highly sensitive to the presence of proline, and found that it did not exhibit filamentous growth. This clearly shows that cells colonizing the kidney are exposed to an environment that requires a functional proline catabolic network to exhibit filamentous growth, a characteristic of renal infections. Our results are consistent with the kidney being a metabolic hub for arginine/proline biosynthesis, which likely increases the levels of these amino acids in this organ.
- The discussion of cells stained with FITC and expressing yEmRFP does not clearly point out that the FITC is only an indicator for those cells that were used to innoculate the tissue and that finding cells without FITC indicates that they are mitotic progeny, indicating that they have been dividing. The authors clearly understand this, but a naive reader may miss this important point if it is not stated explicitly.
We have adjusted the text to explicitly clarify this.
Minor comments:
- Throughout: what is the distinction between utilization of proline for C or for energy? These terms seem to be used interchangeably.
C. albicans is heterotroph that can use proline to generate biomass (gluconeogenesis, etc) and its catabolism generates sufficient amounts of ATP to power growth. Thus, when proline is used as sole carbon source, it can also serves as the sole energy source. In the text, we have tried to be consistent using “carbon source” when discussing proline as a component of growth media, and “energy source” when discussing proline catabolism.
- Introducing the schematic in Fig. 2A at the beginning of Figure 1, would help explain proline catabolism before delving into the growth experiments that rely upon this framework. This should include an explanation, for readers less familiar with the metabolic issues, of the main limitations to catabolizing proline, and the key issues for being able to use proline for nitrogen, carbon, and energy (potentially indicated in the overview figure, e.g. pointing towards gluconeogenesis etc.).
We have considered the reviewers suggestion, however, we believe that the placement of the schematic in Fig 2 is appropriate as is, and where it will hopefully enable readers to more readily grasp the strain construction and experiments documented in Fig.2.
- Saccharomyces can only grow on proline as a nitrogen source, but not as energy/carbon source. Could the authors briefly mention or discuss why this is the case? This is not clearly apparent after reading the manuscript and it leaves the reader confused and trying to understand if the fact that proline is required for carbon utilization is a new finding of this paper or was already known. Do the authors think this is tied to the presence of complex 1 components in C. albicans that are not found in S. cerevisiae. Is this consistent for the pathogenic, but not the non-pathogenic yeasts analyzed in figure 1?
We have adjusted the text to clarify our thoughts regarding this. Indeed, we do believe that a major reason for the ability of C. albicans to efficiently grow using proline as a sole energy source is the presence of Complex I. However, C. glabrata appears to be able to grow well using proline as sole energy source despite apparently lacking Complex I. Consequently, alternative NADH dehydrogenases exist in C. glabrata, but how this is coupled to energy metabolism will require additional work that is out of the scope of the present work.
- 100: While Gdh2 is apparently an important enzyme for generating ammonium, why is it not necessary for macrophage escape and virulence as shown in reference 18? A recent paper from Garbe et al (ref 12) suggests that Gnp2 is the major proline permease in C. albicans and what is known, and not known, about proline uptake would be good to mention, given that PUT gene functions require that proline enters the cells.
We have recently shown that ammonia generation by Gdh2 is dispensable for macrophage escape and documented that phagosome alkalinization is not a requisite for the induction of hyphal growth (Silao et al. 2020). We have referred to the work of Garbe et al., which is consistent with our previous work (Martinéz and Ljungdahl, 2004) where we reported that proline-dependent filamentation is dependent on Csh3. Csh3 is an ER membrane-localized chaperone responsible for catalyzing the proper folding of amino acid permeases, in csh3 null mutant strains, amino acid permeases accumulate in the ER as non-functional unfolded aggregates. Consistently, we have tested and found that proline-induced Put2-GFP expression is dependent on Csh3 (unpublished), clearly establishing that the regulatory effects of proline are dependent on its uptake. We have not generated a gnp2-/- strain, but suspect that we could find growth conditions where such a mutant would be refractory to proline induction. We have adjusted the text to include this information.
- 116: Is the "low sugar environment of the host" referring to a specific niche, such as the GI tract, or human blood? Compared to most natural environments, glucose is abundant in the host, e.g., at ~5 mM, it is the most abundant metabolite in blood, and similarly, in the GI tract, levels can go beyond 50 mM glucose (see e.g. PMIDs 34371983, 21359215). Or is this comment indicating that the in vivo sugar concentration is lower than that in common lab growth media? Please spell out the niche/concentration for clarification - and compare that to other niches that are considered "high sugar environments".
We have adjusted the text to clarify our statement. The natural environment of C. albicans is the human host. Virulent infections are not within the GI with high sugar content, but rather result when C. albicans cells successfully cross into the blood with a relatively low glucose (5 mM), which importantly is a level that does not effectively repress mitochondrial function. A major point of our recent work is that laboratory experiments with C. albicans growing on YPD or SD with 2% glucose (111 mM) examine growth of cells with repressed mitochondrial functions.
- 123: "proline as sole energy source" - suggest "is the source of carbon, nitrogen, and energy"
The text is adjusted (see response to Minor Point 1).
- 142: it is worth noting to readers that C. neoformans is a basidiomycete and thus VERY distant from the other yeasts studied here-it is in a different major phylum of fungi.
Again, thanks for this suggestion, the text is adjusted. We included C. neoformans since the role of proline catabolism has been characterized and linked to its pathogenicity (reviewed in Christgen and Becker, 2018, Antioxi Redox Signal, Ref. 1).
- 143: Here it is implied that put1 and put2 mutant strains do not grow on SPD, but this is not stated explicitly.
The put1 and put2 mutants are unable to grow in/on all media containing proline as sole nitrogen source. The phenotype is very tight that we were able to exploit this as a selection phenotype for reconstitution (Fig. 1A). We have adjusted the text to make this clear.
- 151: The abbreviation SPG is not explained in main text. This was explained in the methods (1% glycerol as primary carbon source).
As suggested, we have defined SPG in the main text.
- Paragraph 156 onwards: this section is particularly hard to read and very dense. Also, it is difficult to understand the significance of these experiments for the overall findings of the paper. Please at least provide a small conclusion / summary at the end of the paragraph that puts the findings into perspective.
We have adjusted text to make it more accessible.
- Figure 2 C: simplifying the scheme (e.g. lots of redundant information, P2 and Mito - just give it one name) would help. This figure may be better in the supplementary material.
The schematic of our subcellular fractionation study uses standard designations routinely used by the cell biology community. We believe that its inclusion will help readers judge the how we mapped the intracellular localization of the reporter proteins, which is essential to understand the proline catabolic network.
- Figure 2B: It is not directly apparent from the micrographs that Put1-RFP localisation is mitochondrial. Co-localisation of the RFP with a mitochondrial dye (e.g., mitotracker) or something similar is required to validate it.
We have previously reported that Put2 is a bona fide mitochondrial protein (by confocal microscopy, subcellular fraction, and co-localization with Mitotracker (Far Red) (Silao et al., Ref 17). The fact that the Put1-RFP associated fluorescence exhibits a distinct mitochondrial signature, is spatially exclusive and exhibits no overlap with the cytosolic pattern of Gdh2-GFP, co-fractionates with Put2-HA and the mitochondrial marker Atp1, should suffice to confirm that Put1-RFP is a mitochondrial localized protein.
- Throughout the manuscript (figure legends): Suggest using "mean" instead of "Ave."
We have adjusted the legends.
- 175: According to the 'Yeasttract' and 'Pathoyeasttract' databases, Put1 regulates at least 36 and 22 genes, in S. cerev. and C. alb., respectively (based on DNA binding and/or regulatory changes). The only gene in common between these two lists of genes is PUT1. Thus, it is quite likely that Put3 regulates many other processes that explain its function and that its major function may not be only to regulate Put1.
We assume that the reviewer is referring to Put3 (instead of Put1). Yes, Tebung et al. (2017) suggested that Put3 also regulates other genes. However, their data show that C. albicans put3 mutant was unable to grow in medium (YCB+Pro) compared to SPD (2% glucose as carbon source) where proline is used merely as a nitrogen source (Tebung et al., Fig. 3A). Our data in Fig. 1C shows that a put3 null strain exhibits residual growth on SPD, which aligns well with the expressed levels of PUT enzymes (Fig. 2D). Our conclusion is that despite being essential for rapid proline-dependent derepression of proline catabolic genes, Put3 is not the only transcription factor operating at the promoters of the PUT genes.
- 175: Is it clear whether the Put3-independent mechanisms are positive or negative with respect to Put1?
We have accumulated evidence that an additional transcription factor positively regulates PUT1 expression and have a manuscript in preparation to describe this factors. The manuscript will focus on the Put3-independent regulation of PUT1, PUT2, and GDH2 expression.
- 218: Suggestion: "growth was indistinguishable".Unless growth curves or growth rates are provided and if one time-point data are the basis for this point, than "rates" is not a relevant term.
The reviewer is correct; we will adjust the text accordingly. We have performed growth assays in a multi-well microplate format (Bioscreen) and found that the growth rates are not statistically different between WT, put1, put2, and put1 put2 strains in the presence and absence of proline in SD with 2% glucose. This is consistent with glucose repression of mitochondrial function, i.e., proline toxicity depends on derepression of mitochondrial function.
- 256 onwards: did the authors test if the ROS scavenging effectively reduced ROS? i.e. does the luminol-HRP assay yield less ROS in +proline +scavenger treatment? This is necessary to effectively conclude that the growth inhibitory effect of proline is due to blocking respiration.
Indeed, we used NAC as a control in the luminol-HRP system and we saw reduction in ROS formation. In fact, this is the underlying reason why we used high levels of NAC for growth rescue (in Fig. 3D). We include the control data as Fig S3F.
- The Figure captions are extremely lengthy and detailed, making it cumbersome to find the relevant information. Suggest moving some of the information, such as additional experimental details, into the methods section.
We have streamlined the figure legends.
- 277-301: Phloxine is not exclusively a live/dead cell indicator-it is an indicator of metabolic activity. In Scerev. and Calb. it also indicates slower growth, opaque growth, and it has been used as an indicator of aneuploidy in C. glabrata (https://journals.asm.org/doi/10.1128/msphere.00260-22) and of diploids vs haploids in S. pombe. The colonies illustrated aer made up of many live cells, and thus the section "Defective proline utilization is linked to cell death" needs to be presented more carefully. In addition, it appears that this section shifts from using defined medium to using rich medium and 37C instead of 30C. Why was this shift necessary?
The reviewer is correct that phloxine (PXB) has been used to identify opaque growth (EFG1-dependent). However, the fact that the accumulation of PXB in the put mutants is evident in both SC5314 and cph1 efg1 backgrounds (Fig. 3G and Fig. S4C) suggests that we are not assaying opaque switching. We mention that we have observed an increase in the number of PI+ cells in put mutants under similar conditions, but as we pointed out, we were unable to reliably quantitate this by FACS due to the clumping of put mutants. Zheng et al 2022, the paper cited by the reviewer, used PXB to assess the ploidy of C. glabrata strains, but their assay was developed using 5 μg/ml PXB, half of the concentration we used. The homogenous accumulation of PXB as the macrocolonies grow (Fig. 3G), suggests that the accumulation is not a consequence of spontaneously occurring ploidy variations. Thus, we believe that the accumulation of PXB does indeed reflect enhanced cell death. The point here is to trace the consequences of proline toxicity and to test the dependency on mitochondrial function. We used complex media, which contains multiple nitrogen sources (amino acids, peptides), to specifically highlight the contribution of proline catabolism in the fitness of C. albicans. The put1, put2 and put1 put2 mutants grow normally on YPD+PXB (30 oC) without accumulating the dye; we only observed visible PXB uptake in put2 after 2-3 days in mature macrocolonies. We attribute the gradual increase in PXB accumulation to be a consequence of glucose becoming limiting, derepressing mitochondrial functions, a requisite for proline toxicity. Consistently, the accumulation is more evident in cells grown on non-fermentable C-sources (Fig. 3G and Fig S4C).
- 295-301: Related to the point above, these results are hard to interpret due to the switch from defined medium in all prior experiments to rich growth medium here. Also, it is not clear why a 48h old YPD culture was chosen to show that the degree of PI staining correlates with mitochondrial activity - is this due to the culture age? It would be more clear to image cells grown on glucose vs. glycerol/lactate, or under repressive / de-repressive glucose concentrations (e.g., as shown in Fig. S4C where a PI+ difference is apparent for 0.2% glucose vs. 2% glucose at 30 oC).
See response to Point 19 for our rationale to switch to rich medium. We have adjusted the text to enhance its readability. In liquid YPD, all strains grow, however, we noticed that the put mutants tend to flocculate (sign of stress in yeast) when cells enter stationary phase, giving rise to erratic OD readings, particularly evident in the put1 mutant. At 48h, the cultures become dense and cells experience glucose limitation, derepress mitochondrial functions and exhibit maximal flocculation (Fig. S4D). In put mutants, the derepression of mitochondrial function results in proline sensitivity. We tested the notion that this would also increase cell death, which it does, see Fig. S4E.
- 313-14: The statement 'the invasion process was dependent on the ability of cells to catabolize proline' doesn't take into account that put mutant cells are defective in filamentous growth irrespective of their utilization of proline...and like the efg1 cph1 double mutant.
Proline-induced filamentous growth is dependent on the catabolism of proline, which activates Efg1 and consequently the hyphal growth program. In Fig. 4A we show that put mutants grown on Spider media, initiate filamentation (as evidence by wrinkled colonies) but do not grow invasively (no halo). In Fig. 4B we developed and used a novel invasion assay to assess growth through a collagen plug. Similar to the control cph1 efg1 mutant, the put mutants exhibit drastically reduced capacity to penetrate through the plug, and reach the D10 media in the transwell (D10 = DMEM with 10% FBS). However, it is important to note that although these results are linked to two distinct processes - the filamentation defect of cph1 efg1 is due to the inability respond to multiple filamentation cues (e.g., CO2, 10% FBS, etc.), whereas the filamentation defect of the put mutants is linked to the inability to catabolize proline and to its toxicity. Clearly, the WT strain relies on proline catabolism, coming from one or three possible sources of proline (see response to Reviewer 3): 1) DMEM/F-12 medium used in the PureCol EZ Gel; 2) diffusion of nutrients up through the collagen from the recovery medium DMEM supplemented with 10% FBS; and 3) the proteolytic breakdown of collagen. Also, in contrast to the put mutants, WT cells are refractory to inhibition by proline.
- 316-327: The results of the experiment described can only be interpreted as an effect of proline catabolism if the three strains (efg1 cph1; put1; put2) have similar growth rates as yeast cells in vitro. Why weren't the cells competed directly (efg1 cph1 vs put cells)?
We believe that the relevant comparisons are to WT. We recovered cells from the top of the collagen (see Fig. 4B inset) to monitor their ability to survive and grow on top of the collagen. We found that the ability to catabolize proline enables WT and cph1 efg1 cells to grow equally well (recovered similar ratio as starting input). This was not the case with the put mutants, they did not grow as well and almost 100% of the cells recovered were WT.23.
Fig 6: The logical order of the experiments, and in the text, is: 1) 4 h window, 2) 26 h window and then 3) ex vivo. The cartoon in 6B should be in this order as well.
Thanks for bringing this issue up. We have adjusted the figure and text placing the schematic time-lines in proper order.
- 337: it is not clear what the 'direct exposure...' is trying to tell us. Can this be made more explicit?
The direct exposure means that the fungal cells are in contact with the culture media at the edges/border of the 3D skin model (see schematic diagram). Hence, fungal cells are in direct contact with 10% FBS, facilitating the observed filamentous growth. The inability of the put mutants to invade the skin model should be evaluated at the center of the artificial epithelium where there is likely a local increased concentration of proline stemming from the proteolytic activities associated with fibroblasts and keratinocytes.
- 340-346: Here proteins with high proline content were used to ask if they could be induce transcription of PUT1 or PUT2 RNA and protein. This experiment is designed only to test the role of these proteins to induce utilization of nitrogen, as glucose is included in the medium. Given that these proline-rich proteins need to be lysed by proteases before they can be imported, and since no import pathways were tested, the results appear to tell us that mucin is more readily digested to peptides that contain proline-but why that is the case is not clear and how it relates to proline utilization is also not clear.
We thank the reviewer for raising this important point. First, we monitored protein not mRNA levels. We will adjust the text to provide better context for this experiment. Briefly, these experiments were initiated as we were perplexed as to why the wildtype cells took such a long time (14 days) to fully invade the collagen matrix (Fig. 4B); we naïvely assumed that fungal cells would secrete proteases to degrade the collagen and assimilate the liberated proline. In going forward, our experimental strategy was to incubate various proteins with a dense culture of cells in HBSS medium (pH 7.4) supplemented with low glucose (3.8 mM) and lactate (0.83 mM). This condition mimics interstitial fluid, where most broad range proteolytic enzymes are inactive or at least operating suboptimal. The results were clear; with the exception of mucin, the proteins did not stimulate Put1 or Put2 expression. We conclude that host-dependent processes play an important role on the release of the amino acids/peptides from these high-proline content proteins (see line 531-553 for discussion). The capacity of mucin to efficiently induce Put1 expression is interesting since mucin is abundant in the gut where systemic infections are thought to originate. It is important to be cautious here, we used a commercial mucin preparation (Sigma, 2 batches) that may contain degradation products, e.g., proline-rich peptides, that can easily be assimilated by C. albicans. Put1 expression is an excellent readout for proline uptake since its expression responds tightly to the presence of proline derived from exogenous supply or from intracellular conversion (Fig. 2D, S2A, S2B).
- 363-369 An alternative is that Put3 induces different proteins important for growth.
We included this possibility in the revised text.
- 379-380-the conclusion for this paragraph is somewhat of an overstatement as there is no analysis of the degree to which proline utilization is a predictor of virulence. It simply shows that put mutants affect the ability to survive in neutrophils.
We have adjusted the text.
- Discussion: The statement that "S. cerevisiae" evolved in high sugar environments is debatable. The natural niche could well be forest soil and tree bark, or insect/wasp guts with arguably little glucose around.
The reviewer is correct, S. cerevisiae can be isolated from diverse environments with variable sugar contents, but it is the capacity to deal with high sugar environments that makes this yeast stand out in comparison to Candida spp. The unique attribute of S. cerevisiae have been exploited and truly benefited humankind in making alcohol and bread. We have amended the text to state this more accurately.
- 469-470-how strong is the 'correlation' between the ability to utilize proline and virulence? Given that different mutants had different effects in different models, this seems like a very loose 'correlation'; it would be good to have some quantitative measures to make this claim.
We have used directed genetic approaches to determine whether a gene/protein is essential for virulence by testing them in currently available infection models. It is important to note that all virulence assays provided a consistent and clear read-out, namely that the inability to catabolize proline significantly reduced the expression of virulence characteristics. Presumably the differences we report are due to the specific nutrient composition (proline and metabolites feeding into the proline catabolic network) and physical parameters intrinsic to each model. In fact, the expression of virulence factors (i.e., hyphal growth) can significantly differ in different organs within a same mouse model (Lionakis et al., 2013) and that virulence outcomes can change depending on mouse background. We fail to see how this can be viewed as loose. This has not been shown before. Please refer to our response to major point 6.
- 500: Was the experiment was done in larvae, and not in adult Drosophila? Fig 5 legend says flies and shows a picture of a fly and larvae are only mentioned much later in the text.
These experiments were performed using adult flies. We now include a reference regarding the levels of arginine in hemolymph in both larvae and adult Drosophila (Priyankage et al., 2012; Anal Chem).
- 512:Why is it presumed that proline accumulates in the mitochondria in put1 mutants? How strong is the presumption?
Despite a great deal of efforts in many labs, the mechanism of proline transport across the mitochondrial membrane is not known. What has been shown in mammalian and plant systems is that proline can readily enter and accumulate in mitochondria where it is catabolized. (https://link.springer.com/article/10.1007/s00425-005-0166-z; https://www.sciencedirect.com/science/article/pii/0003986177902089). Our presumption that proline accumulates in the mitochondria is based on our finding that proline inhibits mitochondrial respiration when Put1, catalyzing the first oxidation reaction, is absent.
- 539: why are MMPs important for digestion of collagen? This is not clear at this point of the Discussion.
In mammalians cells, some secreted MMPs have collagenase activity (e.g., MMP-1) that degrade proteins comprising the extracellular matrix, which releases proline. We emphasize this since the 3D skin model is comprised of dermal fibroblasts and keratinocytes that are known to secrete MMPs (Ref. 69).
- 574: Concluding sentence of this paragraph seems unsubstantiated. There are at least two defects in put2 strains-hyphal growth and growth in general, presumably because of P5C accumulation.
See response to point 21. Proline-induced filamentous growth is dependent on its catabolism, which activates Efg1 and consequently the hyphal growth program. However, there are many potential cues in hosts that could induce hyphal growth in situ. Our finding that strains unable to catabolize proline do not filament, indicates that proline is a key modulator of virulence.
- Fewer abbreviations would make the manuscript easier for non-experts to read. For example, P5C is not defined in the abstract. Furthermore, if an abbreviation is not used more than 3 times, it is not necessary to provide it (e.g., mammalian proteins in the last paragraph).
We have adjusted the text.
typos:
-
82: should read 'is restricted to the mitoch...'
-
102-103: should read 'to evade macrophages'
-
Fig. S4F is mislabelled as Fig. S4G.
Thanks!
**Referees cross-commenting**
Overall, we stand by our initial assessment of the study. However, we were not aware of previous studies that investigated proline utilization in yeasts, as noted by Rev # 2 (https://onlinelibrary.wiley.com/doi/epdf/10.1002/yea.1845). The current study suggests that using proline as an energy/carbon source is more wide-spread, beyond pathogenic yeasts. Further, the C. albicans strain they used for this study (ATCC 10231) was apparently unable to grow on proline in the quoted paper. In light of this, we think the authors should reference this study, tone down the claims about the clear correlation of pathogenicity and proline utilization, and address this apparent discrepancy with the indicated Candida albicans isolate. We note that our review considered this a paper mostly of interest to specialists.
Although other non-pathogenic fungi have been shown to use proline as pointed out by Reviewer 2, this metabolic attribute has not been previously tested in members of the pathogenic Candida spp. complex. We have included the reference and included a statement that many fungi, isolated from diverse environmental niches, can use proline as a carbon source.
Reviewer #1 (Significance (Required)):
- The advance in this paper is conceptual for the proline utilization connection to virulence in a range of species and technical for the in vivo microscopy. Limitations are that the conceptual advance is based only on qualitative work in figure 1 and that the animal studies do not provide a conceptual advance, although the technical advance of in vivo visualization of kidney tissue is impressive and (to the knowledge of this reviewer) quite new as the only prior work was in mouse ears.
In response to the reviewer’s comment regarding Fig. 1, although it is qualitative, it is very reproducible. We even tried several clinical isolates of S. cerevisiae and observed consistent behavior to the standard laboratory strains (i.e., they do not grow on SP medium where proline is used as sole carbon/nitrogen/energy source). We tried to quantify growth of all strain in liquid SP medium at 30 oC using a TECAN microplate reader, but then the results show very erratic reading among species (and replicates) as each behaves differently; C. tropicalis, C. krusei, and C. parapsilosis form pseudohyphae and clump readily, while C. albicans forms hyphae and pseudohyphae.
2.The work fits well as an extension of the body of work from the corresponding author's lab with additions from the labs with expertise in models of infection.
- People interested in yeast metabolism and pathogenic yeast virulence will be the audience for this paper and as written it is for a specialized audience interested in pathogenic yeast metabolism and, perhaps, (although not mentioned at all in the text) for those who want to try PUT gene products as new drug targets.
This was actually mentioned in the last paragraph of the discussion (line 581-582).
- Reveiwer expertise is in pathogenic yeast biology and yeast metabolism. Little expertise in high tech microscopy.
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
The study is part of the continuous work by the authors to dissect the mechanism of utilization of proline as a carbon source in Candida spp. In particular, this work shows that the inability to process proline leads to accumulation of the toxic intermediate P5C and subsequent inhibition of mitochondrial respiration and toxic effect on the cells. Furthermore, the study demonstrates that proline utilization is important for C. albicans kidney colonization. The experiments are meticulously designed and the study adds to the overall understanding of the metabolic utilization of proline as a carbon source and its potential relevance for infection.
I find this work interesting, but the role of Put1 and Put2 in proline utilization is not particularly novel. The novelty here is the subcellular localization of the two proteins. Also, the importance of proline utilization for infection is unclear. The host-pathogen interaction assays are ambiguous as each assay gives different result. Lastly, the authors try to generalize the importance of use of proline as a energy source by other Candida spp.. This is not very surprising, given that it has been reported previously by others (example DOI: 10.1002/yea.1845) and that many pathogenic or closely related to C. albicans species use various amino acids, not only proline, as a carbon source.
Yes, as reviewer 2, we are not surprised that many of the pathogenic members of the Candida spp. complex are able to use proline, but this needed to be checked. The fact that proline can be used as a sole carbon/nitrogen/energy source clearly set them apart from the paradigm yeast S. cerevisiae. A major question is what amino acids are important in the context of the host? To assess this, we have used mutations that specifically block proline utilization. Our past studies demonstrating that proline catabolism is rapidly activated in C. albicans cells phagocytized by macrophages indicates that proline is present in the phagosomal compartment. Furthermore, put mutations clearly affect virulence in flies and murine systems. We are at a loss to understand why the reviewer believes that our data, which consistently shows that proline catabolism is important, is ambiguous.
The expectation that all three mutant strains, i.e., put1, put2 and put3, would behave identically in the different infection models reflects an unnuanced view of how infection works. In fact, differences considered trivial such as the use of mouse background can have a profound effects on virulence. Consequently, it is striking how the diverse infections models consistently and unequivocally demonstrate that proline catabolism affects virulence. Also, it should be appreciated that we are not testing mutations affecting proteins with many overlapping functions, where it may be appropriate to challenge claims as to their direct role in virulence. Here we tested mutants that lack the enzymes that catalyze proline utilization. A more reasonable expectation is that the virulence is commensurate to the specific nutrient composition of model systems (as asked by reviewer#1), which can fluctuate among models (see our response to the major comment 6 of reviewer 1). As it is not practical to precisely test the proline levels in the models, we have worked to identify and focus on critical phenotypes that can be analyzed in vitro. Our findings provide the basis for understanding the virulence and growth properties of the mutants in the context of the complex infection models.
Moreover, the authors take C. albicans as an example to demonstrate the role of PUT in invasion and infection. Proline is known stimulus for hyphal growth in this species, but many other Candida spp., including C. auris, do not filament. So how, aside from supporting growth, proline is linked to infection in these species? I think the authors oversell the importance of proline in Candida spp. pathogenesis and should tone this part down or remove completely. A new story that validates the importance of PUT in non-albicans species can bring clarity to why and where proline is critical for survival and infection.
The fact that proline supports growth in the host environment is one of the critical aspects of our work. The lack of appreciation for this finding represents a common misconception in infection biology. It is not just the ability to gain access to a host and initiate an infection that counts, it is equally important to sustain growth and to thrive within the host. Thus, the adaptation to the host environment is critical. Here we document that proline catabolism not only initiates but sustains an infection acting as a critical carbon/energy source. The inability of the put1 and put2 mutants, which are sensitive to proline, to grow and infect multiple models clearly suggests the substantial quantity of proline is accessible. Also, we have constructed C. glabrata (Fig. S1C) and C. auris (not shown) strains that lack the ability to catabolize proline, and are currently characterizing the virulence properties of these strains. This is out of the scope of the present study.
Major comments: I am not convinced by the data that proline is important to initiate infection. Candida infections of the kidney occur only at late stages of sepsis. The authors need more compelling data to prove that proline is important for infection in the host.
Again, not sure why there is such skepticism here, regardless of whether kidney infections occur late, the fact that in contrast to WT, we do not observe put mutants filamenting, clearly suggesting that the capacity to catabolize proline plays a role in the expression of virulence characteristics of C. albicans. Based on our findings using IVM, which provides 3D information, we can at least conclude that a single isolated C. albicans cell can initiate hyphal growth, initiating a point of infection. In addition, our newly added whole human blood data suggests that proline catabolism is required for survival in the blood; human blood contains high amount of proline, arginine, and ornithine that are all catabolized via the proline catabolic network.
Minor comments: I find the manuscript difficult to read and the discussion part is overly long. Some streamlining and adding a bit more explanation for the rationale of each experiment will make the work easier to follow. Some language/style needs refining as well.
We have attempted to take this critique into account during the revision of the manuscript and have streamlined the text and added explanations regarding the rationale underlying our experimental approaches.
**Referees cross-commenting**
In this manuscripts the authors clarify the cellular compartmentalization of steps in proline catabolism. However, it is not novel that proline is a valuable carbon source. The role of proline utilization for establishing or progression of infection remains ambiguous even after the authors provide different in vivo results. The overall significance of the study is limited.
Please refer to our comments below. We do not understand that the reviewers apparently question the obvious role of proline utilization facilitating virulence.
Reviewer #2 (Significance (Required)):
The strengths of this study are in the experimental design and variety. The data is well presented and visualized. The limitations are as pointed above - I find it especially difficult to figure out where, in a real infection scenario (e.g. breach of the gut barrier and entry into the bloodstream) proline will be the primary energy source. To me the significance of this work is minor.
C. albicans is the primary human fungal pathogen placed under the “Critical Priority Group” by WHO and yet our understanding of nutrient assimilation in this fungal pathogen is only a fraction of what is known in the model yeast S. cerevisiae, which has proven not to be the best paradigm for understanding the regulatory circuits operating in human fungal pathogens. This manuscript, as well as other recent publications, have revisited and corrected earlier assumptions regarding C. albicans growth, providing novel information that reflect important regulatory differences specifically relevant to the life of C. albicans in the host. For example, had it not been for the recent findings (Ref. 10, 18, 31) that show that proline utilization in C. albicans is not subject to nitrogen catabolite repression (NCR) and that glucose represses mitochondrial function, the perception in the field would remain that C. albicans cannot utilize proline as a carbon and/or nitrogen source in the presence of a “preferred” source of nitrogen, which is applicable in the blood that contains high concentrations of possible sources of carbon and nitrogen. Furthermore, the low but constitutive expression of Put2 and the tight highly responsive Put1 expression in response to proline (Fig. 2D, S2A, S2B), suggest that C. albicans is well equipped to productively anticipate proline availability depending on the host status, entirely consistent with its “opportunistic” character. The many incorrect and previously held assumptions regarding C. albicans, uncritically propagated in several influential reviews, likely have hampered efforts to develop novel antifungal therapies. We do not understand, nor accept the view that a more precise understanding of the proline catabolism is incremental.
The type of question raised by the reviewer is exactly what we hope to achieve in the future but to get there we have to have correct assumptions in place, and this is only possible if we have a more thorough understanding of the regulatory mechanisms driving proline utilization in C. albicans. The idea that certain proteins are refractory to degradation by C. albicans suggest that other external factors are triggering the release of amino acids from these proteins. This work however, suggest that proline is likely accessible in the gut due to the presence of proline-rich proteins like mucin (Fig. S5A/B).
Reviewer #3 (Evidence, reproducibility and clarity (Required)):
The manuscript of Silao et al. describes an in-depth investigation of the role of Put1 and Put2 enzymes in proline catabolism and virulence in Candida albicans. This is an extension of previous work in this system. The basic biochemistry and genetics are solid and support the role of these enzymes in the proposed pathway and provide evidence that the build up a toxic intermediate in the absence of Put2 is likely involved in the poor growth of the strain when proline is the only carbon source.
Note that we observe the toxic effects of proline even when it is not the sole carbon source, however, and importantly, toxicity is dependent on mitochondrial function, which is repressed by high levels of glucose. Proline toxicity is observed when glycerol/lactate are present as carbon sources in addition to proline. Under these conditions, mitochondria are not repressed and exogenous proline impairs growth, particularly evident in put2 cells that accumulate the toxic intermediate P5C.
The conclusions regarding its role in virulence are less convincing, particularly the data derived from the collagen invasion assay, the ex vivo skin model and the ex vivo/in vivo imaging. The survival and fungal burden assays support a modest role in virulence and a modest reduction in infectivity (although the presented data for survival does not have statistical significance data reported for the kaplan analysis.
See below for response regarding collagen assay. We have included the significance values derived from Kaplan analysis in the revised Fig. 5B.
The manuscript is clearly written. The methods are well described.
**Referees cross-commenting**
I remain unconvinced of the broad significance of the advances and stand by my assessment that this is for the most part a reasonable study but does not move the field forward. The novel technical aspects are either extensions of previous in vivo imaging or are not well controlled (collagen invasion assay)s.
See below for response.
Reviewer #3 (Significance (Required)):
This is a detailed study of an area that is fairly mature and thus will be of interest to those in the field but does not represent a large advance and is thus truly incremental.
See below for response.
Major limitations of the work are as follows. First, the collagen invasion assay may be flawed. The recovery media is made with DMEM which is a medium that lacks proline and is fairly stringent. Control experiments need to be done to be sure that the mutants grow in the recovery medium. Second, the data from the RHE model are hard to interpret since so few cells are present in the tissue. It is hard to see if there are few filaments of if there are just too few cells to assess in the tissue. Third, in vitro experiments assessing the filamentation of the mutants in the medium in which these assays are preformed need to be done as controls. Candida albicans filaments in many conditions such as tissue culture medium. Spider medium is a strong inducer of filamentation but is very different than in vivo/ ex vivo conditions.
Related to the collagen invasion assay, there is a misunderstanding. The reviewer appears to confuse the put mutations with proline auxotrophy. The put mutants are proline prototrophs and can synthesize proline as they possess a full repertoire of biosynthetic enzymes. In contrast, the put mutants cannot utilize proline to obtain nitrogen or energy. In fact, the presence of excess proline imposes toxicity to the put mutants. There are three possible sources of proline. 1) PureCol EZ Gel is a ready-to-use collagen solution that forms a firm gel when warmed to 37 °C. It contains purified Type I bovine collagen (5 mg/ml) dissolved in DMEM/F-12 medium, which has multiple amino acids, including a substantial amount of arginine. 2) The recovery medium DMEM supplemented with 10% FBS. The presence of FBS provides amino acids and induces filamentous growth. As the reviewer points out, C. albicans grows in this media and exhibits filamentous growth. 3) The proteolytic breakdown of collagen is expected to liberate proline. Consequently, the poor growth of the mutants clearly demonstrate the importance of proline catabolism. Also, the fact that we recovered put mutants surviving on top of the collagen (Fig. 4B, inset) suggests that they remain viable but simply are unable to efficiently invade the collagen. Consistently, microscopic inspection of the wells of the put mutants showed extremely few or even complete absence of invading cells in the recovery medium. We will adjust the text and provide a more detailed description of the experimental set-up. In summary, the main concern of the reviewer with respect to lack of proline is not relevant.
Regarding the 3D-skin model, equal numbers of fungal cells were applied on top of the RHE. To avoid overgrowth, only low numbers (100 C. albicans cells) can be applied for the WT strain, and consequently for all other strains. In contrast to WT, which clearly proliferates, the apparent low level of put1 and put2 cells at the center of the 3D skin model is the consequence of poor growth. The upper layer of the RHE consists of stratified keratinocytes. To grow, WT fungal cells obtain proline either directly from the keratinocyte, from secreted proteases that liberate proline from keratin (proline not as abundant in keratin as in collagen, the main component of the dermis), or from the medium that basolaterally feeds the RHE. At the border of the model leakage from the medium can occur. Our results, showing poor growth of the mutants in the center of the 3D-skin model, entirely consistent with the collagen plug experiments, indicates that proline catabolism plays a determinant role to enable invasive growth.
Lastly, the imaging experiments are highly problematic. First, reference must be made to previous ex vivo imaging reported by the Lionakis lab in 2013. Second, the number of cells imaged is so low that there is no power to make any conclusions. At 24 hr, the mutants may be delayed in filamentation or they may be delayed in establishing infection. There is no way to know what is causing the apparent lack of filaments. This technique as presented is not any higher resolution than traditional histology and in fact histology would provide a more convincing case for reduced filamentation.
These considerations significantly reduce the overall significance of the work.
I work on Candida albicans.
We thank the reviewer for highlighting the beautiful study by Lionakis et al which document the host response, specifically the role of macrophages in mitigating C. albicans infection of the kidney. However, the reviewer apparently failed to recognize that their method is completely differed from ours. Lionakis et al. performed ex vivo imaging of kidney slices using regular confocal imaging, and the authors express an awareness regarding the limitations of this approach. In fact, these authors even state in their discussion that intravital microscopy should be pursued in the future to further investigate Candida-macrophage interactions in the kidney. Also, they point out that kidney-specific factors seem to facilitate rapid filamentous growth of C. albicans. In our work, we have experimentally addressed both of these astute statements. To our knowledge, our work is the first report of imaging a Candida cell infecting a kidney in a living mouse, which on its own is a major development and achievement considering the complexity of the kidney microenvironment. The finding that the put2 mutant does not exhibit filamentous growth in the kidney of a living mouse (24 h) is striking and strongly suggests that a substantial quantity of proline, or amino acids (e.g., arginine) that are metabolized via the proline catabolic network, is present in the kidney. This is clear based on finding that WT C. albicans cells respond accordingly to initiate hyphal growth. Consistent to this, it is well documented that the kidney is a major metabolic hub for arginine and proline metabolism. The work by Lionakis aligns remarkably well with our previous and current work in that put mutants exhibit greatly reduced survivability in co-culture with macrophages and do not evade these primary immune cells due to their inability to induce filamentous growth within the phagosome (Silao et al., 2019). We have adjusted the text to include a discussion that places our work in the context of the Lionakis work.
We have added a Fig. 6C showing an example of the scanned area of the kidney. Further we added the following in the revised legend to indicate that large areas of kidneys were imaged in our assessment of fungal growth and filamentation:
“Sites of colonization where localized using a spiral scan in the Las-X Navigator-module in the FITC channel. The entire area of the renal surface attached to the glass imaging window was scanned; circles highlight examples of regions of interest (ROI) exhibiting stronger and deviating fluorescence from the background. Each ROI was examined in detail using FITC, yEmRFP and autofluorescence. Scale bar, 500 µm.”
CONCLUDING STATEMENT – SUMMARY RESPONSE:
Our current work is based our previous discovery that proline metabolism provides energy to induce and support filamentous growth (PLoS Genetics, 2019). This turned out to be important since we also discovered that C. albicans cells depend on mitochondrial proline metabolism to evade engulfing macrophages, implicating this process as being an important virulence determinant. Consistently, using time-lapse microscopy, we subsequently found that proline catabolic enzymes are rapidly induced in C. albicans cells upon phagocytosis by macrophages. These results demonstrated that proline is present within phagosomes. As exciting as these findings are, they focused on a single phenotype, i.e., filamentation, and were obtained using in vitro experimental approaches. These results demanded that we pursue additional avenues to further characterize and test the in vivo relevance and merely provide a solid background for the current work.
In contrast to reviewer 2 and 3, we do not believe that our finding that proline catabolism plays such a critical role in virulence as being merely “incremental”. We also could not have foreseen that the ability to use proline as an energy source is a common feature of multiple fungal pathogens capable of causing human disease. This is conceptionally very important in that human fungal pathogens, unlike the well-studied yeast Saccharomyces cerevisiae, are not readily found out in nature, and thus have evolved to use a similar spectrum of nutrients as host cells, including cancer cells. It is important for the fungal pathogen community to realize that regulatory switches operating in C. albicans are wired substantially differently to those in S. cerevisiae, and are likely optimized to reflect the actual condition in the host environment. The growing appreciation that diverse cancers are able to shift metabolism to exploit proline as an energy source is strikingly and fascinatingly similar to our findings with pathogenic fungi. This represents a conceptual advance in that it points to the wealth of proline stored within extracellular matrix proteins as providing a potential and significant source of energy for virulent fungal and cancerous growth.
Finally, we strongly believe it is improper to extrapolate virulence properties based on in vitro findings, and that it is essential to actually test host-microbial pathogen interactions using refined in vivo models. Our successful use of advanced intravital microscopy goes beyond traditional and accepted murine infection models and has provided us with a unique state-of-the-art vantage point. Our findings that a single C. albicans cell is able to initiate and establish a site of infection in a kidney within a living mouse is itself important, and coupled to the novel finding that hyphal development at sites of infection depends on the ability of the fungal cells to catabolize proline must reflect the physiological conditions in the kidney. This is not an incremental finding, and we do not understand that reviewers 2 and 3 diminish the significance of these findings. Clearly, our manuscript provides a strong foundation for more detailed and advanced studies.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
The manuscript of Silao et al. describes an in-depth investigation of the role of Put1 and Put2 enzymes in proline catabolism and virulence in Candida albicans. This is an extension of previous work in this system. The basic biochemistry and genetics are solid and support the role of these enzymes in the proposed pathway and provide evidence that the build up a toxic intermediate in the absence of Put2 is likely involved in the poor growth of the strain when proline is the only carbon source.
The conclusions regarding its role in virulence are less convincing, particularly the data derived from the collagen invasion assay, the ex vivo skin model and the ex vivo/in vivo imaging. The survival and fungal burden assays support a modest role in virulence and a modest reduction in infectivity (although the presented data for survival does not have statistical significance data reported for the kaplan analysis.
The manuscript is clearly written. The methods are well described.
Referees cross-commenting
I remain unconvinced of the broad significance of the advances and stand by my assessment that this is for the most part a reasonable study but does not move the field forward. The novel technical aspects are either extensions of previous in vivo imaging or are not well controlled (collagen invasion assay)s.
Significance
This is a detailed study of an area that is fairly mature and thus will be of interest to those in the field but does not represent a large advance and is thus truly incremental.
Major limitations of the work are as follows. First, the collagen invasion assay may be flawed. The recovery media is made with DMEM which is a medium that lacks proline and is fairly stringent. Control experiments need to be done to be sure that the mutants grow in the recovery medium. Second, the data from the RHE model are hard to interpret since so few cells are present in the tissue. It is hard to see if there are few filaments of if there are just too few cells to assess in the tissue. Third, in vitro experiments assessing the filamentation of the mutants in the medium in which these assays are preformed need to be done as controls. Candida albicans filaments in many conditions such as tissue culture medium. Spider medium is a strong inducer of filamentation but is very different than in vivo/ ex vivo conditions.
Lastly, the imaging experiments are highly problematic. First, reference must be made to previous ex vivo imaging reported by the Lionakis lab in 2013. Second, the number of cells imaged is so low that there is no power to make any conclusions. At 24 hr, the mutants may be delayed in filamentation or they may be delayed in establishing infection. There is no way to know what is causing the apparent lack of filaments. This technique as presented is not any higher resolution than traditional histology and in fact histology would provide a more convincing case for reduced filamentation.
These considerations significantly reduce the overall significance of the work.
I work on Candida albicans.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
The study is part of the continuous work by the authors to dissect the mechanism of utilization of proline as a carbon source in Candida spp. In particular, this work shows that the inability to process proline leads to accumulation of the toxic intermediate P5C and subsequent inhibition of mitochondrial respiration and toxic effect on the cells. Furthermore, the study demonstrates that proline utilization is important for C. albicans kidney colonization. The experiments are meticulously designed and the study adds to the overall understanding of the metabolic utilization of proline as a carbon source and its potential relevance for infection. I find this work interesting, but the role of Put1 and Put2 in proline utilization is not particularly novel. The novelty here is the subcellular localization of the two proteins. Also, the importance of proline utilization for infection is unclear. The host-pathogen interaction assays are ambiguous as each assay gives different result. Lastly, the authors try to generalize the importance of use of proline as a energy source by other Candida spp.. This is not very surprising, given that it has been reported previously by others (example DOI: 10.1002/yea.1845) and that many pathogenic or closely related to C. albicans species use various amino acids, not only proline, as a carbon source. Moreover, the authors take C. albicans as an example to demonstrate the role of PUT in invasion and infection. Proline is known stimulus for hyphal growth in this species, but many other Candida spp., including C. auris, do not filament. So how, aside from supporting growth, proline is linked to infection in these species? I think the authors oversell the importance of proline in Candida spp. pathogenesis and should tone this part down or remove completely. A new story that validates the importance of PUT in non-albicans species can bring clarity to why and where proline is critical for survival and infection.
Major comments: I am not convinced by the data that proline is important to initiate infection. Candida infections of the kidney occur only at late stages of sepsis. The authors need more compelling data to prove that proline is important for infection in the host.
Minor comments: I find the manuscript difficult to read and the discussion part is overly long. Some streamlining and adding a bit more explanation for the rationale of each experiment will make the work easier to follow. Some language/style needs refining as well.
Referees cross-commenting
In this manuscripts the authors clarify the cellular compartmentalization of steps in proline catabolism. However, it is not novel that proline is a valuable carbon source. The role of proline utilization for establishing or progression of infection remains ambiguous even after the authors provide different in vivo results. The overall significance of the study is limited.
Significance
The strengths of this study are in the experimental design and variety. The data is well presented and visualized. The limitations are as pointed above - I find it especially difficult to figure out where, in a real infection scenario (e.g. breach of the gut barrier and entry into the bloodstream) proline will be the primary energy source.
To me the significance of this work is minor.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary:
Silao et al make the intriguing observation that yeasts that are generally considered less pathogenic are unable to catabolize proline than Candida albicans. They then, in Candida albicans, construct mutants defective for the two key enzymes (Put1, Put2) required to convert proline to glutamate, which they show to be essential for proline utilization as an energy (carbon) and nitrogen source. The authors proceed to untangle the regulatory aspects of proline degradation, including the respective cellular localization of its key enzymes. They then make the important discovery that strains lacking either Put1 or Put2 suffer from a proline-dependent growth defect, which they attribute to resulting defects in mitochondrial metabolism.
The manuscript then goes on to analyze a broad range of infection models including: reconstituted human epithelial skin model, Drosophila, mouse systemic infections, organ colonization in these mice (kidney, spleen, brain, liver and histochemistry of the kidneys) as well as survival when incubated with cultured human neutrophils. Finally, they use yeast cells constitutively expressing yEmRFP (so that yeasts can be distinguished from other host cells) and coated with FITC before incubation with the host cells (which coats the wall of the original cells, but does not spread to progeny) and they go on to perform an impressive set of analyses of C. albicans growth within mouse kidneys both in vivo and ex vivo, exploiting an implanted window together with intravital imaging with a two photon microscope at different time points. The system is impressive and visualizes tissue invasion by hyphal cells beautifully. Finally, they compare the intra vital images from WT and put2-/- cells and show that, as in vitro, put2-/- cells do not form filaments and do not show extensive invasion of the kidney tissue. While the in vivo aspect of the study includes many different models, it finds defects in virulence for different subsets of put mutants and the relative importance of filamentation vs proline utilization for virulence is not conclusively resolved.
Overall, this is an important and timely manuscript, which significantly contributes to the understanding of how proline metabolism intersects with yeast fitness in the context of infections. However, there are several major concerns regarding some of the conclusions drawn from the study. In addition, some general recommendations that would improve the manuscript are provided.
Specifically, the manuscript provides a very detailed description of experiments and observations. However, in several parts it is difficult to follow and the the reader needs more guidance about the logic involved in reaching conclusion. Specifically, several aspects of the paper are written for experts in Candida (yeast) metabolism. Here, explaining the rationale for some of the experiments, and providing more background information that is not obvious to a non-expert, is required.
In particular, writing a clear and measured summary sentence at the end of each paragraph and a conclusion paragraph that summarizes key findings in simple terms would help make the manuscript more digestible for readers.
In addition, the impressive microscopy and broad range of in vivo experiments is comprehensive but only adds incremental information relevant to proline metabolism-that filamentous growth in vivo and virulence is reduced in cells carrying some mutations in one or more put genes. However, this broad sweep of model systems and the development of the in vivo imagining system might have more impact in a separate paper focused on the real-time in vivo visualization of kidney invasion.
Major comments:
- The main finding that impressed this reviewer is that "removing the ability to catabolize proline, in an organism that evolved to catabolize it, leads to (growth) defects". This point could be better highlighted throughout the manuscript.
- The authors show that deletion strains for proline metabolism have defects that are important for in vivo pathogenicity. This is an important finding. However, as the manuscript reads now, it suggests that the main findings are that the ability to use proline in the respective host niche is key. Mechanistically, the manuscript revolves primarily around defects that arise when deleting PUT1 and/or PUT2 (i.e., an "unknown" toxicity of proline in the case of put1-/- (or put1-/- put2-/-) and the additional P5C-dependent toxicity for put2-/- mutants; see below).
- In order to claim that catabolizing prolines promotes pathogenicity (as opposed to the alternative hypothesis that the inability to catabolize proline leads to the observed defects), additional experiments would be required. For example, the put mutants would need to be compared with mutants that significantly reduce/impair proline uptake, such as the referenced gnp2 mutant (Garbe et al 2022). While the finding that less pathogenic yeast species are unable to catabolize proline is both intriguing and important, it also remains as is presented as a loose, non-quantitative correlation that only tangentially address the question of whether "proline catabolism is key for pathogenicity".
- 238 onwards: The conclusion that "the primary growth inhibitory effect of proline is linked to catabolic intermediates formed by Put1 and that are metabolized further by Put2"does not appear to be fully supported by the evidence. Addition of proline to put1 mutants already reduced OD600 by ~50% (Figure 2); and is further reduced to ~10% when put2 is deleted. This implies that there are two inhibitory effects of proline, not one primary one. At the least, this option should be discussed, including why deletion of PUT1 leads to proline toxicity. The latter is not clear-is it that too much proline accumulates in the cell and this accumulation is toxic? If this is the case, the effect would be expected to be proline concentration dependent. Performing a relatively simple experiment as performed for the put2 mutant (Fig. 3 / S3F) may clarify this issue. Particularly, if the experiment would be coupled with intracellular quantification of proline.
- The caption "P5C mediates a respiratory block" is misleading, as the evidence is not that compelling: Although P5C increases in put2, but not in put1 mutants, and given that both single mutants experience a proline-dependent respiratory defect (Fig. 3E), the results suggest a more complex relationship.
- The virulence assays and in vivo experiments do not present a unifying view: in Drosophila put2∆∆ is less virulent than put1∆∆, which appears similar to put3∆∆. Given that put2 mutants grow slowly, likely because of P5C inhibition, this seems logical. However, in mice, put3∆∆ remains highly virulent while put1∆∆ and put2∆∆ results for survival are mixed. Furthermore, in 4 mouse organs, put1∆∆ and put2∆∆ are not significantly different from one another but are different from wt, while put3∆∆ has no significant reduction in CFU. Kidney histology shows very little invasion by put1 and put2 and more by put3, but visually put3 appears to invade much less than the WT, and the human neutrophil experiment shows effects of put2 or put3 but not put1. This leaves the reader rather confused. It may be worth discussing the reasons for different results in different models. Is the availability of proline in each of the organisms and organs similar?
- The ex vivo and in vivo analysis of the dynamics of C. albicans growth in the host is visually impressive, but it distracts from the focus of the paper and the metabolic findings. Showing that put mutant cells do not form filaments in vivo (as in vitro) does not add much conceptually to the paper. Furthermore, this lovely advance in in vivo visualization is lost at the end of this paper and the authors should consider whether it might fit better in manuscript that could really highlight the in vivo visualization approach.
- The discussion of cells stained with FITC and expressing yEmRFP does not clearly point out that the FITC is only an indicator for those cells that were used to innoculate the tissue and that finding cells without FITC indicates that they are mitotic progeny, indicating that they have been dividing. The authors clearly understand this, but a naive reader may miss this important point if it is not stated explicitly.
Minor comments:
- Throughout: what is the distinction between utilization of proline for C or for energy? These terms seem to be used interchangeably.
- Introducing the schematic in Fig. 2A at the beginning of Figure 1, would help explain proline catabolism before delving into the growth experiments that rely upon this framework. This should include an explanation, for readers less familiar with the metabolic issues, of the main limitations to catabolizing proline, and the key issues for being able to use proline for nitrogen, carbon, and energy (potentially indicated in the overview figure, e.g. pointing towards gluconeogenesis etc.).
- Saccharomyces can only grow on proline as a nitrogen source, but not as energy/carbon source. Could the authors briefly mention or discuss why this is the case? This is not clearly apparent after reading the manuscript and it leaves the reader confused and trying to understand if the fact that proline is required for carbon utilization is a new finding of this paper or was already known. Do the authors think this is tied to the presence of complex 1 components in C. albicans that are not found in S. cerevisiae. Is this consistent for the pathogenic, but not the non-pathogenic yeasts analyzed in figure 1?
- 100: While Gdh2 is apparently an important enzyme for generating ammonium, why is it not necessary for macrophage escape and virulence as shown in reference 18? A recent paper from Garbe et al (ref 12) suggests that Gnp2 is the major proline permease in C. albicans and what is known, and not known, about proline uptake would be good to mention, given that PUT gene functions require that proline enters the cells.
- 116: Is the "low sugar environment of the host" referring to a specific niche, such as the GI tract, or human blood? Compared to most natural environments, glucose is abundant in the host, e.g., at ~5 mM, it is the most abundant metabolite in blood, and similarly, in the GI tract, levels can go beyond 50 mM glucose (see e.g. PMIDs 34371983, 21359215). Or is this comment indicating that the in vivo sugar concentration is lower than that in common lab growth media? Please spell out the niche/concentration for clarification - and compare that to other niches that are considered "high sugar environments".
- 123: "proline as sole energy source" - suggest "is the source of carbon, nitrogen, and energy"
- 142: it is worth noting to readers that C. neoformans is a basidiomycete and thus VERY distant from the other yeasts studied here-it is in a different major phylum of fungi.
- 143: Here it is implied that put1 and put2 mutant strains do not grow on SPD, but this is not stated explicitly.
- 151: The abbreviation SPG is not explained in main text.
- Paragraph 156 onwards: this section is particularly hard to read and very dense. Also, it is difficult to understand the significance of these experiments for the overall findings of the paper. Please at least provide a small conclusion / summary at the end of the paragraph that puts the findings into perspective.
- Figure 2 C: simplifying the scheme (e.g. lots of redundant information, P2 and Mito - just give it one name) would help. This figure may be better in the supplementary material.
- Figure 2B: It is not directly apparent from the micrographs that Put1-RFP localisation is mitochondrial. Co-localisation of the RFP with a mitochondrial dye (e.g., mitotracker) or something similar is required to validate it.
- Throughout the manuscript (figure legends): Suggest using "mean" instead of "Ave."
- 175: According to the 'Yeasttract' and 'Pathoyeasttract' databases, Put1 regulates at least 36 and 22 genes, in S. cerev. and C. alb., respectively (based on DNA binding and/or regulatory changes). The only gene in common between these two lists of genes is PUT1. Thus, it is quite likely that Put3 regulates many other processes that explain its function and that its major function may not be only to regulate Put1.
- 175: Is it clear whether the Put3-independent mechanisms are positive or negative with respect to Put1?
- 218: Suggestion: "growth was indistinguishable".Unless growth curves or growth rates are provided and if one time-point data are the basis for this point, than "rates" is not a relevant term.
- 256 onwards: did the authors test if the ROS scavenging effectively reduced ROS? i.e. does the luminol-HRP assay yield less ROS in +proline +scavenger treatment? This is necessary to effectively conclude that the growth inhibitory effect of proline is due to blocking respiration.
- The Figure captions are extremely lengthy and detailed, making it cumbersome to find the relevant information. Suggest moving some of the information, such as additional experimental details, into the methods section.
- 277-301: Phloxine is not exclusively a live/dead cell indicator-it is an indicator of metabolic activity. In Scerev. and Calb. it also indicates slower growth, opaque growth, and it has been used as an indicator of aneuploidy in C. glabrata (https://journals.asm.org/doi/10.1128/msphere.00260-22) and of diploids vs haploids in S. pombe. The colonies illustrated aer made up of many live cells, and thus the section "Defective proline utilization is linked to cell death" needs to be presented more carefully. In addition, it appears that this section shifts from using defined medium to using rich medium and 37C instead of 30C. Why was this shift necessary?
- 295-301: Related to the point above, these results are hard to interpret due to the switch from defined medium in all prior experiments to rich growth medium here. Also, it is not clear why a 48h old YPD culture was chosen to show that the degree of PI staining correlates with mitochondrial activity - is this due to the culture age? It would be more clear to image cells grown on glucose vs. glycerol/lactate, or under repressive / de-repressive glucose concentrations (e.g., as shown in Fig. S4C where a PI+ difference is apparent for 0.2% glucose vs. 2% glucose at 30{degree sign}C).
- 313-14: The statement 'the invasion process was dependent on the ability of cells to catabolize proline' doesn't take into account that put mutant cells are defective in filamentous growth irrespective of their utilization of proline...and like the efg1 cph1 double mutant.
- 316-327: The results of the experiment described can only be interpreted as an effect of proline catabolism if the three strains (efg1 cph1; put1; put2) have similar growth rates as yeast cells in vitro. Why weren't the cells competed directly (efg1 cph1 vs put cells)?
- Fig 6: The logical order of the experiments, and in the text, is: 1) 4 h window, 2) 26 h window and then 3) ex vivo. The cartoon in 6B should be in this order as well.
- 337: it is not clear what the 'direct exposure...' is trying to tell us. Can this be made more explicit?
- 340-346: Here proteins with high proline content were used to ask if they could be induce transcription of PUT1 or PUT2 RNA and protein. This experiment is designed only to test the role of these proteins to induce utilization of nitrogen, as glucose is included in the medium. Given that these proline-rich proteins need to be lysed by proteases before they can be imported, and since no import pathways were tested, the results appear to tell us that mucin is more readily digested to peptides that contain proline-but why that is the case is not clear and how it relates to proline utilization is also not clear.
- 363-369 An alternative is that Put3 induces different proteins important for growth.
- 379-380-the conclusion for this paragraph is somewhat of an overstatement as there is no analysis of the degree to which proline utilization is a predictor of virulence. It simply shows that put mutants affect the ability to survive in neutrophils.
- Discussion: The statement that "S. cerevisiae" evolved in high sugar environments is debatable. The natural niche could well be forest soil and tree bark, or insect/wasp guts with arguably little glucose around.
- 469-470-how strong is the 'correlation' between the ability to utilize proline and virulence? Given that different mutants had different effects in different models, this seems like a very loose 'correlation'; it would be good to have some quantitative measures to make this claim.
- 500: Was the experiment was done in larvae, and not in adult Drosophila? Fig 5 legend says flies and shows a picture of a fly and larvae are only mentioned much later in the text..
- 512:Why is it presumed that proline accumulates in the mitochondria in put1 mutants? How strong is the presumption?
- 539: why are MMPs important for digestion of collagen? This is not clear at this point of the Discussion.
- 574: Concluding sentence of this paragraph seems unsubstantiated. There are at least two defects in put2 strains-hyphal growth and growth in general, presumably because of P5C accumulation.
- Fewer abbreviations would make the manuscript easier for non-experts to read. For example, P5C is not defined in the abstract. Furthermore, if an abbreviation is not used more than 3 times, it is not necessary to provide it (e.g., mammalian proteins in the last paragraph).
Typos: 1. 82: should read 'is restricted to the mitoch...' 2. 102-103: should read 'to evade macrophages' 3. Fig. S4F is mislabelled as Fig. S4G.
Referees cross-commenting
Overall, we stand by our initial assessment of the study. However, we were not aware of previous studies that investigated proline utilization in yeasts, as noted by Rev # 2 (https://onlinelibrary.wiley.com/doi/epdf/10.1002/yea.1845). The current study suggests that using proline as an energy/carbon source is more wide-spread, beyond pathogenic yeasts. Further, the C. albicans strain they used for this study (ATCC 10231) was apparently unable to grow on proline in the quoted paper. In light of this, we think the authors should reference this study, tone down the claims about the clear correlation of pathogenicity and proline utilization, and address this apparent discrepancy with the indicated Candida albicans isolate. We note that our review considered this a paper mostly of interest to specialists.
Significance
- The advance in this paper is conceptual for the proline utilization connection to virulence in a range of species and technical for the in vivo microscopy. Limitations are that the conceptual advance is based only on qualitative work in figure 1 and that the animal studies do not provide a conceptual advance, although the technical advance of in vivo visualization of kidney tissue is impressive and (to the knowledge of this reviewer) quite new as the only prior work was in mouse ears.
- The work fits well as an extension of the body of work from the corresponding author's lab with additions from the labs with expertise in models of infection.
- People interested in yeast metabolism and pathogenic yeast virulence will be the audience for this paper and as written it is for a specialized audience interested in pathogenic yeast metabolism and, perhaps, (although not mentioned at all in the text) for those who want to try PUT gene products as new drug targets.
- Reviewer expertise is in pathogenic yeast biology and yeast metabolism. Little expertise in high tech microscopy.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Comment 1.
The impact of this study would be greatly enhanced if the authors could provide electrophysiological results validating that intra-VTA infusion of Grin2c siRNA affects the excitability or discharge regularity of different populations of VTA neurons (at least dopaminergic and GABA neurons).
*Reply. The reviewer is suggesting an additional experiment that constitutes a next logical step to further determining the role of NMDA receptors (NMDARs) containing the GluN2C subunit(s) in induction of EPSP in VTA TH+ and TH- neurons; such an experiment could be performed in vivo in behaviorally tested animals, but the recordings would have to be done in anesthetized animals 24h after VTA siRNAs microinjections; an alternative would be an in vitro experiment with slices that would maintain a functional link between dorsal raphe (DR) glutamatergic reward neurons and VTA neurons; we agree that this would constitute an important step forward, and that can be performed once our findings are published. *
Comment 2.
The strategy of targeting Grin2c transcripts with siRNAs is appropriate and the authors implemented a western blot validation to control the effectiveness of their approach. However, due to the large volume of siRNA injected into the VTA (500 nl), the authors should consider extending their western blot validation experiments to structures anatomically close to the VTA and rich in GluN2C subunit such as RMTg. The DRN would also be an interesting structure to show that GluN2C subunit expression is not affected by the siRNA approach.
*Reply. Optogenetic studies have shown that the reward signal initiated by glutamatergic neurons in the dorsal raphe is transmitted to VTA neurons (Liu et al., 2014; McDevitt et al., 2014 Qi et al., 2014;), findings that are consistent with, and that were predicited by, our previous findings (Rompré and Miliaressis, 1985; Boye and Rompré, 2000; Ducrot et al 2013). Moreover, a large body of research carried out with local (VTA) drug injections generated data confirming the role of VTA neurons in reward (See for instance Wise and McDevittt, 2018). Thus, it is reasonable to hypothesizes that it is the reduction of GluN2c (NMDARs that contain this subunit) in VTA neurons that is responsible of the attenuation of reward. Such a hypothesis is further reinforced by our findings that GluN2c and its gene are expressed in VTA neurons. Why should it be within the RMTg? The reviewer likely knows many different studies that have shown that RMTg neurons play a key role in aversion; they provide a strong tonic inhibitory input to reward-relevant VTA neurons and more specifically to VTA DA neurons (see Zhou et al). RMTg neurons receives a strong excitatory input from the lateral habenula; activation of these neurons strongly inhibit reward. Consequently, a logical hypothesis is that a reduction of the glutamatergic excitation of RMTg caused by a reduction of NMDARs that contain GluN2Csubunits would have produce an enhancement of the reward signal, not an attenuation. *
*The DR, site at which the electrical stimulation was delivered is located near 2 mm behind and 3 mm above the injection sites, it is very unlikely that the small volume injected hit the DR. *
Comment 3.
The authors should consider discussing or re-evaluating their findings from their 2015 study which suggested that the effect on reward induced by DRN stimulation was controlled by GluN2A-containing NMDARs most likely located on afferent terminals.
Reply. We cannot understand why we should re-evaluate or re-discuss these findings. It has been repeatedly shown that blockade of GluN2A containing NMDARs by local VTA PPPA and R-CPP microinjections enhances the reward signal initiated by DR electrical stimulation (Bergeron and Rompré, 2013; Ducrot et al., 2013; Hernandez et al., 2015; and the present study (control group); this enhancement effect was not attenuated by a decrease in NMDARs that contain GluN2A subunit(s) (Hernandez et al 2015). Our discussion is reasonable in view of these findings, and the hypothesis that these GluN2A containing NMDARs are located on afferent terminal explains the results.
Comment 4.
In Figure 2, the authors should quantify the results of the colocalization levels of Grin2c and TH in dopaminergic neurons of the substantia nigra pars compacta.
Reply. As mentioned in our reply to comment 2, the quantification of VTA neurons was highly justified by a large body of the literature which is not the case for the substantia nigra pars compacta neurons.
Comment 5.
The results should be presented differently in figure 5 in order to be able to compare on the same graph and with the appropriate statistical analyses (two-way ANOVA), the impact of PPPA infusion or solvent in the SCRGluN2C or siRNA groups.
Reply. Unfortunately, this is not possible because not all subjects were tested with PPPA.
Comment 6. The authors should clarify the N=12 per condition in Figure 3, especially since 11 values for the control conditions are plotted on the histogram.
*Reply. The reviewer is correct there are 11 Subjects in the control group and 12 in the active sirna group. We made the changes to the methods section. *
Comment 7.
Authors should standardize the way they cite literature throughout the manuscript (number or authors).
Reply. Thanks for the suggestion changes have been made to standardize the citations.
Comment 8.
The authors should clarify sentences 102-105 of their introduction, which seem to conflict but ultimately describe similar results.
Reply. Reviewer is correct the following sentences at the end the paragraph were deleted:
*This hypothesis predicts that activation of a given subtype(s) potentiates DA burst firing and DA release, whereas activation of different subtype(s) increases the inhibitory drive to DA neurons. This idea is supported by data mentioned above and others showing that both activation and blockade of VTA NMDARs increase DA burst firing (French et al., 1993), accumbens DA release (Karreman et al., 1996; Westerink et al., 1996; Mathé et al., 1998; Kretschmer, 1999), and stimulate forward locomotion (Kretschmer, 1999; Cornish et al., 2001). Rodents also readily learn to directly self-administer the non-selective NMDAR antagonists, AP-7, into the VTA (David et al., 1998), showing that NMDAR blockade can have positive rewarding properties on its own. *
Comment 9.
The expression of different GluN2 subunits across different regions of the brain has been known since the early 90's as the authors acknowledged. In the abstract, the authors state that GluN2C is "the most abundant subunit of the NMDA receptor expressed in the VTA" (line 67). This idea that GluN2C is "the most abundantly expressed in DR and VTA compared to other Grin2 subunit transcripts" (line 425), is repeated throughout the paper. However, in the Results section they state that GluN2C is present at the same level as GluN2B; something that is also clearly visible in figure 1, where is also clear that GluN2A is also present almost at the same level. The emphasis that GluN2C has a larger representation over 2A and 2B in VTA is not necessary and misleading.
*Reply. The point here was to bring attention to the reader to the expression of GLuN2C, the main target of the current study. As shown in Figure 1, GluN2c is indeed the most abundant in the VTA. *
Comment 10
3) Performing an immunoblot in tissue obtained with a tissue punch of the VTA, the authors confirmed that the GluN2C mRNA detected is translated into protein. Unfortunately, this important data is not showed, and it should be shown. Moreover, immunocytochemistry of GluN2C could help to identify the cellular type where the protein is expressed, something that could be key to better understand the role of NMDARs in the reward pathway. Are 2A/2B expressed in different cells that 2C? What type of cells express 2C? These are just a few of the question that a better and more detailed analysis of 2C expression could provide. Without this, the interpretation of results presented here, as well as previous results, regarding the role of NMDARs continuous being confusing.
Reply. Because we measured GluN2C proteins within the VTA, we infer that some Grin2C detected in VTA TH+ and TH- neurons is translated into proteins, and reduction of the protein expression resulted into a selective attenuation of reward We added a supplementary fig showing the GluN2c protein in different brain regions.
Comment 11.
4) The largest number of 2C positive cells do not express TH complicating the interpretation that 2C is necessary to convey reward information in the DR-VTA circuit. Other effects due to downregulation of 2C could be responsible of the behavior changes observed. Although the authors offer an explanation for this, is not enough. They suggest that 2C maybe involved in a reduction of excitatory inputs into inhibitory interneurons that when downregulated should produce an opposite effect to what is observed. However, without knowing the identity of those GluN2C expressing cells this comment is only speculation and does not rule out a role for other GluN2C expressing cells that are not TH positive.
*Reply. We do consider the hypothesis that the attenuation of reward is due to a reduction of GluN2C in TH- neurons, in fact we discuss both hypothesis, TH+ and TH-. Characterization of the reward-relevant neuronal pathway has been an important aim since Olds and Milner discovery. Our findings constitute, as mentioned in reply to comment 1, and important step forward, and indeed identification of the specific VTA cells that convey the reward signal is another important question that should be addressed. Our findings provide a strong ground to focus on GluN2C but not the other subunits. *
Comment 12.
5) In this line, there is no good explanation why treatment of animals with GluN2A blocker enhances the reward pathway only in animals treated with control siRNA. Two possibilities could explain this. 1) there is some sort of relationship between 2C and 2A that when 2C is absent, PPPA has no effect. Again, it could be important to know if 2C and 2A are expressed in the same cellular type; 2) the control siRNAs are not completely innocuous and may produce unknown effects that alter the functionality of VTA.
*Reply. We believe that our data are strong and valid because the methods we used have been validated and the results with PPPA in control group are similar to those previously published. Previously we have shown that a reduction of VTA GluN2A proteins has no impact on reward per se nor on the enhancement of reward by PPPA (Hernandez et al., 2015). The hypothesis raised by the reviewer that 2C and 2A interact is incompatible with the findings that we obtained. Could it be a non-specific effects like tissue damage. In such a case however we would have observed a decrease in 2A subunits as well which is not the case. *
Comment 13- 16
6) Downregulating 2C suggests that this subunit is vital to relay a reward signal in VTA neurons. The following are comments regarding the analysis of the data of Fig 4 and 5. 7) It is not clear how the maximum and minimum are estimated in order to fit a sigmoidal curve to the data. Are they average of the stable part? Where the error bars on each data point come from? What is the actual value and standard deviation of M50 values?
Reply: As described in the self-stimulation training in the materials and method section
“The data relating to the rate-frequency was fitted to a sigmoid described by the following equation y=Min+((Max-Min) )/(1+[10]^((x50-x)*p) ) where Min is the lower asymptote, Max is the upper asymptote, x50 is the position parameter denoting the frequency at which the slope of the curve is maximal, and p determines the steepness of the sigmoid curve. The resulting fit was used to derive an index of reward defined as the pulse-frequency sustaining a half-maximal rate of responding (M50). Self-stimulation behavior was considered stable when the M50 values varied less than 0.1 log unit for three consecutive days”
The Max, Min and all the free parameters of the equation are the determine by the best-fit parameters by minimizing a chosen merit function. A merit function, also known as a figure-of-merit function, is a function that measures the agreement between data and the fitting model for a particular choice of the parameters. By convention, the merit function is small when the agreement is good. To optimize the merit function, it is necessary to select a set of initial parameter estimates and then iteratively refine the merit parameters until the merit function does not change significantly between iterations. The Levenberg-Marquardt algorithm has been used for nonlinear least squares calculations in the current implementation.
As described in the self-stimulation training and material section.
“.. Four stimulation sweeps were run daily, and the first sweep was considered a warm-up and discarded from the analysis”. The remaining 3 sweeps were fitted to a sigmoid and the parameters were obtained. The error bars correspond to the difference across each sweep”.
- What is the actual value of the M50 SD? Don’t understand why this is relevant? We already provide the SEM.*
8) This type of data is better analyzed by nonlinear regression analysis followed by ANOVA and some post hoc multiple comparison test.
Reply: We totally agree with the reviewer that is why the analysis was done fitting a sigmoid line. In fact, the fitting uses non-linear regression to compare the data points to the function, which in this case is a sigmoid function defined by the equation y=Min+((Max-Min) )/(1+[10]^((x50-x)*p) ) where Min is the lower asymptote, Max is the upper asymptote, x50 is the position parameter denoting the frequency at which the slope of the curve is maximal, and p determines the steepness of the sigmoid curve. In fact, intracranial self-stimulation data has been analysed using non-linear regression models since the seminal work by Coulombe and Miliaresis 1986 [1]
Indeed, after obtaining the results of the parameters, we follow it up with traditional statistics like t test and Anovas
9) Given the large variance of individual data points in Figure 4 and 5, a stricter statistical analysis than a t-test is necessary.
*Reply: Thanks for the suggestion, but we do not fully understand what the reviewer is suggesting. In general, the condition to apply or not a specific statistical test assumes about the underlying distribution the conditions required to conduct a t-test include: the measured values are in ratio scale or interval scale, simple random extraction, homogeneity of variance (i.e., the variability of the data in each group is similar), and normal distribution of data. The normality assumption means that the collected data follows a normal distribution, which is essential for parametric assumption. In all the data presented in figure 4-5 the assumptions are respected and checked (the data is measure in a continues scale, the group assignation was performed randomly, the data does not violate the normality assumption and the variance between the groups is similar. In the only case where the variance assumption was not held the Welsh correction was applied. *
Comment 17
10) Minor comments include the need to refer to figure panels in ascending order in the same sequence as they are described in the text.
Reply: Thanks for the suggestion we made the required changes. Now the figure panels are in the same sequence as they are described.
Comment 18
The role of NMDARs in VTA are explained in a rather confusing manner in the introduction. Lines 104 to 106 need some rewording since it conveys that blockade of NMDARs stimulates reward and that an opposite effect is observed following the blockade of NMDARs.
Reply. We simply report data from the literature. Each statement is supported by the relevant literature.
[1] Coulombe and Miliaressis, “Fitting Intracranial Self-Stimulation Data with Growth Models.”
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary
Given the importance of glutamatergic synaptic transmission in the reward pathway from the dorsal raphe to VTA, the authors set to study the role of GluN2 subunits in a reward behavior. First, using qRT-PCR they quantify the amount of GluN2 subunits in different brain regions. They highlight the presence of GluN2C as the most abundant species of GluN2 subunits in VTA. They also identify that ~50% of TH positive neurons are also positive for GluN2C mRNA. Finally, they downregulate GluN2C in VTA using a commercially available siRNA. Knockdown of GluN2C reduces reward-seeking behavior as it increases the M50 and reduces the maximum response. The authors conclude that "VTA glutamate neurotransmission relays a reward signal initiated by DR stimulation by acting on GluN2C NMDA receptors".
Major comments
- The expression of different GluN2 subunits across different regions of the brain has been known since the early 90's as the authors acknowledged. In the abstract, the authors state that GluN2C is "the most abundant subunit of the NMDA receptor expressed in the VTA" (line 67). This idea that GluN2C is "the most abundantly expressed in DR and VTA compared to other Grin2 subunit transcripts" (line 425), is repeated throughout the paper. However, in the Results section they state that GluN2C is present at the same level as GluN2B; something that is also clearly visible in figure 1, where is also clear that GluN2A is also present almost at the same level. The emphasis that GluN2C has a larger representation over 2A and 2B in VTA is not necessary and misleading.
- Previous reports showed that pharmacological blockade on GluN2B or downregulation of GluN2A, the most common GluN2 subunits in the brain, do not affect the nose-poke behavior the authors use here. The biophysical properties of GluN2C are very different from those of 2B and 2A, therefore the fact that 2C downregulation does affect the behavior observed makes an interesting case for the subunit.
- Performing an immunoblot in tissue obtained with a tissue punch of the VTA, the authors confirmed that the GluN2C mRNA detected is translated into protein. Unfortunately, this important data is not showed, and it should be shown. Moreover, immunocytochemistry of GluN2C could help to identify the cellular type where the protein is expressed, something that could be key to better understand the role of NMDARs in the reward pathway. Are 2A/2B expressed in different cells that 2C? What type of cells express 2C? These are just a few of the question that a better and more detailed analysis of 2C expression could provide. Without this, the interpretation of results presented here, as well as previous results, regarding the role of NMDARs continuous being confusing.
- The largest number of 2C positive cells do not express TH complicating the interpretation that 2C is necessary to convey reward information in the DR-VTA circuit. Other effects due to downregulation of 2C could be responsible of the behavior changes observed. Although the authors offer an explanation for this, is not enough. They suggest that 2C maybe involved in a reduction of excitatory inputs into inhibitory interneurons that when downregulated should produce an opposite effect to what is observed. However, without knowing the identity of those GluN2C expressing cells this comment is only speculation and does not rule out a role for other GluN2C expressing cells that are not TH positive.
- In this line, there is no good explanation why treatment of animals with GluN2A blocker enhances the reward pathway only in animals treated with control siRNA. Two possibilities could explain this. 1) there is some sort of relationship between 2C and 2A that when 2C is absent, PPPA has no effect. Again, it could be important to know if 2C and 2A are expressed in the same cellular type; 2) the control siRNAs are not completely innocuous and may produce unknown effects that alter the functionality of VTA.
- Downregulating 2C suggests that this subunit is vital to relay a reward signal in VTA neurons. The following are comments regarding the analysis of the data of Fig 4 and 5.
- It is not clear how the maximum and minimum are estimated in order to fit a sigmoidal curve to the data. Are they average of the stable part? Where the error bars on each data point come from? What is the actual value and standard deviation of M50 values?
- This type of data is better analyzed by nonlinear regression analysis followed by ANOVA and some post hoc multiple comparison test.
- Given the large variance of individual data points in Figure 4 and 5, a stricter statistical analysis than a t-test is necessary.
- Minor comments include the need to refer to figure panels in ascending order in the same sequence as they are described in the text.
- The role of NMDARs in VTA are explained in a rather confusing manner in the introduction. Lines 104 to 106 need some rewording since it conveys that blockade of NMDARs stimulates reward and that an opposite effect is observed following the blockade of NMDARs.
Overall, the data and analysis still leave too many open questions and the role of GluN2C, vs the other subunits, is not clearly established.
Significance
The study is limited in its scope and possible interpretations. The role of GluN2 subunits in the relay of reward information is only incrementally advanced and still continuous to be confusing.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
This study by Hernandez et al provides a series of molecular, anatomical, and behavioral experiments exploring the distribution and the function of the NMDA Glun2C subunit in the ventral tegmental area (VTA). The authors demonstrate that reward signals originating from the dorsal raphe (DR) are carried to VTA neurons through the activation of GluN2C NMDA receptors. this study did not address the specific role of VTA dopaminergic neurons in mediating the reward signal. The major strengths of this paper are the quality of the FISH experiments and the well-established model of Brain Stimulation Reward targeting the Dorsal Raphe. This study is a follow-up of a previous study published by the same group (2015), which explored the expression of GluN2A/2D subunits in the VTA and their role in reward induced by dorsal raphe stimulation. This is an interesting and original manuscript. However, several issues, concerning the design of the experiment and the interpretation of the data, reduce my enthusiasm.
The impact of this study would be greatly enhanced if the authors could provide electrophysiological results validating that intra-VTA infusion of Grin2c siRNA affects the excitability or discharge regularity of different populations of VTA neurons (at least dopaminergic and GABA neurons).
The strategy of targeting Grin2c transcripts with siRNAs is appropriate and the authors implemented a western blot validation to control the effectiveness of their approach. However, due to the large volume of siRNA injected into the VTA (500 nl), the authors should consider extending their western blot validation experiments to structures anatomically close to the VTA and rich in GluN2C subunit such as RMTg. The DRN would also be an interesting structure to show that GluN2C subunit expression is not affected by the siRNA approach.
The authors should consider discussing or re-evaluating their findings from their 2015 study which suggested that the effect on reward induced by DRN stimulation was controlled by GluN2A-containing NMDARs most likely located on afferent terminals.
In Figure 2, the authors should quantify the results of the colocalization levels of Grin2c and TH in dopaminergic neurons of the substantia nigra pars compacta.
The results should be presented differently in figure 5 in order to be able to compare on the same graph and with the appropriate statistical analyses (two-way ANOVA), the impact of PPPA infusion or solvent in the SCRGluN2C or siRNA groups.
The authors should clarify the N=12 per condition in Figure 3, especially since 11 values for the control conditions are plotted on the histogram.
Authors should standardize the way they cite literature throughout the manuscript (number or authors).
The authors should clarify sentences 102-105 of their introduction, which seem to conflict but ultimately describe similar results.
Significance
This study is a follow-up of a previous study published by the same group (2015), which explored the expression of GluN2A/2D subunits in the VTA and their role in reward induced by dorsal raphe stimulation. This is an interesting and original manuscript.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We thank the reviewers for their insights and comments on this manuscript. Specific responses to reviewer concerns are detailed below. We made a couple of significant changes based on the feedback. First, we performed more experiments to increase biologic replicates and then quantified image data for multiple figures. The new quantitative information added to Figure 3 fully supports our original conclusions about changes to the ONH in Hes-TKO mutants. The quantification of Atoh7, Otx2, Rbpms and Crx expressing cells among the different genotypes revealed interesting differences in Notch intracellular gene requirements for both RGC and cone development. The most startling outcome is that changes in both cell types correlate with significant changes in Otx2, but not Atoh7. This singular finding suggests interesting future work is needed, well beyond the scope of this paper about the molecular mechanisms underlying these cell fates. Second, our data presentation was reorganized with new information added to Fig 1 that clarifies the relationships between Hes1, Hes5, Foxg1 and Pax2; old Figs 6 & 7 about neurogenesis were merged; and some data moved to new Suppl Figs 2 and 5. The numbering for multiple figures changed and a new summary model (now Fig 8) is provided. In addition, the manuscript was completely rewritten to improve clarity. We hope this revised manuscript is acceptable for publication.
Reviewer #1 Summary:
In this study, the authors employed an impressive set of mouse mutant or Cre lines to investigate the complexity of Notch signaling across different stages of retinal development. These comprehensive analyses led to two main findings: 1. Sustained hes1 in the OHS/OS is Notch-independent; 2. Rbpj and Hes1 exhibited opposing roles in cone photoreceptor development. Although the study is potentially interesting, the current manuscript needs the essential research background and quantification, a lack of which significantly reduced the clarity of the manuscript and the credibility of the major conclusions. Also, how the authors organized the results is quite confusing, making the manuscript very difficult to follow.
Response: We agree with all reviewers concerning incomplete quantification of the data. We directly addressed this shortcoming in revised Figs 3 and 6 (the latter combines old Figs 6 +7). To do this, we repeated some IHC experiments to add more replicates and reorganized all of the neurogenesis phenotypic data figures. Our quantifications uncovered several surprising outcomes that clarify our model. For these reasons, the manuscript was exhaustively rewritten. We merged E13 neurogenesis data into revised Figure 6 and moved the most relevant E16 analyses to new supplemental data Fig 5. All changes made should make the paper easier to understand for retinal development, neurogenesis, and Notch pathway aficionados, in addition to readers lacking such expertise.
Major comments: 1. The authors needed to make the quantification for many analyses to strengthen the conclusions, such as Fig. 1F, 1G, and etc.
Response: We quantified optic nerve head (ONL) immunohistochemistry data in the revised Fig 3. We also quantified neurogenesis markers Atoh7, Otx2, Rbpms (RGCs), and Crx at E13 in revised Fig 6 (former Figs 6 and 7). Older stages were moved to a new Suppl Fig 5.
Respectfully, Hes5 mRNA expression in old Fig 1F and 1G shows that Hes5, like other retinal progenitor cell (RPC) markers, expanded in Rax-Cre deletion but not Chx10-Cre deletion conditions. This is analogous to Pax6 and Rax expansion in Rax-Cre;Hes1 CKO eyes and Pax2 mutants (doi: 10.1523/JNEUROSCI.2327-19.2020) (1). In revised Fig 1, we now show analogous expansion of Hes5 mRNA in Pax2 mutant retinas (compare Figs 1F-1I). Because Hes5 RNA in situ hybridization experiments are nonquantitative, we do not discuss the possibility of Hes5 mRNA level changes in labeled cells.
The authors reported many exciting results. However, further mechanistic insights are largely missing. They may focus on one of these exciting findings and give some mechanistic insights. For example, hes1 suppresses hes5 expression as the ONH boundary forms; hes1 expression in the ONH is Notch independent; differential influences of Rbpj and Hes1 on cone development. It is better for the authors to select one of these exciting findings and provide a deeper mechanistic study.
Response: This revision brings fresh focus to Notch regulation of RGC and photoreceptor development, particularly differential influences for Rbpj versus Hes1. We also better support our interpretation of image data in Fig 1. We include new data about the spatial relationships between Hes5-GFP/Pax2 and Hes5-GFP/Foxg1. In summary, we find that as Pax2 becomes restricted to the nasal optic cup prior to the onset of RGC genesis, it becomes mutually exclusive with Hes5-GFP, at the same time that Hes5-GFP+ cells coexpress Hes1. This is consistent with Hes1 indirectly regulating Hes5-GFP as a marker of neurogenic RPCs at the forming ONH. Furthermore, it emphasizes the importance of genetically teasing apart the separate and potentially compensatory roles for Hes1 versus Hes5 undertaken here. These relationships remain poorly resolved during vertebrate CNS development.
Some analyses lack an explanation of the rationale. For example, "To understand if the loss of multiple Hes genes is more catastrophic than Hes1 alone..."(PAGE 7). Please explain its significance.
Response: We assume the reviewer is referring to the first sentence of the last paragraph on this page. We analyzed Hes triple mutant mice (TKO) to understand if removing multiple Hes genes reveals redundant functions. This is an open question, given that Hes1 is expressed in the ONH/OS, which is normally devoid of Hes5 by the time retinal neurogenesis begins. These questions have only been explored in a handful of tissues throughout the body. Also see response to point 2 above. In general, we have expanded the rationale for all of the experiments throughout the revised manuscript.
Significance: In general, many results are quite interesting. However, the significance of these findings is largely hampered in the following aspects: 1. The authors were unable to provide the sufficient research contexts that are essential for understanding many results.2. Many conclusions were solely based on descriptive images but lacked statistical quantification, which significantly weakened many conclusions. 3. Many interesting findings are quite descriptive, and some mechanistic understandings of one of these exciting findings will be beneficial to improve the focus and significance of the study. Current format of the manuscript fits more specialized audience.
Response: During in vivo development, we wished to understand which particular Notch pathway genes can interact in a Notch-dependent versus a Notch-independent manner. Genetic (phenotypic) studies produce extremely rigorous datasets, in our opinion. This revision now extensively quantifies key findings. Here we dissected the "receipt" of a Notch signal by identically testing the functional requirements of particular pathway members. For Mastermind (Maml), there are 3 paralogues, double mutants for Maml1 and Maml3 are early lethal, and no floxed alleles exist, so it was logical to employ the ROSA-dnMaml mouse strain, particularly since it has been discussed throughout the Notch literature as "analogous" to removing either a Notch receptor or Rbpj. Our finding that the dnMAML allele does not function like a Rbpj null in the retina is important for researchers in the broad Notch field to consider when designing and interpreting experiments.
Reviewer #2: Hes genes are effectors of the Notch signaling pathway but can also act down-stream of other signaling cascades. In this manuscript the authors attempt to address the complexity of Hes effectors during optic cup development and retinal neurogenesis. To do so, they compared optic cup patterning and retinal neurogenesis in seven germline or conditional mutant mouse embryos generated with two spatio-temporally distinct Cre drivers. These lines allowed for the analysis of the consequences of perturbing the Notch ternary complex and multiple Hes genes alone or in combination. The authors show that the optic disc/nerve head is regulated by Notch independent Hes1 function. They also confirm that perturbation of Notch signaling interferes with cell proliferation enhancing the production of differentiated ganglion cells, whereas photoreceptor genesis requires both Rbpj and Hes1 with Notch dependent and independent mechanisms. This is a rather complex study that dissects further the role of the Notch pathway and Hes proteins during eye development, a topic that has been addressed in many previous studies but perhaps not with the details that the authors have used here. In this respect, this study adds to current literature but will likely be of interest to retina aficionados. The manuscript reads well and the figures are of very good quality. However, many of the statements are based on qualitative rather than on quantitative analysis. This should be, at least in some cases, remediated, despite the effort that this may require given the number of mouse lines used in the study.
Response: As described in the response to Reviewer 1, we agree and present considerably more quantification data. We extensively reorganized and rewrote this manuscript to emphasize that Hes1 in the ONH/OS is fully Notch-independent and highlight branchpoints in Notch-dependent signaling, for Rbpj versus Hes,1 during early retinal neurogenesis. It is too simplistic that the ternary complex (Rbpj-NICD-Maml) simply activates Hes1 (and/or multiple Hes genes) to regulate downstream signaling targets. This paradigm has been portrayed in the literature numerous times for many processes throughout vertebrate development, homeostasis or relative to particular diseases. By focusing on one tissue and a narrow window of development, our phenotypic studies delved more deeply to show the greater complexity and molecular cross-talk that we think underlie the modulation of signaling levels with in vivo context. Thus, our results are of broad interest and impact to the greater Notch field.
-
The title is somewhat misleading. The authors have explored mostly the role of Hes1, 3 and5. Although these are Notch effectors, there is already evidence that they participate in other pathways This is confirmed by the data present here. I would suggest to eliminate Notch from the title and use instead "Hes" to better reflect the findings. Furthermore, it is unclear why there is a reference to "mutations" or what are the Notch branchpoints to which the authors refer at the beginning of the discussion.
Response: We appreciate the reviewer’s viewpoint but disagree this paper is mostly about Hes genes, as there is a critical direct, comparable evaluation with Rbpj and dn-Maml. Direct comparison of 7 genotypes highlights where each pathway member exhibits idiosyncratic phenotypes. We are striving for a clear, simple title about a very complex topic, involving the in vivo genetic dissection of a signaling pathway. We modified the title to: "Notch pathway mutations do not equivalently perturb mouse embryonic retinal development "
- "Although the Pax6-Pax2 boundary is intact in Rax-Cre;RbpjCKO/CKO eyes, ONH shape was attenuated compared to controls (Fig 3I)". This statement is arguable as the difference seems subtle. Perhaps some kind of quantification would help.
Response: We quantified Pax2+ cells (ONH domain) using the adjacent proximal terminus of the retinal pigmented epithelium (RPE) to indicate a transition from ONH to optic stalk (OS). We also quantified the number of Pax2+Pax6+ double positive cells where the 2 domains abut (boundary cells). Some higher magnification examples are now provided in Fig 3H';3K';3N'. Grossly, the imaging data support that the Pax2+ ONH is expanded in Chx10-Cre;TKO eyes, while boundary cells are most affected in Rax-Cre;HesTKO eyes, due to an expansion of retinal tissue. This is supported by our quantitative data (Fig 3O,3P). We observed even in controls that Pax2-expressing cells show some numerical variability. We attributed this to the position of the section through the ONH, which is a 3-dimsenional ring (torus). Therefore, we quantified additional wild-type controls and mutant samples in the new Fig 3O,3P graphs, improving statistical power, and allowing us to detect quantitative differences.
Page 12 first paragraph. "....but all other genotypes were unaffected". This statement is unclear. All lines in which the Rax-Cre has been used seem to have an increased number of apoptotic cells. This should be better explained
Response: Respectfully, only one genotype, Rax-Cre;Rbpj mutants contain a statistically significant increase in apoptotic cells (Fig 5P). This is demonstrated by one-way ANOVA analyses that included all pairwise comparisons. To ensure that the quantification was not misleading due to changes in tissue morphology, data in Figs 5, 6, and 7 were normalized to optic cup area. The area was traced in FIJI, creating a polygon whose area was determined in square microns. For every section image, the marker+ cells were divided by the square micron area of the retina (excluding the opening for the optic nerve). Such a method is critical for comparison across this allelic series, given the morphologic changes, differences in cell clustering where rosettes form, and reduced proliferation whenever Notch signaling is lost or reduced.
Page 12, end of second paragraph: "E13.5 Chx10-Cre;HesTKO eyes had a milder RGC phenotype (Figs 6G, 6N, 6U), but all other mutants were unaffected (Figs 6E, 6F, 6L, 6M, 6S, 6T). This statement is also rather subjective. The phenotype of Chx10-Cre;HesTKO is quite strong and the other mutants seem to have a phenotype. Some quantifications here will help.
Response: We agree and provide quantification for both Atoh7 and Rbpms positive cells in the revised Figure 6. This is now in the same figure with quantification of Otx2+, Otx2+Atoh7+ and Crx+ cells. The reviewer is correct that both ROSA-dnMaml and both HesTKO mutants have a statistically significant increase in RGCs. Surprisingly, neither of the Rbpj CKO mutants have this outcome (Fig 6Y).
- Page 13, toward the bottom..."...but noted that Chx10-Cre RbpjCKO/CKO eyes were not different from controls (Figs 7E, 7AA)". Again, this statement is questionable as staining for both CRX and Rbpms seem reduced as compared to controls as quantifications in 7AA seems also to indicate (about half?). Did the authors calculate whether there is a statistical difference between controls and Chx10-Cre RbpjCKO/CKO ?
Response: Rbpms+ RGCs and Crx+ photoreceptor precursors were colabeled and quantified on sections for all genotypes. All counts were normalized to area as described above. Upon quantification and ANOVA with pairwise comparisons, there was no statistical difference in Crx+ or Rbpms+ cells between control and Chx10-Cre;Rbpj mutants (new Fig 6Y and Z).
In Fig 7CC the authors should make the effort of including at least one additional sample, 2 biological replicates seem insufficient to draw a conclusion.
Response: The Rax-Cre;Hes1CKO/+ X Hes1CKO/CKO matings stopped producing litters in late 2022. While this manuscript was out for review, we obtained younger mice, from which new control and Rax-Cre; Hes1 mutant littermates were collected, stained, imaged and quantified. Upon adding samples, we found that the outcome was unchanged, but the data better support the lack of a statistical difference in rods between genotypes at E17. These data were moved to revised Suppl Fig 5.
Significance: This is a rather complex study that dissects further the role of the Notch pathway and Hes proteins during eye development, a topic that has been addressed in many previous studies but perhaps not with the details that the authors have used here. In this respect, this study adds to current literature but will likely be of interest to retina aficionados. The manuscript reads well and the figures are of very good quality. However, many of the statements are based on qualitative rather than on quantitative analysis. This should be, at least in some cases, remediated, despite the effort that this may require given the number of mouse lines used in the study.
Response: To increase the impact of our manuscript, we quantified all markers except Tubb3, since its localization in cell bodies and axons make it impossible to assign to individual cells. We feel that this additional quantification strongly improves the quality of our findings and allowed us to make well-supported and novel conclusions. While we certainly believe that the retinal development community will find this paper of interest, it will also be of value to the broader Notch pathway scientific community. In this manuscript, we simultaneously compared phenotypes for Notch pathway genes in signal receiving cells. We could find essentially no studies like this for the mouse CNS and only a few from the Kopan lab about the kidney and immune system. Interestingly, one of us (NLB) is a coauthor on a recent paper about Notch signaling in the cortex, in which ROSA-dnMaml behaves analogously to Notch1CKO or RbpjCKO. This emphasizes that findings in one organ may not recapitulate the "rules" for this pathway for other cell types or tissues (doi: 10.1242/dev.201408)(2). Deeper understanding of how the Notch pathway in the retina functions, analogously or differently, is important. We feel our revised study advances when and where there are "branchpoints" in canonical signaling that may be overlooked in other developing tissues and organs.
Reviewer #3: I have reviewed a manuscript submitted by Bosze et al., which is entitled "Not all Notch pathway mutations are equal in the embryonic mouse retina". The authors focused on Notch signaling pathway. Notch signaling is deeply conserved across vertebrate and invertebrate animal species: in general, two transmembrane proteins, Delta and Notch, interact as a ligand and a receptor, respectively, which induces proteolytic cleavage of Notch receptors to generate Notch intracellular domain (NICD). NICD is translocated into nucleus, then forms the transcription factor complex including Rbpj (also referred to as CBF1) and Mastermind-like (Maml), and activates the transcription of Hes family transcription factors. Three Hes proteins, Hes1, 3, and 5, are important for nervous system development. In the vertebrate developing retina, these Hes proteins inhibit neurogenesis to maintain a pool of neural progenitor cells. In addition to their primary role in neurogenesis, the authors recently reported that Hes1 promotes cone photoreceptor differentiation. In the later stages of development, Hes proteins also promote Müller glial differentiation. In addition, Hes1 is highly expressed in the boundary between the neural retina and optic stalk and required for this boundary maintenance. To understand precise regulation of Notch component-mediated signaling network for retinal neurogenesis and cell differentiation, the authors compared retinal phenotypes in the knockdown of three Notch pathway components, that is (1) Hes1/3/5 cTKO, (2) Rbpj KO, and (3) dominant-negative Maml (dnMaml) overexpression, under the control of two Cre derivers; Rax-Cre and Chx10-Cre. First, the authors found that Hes1 expression in the boundary between optic stalk and neural retina is lost in Rax-Cre; Hes1/3/5 cTKO, but still retained in Rax-Cre; Rbpj KO and Rax-Cre; dnMaml overexpression, suggesting that Delta-Notch interaction is not required for Hes1 expression in the boundary between optic stalk and neural retina. Furthermore, Hes1 expressing boundary region expands distally at the expense of the neural retina in Chx10-Cre; Hes1/3/5 cTKO. Maintenance of ccd2 expression in this expanded boundary area suggests that Hes1 normally maintains a proliferative state in the optic stalk, which may allow these cells to differentiate into astrocyte in later stages. Second, in addition to precocious RGC differentiation in all the Notch component KO, the authors found that, as compared with wild-type, cone and rod photoreceptor genesis is highly enhanced in Rax-Cre; Rbpj KO and Rax-Cre; dnMaml overexpression and mildly enhanced in Chx10-Cre; dnMaml overexpression. On the other hand, in Rax-Cre; Hes1/3/5 cTKO, cone and rod photoreceptor genesis is not enhanced but similar to wild-type level. Since the authors previously reported that cone genesis is reduced in Rax-Cre; Hes1 cKO and Chx10-Cre; Hes1 cKO, so Rax-Cre; Hes1/3/5 cTKO may rescue decrease in cone genesis in single Hes1 cKO. The authors raise the possibility that elevated Hes5 expression in single Hes1 cKO may suppress cone photoreceptor genesis. The authors also found that amacrine cell genesis is significantly suppressed in Rax-Cre; Rbpj KO but not changed in Rax-Cre; dnMaml overexpression and Rax-Cre; Hes1/3/5 cTKO, suggesting that Rbpj is specifically required for amacrine cell genesis. From these observations, the authors propose that there are at least two branchpoints for photoreceptor and amacrine cell genesis in Notch component-mediated signaling network. Their findings are very interesting and provide some new insight on how Notch signaling components are integrated into other signaling pathways and promote to generate diverse but well-balanced retinal cell-types during retinal neurogenesis and cell differentiation, in addition to conventional classic view of Notch signaling pathway. However, one weak point is that, although the authors figured out what kinds of phenotypic difference appear in the KO retinas between these Notch components, the research result is descriptive and less analytical. Most of their conclusions may be supported by their previous works or others; it is still hypothetical. So, it is important to show more analytical data to support their interpretation and more clearly show what is new conceptual advance for Notch signaling pathways.
For example, sustained Hes1 expression in the boundary region between optic stalk and neural retina may be reminiscent to brain isthmus situation. I would like to request the authors to show more direct evidence that Hes1 regulation in optic stalk/retina boundary is independent of Delta-Notch interaction. One possible experiment is whether DAPT treatment phenocopies Rax-Cre; Rbpj KO and Rax-Cre; dnMaml overexpression (Hes1 in optic stalk boundary is normal?).
Response: Usage of the gamma secretase inhibitor DAPT is an interesting experiment as it can phenocopy the loss of Notch signaling in developing tissues. However, the reviewer's proposed DAPT experiment is problematic for two major reasons. First, DAPT blocks the gamma secretase complex, which has more than 90 protein targets in the cell membrane (3). Therefore, DAPT may not be informative for Hes1 regulation given the myriad of expected off-target effects. Second, it would be difficult to treat embryos at the relevant stages with DAPT. Injections into pregnant mice are lethal and we cannot localize drug to the relevant area during in vivo development. Our direct phenotypic comparisons with two Cre drivers strongly indicate that Hes1 is independent of canonical Notch signaling in the developing optic stalk.
We include an extra related data figure (Reviewer Fig 1) showing anti-Hes1 immunolabeling of E13.5 Rax-Cre;Notch1CKO/CKO (n=2) and E13.5 Rax-Cre;Notch2CKO/CKO eyes (n=3). The Notch1 mutant lost oscillating Hes1 expression in retinal progenitors, but the uniform Hes1 ONH domain remains. Interestingly, the Notch2 mutant had essentially no effect on Hes1 (oscillating or sustained), or Hes5 mRNA expression. A Notch2 RNA in situ hybridization demonstrates that Notch2 mRNA was lost in the E13 optic cup and RPE (Rax-Cre expressing tissues). These data emphasize: A) the Notch1-specific dependency of oscillating Hes1 expression in retinal progenitors is absent from the ONH; B) although coexpressed in the same tissue, Notch receptors have unequal activities.
Does Rax-Cre; Rbpj KO; Hes1-cKO phenocopy Rax-Cre; Hes1-cKO (or Rax-Cre; Hes1/3/5 cTKO)?
Response: This is a good question! The first author tried very hard to produce Rax-Cre; Rbpj CKO;Hes1 CKO double mutant embryos. However, these progeny could not be recovered from E10-E13 embryos, despite collecting more than 10 litters. Thus, it is likely that this genotype is lethal before eye formation.
Could the authors identify an enhancer element that drives Hes1 transcription in optic stalk/retina boundary, which should be not overlapped with that of NICD/ Rbpj binding motif? Such additional evidence will make their conclusion more convincing.
Response: Another interesting question. We have been working for >3 years on Hes1 cis regulatory enhancers, but the pandemic greatly delayed progress. The proximal Hes1 600bp upstream region is a generic enhancer that contains Hes1 binding sites for repressing its own expression (4) and has a pair of Rbpj consensus sites for Notch ternary complex activation of Hes1 expression (5,6). Nearby is a binding site occupied by Gli2 in the E16 mouse retina (7). Recently, it was shown that Ikzf4 binds slightly farther away (8). The upstream 1.8 kb region (including the 600bp just described) can drive destabilized GFP or dsRed reporters in early postnatal retinal explants (9). However, this sequence was used to make and analyze a classic Hes1-GFP transgenic reporter mouse, in which GFP was not expressed in the early embryonic mouse optic vesicle or cup (10). Therefore, any early eye-specific enhancer(s) are located farther upstream, in an intron, or downstream (or combination thereof). Public domain epigenetic and chromatin accessibility datasets support this idea. Identifying the gene regulatory logic for Hes1 expression in the eye will be an exciting future story, well beyond this manuscript. We are excited to use live imaging of enhancer reporters to discern oscillating versus sustained activity patterns during early ocular development.
Regarding the conclusion on new branchpoints on photoreceptor and amacrine cell genesis, a model shown in Figure 9 is still hypothetical. Figure 9B indicate a model in which the increase of Otx2+ cells and Crx+ cells in Rax-Cre; Rbpj KO is mediated by Hes1, which is presumed to be activated in Notch-independent signaling. However, Hes1 expression in the neural retina is markedly reduced in Rax-Cre; Rbpj KO (Fig. 2I), which does not fit in with the model.
Response: We removed Fig 9B and now present new models about the Notch-dependent versus -independent roles for both Rbpj and Hes1. The new summary is Fig 8.
So, I would like to request the authors to examine whether the increase of Otx2+ cells and Crx+ cells in Rax-Cre; Rbpj KO, (or Rax-Cre; dnMaml overexpression and Chx10-Cre; dnMaml overexpression) is inhibited by Hes1 KO.
Response: If we understand this correctly, it would mean generating double mutants, some of which we determined are not viable (see the response above, and Suppl Table 2). Given there is only a partial knockdown of Hes1 or Hes5 in either dnMaml mutant we do not believe repeating this in the Hes1 CKO genetic background to be informative and it would take 3 generations to perform.
Second, the authors concluded that both cone and rod genesis are enhanced in Rax-Cre; Rbpj KO by showing the data on Crx/Nr2e3 labeling in Rax-Cre; Hes1 cKO in Fig. 7BB. However, as the authors mentioned in the manuscript, Hes5 expression is elevated in Rax-Cre; Hes1 cKO (Fig. 1G). So, since Rax-Cre; Hes1 cKO has residual Hes activity in the retina, Fig. 7BB should be replaced with labeling of Crx/Nr2e3 in Rax-Cre; Hes1/3/5 cTKO.
Response: Unfortunately, Rax-Cre;HesTKO embryos do not live past E13 (Suppl Table 2). Thus, we cannot evaluate rods, whose genesis starts around E13.5. Revised Fig 1G shows the Hes5 domain is shifted with the expansion of retinal tissue in E13.5 Hes1 single mutants, but importantly, also analogously shifted in Pax2 mutants (Fig 1H). We do not conclude that mRNA levels are "elevated" since mRNA in situ hybridization is not a quantitative technique. Our initial examination of rods in E17 Rax-Cre;Hes1 CKO mutants tested the idea of a fate shift from cones to rods. However, deeper quantification (Suppl Fig 5) do not support such a fate change.
Furthermore, possibly, it is best to examine labeling of the retinas of Rax-Cre; Rbpj KO with rod and cone-specific markers and confirm that the number of both rods and cones is significantly increased. Third, as for defects in amacrine cells genesis in Rax-Cre; Rbpj KO, I would like to request the authors to show the data on Crx10-Cre; Rbpj KO. Although Rbpj KO is mosaic in Crx10-Cre; Rbpj KO, we can distinct Rbpj KO cells by GFP expression (Fig. S2C, C', C'). So, the authors can confirm that amacrine cell genesis is inhibited in a cell-autonomous manner in Crx10-Cre; Rbpj KO retinas but not in Crx10-Cre; dnMaml overexpression. Addition of such data will make the authors' conclusion is more convincing.
Response: Suppl Table 1 lists multiple references (two from the NLB lab) that demonstrated both a rod and cone increase in Rbpj loss-of-function conditions. Chx10;Rbpj CKO animals were evaluated by Zheng et al., who showed an amacrine loss phenotype in these mutants (11). This is equivalent to what we see in our Rax-Cre;Rbpj CKO data, but without the complications of Chx10 mosaic Cre expression upon Rbpj deletion.
Other comments: 1) Title of this manuscript is "Not all Notch pathway mutations are equal in the embryonic mouse retina". However, this title is quite obscure in what is research advancement of their findings. I suggest the authors to include more concrete and conclusive sentence in the title, for example "Hes and Rbpj differentially promotes retina/optic stalk boundary maintenance and photoreceptor genesis, in parallel with neurogenic inhibition by Notch signaling pathway".
Response: We appreciate the reviewer's perspective. We are striving for a relatively simple title about a very complex topic, involving the in vivo genetic dissection of a signaling pathway. We modified the title to "Notch pathway mutations do not equivalently perturb mouse embryonic retinal development ".
2) The "Results" section is a bit difficult to follow logics without detailed knowledge on roles of Notch signaling in mouse retinal development. I suggest the authors to improve a writing style of "Results" section for readers without such detailed knowledge on mouse Notch mutant phenotypes to follow logical flow more easily. There are many additional descriptions on research background before start to mention results. Such introductory sentences should be moved to the "Introduction" section, by which logical flow in the Results section should be simpler. In addition, the authors should show a concrete question at the beginning of each result subsection. Furthermore, the authors sometimes jump over from one result subsection and suddenly move to cite another figure panel in a far ahead subsection whose data has not been explained. Such a back-and-forth citation of figure data generally makes it difficult to follow logical flow.
Response: We now present a considerable amount of new quantified data, reorganized multiple figures, and extensively rewrote the paper. We significantly revised the summary figure to improve clarity. In addition, Suppl Table 1 provides a wealth of background information to orient the reader on this topic. We feel that this extensive revision has greatly improved the quality, logical flow, and readability of the manuscript.
3) In addition, figure configuration is not well organized. Each figure compared some particular marker expression in wild-type, Rax-Cre; HesTKO, Rax-Cre; Rbpj cKO, Rax-Cre; dn-Maml-GFP, Chx10-Cre; HesTKO, Chx10-Cre; Rbpj cKO, Chx10-Cre; dn-Maml-GFP. For example, Fig. 2 shows Hes1 for inhibition of neurogenesis, Fig. 3 shows Vsx2; Mitf and Pax2; Pax6 for retinal pigmented epithelium and optic stalk, Fig. 6 shows Atoh7, Rbpms, and Tubb3 for retinal ganglion cells. Fig. 7 shows Crx, Otx2, and Thrb2 for photoreceptor differentiation. Fig. 8 shows Prdm1, and Ptf1a for photoreceptors and amacrine cells. Although this figure configuration is convenient to show phenotypic difference between different genetic mutations, it is difficult to know how each differentiation steps are spatially and temporally coordinated during development. At least, I recommend the authors to show one summary figure, which shows spatio-temporal expression profile of retinal markers in wild-type mouse retinas.
Response: We recognize this point and completely reorganized and combined Figs 6 and 7 to improve clarity. New Figure 6 presents E13 quantification for Atoh7, Otx2, Atoh7/Otx2, Rbpms and Crx expressing retinal populations. E16-E17 data were condensed and moved to a new Suppl Fig 5.
4a) Page 7, line 7-10 "With earlier deletion using Rax-Cre, hes5 mRNA abnormally extended into the optic stalk": I wonder how the authors define the optic stalk. It is likely that optic stalk area (Pax2+, Vax1+ area) is shifted to more proximal (depart from the optic cup and move toward the brain), and neural retina is expanded accordingly (Fig. 4B, 4F), resulting in expansion of hes5 expression. Thus, it may be better to mention that optic stalk/neural retina boundary is abnormally shifted toward the brain.
Response: The retina, including the optic nerve head, ends where the adjacent RPE terminates. This is conspicuous morphologically in our sections. We also defined this by colabeling for Pax2 and Pax6, which is now quantified in revised Fig 3. To clarify this further, we added the words " in all panels the brain is to the right" in the Fig 4 legend.
4b) Page 8, line 14-15, "ONH/OS cells still express it (Hes1), demonstrating that sustained Hes1 is independent of Notch": I presume that Cre-Rax drives Cre in neural retina as well as optic stalk and pigmented epithelium. However, it is likely that Rbpj is not expressed in optic stalk/neural retina boundary area in wild type (Fig. S2A). No expression of Rbpj in optic stalk/neural retina boundary may support that Hes1 expression in this boundary area is Notch-independent. However, Rbpj expression is retained in some vitreal cells near optic nerve head in Rax-Cre; Rbpj-CKO retinas (Fig. S2B). What are these Rbpj+ cells? I would like to request the authors to confirm that Rbpj expression is completely absent in both neural retina and optic stalk in Rax-Cre; Rbpj-CKO mice. Otherwise, this conclusion is still not fully supported.
Response: We show the Rax-Cre lineage in Suppl Fig 2 via the Ai9 (tomato) reporter. The results are striking, with all of the optic cup derivatives (retina, RPE, ONH, optic stalk, and presumptive ciliary tissue and iris) being tomato positive, while the well-described population of vascular cells in the hyaloid space lack tomato expression. Furthermore, our figure shows that Rbpj expression is only absent from the optic cup derivates, rather than the vascular structures in the vitreous. Vascular cells also depend on the Notch pathway and express Rbpj. Based on considerable evidence from the literature and our lineage experiments, the population of cells the reviewer highlights represents the hyaloid vasculature and associated cell types. It does not represent any population that derives from neuroectoderm.
4c) Page 9, line 16-18, "Foxg1 had spread into the nasal optic stalk": Is Foxg1 expanded nasal area really "OS" rather than expanded retina? I suggest the authors to confirm molecular markers Pax2 expression is overlapped with Foxg1. Otherwise, it is difficult to conclude that foxg1 is expanded into the optic stalk territory, because foxg1 is normally a marker of retina. Indeed, Fig. 3K shows pax2 expression is shifted into more inside towards the brain, suggesting that neural retina is expanded. Please explain the situation.
Response: Foxg1 (BF-1) mRNA and protein are found in the nasal retina and are expressed in other brain tissues. Multiple studies show Foxg1 in the nasal side of the E10 optic cup/retina/optic stalk and developing hypothalamus (See extra data figure Reviewer Fig 2; top row figure is data from Smith et al., 2017 (12) with Foxg1 mRNA in purple. Also see our new manuscript panel Fig 1C. We include here for reviewers (extra data Reviewer Fig 2 showing E13 ocular cryosections colabeled for Foxg1 and Pax2, highlighting their relationship in the retina, optic stalk and adjacent forming hypothalamus. On page 9 the text now reads "At E13.5 Rax-Cre;HesTKO eyes, the Foxg1 nasal retinal domain was contiguous with the nasal optic stalk (Suppl Fig 4D). This is reminiscent of younger stages (Fig 1C), since normally at E13.5, Foxg1 in the nasal optic cup/retina is separated from expression in the ONH/OS (Suppl Fig 4A). Based on the expansion of Pax6, Vsx2 and Hes5 RPC domains into the optic stalk, we conclude that the change in Foxg1 similarly reflects an extension of retinal tissue."
4d) Page 10, line 4-5, In Rax-Cre; Hes1/3/5 cTKO eye, this tissue (RPE) extended into the optic stalk": This description seems to be incorrect. A part of Pax2 area, which is adjacent to the neural retina, contacts with RPE in wild type (Fig. 3AH), so most of RPE covers the neural retina even in Fig. 3DK.
Response: We disagree with the reviewer’s interpretation. Fig 3D shows Mitf labeling of RPE nuclei. Figure 3K shows the adjacent section labeled with Pax2 and Pax6 (labels both retina and RPE). As the retina extended "towards the brain", the RPE analogously extends and surrounds the retinal domain. We also added higher magnification data panels 3H, 3K and 3N, showing merged and single channels.
4e) Page 10, line 22-23, "For Chk10-Cre; Hes1/3/5 cTKO, there was a unique presence of ectopic Pax2 within the retinal territories": I wonder if this description is correct. I suspect that proliferative Pax2+ cells expand into regressing territory of Hes KO retinal cells, which undergo precocious neurogenesis and lose proliferative activity, in Chk10-Cre; HesTKO. In this case, it is possible that the Pax2/Pax6 interface may be maintained. Please show red and green channel panels for Fig. 3N to confirm that there is ectopic pax2 and pax6 double positive cells.
Response: New quantification in revised Fig 3 (see panels O,P) fully supports our original conclusion. Only Chx10-Cre;HesTKO mutants have a statistically significant increase in Pax2+ cells. There are not more Pax2+Pax6+ double labeled cells. Only this particular genotype has an increase in Pax2+ single labeled cells.
5a) Page 11, line 20-25. There seems to be inconsistency between result description and image data of Fig. 5A-G, and histogram Fig. 5O. Authors mentioned that a modest loss of pH3+ cell fraction in Chx10-Cre; Hes1/3/5 cTKO but not in Rax-Cre; Hes1/3/5 cTKO. However, Fig. 5D indicates severe reduction of pH3+ cell fraction in Rax-Cre; Hes1/3/5/ cTKO, which is similar to reduction of pH3+ cell fraction in Rex-Cre; Rbpj (Fig. 5B), but histogram data is different (Fig. 5O). Furthermore, pH3+ cell fraction is severely reduced in Chx10-Cre; ROSA(dn-Maml-GFP) (Fig. 5F) and modestly reduced in Chx10-Cre; Hes1/3/5 cTKO (Fig. 5G). However, pH3+ cell fraction seems to be normal in Chx10-Cre; Rbpj (Fig. 5E). These Chx10-Cre image data do not match the histogram of Fig. 5O. Please check their situation.
Response: Images in old Figs 5-8 were normalized using area measurements, see methods and above comments (note: old Figs 6&7 were combined into new Fig 6). One-way ANOVA with pairwise comparisons for each mutant genotype compared to control were calculated using Prism. All genotypes except two have a statistically significant loss of M phase cells and we discuss possibilities for this outcome (Fig 5O). A normalization method for the sampled area is an essential component of these studies since morphologic differences are apparent for particular genotypes. The quantitative data are consistent with our original conclusions.
5b) Fig. 5H-N, P: I wonder if the stage E13 is appropriate to evaluate cell death and survival because optic cup already becomes smaller in Rax-Cre; Rbpj, Hes1/3/5 cTKO, or ROSA(dn-MAML-GFP) than in wild-type control. I suggest the authors examine more earlier stage.
Response: While an earlier effect is possible, we only observed size differences in a subset of the genotypes. Thus, E13 serves as a critical timepoint to examine early developmental phenotypes across the totality of our mutant conditions. It is also first age when the ONH is fully formed.
5c) Page 12, line 19-20, "all other mutants (Chx10-Cre; Rbpj, and Chx10-Cre; ROSA(dn-MAML-GFP) were unaffected (Fig. 6EF, LM, ST)": It is likely that atoh7 expressing cells are mildly decreased and neuronal marker, Tubb3 and Rbpms-expressing cells are increased in Chx10-Cre; Rbpj, and Chx10-Cre; ROSA(dn-MAML-GFP). I requested the authors to evaluate the fraction of these markers in retinal area statistically in all the cases.
Response: As described above, we quantified Atoh7 and Rbpms nuclear expression by immunohistochemistry. We do not believe that Tubb3+ cells can be reliably quantified. Nonetheless, it is useful to qualitatively show the extent of excess neuron formation. Importantly, we observed that it is not the Atoh7 status that matters for RGC formation, rather it is the Otx2 expression status. This is in good agreement with single cell-RNA transcriptomics data from Wu et al 2021 showing that Atoh7 mRNA in all early transitional RPCs remains fairly constant and its loss does not block the formation of early RGC cell states (13). By contrast Otx2 fluctuates but remains expressed in transitional RPCs that progress to photoreceptor lineages.
6a) Page 7, line 19 "Ectopic blood vessels protruded from the ONH (Fig. 1K, 1L)": It is difficult to see blood vessel structures in these panels (Fig. 1I-L). Please show some molecular marker of blood vessels to confirm how blood vessel is organized in Hes1/3/5 cTKO.
Response: These vascular structures are highly conspicuous by morphology in the H&E insets. Nonetheless, we used adjacent P21 sections to immunolabel for Endomuscin (14) and Tubb3 antibodies. This colabeling confirms the morphology and position of ectopic blood vessels in the abnormal tissue masses in Chx10-Cre;HesTKO mutant eyes. Ectopic tissue contains only rare Tubb3+ cells or cell processes suggesting it is overwhelmingly nonneural. All P21 data were moved to a new Suppl Fig 2. A full detailing of vascular phenotypes is beyond the scope of this manuscript and, interestingly, would be potentially attributable to non-autonomous effects of perturbing the Hes genes in the adjacent retina.
6b) Fig. 5: Increase of pH3 fraction indicates several possibilities, for example (1) increased fraction of mitotic cells due to precocious neurogenesis, (2) increased fraction of mitotic cells due to activated cell proliferation of retinal progenitor cells, (3) increased cell-cycle arrest in M phase due to some stress response of progenitor cells. So, I suggest the authors to examine (1) BrdU percentage of retinal section area, (2) the percentage of pH3+ cells in PCNA+ retinal cells.
Response: The data listed in Suppl Table 1 presents a unified picture that disrupting Notch signaling reduced proliferation. This paradigm extends to other model organisms (e.g., Drosophila, chick, frog, zebrafish and even to nonneural tissues). We included the phospho-histone H3 staining so readers would see how the six mutants evaluated in this study align with this paradigm, providing confidence for the novel findings in other figures. A full evaluation of cell cycle kinetics is interesting, but beyond the scope and focus of this manuscript.
6c) Fig. 5: It is better that cell death fraction will be evaluated by TUNEL and labeling with anti-activated caspase 3 antibody.
Response: We disagree. The DNA repair enzyme PARP is inactivated upon cleavage by activated caspase 3. There are currently ~3,600 citations that use it as a marker of apoptosis. PARP also has a separate and very specific role in maintaining the integrity of sperm DNA. This antibody works on all metazoans and is amenable to many tissue preparations and fixatives, making it easy to use, robust and quantifiable.
7a) Please show red channel (Hes1) image in Fig1BC.
Response: This was added to Revised Fig 1 (Fig 1A).
7b) Fig. 1DH should be shown in neighbor. Fig. 1H should be assigned as Fig. 1E.
Response: The new Fig 1 layout addresses this point.
7c) Fig. S2D, F, H, J: Please show GFP green channel as well. Otherwise, it is difficult to see non-overlapping expression in optic stalk area.
Response: In the revision, this is Suppl Fig 3. Chx-10-Cre is not expressed by ONH-OS cells (1). The green and fuchsia overlap (coexpression) in RPCs is white, we feel this is fairly clear. If needed, all readers can turn on and off the green channel in the final PDF version of this figure to compare GFP with Hes1 expression for those panels.
7d) Fig. 9B: It is better to show Rax-Cre: Hes1/3/5 TKO rather than Rax-Cre: Hes1 cKO. 7e) Fig. 9B: Lettering "Rbpj mutant" should be revised as "Rax-Cre: Rbpj KO".
Response: Fig 9B was removed so these terms are now irrelevant. Our models are presented in new Fig 8.
Significance: The senior author of this manuscript, Dr. Nadean Brown, is an expert scientist who has investigate the role of Notch signaling pathway in vertebrate ocular tissue, including the neural retina and lens. In general, Notch signaling pathway consists of signaling stream from the interaction of Delta and Notch, Notch receptor activation by proteolytic cleavage, translocation of Notch intracellular domain (NICD) into nucleus, formation of transcription factor complex consisting of NICD/Rbpj/Maml, to the transcriptional activation of Notch target genes, Hes family transcription factors. Finally, Hes suppresses neurogenic program and maintain a pool of neural progenitor cells. Therefore, Notch is a key factor to regulate the balance between neurogenesis and progenitor proliferation. In this manuscript, the authors investigated retinal phenotypes in the knockout mice of different Notch signaling components, including Rbpj, Maml, and Hes. They found that functions of these three factors are not always equal in retinal cell differentiation; rather, they specifically regulate a particular step of retinal development. The authors propose the possibility that each of Notch signaling components may be modified by other signaling pathways and achieve some new roles beyond the conventional frame of classic Notch signaling pathway. In this point, this work has a potential to provide a new conceptual advance in the field of developmental and cell biology.
We fully agree this work is a significant advance for the fields of developmental and cell biology. Our findings provide new information and stimulate fresh ideas for anyone working on signal transduction and signal integration.
References cited:
- Bosze et al., 2020 Journal of Neuroscience Vol 40:1501-13; Bosze et al. 2021 Dev Biol Vol 472:18-29.
- Han et al., 2023 Development Vol 150 dev201408.
- Kopan and Ilagan, 2004 Nat Rev Cell Biol. Vol 5:499-504
- Hirata et al., 2002 Science Vol 298:840-3
- Friedmann and Kovall, 2010 Protein Sci. Vol 19:34-46
- Ong et al., 2006 JBC Voll24:5106-19
- Wall et al., 2009 J Cell Biol. Vo 184: 101-12.
- Javed et al., 2023 Development Vol 150:dev200436
- Matuda and Cepko 2007 PNAS Vol 104: 1027-1032
- Ohtsuka et al., 2006 Mol. Cell Neurosci. Vol 31:109-22
- Zheng et al., 2009 Molecular Brain Vol 2:38
- Smith et al., 2017 Journal of Neuroscience Vol 37:7975-93.
- Wu et al., 2021 Nature Communications Vol 12:1465: doi 10.1038/s41467-021-21704-4
- Saint-Geniez et al., 2009 IOVS Vol 50: 311-21.
-
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
I have reviewed a manuscript submitted by Bosze et al., which is entitled "Not all Notch pathway mutations are equal in the embryonic mouse retina". The authors focused on Notch signaling pathway. Notch signaling is deeply conserved across vertebrate and invertebrate animal species: in general, two transmembrane proteins, Delta and Notch, interact as a ligand and a receptor, respectively, which induces proteolytic cleavage of Notch receptors to generate Notch intracellular domain (NICD). NICD is translocated into nucleus, then forms the transcription factor complex including Rbpj (also referred to as CBF1) and Mastermind-like (Maml), and activates the transcription of Hes family transcription factors. Three Hes proteins, Hes1, 3, and 5, are important for nervous system development. In the vertebrate developing retina, these Hes proteins inhibit neurogenesis to maintain a pool of neural progenitor cells. In addition to their primary role in neurogenesis, the authors recently reported that Hes1 promotes cone photoreceptor differentiation. In the later stages of development, Hes proteins also promote Müller glial differentiation. In addition, Hes1 is highly expressed in the boundary between the neural retina and optic stalk and required for this boundary maintenance.
To understand precise regulation of Notch component-mediated signaling network for retinal neurogenesis and cell differentiation, the authors compared retinal phenotypes in the knockdown of three Notch pathway components, that is (1) Hes1/3/5 cTKO, (2) Rbpj KO, and (3) dominant-negative Maml (dnMaml) overexpression, under the control of two Cre derivers; Rax-Cre and Chx10-Cre.
First, the authors found that Hes1 expression in the boundary between optic stalk and neural retina is lost in Rax-Cre; Hes1/3/5 cTKO, but still retained in Rax-Cre; Rbpj KO and Rax-Cre; dnMaml overexpression, suggesting that Delta-Notch interaction is not required for Hes1 expression in the boundary between optic stalk and neural retina. Furthermore, Hes1 expressing boundary region expands distally at the expense of the neural retina in Chx10-Cre; Hes1/3/5 cTKO. Maintenance of ccd2 expression in this expanded boundary area suggests that Hes1 normally maintains a proliferative state in the optic stalk, which may allow these cells to differentiate into astrocyte in later stages.
Second, in addition to precocious RGC differentiation in all the Notch component KO, the authors found that, as compared with wild-type, cone and rod photoreceptor genesis is highly enhanced in Rax-Cre; Rbpj KO and Rax-Cre; dnMaml overexpression and mildly enhanced in Chx10-Cre; dnMaml overexpression. On the other hand, in Rax-Cre; Hes1/3/5 cTKO, cone and rod photoreceptor genesis is not enhanced but similar to wild-type level. Since the authors previously reported that cone genesis is reduced in Rax-Cre; Hes1 cKO and Chx10-Cre; Hes1 cKO, so Rax-Cre; Hes1/3/5 cTKO may rescue decrease in cone genesis in single Hes1 cKO. The authors raise the possibility that elevated Hes5 expression in single Hes1 cKO may suppress cone photoreceptor genesis. The authors also found that amacrine cell genesis is significantly suppressed in Rax-Cre; Rbpj KO but not changed in Rax-Cre; dnMaml overexpression and Rax-Cre; Hes1/3/5 cTKO, suggesting that Rbpj is specifically required for amacrine cell genesis. From these observations, the authors propose that there are at least two branchpoints for photoreceptor and amacrine cell genesis in Notch component-mediated signaling network.
Their findings are very interesting and provide some new insight on how Notch signaling components are integrated into other signaling pathways and promote to generate diverse but well-balanced retinal cell-types during retinal neurogenesis and cell differentiation, in addition to conventional classic view of Notch signaling pathway. However, one weak point is that, although the authors figured out what kinds of phenotypic difference appear in the KO retinas between these Notch components, the research result is descriptive and less analytical. Most of their conclusions may be supported by their previous works or others; it is still hypothetical. So, it is important to show more analytical data to support their interpretation and more clearly show what is new conceptual advance for Notch signaling pathways.
For example, sustained Hes1 expression in the boundary region between optic stalk and neural retina may be reminiscent to brain isthmus situation. I would like to request the authors to show more direct evidence that Hes1 regulation in optic stalk/retina boundary is independent of Delta-Notch interaction. One possible experiment is whether DAPT treatment phenocopies Rax-Cre; Rbpj KO and Rax-Cre; dnMaml overexpression (Hes1 in optic stalk boundary is normal?). Does Rax-Cre; Rbpj KO; Hes1-cKO phenocopy Rax-Cre; Hes1-cKO (or Rax-Cre; Hes1/3/5 cTKO)? Could the authors identify an enhancer element that drives Hes1 transcription in optic stalk/retina boundary, which should be not overlapped with that of NICD/ Rbpj binding motif? Such additional evidence will make their conclusion more convincing.
Regarding the conclusion on new branchpoints on photoreceptor and amacrine cell genesis, a model shown in Figure 9 is still hypothetical. Figure 9B indicate a model in which the increase of Otx2+ cells and Crx+ cells in Rax-Cre; Rbpj KO is mediated by Hes1, which is presumed to be activated in Notch-independent signaling. However, Hes1 expression in the neural retina is markedly reduced in Rax-Cre; Rbpj KO (Fig. 2I), which does not fit in with the model. So, I would like to request the authors to examine whether the increase of Otx2+ cells and Crx+ cells in Rax-Cre; Rbpj KO, (or Rax-Cre; dnMaml overexpression and Chx10-Cre; dnMaml overexpression) is inhibited by Hes1 KO. Second, the authors concluded that both cone and rod genesis are enhanced in Rax-Cre; Rbpj KO by showing the data on Crx/Nr2e3 labeling in Rax-Cre; Hes1 cKO in Fig. 7BB. However, as the authors mentioned in the manuscript, Hes5 expression is elevated in Rax-Cre; Hes1 cKO (Fig. 1G). So, since Rax-Cre; Hes1 cKO has residual Hes activity in the retina, Fig. 7BB should be replaced with labeling of Crx/Nr2e3 in Rax-Cre; Hes1/3/5 cTKO. Furthermore, possibly, it is best to examine labeling of the retinas of Rax-Cre; Rbpj KO with rod and cone-specific markers and confirm that the number of both rods and cones is significantly increased. Third, as for defects in amacrine cells genesis in Rax-Cre; Rbpj KO, I would like to request the authors to show the data on Crx10-Cre; Rbpj KO. Although Rbpj KO is mosaic in Crx10-Cre; Rbpj KO, we can distinct Rbpj KO cells by GFP expression (Fig. S2C, C', C'). So, the authors can confirm that amacrine cell genesis is inhibited in a cell-autonomous manner in Crx10-Cre; Rbpj KO retinas but not in Crx10-Cre; dnMaml overexpression. Addition of such data will make the authors' conclusion is more convincing.
Other comments are shown below.
- Title of this manuscript is "Not all Notch pathway mutations are equal in the embryonic mouse retina". However, this title is quite obscure in what is research advancement of their findings. I suggest the authors to include more concrete and conclusive sentence in the title, for example "Hes and Rbpj differentially promotes retina/optic stalk boundary maintenance and photoreceptor genesis, in parallel with neurogenic inhibition by Notch signaling pathway".
- The "Results" section is a bit difficult to follow logics without detailed knowledge on roles of Notch signaling in mouse retinal development. I suggest the authors to improve a writing style of "Results" section for readers without such detailed knowledge on mouse Notch mutant phenotypes to follow logical flow more easily. There are many additional descriptions on research background before start to mention results. Such introductory sentences should be moved to the "Introduction" section, by which logical flow in the Results section should be simpler. In addition, the authors should show a concrete question at the beginning of each result subsection. Furthermore, the authors sometimes jump over from one result subsection and suddenly move to cite another figure panel in a far ahead subsection whose data has not been explained. Such a back-and-forth citation of figure data generally makes it difficult to follow logical flow.
- In addition, figure configuration is not well organized. Each figure compared some particular marker expression in wild-type, Rax-Cre; HesTKO, Rax-Cre; Rbpj cKO, Rax-Cre; dn-Maml-GFP, Chx10-Cre; HesTKO, Chx10-Cre; Rbpj cKO, Chx10-Cre; dn-Maml-GFP. For example, Fig. 2 shows Hes1 for inhibition of neurogenesis, Fig. 3 shows Vsx2; Mitf and Pax2; Pax6 for retinal pigmented epithelium and optic stalk, Fig. 6 shows Atoh7, Rbpms, and Tubb3 for retinal ganglion cells. Fig. 7 shows Crx, Otx2, and Thrb2 for photoreceptor differentiation. Fig. 8 shows Prdm1, and Ptf1a for photoreceptors and amacrine cells. Although this figure configuration is convenient to show phenotypic difference between different genetic mutations, it is difficult to know how each differentiation steps are spatially and temporally coordinated during development. At least, I recommend the authors to show one summary figure, which shows spatio-temporal expression profile of retinal markers in wild-type mouse retinas.
- There are several logically incorrect sentences or inconsistent sentences in the results section. Please respond my comment below.
- a) Page 7, line 7-10 "With earlier deletion using Rax-Cre, hes5 mRNA abnormally extended into the optic stalk": I wonder how the authors define the optic stalk. It is likely that optic stalk area (Pax2+, Vax1+ area) is shifted to more proximal (depart from the optic cup and move toward the brain), and neural retina is expanded accordingly (Fig. 4B, 4F), resulting in expansion of hes5 expression. Thus, it may be better to mention that optic stalk/neural retina boundary is abnormally shifted toward the brain.
- b) Page 8, line 14-15, "ONH/OS cells still express it (Hes1), demonstrating that sustained Hes1 is independent of Notch": I presume that Cre-Rax drives Cre in neural retina as well as optic stalk and pigmented epithelium. However, it is likely that Rbpj is not expressed in optic stalk/neural retina boundary area in wild type (Fig. S2A). No expression of Rbpj in optic stalk/neural retina boundary may support that Hes1 expression in this boundary area is Notch-independent. However, Rbpj expression is retained in some vitrial cells near optic nerve head in Rax-Cre; Rbpj-CKO retinas (Fig. S2B). What are these Rbpj+ cells? I would like to request the authors to confirm that Rbpj expression is completely absent in both neural retina and optic stalk in Rax-Cre; Rbpj-CKO mice. Otherwise, this conclusion is still not fully supported.
- c) Page 9, line 16-18, "Foxg1 had spread into the nasal optic stalk": Is Foxg1 expanded nasal area really "OS" rather than expanded retina? I suggest the authors to confirm molecular markers Pax2 expression is overlapped with Foxg1. Otherwise, it is difficult to conclude that foxg1 is expanded into the optic stalk territory, because foxg1 is normally a marker of retina. Indeed, Fig. 3K shows pax2 expression is shifted into more inside towards the brain, suggesting that neural retina is expanded. Please explain the situation.
- d) Page 10, line 4-5, In Rax-Cre; Hes1/3/5 cTKO eye, this tissue (RPE) extended into the optic stalk": This description seems to be incorrect. A part of Pax2 area, which is adjacent to the neural retina, contacts with RPE in wild type (Fig. 3AH), so most of RPE covers the neural retina even in Fig. 3DK.
- e) Page 10, line 22-23, "For Chk10-Cre; Hes1/3/5 cTKO, there was a unique presence of ectopic Pax2 within the retinal territories": I wonder if this description is correct. I suspect that proliferative Pax2+ cells expand into regressing territory of Hes KO retinal cells, which undergo precocious neurogenesis and lose proliferative activity, in Chk10-Cre; HesTKO. In this case, it is possible that the Pax2/Pax6 interface may be maintained. Please show red and green channel panels for Fig. 3N to confirm that there is ectopic pax2 and pax6 double positive cells.
- There seems to be some mismatch descriptions between image data and histogram (or text in the result section). Please respond my comments below.
- a) Page 11, line 20-25. There seems to be inconsistency between result description and image data of Fig. 5A-G, and histogram Fig. 5O. Authors mentioned that a modest loss of pH3+ cell fraction in Chx10-Cre; Hes1/3/5 cTKO but not in Rax-Cre; Hes1/3/5 cTKO. However, Fig. 5D indicates severe reduction of pH3+ cell fraction in Rax-Cre; Hes1/3/5/ cTKO, which is similar to reduction of pH3+ cell fraction in Rex-Cre; Rbpj (Fig. 5B), but histogram data is different (Fig. 5O). Furthermore, pH3+ cell fraction is severely reduced in Chx10-Cre; ROSA(dn-Maml-GFP) (Fig. 5F) and modestly reduced in Chx10-Cre; Hes1/3/5 cTKO (Fig. 5G). However, pH3+ cell fraction seems to be normal in Chx10-Cre; Rbpj (Fig. 5E). These Chx10-Cre image data do not match the histogram of Fig. 5O. Please check their situation.
- b) Fig. 5H-N, P: I wonder if the stage E13 is appropriate to evaluate cell death and survival because optic cup already becomes smaller in Rax-Cre; Rbpj, Hes1/3/5 cTKO, or ROSA(dn-MAML-GFP) than in wild-type control. I suggest the authors examine more earlier stage.
- c) Page 12, line 19-20, "all other mutants (Chx10-Cre; Rbpj, and Chx10-Cre; ROSA(dn-MAML-GFP) were unaffected (Fig. 6EF, LM, ST)": It is likely that atoh7 expressing cells are mildly decreased and neuronal marker, Tubb3 and Rbpms-expressing cells are increased in Chx10-Cre; Rbpj, and Chx10-Cre; ROSA(dn-MAML-GFP). I requested the authors to evaluate the fraction of these markers in retinal area statistically in all the cases.
- Some experiments are necessary to improve their design. Please respond my comments below.
- a) Page 7, line 19 "Ectopic blood vessels protruded from the ONH (Fig. 1K, 1L)": It is difficult to see blood vessel structures in these panels (Fig. 1I-L). Please show some molecular marker of blood vessels to confirm how blood vessel is organized in Hes1/3/5 cTKO.
- b) Fig. 5: Increase of pH3 fraction indicates several possibilities, for example (1) increased fraction of mitotic cells due to precocious neurogenesis, (2) increased fraction of mitotic cells due to activated cell proliferation of retinal progenitor cells, (3) increased cell-cycle arrest in M phase due to some stress response of progenitor cells. So, I suggest the authors to examine (1) BrdU percentage of retinal section area, (2) the percentage of pH3+ cells in PCNA+ retinal cells.
- c) Fig. 5: It is better that cell death fraction will be evaluated by TUNEL and labeling with anti-activated caspase 3 antibody.
- Panel configuration of Figures should be revised as below.
- a) Please show red channel (Hes1) image in Fig1BC.
- b) Fig. 1DH should be shown in neighbor. Fig. 1H should be assigned as Fig. 1E.
- c) Fig. S2D, F, H, J: Please show GFP green channel as well. Otherwise, it is difficult to see non-overlapping expression in optic stalk area.
- d) Fig. 9B: It is better to show Rax-Cre: Hes1/3/5 TKO rather than Rax-Cre: Hes1 cKO.
- e) Fig. 9B: Lettering "Rbpj mutant" should be revised as "Rax-Cre: Rbpj KO".
Significance
The senior author of this manuscript, Dr. Nadean Brown, is an expert scientist who has investigate the role of Notch signaling pathway in vertebrate ocular tissue, including the neural retina and lens. In general, Notch signaling pathway consists of signaling stream from the interaction of Delta and Notch, Notch receptor activation by proteolytic cleavage, translocation of Notch intracellular domain (NICD) into nucleus, formation of transcription factor complex consisting of NICD/Rbpj/Maml, to the transcriptional activation of Notch target genes, Hes family transcription factors. Finally, Hes suppresses neurogenic program and maintain a pool of neural progenitor cells. Therefore, Notch is a key factor to regulate the balance between neurogenesis and progenitor proliferation. In this manuscript, the authors investigated retinal phenotypes in the knockout mice of different Notch signaling components, including Rbpj, Maml, and Hes. They found that functions of these three factors are not always equal in retinal cell differentiation; rather, they specifically regulate a particular step of retinal development. The authors propose the possibility that each of Notch signaling components may be modified by other signaling pathways and achieve some new roles beyond the conventional frame of classic Notch signaling pathway. In this point, this work has a potential to provide a new conceptual advance in the field of developmental and cell biology.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Hes genes are effectors of the Notch signaling pathway but can also act down-stream of other signaling cascades. In this manuscript the authors attempt to address the complexity of Hes effectors during optic cup development and retinal neurogenesis. To do so, they compared optic cup patterning and retinal neurogenesis in seven germline or conditional mutant mouse embryos generated with two spatio-temporally distinct Cre drivers. These lines allowed for the analysis of the consequences of perturbing the Notch ternary complex and multiple Hes genes alone or in combination. The authors show that the optic disc/nerve head is regulated by Notch independent Hes1 function. They also confirm that perturbation of Notch signaling interferes with cell proliferation enhancing the production of differentiated ganglion cells, whereas photoreceptor genesis requires both Rbpj and Hes1 with Notch dependent and independent mechanisms.
This is a rather complex study that dissects further the role of the Notch pathway and Hes proteins during eye development, a topic that has been addressed in many previous studies but perhaps not with the details that the authors have used here. In this respect, this study adds to current literature but will likely be of interest to retina aficionados. The manuscript reads well and the figures are of very good quality. However, many of the statements are based on qualitative rather than on quantitative analysis. This should be, at least in some cases, remediated, despite the effort that this may require given the number of mouse lines used in the study. Specific comments are listed below:
- The title is somewhat misleading. The authors have explored mostly the role of Hes1, 3 and5. Although these are Notch effectors, there is already evidence that they participate in other pathways This is confirmed by the data present here. I would suggest to eliminate Notch from the title and use instead "Hes" to better reflect the findings. Furthermore, it is unclear why there is a reference to "mutations" or what are the Notch branchpoints to which the authors refer at the beginning of the discussion.
- "Although the Pax6-Pax2 boundary is intact in Rax-Cre;RbpjCKO/CKO eyes, ONH shape was attenuated compared to controls (Fig 3I)". This statement is arguable as the difference seems subtle. Perhaps some kind of quantification would help.
- Page 12 first paragraph. "....but all other genotypes were unaffected". This statement is unclear. All lines in which the Rax-cre has been used seem to have an increased number of apoptotic cells. This should be better explained
- Page 12, end of second paragraph: "E13.5 Chx10-Cre;HesTKO eyes had a milder RGC phenotype (Figs 6G, 6N, 6U), but all other mutants were unaffected (Figs 6E, 6F, 6L, 6M, 6S, 6T). This statement is also rather subjective. The phenotype of Chx10-Cre;HesTKO is quite strong and the other mutants seem to have a phenotype. Some quantifications here will help.
- Page 13, toward the bottom..."...but noted that Chx10-Cre RbpjCKO/CKO eyes were not different from controls (Figs 7E, 7AA)". Again, this statement is questionable as staining for both CRX and Rbpms seem reduced as compared to controls as quantifications in 7AA seems also to indicate (about half?). Did the authors calculate whether there is a statistical difference between controls and Chx10-Cre RbpjCKO/CKO ?
- In Fig 7CC the authors should make the effort of including at least one additional sample, 2 biological replicates seem insufficient to draw a conclusion.
Significance
This is a rather complex study that dissects further the role of the Notch pathway and Hes proteins during eye development, a topic that has been addressed in many previous studies but perhaps not with the details that the authors have used here. In this respect, this study adds to current literature but will likely be of interest to retina aficionados. The manuscript reads well and the figures are of very good quality. However, many of the statements are based on qualitative rather than on quantitative analysis. This should be, at least in some cases, remediated, despite the effort that this may require given the number of mouse lines used in the study.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary: In this study, the authors employed an impressive set of mouse mutant or Cre lines to investigate the complexity of Notch signaling across different stages of retinal development. These comprehensive analyses led to two main findings: 1. Sustained hes1 in the OHS/OS is Notch-independent; 2. Rbpj and Hes1 exhibited opposing roles in cone photoreceptor development. Although the study is potentially interesting, the current manuscript needs the essential research background and quantification, a lack of which significantly reduced the clarity of the manuscript and the credibility of the major conclusions. Also, how the authors organized the results is quite confusing, making the manuscript very difficult to follow.
Major comments:
- The authors needed to make the quantification for many analyses to strengthen the conclusions, such as Fig. 1F, 1G, and etc.
- The authors reported many exciting results. However, further mechanistic insights are largely missing. They may focus on one of these exciting findings and give some mechanistic insights. For example, hes1 suppresses hes5 expression as the ONH boundary forms; hes1 expression in the ONH is Notch independent; differential influences of Rbpj and Hes1 on cone development. It is better for the authors to select one of these exciting findings and provide a deeper mechanistic study.
- Some analyses lack an explanation of the rationale. For example, "To understand if the loss of multiple Hes genes is more catastrophic than Hes1 alone..."(PAGE 7). Please explain its significance.
Significance
In general, many results are quite interesting. However, the significance of these findings is largely hampered in the following aspects: 1. The authors were unable to provide the sufficient research contexts that are essential for understanding many results.2. Many conclusions were solely based on descriptive images but lacked statistical quantification, which significantly weakened many conclusions. 3. Many interesting findings are quite descriptive, and some mechanistic understandings of one of these exciting findings will be beneficial to improve the focus and significance of the study.
Current format of the manuscript fits more specialized audience.
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
The authors do not wish to provide a response at this time.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Schiano and colleagues present data on two mouse knock-in models with a missense mutation in uromodulin (C171Y and R186S). A strength of the paper is that the mutations are found in patients with autosomal dominant tubulointerstitial kidney disease (ADTKD) but lead to divergent disease progression. The mouse models are characterized in detail examining changes in uromodulin processing, plasma and urine biochemistry and transcript levels by RNA-sequencing. These findings combined with studies in collecting duct lines provide evidence that the extent of uromodulin aggregate formation is related to the severity of the disease and mechanisms are provided to explain these findings including clearance pathway which might be targeted in the future. Overall, there is a large quantity of good data in the manuscript which moves our understanding of uromodulin mutations forward. However, there are some issues that need to be addressed as outlined below.
Major Comments
- In the Introduction, the authors state that the current mouse models have only provided limited information warranting this new study. More information is required here to provide a stronger rationale. What are the specific weaknesses of the prior approaches and what precise questions remain unanswered and how is this hindering therapeutic development. Subsequently, how does this study fill these gaps in our knowledge? This narrative of highlighting the new aspects of this study should also run through the Abstract of the paper more prominently.
- The authors have selected two missense mutations from the Belgo-Swiss ADTKD Registry to subsequently model in mice. Are these mutations also present at a high prevalence in other genetic studies of ADTKD? The authors indicate that the patients with a Arg185Ser mutation have a faster progression than Cys170Tyr. One caveat here is that in Supplementary Table 1-2, the patients with Arg185Ser are predominately male and those with Cys170Tyr predominately female. Therefore, is gender playing a role here with males more susceptible to renal disease. Taking this concept forward, if the generated mice are separated by gender are comparable results seen in pathology and renal function parameters than if the animals are grouped together as presented in the paper.
- In Figure 1D, an examination of kidney biopsies is undertaken. Can the authors provide any quantification across multiple samples/sections/cells to strengthen this data? The authors measure CD3+ cells in their mouse models - any evidence of these cells in the human biopsies.
- In Figure 2C, the quantification presented does not seem to fully reflect the pattern of the blot shown, for example, increase in total signal seen in homozygous mice versus heterozygous C171Y mice. As one of the focuses of the paper is the formation of uromodulin aggregates, perhaps there is a rationale for the core and HMW proteins to be quantified separately, rather than the ratio between them.
- The authors use electron microscopy (Figure 2F) to conclude that expansion and hyperplasia of the ER occurs in their mutant mice. A representative snapshot is shown, but can quantification be provided to strengthen this data.
- A detailed assessment of plasma and urine biochemistry has been made. As highlighted above, separating this data by sex could be helpful. It is stated that the C171Y mice have a progressive increase in BUN at 4 months, but this statement requires clarification. Are the authors referring to a progressive change over time or with respect to gene dosage? An additional measurement of creatinine clearance might also be useful here. Are there any changes in glomerular function? Significant changes are also found in the urine of C171 heterozygous mice (in sodium and creatinine) but not in the homozygous animals. Any explanation for these findings which are not mentioned in the text? Some of the data is not reported corrected, for example it is stated that uric acid excretion is reduced at 1 month, but this has not been measured then. The conclusion that there are strong gene-dosage effects in both models seems strong. The reviewer agrees this holds for BUN but is not so clear cut for other parameters such as diuresis and osmolarity in C171Y mice. This should be refined.
- An interesting analysis is presented on the effect of partial and total denaturation treatments of uromodulin. The reproducibility of these experiments is unclear. Please clarify. Do the authors have any information on how the protein structure of uromodulin might change due to these mutations, for example by structural modelling?
- Next, the authors delete a wild-type allele in the R186S mice and examine the severity of disease. In Figure 4D and E it would be more informative to also present the specific changes in HMW and core proteins separately. Is there really a pronounced reduction in premature uromodulin in Figure 4E? Why have the authors focused on CD3+ cells as a marker of inflammation, how about other cell types such as macrophages? The rationale needs to be provided here. Are there changes in fibrosis by histology? Importantly, there appears to be no changes in clinical parameters when the wild-type allele is deleted, so is the main conclusion of this part that the deletion of the wild-type allele has no effect on disease severity, despite some of the gene changes observed.
- In Figure 5, the relationship between the amount of uromodulin aggregates and the UPR pathway, fibrosis and inflammation is examined. As highlighted above, the methodology to determine the number of uromodulin aggregates needs to be considered. It is unclear in Figure 5C how this parameter has been generated. Can the authors present the data in this panel as individual mice of all six groups rather than the grouped analysis currently done. This would distinguish if the individual mice with greatest uromodulin aggregates also had the most fibrosis and inflammation and strengthen the presentation of this data.
- In your RNA-sequencing data, please clarify if the mice were of the same sex. Interesting changes are found, but the final conclusion is that the transcription signals recapitulate severe ADTMD. This seems an overinterpretation and to strengthen this section the authors could go back to their biopsy samples and examine some of the expression patterns of the novel genes they have identified. Similarly, can any of the novel transcripts identified in the RNA-seq be examined (and/or) altered in the cell lines they have generated with the same mutations in uromodulin.
- Using their cells the authors show the autophagy may be involved in the clearance of uromodulin in R185S mutants. However, this pathway is not explored in vivo, an assessment of autophagy in these mice would strengthen this connection.
Minor
- The authors should present full Western blots in their Supplementary data
- Figure 2C (and others). Please clarify and label clearly the blots from 1 month and 4-month-old mice.
Significance
Schiano and colleagues present data on two mouse knock-in models with a missense mutation in uromodulin (C171Y and R186S). A strength of the paper is that the mutations are found in patients with autosomal dominant tubulointerstitial kidney disease (ADTKD) but lead to divergent disease progression. The mouse models are characterized in detail examining changes in uromodulin processing, plasma and urine biochemistry and transcript levels by RNA-sequencing. These findings combined with studies in collecting duct lines provide evidence that the extent of uromodulin aggregate formation is related to the severity of the disease and mechanisms are provided to explain these findings including clearance pathway which might be targeted in the future. Overall, there is a large quantity of good data in the manuscript which moves our understanding of uromodulin mutations forward. However, there are some issues that need to be addressed; in particular the authors should (i) precisely outline the novelty of their study compared with the prior literature; (ii) clarify the reproducibility of their experiments; (iii) refine areas of overinterpretation in the manuscript; (iv) consider the potential role of gender in their findings and (v) complete the circle in some of their findings, for example examining the novel genes identified in their RNA-sequencing in their human biopsy samples and examining autophagy in their mouse models. These changes will considerably strengthen their article.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
UAKD, a subtype of ADTKD, is extensively studied, although it is an rare inherit kidney disease. Using a knock-in strategy, the authors raised a novel concept that the differences in allelic and gene dosage of Umod mutation triggered distinct protein catabolic pathways, yielding distinct phenotypes and prognosis. The functional mechanisms include that UmodR186S mutation caused insoluble uromodulin aggregates resulting in activation of autophagy, and UmodC171Y mutation led to uromodulin misfolding and touched off ubiquitin-dependent ERAD pathway. Accordingly, the authors tested whether enhancing autophagy attenuates the accumulation of UmodR186S protein in cell cultures. Based on these observations, the authors suggested a strategy to improve clearance of mutant uromodulin. This study was carried out by a team with strong reputation in this area. However, the story appears to be incomplete and in vivo testing of their therapeutic strategy is needed to improve this research.
Specific comments
- Figure 1D: Images at low magnification do not show DAPI, therefore there is no information on the total number of cells in the selected field. Nephron loss (represented by glomeruli) did not appear to differ between UMOD p C170Y and UMOD p R185S, which is inconsistent with the overall conclusions. In addition, PAS staining should be added in Figure 1D.
- Figure 2E: in image of C171Y/+, this is no corresponding tubules which is represented by the insert. Figure 2F lower panel, the bars in EM fields are same, indicating a hypertrophy of nuclei in R186S? Figure 2G: how about serum creatinine in these mice? In addition, signs of catabolism (e.g., loss of body weight) are associated with these KI mice?
- Figure 3C: what is rationale of using two high speed centrifuges. Please state briefly in method.
- Figure 4: histologic assessment of progression is missing here, please add images of PAS, Masson staining at low magnification
- Figure 5: Can the authors provide low magnification images (40X) for each condition? A histological evaluation of kidney damage is critical to support the conclusion.
- Figure 6: Why are no ubiquitin-related catabolic processes or pathways enriched in C171Y? The authors should perform GSEA analysis to determine whether defined gene sets have significant differences between C171Y and R186S.
- Following the experiments in Figures 7 and 8, the authors should assess whether administration of autophagy agonists could improve kidney injury and function in R186S mice.
Significance
Although ADTKD is an rare inherit kidney disease, the authors provide new insight into its pathogenesis. As nephrologist, I agreed with the observations and conclusions provided by the study. However, sufficient histological assessment and in vivo validation of the proposed therapeutic strategy would significantly improve this study.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Uromodulin (Tamm-Horsfall protein) is the most abundant protein excreted in human urine.<br /> It plays role in protection against urinary tract infections and renal stones. Mutations in UMOD gene encoding uromodulin cause Autosomal Dominant Tubulointerstitial Disease (ADTKD) that slowly progresses to chronic kidney disease.
In this manuscript, Schiano et al. isolate 12 missense UMOD mutations, which they classify into two groups by age occurrence. They then proceed to study two of these mutations: one from the earlier-onset - Arg185Ser - and the second from the later-onset - Cys170Tyr.
The authors generate UmodC171Y and UmodR186S knock-in mice with distinct dynamic pathways impacting on ADTKD progression. These mutations are equivalent with UMOD mutations (C170Y and R185S) in patients. UmodC171Y and UmodR186S knock-in mice show impaired uromodulin biogenesis, with strong allelic and gene-dosage effects. The trafficking problem of ADTKD-UMOD mutants, involving ER retention, ER stress, and activation of the UPR is recapitulated in mIMCD-3 cells, where the R185S mutant reveals more aggregates that are triggering PERK and IRE1 pathways and ER stress responses.
The manuscript is well written, experiments are in general well described and performed, results offer important insights on cellular events eventually leading to organ damage in ADTKD resulting from missense mutation in the UMOD gene.<br /> The part of the work investigating the degradation mode of two different UMOD mutants, one relying on proteasomal and one relying on lysosomal clearance, is the most interesting for a general audience. Unfortunately, this last part of the work is too preliminary to be accepted as it is.
Comments/Suggestions:
- Selection of the UMOD variants, page 5: "R185S and C170Y are the most prevalent mutants in the clusters" please document/add reference.
- Fig. 1D: please show the position of the insets in the UMOD and BiP panels. Please separate the IF panels from the Picrosirius red panels (these are not the same samples that are shown),<br /> Formally, the BiP panels in Fig. 1D reveal that there is more BiP in cells expressing R185S. That this correlates with UPR induction (as confirmed in Fig. x) should be written at the end of page 5 to make this issue clear for non-experts.<br /> In Fig. 1D, the signal of BiP is not visible in WT and C170Y tissue/cells, which is odd because BiP is abundant protein. Moreover, the differences in BiP levels quantified in WB (semi-quantitative analyses) are not that dramatic in the mouse model (SFig. 3). Which panel in SFig. 3 (mouse) should be representative of the IF shown in Fig. 1D (patients)?<br /> Fig. 1D: Magnification of these images is not sufficient to conclude that R185S accumulates in the ER, and that WT and C170Y are at the apical cell's membrane as written (page 5). Authors should refer to Suppl Fig 1C, where individual cells are visible.<br /> Authors should briefly explain at the end of page 5 how the P. red staining in Fig. 1D informs on fibrosis.
- In the analyses of misfolded UMOD mutants (e.g., Fig. 2, 3, 4, ...) one would expect a test showing that BiP associates with R185S>C170Y>WT.
- Fig. 2F: in R186S there is a dramatic enlargement (at least 2x) of nuclei. Can the authors comment on that?
- Fig. 7E: Shouldn't one expects apical signal for C170Y?
-
Fig. 7F: Why there is apical signal for R185S (and not for C170Y)?
-
The part covering the degradation of the two UMOD variants would be of great interest for a wide audience of cell biologists. However, these data are too preliminary and, in this form, inconclusive.<br /> Few examples: MG132 is a non-specific inhibitor of the proteasome, which may enhance endogenous and trans-gene expression (check in Pubmed "mg132 promoter" for relevant literature). Thus, an increase in the intracellular level of C170Y on MG132 treatment does not necessarily indicate inhibition of the protein's proteasomal turnover. It could also, at least in part, be caused by an increased synthesis of UMOD. The authors should show that MG132 does not increase synthesis of mutant UMOD (or use the more selective proteasome inhibitor PS-341 in their experiments); similarly, the data on R185S do not prove that this protein is client of autophagy. They rather show that autophagy removes the protein when cells are under nutrient restriction (note that starvation activates bulk autophagy, the non-selective lysosomal clearance of cellular components). To show that misfolded R185S is removed from cells by misfolded protein-induced ER-phagy (i.e., ER-to-lysosome-associated degradation), the authors should monitor in WB the accumulation of R185S in the presence of BafA1 and/or in IF the accumulation of R185S within lysosomes in the presence of BafA1.
Minor comments
- Figure 1B: dotted lines should be defined in the legend.
- Figure 1C: "phenotypes are denoted as indicated". The color-code used for the phenotype is unclear to me. For example, what is the phenotype of the V.2 (grey square)?
- The meaning of "Unlike in UMOD R185S cells, higher SQSTM1 puncta colocalizing with uromodulin were initially present in C170Y mutant cells and further accumulated in MG132-treated cells (Supplementary Figures 10A, B). These data suggest that mutant cells respond differently to UPS inhibition, with C170Y mutant uromodulin being mainly targeted to this pathway." (page 14) and the interpretation of the results shown in 10A and 10B is unclear to me.
- Page 7: "The UmodC171Y mice showed a progressive increase in BUN at 4 months" please define BUN.
- Please, provide a complete list of primary antibodies used for immunoblotting, immunohistochemistry, and immunofluorescence staining.
Significance
The manuscript is well written, experiments are in general well described and performed, results offer important insights on cellular events eventually leading to organ damage in ADTKD resulting from missense mutation in the UMOD gene.<br /> The part of the work investigating the degradation mode of two different UMOD mutants, one relying on proteasomal and one relying on lysosomal clearance, is the most interesting for a general audience. Unfortunately, this last part of the work is too preliminary to be accepted as it is.
My expertise: protein quality control, ER-phagy
-
-
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
1. General Statements [optional]
This study represents a detailed analysis of the mechanistic bases of Atg15 function in autophagy, which relates back to our initial studies of autophagy published by our group 30 years ago in JCB (10.1083/jcb.119.2.301), where we reported autophagy by disrupting vacuolar protease function. We report that Atg15 is the sole vacuolar lipase in yeast, and that it exhibits broad activity on a range of lipids. Following submission of our study to Review Commons, we have received favorable feedback from all three reviewers. We plan to perform the revisions below within one month, following which we will submit a full revision to JCB with complete point-by-point responses to the reviewers. We are confident that this study will be of interest to the broad readership of JCB and trust that you will find it worthy of further consideration for publication.
2. Description of the planned revisions
Reviewers 1 and 3 suggested that we should confirm whether Atg15 is indeed the sole vacuolar lipase using lipids other than NBD-PE. While we have already shown that the kinase-dead S332A variant is non-function in vacuolar lysates, we will further address this comment by determining whether vacuolar lysates isolated from _atg15_Δ cells are able to process other lipid species. We will also collect replicates and quantify data for all figures to address comments made by the reviewers.
We also received a comment from reviewer 2 asking us to determine the function and expression level of vector-borne ATG15 and ATG15-Flag expressed in the _atg15_Δ background strain. We will provide these data, along with a comparison with results from WT cells, in our revision.
Reviewer 1 indicated that we need to address the localization of Atg15 in more detail. We plan to better explain the results of our initial analyses, as well as collecting more detailed data using super-resolution microscopy, and these data will be analyzed and discussed in further detail.
Regarding the text, we will update the results, discussion and methods to make these easier to follow, as pointed out by reviewer 1.
A complete point-by-point response to reviewer comments will be provided in the full revision.
3. Description of the revisions that have already been incorporated in the transferred manuscript
No revisions yet carried out.
4. Description of analyses that authors prefer not to carry out
Reviewer 3 suggested that when considering Atg15 lipase activity we provide information about the lipid makeup of autophagic body membranes. While we agree that this is an interesting suggestion, our pilot experiments have indicated to us that this analysis is complex and will generate a very large amount of additional data and technical details that would need to be supplemented, clearly exceeding the scope of this study. Further, while we are currently performing these analyses, it will take significant additional time to bring these experiments to a conclusion in line with the reviewer’s comment.
On a related note, reviewer 3 suggested that we provide more detailed analyses of the degradation products arising from Atg15 lipase activity to provide some context into our finding that Atg15 acts on purified autophagic body membranes. We have collected initial lipidomic data for vacuolar extracts following the induction of autophagy (see attached figure), and have confirmed that we detect lysophospholipids in a manner that quantitatively depends on the amount of Atg15. However, as we feel that these data require further careful and time-consuming lipidomic analyses, as well as a nuanced discussion of results arising, we plan to publish these data in a separate, detailed paper and not in the present study.
With regard to reviewer 1’s comment about the vulnerability of Atg15 to the presence of detergent, we agree that this is an important point, but we can not eliminate the possibility that a very small amount of Atg15 exhibits lipase activity that is detected by this assay. The key message of our study is that Atg15 is activated by proteases in the vacuole to function as a broad-activity lipase; we feel that a detailed investigation of the active fragment of Atg15 is secondary to this finding and would unfortunately be very difficult to determine using currently available techniques, especially when considering the expression of Atg15. While it would be very nice to have these data, we therefore cannot provide these data in the full revision.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
This manuscript by Kagohashi and colleagues provide evidence of the enzymatic activity of ATG15 as a phospholipase B with a broad substrate specificity and dissect the mechanisms by which this protein is activated in the vacuole to promote the hydrolysis of autophagic bodies. The manuscript is very clear and well written, the scientific and experimental concepts are clearly presented and easy to follow. This is excellent biochemistry with very well-thought concepts and well-designed experiments. I am convinced by the authors' results and conclusions which, for the most part, are justified by appropriate experiments and conclusive data.
Main points:
- The authors claim that they show that ATG15 is the sole vacuolar phospholipase (see abstract). This conclusion is based on the in vitro analysis of the hydrolysis of NBD-PE (a fluorescent, thus not physiological, phospholipid). Fig. 1 indeed show the absence of NBB-PE hydrolysis in cells lacking ATG15 or expressing a catalytic dead version of the protein, which supports the authors' conclusion. But (1) this does not reflect the hydrolysis of physiological phospholipids in the vacuole, (2) this is only based on the analysis of one phospholipid (PE), (3) this is not consistent with results presented in Fig.5 C-F, in which, in the absence of ATG15 or when the catalytic dead version of the protein is expressed, there is clearly still some hydrolysis of PC, PG and PI. Concerning Fig. 4, the authors state that 'the commercially available NBD-PC and NBD-PG had been somewhat decomposed' and it is unclear to me if the lanes marked by an oblique line correspond to the lysate of atg15D cells or to NBD-PL alone. If this corresponds to the NBD-PL alone, I suggest that the authors perform the experiment presented in Fig.1 (at least Fig. 1C), with additional NBD-PL to actually test for residual phospholipases activity in the absence of ATG15.
I also suggest that the authors perform lipid analyses of purified vacuoles including engulfed organelles (autophagic bodies, MVBs etc.) to detect changes when put in contact with vacuolar lysates from WT, ATG15D cells and ATG15S332A, which will be more physiological that the use of NBD-PL, and could therefore support their conclusion.<br /> - The use of NBD-PL is very powerful and support the authors conclusions, but the paper lacks from physiological results as stated above. For instance, concerning the efficiency and substrate specificity of ATG15: what is the actual lipid composition of autophagic bodies ? How efficient is ATG15 in regard to the lipids that mainly compose the membrane of autophagic bodies ? Can the authors quantitatively compare the activity of ATG15 from one phospholipid to the other ? Here the experiments are performed on lipids in solution, what about hydrolysis activity on lipids in membranes ? As mentioned in my comment above, I suggest that the authors perform tests with purified autophagy bodies, or, at least, on reconstituted vesicles with a composition similar to what is found in autophagic bodies to assess the activity of ATG15 in physiological conditions.<br /> - The results and data presented by the authors are clear and seem unequivocal for the main parts but none of the results are quantified and there is no statistical analyses provided. How many times were the experiments repeated and how consistent are the results ? The authors must provide quantitative information and stats for all the figures.
Significance
Although it has been long known that ATG15 is required for the degradation of autophagic bodies, how this protein which transits to the vacuole through the MVB pathway can be activated in the vacuole to specifically target autophagic bodies and/or its cargo, remained completely unknown. The results presented here, pending their confirmation with additional experiments, thus fill an important gap in knowledge to understand the last crucial steps of the autophagy pathway which had remained largely elusive across organisms. Autophagy is critical for the physiology and development of all eucaryotes with major implication in human diseases. This manuscript will thus be of interest not only for the autophagy community but also for a broader general scientific community with potential applications in medical sciences. The results presented here also provide crucial elements to understand lipid hydrolysis in the vacuole and how this is finely regulated to ensure proper disruption of autophagic bodies, and thus, to the support the finality of autophagy degradation, while maintaining the integrity of the vacuolar membrane. In that context, this paper will influence all cell biologists by providing knowledge of the function, activities and homeostasis of the vacuole. This work raises the question of how ATG15 is specifically addressed to the membrane of autophagic bodies in the vacuole which will be the subject for future exciting research.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Atg15, a membrane-bound phospholipase targeted to the vacuole via the MVB pathway, has been studied in recent years. It is synthesized as an inactive proenzyme activated by vacuolar enzymes and is responsible for the degradation of the autophagic bodies' membranes. While its physiological function is well characterized, the biochemical details of its activation and overall activity remain largely unknown.
In the present study, Kagohashi et al conducted a comprehensive investigation to understand the mechanisms involved in the disruption of autophagic bodies (ABs) membranes. They focused on the activities of Atg15 and Pep4/Prb1 and employed primarily in vitro methods to elucidate the functional mechanism of Atg15. Purified Atg15 and ABs were used in the experiments. According to the proposed model, Pep4/Prb1 processes and activates Atg15 during its localization to the AB membrane, and this activation is necessary for Atg15's lipase activity. To support this model, the authors performed in vitro assays using purified proteins, vacuole and ABs purification, genetics, mutations, lipase activity assays, and morphological examination of autophagic bodies using a super-resolution fluorescence microscope. Their findings demonstrated that the activity of Pep4/Prb1 is required for Atg15's lipase activity, and Atg15 functions as a vacuolar lipase. The importance of the lipase motif for Atg15's activity was confirmed through the use of hydrolase mutants and purified Atg15 from both wild-type and mutant samples. Overall, the manuscript provides a comprehensive and solid analysis of Atg15 that will most likely interest the cell biology community. The experiments are well-controlled, and the conclusions are based on solid experimental data.
There are only a couple of minor issues that deserve the authors' attention:
Figure 1c shows a lower level of NBD-LPE in cells expressing ATG15 from a plasmid compared to the wild type, indicating that the plasmid did not fully restore the lipase activity. Additionally, the exact details for Atg15 expression should be explicitly described.
To ensure transparency and reproducibility, the authors should provide information about the specific expression vector(s) used for the plasmids in the study.
Significance
As indicated above, the study provides elaborate and solid characterization of an important enzyme that has been previously mainly functionally characterized.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary:
The rupture of single membrane-bound autophagic bodies is essential to release and catabolize contents of autophagosomes deposited in the vacuole. The phospholipase Atg15 has been thought to play an important role in this process. This study establishes methods to analyze phospholipase activity in isolated Saccharomyces cerevisiae vacuoles and elucidates the mechanisms that activate Atg15. Using an elegant cell-free assay the authors demonstrate that vacuolar extracts can cleave phosphatidyl ethanolamine in an Atg15 and Pep4/Prb-dependent manner. Atg15 is cleaved in the presence of Pep4/Prb, likely causing the release of Atg15 cytosolic domain in the vacuole. An Atg15 construct lacking the transmembrane anchor retains its lipase activity and when artificially targeted to vacuole using CPY tag localizes to autophagic bodies. The authors also establish the minimum construct of Atg15 that is sufficient to execute lipase function. The authors then isolate Atg15 from vacuolar extracts using a FLAG tag-based pulldown and show that the FLAG eluate is sufficient to cleave a range of phospholipids. Finally, using a protease-protection assay the authors show that Atg15 isolated using FLAG resin can cause disruption of isolated autophagic bodies.
Major comments:
- Throughout the manuscript, TLC data and Ape1 maturation data are not quantified. The authors should include data on replicates and quantitation for all TLC and Ape1 processing data.
- The conclusion that Atg15 is the sole source of phospholipase activity is based on cleavage of NBD-PE alone. It is not clear why specifically PE was chosen to test lipase activity of Atg15. It is possible that Atg15 has a higher preference for PE as has been shown previously (Ramya and Rajsekaran 2016). Have the authors tested to see if other phospholipids can be cleaved by vacuolar lysates derived from Atg15 knockout cells? This should be investigated further before concluding that Atg15 is the sole source of all lipase activity in vacuolar extracts.
- Atg15 overexpressed and purified from Saccharomyces cerevisiae is shown to be sufficient to catalyze the cleavage of PE (among other phospholipids). How do the authors reconcile this finding with their observations on the requirement of Pep4 and Prb? This information should be included in the discussion.
- Regarding Figure 3 and movie EV3, especially the lower panel, the overlap of cherry-Atg8 (autophagic bodies) and CPY(1-50)-Atg15(DN35)-mNG is not very clear. There appear to be several CPY(1-50)-Atg15(DN35)-mNG rings that do not surround Atg8.
- a. Are these images from a single stack or represent the entire volume of the cell? This result could be better represented as a line profile and through a correlation analysis.
- b. The finding that CPY(1-50)-Atg15(DN35) binds autophagic bodies is interesting, but it should be demonstrated with native/wild type protein. This can be achieved by expressing lipase deficient Atg15-mNG in rapamycin-treated cells, which should have intact accumulated autophagic bodies.
- c. Atg15-mNG also localizes to a ring-like structure outside the vacuole. The authors should comment on the potential impact of this finding.
- The rationale for using detergent solubilized and FLAG-eluted Atg15 to test lipase activity with other phospholipids (LPC, PI, PC and PG) is not clear. Detergent solubilized and FLAG-eluted Atg15 is degraded (Figure4C). Does this mean that degraded forms of Atg15 exhibit broader lipase activity? The authors should test for breakdown of other phospholipids with whole vacuolar extracts or vacuolar pellet fraction that has intact membrane bound Atg15. If only degraded forms of Atg15 show broad phospholipid lipase activity, then this will be informative about regulation of Atg15 function.
- Figure6B: ProteinaseK is a broad-spectrum protease. It is unclear why it would specifically cleave GST-GFP and prApe1 to produce single bands (and not a smear) corresponding to free-GFP and dApe1. This result can be explained better.
Minor comments:
- Fig1E legend states, "Each vacuolar lysates were added at a volume ratio of 1:5:25". It's not clear what this means or what this ratio is for. In general figure legends need to be more descriptive on how the experiment was performed.
- It's not clear what processed Atg15 (pcrAtg15) refers to in Figure4C. Is it indicating the smear around the 75kDa band? This should be explained clearly in the figure legend and the results section.
Significance
The phospholipase Atg15 is known to play a crucial role in the degradation of autophagic bodies within the vacuole. However, the regulatory mechanisms that prevent detrimental lipase activity of Atg15 have remained unclear. This study shows that proteolytic processing and membrane binding could activate Atg15, thereby providing important insights into the mechanism of Atg15 regulation.<br /> Using isolated autophagic bodies and vacuolar extract, the results here show direct disruption of autophagic bodies by Atg15. The cell-free assay to assess lipase activity can be further utilized to analyze vacuolar function. These finding will be of interest to a audience interested in various forms of autophagy and vacuolar degradation.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
1. General Statements [optional]
Reply to general assessment of referee #2:
- General assessments: The current study adds some to these observations…some of these observations are incremental…biological significance is limited. While this reviewer does not suggest additional experimentation, this manuscript would be suitable as a resource paper.
Reply: It appears we were not clear enough in explaining the novel aspects of our study.
The starting points are two published studies from our lab demonstrating a global increase of ISGF3 association with ISG promoters in IFNγ-treated cells and a remarkable similarity of IFN-γ and type I IFN-induced early transcriptome changes. These findings challenge the notion in the field (as mentioned by the referee) that IFNγ specificity is produced by the predominant deployment of STAT1 homodimers. We thus tested the hypothesis that the specificity of the IFNγ-induced transcriptome is generated over time, rather than during the early response, and relies on secondary responses to transcription factors such as IRF1. In contrast, IRF1 plays no or only a small role in the type I IFN response that utilises ISGF3 and/or unknown secondary factors in the delayed response. We tested this hypothesis with PRO-seq technology to rule out confounding effects of mRNA processing over a 48h period. The data are clear in showing that many genes associated with the antibacterial or anti parasite profile of activated macrophages are indeed much more abundant in late-stage rather than briefly IFNγ-treated macrophages and these delayed changes are to a large extent dependent on IRF1. Our findings are based on the best available technologies, a combination of nascent transcript analysis with genetics and protein interaction studies. In addition, our findings rule out alternative models of sustained or secondary ISG transcription, such as the employment of alternative ISGF3 complexes (such as STAT2-IRF9) or of ISGF3 complexes formed with unphosphorylated STAT1 and STAT2. We provide evidence for higher order waves of transcription caused by unknow transcription factors that are produced by transcriptional activation of ISGF3 or IRF1 target genes and identify candidates among the AP1 and Ets transcription factor families. We agree that some of the data are confirmatory rather than novel (i.e. some of the genes we describe were known from previous literature to be IRF1 targets), but it is the systems approach of our study, and particularly the delineation of conditions under which the largely neglected delayed response diverts the IFNβ and IFNγ-induced transcriptomes, that generates a comprehensive and conclusive view of IFNγ acting predominantly as a macrophage activating factor, and IFNβ being an essential antiviral cytokine. We do think this main outcome is immunologically meaningful and not incremental. For this reason, we would prefer to publish the paper as a relevant contribution to innate immunology rather than a resource. Emphasizing our point, a paper appeared in ‘Cell’ while our study was under review, showing that human IRF1 mutations cause mendelian susceptibility to mycobacterial disease (MSMD), a term coined by JL Casanova and colleagues for immunological defects that reduce the ability of macrophages to cope with intracellular bacteria (new ref. 65). This important study emphasizes the main conclusions of our study about the relevance of IRF1 for macrophage activation. We discuss this paper on p. 14 lines 9-14.
Revision: We tried to better explain the scientific motivation for this study and the significance of the results (p. 4, lines, lines 12-25).
Revision plan: n. a.
2. Description of the planned revisions
Referee #3; major comment 1:
In Fig. 1d is difficult to interpret and misleading for many reasons. First, the cluster numbering is disconnected from the cluster order; why not numbering them based on the hierarchical clustering and writing the cluster number besides the cluster itself? Second, having a 2-color gradient is misleading; negative values shouldn't be in the same color tone than the positive values. Third, the authors did not provide adequate rationale behind using only the top 1,000 most expressed gene? Why not using all the differentially expressed genes in at least one of the condition to provide a comprehensive analysis? Could this potentially lead to bias in the data, and is there any information lost by not using the - lower - expressed genes fraction? Fourth, it is not clear what the color scale is representing and how the data was transformed. Was a mean centering of the expression values of the log2FC applied to the RNA-seq data to facilitate clustering? Mean centering and z-scoring is a common technique used to adjust expression data, but it can potentially exaggerate differences between samples. More information about the data and analysis should be provided, as it is difficult to determine whether this was a valid approach or not.
Reply:
- To create the heatmap, we used the pheatmap package from R and the cutree_rows option to separate 11 clusters with strikingly different patterns of gene expression based on visual exploration. The numbering was autogenerated by the program.
- The data is now shown in red-blue.
- We restricted our list to only 1000 genes from each comparison as we aimed to analyze the prominent patterns of gene expression across timepoints. Considering all differentially expressed genes based on a padj value would also include genes expressed at very low levels as evident from the low baseMean values obtained from DESeq2. Hence, we applied a selection of 1000 genes which effectively represented the major patterns of gene expression across timepoints.
- Variance stabilized transformation was applied on read counts obtained from PRO-seq using the DESeq2 package. The transformed reads were z-score normalized and used for performing hierarchical clustering by the “Ward.D2” method using the pheatmap package in R. A total of 3126 genes were used for this analysis. 11 distinct clusters were defined using cutree_rows option. The color scale represents z-score normalized counts. The genes represented in the heatmap were selected based on the following criteria: each timepoint of interferon treatment was compared to the homeostatic condition (untreated sample) in wildtype BMDMs. The differentially expressed genes from each comparison were selected based on the filtering criteria: absolute log2FoldChange >=1 and adjusted p value <0.01 by Wald test. Following the differential analysis, the first 1000 differentially expressed genes in each treatment condition (ordered based on adjusted p values) were selected for both IFN types and combined and selected for creating a list which consisted of 3126 unique genes. The scale in the heatmap represents z-scores of variance-stabilized reads, calculated across all genotype and treatment conditions, separately for each IFN type.
Revision plan: We will label the clusters with the cluster number next to it in addition to the color codes.
Referee #3; major comment 3:
The large standard deviation bars in the claim that ChIP data confirmed the binding of ISGF3 components to the promoter of Mx2 cast doubt on the validity of the results and conclusions. The authors should consider additional experiments or complementary analyses to validate their findings. Or alternative, to adjust their claims accordingly.
Reply: To demonstrate sufficient quality of the data the ratio of Stat1/ Stat2 was calculated for early (1.5hrs) and late (48h) separately. The unpaired two-tailed t test comparing this ratio between 1.5 hrs and 48hs, shows that they are not significantly different. This indicates that all ISGF3 components are associated with ISG during both early and delayed responses, i. e., that STAT2/IRF9 complexes are unlikely to contribute to delayed ISG control. However, we agree with the referee that the standard deviations of the kinetic ChIP experiment are high and that it would be good to generate additional data.
Revision plan: We will perform additional ChIP experiments to improve the statistical power of the results in fig. S2c.
Referee #3, major comment 6:
The authors interpret their ATAC-seq and ChIP-seq results based on a 2kb window to the TSS of genes, not considering relatively close enhancers or longer range cis-regulatory interactions in their interpretation. For example, they mention on p.7 "Contrasting the strong binding of IRF9 and IRF1 to the Mx2 (cluster 2) and Gbp2 (cluster 9) promoters, respectively, we saw no evidence for direct binding to Lrp11 (cluster 3) and Ptgs2 (cluster 10)", but on Fig 3d they show only the proximal regions. No scale bars are shown either. Moreover, exploring the same published IRF1 ChIP-seq dataset, there is a clear IRF1 binding site at the promoter of Ptgs2, while the authors report none.
Reply:
- According to the literature (e. g. refs. 11, 27), most IFN-induced accessibility changes occur in the vicinity of the TSS of ISG. This is further strengthened by the data shown in this manuscript. In addition, most functionally validated GAS and ISRE sequences are in the DNA interval chosen for our analysis. While distal ISG enhancers have been reported (e. g. DOI: 10.26508/lsa.202201823), an analysis beyond the placement of most control regions increases the risk of wrong assignments between ISG and their regulatory elements, hence the causality between transcription factor binding and accessibility changes.
- We extended the regions for the analysis of the Lrp11 and Ptgs2 regulatory regions and found no evidence for the binding of ISGF3 or IRF1. We find no evidence for a clear peak in the Ptgs2 promoter. There is a peak called by the Macs2 algorithm, but visual inspection of the track (bigwig file) shows it consists of a minor increase in reads above background that does not suggest a bona fide IRF1 binding site (see below). This view is supported by our inability to find an IRF binding site in the vicinity of the peak.
IRF1 binding indicated by bigWig browser tracks and corresponding peakfiles detected at the locus. We identified the peakfile from Langlais et al., 2016 and identified peaks using MACS2, however using mm10 genome as the analysis in the original paper was done with mm9 genome. The peak identified here appears to be an artefact of the MACS2 program as there is no evident enrichment at the gene promoter region upon inspection of the bigWig files.
Revision plan: Scales will be added to the browser tracks as requested.
Referee #3, major comment 7:
Lack of statistical analysis on chromatin accessibility claims: The authors claim that ATAC-seq data in BMDMs stimulated with IFNβ or IFNγ for a short (1.5 hours) or long (48 hours) period reveals a striking similarity between transcription and the general trends of chromatin accessibility at regions up to 1000 bp upstream of the TSS (Fig. 2a), suggesting continuous chromatin remodeling during the transcriptional response. However, I would like to know if this conclusion is well-supported by the correlation between the chromatin accessibility from ATAC-seq data from only one sample and the PRO-seq data.
Reply: See revision plan.
Revision plan: We will analyze single experiments whether they support the conclusions derived from the z-score of the triplicate samples.
Referee #3, major comment 8:
The need for additional experiments to verify claims such as the dependence of Ifi44 on IRF1 for gaining ATAC signal, as stated in the claim, "Expression required IRF1 for both, but accessibility of the Ifi44 regulatory region depended upon IRF1 whereas that of Gbp2 acquired an open structure independently of IRF1 (Fig. 5c).
Reply: We think the lack of clarity might be related to the size of figures 5a and 5b and the density of the dots in some areas of the plot. We agree it is very difficult to assign our gene labels unambiguously to a single dot.
Fig. 5a combines ATACseq data in wt and IRF1 knockout cells with the expression data from the Pro-seq experiment, Fig. 5b is the same set-up, but IRF9-deficient macrophages are analyzed.
Blue dots show ATACseq signals induced by IFN treatment. Violet dots represent genes that require IRF1 (Fig. 5a) or IRF9 (Fig. 5b) for transcriptional induction. Yellow dots mark genes such as IFI44 requiring IRF1 (Fig. 5a) or IRF9 (Fig. 5b) for both expression and the accessibility change in the promoter region. Fig. 5c visualizes representative examples of genes whose accessibility is coupled to the transcription factor dependence of the transcriptional induction (IFI44), or not (Gbp2). Thus Fig. 5c must be interpreted based on the dot color code in fig. 5a and we admit this has been difficult with the figure in its present form.
Revision plan: We will improve the clarity of figs 5a and 5b in several ways:
- We will label the panels to better indicate the intersected data sets.
- We will increase the size of the panels and figure legends and make sure that the correspondence between gene names and dots are unambiguous.
- We will include trend lines of the Ifi44 and Gbp2 genes to visualize their induction and IRF1 dependence.
Referee #3, major comment 13 (see also section 3):
The authors have not adequately addressed the methodological limitations in their discussion, which extends beyond the aforementioned comments. It is suggested they include a comprehensive discussion of the claims made pertaining to the necessity of IRF1 for accessibility and the potential biases in the interactomes, along with their associated consequences.
Reply: The contribution of IRF1 to the accessibility of ISG promoters emerges from the data in figures 5a, whose clarity will be improved (see reply to point 8). We do not interpret the impact of IRF1 beyond the data, in fact we state a relatively minor effect of IRF1 in the control of promoter accessibility (p. 10, lines 20-22) and we have added a reference in agreement with an impact of IRF1 on basal expression of antiviral genes (ref. 39, as suggested by the referee).
We have added discussion on potential limitations of the TurboID approach (p. 11, lines 22-24 and p. 15, lines 3-11).
Revision plan: Improvement of fig 5a (see ref. #3, point 8).
Referee #3, minor comment 2
Fig 1e. The color scales on the GO enrichment graphs are misleading since they use the same blue-to-red gradient for adj p-values ranging from 10-25 to 10-49 and 0.008 to 0.016, which could be considered non significant.
Reply: We agree that this is confusing. It results from automated assignments of the color gradients by the software.
Revision plan: We will investigate possibilities to change color codes for different ranges of p values.
Referee #3, minor comment 4
The incomplete schema in Figure 1a, which only focuses on PRO-seq and does not include the ATAC-seq element.
Reply: We will add a new figure to visualize the set-up of the ATAC seq experiments and their intersection with the Pro-seq data.
Revision plan: We will add a new figure in accordance with the referee’s request.
Referee #3, minor comment 6
The clearer labeling of Figure 5a and 5b.
Reply: Please refer to our reply to major point 8.
Referee #3, minor comment 10
Fig S1b, S3b. The PRO-seq was generated in triplicates, hence these graphs should include the Log2FC for the individual data points.
Reply: The Log2FC from DESeq2 were calculated from the triplicates, the software does not compute Log2FC from individual replicates.
Revision plan: We mention the p-values for the Log2FC to show the degree of consistency (figure legends). We will provide a table with log2FC and corresponding padj values of the genes represented at each timepoint (table_showing_padj_values_and_log2fc).
Referee #3, minor comment 12
In the genomic snapshot shown, only bars or fading triangles are shown in place of the gene body. The authors should provide an accurate gene structure; i.e., exons and introns.
Reply: We will try to include the exon-intron structure wherever the size of the figure allows this.
Revision: n. a.
Revision plan: If figure size permits, we will add the exon-intron structure of the genes in browser tracks as requested.
3. Description of the revisions that have already been incorporated in the transferred manuscript
Referee #1, major comment 1
Figure 2. Difficult to interpret data as it is presented. Consider quantifying figure 2C in order to make "changes in Pol II pausing were more pronounced during IFNb signaling" statement more apparent.
Reply: We presented the pausing data in two different graphic representations (figures 2c and S2) to make the understanding of the information content easier. In hindsight we may have generated more confusion than clarity.
Revision: We removed the original figure 2c and replaced it with original figure S2. This representation is quite intuitive as the graphs represent a direct quantitative logarithmic display whether and how much the relative amount of paused polymerase changes when comparing IFN-treated and untreated cells. The calculation of these ratios is now explained better in the legend to figure 2.
Referee #1, major comment 2
How are you distinguishing autocrine signaling in the BMDMs driven by IFN treatment from late transcripts (for example, at 48 hours are differential genes due to autocrine cytokine signaling or are they truly late transcripts)?
Reply: We do not exclude autocrine effects. In case of ISG, the most likely autocrine factor would be secreted interferon. According to our Proseq data, the differentially expressed genes do not include any interferon genes. That being said, it is possible that the transcription factors from the AP1 family we hypothesize as drivers of secondary or tertiary waves of transcription are activated by non-IFN cytokines secreted from IFN-treated cells (see also reply to comment 3).
Revision: We now mention that enhanced IFN production is not sustaining ISG responses (p.5 lines 18/20). We mention the possibility that secreted factors may drive secondary or tertiary waves of ISG transcription (p. 8, lines 21/23).
Referee #1, major comment 3
Figure 3D. Authors choose Gbp2 (as positive control for IFNg driven gene), but don't show that Gbp2 is a IFNb independent gene. Consider using IRF1 KO BMDMs in this data as well.
Reply: This is a misunderstanding. Gbp2 is not shown as an IFNγ-specific gene (it’s induction by both IFN types has been shown previously and emerges from our Pro-seq analysis, see also response to minor issue no. 2). It represents the cluster of genes that are sustained specifically after IFNγ treatment in an IRF1-dependent manner. The purpose of fig. 3D is to show that not all ISGF3/IRF9-dependent genes have promoter binding sites for ISGF3 and not all IRF1-dependent genes have binding sites for IRF1. This suggests indirect effects of both transcription factors in sustaining IFN-induced transcription (in line with the referee’s comment 1).
Previous figure S3e (now S2f) confirms binding of IRF1 to the GBP2 promoter by ChIP with kinetics correlating to its transcriptional effect. This experiment is normalized with an IgG control. IRF1 knockout cells did not produce a ChIP signal with IRF1 antibody, as expected (data not shown).
Revision: We better explain the rationale behind the experiments shown in figure 3D (text on p8, lines 12-16). In addition, we show the trend line of Gbp2 expression in WT vs IRF1KO as well as that of additional genes showing delayed/sustained responses in the new Figure S3.
Referee #1, minor comment 2
Define known IFNg and IFNb driven genes when they are introduced in figure 2 rather than in discussion.
Reply: Following the referee’s suggestion we provide the examples of IFNβ and IFNγ-controlled genes and the characteristics of their regulation in the context of our description of the results displayed by fig. 2 (p.6 lines 15-21). This includes Gbp2 (see major issue no. 3).
Revision: The text on p. 6 lines 15-21 has been modified in accordance with the request.
Referee #1, minor comment 4
Unclear whether IRF1 expression in figure 3A is from whole cell lysate or nuclear fraction.
Reply: We indicate in the figure legend that whole cell lysates were used.
Revision: We added a sentence with the relevant information in the legend of figure 3.
Referee #1, minor comment 5
Authors suggest IFNb treatment induces less IRF1 at later time points, however loading control also seems slightly lower than other considerations. Is it possible that IFNb treated cells are dying at later time points, given that type I IFN signaling can be pro-apoptotic.
Reply: The graph below the blot represents quantified IRF1 signals, normalized to the loading control. It shows that the differences are not generated by unequal loading of the blotted gel. We and others have shown that IFNβ may indeed enhance macrophage death, however only when the cells are simultaneously infected with an intracellular pathogen (e.g. new ref. 25). These studies also show that treatment with IFNβ alone over periods used in the present study does not affect macrophage viability.<br /> Revision: We added a sentence about the viability of IFN-treated macrophages (p. 4, lines 31-32).
Revision plan: n. a.
Referee #2, major comment 3
The sequencing and BioID data are not submitted to public databases.
Reply: An accession number has been added.
Revision: The accession number was added on p.29, line 25.
Referee #3, major comment 1 (see also revision plan, section 2):
Revision: The rationale for using the top 1.000 genes is explained (p.5, lines 7-9). The description of the pro-seq read count processing has been extended in accordance with our reply to the referee in the legend of figure 1d and in the methods section (p. 33, lines following line 10.)
Referee #3, major comment 2
Fig 2c. The authors claim that RNA Pol II pausing is a major factor in controlling the dynamics of ISG transcription. However, they did not provide sufficient explanation of the results, and in all fairness there is not much variation between the clusters to sustain the claim that this is a major factor in ISG transcriptional control.
Reply: We agree with the referee that we cannot posit RNA pol II pausing as a major factor for the differences of transcriptional control of ISG in individual clusters. We have made sure to remove any statements suggesting this possibility. We also try to better integrate our findings with RNA pol II pausing into the existing literature.
Revision: We added relevant literature on p. 6 lines 28-30 and p. 7, lines 4-6.
Referee #3, major comment 4
On p.5, the authors mention "Representative browser tracks from the Gbp2 and Slfn1 genes further validate this observation" but they are simply referring to genome browser snapshot, i.e., specific genomic examples, extracting from the same single dataset. Without using an independent dataset, this can not "further validate" the initial findings.
Reply: We agree the wording is incorrect.
Revision: We changed the paragraph describing this experiment (p. 6, lines 15-21).
Referee #3, major comment 5
IRF1 was successfully pulled down with STAT1 bait but not in the reciprocal experiment. The author should discuss this point as it is important for the conclusions. Could it potentially indicate issues with the technique used, and if this could introduce any bias into the results. The statement, "In contrast, interactors of the IRF1 bait did not include STAT1. This discrepancy could result from steric constraints of the tagged proteins due to the limitation of the 10nm distance reached by the biotin ligase," does not seem to be sufficient to explain this discrepancy.
Reply: STAT1 was present in the IRF1 pull-down and the interaction increased significantly after IFN treatment but after normalization to the NLS control it did not conform to our criterium of a 95% confidence interval for the FDR. To be consistent we did not include it in the list of IRF1 interactors. We have observed on several occasions that the significance of proximity is not reciprocal, even for well- documented physical interactions. A prime example for this is the interaction between STAT1 and IRF9 in IFN-treated cells which is recorded in the STAT1 pull-down, but not that with IRF9 (ref. 10). Apart from steric reasons the lack of reciprocity may result from different signal/noise ratios in pull downs with different baits.
Revision: We mention that IRF1 was a STAT1 interactor below the statistical cut-off (p. 11, lines 26-28) as well as the possibility of different signal/noise ratios in the IRF1 and STAT1 pull-downs on p.11, lines 22-24.
Referee #3, major comment 9
In the figure legends, there is missing information about the number of times experiments were replicated, suggesting that some were done a single time. Moreover, some graphs are missing statistical analysis, e.g., in Fig S3cS3e, S3f, the ChIP-qPCR experiments were done on biological triplicates, there is no mention of statistical test performed, it is not mentioned what the error bars represents (SD, SEM, etc.) and the variance is large, but the authors still interpret these results as significant enrichment of the transcription factors to the Mx2 promoter.
Reply: Where missing the relevant information has been added to figure legends. In brief, all experiments represent at least three biological replicates. The only exception is the western blot shown in figure S3a, (no S2a) which represents two independent replicates. Here, the clarity of the difference of IRF1 expression and the fact that the only purpose is to show that Raw264.7 macrophages behave like bone marrow-derived macrophages in fig. 3a justifies the omission of another replicate (please see also answer to point 3).
Revision: The relevant information has been added to figure legends where necessary (figs. 1, a, 3a, 6a-f, S1, S4, S5).
Referee #3, major comment 10
Another example are the RNA Pol II pausing index ratios, which show minor variations and not are supported by statistics to support a possible significance. Proper description, replication and statistical analyses of the results are critical.
Reply: We agree.
Revision: Statistics underlying the RNA Pol II pausing data are included in supplementary data 2.
Referee #3, major comment 11
The authors used CRISPR-Cas9 genome editing to generate knockout cell lines. However, they did not verify the knockouts at the protein level. Further experiments could confirm that the targeted proteins are not expressed in the knockout cell lines.
Reply: We included a western blot showing the lack of IRF1 and STAT1 expression in the respective cell lines.
Revision: New figure S6.
Referee #3, major comment 12
On p.9, it is mentioned "IRF1 affects chromatin structure ...". Here chromatin structure is related to minor changes in chromatin accessibility, this can not be qualified as changes in chromatin structure.
Reply: ‘structure’ has been changed in accordance with the request.
Revision: ‚structure‘ has been replaced with ‘accessibility’. (p. 10, lines 19 and 21).
Referee #3, major comment 13 (see also section 2, revision plan, major comment 8)
The authors have not adequately addressed the methodological limitations in their discussion, which extends beyond the aforementioned comments. It is suggested they include a comprehensive discussion of the claims made pertaining to the necessity of IRF1 for accessibility and the potential biases in the interactomes, along with their associated consequences.
Reply: The contribution of IRF1 to the accessibility of ISG promoters emerges from the data in figures 5a, whose clarity will be improved (see reply to point 8). We do not interpret the impact of IRF1 beyond the data, in fact we state a relatively minor effect of IRF1 in the control of promoter accessibility (p. 10, lines 20-22) and we have added a reference in agreement with an impact of IRF1 on basal expression of antiviral genes (ref. 39, as suggested by the referee).
We have added discussion on potential limitations of the TurboID approach (p. 11, lines 22-24 and p. 15, lines 3-11).
Revision: Change of the discussion section (p. 11, lines 22-24 and p. 15, lines 3-11).
Revision plan: Improvement of fig 5a (see ref. #3, point 8).
Referee #3, major comment 15
The work should be discussed in the context of the demonstrated physiopathological evidence of the IRF1 and IRF9 functions. IRF9 (Hernandez et al., JEM 2018) and more recently IRF1 (Rosain et al Cell, 2023) were identified as causing non overlapping phenotypes in human patients carrying loss-of-function mutations for these genes. The authors must interpret their results in this context.
Reply: We thank the referee for reminding us about the importance of these papers for our work.
Revision: The papers have been mentioned and discussed (p. 13 lines 19-28 and p.14, lines 9-14).
Referee #3, minor comment 3
The inconsistency in the title referring to IFNb as Type 1 but using IFNg instead of Type 2 nomenclature, perhaps consistency is best.
Reply: We agree about the importance of consistency but find ourselves in yet another quandary. While the use of ‘type I IFN’ is clearly indicated and widely used as a collective name for this group of cytokines, the use of ‘type II IFN’ for IFNγ is rare because it is the only member of this type. Hence, we decided for sticking with convention at the expense of a bit of consistency. We agree about the title, though, and have changed type I IFN to IFNβ.
Revision: We adapted the title in agreement with the referee’s comment.
Referee #3, minor comment 5
Figure 6d includes a color scale of -1 to +3, but it is unclear what these values represent and how they were calculated per interactor. The figure legend should be revised to clarify this information.
Reply: We agree. The relevant information has been added to the figure legend.
Revision: We added information (log2FC with regard to the NLS control) to the legend of fig. 6d.
Referee #3, minor comment 9
Fig 1e, S1c. Graphs having circles of varying sizes in function of a value are named "bubble plots" and not "dot plots".
Reply: Thank you for pointing this out, we corrected our mistake.
Revision: We changed dot plot to bubble plot in legend to figure S1c.
Referee #3, minor comment 11
Fig S3c legend. It is mentioned "Graph represents RT-qPCR of genomic Mx2". RT-qPCR usually stands for reverse transcription quantitative PCR, hence we suggest to change to "ChIP-qPCR" or qPCR. Confusingly, in the literature the term "RT-PCR" is used for real-time PCR and "qPCR" for quantitative PCR. Also, the authors should be specific about the "genomic" region targeted; the graphs mention "promoter", hence it would be appropriate to use the same designation in the legend.
Reply: We agree and thank the referee for correction of the terminology.
Revision: We changed RT-PCR to qPCR throughout the manuscript. Moreover, we specifically refer to ‘promoter region’ as the amplified DNA.
Referee #3, minor comment 12
Fig S3e. The y-axis names are missing.
Reply: Thanks for spotting this.
Revision: The y axis in the figure received its proper label.
Referee #3, minor comment 14
Raw cells are sometimes spelled as "Raw" and other times as "RAW". Please choose one for consistency.
Revision: This inconsistency has been corrected
Referee #3, minor comment 15
In p.10 l.20, the figure number is missing.
Revision: We corrected this mistake.
4. Description of analyses that authors prefer not to carry out
Referee #1, minor comment 1
Simplify figure 4B- consider focusing on most differentially expressed genes between clusters
Reply: The purpose of fig. 4B is to provide a visual overview of the kinetics of eRNA transcription in response to both IFN types and of the effects of IRF9 and IRF1 knockouts. This information needs to be given to demonstrate the similarities and differences between the control of eRNA and the corresponding ISG transcripts in the different regulatory clusters (as shown in figs. 1d and 2a).
Simplifying the figure would mean to separate it according to time point, IFN type treatment or knock-out effect. We think this would require to mentally reassemble the figure to understand the interrelationships between these parameters. To our opinion the visual display of the data interrelationship in fig. 4B facilitates the impropriation of the information content.
Revision: n. a. - we hope our reasoning has become sufficiently clear.
Revision plan: n. a.
Referee #1, minor comment 3
Clarify which cell types (IRF1 KO vs IRF9 KO) are used in figure 5 A/B.
Reply: The cell type (bone marrow-derived macrophages) is mentioned in the first sentence of the figure legend. Since all experiments except the Bio-ID experiment were performed with this cell type we decided not to label each figure.
Revision: n. a.
Revision plan: n. a.
Referee #2, major comment 2 and referee #3, major comment 14
Ref #2: Biological significance is limited as this study is largely descriptive and they do not test the hits obtained from BioID.
Ref #3: Although the TurboID experiments identify known STAT1 and IRF1 interactors, the proposed new interactors are numerous, and none are validated through independent co-IP experiments. Moreover, the results are very noisy, with little differences between untreated BMDMs (where IRF1 is barely expressed) and IFN-treated conditions.
Reply: The big advantage of BioID or TurboID is the ability to score proximity and very transient interactions. Validating BioID hits with technologies such as coIP is not particularly useful as the two technologies will obviously produce different interactomes. In fact, we show in this manuscript that IRF1 and STAT1 show proximity, but they do not form a stable complex under co-IP conditions. This leaves genetic approaches (LOF or GOF) as alternatives. However, apart from the workload (> 100 genes would have to be knocked out or their products overexpressed), most of our hits are expected to produce very broad effects in such experiments, hard to interpret regarding ISGF3 and IRF1 activities.
In view of this situation, we publish exclusively the high confidence nuclear interactors identified in our screen: biological replicates were performed in triplicate, a stringent internal control (TurboID-NLS) was used, and a stringent statistical cut-off for high-confidence interactors (95% FDR between groups) was applied. We further account for the experimental situation by limiting interpretation of the data to confirmed molecular events. For example, STAT1 dimers and the ISGF3 complex are required for histone acetylation in response to IFN, and ISGF3 is known to contribute to the exchange of the H2AZ histone variant (refs 11, 14, 71, 72). Our data show that IRF1 contributes to promoter accessibility changes and this is in line with its proximity to a remodelling complex. Thus, the BioID data indeed validate previous findings. However, in agreement with the referee’s comment, some of the data remain descriptive (such as the intriguing proximity of both STAT1 and IRF1 to nuclear products of ISG). To determine the importance of this molecular proximity is a major undertaking and beyond the scope of this study.
Revision: We added discussion to state the difficulty of validating TurboID-based interactions and the limitations of the TurboID experiments (p.15 lines 3-11).
Referee #3, minor comment 1
In most graphs the expression values or log2FC are shown separately for IFNb and IFNg, however in the heatmaps (Fig 1d, S1d) the IFNb and IFNg results are intercalated keeping them side-by-side for each time point, which makes them more difficult to interpret.
Reply: We are in a quandary about the design of the figure. On the one hand our goal is to visualize gene clusters with distinct behaviors for each IFN type. For this purpose, it would be advantageous to separate the IFN types. On the other hand, we aim at showing similarities and differences between genes induced by each IFN type, for this purpose it is better to maintain the current sample order. While understanding the referee’s point, we prefer to keep the figure as it is, because the suggested change will not increase its overall clarity.
Revision: n. a.
Revision plan: n. a.
Referee #3, minor comment 7
The statement that "IFN-I are the more important mediators of antiviral immunity" is not entirely accurate and may be an oversimplification, as there are certainly articles which suggest a larger role for type ll IFN elements than type l (ref: Yamane D et al., 2019 Nature microbiology). While yes, IFN-I plays a critical role in the innate immune response to viral infections, IFNγ also has antiviral activity and is involved in the adaptive immune response to viral infections, and in some instances to a larger extent than IFN l.
Reply: The Yamane et al study (now mentioned on p 10, lines 22-25 and referenced) agrees with our findings because it shows that IRF1 contributes to the basal expression of an ISRE-driven ISG subset. Our statement about the predominant role of type I IFN versus IFNγ refers to genetic data in both humans (mainly Casanova’s work including effects of autoantibodies against type I IFN, see also the paper about human STAT2 deficiency in the June 15th issue of the JCI, https://doi.org/10.1172/JCI168321) and mice (hundreds of papers) showing that disruption of type I IFN synthesis or response causes profound effects of antiviral immunity (i.e. resulting susceptibilities are first and foremost to viral pathogens) whereas susceptibilities as a consequence of disrupting the IFNγ pathway are first and foremost to intracellular nonviral pathogens such a mycobacteria. In fact, the term mendelian susceptibility to mycobacterial disease (MSMD) was coined by Casanova and colleagues to describe a variety of human mutations that include those of the IFNγ, but not the type I IFN pathway.
Maybe more importantly, the Rosain et al. paper mentioned by the referee which appeared in ‘Cell’ while our study was under review, shows that human IRF1 mutations also fall into the MSMD category (new ref. 65). In contrast, the authors did not observe diminished antiviral immunity. This emphasizes the main conclusions of our study about the relevance of IRF1 for macrophage activation. We discuss this paper on p 14. lines 9-14.
Obviously, this does not exclude a role of type I IFN in nonviral infection or of IFNγ in viral infection, in fact much of our own work has been dedicated to a role of type I IFN in infections with L. monocytogenes. Nevertheless, we think that in a generic statement about the difference between type I IFN and IFNγ it is correct to label the former as predominantly antiviral and the latter predominantly as a macrophage activating factor against nonviral, intracellular pathogens.
Revision: We added discussion of Rosain et al. (ref. 65) on p 14. lines 9-14.
Referee #3, minor comment 8
The authors claim that a significant portion of ISG promoters is associated with ISGF3 upon IFNγ receptor engagement and that the transcriptomes of macrophages treated briefly with IFNβ or IFNγ exhibit remarkable similarity and sensitivity to Irf9 deletion. However, I am uncertain about the extent of consensus on this claim.
Reply: The data were surprising but supported by ChIP-seq and RNA-seq in wt and IRF9 ko macrophages (ref 10). Data in a follow-up study (ref. 11) and in this manuscript support our original conclusion by demonstrating the impact of the IRF9 ko on IFNγ responses. Importantly, we don’t claim this is true in all cell types, it may well depend on STAT/IRF9 expression levels and tonic IFN signaling.
Revision: n. a.
Revision plan: n. a.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary:
This manuscript by Geetha et colleagues addresses the differences and similarities in gene expression control between Type I IFN (IFNβ) and Type II IFN (IFNγ) signaling. The authors aim to determine the factors responsible for the partitioning of IFNβ and IFNγ-induced transcriptomes and their propagation of diverse biological responses. The authors mention the JAK-STAT paradigm of IFN signaling, which posits that ISGF3 dominates transcriptional responses to IFN-I, whereas GAF is critical for the generation of an IFNγ-specific transcriptome. However, recent investigations suggest that the ISGF3 complex may also play a role in IFNγ signaling. The authors investigate the contributions of IRF1, ISGF3, and noncanonical versions of the ISGF3 complex to the transcriptome divergence produced by IFN-I or IFNγ signaling. They used nascent transcript sequencing to determine how ISGs expression are temporally controlled by the ISGF3 complex or IRF1 and show that temporal control of ISG expression includes transcription factor recruitment, enhancer activation, changes of chromatin accessibility, and control of RNA pol II pausing. The authors also investigate cooperativity between STAT1 and IRF1 correlates with different nuclear interactomes. In its current form, the manuscript suffers from a lack of independent experiment replications and nuance in the interpretation of the results.
Major comments:
- In Fig. 1d is difficult to interpret and misleading for many reasons. First, the cluster numbering is disconnected from the cluster order; why not numbering them based on the hierarchical clustering and writing the cluster number besides the cluster itself? Second, having a 2-color gradient is misleading; negative values shouldn't be in the same color tone than the positive values. Third, the authors did not provide adequate rationale behind using only the top 1,000 most expressed gene? Why not using all the differentially expressed genes in at least one of the condition to provide a comprehensive analysis? Could this potentially lead to bias in the data, and is there any information lost by not using the - lower - expressed genes fraction? Fourth, it is not clear what the color scale is representing and how the data was transformed. Was a mean centering of the expression values of the log2FC applied to the RNA-seq data to facilitate clustering? Mean centering and z-scoring is a common technique used to adjust expression data, but it can potentially exaggerate differences between samples. More information about the data and analysis should be provided, as it is difficult to determine whether this was a valid approach or not.
- Fig 2c. The authors claim that RNA Pol II pausing is a major factor in controlling the dynamics of ISG transcription. However, they did not provide sufficient explanation of the results, and in all fairness there is not much variation between the clusters to sustain the claim that this is a major factor in ISG transcriptional control.
- The large standard deviation bars in the claim that ChIP data confirmed the binding of ISGF3 components to the promoter of Mx2 cast doubt on the validity of the results and conclusions. The authors should consider additional experiments or complementary analyses to validate their findings. Or alternative, to adjust their claims accordingly.
- On p.5, the authors mention "Representative browser tracks from the Gbp2 and Slfn1 genes further validate this observation" but they are simply referring to genome browser snapshot, i.e., specific genomic examples, extracting from the same single dataset. Without using an independent dataset, this can not "further validate" the initial findings.
- IRF1 was successfully pulled down with STAT1 bait but not in the reciprocal experiment. The author should discuss this point as it is important for the conclusions. Could it potentially indicate issues with the technique used, and if this could introduce any bias into the results. The statement, "In contrast, interactors of the IRF1 bait did not include STAT1. This discrepancy could result from steric constraints of the tagged proteins due to the limitation of the 10nm distance reached by the biotin ligase," does not seem to be sufficient to explain this discrepancy.
- The authors interpret their ATAC-seq and ChIP-seq results based on a 2kb window to the TSS of genes, not considering relatively close enhancers or longer range cis-regulatory interactions in their interpretation. For example, they mention on p.7 "Contrasting the strong binding of IRF9 and IRF1 to the Mx2 (cluster 2) and Gbp2 (cluster 9) promoters, respectively, we saw no evidence for direct binding to Lrp11 (cluster 3) and Ptgs2 (cluster 10)", but on Fig 3d they show only the proximal regions. No scale bars are shown either. Moreover, exploring the same published IRF1 ChIP-seq dataset, there is a clear IRF1 binding site at the promoter of Ptgs2, while the authors report none.
- Lack of statistical analysis on chromatin accessibility claims: The authors claim that ATAC-seq data in BMDMs stimulated with IFNβ or IFNγ for a short (1.5 hours) or long (48 hours) period reveals a striking similarity between transcription and the general trends of chromatin accessibility at regions up to 1000 bp upstream of the TSS (Fig. 2a), suggesting continuous chromatin remodeling during the transcriptional response. However, I would like to know if this conclusion is well-supported by the correlation between the chromatin accessibility from ATAC-seq data from only one sample and the PRO-seq data. The need for additional experiments to verify claims such as the dependence of Ifi44 on IRF1 for gaining ATAC signal, as stated in the claim, "Expression required IRF1 for both, but accessibility of the Ifi44 regulatory region depended upon IRF1 whereas that of Gbp2 acquired an open structure independently of IRF1 (Fig. 5c)."
- In the figure legends, there is missing information about the number of times experiments were replicated, suggesting that some were done a single time. Moreover, some graphs are missing statistical analysis, e.g., in Fig S3cS3e, S3f, the ChIP-qPCR experiments were done on biological triplicates, there is no mention of statistical test performed, it is not mentioned what the error bars represents (SD, SEM, etc.) and the variance is large, but the authors still interpret these results as significant enrichment of the transcription factors to the Mx2 promoter. Another example are the RNA Pol II pausing index ratios, which show minor variations and not are supported by statistics to support a possible significance. Proper description, replication and statistical analyses of the results are critical.
- The authors used CRISPR-Cas9 genome editing to generate knockout cell lines. However, they did not verify the knockouts at the protein level. Further experiments could confirm that the targeted proteins are not expressed in the knockout cell lines.
- On p.9, it is mentioned "IRF1 affects chromatin structure ...". Here chromatin structure is related to minor changes in chromatin accessibility, this can not be qualified as changes in chromatin structure.
- The authors have not adequately addressed the methodological limitations in their discussion, which extends beyond the aforementioned comments. It is suggested they include a comprehensive discussion of the claims made pertaining to the necessity of IRF1 for accessibility and the potential biases in the interactomes, along with their associated consequences.
- Although the TurboID experiments identify known STAT1 and IRF1 interactors, the proposed new interactors are numerous and none are validate through independent co-IP experiments. Moreover, the results are very noisy, with little differences between untreated BMDMs (where IRF1 is barely expressed) and IFN-treated conditions.
- The work should be discussed in the context of the demonstrated physiopathological evidence of the IRF1 and IRF9 functions. IRF9 (Hernandez et al., JEM 2018) and more recently IRF1 (Rosain et al Cell, 2023) were identified as causing non overlapping phenotypes in human patients carrying loss-of-function mutations for these genes. The authors must interpret their results in this context.
Minor comments:
- In most graphs the expression values or log2FC are shown separately for IFNb and IFNg, however in the heatmaps (Fig 1d, S1d) the IFNb and IFNg results are intercalated keeping them side-by-side for each time point, which makes them more difficult to interpret. Suggestion to show the IFNb data first and followed by the IFNg results.
- Fig 1e. The color scales on the GO enrichment graphs are misleading since they use the same blue-to-red gradient for adj p-values ranging from 10-25 to 10-49 and 0.008 to 0.016, which could be considered non significant.
- The inconsistency in the title referring to IFNb as Type 1 but using IFNg instead of Type 2 nomenclature, perhaps consistency is best.
- The incomplete schema in Figure 1a, which only focuses on PRO-seq and does not include the ATAC-seq element.
- Figure 6d includes a color scale of -1 to +3, but it is unclear what these values represent and how they were calculated per interactor. The figure legend should be revised to clarify this information.
- The clearer labeling of Figure 5a and 5b.
- The statement that "IFN-I are the more important mediators of antiviral immunity" is not entirely accurate and may be an oversimplification, as there are certainly articles which suggest a larger role for type ll IFN elements than type l (ref: Yamane D et al., 2019 Nature microbiology). While yes, IFN-I plays a critical role in the innate immune response to viral infections, IFNγ also has antiviral activity and is involved in the adaptive immune response to viral infections, and in some instances to a larger extent than IFN l.
- The authors claim that a significant portion of ISG promoters is associated with ISGF3 upon IFNγ receptor engagement and that the transcriptomes of macrophages treated briefly with IFNβ or IFNγ exhibit remarkable similarity and sensitivity to Irf9 deletion. However, I am uncertain about the extent of consensus on this claim.
- Fig 1e, S1c. Graphs having circles of varying sizes in function of a value are named "bubble plots" and not "dot plots".
- Fig S1b, S3b. The PRO-seq was generated in triplicates, hence these graphs should include the Log2FC for the individual data points.
- Fig S3c legend. It is mentioned "Graph represents RT-qPCR of genomic Mx2". RT-qPCR usually stands for reverse transcription quantitative PCR, hence we suggest to change to "ChIP-qPCR" or qPCR. Confusingly, in the literature the term "RT-PCR" is used for real-time PCR and "qPCR" for quantitative PCR. Also, the authors should be specific about the "genomic" region targeted; the graphs mention "promoter", hence it would be appropriate to use the same designation in the legend.
- Fig S3e. The y-axis names are missing.
- In the genomic snapshot shown, only bars or fading triangles are shown in place of the gene body. The authors should provide an accurate gene structure; i.e., exons and introns.
- Raw cells are sometimes spelled as "Raw" and other times as "RAW". Please choose one for consistency.
- In p.10 l.20, the figure number is missing.
Significance
Nature and significance of the advance:
The paper presents an investigation of the transcriptional response to IFNβ and IFNγ in mouse bone marrow-derived macrophages and identifies key factors controlling the dynamics of interferon-stimulated gene (ISG) expression. The study employs cutting-edge technologies such as PRO-seq and ATAC-seq to assess transcriptional and chromatin accessibility changes, respectively. The results can potentially provide new insights into the transcriptional regulation of ISGs and the factors controlling their expression, which have significant implications for understanding the immune response to viral infection and cancer. Overall, the work could represent a conceptual advance in the field of immunology and epigenetics surrounding the transcriptional regulation of IFN, but validations and further mechanistic results are required.
Contextualization of the work:
The study builds on previous research on the transcriptional response to interferons but provides a more detailed and comprehensive investigation of the underlying mechanisms. Some of the key references that the authors build on include studies on the role of IRF9 in interferon signaling, the regulation of chromatin accessibility during immune activation, and the characterization of interferon-stimulated gene expression. However, the current study goes beyond these previous studies by integrating multiple approaches to examine the transcriptional and epigenetic changes that occur during interferon signaling of two types, I and II.
Audience and potential impact:
The findings of the study are likely to be of interest to a wide range of researchers in the fields of immunology, molecular biology, and epigenetics, as well as those interested in the transcriptional regulation. The study may also be of interest to clinical researchers investigating the use of interferons as therapies for viral infections and cancer. The identification of factors controlling ISG expression may have implications for the development of new interferon-based therapies, as well as for understanding the mechanisms of resistance to interferon treatment in patients.
Field of expertise:
Overall, the study is contributing to our understanding of the differiential transcriptional response to interferons and the factors controlling ISG expression. Upon provide further mechanistic demonstrations and validations, the work could have significant implications for both basic and clinical research.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
- This interesting study addresses underlying molecular mechanisms that distinguish transcriptomes induced by type I and II IFNs. It is widely accepted that they induce distinct and overlapping genes. The IFN field has shown that type I IFNs can induce both ISGF3 (STAT1/STAT1/IRF9) and GAS (STAT1/STAT1) activation, while type II IFNs only induce GAS elements. The current study adds to some of these observations, including the cooperation of ISGF3 and IRF1 at later time points. They show that ISGF3 and IRF1 can affect enhancers and modify chromatin accessibility. While some of these observations are incremental, this study would significantly interest the interferon community.
- Biological significance is limited as this study is largely descriptive and they do not test the hits obtained from BioID.
- The sequencing and BioID data are not submitted to public databases.
Significance
This interesting study addresses underlying molecular mechanisms that distinguish transcriptomes induced by type I and II IFNs. It is widely accepted that they induce distinct and overlapping genes. The IFN field has shown that type I IFNs can induce both ISGF3 (STAT1/STAT1/IRF9) and GAS (STAT1/STAT1) activation, while type II IFNs only induce GAS elements. The current study adds to some of these observations, including the cooperation of ISGF3 and IRF1 at later time points. They show that ISGF3 and IRF1 can affect enhancers and modify chromatin accessibility. While some of these observations are incremental, this study would significantly interest the interferon community.
While this reviewer does not suggest additional experimentation, this manuscript would be suitable as a resource paper.
My expertise is in innate immunity.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
The authors examine the differences between the genes induced by type I IFNs and IFNg by examining nascent transcripts over a prolonged period of time. The overall question being asked is very broad and the authors generate a massive amount of data that is hard to understand and interpret. The authors also fail to take into consideration the secondary genes induced by products of primary genes. For example, IFNb will induce other type I IFNs that will act in cis or trans to induce secondary ISGs. Also, it is not clear what effect cell death has on gene expression especially at later time points. The differential roles of ISFG3 (IRF9) and IRF1 are interesting but the biological meaning or outcomes of differences in gene expression at 24 and 48 hours is not entirely clear to this reviewer.
Major Issues:
- Figure 2. Difficult to interpret data as it is presented. Consider quantifying figure 2C in order to make "changes in Pol II pausing were more pronounced during IFNb signaling" statement more apparent.
- How are you distinguishing autocrine signaling in the BMDMs driven by IFN treatment from late transcripts (for example, at 48 hours are differential genes due to autocrine cytokine signaling or are they truly late transcripts)?
- Figure 3D. Authors choose Gbp2 (as positive control for IFNg driven gene), but don't show that Gbp2 is a IFNb independent gene. Consider using IRF1 KO BMDMs in this data as well.
Minor Issues:
- Simplify figure 4B- consider focusing on most differentially expressed genes between clusters
- Define known IFNg and IFNb driven genes when they are introduced in figure 2 rather than in discussion
- Clarify which cell types (IRF1 KO vs IRF9 KO) are used in figure 5 A/B.
- Unclear whether IRF1 expression in figure 3A is from whole cell lysate or nuclear fraction.
- Authors suggest IFNb treatment induces less IRF1 at later time points, however loading control also seems slightly lower than other considerations. Is it possible that IFNb treated cells are dying at later time points, given that type I IFN signaling can be pro-apoptotic.
Significance
I accepted the request to review the paper based on the abstract and the idea that this was mechanistic investigation of the role of ISGF3 and IRF1 in regulation of genes induced by type I IFN and IFNg. However, after thorough reading of the paper, I feel that I am not aptly qualified to evaluate all aspects of the manuscript. Many of the data are bioinformatic analysis and I do not have sufficient expertise to either understand the analysis or offer my interpretation of the conclusions drawn by the authors. I suggest that the best path forward is to find another suitable reviewer.. Hopefully, other reviewers have already offered you their suggestions to make an informed decision.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
1. General Statements
We would like to thank the reviewers for their careful reading of our manuscript and constructive comments.
2. Description of the planned revisions
Reviewer 1) “Indeed, the manuscript describe the alteration of total brain O-GlcNAc levels, but understanding pathways or protein specific changes would allow to identify the mechanisms potentially at the basis of the development of intellectual disability.”
Response: While finding the pathways involved in phenotypes described here is beyond the scope of the present manuscript, we plan to include RNAi experiments elucidating cell types responsible for the sleep phenotype observed in sxc mutant flies.
Reviewer 3) “2) Lacing fly food with compounds can sometimes lead to phenotypes not actually caused by the drug. There are reports I have previously seen where the compound can make the food more aversive or attractive, both leading to results not due to the drug. Specifically, it has been previously reported that starved flies (if the compound leads to aversion from the food and causes starvation) will reduce the bouts of sleep in Drosophila ( Masek et al J Exp Biol 2014; Figure 4). Do the authors know if the TMG treated food eaten at the same level as normal food? Is there the potential for a starvation phenotype?”
Response: We appreciate this insight and we plan to perform this control experiment. Briefly, this will entail measuring male adult ingestion of Thiamet G laced food by adding Blue No. 1 dye and measuring absorbance of lysed flies, as previously described in Wong et al. 2009 (PMID: 19557170).
3. Description of the revisions that have already been incorporated in the transferred manuscript
Reviewer 1) “In figure 1C the blot show a different MW range compared to blots 1A and 1B, author should correct. “ and “For figure 1 and 2 the dot graph are too small and difficult to read”
Response: The figures have been amended to address this.
Reviewer 3) “In the methods - Neuromuscular Junction Immunohistochemistry - which muscles and which types of boutons were imaged was not denoted in this section - it is described in results (lines 210-211) but should be in methods for ease to the reader.”
Response: The methods section has been amended.
“The statistics and data analyses are some of the best I have seen to date. One concern is the removal of a single outlier data point described at line 575. Was this necessary? Does it change the data? If not, I would recommend leaving it in. If it does, I would further recommend additionally biasing toward the alternative hypothesis by additionally removing the data point that lies furthest from the outlier. This would reduce bias.”
Response: Removal of an outlier does indeed change the results of the data. Following the suggestions of the reviewer, we re-analyzed our data removing the minimum for the group for which we previously removed an outlier (the maximum).
“1) line 391 mentions that feeding higher doses of TMG results in a non-rescue phenotype. Is there any data to support this statement (maybe supplementally) to give the reader the full picture of the availability of this compound? For example, how far above 250 uM does this happen?”
Response: This statement refers to adult Thiamet G feeding experiments, and the data to support this statement can be found in figures 2B and S2A. This statement has been amended for clarity and to include the caveat that even higher doses of TMG were not trialed.
4. Description of analyses that authors prefer not to carry out
Reviewer 1) “Authors employed RL2 antibody for O-GlcNac detection, however it recognized mainly high MW proteins and it would be nice to obtain the alteration profile of low MW proteins at the same conditions.”
Response: We agree that the use of a single method for detecting O-GlcNAcylation is limited, however, there is no reason to believe that immunoblotting using this antibody would bias the interpretation of the effects of mutations studied here on global O-GlcNAcylation. Specifically, there is no reason to believe low molecular weight proteins are recognized and modified by OGT differently to high molecular weight proteins. While gaining insight into substrate specific alterations in O-GlcNAcylation is of great interest to us, this is technically very challenging and beyond the scope of this study.
Reviewer 2) “… would it be possible for the authors to overexpress specifically in neurons wildtype OGT postnatally on a mutant background and quantify the effects on neuro-muscular synapse number and morphology? It would be interesting to compare these data with a similar experiment where they overexpress wildtype OGT in the corresponding muscle.”
Response: While temporal control of transgene expression is possible in Drosophila, it is not a technique that we routinely use and would require extensive optimization to include in the present manuscript.
_Reviewer 3) “In Figure 3D the authors show sxcWT compared with OgaKO with no significant difference at ~20 boutons in the count. Other work done by [47] in their reference list (ref 47: Figure 2D) shows an increase in OgaKO boutons vs WT and also shown in [50] (ref 50; Figure 4B) where # of boutons in 1B muscle 4 is increased in OgaKO significantly. There appears to be a difference in what was found with OgaKO vs controls in the authors' results vs these two manuscripts and it should be noted and explained to the reader.” _
Response: This is indeed an inconsistency we have observed, however, looking at reference Fenckova et al. 2022 (47 in our manuscript) we find that in figure legend 2 the following is stated: “None of the parameters is significantly affected in the OgaKO larvae (N = 30, in purple; OgaKO experiments were performed simultaneously and first published here [53] with significantly increased bouton counts (p <0.05) without multiple testing correction)” Reference [53] in the quote refers to Muha et al. 2020 (reference 50 in our manuscript). Therefore, it appears that this effect is too weak to withstand multiple correction testing, which we employ in our analysis.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
The manuscript written by Czajewski et al. "Rescuable sleep and synaptogenesis phenotypes in a Drosophila model of O-GlcNAc transferase intellectual disability" is a novel approach to examining genetic missense mutations representing a patient derived OGT mutation in quantifiable phenotypes coupled with genetic and pharmacological manipulation. The authors find novel contradictory results in synaptic bouton parameters than previous work leading to increased interest in these results. The authors also use pharmacological intervention to reverse the phenotypes derived from the OGT mutations creating an interesting path forward for these types of studies. The manuscript was well written, the experiments are sounds, and the analyses are extremely well done. The manuscript would benefit from addressing a few concerns:
Minor:
In the methods - Neuromuscular Junction Immunohistochemistry - which muscles and which types of boutons were imaged was not denoted in this section - it is described in results (lines 210-211) but should be in methods for ease to the reader.
The statistics and data analyses are some of the best I have seen to date. One concern is the removal of a single outlier data point described at line 575. Was this necessary? Does it change the data? If not, I would recommend leaving it in. If it does, I would further recommend additionally biasing toward the alternative hypothesis by additionally removing the data point that lies furthest from the outlier. This would reduce bias.
Major:
In Figure 3D the authors show sxcWT compared with OgaKO with no significant difference at ~20 boutons in the count. Other work done by [47] in their reference list (ref 47: Figure 2D) shows an increase in OgaKO boutons vs WT and also shown in [50] (ref 50; Figure 4B) where # of boutons in 1B muscle 4 is increased in OgaKO significantly. There appears to be a difference in what was found with OgaKO vs controls in the authors' results vs these two manuscripts and it should be noted and explained to the reader.
The results working with Thiamet G (TMG) is very interesting and needs a bit more clarification. I tried to find other research where TMG is fed to Drosophila, and could not find this, and I suspect this is novel and very interesting, especially as a tool. However, I do have concerns about the details for this feeding and would like to further understand a few things that came up in the manuscript that need to be addressed:
- line 391 mentions that feeding higher doses of TMG results in a non-rescue phenotype. Is there any data to support this statement (maybe supplementally) to give the reader the full picture of the availability of this compound? For example, how far above 250 uM does this happen?
- Lacing fly food with compounds can sometimes lead to phenotypes not actually caused by the drug. There are reports I have previously seen where the compound can make the food more aversive or attractive, both leading to results not due to the drug. Specifically, it has been previously reported that starved flies (if the compound leads to aversion from the food and causes starvation) will reduce the bouts of sleep in Drosophila ( Masek et al J Exp Biol 2014; Figure 4). Do the authors know if the TMG treated food eaten at the same level as normal food? Is there the potential for a starvation phenotype?
Significance
There is a novel technique in this manuscript that could enhance OGT research in Drosophila, which is significant.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
The authors of this manuscript describe the effect on neuronal development and function in drosophila of OGT mutations derived from patients with intellectual disability. OGT is an enzyme that adds the posttranslational modification O-GlcNAc to proteins. Once added, O-GlcNAc can be removed by the enzyme OGA. O-GlcNAc cycling on and off proteins has been associated not only with intellectual disability but a range of other brain-dependent disorders. However, molecular mechanisms by which O-GlcNAc cycling may affect brain development and function are largely unclear. It is equally unclear whether and how disorders associated with OGT mutations may be treated. This manuscript presents evidence that it is possible to rescue neurological phenotypes dependent on patient-derived OGT mutations using genetic or pharmacological manipulations of OGA. These results strongly suggest that at least some aspects of the phenotype of patient-derived OGT mutations depend on O-GlcNAc cycling rather than other mechanisms. Excitingly, they also suggest that it may be possible to treat patients suffering from OGT mutations with drugs that target OGA after the baby has been born. This last point is critical not only for the field of OGT-associated disorders but for the whole field of intellectual disability.
Minor comment:
While the manuscript delivers its message clearly with a simple and concise language, the manuscript would become even stronger if the observation that some aspects of intellectual disability can be treated postnatally is substantiated with additional methods that are more specific. The current data are also somewhat difficult to interpret because the pharmacological and genetic manipulations of OGA used so far may not be a direct rescue of the OGT mutations, which the authors also point out. For example, would it be possible for the authors to overexpress specifically in neurons wildtype OGT postnatally on a mutant background and quantify the effects on neuro-muscular synapse number and morphology? It would be interesting to compare these data with a similar experiment where they overexpress wildtype OGT in the corresponding muscle. These experiments would both strengthen their finding that it is possible to rescue neurodevelopmental conditions postnatally and give further evidence to the molecular mechanism by which OGT affects neurodevelopment.
Significance
In summary, while it is a short manuscript and on a topic studied previously, its data are novel, clearly presented and would appeal to researchers within and outside the field of O-GlcNAc. It is ready for publication as it has been submitted but including more experiments along the lines suggested above would help it reach one level higher.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
The manuscript from Czajewski and colleagues demonstrates that patients-derived OGT mutation can lead to reduced O-GlcNAc levels, which can be rescued by genetic OGA ablation or pharmacological OGA inhibition. Several studies in the last decade demonstrated that O-GlcNac homeostasis is crucial for brain development and function and that its alteration is deeply involved in neurodegeneration and cognitive decline. Therefore rescuing protein O-GlcNAcylation by targeting OGT/OGA cycling could represent a valuable therapeutic approach for intellectual disability. Results obtained by the authors are very promising and support the notion of a mutual interplay between OGT and OGA in regulating brain O-GlcNAc levels. Furthermore, the partial rescue of synaptogenesis and sleep stability support the efficacy of OGA reduction in rescuing O-GlcNAc levels.<br /> I do not find Major flaws in the manuscript structure or in the experimental approach, however I believe that the manuscript would benefit of the analysis of the molecular target that lead to brain defects under OGT mutation and that are rescued after OGA inhibition. Indeed, the manuscript describe the alteration of total brain O-GlcNAc levels, but understanding pathways or protein specific changes would allow to identify the mechanisms potentially at the basis of the development of intellectual disability . Furthermore, it would be also interesting to understand if the mutation of OGT has direct or indirect effects on Ser/Thr phosphorylation levels.
Minor comments:
Authors employed RL2 antibody for O-GlcNac detection, however it recognized mainly high MW proteins and it would be nice to obtain the alteration profile of low MW proteins at the same conditions.
In figure 1C the blot show a different MW range compared to blots 1A and 1B, author should correct.
For figure 1 and 2 the dot graph are too small and difficult to read
Significance
General assessment: I believe that the study is well executed and interesting since it nicely demonstrate the influence of OGT mutation on O-GlcNAc levels and the efficacy of OGA reduction in rescuing the process and in improving synaptogenesis and sleep stability. However, I also believe that a better understanding of the molecular mechanisms involved could substantially improve the study.
Advance: the present study provide further knowledge about the physio/pathological role of OGT/OGA cycling in the brain.
Audience: basic researchers
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
1. General Statements [optional]
Here we describe the experiments that will be performed as specifically requested by the reviewers to strengthen the main conclusions of the manuscript, and we also justify the utilization of a specific shRNA for KIS knockdown.
2. Description of the planned revisions
Reviewer 1
-
- Building on the experiments they perform in a KIS knock-down context (e.g. Fig. 3B, or previously described spine phenotype), the authors should investigate whether inhibiting PTBP2 in this context (through shRNA or expression of a phospho-mimetic construct) might suppress the phenotypes observed when inactivating KIS.*
We will use shRNAs against PTBP2 to test the functional interactions with KIS on CamK2b splicing as in Fig. 3B and we will also assess possible effects on spine morphogenesis. Since it does not show dominant negative effects, the phosphomimetic mutant of PTBP2 will not be included in these experiments.
- Based on Figures 1E and 3A, it seems that KIS downregulation affects both exon inclusion and exon skipping, and that its function in exon usage is only partly explained by modulation of PTBP2-dependent exons. Have the authors analyzed the populations of PTBP2-dependent exons that are regulated by KIS in an opposite manner? This may point to specific classes of transcripts (in terms of expression pattern, function, molecular signature) important in the context of endogenous neuronal differentiation.*
We will extend our analysis to exons that are regulated by KIS and PTBP2 in the same direction. We fully agree with the reviewer that these data may uncover gene sets with specific functional implications different from those in which KIS and PTBP2 counteract each other.
Reviewer 2
-
- FigEV4 (also introductory text on p3): RRMs 3 and 4 of PTBP1/2/3 fold as a single back to back packed didomain - with the so-called linker contributing to the didomain fold (e.g. PMID: 24688880, PMID: 16179478) and also extending the RNA binding surface by creating a positive patch (e.g. PMID:20160105 PMID: 24957602). AlphaFold successfully predicts the didomain in full length PTBP2 (https://alphafold.ebi.ac.uk/entry/A0A7I2RVZ4). The authors should therefore use AlphaFold2 to predict the RRM3-4 di-domain structure of wt and phosphomimetic mutant PTBP2s. Phosphorylation of S434 or S434D, which is on the C-terminal end of RRM3 may have no predicted effect on RRM3 alone (FigEV4), but it could conceivably disrupt didomain packing, which could itself have important knock-on consequences for RNA binding. In addition, the introduction of negative charges at S434 might affect the ability of R438, K440 & K441 to interact with RNA. An image of the didomain charge density of WT and mutant PTBP2 would be useful to address this.*
As suggested by the reviewer, we have considered the di-domain structure of RRM3 and RRM4, and AlphaFold2 predicted no effects by the phosphomimetic residues. We will add these data to the revised version of the manuscript.
- Figure 4 could also easily go further in experimentally testing the effects of individual phosphomimetic mutations upon protein-protein interactions (Alphafold predicts that S178D, but not S308 or S434D, should affect Y244 mediated interactions, such as MATR3). The co-IP approach in Fig 4A could readily be used with FLAG-PTBP2 mutants. Likewise, consequences of individual mutations upon RNA binding (Fig 4D) could be tested. The use of a Y244N mutant here would test whether the loss of RNA binding is a consequence of the loss of protein-protein interactions. Such experiments are not essential, but they are readily carried out and have the potential to unravel the consequences of the individual phosphorylation events (more correctly of phosphomimetic mutants).*
Extending the analysis to this residue will be a very interesting contribution to the article. After building the Y244N mutant we will test PTBP2 interactions with protein partners and the splicing reporter RNA as in Fig. 4A-D.
Reviewer 3
- Part of the reported splicing changes might reflect an indirect consequence of an altered differentiation contributing to the correlation observed in figure 1F. It would be interesting to confirm splicing changes using shorter incubation times with the shRNA compared to the 11 days used in this study.*
The levels of splicing regulators such as PTBP1 and PTBP2 change quite markedly during the initial phases of neuronal differentiation (Zheng et al 2012). However, we observed no change in their levels when comparing KIS knockdown to control conditions, suggesting no major upstream effects on the differentiation program per se. In any event, we will analyse expression levels of transcription factors key to neuronal differentiation.
- Previous papers of the group described a function of KIS in translation (Cambray et al 2009, Pedraza et al 2014). This is not discussed here. For example, the possibility that RBPs are regulated by KIS at the translation level is not excluded by the analysis in Fig EV2a.*
In our experiments coexpressing KIS with splicing factors in HEK293 cells (Fig. 4A) we did not observe any reduction in their levels. We will include the corresponding immunoblots from input samples in the revised version of the paper. We will also measure PTBP2, Matrin3 and hnRNPM levels by immunoblots in KIS-knockdown cortical neurons to test this possibility further.
3. Description of the revisions that have already been incorporated in the transferred manuscript
(None at this stage)
4. Description of analyses that authors prefer not to carry out
Reviewer 3
-
- To minimize possible off target problems, the RNAseq analysis would be more convincing if replicated with a second shRNA to knockdown KIS.*
The efficiency of the selected shRNA had been validated both by the supplier (Sigma) and in our previous work, which also included a complementation assay (see Fig. 4 in Pedraza et al 2014).
-
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
In this manuscript, the authors explored the function of the protein kinase KIS in splicing regulation associated with neuronal differentiation in vitro. KIS is a serine threonine kinase known to phoshorylate splicing factors such as SF1 and SUGP1, and to be preferentially expressed in adult brain in mammals. Using an shRNA based approach, the authors characterize cassette exon usage upon partial KIS depletion in cultured mouse cortical neurons. In parallel using mass spectrometry of proteins in KIS overexpressing HEK293 cells, they identify potential KIS substrates including the splicing regulator PTBP2. They confirm that recombinant KIS can phosphorylates PTBP2 in vitro. They show a correlation between KIS-activated and PTBP2-inhibited exons using published data for this factor. They report opposite effects of KIS and PTBP2 on CamKIIB splicing and Finally, coimmunoprecipitation and FRET experiments suggest that KIS inhibits the interactions of PTBP2 with known protein binders, hnRNPM and Matrin3 as well as with RNA. Altogether these data suggest that KIS downregulates PTBP2 during neuronal differentiation.
Major comments:
Overall the manuscript is well written and the data are interesting. However several points could have been more extensivelly studied or discussed to achieve a stronger demonstration of the role of KIS in PTBP2 phosphorylation and neuronal differentiation.
- To minimize possible off target problems, the RNAseq analysis would be more convincing if replicated with a second shRNA to knockdown KIS.
- Part of the reported splicing changes might reflect an indirect consequence of an altered differentiation contributing to the correlation observed in figure 1F. It would be interesting to confirm splicing changes using shorter incubation times with the shRNA compared to the 11 days used in this study.
- Standard deviation is more relevant to describe data dispersion in all figures.
- Previous papers of the group described a function of KIS in translation (Cambray et al 2009, Pedraza et al 2014). This is not discussed here. For example, the possibility that RBPs are regulated by KIS at the translation level is not excluded by the analysis in Fig EV2a.
Minor comments:
Figure 1:
The authors state that : "KIS...accumulates in nuclear sub-structures adjacent to those formed by splicing factors". As the figure presents in fact GFP-KIS, it should be mentioned, and how this localisation is relevant for endogenous KIS should be adressed.
Fig EV1: SI range in pannel D is very different from that in pannel C and Fig1E.
On page 4 "KIS expression reached maximal levels in hippocampal cultures (Fig 1B)." However the figure legend indicate that this analysis was performed with cortical neurons. The use of cortical or hippocampal neurons along the manuscript should be clarified.
page 4 " KISK54A, a point mutant without kinase activity" The authors should indicate the reference.
Figure EV2C: It is not clear whether the Coomassie staining and autoradiography do correspond to the same gel.
Figure 3C The authors use a dual fluorescence reporter to analyse PSD95 exon 18 splicing. However the well to well variability in such experiments might be elevated. Not only the cells number in a single well but also the number of replicates should be indicated and well to well variability reported.
Figure 3D. The precise timing for the transfection and culture of cells before staining is unclear
Figure 4A. The input should be loaded to evaluate the coIP efficiencies and ascertain that KIS does not downregulate Matrin3 and hnRNPM levels.
Figure EV4A. No difference of Matrin3 binding is to be seen on the gel. In addition, the authors should confirm that PTBP2 or binders are phosphorylated by recombinant KIS. The preparation of GST-KIS is not described. Page 6: "We found that PTBP2-inhibited exons are significantly (FDR=0.001) enriched in KIS knockdown neurons, supporting the notion that KIS acts on AS, at least in part, by inhibiting PTBP2 activity." This should be rephrased as in fact PTBP2-inhibited exons are enriched among KIS activated exons. Page 10: "SUGP1 is one of the most enriched proteins in our KIS phosphoproteome (see Fig 2A)". Phosphorylation and interaction with KIS was already reported by Arfelli and coll. 2023 supplementary figure 2.
" It forms part of the spliceosome complex, interacts with the general splicing factor U2AF2 and has been reported to play an important role in branch recognition by its association with SF3B1." A reference is needed there.
The authors previously reported a differentiation defect in cultured neurons 'Cambray et al, 2008' that was not observed by another group (Manceau et al., PLOS One 2012). This should be discussed in view of these more recent results. Is there any differentiation defect in the experiments reported there?
Statistical values are difficult to read in the figures. Please use larger fonts.
Significance
This manuscript brings new elements supporting the function of the protein kinase KIS in splicing regulation in neurons. In particular it identifies for the first time the splicing regulator PTBP2 as a substrate for KIS.
It will be of interest to a specialized audience of researchers interested in splicing regulators in neuronal differentiation.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary
The manuscript by Moerno-Aguilera et al. shows that the brain enriched protein kinase KIS targets the well known neuronal splicing regulator PTBP2 and several of its interaction partners. As a consequence, PTBP2 activity is down-regulated. Using cultured primary immature neurons they show that KIS expression increases during differentiation and that shRNA knockdown of KIS alters the splicing of many alternative exons. Phosphoproteomic anlaysis of HEK293 cells transfected with KIS or a kinase dead mutant (K545A) show that it phosphoryates both PTBP2 as well as a cluster of proteins that are known to interact with PTBP2 or its paralog PTBP1. By comparing the new data on KIS-dependent splicing with previous data-sets on PTBP2-dependent splicing targets they show that KIS appears to act antagoniostically with PTBP2 when it acts as a repressive regulator, but not when it is an activator. Using combinations of wt and kinase-dead KIS with PTBP2 mutants in the 3 main phsophorylation sites (3SA - non-phosphorylatable, S3D - phosphomimetic) to look at the effects on a known PTBP2 functional target, PSD95, they show that the likely effect of KIS is to antagonise PTBP2 function by phosphorylation at one or more of three residues (S178, S308, S434). Finally, they show that transfected KIS (but not K54A) reduces known protein-protein interactions of PTBP2 and that the triple phosphomimetic PTBP2 mutant shows reduced binding to RNA. Alphafold2 predictions show that the S178 phosphomimetic mutant might alter the conformation of the RRM2 domain, in particular altering the environment of Y244, which has been shown in PTBP1 to be critical for interaction with MATR3 and other coregulators.
Major points
In general, the conclusions drawn are consistent with the data. I have a few suggestions where the authors could either extend their findings with a few straightforward additional experiments, or clarify some of the existing data.
FigEV4 (also introductory text on p3): RRMs 3 and 4 of PTBP1/2/3 fold as a single back to back packed didomain - with the so-called linker contributing to the didomain fold (e.g. PMID: 24688880, PMID: 16179478) and also extending the RNA binding surface by creating a positive patch (e.g. PMID:20160105 PMID: 24957602). AlphaFold successfully predicts the didomain in full length PTBP2 (https://alphafold.ebi.ac.uk/entry/A0A7I2RVZ4). The authors should therefore use AlphaFold2 to predict the RRM3-4 di-domain structure of wt and phosphomimetic mutant PTBP2s. Phosphorylation of S434 or S434D, which is on the C-terminal end of RRM3 may have no predicted effect on RRM3 alone (FigEV4), but it could conceivably disrupt didomain packing, which could itself have important knock-on consequences for RNA binding. In addition, the inrtoduction of negative charges at S434 might affect the ability of R438, K440 & K441 to interact with RNA. An image of the didomain charge density of WT and mutant PTBP2 would be useful to address this.
Figure 4 could also easily go further in experimentally testing the effects of individual phosphomimetic mutations upon protein-protein interactions (Alphafold predicts that S178D, but not S308 or S434D, should affect Y244 mediated interactions, such as MATR3). The co-IP approach in Fig 4A could readily be used with FLAG-PTBP2 mutants. Likewise, consequences of individual mutations upon RNA binding (Fig 4D) could be tested. The use of a Y244N mutant here would test whether the loss of RNA binding is a consequence of the loss of protein-protein interactions. Such experiments are not essential, but they are readily carried out and have the potential to unravel the consequences of the individual phorphoryation events (more correctly of phosphomimetic mutants).
Minor
Do KIS regulated exons show enrichment of motifs associated with PTBP2, consistent with the proposed model - particularly CU-rich motifs upstream of exons that are more repressed upon KIS shRNA treatment.
For the splicing analysis pipeline, how were exon-exon junction reads treated? If "only exons with more than 5 reads in all samples" were considered, will this not exclude highly regulated exons that are completely skipped under one condition?
The Introduction mentions U2AF homology (UHM) domains, but neglects to discuss their known binding partners - ULMs (UHM ligand motifs), which contain an essential tryptophan. It would be useful for the discussion to highlight whether any direct KIS interactors possess ULMs and how this relates to the phospho-targets identified here. The authors may wish to draw the parallel with the structurally analagous way that PTBP1 (and presumably PTBP2) interact with their short peptide ligand motifs.
Figure EV2C. The S3A and S308A mutations clearly reduce phosphorylation. However, the effects of S178A and S434A are far less clear. Presumably the quantitation shown in the lower panel of EV2C relies on normalization to PTBP2 protein input, which appears quite variable in the Coomassie gel. It might be better to repeat the experiment with uniform protein inputs. Minimally, details of the quantitation approach should be added to Materials and Methods.
Fig 3D shows PTBP2 overexpression, but the main text (p7) states KIS overexpression.
Fig 4B should have a scale bar for the FRET signal
Fig 4E should indicate the location of S178
Significance
This interesting, clear and concise manuscript provides important new insights into the way that a neuron specific kinase can regulate neuronal splicing networks by phosphorylating and thereby downregulating the known neuronal splicing regulator PTBP2. Alternative splicing is known to play a particularly important role in neurons, so this demonstration of an additional layer of regulation by post-translational modification should make the manuscript of wide interest to investigators of splicing regulation, neuronal differentiation and maturation.
Issues that are not addressed in the manuscript include; i) how does KIS specifically target PTBP2 and related proteins? The UHM domain can mediate interaction with ULM containing splicing factors (such as U2AF2, SF3B1), but none of the identified targets have known ULMs. ii) the consequences of individual phoshomimetic mutants upon protein-protein interactions and RNA binding could readily be explored further using computational and experimental methods already used in the manuscript.
For context, this reviewer has a direct interest in the mechanisms of regulation of alternative splicing, but not in the context of neurons (though I am familiar with a lot of the relevant literature), and I do not have expertise in neuronal cell biology.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary
In this manuscript, the authors characterized the molecular function of the brain-enriched kinase KIS by combining transcriptome-wide approaches with molecular and functional studies. They uncover that KIS regulates isoform selection of genes involved in neuronal differentiation and inhibits through phosphorylation the capacity of the splicing regulator PTB2 to interact with both target RNAs and protein partners.
Major comments
-
This is a very clear and well-written manuscript presenting high-quality and carefully controlled experimental results. The authors used an impressive range of approaches (transcriptome-wide exon usage, phospho-proteomic, imaging, biochemical assays..) to profile exon usage alterations upon KIS knock down and provide a mechanistic understanding of how KIS regulate the splicing activity of PTBP2. Specifically, they convincingly demonstrate that the phosphorylation of PTBP2 by KIS leads to both dismantling of PTBP2 protein complexes and impaired RNA binding. My only main concerns relate to the understanding of the biological context in which the mechanism studied may be at play. That KIS can counteract PTB2 activity through direct phosphorylation has been very clearly shown by the authors using overexpression of KIS and /or PTB constructs in different contexts (HEK293T cells, N2A cell line, hippocampal neurons). Whether this occurs endogenously in the context of neuronal differentiation, and how much this contributes to the overall phenotypes induced by KIS inactivation, is less clear. While fully investigating the interplay between KIS and PTB2 in the context of neuronal differentiation is beyond the scope of this study, the three following points could be addressed to provide some evidence in this direction.
-
Building on the experiments they perform in a KIS knock-down context (e.g. Fig. 3B, or previously described spine phenotype), the authors should investigate whether inhibiting PTBP2 in this context (through shRNA or expression of a phospho-mimetic construct) might suppress the phenotypes observed when inactivating KIS.
- Based on Figures 1E and 3A, it seems that KIS downregulation affects both exon inclusion and exon skipping, and that its function in exon usage is only partly explained by modulation of PTBP2-dependent exons. Have the authors analyzed the populations of PTBP2-dependent exons that are regulated by KIS in an opposite manner? This may point to specific classes of transcripts (in terms of expression pattern, function, molecular signature) important in the context of endogenous neuronal differentiation.
- The authors should better discuss when and where they think PTBP2 phosphorylation by KIS might be relevant. Is there evidence that this process (or PTBP2 complex assembly) might be regulated upon differentiation or plasticity?
Minor comments
- Figures and associated legends are overall very clear and well-organized. Addressing the following points would however help improving the clarity of some Figures:
- In Figure 2EV2C legend, the characteristics of the 3SA constructs are not described
- the difference between Figure EV1A and Figure 1H classifications is unclear, nor the interpretation regarding the different GO classes identified
- Whether PTBP2 is endogenously the major target of KIS explaining transcriptome-wide changes in exon selection is a possibility that remains to be demonstrated. Thus, the authors should correct and tune down the following sentences: "KIS phosphorylation counteracts PTBP2 activity and thus alters isoform expression patterns ..." (end of introduction) "PTBP2 being one of the most relevant phosphotargets" (results, end of the second section)
Significance
- The splicing regulator PTBP2 is a known master regulator of neuronal fate whose tightly controlled expression drives the progenitor-to-neuron transition as well as the establishment of neuronal differentiation programs. How this protein is regulated at the post-translational level has so far remains poorly investigated. In this manuscript, the authors provide a thorough mechanistic understanding of how KIS-mediated phosphorylation of PTB2 impacts on its regulation of exon usage. They also provide a transcriptome-wide view on the function of the brain-enriched KIS kinase in exon usage, uncovering its broad functions in alternative splicing. If the physiological context in which KIS-mediated phosphorylation of PTB2 is induced remains to be precisely defined, this work opens interesting new perspectives on regulatory mechanisms at play during neuronal differentiation. Providing extra lines of evidence indicating that KIS acts on neuronal functions through PTBP2 phosphorylation will help further strengthen this aspect.
- This manuscript will be of interest to different large communities interested on one hand on the regulation of gene expression programs underlying neuronal differentiation and on the other hand on the molecular regulation of major complexes involved in alternative splicing and isoform selection. It opens new perspectives related to the spatiotemporal regulation of neuronal isoform selection.
-
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1* (Evidence, reproducibility and clarity (Required)): *
* Srinivasan et al. present a comprehensive study on systematizing the structure-dynamics-function relation of lipid transfer proteins (LTPs), combining extensive molecular simulations and complementary experiments. Indeed, the current state-of-the-art in the field is quite chaotic and fractional, and such systematic studies are necessary to advance our general and conceptual understanding of the mechanisms of action of LTPs. The selected techniques and research strategies are all suitable, their description is sufficient and enables reproducibility; the obtained results are carefully presented and discussed; the conclusions are adequately supported by the data.
Given my primarily computational background, I evaluated mainly the simulation part of the manuscript. Considering experiments, I do not see any significant flows or deficiencies that could diminish the value of the data and following conclusions given in the manuscript. I would even suggest improving the abstract by more explicitly saying that this work includes experimental measurements because it currently reads like purely computational work was performed. *
We thank Reviewer #1 for the positive evaluation of our work. The abstract has now been updated to include that our work allows us to interpret existing data but also to design and perform new experimental measurements.
* Major comments: *
1) Although I like the central message of the paper and have no objections, I am curious whether the conclusion "a more "dynamic" or/and "mobile" part of the protein interacts with the membrane or any other (macro)(bio)molecule" makes sense globally and is not limited to LTPs. For example, it is a reasonable assumption that a more flexible part of the protein, i.e., capable of adopting necessary binding configurations, would be a more likely interacting spot. Locking in a less flexible and more specific configuration upon binding with a target molecule is also anticipated and quite typical, e.g., when ligands interact with target proteins, thereby blocking their function. The authors themselves recognize this paradigm as referring to the enzymes' dynamics. It would be great if authors could comment more on dynamics-function relation, referring to the existing literature, where such observations were/were not observed for different protein families. Performing simulations on proteins that do not exhibit such a feature and do not belong to LTPs, but, e.g., structurally similar to some of the studied LTPs, would be an excellent addition too, highlighting this signature characteristic of LTPs.
We have now added a discussion comparing the mechanism we observe with those described for other proteins such as membrane transporters and receptors. Since those proteins are very different and have been already thoroughly characterized (including with molecular simulations) we don’t think that additional simulations are required. Also, concerning protein binding dynamics, we refer to the excellent review of Wade and coworkers: "Acc. Chem. Res. 2016, 49, 5, 809–815"
"____Notably, the conformational plasticity we observe for LTPs is reminiscent of other, previously described, functional protein mechanisms, including enzyme dynamics during catalysis (____DOI: 10.1126/science.1066176____), the alternating-access model of membrane transporters (____https://doi.org/10.1038/nsmb.3179____) or GPCR dynamics (____https://doi.org/10.1021/acs.chemrev.6b00177____). In all these cases, protein dynamics is strongly coupled to ligand binding (____https://doi.org/10.1021/acs.accounts.5b00516____) and protein function, be it for signaling, transport or enzymatic activity. Unlike for these fields, however, the contribution of structural and spectroscopic studies to uncover LTP dynamics remains quite limited, and our simulations provide an important contribution to fill this gap. We hope that our results will motivate researchers to increase efforts to experimentally quantify LTPs conformational plasticity, e.g. by structural determination of LTPs in different states (or bound to different lipids) or by single-molecule spectroscopy studies."
*Minor comments: *
*
1) Fig 1d. What is so special in Lysine compared to Arginine? Is there any disbalance in their presence in studied proteins? Any correlations between the binding affinity of certain amino acids and their overall presence on the protein surface? *
Indeed, there is disbalance in the presence of lysine and arginine residues in our proteins. The relation between the number of these residues in our dataset is Lys:Arg = 1.6:1. On top of that, and as described in (Tubiana T et al PLoS Comput Biol. 2022 ;18(12):e1010346) lysine is preferred over arginine in peripheral membrane proteins, likely because it induces fewer perturbations in the lipid bilayer. Our data also agree with Tubiana et al, concerning the correlation between abundance of specific residues on the protein surface and membrane binding.
* 2) Fig S1. GM2A and TTPA seem to be irreversibly adsorbed to the membrane on the microsecond timescale in most replicas. Is anything special in these proteins? Did this affect the sampling of a claimed membrane-binding interface?*
Our interpretation of the different adsorption profile of GM2A and TTPA is that these two proteins appear to have higher membrane affinity in our computational assay in comparison with the other proteins in our dataset. However, this has no effect on the membrane-binding interface as the proteins are still able to undergo significant tumbling before binding to the lipid bilayer, as demonstrated by the angle between the two main protein axes and the bilayer normal before membrane binding (Fig. S8 in Supplementary Information).
* 3) A related follow-up question. Multiple replicas were performed to identify the membrane-binding interface. However, if I understand well, the initial orientation of the protein with respect to the membrane was always the same. I found it a pity since performing multiple replicas starting from different initial geometries (e.g., rotating the protein in a somewhat systematic way) would likely result in a more efficient exploration of the conformation space. Can the authors comment on whether this predefined initial configuration could negatively affect the results? Performing a few additional simulations for the most problematic proteins I mentioned earlier (GM2A and TTPA) could be a nice opportunity to apply this strategy. *
In our protocol, all proteins start from the same initial orientation but undergo significant tumbling in solution before interacting with the lipid bilayer, including for the two most extreme cases, GM2A and TTPA (Fig. R1). Hence, we think that there is no bias for what pertains to the final membrane interacting region. We have added the Fig. R1 in Supplementary Information (Fig. S8) and added the following text in the Methods Section:
"____Despite starting from a single orientation, all proteins undergo extensive tumbling before binding to the bilayer, as illustrated by the angle between the two principal protein axes and the membrane normal for the two proteins that display the highest binding propensity, GM2A and TTPA (Fig. S8)."
* 4) How was the volume of the cavity affected by mutations in STARD11 and Mdm12? Do these data somehow correlate with the experimentally observed reduced efficiency of the lipid transfer? *
Our data on the volume of the cavity in STARD11 and Mdm12 are inconclusive. However, we caution from such a simplistic interpretation, since it completely neglects the lipid-bound conformation that normally has a much larger cavity than the apo form (Fig. 3).
*5) I would appreciate it if the authors considered playing with the templates of the main Figures at later stages because in the current version, and when printed on A4 paper, the readability of certain graphs and pictures is uncomfortable and sometimes even impossible. Obviously, the final schematics would depend on the journal and its formatting. *
We will modify the templates of the main Figures to improve readability according to journal formatting.
* **Referees cross-commenting** *
* I would like to acknowledge the thoughtful and detailed reviews provided by other reviewers. I do like their reports, and I believe that by addressing the reviewers' comments and incorporating their revisions, the article will significantly improve in terms of scientific rigor and contribution to the field. *
*Reviewer #1 (Significance (Required)):
This manuscript is a solid scientific work addressing gaps in our knowledge about Lipid Transfer Proteins by employing state-of-the-art methods. It advances the field on conceptual and fundamental levels. This study is of interest to both computational biophysicists and physical chemists (to whom I belong myself) as well as experimentalists, who seek a rational explanation of the experimental observations. *
We thank the reviewer again for the positive evaluation of the significance of our work.
Reviewer #2* (Evidence, reproducibility and clarity (Required)): *
* Summary:
In a combined computational and experimental study, the authors provide insights into general features of lipid transfer proteins (LTPs), which play key roles in lipid trafficking: Through molecular dynamics simulations of a diverse set of 12 shuttle-like LTPs, they demonstrate that LTPs consistently exist in an equilibrium between two or more conformations, whose populations are modulated by a bound lipid, and that residues significantly involved in these collective conformational changes typically interact with a membrane. Their simulations indicate that conformational plasticity is a general feature of LTPs, leading them to suggest that the ability to change conformations is essential for LTP function. They test the generality of this hypothesis through in cellulo assays of two LTPs (STARD11 and Mdm12) that were not originally simulated. While experiments of STARD11 support their hypothesis, those presented for Mdm12 provide ambiguous results. *
*
Major comments: *
* Throughout the manuscript, it's stated that common 'dynamical features' correlate with LTP function. The accuracy of this statement is unclear since 'dynamical features' are never precisely defined and, while equilibrium conformational ensembles are characterized, dynamics (ie kinetics or time-dependent observables) are not. Please clarify.*
We plan to improve the scholarly presentation of our article to clarify this issue. In short, two distinct properties modulate protein function: 1. Conformational plasticity, i.e. the (thermodynamic) ability of the protein to adopt different conformations (and with different populations depending on the bound substrate). 2. Conformational “dynamics”, i.e. the propensity to exchange between these different thermodynamic states. This ability depends on the free energy barriers between different states and it is intrinsically a kinetic (rather than thermodynamic) property.
*More importantly, further evidence is needed to determine a correlation with *function*. LTPs are suggested to have faster transfer rates (a measure of function) if the apo form adopts a substantial population of holo-like conformations, akin to enzyme preorganization. This is further tested by rationally mutating STARD11 and Mdm12. However, the support for this conclusion and if these mutations alter the LTPs conformational ensembles as desired is unclear: *
In our opinion, the interpretation suggested by Reviewer #2 that there is a “correlation” between transfer rates and the overlap of apo-like and holo-like conformations, though fascinating, cannot be derived from the available data at this stage, and we did not mean to imply as such. Rather, lipid transport is a complex phenomenon that involves several steps (membrane binding/unbinding, lipid uptake/release,…). Our simulations indicate that protein conformational plasticity, including potentially the overlap between apo-like and holo-like conformations, also influences lipid transfer rates. We will clarify this aspect in the text.
* Is there a quantitative correlation between the overlap of apo and holo conformational distributions (as could be quantified by KL divergence or Wasserstein distance, for example) and difference in transfer rates as suggested by Fig S6?*
We plan to compute quantitative correlation between apo and holo conformational distribution for Fig.S6 and for mutant simulations (see answer below) but, as discussed above, we are skeptical that we will observe a clear correlation.
* The conclusion and the generality of the findings would be greatly strengthened if a correlation can be shown for other LTPs through additional simulations of mutants whose transfer rates have been previously characterized experimentally in the literature. (For example: Ryan 2007 PMID 17344474, Grabon 2017 PMID 28718450, Iaea 2015 PMID 26168008, among many others)*
We are currently running simulations of several mutants to address this point and provide additional data/context.
* While differences in the apo conformational ensembles of the WT and mutants are observed in Fig S7b and d, if these mutations reduce overlap with holo-like conformations is not determined. Simulations of the WT holo forms are needed to properly test this hypothesis. *
We are currently performing these simulations.
- For Mdm12, mutations are specifically made to "lock the protein in the apo-like state;" however, the mutant adopts conformations distinct from the apo form as show in Fig S7d. How do the authors interpret the results of the cellular assays considering this and could it help explain why the mutant has similar kinetics to WT? What may explain the puzzling results of similar transfer kinetics but differing mitochondrial morphology? *
As discussed above, interpretation of lipid transport rates based exclusively on apo and holo conformational population is premature, as this is a complex mechanism that depends on many variables. For what concerns the experimental results, we think three explanations are possible: 1. Mitochondrial morphology could be more sensitive to small variations in lipid composition than our METALIC assay. 2. Our assay only quantifies transport of unsaturated PC and PE species, and we can’t quantify variations in transport of other lipid species that are likely to also be transported by ERMES, such as PS and PA. 3. According to a recent structural model (Wozny et al, Nature 618, 88–192, 2023), Mdm12 might be part of a tunnel-like LTP complex in which it doesn't establish direct interactions with nearby organellar membranes. As such, its mechanism might be different from the one described here for other shuttle-like lipid transport domains. We will discuss these possibilities in the main text.
- Confounding factors potentially complicate the interpretation of the in cellulo experiments. Simpler in vitro experiments may be better suited to determine if altering LTP's biophysical properties, namely rationally altering the population of apo- vs holo-like configurations, quantitatively affects transport rates as suggested.*
We agree with Reviewer #2 that this information could be useful. However, this is beyond our technical abilities, and it would require lengthy and expensive experiments that are unlikely to be completed within a reasonable time framework for a revision (3 months). We have rather opted to better discuss our model in the context of published in vitro lipid transport experiments.
- The abstract, intro, and title highlight that the manuscript's findings are indicative of and correlated with *function* but on p. 12 it's foreseen "that future studies will focus on the functional consequence of such observation." Please reconcile these conflicting statements and ensure connections to function are accurately described. The current title is rather bold. *
We will rewrite and clarify the extent of our hypotheses and validations.
* All mentions of "correlation" throughout the manuscript need to be quantitatively evaluated or properly qualified. In addition to that mentioned above regarding Fig S6, what is the correlation coefficient between residues' contribution to PC1 and membrane interaction frequency (Fig 2)? *
To address this point, we will quantify the correlation between residues' contribution to PC1 and membrane interaction frequency. However, we expect a low correlation between residues' contribution to PC1 and membrane interaction frequency for at least two main reasons. __ First, not all residues contributing to PC1 interact with membranes, but only a subset, as discussed above. Second, our methodology to compute membrane binding, based on the geometric distance between residues and bilayer, is intrinsically quite noisy (since residues in proximity of bona fide membrane binding regions will also appear as involved in membrane binding), thus making quantification of correlations somewhat inaccurate. Rather, we will try to explain in the text that our observations are not of "correlation" but rather of dependence/association, and we will use quantitative measures to quantify these properties (such as rank correlation coefficients or multivariate analyses).__
* Residue's contributions to collective conformational changes are found to be indicative of membrane binding. Yet, membrane interacting residues are identified from CG simulations that cannot capture such collective conformational changes due to the use of an elastic network. Given that the CG simulations agree with previous experimental findings, this suggests that collective conformational changes are not important for membrane binding. *
We disagree with this interpretation by Reviewer #2 of our data: we do not claim that residue's contributions to collective conformational changes is indicative of membrane binding. Rather, membrane binding happens at protein regions displaying high contribution to collective conformational changes. This distinction is subtle but important: protein motion does not determine membrane binding regions. Rather, it appears that, for LTPs, membrane binding regions are also characterized by collective motions (suggesting function). We will clarify this in the main text.
*Are similar conclusions drawn from residues' RMSFs? In other words, are local conformational fluctuations just as indicative of membrane binding? *
We will compute protein residues’ RMSFs and compare it with the membrane binding data. However, given that RMSF is representative of thermal fluctuations, we again expect a bad correlation between RMSF and membrane binding. On the other hand, we indeed observe that most membrane binding regions are protein loops, but this is not unexpected (e.g. Tubiana et al, PLoS Comput Biol. 2022 Dec; 18(12): e1010346.). However, such observation does not provide any information on lipid transport, but only on the mechanism of membrane binding. Rather, the observation of a relationship between membrane binding and global motion is more interesting, since the latter is often indicative of protein function.
*The stated correlation may in fact be spurious and instead arise because residues at the entrance to LTP's hydrophobic cavities need to be positioned at the membrane surface for productive lipid uptake and these same residues must undergo significant conformational changes to allow lipid entry. *
This is exactly what we think it is happening and what our data suggest. However, one must remember that our simulations allow us to predict the membrane binding interface, that is often difficult to determine experimentally (and often via indirect evidence). Hence our data provide novel evidence in this direction.
*Is proximity to cavity entrance more or less correlated with membrane binding than 'dynamics'? *
If we consider that, as discussed before, dynamics does not correlate with membrane binding (there are many dynamical regions that are not at the membrane interface), it is safe to assume that proximity to cavity entrance would correlate more with membrane binding. However, we have to consider that often we do not know where the cavity entrance in LTPs is located simply based on structure alone, and hence our approach provides important clues into this process.
p.12 speculatively suggests "the high degree of protein dynamics we observed in membrane proximal regions could potentially facilitate the energetically unfavorable reaction that involves the extraction of a lipid from a membrane." Yet, the logic behind this idea does not make sense since a free energy barrier, an equilibrium thermodynamic quantity, cannot be lowered by changes in dynamics. Please explain.*
Our current understanding of the mechanism of lipid extraction is quite poor. However, both using chemical intuition and following a recent MD study on one LTP (Rogers et al, 2023, Plos Comp Biol), it is safe to assume that the hydrophobic environment around the lipid is important for its stabilization in the lipid bilayer. Hence, reducing the number of hydrophobic contacts between the lipid and its environment could facilitate transport. A highly dynamic protein, by cycling between different conformations, could “stir” the bilayer, and hence decrease the number of contacts between the lipid and its environment favoring transport. We will clarify this point in the text.
*Examining how the LTPs impact membrane properties would offer insight into the functional relevance of such residues for lipid extraction. *
Indeed, our point above is connected to this one. We are performing simulations to compute hydrophobic contacts in bilayer as proposed in (Rogers et al, 2023, Plos Comp Biol).
The authors highlight that a bound lipid alters LTPs' conformational ensembles akin to "conformational selection" or "induced fit." How sensitive are these findings to the bound lipid species? Do LTPs with multiple known substrates exhibit an increasing diversity of holo conformations and are different conformations stabilized by different substrates? Would similar observations (Fig 3) be made with a lipid that is not known to be transferred by a given LTP? An interesting future direction would be to examine if lipid substrate specificity could be assessed by comparing conformational ensembles to that of a known substrate and/or by overlap with the apo ensemble.
We deem that the role of lipid specificity on LTP conformational plasticity is beyond the scope of the current work. While this topic is certainly worth future investigations, we must point out that (i) not all proteins bind/transport multiple lipids (at least according to current knowledge) and (ii) only few LTPs have been structurally characterized bound to different lipids (Osh4, Osh6, …). This limitation prevents a wide generalization, and we prefer not to speculate on this topic. So far, we have tested our approach for Osh4 bound to cholesterol or PI(4)P and found that indeed the protein exhibits different holo conformations (in agreement with the experimental data) when bound to different substrates. We have added a short comment on this topic in the Discussion section.
"____We foresee that future studies will focus on the functional consequence of such observation, and most notably to the characterization of the extent to which such conformational changes affect multiple steps of protein function, including membrane binding or lipid extraction and release, and whether these are further modulated when different lipids are being transported."
For LTPs to transfer lipids between membranes, transitions between apo and holo forms ought to occur when LTPs are membrane bound. How does membrane binding influence the conformational ensembles observed in solution? Does it promote conformational changes between apo- and holo-like structures, as suggested to regulate lipid uptake and release by previous studies of Osh/ORP, Ups/PRELI, and START family members? (For example: Miliara 2019 PMID 30850607, Watanabe 2015 PMID 26235513, Grabon 2017 PMID 28718450, Iaea 2015 PMID 26168008, Kudo 2008 PMID 18184806, Dong 2019 PMID 30783101) While answering these questions would require further computational effort, doing so will allow more accurate assessment of the role of conformational changes in LTP function.
We can’t unfortunately currently quantify how membrane binding influences the conformational ensembles observed in solution, as the slowdown in diffusion at the water-membrane interface makes this task computationally challenging (and certainly not feasible within the time framework of a review). We have so far tested two different proteins and have not succeeded in converging their conformational distribution when membrane-bound despite long MD simulations that lasted several months (even though the non-converged data indicate sampling of both “open” and “closed” conformations). Interestingly, our observations are in qualitative agreement with a recent study on CPTP (Rogers et al, PLOS Comp Biol, 2023), where membrane-bound CPTP is able to sample different conformations (“open” and “closed”) but not to transition between the two states in 300 ns-long MD simulations.
* The authors motivate the study with the *assumption* that a common molecular mechanism of LTP function exists. Yet LTPs have evolved diverse sequences, structures, and substrate preferences; thus there seems to be no a priori requirement (or even necessarily a benefit) for a single molecular mechanism. What evidence then supports this premise? While previous studies are limited to individual LTPs, when viewed altogether retrospectively, they suggest features that could be shared among LTPs. Synthesizing previous studies and more thoroughly referencing them (only 5 are cited in the intro on p. 3) would strengthen both the premise and findings of the manuscript. *
Indeed, despite having different structures, substrates and the ability to target distinct organelles, previous evidence on LTPs seem to suggest a potential role for protein conformational plasticity for function, e.g. for Osh/ORP (Jun Im et al, Nature 2005; Canagarajah et al, JMB 2008; Moser von Filseck et al, Nat Comm, 2015; Lipp et al, Nat Comm. 2019,...), StART (Arakane et al, PNAS, 1996; Feng et al, Biochemistry, 2000; Grabon et al, JBC, 2017; Khelashvili et al, eLife, 2019;...) and PITP domains (Tremblay et al, Archives of Biochemistry and Biophysics, 2005; Ryan et al, MBOC, 2007; …). Our simulations provide additional evidence in this direction and allow for generalizing these observations, allowing to draw parallelisms with “enzyme-like” or transporter-like” features that could be exploited for further design of testable hypotheses. We will rewrite our text to better contextualize/acknowledge previous findings and to clarify these points.
*The LTPs investigated are known to target distinct membranes. Should they then be expected to share structural or sequence-based features predictive of membrane binding interfaces, as motivates the analysis in Fig 1d, 1e, and S3? Or is it beneficial for LTPs to recognize membranes in different ways? *
Since membrane binding is membrane/organelle-specific, it is possible that residue’s diversity in membrane binding interfaces could indeed be beneficial for this diversity. We will add this comment as a potential explanation of our finding of a lack of conserved sequence-based features for membrane binding interfaces.
*
Minor comments:*
* 2 "making lipid transfer across the cytoplasm a potentially energetically favorable process": Is it meant that it is less energetically costly than transfer without a LTP? Why it would be energetically favorable is unclear (and would indicate that the LTP sequesters lipids away from membranes instead of transferring them between membranes). *
Yes, this is what we meant. We will rewrite this appropriately.
* 3 "The excellent agreement between the membrane interface determined from the simulations and the experimentally-proposed one available for... Osh6" is missing a citation. *
We have now added the relevant citation.
* The plots in Fig 1d and S3 are difficult to interpret. Bar plots, for example, would allow easier comparison and evaluation. Currently, it seems that most proteins individually exhibit some of the same trends observed among the whole set, counter to the conclusion on p 5. *
We will improve the presentation of our Figures.
* Negatively charged residues engage in a number of membrane interactions (Fig 1d and S3). What is a potential explanation for this unconventional observation? *
One possible interpretation is that negatively charged residues could interact with positively charged moieties (ethanolamine, choline) of PC and PE lipids.
* How much variance is captured by PC1, and how many PCs are needed to capture most of the variance in the conformations? *
PC1 explains 38 % of the total variance, by average, whereas PC2 accounts for 17 % of it. Therefore, PC1 and PC2 capture most of the variance in almost all cases.
We have also added this to the text:
"____We specifically focused on PC1 as it explains most of the variance in the dynamics (38% on average for all the proteins in our dataset, see Supplementary Table 2).____ "
We have computed this variance and we have added this analysis in Supplementary Information.
* Plots in Fig 3, especially panels c and d are difficult to see. Please make the panels larger (perhaps a 3 x 4 layout instead of 2 x 6 would work better). *
We will improve the presentation of our Figures.
* 8 "these conformational changes are localized in protein regions that interact with the lipid bilayer" is contradicted by the results in Fig 2b showing that all residues with large contributions to PC1 do not interact with the membrane and discussed on p 5. *
As discussed above, we don’t observe “correlation” between membrane binding and conformational plasticity, but we rather observe that membrane binding regions display high conformational plasticity (the opposite is not true). We will further clarify in the text.
*
8 "in the absence of bound lipids, it is able to sample multiple conformations" is not supported by the orange distributions in Fig 3d that appear unimodal. Is it instead meant that the apo form exhibits larger variance in cavity volume? *
Yes, this is what we meant. We’ll clarify.
*
Please clarify if the elastic network was constructed to maintain the holo or apo structures of each protein and if a bound lipid was used in the CG simulations. *
For membrane binding CG simulations, we used the apo structure and no bound lipid was used in the simulations. However, analogous simulations in the holo form (not shown) have essentially identical membrane binding interfaces.
*
Was *CHARMM* TIP3P used? *
Yes.
* Please clarify how membrane interacting residues were defined and how interaction frequency was calculated from the longest duration of interaction. *
We will add this explanation in the Methods. The method is identical to (Srinivasan et al, Faraday Discussion, 2021).
* Refs 16 and 45 refer to the same paper. *
Thanks, it is now corrected!
* Reviewer #2 (Significance (Required)): *
* General assessment: *
* The work aims to tackle a grand question regarding membrane homeostasis mechanisms-what are universal principles underlying LTP function-and offers initial insights; however, further evidence is needed to support the conclusions as written, and some key results require further investigation and explanation. *
*Advance and audience: *
*
By concurrently investigating the largest number of lipid transfer proteins to-date, the authors provide data invaluable for uncovering general mechanisms of non-vesicular lipid transport and advancing our understanding of membrane homeostasis mechanisms. By illuminating the wide-spread importance of conformational plasticity among lipid transfer proteins, the work presents a conceptual advance in our understanding of lipid transfer mechanisms and unifies previous studies. Because the manuscript emphasizes common biophysical principles and draws connections to enzyme biophysics, it ought to be of interest not only to membrane biologists but biochemists and molecular biologists more broadly.*
We thank Reviewer #2 for the very positive evaluation of the significance of our work and for the in-depth analysis provided that will certainly help improve the quality of our work.
Reviewer #3* (Evidence, reproducibility and clarity (Required)): *
*The article "Conformational dynamics of lipid transfer domains provide a general framework to decode their functional mechanism." by Sriraksha Srinivasan, Andrea DiLuca, Arun Peter, Charlotte Gehin, Museer Lone, Thorsten Hornemann, Giovanni D'Angelo and Stefano Vanni study the interaction of Lipid transport Domains with membranes. This is done mainly by molecular modelling but also with selected experimental validations. *
* Major comments: *
* - The key conclusions are generally well supported by the analysis. - The authors could however analyze in more details some aspects in which specific cases appear. For example, p3 "multiple binding and unbinding events, as shown by the minimum distance curves" does not give an entire description of the variability seen in Fig S1, e.g. LCN1 versus GM2A.*
We now discuss in more detail the variability seen in Fig. S1 and attribute it to different membrane binding affinities of the proteins in our dataset. We also discuss how this variability could reflect the diversity of organellar membranes to which these proteins bind in vivo.
"____Notably, the proteins in our dataset display distinct binding affinities, with some proteins showing very transient binding while others remain membrane-bound for most of the simulation trajectory (Fig. S1). This behavior could be, in part, attributed to the wide diversity of organellar membranes to which the LTDs in our dataset bind to in vivo, and to the comparative simplicity of our in silico model DOPC lipid bilayers."
- Later the "excellent agreement" for the data in Fig S2 is not quantified which does not allow the reader to know whether it better than would have been with other methods (SASA, OPM, DREAM). *
We have explicitly quantified this agreement by providing a direct comparison between the experimental results and our in silico assay, and we further compared it against two alternative methods: OPM and DREAMM. In detail, we have identified 12 experimentally-characterized spots suggested to be involved in membrane binding in our protein dataset (see shaded blue regions in Fig. S2). Of those 12, our method identifies all of them (100%), while DREAMM identifies 7 of them (58 %) and OPM 4 out of 8 (50 %), since of the 12 proteins we tested, only 7 are available in the OPM database. Overall, even if our approach is much noisier than the others, and thus suggesting multiple binding regions that are not currently supported by experimental observations, using physics-based methodologies appears to remain a preferable strategy to characterize the binding of peripheral proteins to lipid bilayers. Given the limited size of our dataset, we prefer not to make a direct comparison between our assay and OPM/DREAMM in the main text as this won't be representative of the various methodologies.
*p5 commenting on Fig2b the case of Osh6 that appears to disagree should probably be mentioned. *
We now discuss this case, and attribute to this disagreement to insufficient sampling for the peculiar case of Osh6:
"____One interesting exception in our database appears to be Osh6, where the experimentally determined membrane-binding region at the N-terminus (https://doi.org/10.1038/s41467-019-11780-y) is only marginally binding to the lipid bilayer in silico and it also appears to have limited contribution to PC1. However, our simulations are unable to sample the large conformational changes that the N-terminal lid of Osh6 has been proposed to undergo from its lipid-bound to its apo state, indicating that insufficient sampling could be the reason for this apparent discrepancy."
*
-The data and the methods are generally well presented allowing to be reproduced.
- The experiments adequately replicated with adequate statistical analysis. *
* Minor comments: *
* - When presenting the dataset the authors could probably detail a bit more the protocol undertaken to chose the cases. In particular it is unclear whether the chosen proteins have any membrane selectivity, which in principle could be affected by the choice of lipid used here.*
We have now added in Table 1 a column with a list of potential organelles the different LTPs have been shown to localize to (source: UniProt). As model membrane bilayer, we opted to use a pure DOPC bilayer, for both simplicity and to compare membrane binding in a uniform setting. We foresee that future studies investigating the membrane specificity of the various proteins will shed further light into the molecular mechanism of LTPs. Finally, we also indicate that our choice of proteins was mainly driven by the availability of lipid-bound structures in the protein data bank. We have added the following sentences in the main text:
"____Specifically, we selected all LTPs for which a crystallographic structure in complex with a lipid was available at the start of our project, plus two additional proteins (GM2A and LCN1) to increase the structural diversity of our dataset (Fig. 1a)"
and
"____Notably, the proteins in our dataset display distinct binding affinities, with some proteins showing very transient binding while other remain membrane-bound for most of the simulation trajectory (Fig. S1). This behavior could be, in part, attributed to the wide diversity of organellar membranes to which the LTDs in our dataset bind to in vivo, and to the comparative simplicity of our in silico model DOPC lipid bilayers."
*- The authors could probably give some indication of how much of the variance is explained by PC1 and comment briefly on the choice to ignore other PCs. *
PC1 explains 38 % of the total variance, on average. This means that PC1 has a large contribution to the variance, especially in comparison to the other PCs. For instance, PC2 only accounts for 17 % of the total variance. This is the reason we limited our discussion to PC1. We have added a table in supplementary Information quantifying the variance explained by PC1 and PC 2 and added the following sentence in the main text:
"____We specifically focused on PC1 as it explains most of the variance in the dynamics (38% on average for all the proteins in our dataset)____. "
* - When analyzing the residues involved in the interaction with the membrane the results could probably be compared with that of the systematic analysis performed recently: Tubiana, T., Sillitoe, I., Orengo, C., & Reuter, N. (2022). Dissecting peripheral protein-membrane interfaces. PLOS Computational Biology, 18(12), e1010346. *
We have added in the text a reference to the work by Tubiana et al and we have further stressed that our results agree with previous observations (including theirs). This includes the preference for Lys over Arg and the importance of protruding hydrophobes:
"____Concomitant analysis of all LTDs (Fig. 1d) indicates that the membrane binding interface of LTDs is enriched in the positively charged amino acid Lysine, as this amino acid is less membrane-disruptive than Arginine22, and aromatic/hydrophobic ones (Phe, Leu, Val, Ile). This confirms previous observations, as (i) binding of negatively charged lipids via positively charged residues and (ii) hydrophobic insertions are two of the main mechanisms involved in membrane binding by peripheral proteins22-27."
* - In the discussion on allostery/conformational selection might not be centered so much on enzymes. *
We thank the reviewer for this important observation. We have now included in the Discussion the following paragraph that provides additional references and discussion of membrane transporters and receptors.
"____Notably, the conformational plasticity we observe for LTPs is reminiscent of other, previously described, functional protein mechanisms, including enzyme dynamics during catalysis (____DOI: 10.1126/science.1066176____), the alternating-access model of membrane transporters (____https://doi.org/10.1038/nsmb.3179____) or GPCR dynamics (____https://doi.org/10.1021/acs.chemrev.6b00177____). In all these cases, protein dynamics is strongly coupled to ligand binding and protein function, be it for signaling, transport or enzymatic activity. Unlike for these fields, however, the contribution of structural and spectroscopic studies to uncover LTP dynamics remains quite limited, and our simulations provide an important contribution to fill this gap. We hope that our results will motivate researchers to increase efforts to experimentally quantify LTPs conformational plasticity, e.g. by structural determination of LTPs in different states (or bound to different lipids) or by single-molecule spectroscopy studies."
* Reviewer #3 (Significance (Required)): *
*
The article shows convincing results on the debated issue of the mechanism of lipid transport by lipid transfer proteins. *
First the study employs molecular modelling to allow a rather large test on 12 cases. The molecular dynamics experiments allow the authors to draw clear hypotheses on role of protein dynamics on the interaction with membranes and the effect on bound lipids on the modification of this dynamics.
*Then the authors use this knowledge to design experiments that largely confirm those hypotheses. The results should therefore be interesting for a large audience of biochemists and cell biologists interested in lipid transport in the cell. *
We thank Reviewer #3 for its very positive evaluation and contextualization of our work.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
The article "Conformational dynamics of lipid transfer domains provide a general framework to decode their functional mechanism." by Sriraksha Srinivasan, Andrea DiLuca, Arun Peter, Charlotte Gehin, Museer Lone, Thorsten Hornemann, Giovanni D'Angelo and Stefano Vanni study the interaction of Lipid transport Domains with membranes. This is done mainly by molecular modelling but also with selected experimental validations.
Major comments:
- The key conclusions are generally well supported by the analysis.
- The authors could however analyze in more details some aspects in which specific cases appear. For example, p3 "multiple binding and unbinding events, as shown by the minimum distance curves" does not give an entire description of the variability seen in Fig S1, e.g. LCN1 versus GM2A. Later the "excellent agreement" for the data in Fig S2 is not quantified which does not allow the reader to know whether it better than would have been with other methods (SASA, OPM, DREAM). p5 commenting on Fig2b the case of Osh6 that appears to disagree should probably be mentioned.
- The data and the methods are generally well presented allowing to be reproduced.
- The experiments adequately replicated with adequate statistical analysis.
Minor comments:
- When presenting the dataset the authors could probably detail a bit more the protocol undertaken to chose the cases. In particular it is unclear whether the chosen proteins have any membrane selectivity, which in principle could be affected by the choice of lipid used here.
- The authors could probably give some indication of how much of the variance is explained by PC1 and comment briefly on the choice to ignore other PCs.
- When analyzing the residues involved in the interaction with the membrane the results could probably be compared with that of the systematic analysis performed recently: Tubiana, T., Sillitoe, I., Orengo, C., & Reuter, N. (2022). Dissecting peripheral protein-membrane interfaces. PLOS Computational Biology, 18(12), e1010346.
- In the discussion on allostery/conformational selection might not be centered so much on enzymes.
Significance
The article shows convincing results on the debated issue of the mechanism of lipid transport by lipid transfer proteins.
First the study employs molecular modelling to allow a rather large test on 12 cases. The molecular dynamics experiments allow the authors to draw clear hypotheses on role of protein dynamics on the interaction with membranes and the effect on bound lipids on the modification of this dynamics. Then the authors use this knowledge to design experiments that largely confirm those hypotheses.
The results should therefore be interesting for a large audience of biochemists and cell biologists interested in lipid transport in the cell.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary:
In a combined computational and experimental study, the authors provide insights into general features of lipid transfer proteins (LTPs), which play key roles in lipid trafficking: Through molecular dynamics simulations of a diverse set of 12 shuttle-like LTPs, they demonstrate that LTPs consistently exist in an equilibrium between two or more conformations, whose populations are modulated by a bound lipid, and that residues significantly involved in these collective conformational changes typically interact with a membrane. Their simulations indicate that conformational plasticity is a general feature of LTPs, leading them to suggest that the ability to change conformations is essential for LTP function. They test the generality of this hypothesis through in cellulo assays of two LTPs (STARD11 and Mdm12) that were not originally simulated. While experiments of STARD11 support their hypothesis, those presented for Mdm12 provide ambiguous results.
Major comments:
Throughout the manuscript, it's stated that common 'dynamical features' correlate with LTP function. The accuracy of this statement is unclear since 'dynamical features' are never precisely defined and, while equilibrium conformational ensembles are characterized, dynamics (ie kinetics or time-dependent observables) are not. Please clarify.
More importantly, further evidence is needed to determine a correlation with function. LTPs are suggested to have faster transfer rates (a measure of function) if the apo form adopts a substantial population of holo-like conformations, akin to enzyme preorganization. This is further tested by rationally mutating STARD11 and Mdm12. However, the support for this conclusion and if these mutations alter the LTPs conformational ensembles as desired is unclear:
- Is there a quantitative correlation between the overlap of apo and holo conformational distributions (as could be quantified by KL divergence or Wasserstein distance, for example) and difference in transfer rates as suggested by Fig S6?
- The conclusion and the generality of the findings would be greatly strengthened if a correlation can be shown for other LTPs through additional simulations of mutants whose transfer rates have been previously characterized experimentally in the literature. (For example: Ryan 2007 PMID 17344474, Grabon 2017 PMID 28718450, Iaea 2015 PMID 26168008, among many others)
- While differences in the apo conformational ensembles of the WT and mutants are observed in Fig S7b and d, if these mutations reduce overlap with holo-like conformations is not determined. Simulations of the WT holo forms are needed to properly test this hypothesis.
- For Mdm12, mutations are specifically made to "lock the protein in the apo-like state;" however, the mutant adopts conformations distinct from the apo form as show in Fig S7d. How do the authors interpret the results of the cellular assays considering this and could it help explain why the mutant has similar kinetics to WT? What may explain the puzzling results of similar transfer kinetics but differing mitochondrial morphology?
- Confounding factors potentially complicate the interpretation of the in cellulo experiments. Simpler in vitro experiments may be better suited to determine if altering LTP's biophysical properties, namely rationally altering the population of apo- vs holo-like configurations, quantitatively affects transport rates as suggested.
- The abstract, intro, and title highlight that the manuscript's findings are indicative of and correlated with function but on p. 12 it's foreseen "that future studies will focus on the functional consequence of such observation." Please reconcile these conflicting statements and ensure connections to function are accurately described. The current title is rather bold.
All mentions of "correlation" throughout the manuscript need to be quantitatively evaluated or properly qualified. In addition to that mentioned above regarding Fig S6, what is the correlation coefficient between residues' contribution to PC1 and membrane interaction frequency (Fig 2)?
Residue's contributions to collective conformational changes are found to be indicative of membrane binding. Yet, membrane interacting residues are identified from CG simulations that cannot capture such collective conformational changes due to the use of an elastic network. Given that the CG simulations agree with previous experimental findings, this suggests that collective conformational changes are not important for membrane binding. Are similar conclusions drawn from residues' RMSFs? In other words, are local conformational fluctuations just as indicative of membrane binding? The stated correlation may in fact be spurious and instead arise because residues at the entrance to LTP's hydrophobic cavities need to be positioned at the membrane surface for productive lipid uptake and these same residues must undergo significant conformational changes to allow lipid entry. Is proximity to cavity entrance more or less correlated with membrane binding than 'dynamics'?
p. 12 speculatively suggests "the high degree of protein dynamics we observed in membrane proximal regions could potentially facilitate the energetically unfavorable reaction that involves the extraction of a lipid from a membrane." Yet, the logic behind this idea does not make sense since a free energy barrier, an equilibrium thermodynamic quantity, cannot be lowered by changes in dynamics. Please explain. Examining how the LTPs impact membrane properties would offer insight into the functional relevance of such residues for lipid extraction.
The authors highlight that a bound lipid alters LTPs' conformational ensembles akin to "conformational selection" or "induced fit." How sensitive are these findings to the bound lipid species? Do LTPs with multiple known substrates exhibit an increasing diversity of holo conformations and are different conformations stabilized by different substrates? Would similar observations (Fig 3) be made with a lipid that is not known to be transferred by a given LTP? An interesting future direction would be to examine if lipid substrate specificity could be assessed by comparing conformational ensembles to that of a known substrate and/or by overlap with the apo ensemble.
For LTPs to transfer lipids between membranes, transitions between apo and holo forms ought to occur when LTPs are membrane bound. How does membrane binding influence the conformational ensembles observed in solution? Does it promote conformational changes between apo- and holo-like structures, as suggested to regulate lipid uptake and release by previous studies of Osh/ORP, Ups/PRELI, and START family members? (For example: Miliara 2019 PMID 30850607, Watanabe 2015 PMID 26235513, Grabon 2017 PMID 28718450, Iaea 2015 PMID 26168008, Kudo 2008 PMID 18184806, Dong 2019 PMID 30783101) While answering these questions would require further computational effort, doing so will allow more accurate assessment of the role of conformational changes in LTP function.
The authors motivate the study with the assumption that a common molecular mechanism of LTP function exists. Yet LTPs have evolved diverse sequences, structures, and substrate preferences; thus there seems to be no a priori requirement (or even necessarily a benefit) for a single molecular mechanism. What evidence then supports this premise? While previous studies are limited to individual LTPs, when viewed altogether retrospectively, they suggest features that could be shared among LTPs. Synthesizing previous studies and more thoroughly referencing them (only 5 are cited in the intro on p. 3) would strengthen both the premise and findings of the manuscript.
The LTPs investigated are known to target distinct membranes. Should they then be expected to share structural or sequence-based features predictive of membrane binding interfaces, as motivates the analysis in Fig 1d, 1e, and S3? Or is it beneficial for LTPs to recognize membranes in different ways?
Minor comments:
p. 2 "making lipid transfer across the cytoplasm a potentially energetically favorable process": Is it meant that it is less energetically costly than transfer without a LTP? Why it would be energetically favorable is unclear (and would indicate that the LTP sequesters lipids away from membranes instead of transferring them between membranes).
p. 3 "The excellent agreement between the membrane interface determined from the simulations and the experimentally-proposed one available for... Osh6" is missing a citation.
The plots in Fig 1d and S3 are difficult to interpret. Bar plots, for example, would allow easier comparison and evaluation. Currently, it seems that most proteins individually exhibit some of the same trends observed among the whole set, counter to the conclusion on p 5.
Negatively charged residues engage in a number of membrane interactions (Fig 1d and S3). What is a potential explanation for this unconventional observation?
How much variance is captured by PC1, and how many PCs are needed to capture most of the variance in the conformations?
Plots in Fig 3, especially panels c and d are difficult to see. Please make the panels larger (perhaps a 3 x 4 layout instead of 2 x 6 would work better).
p. 8 "these conformational changes are localized in protein regions that interact with the lipid bilayer" is contradicted by the results in Fig 2b showing that all residues with large contributions to PC1 do not interact with the membrane and discussed on p 5.
p. 8 "in the absence of bound lipids, it is able to sample multiple conformations" is not supported by the orange distributions in Fig 3d that appear unimodal. Is it instead meant that the apo form exhibits larger variance in cavity volume?
Please clarify if the elastic network was constructed to maintain the holo or apo structures of each protein and if a bound lipid was used in the CG simulations.
Was CHARMM TIP3P used?
Please clarify how membrane interacting residues were defined and how interaction frequency was calculated from the longest duration of interaction.
Refs 16 and 45 refer to the same paper.
Significance
General assessment:
The work aims to tackle a grand question regarding membrane homeostasis mechanisms-what are universal principles underlying LTP function-and offers initial insights; however, further evidence is needed to support the conclusions as written, and some key results require further investigation and explanation.
Advance and audience:
By concurrently investigating the largest number of lipid transfer proteins to-date, the authors provide data invaluable for uncovering general mechanisms of non-vesicular lipid transport and advancing our understanding of membrane homeostasis mechanisms. By illuminating the wide-spread importance of conformational plasticity among lipid transfer proteins, the work presents a conceptual advance in our understanding of lipid transfer mechanisms and unifies previous studies. Because the manuscript emphasizes common biophysical principles and draws connections to enzyme biophysics, it ought to be of interest not only to membrane biologists but biochemists and molecular biologists more broadly.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Srinivasan et al. present a comprehensive study on systematizing the structure-dynamics-function relation of lipid transfer proteins (LTPs), combining extensive molecular simulations and complementary experiments. Indeed, the current state-of-the-art in the field is quite chaotic and fractional, and such systematic studies are necessary to advance our general and conceptual understanding of the mechanisms of action of LTPs. The selected techniques and research strategies are all suitable, their description is sufficient and enables reproducibility; the obtained results are carefully presented and discussed; the conclusions are adequately supported by the data.
Given my primarily computational background, I evaluated mainly the simulation part of the manuscript. Considering experiments, I do not see any significant flows or deficiencies that could diminish the value of the data and following conclusions given in the manuscript. I would even suggest improving the abstract by more explicitly saying that this work includes experimental measurements because it currently reads like purely computational work was performed.
Major comments:
- Although I like the central message of the paper and have no objections, I am curious whether the conclusion "a more "dynamic" or/and "mobile" part of the protein interacts with the membrane or any other (macro)(bio)molecule" makes sense globally and is not limited to LTPs. For example, it is a reasonable assumption that a more flexible part of the protein, i.e., capable of adopting necessary binding configurations, would be a more likely interacting spot. Locking in a less flexible and more specific configuration upon binding with a target molecule is also anticipated and quite typical, e.g., when ligands interact with target proteins, thereby blocking their function. The authors themselves recognize this paradigm as referring to the enzymes' dynamics. It would be great if authors could comment more on dynamics-function relation, referring to the existing literature, where such observations were/were not observed for different protein families. Performing simulations on proteins that do not exhibit such a feature and do not belong to LTPs, but, e.g., structurally similar to some of the studied LTPs, would be an excellent addition too, highlighting this signature characteristic of LTPs.
Minor comments:
- Fig 1d. What is so special in Lysine compared to Arginine? Is there any disbalance in their presence in studied proteins? Any correlations between the binding affinity of certain amino acids and their overall presence on the protein surface?
- Fig S1. GM2A and TTPA seem to be irreversibly adsorbed to the membrane on the microsecond timescale in most replicas. Is anything special in these proteins? Did this affect the sampling of a claimed membrane-binding interface?
- A related follow-up question. Multiple replicas were performed to identify the membrane-binding interface. However, if I understand well, the initial orientation of the protein with respect to the membrane was always the same. I found it a pity since performing multiple replicas starting from different initial geometries (e.g., rotating the protein in a somewhat systematic way) would likely result in a more efficient exploration of the conformation space. Can the authors comment on whether this predefined initial configuration could negatively affect the results? Performing a few additional simulations for the most problematic proteins I mentioned earlier (GM2A and TTPA) could be a nice opportunity to apply this strategy.
- How was the volume of the cavity affected by mutations in STARD11 and Mdm12? Do these data somehow correlate with the experimentally observed reduced efficiency of the lipid transfer?
- I would appreciate it if the authors considered playing with the templates of the main Figures at later stages because in the current version, and when printed on A4 paper, the readability of certain graphs and pictures is uncomfortable and sometimes even impossible. Obviously, the final schematics would depend on the journal and its formatting.
Referees cross-commenting
I would like to acknowledge the thoughtful and detailed reviews provided by other reviewers. I do like their reports, and I believe that by addressing the reviewers' comments and incorporating their revisions, the article will significantly improve in terms of scientific rigor and contribution to the field.
Significance
This manuscript is a solid scientific work addressing gaps in our knowledge about Lipid Transfer Proteins by employing state-of-the-art methods. It advances the field on conceptual and fundamental levels. This study is of interest to both computational biophysicists and physical chemists (to whom I belong myself) as well as experimentalists, who seek a rational explanation of the experimental observations.
-
- Jun 2023
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
The authors do not wish to provide a response at this time.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Chakraborty et al describe the biochemical and structural characterization of Spiroplasma FtsZ and report that the protein has unusual properties compared to other FtsZ. Sedimentation and GTPase measurements showed that whereas the wild-type protein has a high critical concentration and low GTPase activity, a mutant predicted to facilitate FtsZ cleft opening (F224M) exhibited lower critical concentration and higher GTPase activity. In addition, the crystal structures of both wild-type and F224M SmFtsZ revealed a unique domain-swapped dimer configuration in which one of the monomers in each dimer exhibited an R/T hybrid or intermediate conformation, with the NTD in the T state and the CTD in the R state. The T state of FtsZ has only been observed before when the protein crystallizes as filaments. Thus, the crystal structure of SmFtsZ - which is not assembled in filaments - was interpreted as capturing a conformational state that could explain the kinetic polarity of FtsZ (preferential addition of subunits to the CTD-exposed end of FtsZ filament).
This is a good quality manuscript overall, but which could still be improved by the suggestions below. In terms of significance, it provides new data to support current models for FtsZ assembly mechanism but no major new insights. The findings are interesting for a more specialized audience.
Major points
- The peculiar biochemical properties of SmFtsZ (high CC, low GTPase) are well documented and interesting but deserve further critical assessment to rule out artifacts. The EM in Fig 1B suggests abundant aggregated protein (not monomers), in addition to filament bundles, which suggests that SmFtsZ is not stable under the experimental conditions used. There are reports that some FtsZ will lose nucleotide during purification and become partially unfolded and unstable (doi.org/10.1111/febs.15235). Figure S1E suggests that the same may be happening here, as the amount of GDP released by SmFtsZ seems to be lower than expected if all the protein had nucleotide. Perhaps the authors should repeat their experiments with SmFtsZ purified in the presence of GDP, which should stabilize the protein, to confirm that the biochemical properties of the protein stay the same.
- Another unexpected observation is that the SmFtsZ bundles are quite short despite the low GTPase activity of the protein, whereas mutant F224M forms much longer bundles and is a stronger GTPase. In general, filament length correlates inversely with GTPase activity, if measurements are being made at steady state. However, no kinetic (light scattering or fluorescence) experiments seem to have been done to ensure measurements were done in steady state. The authors do try to explain the odd behavior of SmFtsZ but the idea that the increase in GTPase reflects a faster kinetics of nucleation and elongation is not necessarily true. GTP turnover is usually limited by the kinetics of filament disassembly not by assembly. However, it is possible that in reactions with a mutant that is much better at nucleation there will be many more filaments than with a poorly nucleating protein and, thus, more filament ends for subunit turnover. A complicator to these experiments is that they were carried out in high magnesium and at pH 6.5 which favor bundling, and bundling affects subunit and GTP turnover in ways that are hard to account for. Ideally, experiments aimed at properly determining the kinetic properties of FtsZ should be carried out under conditions that avoid bundling (pH 7.4-7.7, 2-5 mM Mg2+) and include proper kinetic measurements, such as light scattering. Thus, before any hard conclusions can be drawn about the properties of SmFtsZ, the authors may wish to revisit some of their biochemical experiments in light of the caveats pointed out here.
- A central part of the paper is the description of the intermediate R/T conformation but that was a bit confusing and perhaps could be improved. The first thing would be to more clearly define what are the structural changes of the NTD in the T conformation. From other publications, it seems that the NTD undergoes little alteration upon switching to the T conformation, the main one being the flipping of the guanine of the bound nucleotide. But if the NTD structure remains essentially the same, what causes the flipping of the guanine? My impression was that guanine flipping was caused by the downward movement of H7 but if H7 and its attached elements (H6, S6) are moving, why is this not manifested as a significant structural change in the NTD in the T state? Moreover, from Figs. 3C and 5A we conclude that the relative position of H7 in the R/T structures is the same as in R structures. If H7 has not changed in the R/T structure, can you call this a T structure? Also, if there is no H7 movement, what caused the change in guanine angle?
- The observation that the intermediate conformation was detected in a swapped-dimer is always a matter of some concern, as domain swapping imposes additional constraints on the conformational freedom of a protein and generates structures that are often different from their non-swapped counterparts. This seems to be the case for other FtsZ domain-swapped structures, which were outliers in the extensive comparisons made by Wagstaff et al (doi.org/10.1128/mBio.00254-17) and also stand out in the analysis in Fig. 3BC. Perhaps the authors should discuss more thoroughly why this structure must reflect a natural conformation of FtsZ.
- Still regarding the structural basis of kinetic polarity, it would be desirable to present a more complete view of the debate in the field about this issue. For example, Ruiz et al, (doi.org/10.1371/journal.pbio.3001497) recently provided structural arguments for the NTD being the face used for monomer addition without detecting the same intermediate form reported in this manuscript. How do their data and arguments differ from your findings? More generally, isn´t the fact that the NTD does not change substantially as FtsZ transitions from R to T already an argument for the NTD being the surface used for monomer addition?
- l. 74 "led us to propose a structural basis for the kinetic polarity of FtsZ, where transition of the NTD to the T-state conformation driven by GTP binding is sufficient to add a GTP-bound monomer to the bottom interface of the FtsZ filament." This statement suggests that GTP is necessary for the intermediate conformation but this is not supported by the data, as the GDP bound 7YSZ structure also has one monomer in the intermediate conformation. As far as I can tell, there is no structural evidence to suggest that the nucleotide gamma phosphate plays any role in the R-T transition. Even the role of the gamma phosphate in organizing the T3 loop in an assembly-conducive conformation seems to still be a controversial matter in the field. According to Matsui 2014 (doi.org/10.1074/jbc.M113.514901) "based on the results of the present study as well as on the structures deposited previously by other groups (PDB codes 2RHL, 2RHO, 2Q1X, and 2Q1Y) (43, 44), nucleotide exchange appears not to directly induce a structural change in the monomer, including the T3 loop."
- The experiments with the reciprocal cleft mutation in E. coli are not very informative as it is difficult to correlate the division defect in vivo with specific kinetic defects of the mutant FtsZ. The authors should have at least done a basic characterization of the E. coli mutant in vitro to demonstrate that it is altered in its CC alone. In fact, the dominant negative effect of the mutation in vivo is not something one expects from a poorly nucleating protein, which, if anything, should have a hard time poisoning the endogenous protein. The effect on ring compaction also suggests that the mutation must affect the protein in a broader way, perhaps including filament geometry. I would suggest that this part of the manuscript could be excluded without any loss for the SmFtsZ conclusions.
Minor points
- l. 14 "CTD of the nucleotide-bound monomer cannot bind to the NTD-exposed end of the filament unless relative rotation of the domains leads to cleft opening." This is not accurate. There is no steric impediment to this reaction. Monomers in R conformation should be able to add to the NTD end of the filament as well, even if this is slower than the opposite reaction. The absence of growth from the NTD end is because the rate of addition/conformational change is slower than the rate of GTP hydrolysis.
- The comparison between the 7YOP (B) structure and the S. aureus 3WGN structure to show the effect of the gamma phosphate on T3 loop structure should be presented in a single figure, instead of being split between Fig. 4 and Fig. S2, and preferably using similar poses of the two structures. In the current state, it is quite hard to visualize the similarities mentioned by the authors.
- In contrast to what´s in the main text (l. 130), the chain with continuous density in Figure 2 is assigned as B, not A. Please clarify which is correct.
- l. 271 pBAD is the plasmid name, not the promoter. The promoter is PBAD(subscript).
Significance
This is a good quality manuscript overall, but which could still be improved by the suggestions below. In terms of significance, it provides new data to support current models for FtsZ assembly mechanism but no major new insights. The findings are interesting for a more specialized audience.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary
This is a study of cell division protein SmFtsZ from Spiroplasma melliferum, a cell wall-less Mollicutes bacterium where FtsZ may provide the primary force for division. Using X-ray crystallography, biochemical and microbiological experiments, the authors provide insight into how FtsZ's relaxed (R) to tense (T) conformational switching and its GTPase activity explain the kinetic polarity of FtsZ filament treadmilling. They propose: 1) an intermediate R/T state of FtsZ that facilitates preferential binding of N-terminal domain (NTD) of a monomer to C-terminal domain (CTD) of the terminal subunit at the filament bottom end; 2) that R to T switching is the rate-limiting step of FtsZ polymerization; 3) a T3 loop mechanism for GTP gamma phosphate triggering FtsZ polymerization.
All comments and criticisms below are made for the sake of this interesting study.
General Comments
The study is well thought, carefully executed, and the manuscript is well written. However, the first conclusion is not convincing, because it is based on a misleading analysis; and the third conclusion is complicated by the use of an unqualified analog of GTP. SmFtsZ crystallizes as a dimer with the NTD and CTD domains swapped and a NTD-NTD contact. Mechanistic conclusions drawn from this unusual structural context are largely speculative, as they may not hold for normal FtsZ assembly. The NTD structure changes really very little between R-FtsZ and T-FtsZ, so that it is probably incorrect to define a T-NTD/R-CTD intermediate conformation from the guanine ring angle, as will be reasoned below. In addition, the GTP analog GMPPNP employed to investigate the effects of the gamma phosphate is not demonstrated to promote FtsZ assembly as GTP does; in fact, its beta-gamma phosphate geometry in the SmFtsZ structure is clearly different from GTP in other FtsZ structures. This raises the concern that GMPPNP may be not a bona fide functional analog of GTP for FtsZ.
The authors should moderate the first and third claims, keeping speculations for discussion. Additional experiments required to assess the activity of GMPPNP inducing FtsZ assembly should be reported, even if the result was negative. Authors may consider partially refocusing the manuscript, including the title, towards the mechanism of the R to T transition, with Phe224Met modulating the opening of the cleft between NTD and CTD. Careful discussion of the structural basis of the kinetic polarity of FtsZ filaments in the light of previous and current results should be fine. In addition, SmFtsZ is now the third FtsZ that has been crystallized as a domain swapped dimer, suggesting a tendency for intramolecular dissociation of NTD and CTD with potential mechanistic implications, as the authors point out by the attractive end of the discussion.
Specific comments (major and minor)
Line 37 should read "...connected via H7 helix (15), with divergent C-terminal extensions".
Line 55 Please note that the kinetic polarity of FtsZ has been deduced from mutational analysis (rather than observed as in the case of microtubules)
Line 75 ""..transition of the NTD to the T-state conformation driven by GTP binding is sufficient..." This sentence appears conceptually wrong, because the R of T conformation of FtsZ is deemed independent of GTP or GDP binding in the literature (for example, Ref 23)
Line 89 should read " in the presence of GTP and Mg2+ and not with GDP and Mg2+"
Line 90-Figure 1A. The greyish gel electrophoresis image and those in SI require improving staining or photos. Standard Coomassie staining typically gives less background and better contrast.
Line 90. Were the SmFtsZ filaments single or multiple in EM?
Line 92. "...other characterized bacterial FtsZs" Some references should be cited
Line 107 suggesting -> indicating
Lines 120-122 " a truncated construct....SmFtsZdeltaCt showed similar GTPase activity as the wild type" is repeated from lines 110-111 above
Line 124. Why the choice of GMPPNP, rather than GTP or GMPCPP?. Have SmFtsZ structures with GTP or GMPCPP been attempted?
Line 124. It would be helpful to the reader to explain here that structure 7YSZ has two GDP-bound chains whereas structure 7YOP has GDP in chain A and GMPPNP in chain B.
Lines 131 and 133. The names of chain A and chain B are swapped in the text Figure 2A-D. Consider enhancing the nucleotide tracing for easier visualization
Line 141 and Figure 2F. Why change from the refraction detector in panel E to the absorbance detector in panel F? Importantly, how to know whether the shoulder corresponds to a dimer or to an extended monomer, and was the column calibrated?. In any case, do extended monomers and domain swapped dimers exist in solution? Additional crosslinking experiments, and analytical ultracentrifugation if available, could provide interesting results, although this is not a strict requirement for this manuscript.
Lines 155-157 and Figure 3. The "GTP-bound T-state" 3WGN structure is not GTP but GTP-gamma S-bound, which makes a difference. 3WGM is GTP-bound SaFtsZ, although with a truncated loop T7. There is an unnecessary mix of FtsZs from different species in structures 2RHL and 3VOA; using instead 5H5G-molecule A (T-state, GDP) and 5H5G-molecule B (R-state, GDP) would simplify the structures employed for comparison in Figure 3 to a single species, SaFtsZ. In fact, 5H5G is employed as a reference in Figure 3C, although the distinction between 5H5G molecules A and B is not mentioned.
Lines 157-160. The guanine ring angle depends on a stacking interaction with Phe183 form helix H7, which shifts in known FtsZ R and T structures. But this part of the structure is actually missing from the so called "T-state GDP" and "T-state GTP" SmFtsZ swapped domain structures. Instead, the guanine ring interacts with the main chain carbonyl of Phe137, an interaction which is not observed in the standard R or T FtsZ structures employed for comparison. This makes using the guanine ring angle alone misleading for conformational classification of SmFtsZ. In addition, both SmFtsZ "T-state" structures show a R-like Arg29 disengaged from interacting with the guanine (Figure 3), contrary to the interaction observed in the FtsZ T conformation. The overall conformation of the SmFtsZ structures does correspond to R-FtsZ. However, the swapped domain context of the SmFtsZ structure hampers meaningful comparisons with other FtsZ structures at a detailed local level around the guanine ring.
Lines 175-177. "We concluded that in B chain the nucleotide-bound NTD is in T-state...". Importantly, the structure of the NTD of FtsZ, not including helix H7, is known to be very similar in the R and T conformations; differences are the position of helix H7, the position of the CTD relative to the NTD and the opening of the interdomain cleft (refs 23 and 24). The guanine ring angle is clearly related to the H7-Phe183 shift. Therefore, distinguishing R and T-conformations of the NTD in FtsZs and in SmFtsZ in particular seems unsupported by experimental data.
Lines 197-199. Checking known FtsZ structures shows that Gly71 in loop T3 can be flipped out or in with GDP in both R and T conformation, whereas it is out with GTP or its analogs, making room for the gamma phosphate. It is interesting that the authors now observe this change with SmFtsZ, comparing the structures of GDP-bound and GMPPNP-bound protein. However, they should analyze and mention the precedents in the PDB, not only the GTP-gamma-S-bound 3WGN, and draw their conclusion very carefully due to the swapped domain context. There are known interactions made by the nucleotide gamma phosphate (PDB 3WGM) and one analog (PDB 7OHK) across the association interface in FtsZ filaments that explain FtsZ polymerization. In addition, is loop T3 really stabilized by the gamma phosphate of by filament formation?
Lines 202-210. Tyr145 is not part of loop T5 but of helix H5. The observed interplay between loop T3 Pro73 and H5 Tyr145 is an attractive feature (apparently reminiscent of the tubulin T3-T5 story, but see Discussion). Please indicate if this has not been pointed out before in other FtsZs with the residue corresponding toTyr145, and consider analyzing existing FtsZ structures for T3-H5/T5 cross talk in different nucleotide states.
Lines 212-324. The last three sections of Results convincingly demonstrate how residue 224 Phe/Met in the cleft between CTD and NTD modulates SmFtsZ assembly, EcFtsZ assembly, and E. coli cell division. In addition to this study, is it known whether SmFtsZ can replace EcFtsZ for E. coli cell division?
Line 220 and Figure S3A. Please explain the color code in this Figure.
Line 243. How can it be proposed that SmFtsZF224M could not be crystallized with GMPPNP probably due to efficient filament formation, if the activity of GMPPNP inducing filament formation has not been documented?
Figure 6 panel F. The NeonGreen Z-ring microscopy images need enlargement to be properly appreciated.
Discussion Line 342. Please notice that loop T3 is not always disordered with GDP. The proposal lacks an analysis of other FtsZ structures, in addition to 3WGN, and ignores intermolecular interactions of the nucleotide gamma phosphate and the coordinated Mg2+ ion (Matsui et al, 2014 J Biol Chem; Ruiz et al, 2022 PLoS Biol).
Discussion Lines 356-370. The similarities to the classical GTP/GDP-dependent T3-T5 cross talk in the tubulin-RB3 complex (reviewed in Ref 27) is appealing, but notice that this was curved R-state tubulin with an accessory protein. But maybe the nucleotide dependent T3-T5 cross talk does not take place in T-tubulin from cryoEM microtubule structures with GDP and GTP (LaFrance et al and Nogales 2022 PNAS)?. And the authors should carefully check the tubulin T3 and T5 loop GDP/GTP-dependent conformations in the recently available cryoEM structures of free tubulin heterodimers (R-state) bound to GDP (PDB 7QUC) and GTP (PDB 7QUD) without any accessory proteins, which differ from the classical view.
Discussion Lines 371-379. It should be noticed that a simpler interpretation of the results is that SmFtsZ is in the R-state, with R-CTD and R-H7, whereas the NTD is practically the same in both R and T states, as for other FtsZs (Ref 23). The T-like guanine angle may result from anomalous interactions of the swapped domains in SmFtsZ.
Discussion Lines 381-384. There is really no need to postulate a NTD transition from R- to T-state in order to propose a kinetic polarity for the FtsZ filament from structure. In fact, having the NTD conformation constant results in a monomer top interface that is pre-formed for association and with the help of GTP should bind to the filament bottom subunit, as already proposed in Ref 35.
Referees cross-commenting
In addition to the concerns shared by the reviewers, especially those related to the existance or the role of distinct R and T conformations of the NTD of FtsZ, as welll as the individual reviewer concerns, we would like to highlight the relevance of:
The comment of reviewer 1, requiring more information on the biological role of FtsZ in cell division of Spiroplasma and whether it forms a ring.
Comment 2 of reviewer 3, requiring time-dependance of SmFtsZ polymerization and GTPase data, which are essential for properly analyzing the GTPase activity.
Significance
This interesting work, if successfully revised, will provide valuable insight into how the FtsZ polymerization switch and the nucleotide binding loops work for assembly of polar filaments, employing FtsZ from a wall-less bacterium. Please see the comments above for the existing literature context of the manuscript. This paper will be possibly suitable for a general biological audience, in addition to microbiologists and cytoskeletal researchers.
This review has been prepared by biochemistry and structural biology experts familiar with FtsZ, hoping that it may be useful to the authors.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary: This paper reports the biochemical and structural characterization of FtsZ from a wall-less bacterial organism, Spiroplasma melliferum. From the analysis of the crystal structures (and comparison to known structures) the authors propose a model to explain the kinetic polarity of FtsZ treadmilling that was derived from a mostly genetic analysis (ref 26). In that model FtsZ with GTP bound adds to the bottom end of a filament with the C-terminal domain then shifting to the T-state. The status of the N-ter (whether in the T or R-state was not considered). Here the authors have proposed that they have captured an intermediate with the N-ter in the T-state and the C-ter in the R-state. It is proposed that this form adds to the bottom of a filament with the C-ter now adopting the T-state. I am not convinced this model is supported by the data as it is not clear when the N-ter domain switches to the T-state (before or after addition the end of a filament).
Significance
Note: the authors define the N-ter being in the T-state vs R-state based on the orientation of the guanine ring. The C-ter domain is in the T vs R-state based on whether the cleft is open or closed respectively.
The basis of the authors' model comes mostly from the analysis of the crystal structure of FtsZ from the wall-less bacterial that was obtained in this study. The crystal structure revealed an unusual swapped dimer. Although in solution this FtsZ is a monomer, it crystallized as a swapped dimer indicating that during crystallization FtsZ domains came apart and reassociated with the opposite domains from another monomer. Careful analysis reveals that in one monomer the N-ter domain is in the T-state whereas in the other the N-ter domain is in the R-state (independent of nucleotide; GDP or GMPCPP). Although the N-ter domain is in the T-state in both monomers there are some differences - with GMPCPP the T3 loop is ordered whereas it is disordered with GDP. Also, they propose that the orientation of Gly71 is such in the GTP state that it favors interaction with the bottom end of a filament.
Is it known whether FtsZ assembles into a Z ring and is required for cell division in this organism?
In the dimer both C-terminal domains are in the R-state. From this the authors propose that the one monomer in the dimer is in the R-state whereas the other is in transition state (T-for N-ter and R-for C-terminal domain).
The authors analyze sequences of FtsZ from different bacteria and notice that position 242 is a Phe in their organism whereas it is a Met in other bacteria. They wonder whether this residue influences the C-ter transitioning to the T-state so they swap residues - putting a Met in Sm and a Phe in Ecoli at this position. Interestingly, they notice that Sm-FtsN-met results in increased GTPase activity but longer filaments - this seems contradictory as higher GTPase is usually associated with shorter filaments - e.g. increased Mg slows GTPase activity and increased filament length and bundling. The Ec-FtsZ-Phe mutant displays increased cell length but not sure this can be ascribed to an effect on the GTPase activity.
Overall, the work is well done and it comes to interpretation and whether the data support the model. The emphasis is on the N-ter getting to the T-state, but I am not sure that is the important step. It seems to me that rate-limiting step in FtsZ assembly is the C-ter getting into the T-state, which happens when a subunit is added to the end of a filament. Obviously the N-ter has to get to the T-state as well but how that happens is not clear. Presumably, it happens as a GTP-bound monomer in the R-state adds to the end of a filament resulting in the N-ter adopting the T-state followed by the C-ter adopting the T-state. In other words the T-state is only achieved by addition of a subunit to the end of the filament.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
__Reviewer 1____: __
1-Localization of ESYT1 and SYNJ2BP
The claim of a localization at ER-mitochondria contacts relies on two type of assays. Light microscopy and subcellular fractionation. Concerning microscopy, while the staining pattern is obviously colocalizing with the ER (a control of specificity of staining using KO cells would nevertheless be desirable)
the idea that ESYT1 foci "partially colocalized with mitochondria" is either trivial or unfounded
Every cellular structure is "partially colocalized with mitochondria" simply by chance at the resolution of light microscopy
If the meaning of the experiment is to show that ESYT1 'specifically' colocalizes with mitochondria, then this isn't shown by the data
There is no quantification that the level of colocalization is more than expected by chance
nor that it is higher than that of any other ER protein
Moreover, the author's model implies that ESYT1 partial colocalization with mitochondria is, at least partially, due to its interaction with SYNJ2BP. This is not tested.
- To analyze and measure MERCs parameters and functions, we used a set of validated methods described in the following specialized review articles (Eisenberg-Bord, Shai et al. 2016, Scorrano, De Matteis et al. 2019).
- To support and confirm the localization of ESYT1-SYNJ2BP complex at MERCs, we performed supplementary BioID analysis using ER target BirA*, OMM targeted BirA* and ER-mitochondria tether BirA* (Table S1, Figure S1 and Figure 1 A and B). These results confirmed the specificity of the interaction of the 2 partners. ESYT1 is not identified as a prey in OMM BioID and SYNJ2BP is not identified in ER BioID, on the other hand both partners are identified in the ER-mitochondria tether BioID.
- To improve our description of the partial localization of ESYT1 at mitochondria, we performed a quantitative analysis using confocal microscopy on control human fibroblasts stably overexpressing SEC61B-mCherry as an ER marker which were labelled with ESYT1 and TOMM40 for mitochondria. We measured the % of ESYT1 signal colocalizing with mitochondria and the % of mitochondria positive for ESYT1 (Figure 1E).
-
To demonstrate than ESYT1 partial colocalization with mitochondria is, at least partially, due to its interaction with SYNJ2BP, we performed a quantitative analysis using confocal microscopy. Human control fibroblasts, KO SYNJ2BP fibroblasts and SYNJ2BP overexpressing fibroblasts were labelled with ESYT1, TOMM40 for mitochondria and CANX for ER. We measured the % of ESYT1 signal colocalizing with mitochondria in each condition (Figure 3C). Membranes (MAM) can be purified and are enriched for proteins that localize at ER-mitochondria contacts. This idea originated in the early 90's and since then, myriad of papers has been using MAM purification, and whole MAM proteomes have been determined. Yet the evidence that MAM-enriched proteins represent bona fide ER-mitochondria-contact-enriched proteins (as can nowadays be determined by microscopy techniques) remain scarce. Here, anyway, ESYT1 fractionation pattern is identical to that of PDI, a marker of general ER, with no indication of specific MAM accumulation.
-
To highlight the enrichment of ESYT1 in the MAM fraction, we quantified the ESYT1 signal in each fraction. Those results show a similar fractionation pattern than the MAM resident protein SIGMAR1 (Figure 1F). For SYNJ2BP, it is different as it is more enriched in the MAM than the general mitochondrial marker PRDX3. However, PRDX3 is a matrix protein, making it a poor comparison point, since SYNJ2BP is an OMM protein.
-
To confirm the partial enrichment of SYNJ2BP in the MAM fraction compared to another outer mitochondrial membrane protein, we added the signal of the well characterized OMM protein CARD19 (Rios, Zhou et al. 2022). Again, the model implies that ESYT1 and SYNJ2BP accumulation in the MAM should be dependent on each other. This is not tested.
-
As describe above, we demonstrated in Figure 3C than the accumulation of ESYT1 at mitochondria is, at least partially, dependent on the quantity of SYNJ2BP.
- We moreover showed a reciprocal effect in Figure 3E. A quantitative analysis using confocal microscopy demonstrated that the effect of SYNJ2BP overexpression on MERCs formation is partially dependent of the presence of ESYT1. 2-ESYT1-SYNJ2BP interaction.
The starting point of the paper is a BioID signal for SYNJ2BP when BioID is fused to ESYT1. One confirmation of the interaction comes in figure 4, using blue native gel electrophoresis and assessing comigration. Because BioID is promiscuous and comigration can be spurious, better evidence is needed to make this claim. This is exemplified by the fact that, although SYNJ2BP is found in a complex comigrating with RRBP1, according to the BN gel, this slow migrating complex isn't disturbed by RRBP1 knockdown, but is somewhat disturbed by ESYT1 knockdown. More than a change in abundance, a change in migration velocity when either protein is absent would be evidence that these comigrating bands represent the same complex.
- We showed in Figure 4C that the presence of SYNJ2BP in a complex of a similar molecular weight that ESYT1 (410KDa) is totally dependent of the presence of ESYT1, suggesting an interaction of the 2 proteins.
-
To confirm this interaction, in figure 4A we analyzed on BN cells overexpressing SYNJ2BP together with a 3xFlag tagged version of ESYT1. As a result of the addition of the Flag tag, the complex positive for ESYT1 shifted to a higher molecular weight. The complex positive for SYNJ2BP shifted to a similar the molecular weight, demonstrating the interaction and dependence of the 2 partners. ESYT1-SYNJ2BP interaction needs to be tested by coimmunoprecipitation of endogenous proteins, yeast-2-hybrid, in vitro reconstitution or any other confirmatory methods.
-
To confirm the interaction of the 2 partners, we performed co-immunoprecipitation of the ESYT1-3xFlag protein that we showed in Figure 1H to form complexes similar to the endogenous protein. SYNJ2BP is found as the strongest prey, followed by ESYT2 and SEC22B two described interactors of ESYT1, confirming the quality of the analysis (Table S2) (Giordano, Saheki et al. 2013, Gallo, Danglot et al. 2020). 3-Tethering by ESYT1- SYNJ2BP.
This is assessed by light and electron microscopy. Absence of ESYT1 decreases several metrics for ER-mitochondria contacts (whether absence of SYNJ2BP has the same effect isn't tested).
- Using PLA (proximity ligation assay) we demonstrated that the loss of SYNJ2BP leads to a decrease in MERCs (Figure 7 H and I), confirming previous studies (Ilacqua, Anastasia et al. 2022, Pourshafie, Masati et al. 2022). This interesting phenomenon could be due to many things, including but not limited to the possibility that "ESYT1 tethers ER to mitochondria".
This statement and the respective subheading title are therefore clearly overreaching and should be either supported by evidence or removed.
Indeed, absence of ESYT1 ER-PM tethering and lipid exchange could have knock-on effects on ER-mito contacts, therefore strong statements aren't supported.
Moreover, the effect on ER-mitochondria contact metrics could be due to changes in ER-mitochondria contact indeed but may also reflect changes in ER and/or mitochondria abundance and/or distribution, which favour or disfavour their encounter. Abundance and distribution of both organelles are not controlled for.
-
The mitochondrial phenotypes caused by the loss of ESYT1 are all rescued by the introduction of an artificial mitochondrial-ER tether, demonstrating that they are due to loss of the tethering function of ESYT1. Finally, the authors repeat a finding that SYNJ2BP overexpression induces artificial ER-mitochondria tethering. Again, according to the model, this should be, at least in part, due to interaction with ESYT1. Whether ESYT1 is required for this tethering enhancement isn't tested.
-
As described above, we demonstrated in Figure 3C that the accumulation of ESYT1 at mitochondria is, at least partially, dependent on the quantity of SYNJ2BP.
- We moreover showed a reciprocal effect in Figure 3F. A quantitative analysis using confocal microscopy demonstrated that the effect of SYNJ2BP overexpression on MERC formation is partially dependent of the presence of ESYT1. 4-Phenotypes of ESYT1/SYNJ2BP KD or KO.
The study goes in details to show that downregulation of either protein yields physiological phenotypes consistent with decreased ER-mitochondria tethering. These phenotypes include calcium import into mitochondria and mitochondrial lipid composition.
Figure 5 shows that histamine-evoked ER-calcium release cause an increase in mitochondrial calcium, and this increase is reduced in absence of ESYT1, without detectable change in the abundance of the main known players of this calcium import. This is rescued by an artificial ER-mitochondria tether. However, Figure 5D shows that the increase in calcium concentration in the cytosol upon histamine-evoked ER calcium release is equally impaired by ESYT1 deletion, contrary to expectation. Indeed, if the impairment of mitochondrial calcium import was due to improper ER-mitochondria tethering in ESYT1 mutant cells, one would expect more calcium to leak into the cytosol, not less.
The remaining explanation is that ESYT1 knockout desensitizes the cells to histamine, by affecting GPCR signalling at the PM, something unexplored here.
In any case, a decreased calcium discharge by the ER upon histamine treatment, explains the decreased uptake by mitochondria.
The authors argue that ER calcium release is unaffected by ESYT1 KO, but crucially use thapsigargin instead of histamine to show it. Thus, the most likely interpretation of the data is that ESYT1 KO affects histamine signalling and histamine-evoked calcium release upstream of ER-mitochondria contacts.
- Silencing ESYT1 impairs SOCE efficiency in Jurkat cells (Woo, Sun et al. 2020), but not in HeLa cells (Giordano, Saheki et al. 2013, Woo, Sun et al. 2020). Analysis of the role of ESYT1 in HeLa cells prevents confounding effects due to the loss of ESYT1 at ER-PM. In this model, knock-down of ESYT1 led to a decrease of mitochondrial Ca2+ uptake from the ER upon histamine stimulation, as monitored by genetically encoded Ca2+ indicator targeted to mitochondrial matrix (Figure 5A and B). ESYT1 silencing in HeLa cells did not impact ER Ca2+ store measured by the ER-targeted R-GECO Ca2+ probe (Figure 5C and D). The expression of the artificial mitochondria-ER tether was able to rescue mitochondrial Ca2+ defects observed in ESYT1 silenced cells (Figure 5B), confirming that the observed anomalies are specifically due to MERC defects.
- In contrast loss of ESYT1 impaired SOCE efficiency in fibroblasts (Figure 6 A and B). This phenotype was fully rescued by re-expression of ESYT1-Myc but not the artificial tether. We therefore investigated the influence of ESYT1 loss on cytosolic Ca2+ concentration following ATP (Figure 6F to H) or histamine stimulation (Figure S3 D to F), both of which showed a reduced cytosolic Ca2+ concentration and uptake in ESYT1 KO cells. This phenotype was fully rescued by the re-expression of ESYT1-Myc but not the artificial tether. Measurment of cytosolic Ca2+ after tharpsigargin treatment in Ca2+-fee media, an inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase SERCA that blocks Ca2+ pumping into the ER, showed that ESYT1 KO does not influence the total ER Ca2+ pool (Figure 6K and L). However, ER-Ca2+ release capacity upon histamine stimulation (Figure 6I and J) is decreased in ESYT1 KO cells. This phenotype was fully rescued by the re-expression of ESYT1-Myc but not the artificial tether. Loss of ESYT1 decreased the Ca2+ uptake capacities of mitochondria after activation with histamine (Figure S3 A to C) or ATP (Figure 6 C to E). This phenotype was rescued by re-expression of ESYT1-Myc and also the engineered ER-mitochondria tether. Thus, despite the ER-Ca2+ release defect observed after ESYT1 loss, the artificial tether fully rescued the mitochondrial phenotype.
-
These results highlight the distinct and dual roles of ESYT1 in Ca2+ regulation at the ER-PM and at MERCs. The data with SYNJ2BP deletion are more compatible with decreased ER-mito contacts, as no decreased in cytosolic calcium is observed. This is compatible with the previously proposed role of SYNJ2BP in ER-mitochondria tethering, but the difference with ESYT1 rather argue that both proteins affect calcium signaling by different means, meaning they act in different pathways.
-
We explain the different results concerning cytosolic calcium by the fact that ESYT1 is a bi-localized protein with dual functions on cellular calcium. Implicated both in SOCE at ER-PM and in mitochondrial calcium uptake at MERCs. On the other hand, SYNJ2BP is only present at MERCs and its loss do not influence PM-ER signaling or ER-Ca2+ release. Finally, the study delves into mitochondrial lipids to "investigated the role of the SMP-domain containing protein ESYT1 in lipid transfer from ER to mitochondria". In reality, it is not ER-mitochondria lipid transport that is under scrutiny, but general lipid homeostasis, and changes in ER-PM lipids could have knock-on effects on mitochondrial lipids without the need to invoke disruptions in ER-mitochondria transfer activity.
-
The fact that the artificial tether, which specifically rescue MERCs, fully rescue the lipid phenotype argue for a direct loss of MERCs tethering function when ESYT1 is missing. The changes observed are interesting but could be due to anything. Surprisingly, PCA analysis shows that the rescue of the knockout by the ESYT1 gene clusters with the rescue by the artificial tether, and not with the wildtype. This indicates that overexpressing either ESYT1 or a tether cause similar lipidomic changes. These could be due, for instance, to ER stress caused by protein overexpression, and not to a rescue.
-
In order to verify if the overexpression of ESYT1 or the artificial tether induces ER stress, we performed a WB analysis to compare markers of ER stress in control fibroblasts, KO ESYT1 fibroblasts, KO ESYT1 fibroblasts overexpressing ESYT1-Myc or the tether (Figure S4C). This showed no changes in the levels of several different markers of ER stress or cell death. __Reviewer 2____: __
1) the interaction between those proteins is direct,
2) if SYNJ2BP is necessary and sufficient to localize E-Syt1 at MERC, and
3) if MERCs extension induced by SYNJ2BP is dependent on E-Syt1.
Those points are important to investigate because SYNJ2BP has already been shown to induce MERCs by interacting with the ER protein RRBP1. In addition, some experiments need to be better quantified.
Major comments: E-syt1/SYNJ2BP in MERCs formation: the authors provide several convincing lines of evidence that both proteins are in the same complex (proximity labelling, localization in the same complex in BN-PAGE, localization in MAM) but it is not clear in which extent the direct interaction between both proteins regulates ER-mitochondria tethering. 1- Pull down experiments or BiFC strategy could be performed to show the direct interaction between both proteins.
- We showed in Figure 4C that the presence of SYNJ2BP in a complex of a similar molecular weight to that ESYT1 (410KDa) is totally dependent of the presence of ESYT1, suggesting an interaction of the 2 proteins.
- To confirm this interaction, in figure 4A we analyzed on BN cells overexpressing SYNJ2BP together with a 3xFlag tagged version of ESYT1. As a result of the addition of the Flag tag, the complex positive for ESYT1 shifted to a higher molecular weight. Significantly, the complex positive for SYNJ2BP shifted to a similar the molecular weight, demonstrating the interaction and dependence of the 2 protein partners.
-
To confirm the interaction of the 2 partners, we performed co-immunoprecipitation of the ESYT1-3xFlag protein (Table S2). SYNJ2BP was found as the strongest prey, followed by ESYT2 and SEC22B two described interactors of ESYT1, confirming the quality of the analysis (Giordano, Saheki et al. 2013, Gallo, Danglot et al. 2020). 2- SYNJ2BP OE has already been demonstrated to increase MERCs and this being dependent on the ER binding partners RRBP1 (10.7554/eLife.24463). Therefore, it would be of interest to perform OE of SYNJ2BP in KO Esyt1 to address the question of whether ESyt1 is also required to increase MERCs.
-
A quantitative analysis using confocal microscopy demonstrated that the effect of SYNJ2BP overexpression on MERCs formation is partially dependent of the presence of ESYT1 (Figure 3F). 3- The authors show that Esyt1 punctate size increases when SYNJ2BP is OE (Fig3C), but this can be indirectly linked to the increase of MERCs in the OE line. Thus, it could be interesting to test if the number/shape of E-syt1 punctate located close to mitochondria decreases in KO SYNJ2B. This could really show the dependence of SYNJ2BP for E-syt1 function at MERCs.
-
To improve our description of the partial localization of ESYT1 at mitochondria, we performed a quantitative analysis using confocal microscopy on control human fibroblasts stably overexpressing SEC61B-mCherry as an ER marker which were labelled with ESYT1 and TOMM40 for mitochondria. We measured the % of ESYT1 signal colocalizing with mitochondria and the % of mitochondria colocalizing with ESYT1 (Figure 1E).
-
To demonstrate than ESYT1 partial colocalization with mitochondria is, at least partially, due to its interaction with SYNJ2BP, we performed a quantitative analysis using confocal microscopy. Human control fibroblasts, KO SYNJ2BP fibroblasts and SYNJ2BP overexpressing fibroblasts were labelled with ESYT1, TOMM40 for mitochondria and CANX for ER. We measured the % of ESYT1 signal colocalizing with mitochondria in each condition (Figure 3C). Lipid analyses: the results of MS on isolated mitochondria clearly show that mitochondrial lipid homeostasis is affected on KO-Syt1 and rescued by expression of Syt1-Myc and artificial mitochondria-ER tether. However, p.15, the authors wrote "The loss of ESYT1 resulted in a decrease of the three main mitochondrial lipid categories CL, PE and PI, which was accompanied by an increase in PC ». As the results are expressed in mol%, this interpretation can be distorted by the fact that mathematically, if the content of one lipid decreases, the content of others will increase. I would suggest to express the results in lipid quantity (nmol)/mg of mitochondria proteins instead of mol%. This will clarify the role of E-Syt1 on mitochondrial lipid homeostasis and which lipid increase and decrease.
-
We changed the sentence in the text as suggested. Also it could be of high interest to have the lipid composition of the whole cells to reinforce the direct involvement of E-Syt1 in mitochondrial lipid homeostasis and verify that the disruption of mitochondrial lipid homeostasis is not linked to a general perturbation of lipid metabolism as this protein acts at different MCSs.
-
This is beyond the scope of the project and we would argue that the results of such an experiment would be difficult to interpret. To better understand the impact of Esyt1 of mitochondria morphology, the author could analyze the mitochondria morphology (size, shape, cristae) on their EM images of crt, KO and OE lines. Indeed, on OE (Fig3A), the mitochondria look bigger and with a different shape compared to crt.
-
As we do not observe obvious differences in mitochondrial morphology between control, KO and OE fibroblasts we do not think that quantitative analysis would add to the understanding of the effect of ESYT1 on mitochondrial function. Also, they performed a lot of BN-PAGE. Is it possible to check whether the mitochondrial respiratory chain super-complexes are affected on Esyt1 KO line compared to crt?
-
We decided to remove the data on the metabolic consequences of ESYT1 loss since it was too preliminary and required deeper investigations, focusing instead on the effect of ESYT1 loss on calcium homeostasis. Quantifications: some western blots needs to be quantified (Fig 5K, 6J, S3E);
-
We did not observe obvious differences in the protein levels so we think that quantitation would not add significantly to the understanding of the differences in calcium dynamics that we report. Fig1A: Can the author provide a higher magnification of the triple labeling and perform quantification about the proportion of E-Syt1 punctate located close to mitochondria?
-
We added higher magnification of the same area in all channels and arrows that point to the foci of ESYT1 colocalizing with both ER and mitochondria (Figure 1D).
-
To improve our description of the partial localization of ESYT1 at mitochondria, we performed a quantitative analysis using confocal microscopy on control human fibroblasts stably overexpressing SEC61B-mCherry as an ER marker which were labelled with ESYT1 and TOMM40 for mitochondria. We measured the % of ESYT1 signal colocalizing with mitochondria and the % of mitochondria colocalizing with ESYT1 (Figure 1E). Minor comments:
-
Fig1E + text: according to the legend, the BN-PAGE has been performed on Heavy membrane fraction. Why the authors speak about complexes at MAM in the text of the corresponding figure? Is-it the MAM or the heavy fraction (MAM + mito + ER...)? If BN have been performed from heavy membranes, it is not a real proof that E-syt1 is in MAMs.
-
Heavy membranes have been used in this experiment. The text and conclusions have been changed accordingly.
-
On fig3C (panel crt): it seems like SYNJ2BP dots are not co-localizaed with mito. Is this protein targeted to another organelle beside mitochondria?
-
It is not described that SYNJ2BP would be targeted to another organelle beside mitochondria. It is possible that those dots outside of mitochondria could be non-specific signals from the antibody we used.
-
Fig4A: can the author provide a control of protein loading (membrane staining as example) to confirm the decrease of E-Syt1 in siSYNJ2BP?
-
As we performed this experiment only once we have removed the statement suggesting a decrease in ESYT1 protein in response to the siSYNJ2BP.
-
Fig5E/F: it is not clear to me why the expression of E-Syt1 in the KO is not able to complement the KO phenotype for cytosolic Ca++. Can the authors comment this?
-
We performed further analysis using ATP to trigger calcium release from the ER (figure 6 F to H). In those conditions, expression of ESYT1 in the KO is able to complement the KO phenotype for cytosolic Ca2+. __Reviewer 3____: __
Main points 1. Confirming the MERC localization of ESYT1 should include some more of tethering factors as demonstrated interactors (some are mentioned above) and should not be limited to lipid homeostasis.
- As shown in Figure 1B, VAPB, PDZD8 and BCAP31 are found as preys in the ESYT1 bioID analysis. Those proteins have been described as MERC tethers, their loss leading to mitochondrial calcium defects. To support and confirm the specificity of ESYT1-SYNJ2BP complex at MERCs, we performed a supplementary BioID analysis using ER targeted BirA* and OMM targeted BirA* (Table S1, Figure S1 and Figure 1 A and B). These results confirmed the specificity of the interaction of the 2 partners. ESYT1 is not identified as a prey in OMM BioID and SYNJ2BP is not identified in ER BioID. Additional ER-mitochondria tether BirA* analyses showed that tether-BirA* identified both ESYT1 and SYNJ2BP as a prey at MERCs, confirming the localisation of this interaction. Interestingly, a large majority of the known MERCs tethers VAPB-PTPIP51, MFN2, ITPRs, BCAP31 are also found as preys in the tether-BirA* (Figure 1B), confirming the quality of these data.
- To confirm the interaction of the 2 partners, we performed co-immunoprecipitation of the ESYT1-3xFlag protein. SYNJ2BP is found as the strongest prey, followed by ESYT2 and SEC22B two described interactors of ESYT1, confirming the quality of the analysis (Table S2) (Giordano, Saheki et al. 2013, Gallo, Danglot et al. 2020).
The fact that in ESYT1 KO cells both mitochondrial calcium transfer and cytosolic calcium accumulation are accompanied by decreased ER-cepia1ER signal decay upon histamine addition suggest that the main reason for ER-mitochondria calcium transfer defects are due to impaired SOCE. Calcium-free medium and histamine are used to show that ESYT1 does not affect ER calcium content. However, if it affects SOCE, then the absence of extracellular calcium would abolish such an effect; moreover, histamine does not test for leak effects. As additional information, the authors should investigate whether ER calcium content is affected by the presence of extracellular calcium in the ko scenario using thapsigargin. The authors should inhibit SOCE to test whether this mechanism is affected in ESYT1 KO and could account for observed signal differences. Excluding SOCE is critical, since any change in calcium entry from the outside would potentially negate a role of ESYT1 in mitochondrial calcium uptake.
- Silencing ESYT1 impairs SOCE efficiency in Jurkat cells (Woo, Sun et al. 2020), but not in HeLa cells (Giordano, Saheki et al. 2013, Woo, Sun et al. 2020). Analysis of the role of ESYT1 in HeLa cells prevents confounding effects due to the loss of ESYT1 at ER-PM. In this model, knock-down of ESYT1 led to a decrease of mitochondrial Ca2+ uptake from the ER upon histamine stimulation, as monitored by genetically encoded Ca2+ indicator targeted to mitochondrial matrix (Figure 5A and B). ESYT1 silencing in HeLa cells did not impact ER Ca2+ store measured by the ER-targeted R-GECO Ca2+ probe (Figure 5C and D). The expression of the artificial mitochondria-ER tether was able to rescue mitochondrial Ca2+ defects observed in ESYT1 silenced cells (Figure 5B), confirming that the observed anomalies are specifically due to MERC defects.
- In contrast loss of ESYT1 impaired SOCE efficiency in fibroblasts (Figure 6 A and B). This phenotype was fully rescued by re-expression of ESYT1-Myc but not the artificial tether. We therefore investigated the influence of ESYT1 loss on cytosolic Ca2+ concentration following ATP (Figure 6F to H) or histamine stimulation (Figure S3 D to F), both of which showed a reduced cytosolic Ca2+ concentration and uptake in ESYT1 KO cells. This phenotype was fully rescued by the re-expression of ESYT1-Myc but not the artificial tether. Measurment of cytosolic Ca2+ after tharpsigargin treatment in Ca2+-fee media, an inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase SERCA that blocks Ca2+ pumping into the ER, showed that ESYT1 KO does not influence the total ER Ca2+ pool (Figure 6K and L). However, ER-Ca2+ release capacity upon histamine stimulation (Figure 6I and J) is decreased in ESYT1 KO cells. This phenotype was fully rescued by the re-expression of ESYT1-Myc but not the artificial tether. Loss of ESYT1 decreased the Ca2+ uptake capacities of mitochondria after activation with histamine (Figure S3 A to C) or ATP (Figure 6 C to E). This phenotype was rescued by re-expression of ESYT1-Myc and also the engineered ER-mitochondria tether. Thus, despite the ER-Ca2+ release defect observed after ESYT1 loss, the artificial tether fully rescued the mitochondrial phenotype.
- These results highlight the distinct and dual roles of ESYT1 in Ca2+ regulation at the ER-PM and at MERCs.
The authors claim that ER-Geco measurements show that no change of ER calcium was observed. However, they use thapsigargin treatment and then get a peak, when the signal should show a decrease due to leak. This suggests they did not use ER-Geco in Figure S3C. What was measured and what does it mean?
- We used R-GECO (not ER-GECO) which measures the cytosolic calcium.
- We measured total ER Ca2+ store using the cytosolic-targeted R-GECO Ca2+ probe upon thapsigarin treatment, an inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase SERCA that blocks Ca2+ pumping into the ER (Figure 5C and D) and observed no difference in our different conditions.
The findings on growth in galactose medium are intriguing but are not accompanied by respirometry to confirm mitochondria are compromised upon ESYT1 KO.
- We decided to remove the data on the metabolic consequences of ESYT1 loss since it was to preliminary and required deeper investigations, focusing instead on the effect of ESYT1 loss on calcium homeostasis
Minor points: 1. The authors mention they measure mitochondrial uptake of "exogenous" calcium by applying histamine. They should specify that these measures transferred calcium from the ER rather than uptake of calcium from the exterior (directly at the plasma membrane).
-
The text was clarified as suggested.
-
Expression levels of IP3Rs are not very indicative of any change of their activity. The authors should discuss how ESYT1 could affect their PTMs.
- A large numer of post translational modifications are known to regulate IP3R activity (Hamada and Mikoshiba 2020), and it is possible that the loss of ESYT1 could interfere with these modifications, but an exploration of this issue is beyond the scope of this study. The text was clarified as suggested. Eisenberg-Bord, M., N. Shai, M. Schuldiner and M. Bohnert (2016). "A Tether Is a Tether Is a Tether: Tethering at Membrane Contact Sites." Dev Cell 39(4): 395-409.
Gallo, A., L. Danglot, F. Giordano, B. Hewlett, T. Binz, C. Vannier and T. Galli (2020). "Role of the Sec22b-E-Syt complex in neurite growth and ramification." J Cell Sci 133(18).
Giordano, F., Y. Saheki, O. Idevall-Hagren, S. F. Colombo, M. Pirruccello, I. Milosevic, E. O. Gracheva, S. N. Bagriantsev, N. Borgese and P. De Camilli (2013). "PI(4,5)P(2)-dependent and Ca(2+)-regulated ER-PM interactions mediated by the extended synaptotagmins." Cell 153(7): 1494-1509.
Hamada, K. and K. Mikoshiba (2020). "IP(3) Receptor Plasticity Underlying Diverse Functions." Annu Rev Physiol 82: 151-176.
Ilacqua, N., I. Anastasia, D. Aloshyn, R. Ghandehari-Alavijeh, E. A. Peluso, M. C. Brearley-Sholto, L. V. Pellegrini, A. Raimondi, T. Q. de Aguiar Vallim and L. Pellegrini (2022). "Expression of Synj2bp in mouse liver regulates the extent of wrappER-mitochondria contact to maintain hepatic lipid homeostasis." Biol Direct 17(1): 37.
Pourshafie, N., E. Masati, A. Lopez, E. Bunker, A. Snyder, N. A. Edwards, A. M. Winkelsas, K. H. Fischbeck and C. Grunseich (2022). "Altered SYNJ2BP-mediated mitochondrial-ER contacts in motor neuron disease." Neurobiol Dis: 105832.
Rios, K. E., M. Zhou, N. M. Lott, C. R. Beauregard, D. P. McDaniel, T. P. Conrads and B. C. Schaefer (2022). "CARD19 Interacts with Mitochondrial Contact Site and Cristae Organizing System Constituent Proteins and Regulates Cristae Morphology." Cells 11(7).
Scorrano, L., M. A. De Matteis, S. Emr, F. Giordano, G. Hajnoczky, B. Kornmann, L. L. Lackner, T. P. Levine, L. Pellegrini, K. Reinisch, R. Rizzuto, T. Simmen, H. Stenmark, C. Ungermann and M. Schuldiner (2019). "Coming together to define membrane contact sites." Nat Commun 10(1): 1287.
Woo, J. S., Z. Sun, S. Srikanth and Y. Gwack (2020). "The short isoform of extended synaptotagmin-2 controls Ca(2+) dynamics in T cells via interaction with STIM1." Sci Rep 10(1): 14433.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Janer et al. have identified ESYT1 as a novel tether between the ER and mitochondria (MERCs) with roles in lipid and calcium homeostasis. They discovered extended synaptotagmin (ESYT1) in a BioID screen, where it interacts with SYNJ2BP and forms a high molecular weight complex. The study addressed a lack of information at the level of mammalian cell system, where a key protein complex known from yeast (ERMES) is absent, suggesting other proteins take over this critical role. These proteins then control the production of cardiolipin and PE, two lipid types essential for the functioning of mitochondria. They contain SMP motifs as a signature domain required for lipid transport. ESYT1 had previously been found to mediate lipid transfer at the plasma membrane and at peroxisomes, but the authors found it also localizes to MERCs. In a BioID screen, they have found numerous ER proteins with known roles in MERC tethering (e.g., EMC complex, BAP31, VAPB or TMX1). They have decided to focus on the aforementioned pair, which they demonstrate is enriched on MERCs (ESYT1) and mitochondria (SYNJ2BP), respectively, forming high molecular weight complexes, as detected by BN gels. Unlike RRBP1-SYNJ2BP, this complex is not dependent on ongoing protein synthesis. Upon generation of ESYT1 KO fibroblasts, they show that this SMP protein compromises MERC formation through electron microscopy. SYNJ2BP overexpression specifically increases contacts, as again shown by EM, independent of mitochondrial dynamics.
In its present form, the manuscript accurately describes the role of the ESYT1-SYNJ2BP complex for MERCs. The study contains nice lipidomics that reinforce this point and suggest a metabolic consequence. This latter observation is, however, very basic and requires some extension by assaying respirometry. The calcium phenotype is currently not fully characterized either. Interference with SOCE remains a possibility and if true, this would compromise the statement that the complex also controls calcium signaling. Both would need to be investigated better to either confirm or reject these roles, in my opinion, an important question. Overall, the manuscript contains interesting characterization of a tether that could have important consequences for calcium signaling, which would be an exciting finding.
Main points
- Confirming the MERC localization of ESYT1 should include some more of tethering factors as demonstrated interactors (some are mentioned above) and should not be limited to lipid homeostasis.
- The fact that in ESYT1 KO cells both mitochondrial calcium transfer and cytosolic calcium accumulation are accompanied by decreased ER-cepia1ER signal decay upon histamine addition suggest that the main reason for ER-mitochondria calcium transfer defects are due to impaired SOCE. Calcium-free medium and histamine are used to show that ESYT1 does not affect ER calcium content. However, if it affects SOCE, then the absence of extracellular calcium would abolish such an effect; moreover, histamine does not test for leak effects. As additional information, the authors should investigate whether ER calcium content is affected by the presence of extracellular calcium in the ko scenario using thapsigargin.
- The authors should inhibit SOCE to test whether this mechanism is affected in ESYT1 KO and could account for observed signal differences. Excluding SOCE is critical, since any change in calcium entry from the outside would potentially negate a role of ESYT1 in mitochondrial calcium uptake.
- The authors claim that ER-Geco measurements show that no change of ER calcium was observed. However, they use thapsigargin treatment and then get a peak, when the signal should show a decrease due to leak. This suggests they did not use ER-Geco in Figure S3C. What was measured and what does it mean?
- The findings on growth in galactose medium are intriguing but are not accompanied by respirometry to confirm mitochondria are compromised upon ESYT1 KO.
Minor points:
- The authors mention they measure mitochondrial uptake of "exogenous" calcium by applying histamine. They should specify that this measures transferred calcium from the ER rather than uptake of calcium from the exterior (directly at the plasma membrane).
- Expression levels of IP3Rs are not very indicative of any change of their activity. The authors should discuss how ESYT1 could affect their PTMs.
Significance
The study is certainly of high interest due to its implications for cell metabolism and calcium signaling. It contains very strong data on MERC formation and lipidomics. However, the calcium and metabolic aspects are currently not well developed and require improvements.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
The work of Janer and al. investigates the role of E-Syt1, a well known lipid transfer protein tethering ER and PM and ER and peroxisome, at ER-mitochondria contact sites (MERCs). E-Syt1 was identified has a putative MERCs component by proximity labeling performed from four SMP domain containing proteins. They identified the mitochondrial SYNJ2BP as a binding partner of E-Syt1 only. By different biochemical and microscopy approaches, they show that 1) E-Syt1 is located at MERCs and is involved in MERCs formation, 2) SYNJ2BP is located at MERCs and regulate the extent of MERCs in cells, 3) E-Syt1 and SYNJ2BP are located in MAM and in the same high molecular weight complex. Then, they show that both proteins impaired ER-mitochondria Ca++ exchange and that E-Syt1 influences mitochondrial lipid homeostasis, both phenotypes being rescued by artificial tether showing that only the tethering function of E-Syt1 is required. The proximity labelling experiments suggests SYNJ2BP as the mitochondrial partners of E-Syt1, however, from the data, it is not clear whether 1) the interaction between those proteins is direct,2) if SYNJ2BP is necessary and sufficient to localize E-Syt1 at MERC, and 3) if MERCs extension induced by SYNJ2BP is dependent on E-Syt1. Those points are important to investigate because SYNJ2BP has already been shown to induce MERCs by interacting with the ER protein RRBP1. In addition, some experiments need to be better quantified.
Major comments:
E-syt1/SYNJ2BP in MERCs formation: the authors provide several convincing lines of evidence that both proteins are in the same complex (proximity labelling, localization in the same complex in BN-PAGE, localization in MAM) but it is not clear in which extent the direct interaction between both proteins regulates ER-mitochondria tethering.
- Pull down experiments or BiFC strategy could be performed to show the direct interaction between both proteins;
- SYNJ2BP OE has already been demonstrated to increase MERCs and this being dependent on the ER binding partners RRBP1 (10.7554/eLife.24463). Therefore, it would be of interest to perform OE of SYNJ2BP in KO syt1 to address the question of whether Syt1 is also required to increase MERCs.
- The authors show that Syt1 punctate size increases when SYNJ2BP is OE (Fig3C), but this can be indirectly linked to the increase of MERCs in the OE line. Thus, it could be interesting to test if the number/shape of E-syt1 punctate located close to mitochondria decreases in KO SYNJ2B. This could really show the dependence of SYNJ2BP for E-syt1 function at MERCs. Lipid analyses: the results of MS on isolated mitochondria clearly show that mitochondrial lipid homeostasis is affected on KO-Syt1 and rescued by expression of Syt1-Myc and artificial mitochondria-ER tether. However, p.15, the authors wrote "The loss of ESYT1 resulted in a decrease of the three main mitochondrial lipid categories CL, PE and PI, which was accompanied by an increase in PC ». As the results are expressed in mol%, this interpretation can be distort by the fact that mathematically, if the content of one lipid decreases, the content of others will increase. I would suggest to express the results in lipid quantity (nmol)/mg of mitochondria proteins instead of mol%. This will clarify the role of E-Syt1 on mitochondrial lipid homeostasis and which lipid increase and decrease. Also it could be of high interest to have the lipid composition of the whole cells to reinforce the direct involvement of E-Syt1 in mitochondrial lipid homeostasis and verify that the disruption of mitochondrial lipid homeostasis is not linked to a general perturbation of lipid metabolism as this protein acts at different MCSs.
Role of Syt1 in mitochondria: the authors show a perturbation of ER-mito Ca exchange and mitochondrial lipid homeostasis in KO-Syt1 as well as a growth defect of cells grown on galactose media. Modification of lipid mitochondrial lipid homeostasis often leads to defect in mitochondria morphology and mitochondria respiration, usually because of defects in supercomplexes assembly. To better understand the impact of Syt1 of mitochondria morphology, the author could analyze the mitochondria morphology (size, shape, cristae) on their EM images of crt, KO and OE lines. Indeed, on OE (Fig3A), the mitochondria look bigger and with a different shape compared to crt. Also, they performed a lot of BN-PAGE. Is it possible to check whether the mitochondrial respiratory chain super-complexes are affected on Syt1 KO line compared to crt? <br /> Quantifications: some western blots needs to be quantified (Fig 5K, 6J, S3E); Fig1A: Can the author provide a higher magnification of the triple labeling and perform quantification about the proportion of E-Syt1 punctate located close to mitochondria?
Minor comments:
- Fig1E + text: according to the legend, the BN-PAGE has been performed on Heavy membrane fraction. Why the authors speak about complexes at MAM in the text of the corresponding figure? Is-it the MAM or the heavy fraction (MAM + mito + ER...)? If BN have been performed from heavy membranes, it is not a real proof that E-syt1 is in MAMs.
- On fig3C (panel crt): it seems like SYNJ2BP dots are not co-localizaed with mito. Is this protein targeted to another organelle beside mitochondria?
- Fig3C: can the author show each channel alone and not only the merge to better appreciate mito and ER shape in control vs OE lines (as in fig S2)
- Fig4A: can the author provide a control of protein loading (membrane staining as example) to confirm the decrease of E-Syt1 in siSYNJ2BP?
- Fig5E/F: it is not clear to me why the expression of E-Syt1 in the KO is not able to complement the KO phenotype for cytosolic Ca++. Can the authors comment this.
Significance
Sevral mitochondrial-ER tethers as well as some proteins involved in Ca and/or lipid exchanges have been identified in mammals. E-Syt1 is well known to be located at ER-PM contact sites as well as ER-peroxisomes, and the presence of E-Syt1 at MERCs and its role in Ca++ and lipid exchange are new exciting results further showing the versatility of this protein. The results concerning E-Syt1 in Ca++ and lipid exchange are very convincing. In addition, the proximity labeling performed from four different SMP domain containing proteins is a highly valuable source of information for future work about interaction networks of those proteins. What is less in the study is the involvement of E-Syt1 interaction with SYNJ2BP for localization and function at MERCs and vice versa. Indeed, SYNJ2BP has already been shown to promote MERCs extension and to interact with the ER protein RRBP1. Thus, it will be of interest to further investigate E-Syt1/SYNJ2BP interaction at MERCs.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
This manuscript reports the results of a study of the potential involvement of the SMP-domain-containing protein ESYT1 in ER-mitochondria tethering, and Ca+ and lipid exchange between the two organelles. SMP-domain proteins have been shown to localize to membrane contact site and have lipid transport activity. Esyt proteins have thus far been found at ER-plasma-membrane (PM) contacts. Here, starting from a BioID screen for partners of various SMP-domain proteins, the study focuses on a potential new interaction between ER-resident ESYT-1 and the mitochondrial outer-membrane protein SYNJ2BP. Then using a host of different approaches, the study concludes with a model in which ESYT-1-SYNJ2BP interaction tethers ER and mitochondria to regulate ion and lipid exchange between the two organelles.
This model would be very novel and interesting, as ESYT proteins have thus far only been detected at ER-PM contacts. However, the data supporting it are not unambiguous, are subject to alternative interpretation, and are sometimes contrary to the interpretation that the authors make of them. A lot of the reasoning behind the interpretation seems to be based on the fact that the authors have a hypothesis of what the effect of impacting ER-mitochondria should be, a priori, and when they observe such effects, they take it as evidence that they have indeed impacted tethering, disregarding alternative hypotheses and the possibility that the same effects can be wrought by entirely different mechanisms. Thus, the manuscript takes a few steps to involve ESYT1 in ER-mitochondria contacts but fails to make a decisive point.
Here are major points:
- Localization of ESYT-1 and SYNJ2BP. The claim of a localization at ER-mitochondria contacts relies on two type of assays. Light microscopy and subcellular fractionation. Concerning microscopy, while the staining pattern is obviously colocalizing with the ER (a control of specificity of staining using KO cells would nevertheless be desirable), the idea that ESYT1 foci "partially colocalized with mitochondria" is either trivial or unfounded. Every cellular structure is "partially colocalized with mitochondria" simply by chance at the resolution of light microscopy. If the meaning of the experiment is to show that ESYT1 'specifically' colocalizes with mitochondria, then this isn't shown by the data. There is no quantification that the level of colocalization is more than expected by chance, nor that it is higher than that of any other ER protein. Moreover, the author's model implies that ESYT1 partial colocalization with mitochondria is, at least partially, due to its interaction with SYNJ2BP. This is not tested.
The subcellular fractionation assays are grounded on the idea that Mitochondria-Associated (ER) Membranes (MAM) can be purified, and are enriched for proteins that localize at ER-mitochondria contacts. This idea originated in the early 90's and since then, myriad of papers has been using MAM purification, and whole MAM proteomes have been determined. Yet the evidence that MAM-enriched proteins represent bona fide ER-mitochondria-contact-enriched proteins (as can nowadays be determined by microscopy techniques) remain scarce. Here, anyway, ESYT1 fractionation pattern is identical to that of PDI, a marker of general ER, with no indication of specific MAM accumulation. For SYNJ2BP, it is different as it is more enriched in the MAM than the general mitochondrial marker PRDX3. However, PRDX3 is a matrix protein, making it a poor comparison point, since SYNJ2BP is an OMM protein.
Again, the model implies that ESYT1 and SYNJ2BP accumulation in the MAM should be dependent on each other. This is not tested. 2. ESYT1-SYNJ2BP interaction. The starting point of the paper is a BioID signal for SYNJ2BP when BioID is fused to ESYT1. One confirmation of the interaction comes in figure 4, using blue native gel electrophoresis and assessing comigration. Because BioID is promiscuous and comigration can be spurious, better evidence is needed to make this claim. This is exemplified by the fact that, although SYNJ2BP is found in a complex comigrating with RRBP1, according to the BN gel, this slow migrating complex isn't disturbed by RRBP1 knockdown, but is somewhat disturbed by ESYT1 knockdown. More than a change in abundance, a change in migration velocity when either protein is absent would be evidence that these comigrating bands represent the same complex.
ESYT1-SYNJ2BP interaction needs to be tested by coimmunoprecipitation of endogenous proteins, yeast-2-hybrid, in vitro reconstitution or any other confirmatory methods. 3. Tethering by ESYT1- SYNJ2BP. This is assessed by light and electron microscopy. Absence of ESYT1 decreases several metrics for ER-mitochondria contacts (whether absence of SYNJ2BP has the same effect isn't tested). This interesting phenomenon could be due to many things, including but not limited to the possibility that "ESYT1 tethers ER to mitochondria".This statement and the respective subheading title are therefore clearly overreaching and should be either supported by evidence or removed. Indeed, absence of ESYT1 ER-PM tethering and lipid exchange could have knock-on effects on ER-mito contacts, therefore strong statements aren't supported. Moreover, the effect on ER-mitochondria contact metrics could be due to changes in ER-mitochondria contact indeed, but may also reflect changes in ER and/or mitochondria abundance and/or distribution, which favour or disfavour their encounter. Abundance and distribution of both organelles are not controlled for.
Finally, the authors repeat a finding that SYNJ2BP overexpression induces artificial ER-mitochondria tethering. Again, according to the model, this should be, at least in part, due to interaction with ESYT1. Whether ESYT1 is required for this tethering enhancement isn't tested. 4. Phenotypes of ESYT1/SYNJ2BP KD or KO. The study goes in details to show that downregulation of either protein yields physiological phenotypes consistent with decreased ER-mitochondria tethering. These phenotypes include calcium import into mitochondria and mitochondrial lipid composition.
Figure 5 shows that histamine-evoked ER-calcium release cause an increase in mitochondrial calcium, and this increase is reduced in absence of ESYT1, without detectable change in the abundance of the main known players of this calcium import. This is rescued by an artificial ER-mitochondria tether.
However, Figure 5D shows that the increase in calcium concentration in the cytosol upon histamine-evoked ER calcium release is equally impaired by ESYT1 deletion, contrary to expectation. Indeed, if the impairment of mitochondrial calcium import was due to improper ER-mitochondria tethering in ESYT1 mutant cells, one would expect more calcium to leak into the cytosol, not less. The remaining explanation is that ESYT1 knockout desensitizes the cells to histamine, by affecting GPCR signalling at the PM, something unexplored here. In any case, a decreased calcium discharge by the ER upon histamine treatment, explains the decreased uptake by mitochondria. The authors argue that ER calcium release is unaffected by ESYT1 KO, but crucially use thapsigargin instead of histamine to show it. Thus, the most likely interpretation of the data is that ESYT1 KO affects histamine signalling and histamine-evoked calcium release upstream of ER-mitochondria contacts.
The data with SYNJ2BP deletion are more compatible with decreased ER-mito contacts, as no decreased in cytosolic calcium is observed. This is compatible with the previously proposed role of SYNJ2BP in ER-mitochondria tethering, but the difference with ESYT1 rather argue that both proteins affect calcium signalling by different means, meaning they act in different pathways.
Finally, the study delves into mitochondrial lipids to "investigated the role of the SMP-domain containing protein ESYT1 in lipid transfer from ER to mitochondria". In reality, it is not ER-mitochondria lipid transport that is under scrutiny, but general lipid homeostasis, and changes in ER-PM lipids could have knock-on effects on mitochondrial lipids without the need to invoke disruptions in ER-mitochondria transfer activity. The changes observed are interesting but could be due to anything. Surprisingly, PCA analysis shows that the rescue of the knockout by the ESYT1 gene clusters with the rescue by the artificial tether, and not with the wildtype. This indicates that overexpressing either ESYT1 or a tether cause similar lipidomic changes. These could be due, for instance, to ER stress caused by protein overexpression, and not to a rescue.
In any case the data here do not support the strong statement "Together these results demonstrate that ESYT1 is required for lipid transfer from ER to mitochondria [...]".
Significance
This model would be very novel and interesting, as ESYT proteins have thus far only been detected at ER-PM contacts. However, the data supporting it are not unambiguous, are subject to alternative interpretation, and are sometimes contrary to the interpretation that the authors make of them. A lot of the reasoning behind the interpretation seems to be based on the fact that the authors have a hypothesis of what the effect of impacting ER-mitochondria should be, a priori, and when they observe such effects, they take it as evidence that they have indeed impacted tethering, disregarding alternative hypotheses and the possibility that the same effects can be wrought by entirely different mechanisms. Thus, the manuscript takes a few steps to involve ESYT1 in ER-mitochondria contacts but fails to make a decisive point.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We are grateful to both reviewers for reviewing our manuscript, and for providing very helpful feedback as to how we can improve this work. We have now implemented nearly all of the changes as recommended, and provide responses to these points below.
In terms of novelty, while recent pre-prints and publications have suggested that the application of multi-omics analysis improves GRN inference, there has yet to be a systematic comparison of linear and non-linear machine learning methods for GRN prediction from single cell multi-omic data. here are many computational and statistical challenges to such a study, and we therefore believe that others in the field will be especially interested in our systematic comparison of network inference methods, especially given the increased interest and utility of multi-omic data.
In addition, we report the first comprehensive inference of GRNs in early human embryo development. This is a particularly challenging to study developmental context given genetic variation, limitations of sample size due to the precious nature of the material and regulatory constraints. We anticipate that the methodology we developed and datasets we generated will be informative for computational, developmental and stem cell biologists.
We have uploaded all the network predictions on FigShare and these can be accessed using the following link: https://doi.org/10.6084/m9.figshare.21968813. In addition, we anticipate that the computational and statistical codes and pipelines we developed (available on https://github.com/galanisl/early_hs_embryo_GRNs) will be applied to other cellular and developmental contexts, especially in challenging contexts such as human development, non-typical model organisms and in clinically relevant samples.
Reviewer 1
Major comments
- The proposed strategy (i.e. combining gene expression-based regulatory inference with cis-*regulatory evidence) have been well developed (and implemented) by multiple published works like SCENIC and CellOracle, which is also properly acknowledged by the authors in the discussion section too. This leads to a serious concern on the major methodological contribution of this work. *
We would like to note that our study is the first to comprehensively evaluate machine learning linear or non-linear gene regulatory network prediction strategies from single-cell transcriptional datasets combined with available multi-omic data. We also apply these methods to a challenging to study context of human early embryogenesis. There are specific methodological challenges arising in this context that other published work has not yet addressed. In particular, the precious nature of the source material means that sample sizes are limited, unlike the contexts where SCENIC and CellOracle were applied. Notably, the numbers of cells available for downstream analysis is typically several orders of magnitude fewer than when scRNA-seq data are collected from adult human tissue or from cell culture. This restriction on sample sizes places corresponding restrictions on statistical power, and is therefore likely to mean that different statistical network inference methodologies are optimal in specific contexts. Furthermore, the inclusion of multi-omic data from complementary platforms (such as ATAC-seq data) becomes even more important in this context to mitigate the effect of reduced sample sizes. These issues are very important for choice of gene regulatory network inference methodology in relation to studies of human embryo development, and ours is the first study to address these issues directly in any context. We have further clarified the novelty of our work in the manuscript in the abstract, introduction and discussion sections.
- Most of the compared network reconstruction methods involve hyper-parameters setup (e.g., *sparsity regularization weights of the regression methods). The authors did not discuss how these hyper-parameters were chosen. *
For sparse regression, the hyperparameter controlling sparsity was set by cross-validation (CV), using the internal CV function of the R package. All default settings for GENIE3 were used. This information has now been added to the manuscript (in the Methods section), along with a description of the implementation of the mutual information method we use.
- For the real-world blastocyst data, the network prediction methods were compared in terms of their reproducibility across validation folds (Fig. 3, Fig. S4-6). However, reproducibility does not necessarily imply accuracy. In fact, statistical learning methods are generally subject to the bias-variance tradeoff, where lower variance (i.e., higher reproducibility) could imply higher bias in model prediction. While there is a lack of gold-standard ground truth to evaluate network accuracy in real biological systems, silver-standards like the ranking of known regulatory interactions in the predictions could be employed as an indirect estimate.
We thank the reviewer for the opportunity to clarify this point. We would like to avoid any misunderstanding of the reproducibility statistic R, as follows. A higher value of R indicates that the fitted model would generalise well to new data; i.e., R=1 indicates that the model is robust (stable) to perturbations of the data-set. We note that this is not the same as analysing the residual variance of the data after model fitting and related over-fitting (i.e., bias-variance trade-off). The variance that is referred to when discussing bias-variance trade-off is the mean-squared error (of data compared to model), which is not the same as what is assessed by reproducibility statistic R . Specifically, R is a Bayesian estimate of the posterior probability of observing a gene regulation given the data. R is calculated by taking a random sample of the data, doing the network inference again, checking if each gene regulation still appears in the GRN, and then recording (as the R statistic) the average fraction of inclusions over many repetitions. So when we have R close to 1, this indicates that our model predictions generalise well to new data, which is the opposite of what is suggested in this comment. In summary, the accuracy quantified by the reproducibility statistic R relates to the stability of the model predictions to perturbation of the data. We thank the reviewer for the helpful comment to draw our attention to this point, and have now clarified this point in the manuscript on page 6 line 252.
- The gene set enrichment results were reported only on EPI and TE cell types (Fig. 4C and Fig. *S12), due to the reason that CA data is only available for TE and ICM. However, many of the other results presented in Fig. 3-6 did include the PE cell type albeit using the same CA data. It is not particularly convincing why the cell type inclusion standard for gene set enrichment is different from the other results. *
We thank the reviewer for noting this and would like to clarify that we restricted the analysis to the EPI and TE, because similar lists of gene-sets were not available for primitive endoderm, where it is currently unclear which pathways are most relevant to this cell type. This has now been clarified in the manuscript on page 8, line 337.
- The authors cited TF binding in cis-regulatory regions as supporting evidence of several MICA-inferred regulatory interactions (e.g., NANOG -> ZNF343). However, the same cis-regulatory *evidence has already been used in the CA filtering step. All interactions passing CA filtering should in principle have TF-binding support. It would be more convincing if the authors provided other types of evidence as independent support, such as genetic associations like eQTL, experimental perturbations like gene knockdown/knockout, etc. *
We appreciate the reviewer’s point. We address this by describing published ChIP-seq validation in human pluripotent stem cells which is widely used as a proxy for the study of the epiblast. We feel that the ChIP-seq validation in this context is an appropriate independent validation to support the MICA-inferred cis regulatory interactions predicted from the human embryo datasets we analysed. Our inferences from ATAC-seq data cannot identify TF-DNA binding directly. ChIP-seq data is a widely accepted independent methods to support the inferred interactions from ATAC-seq data.
We agree that knockdown/knockout would provide further evidence suggesting gene regulation, and indeed these are experiments we would like to conduct systematically in the future, but such perturbations are difficult to achieve at genome-wide scale, especially with very restricted quantities of human embryo material. Notably, these studies would not be evidence of direct regulation and the gold-standard in our opinion is to perturb the cis regulatory region to demonstrate its functional importance in gene regulation. These are important experiments to conduct systematically in the future. We also note that assessing quantitative trait loci in the context of human pre-implantation embryos is extremely challenging due to the restricted sample sizes and genetic variance in the samples collected.
*- Many of the MICA-inferred regulatory interactions do not exhibit Spearman correlation (Fig. 5, Fig. S17), which could probably be explained by the ability of mutual information to capture complex non-monotonic dependencies. It would be interesting to provide further investigation on these "uncorrelated" edges, which may help demonstrate the superiority of mutual information over Spearman correlation. *
This has been added as a new Fig.S18.
- The authors conducted immunostaining experiments to validate the MICA-inferred regulatory *interaction between TFAP2C and JUND. While the identified protein co-localization is a step further than RNA co-expression, it is still correlation rather than causality. Additional evidence like the effect of knockout/knockdown perturbations would be more convincing. *
We agree with Reviewer 1 that experimental perturbations of TFAP2C and JUND to determine what consequence this has for interactions between these proteins would be informative. However due to the complexity of such an investigation in human embryos, we feel that this is beyond the scope of the current study. One option is to conduct the perturbations in human pluripotent stem cells, however it is unclear if the GRN in this context reflects the same interactions as human embryos and is a distinct question to address in the future. Moreover, while knockdown/knockout studies would be suggestive of up-stream regulation, it will not address the question of whether this is a direct or indirect effect without systematic further analysis including transcription factor-DNA binding (such as CUT&RUN, CUT&Tag or ChIP-seq) analysis as well as perturbations of the putative cis regulatory regions. These are all exciting future experiments and our study provides us and others with hypotheses to functionally test in the future. These are future directions and we have clarified this in the discussion section on page 16, line 576.
__Minor comments __
- *The γ symbols in AP-2γ are not correctly rendered. *
We note that this applies only to the way AP-2γ appears on the Review Commons website, and we are trying to fix this issue. We hope this transformation after the manuscript upload will not apply to a subsequent transfer to a journal.
- The UMAP figures (Fig. 4A, Fig. S7) are of low resolution compared to other figures.
We thank the reviewer for noting this. These figures have now been added as vector graphics files to overcome this issue.
- As the authors are focused on studying the blastocyst regulatory network, the inferred regulatory interactions should be provided as supplementary data.
We have included all of the inferred gene regulatory interactions as a supplementary folder for the MICA predictions using FigShare: doi.org/10.6084/m9.figshare.21968813. We have included code to reproduce the inferred gene regulatory interactions for the other methods which we compared to MICA. Because this includes 100,000 regulatory interactions per method, we feel that it would be impractical to include the alternative inferred interaction as supplementary data.
Reviewer 2
Minor comments
*- In the abstract, it would be adequate to already mention which normalisation method works the best. *
This has now been added to the abstract and we appreciate this suggestion.
*- In Fig. 1: *
* Describe what are squares and circles
This information has been included in the figure 1 legend.
** In the GRNs refined by keeping CA-predicted regulations only, mention that this are Cis interactions *
We have modified the figure 1 legend and the text on page 5, line 224 to clarify that these are putative cis-regulatory interactions.
* The ATAC seq shows KRT8, GATA3, RELB motifs, while the rest of the figure is very general. Maybe make the ATAC-seq peaks panel also as a sketch and relate it to the square/circles graphs on the right hand side to showcase how the filtering of the network is performed.
We appreciate this suggestion and modified figure 1 accordingly.
** The caption says Five GRN inference approaches, while abstract and text say 4. If is clear after reading that the 5th is a random approach. However, it was a surprise at first. *
We have modified the figure 1 legend to clarify that we also compared random prediction in addition to the 4 GRN inference approaches.
*- How the Simulation study was performed is not understandable for non experts as it is described in the Methods section. This is an important approach in general, and I think the audience would benefit if the authors add a full section about it in their supplementary data. *
Further details have now been added to the subsection ‘simulation study’ in the Methods section.
*- Fig. 2: *
** As it is, it is hard to tell the difference between GRN inference methods for a given sample size and number of regulators. Could the authors add a comparative panel for this (maybe some scatter plots would be enough)? MI by itself looks worse here? *
We thank the reviewer for this helpful suggestion. This comparative plot has now been included in figure 2 and indicates that MI is on par with the other GRN inference methods using simulation RNA-seq data.
*- When mentioning "samples" (e.g. last paragraph of section 1 in results), do the authors refer to "cells"? *
We appreciate the reviewer pointing this out and have amended the text throughout to state that these are cells.
*- What about normalisation effects in the simulated data? *
With regards to the simulated data, normalisation effects are not relevant as we are generating data that are idealised and therefore not subject to unwanted sources of variation such as read depth. However, in future work, this could be investigated with an expanded simulation study and we appreciate the reviewer’s suggestion.
*- Figure S7 should be cited in the first paragraph of section 2 in results. *
This has now been cited.
*Could the authors add a panel to indicate whether the data is SMART-seq2 or 10X. *
We thank the reviewer for the suggestion to clarify this, which we think is an important point. We have included a statement that all data used was generated using the SMART-seq2 sequencing technique in the figure legend. The choice of sequencing method/depth of sequencing will likely impact on the choice of GRN inference method and we have also clarified this in the discussion section on page 13, line 516.
*- In the association of inferred GRNs to human blastocyst cell lineages, the authors find the GRN edges predicted that overlap between the 4 inference methods in each cell type. Do they, therefore, recommend to always use more than one GRN inference method? *
Identifying overlapping inferences by comparing more than one GRN inference method may be a strategy to identify network edges with more confidence due to the agreement between several inference methodologies. However, this strategy may also miss some edges which can only be detected by one method and not another. We have included a statement in the discussion section to clarify this point on page 15, line 571.
- If the CA data used was only generated for the TE and ICM only, how do the authors use it to perform MICA on PE?
We appreciate that this is confusing and have since revised the manuscript on page 5, line 223 to state that the inner cell mass (ICM), comprises EPI (epiblast) and PE (primitive endoderm) cells. It may be that we miss putative cis-regulatory interactions if the ICM CA data does not reflect developmentally progressed PE and EPI cells and we have noted this caveat in the discussion section on page 15, line 561.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
In this work, Alanis-Lobato et al apply different GRN inference methods on scRNA-seq data from human blastocysts. By integrating the data with ATACseq, they manage to address the small sample size challenge and predict novel TF-gene interactions that they later validate with immunofluorescence. Main take-home-messages from this work are that proper GRN inference methods work better upon integration of different omic technologies (here RNA and ATAC seq) and proper data normalisation strategies (logTPM or logFPKM).
Hereby I present some minor concerns and questions that I have after reading the manuscript, that I hope the authors can address.
- In the abstract, it would be adequate to already mention which normalisation method works the best.
- In Fig. 1:
- Describe what are squares and circles
- In the GRNs refined by keeping CA-predicted regulations only, mention that this are Cis interactions
- The ATAC seq shows KRT8, GATA3, RELB motifs, while the rest of the figure is very general. Maybe make the ATAC-seq peaks panel also as a sketch and relate it to the square/circles graphs on the right hand side to showcase how the filtering of the network is performed.
- The caption says Five GRN inference approaches, while abstract and text say 4. If is clear after reading that the 5th is a random approach. However, it was a surprise at first.
- How the Simulation study was performed is not understandable for non experts as it is described in the Methods section. This is an important approach in general, and I think the audience would benefit if the authors add a full section about it in their supplementary data.
- Fig. 2:
- As it is, it is hard to tell the difference between GRN inference methods for a given sample size and number of regulators. Could the authors add a comparative panel for this (maybe some scatter plots would be enough)? MI by itself looks worse here?
- When mentioning "samples" (e.g. last paragraph of section 1 in results), do the authors refer to "cells"?
- What about normalisation effects in the simulated data?
- Figure S7 should be cited in the first paragraph of section 2 in results. Could the authors add a panel to indicate whether the data is SMART-seq2 or 10X.
- In the association of inferred GRNs to human blastocyst cell lineages, the authors find the GRN edges predicted that overlap between the 4 inference methods in each cell type. Do they, therefore, recommend to always use more than one GRN inference method?
- If the CA data used was only generated for the TE and ICM only, how do the authors use it to perform MICA on PE?
Significance
In this paper, one main message is that to infer GRN one should combine different omic datasets. This does not come as a surprise and has been published before. What it is very well addressed in this study is the problem of the sample size: the authors decide to test GRN inference methods in the human blastocyst, for which currently we do not have a lot of sequencing data available. Interestingly, they find that 1k cells should be enough to infer relevant GRN. Maybe the manuscript would benefit if the authors emphasize this more in their text.
Interestingly, and despite the fact that the sample size here is below 1k, the authors identify novel regulatory relationships between TFs for different cell types, that they also validate.
This paper will be relevant to a wide audience of scientists interested in human developmental biology, or in the development of computational approaches to analyse single cell sequencing data.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary
The authors proposed MICA strategy as an attempt to infer gene regulatory network at the blastocyst stage of early embryo development which features limited sample size. While the motivation seems reasonable to me and the results showed several interesting insights, the methodological novelty and significance of this study need further elaboration, and the evaluation/benchmark part is largely insufficient.
Major comments
- The proposed strategy (i.e. combining gene expression-based regulatory inference with cis-regulatory evidence) have been well developed (and implemented) by multiple published works like SCENIC and CellOracle, which is also properly acknowledged by the authors in the discussion section too. This leads to a serious concern on the major methodological contribution of this work.
- Most of the compared network reconstruction methods involve hyper-parameters setup (e.g., sparsity regularization weights of the regression methods). The authors did not discuss how these hyper-parameters were chosen.
- For the real-world blastocyst data, the network prediction methods were compared in terms of their reproducibility across validation folds (Fig. 3, Fig. S4-6). However, reproducibility does not necessarily imply accuracy. In fact, statistical learning methods are generally subject to the bias-variance tradeoff, where lower variance (i.e., higher reproducibility) could imply higher bias in model prediction. While there is a lack of gold-standard ground truth to evaluate network accuracy in real biological systems, silver-standards like the ranking of known regulatory interactions in the predictions could be employed as an indirect estimate.
- The gene set enrichment results were reported only on EPI and TE cell types (Fig. 4C and Fig. S12), due to the reason that CA data is only available for TE and ICM. However, many of the other results presented in Fig. 3-6 did include the PE cell type albeit using the same CA data. It is not particularly convincing why the cell type inclusion standard for gene set enrichment is different from the other results.
- The authors cited TF binding in cis-regulatory regions as supporting evidence of several MICA-inferred regulatory interactions (e.g., NANOG -> ZNF343). However, the same cis-regulatory evidence has already been used in the CA filtering step. All interactions passing CA filtering should in principle have TF-binding support. It would be more convincing if the authors provided other types of evidence as independent support, such as genetic associations like eQTL, experimental perturbations like gene knockdown/knockout, etc.
- Many of the MICA-inferred regulatory interactions do not exhibit Spearman correlation (Fig. 5, Fig. S17), which could probably be explained by the ability of mutual information to capture complex non-monotonic dependencies. It would be interesting to provide further investigation on these "uncorrelated" edges, which may help demonstrate the superiority of mutual information over Spearman correlation.
- The authors conducted immunostaining experiments to validate the MICA-inferred regulatory interaction between TFAP2C and JUND. While the identified protein co-localization is a step further than RNA co-expression, it is still correlation rather than causality. Additional evidence like the effect of knockout/knockdown perturbations would be more convincing.
Minor comments
- The γ symbols in AP-2γ are not correctly rendered.
- The UMAP figures (Fig. 4A, Fig. S7) are of low resolution compared to other figures.
- As the authors are focused on studying the blastocyst regulatory network, the inferred regulatory interactions should be provided as supplementary data.
Significance
Given the concerns listed above, I still hold doubts on the significance of the manuscript in its current form. In particular, the major contribution of this work, in methodological senses, seems to be the specific choice of mutual information for regulatory inference in the low-data regime, which may have a limited audience and impact.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
1. Point-by-point description of the revisions
Reviewer #1
Evidence, reproducibility and clarity (Required):
In this paper by Wideman et al, the authors seek to determine the role of cellular iron homeostasis in the pathogenesis of murine malaria.
The authors to attempt to disentangle the effects of anemia from that of cellular iron deficiency. The authors elegantly make use of a murine model of a rare human mutation in the transferrin receptor. This mutation leads to decreased receptor internalization and decreased cellular iron, but otherwise healthy mice. Using this model, the authors use a P. chabaudi infection model and show an increase in pathogen burden and a decrease in pathology. They show in some detail that the immune response to P. chabaudi infection is blunted, both T and B-cell responses are attenuated in the TfRY20H/Y20H model, and the block in proliferation can be rescued by exogenous iron supplementation. They also show that decreased cellular iron attenuates liver pathology through potentially multiple mechanisms.
Minor comments:
-
The peak of parasitemia is relatively low (approx..3%) compared to other published studies (e.g. PMID: 22100995, 16714546, 31110285) where the peak in C57BL/6 mice reached 25 - 40%. Can the authors account for this low parasitemia?
Response: We thank the reviewer for their constructive comments and appreciate that they are highlighting this important point. It has previously been shown (PMID: 23217144, 23719378) that mosquito-transmission of P. chabaudi leads to significantly lower parasitaemia (“Recently mosquito-transmitted parasites were used to mimic a natural infection more closely, as vector transmission is known to regulate Plasmodium virulence and alter the host’s immune response (48-50). Consequently, parasitaemia is expected to be significantly lower upon infection with recently mosquito-transmitted parasites, compared to infection with serially blood-passaged parasites that are more virulent (48,49).”
-
Figure 1K - At homeostasis, serum iron is low in TfR mice however increases to significantly higher than the WT mice at 8 days post infection. Do the authors have an explanation on why these dramatic changes in serum iron are seen?
Response: During malaria infection, RBC lysis releases haem and iron into circulation, which leads to an increase in serum iron levels. This effect is observed in both wild-type and TfrcY20H/Y20H mice infected with P. chabaudi (Supplementary Figure 1F & Figure 1K). However, the significantly higher serum iron levels observed in infected TfrcY20H/Y20H mice can likely be explained by their decreased capacity for transferrin receptor-1 mediated iron uptake, leading to relatively slower uptake and storage of circulating transferrin-bound iron into tissues. This has been clarified in the manuscript (line 142-143):
“The elevated serum iron observed in infected TfrcY20H/Y20H mice was consistent with their restricted capacity to take up transferrin-bound circulating iron into tissues.”
-
Figure S3 - Is it surprising that no effects on splenic neutrophils are seen? Were neutrophils quantified at any other point? These would also be expected to have a role in both the control of malaria infection and on any pathology.
Response: We thank the reviewer for raising this interesting question. It is known that neutrophils can be sensitive to cellular iron deficiency (PMID: 36197985) and that neutrophils can play an important part in malaria infection (PMID: 31628160). However, the magnitude and significance of the neutrophil response to recently mosquito-transmitted P. chabaudi parasites has not been thoroughly investigated. A recent study demonstrated that monocytes and macrophages may be more important than granulocytes in the early response to recently mosquito-transmitted P. chabaudi infection (PMID: 34532703).
Moreover, we performed neutrophil quantifications in our initial experiments and found that the splenic neutrophil response was not altered in TfrcY20H/Y20H mice eight days after infection. Additionally, no neutrophil infiltration was observed in the liver of either genotype upon P. chabaudi infection. In light of these findings, we did not characterise the neutrophil response further, as it appeared unlikely that neutrophils were the principal causal agent of either the altered immunity or pathology, in this context. However, we agree with the reviewer that larger question of whether neutrophil iron plays a role in the pathology of malaria is an interesting open question which we hope future studies can elucidate.
A section was added to the discussion to address the role of innate immune cells in our model (line 354-363):
“The inhibited innate immune response to P. chabaudi in TfrcY20H/Y20H mice likely contributed to both the increased pathogen burden and the decreased liver pathology. Splenic MNPs are important for controlling parasitaemia (34,35,72), but MNPs are also vital for maintaining tissue homeostasis and preventing tissue damage in malaria (43,73). Although other innate cells, such as neutrophils, NK cells and γδT cells are an important part of the immune response to malaria, only the MNP response was distinctly impaired in TfrcY20H/Y20H mice. Notably, neutrophils are known to be sensitive to iron deficiency (16,74) and to affect both immunity and pathology in malaria (75,76). However, in the context of recently mosquito-transmitted P. chabaudi it appears that monocytes and macrophages, rather than granulocytes, may be particularly important for parasite control and tissue homeostasis (43,72).”
Changes to the text:
-
Fig S1EandF - Please add to the figure legend that these were measured at homeostasis.
Response: This clarification has been added to the legend of Supplementary Figure 1 (line 954-957).
-
Figure 3 - In the legend, H and I are the wrong way around.
Response: The legend of Figure 3 has been corrected accordingly (line 888-890).
-
Figure 4 - please add the units of concentration of FeSO4 to all panels
Response: The units of concentration for FeSO4 and AFeC have been added to all panels of Figure 4 and 6, respectively.
-
Line 246 - The authors state: "there was some evidence of decreased malaria-induced hepatomegaly" however there is no significant difference between WT and TfR mice and both show significant hepatomegaly. I feel that this line should be reworded.
Response: The sentence (line 252-254) has been reworded as follows:
“Furthermore, while both genotypes developed malaria-induced hepatomegaly, there was a trend toward less severe hepatomegaly in TfrcY20H/Y20H mice (Figure S5C).”
Significance (Required):
This work is one of the first to attempt to define the requirements for cellular iron in malaria infection. This is a difficult topic, as infection and associated inflammation and the red blood cell destruction caused by malaria all have complex effects on iron within the body. This study fits well with previous observations showing that anemia can be protective as it both prevents parasite growth and limit immunopathology. This work advances the field by demonstrating a cell intrinsic role for iron in malaria infection. There is a broad possible audience for this work, including malaria researchers, immunologists and people interested in the role or iron, both at a cellular level and systemically.
Reviewer #2
Evidence, reproducibility and clarity (Required):
In this manuscript, the authors have studied the role of iron deficiency in the host response to Plasmodium infection using a transgenic mouse model that carries a mutation in the transferrin receptor. They show that restricted cellular iron acquisition attenuated P. chabaudi infection- induced splenic and hepatic immune responses which in turn mitigated the immunopathology, even though the peak parasitemia was significantly high in the mutant mice. Interestingly, the course of parasite infection doesn't seem to be affected in the mutant mice compared to the wildtype mice despite the induction of poor immune responses. The authors show that the decreased cellular iron uptake broadly impact both innate and adaptive components of the immune system. Conversely, free iron supplementation restored the immune cell functions.
-
The study is well performed, and the manuscript is well written. However, the authors should show how conserved the role of cellular iron is across other rodent malaria parasite species at least with * yoelii or P. berghei* blood stage infection models. This question becomes critical to address in order to understand broad relevance to human malaria infections where both the host and parasites are genetically diverse.
Response: We thank the reviewer for appreciating our study and for the thoughtful comments. We agree with the reviewer that the diverse genetic background of both parasites and hosts makes it difficult to draw broad conclusions about human malaria infection from animal studies performed in a laboratory setting. The recently mosquito-transmitted P. chabaudi chabaudi AS blood-stage infection model replicates many key features of mild to moderate malaria infection in humans, such as low parasitaemia, anaemia, cyto-adhesive sequestration in microvasculature, and self-resolving immunopathology. Importantly, the immune response elicited by recently mosquito-transmitted parasites also more closely mimics the immune response to a natural infection (PMID: 23719378). Therefore, we consider the recently mosquito-transmitted P. chabaudi chabaudi AS model as the most relevant to answer our particular research questions.
Furthermore, specific pathogen-free parasitised erythrocyte stabilates made from recently mosquito-transmitted P. berghei or P. yoelii parasites are unfortunately not readily accessible (e.g. through the European Malaria Reagent Repository), in contrast to P. chabaudi. Consequently, preparing and characterising recently mosquito-transmitted strains to perform the experiments suggested by the reviewer would require a substantial amount of additional time and labour, which we deem out of scope for this study.
In the design of our model we have also taken care to minimise the effects of anaemia, something which would be difficult or impossible to achieve using serially blood passaged P. yollii or P. berghei parasites. Both P. yoelii and P. berghei merozoites preferentially invade immature RBCs (PMID: 34322397) making readouts such as parasitaemia far more sensitive to small variations in erythropoietic output. In addition, the extensive RBC destruction caused by most serially blood-passaged murine Plasmodium strains would likely exaggerate any erythropoietic impairment caused by the TfrcY20H/Y20H mutation.
Although we strongly believe that the chosen mouse model of malaria is the most appropriate for our study, ultimately, no mouse model can replicate all features of human malaria infection. Inevitably, the direct relevance of animal studies for human infection will always be somewhat opaque. Hence, we respectfully disagree with the reviewer that repeating the experiments with additional murine malaria parasite species would allow us to extrapolate conclusions about human malaria infection. Such experiments would also conflict with the 3Rs principles that govern work with animals in the UK (https://nc3rs.org.uk/). Especially, because most strains of P. yoelii and P. berghei cause severe or non-resolving infections and have a significant negative impact on animal welfare.
In our opinion, the logical continuation of this study must be to utilise the insights from our research to inform future human studies on the relationships between iron deficiency and malaria-related immunopathology. However, we agree that this is an important topic and have added a section addressing the broad relevance of our findings to the discussion (line 393-396):
“It remains to be seen what the broader importance of cellular iron is in human malaria infection, in particular within the diverse genetic context of both humans and parasites found in malaria endemic regions. Murine models of malaria are useful in providing hypothesis-generating results, but such findings ultimately ought to be confirmed and developed further through studies in human populations.”
-
Since, restricted cellular iron uptake mitigates the immunopathology, the authors should explore whether this could also relieve the cerebral malaria condition that is caused by the hyper inflammation in the brain. They should use the * berghei* ANKA parasite strain which causes t cerebral malaria in mice. I think would increase impact of the paper.
Response: Although we agree that this would be an interesting line of inquiry, we think that it is outside of the scope of this study, which predominantly aims to characterise and study the effects of cellular iron deficiency in host cells, particularly immune cells, during mild to moderate malaria infection. The severe pathology underlying cerebral malaria differs greatly from that of a self-resolving blood-stage infection. Furthermore, the relevance to human cerebral malaria of the P. berghei ANKA model is controversial within the field (PMID: 21288352) and as a severe infection its use would again conflict with the 3Rs principles.
Minor comments:
-
Line 222: repeating word, "iron iron-supplemented...."
Response: The sentence has been corrected (line 228).
-
Figure 3C, S4C & S5F: Why Mann-Whitney test is performed in these particular graphs, whereas rest of the two groups comparison were done using Welch's test? The authors should clearly mention this in the methods section.
Response: We apologise if this was unclear in the manuscript. We routinely tested all our datasets for normality to identify the appropriate tests for each dataset. In case of the graphs shown in figure 3C, S4C and S5F, the dataset did not pass the D’Agostino-Pearson normality test and we therefore applied a non-parametric test (i.e. Mann-Whitney), in contrast to the other datasets that passed the test for normal or lognormal distribution. This has been further clarified in the method section (line 581-586):
“The D’Agostino-Pearson omnibus normality test was used to determine normality/lognormality. Parametric statistical tests (e.g. Welch’s t-test) were used for normally distributed data. For lognormal distributions, the data was log-transformed prior to statistical analysis. Where data did not have a normal or lognormal distribution, or too few data points were available for normality testing, a nonparametric test (e.g. Mann-Whitney test) was applied.“
-
Have authors explored whether gamma-delta T cell responses are affected in the mutant mouse strain compared to wildtype mice as they are one of the early responders and the key cytokine producing cells against the Plasmodium blood stage infection.
Response: __We thank the reviewer for this valuable comment. We briefly explored the role of γδT cells, but did not observe a significant difference in splenic γδT cell numbers between wild-type and TfrcY20H/Y20H mice, eight days post-infection (__Reviewer Figure 1). It is of course possible that γδT cell numbers were affected at an earlier stage, or that γδT cell function (e.g. cytokine production) was affected by cellular iron deficiency during P. chabaudi infection. However, γδT cells may also be less sensitive to cellular iron deficiency than conventional T cells, as has been previously demonstrated for developing T cells (PMID: 7957580).
A section was added to the discussion to address the role of innate immune cells in our model (line 354-363):
“The inhibited innate immune response to P. chabaudi in TfrcY20H/Y20H mice likely contributed to both the increased pathogen burden and the decreased liver pathology. Splenic MNPs are important for controlling parasitaemia (34,35,72), but MNPs are also vital for maintaining tissue homeostasis and preventing tissue damage in malaria (43,73). Although other innate cells, such as neutrophils, NK cells and γδT cells are an important part of the immune response to malaria, only the MNP response was distinctly impaired in TfrcY20H/Y20H mice. Notably, neutrophils are known to be sensitive to iron deficiency (16,74) and to affect both immunity and pathology in malaria (75,76). However, in the context of recently mosquito-transmitted P. chabaudi it appears that monocytes and macrophages, rather than granulocytes, may be particularly important for parasite control and tissue homeostasis (43,72).”
Significance (Required):
Overall, the study provides novel insights into the role of iron in the immune response to Plasmodium blood stage infection using a rodent malaria model and the interplay of infection, immunity and the development of pathology. As such it is an important study.
Reviewer #3
Evidence, reproducibility and clarity (Required):
Herein Wideman provide novel and important evidence on the role of iron availability for mounting an efficient immune response in a malaria infection model. They employed TfRC Y201H/Y201H mice which develop iron deficiency due to impaired cellular ingestion of transferrin bound iron. They found that those mice develop higher peak parasitemia after vector borne exposure to Pl. chabaudi chabaudi which was paralleled by an impaired immune response as reflected by altered CD4 cell activation, reduced IFN-g formation or reduced B-cell responsiveness. Those deficiencies could be re-covered upon ex vivo iron supplementation pointing to the importance of iron availability for mounting-CD4+ and B-cell specific anti-plasmodial immune responses at the initial phase of infection. However, TFRC mutated mice were able to clear infection over time in a comparable fashion to wt mice.
This excellent study is important in convincingly showing (by employing high quality immunological analyses) the importance of cellular iron deficiency on immune responses in an infection model of general interest. It also indicates that overwhelming immune response as seen in wt mice is associated with organ damage over time.
Minor comments:
-
The authors should discuss why and how TFRC mutated mice were able to control infection over time in a comparable fashion as wt mice although peak parasitemia was significantly higher?
__Response: __We thank the reviewer for the helpful feedback on our study and for posing this interesting question. It does indeed appear as if the immune response, while significantly inhibited in the TfrcY20H/Y20H mice, is still sufficient to clear the infection. It is plausible that the early cell-mediated immune response is inhibited to the degree that parasite control is impaired, resulting in higher peak parasitaemia in TfrcY20H/Y20H mice. In contrast, parasite clearance is comparable and contemporary in both genotypes. Based on the fact that parasite clearance occurs at a time when a substantial adaptive immune response is expected to emerge, we hypothesize that this significantly contributes to pathogen clearance. Thus, it seems likely that the humoral response in TfrcY20H/Y20H mice, even if inhibited, may still be effective enough to clear the parasites and prevent recrudescence.
As malaria infection progresses, RBC loss and increasing anaemia also contributes to limiting exponential parasite growth. This occurs more or less equally in both genotypes, but it could be particularly important for parasite control in the TfrcY20H/Y20H mice that have an inhibited immune response.
We have added a section to the discussion to address this (line 380-386):
“Despite the higher peak parasitaemia in TfrcY20H/Y20H mice, both genotypes were able to clear P. chabaudi parasites at a comparable rate and prevent recrudescence. It follows that even a weakened humoral immune response appears to be sufficient to control P. chabaudi infection. However, our study did not investigate the effects of immune cell iron deficiency on the formation of long-term immunity, which may have been more severely affected. The impaired GC response, in particular, suggests that iron deficiency could counteract the formation of efficient immune memory to subsequent malaria infections.”
-
The authors and others have previously shown (Frost J et al. Sci Adv 2022, Hoffmann et al. EBioMedicine 2021) that iron deficiency results in reduced neutrophil numbers in different infection models. This could also have contributed to the observed effect in initial infection control but may have also been linked altered histopathology seen in Figure 7. However, no mention of neutrophil numbers in this model is made. It would be important if the authors could provide information on neutrophil numbers (only if this analysis has been already performed) and discuss this issue in association with their observation.
Response: We appreciate that the reviewer has brought attention to this important topic. As they mention, iron deficiency can have a negative impact on the neutrophil response (PMID: 36197985, 34488018) but it can also cause a maladaptive excessive neutrophil response due to failed adaptive immunity (PMID: 33665641). In this study, we show that there is no difference in splenic neutrophil numbers between wild-type and TfrcY20H/Y20H mice, eight days after P. chabaudi infection (Figure S3B). Moreover, the histopathologists detected no liver neutrophil infiltration in either genotype, but rather observed infiltration of mononuclear leukocytes upon P. chabaudi infection. Hence, it appears unlikely that neutrophils were a major contributor to differences in either immunity or pathology in this specific context. However, we cannot definitively rule out that neutrophil numbers were affected earlier in the infection or that neutrophil function was impaired due to cellular iron deficiency.
A section was added to the discussion to address the role of innate immune cells in our model (line 354-363):
“The inhibited innate immune response to P. chabaudi in TfrcY20H/Y20H mice likely contributed to both the increased pathogen burden and the decreased liver pathology. Splenic MNPs are important for controlling parasitaemia (34,35,72), but MNPs are also vital for maintaining tissue homeostasis and preventing tissue damage in malaria (43,73). Although other innate cells, such as neutrophils, NK cells and γδT cells are an important part of the immune response to malaria, only the MNP response was distinctly impaired in TfrcY20H/Y20H mice. Notably, neutrophils are known to be sensitive to iron deficiency (16,74) and to affect both immunity and pathology in malaria (75,76). However, in the context of recently mosquito-transmitted P. chabaudi it appears that monocytes and macrophages, rather than granulocytes, may be particularly important for parasite control and tissue homeostasis (43,72).”
-
In addition, alternative mechanism leading to immune tolerance and reduced tissue damage such as induction of heme oxygenase-1, which is also affected by systemic iron availability, should be discussed.
Response: __An addition was made to the results section and to Figure S5 to address this reviewer comment (line __269-274):
“In addition, we measured the expression of two genes that are known to have a hepatoprotective effect in the context of iron loading in malaria: Hmox1 (encodes haemoxygenase-1) and Fth1 (encodes ferritin heavy chain). Liver gene expression of Hmox1 was higher in TfrcY20H/Y20H mice, while the expression of Fth1 did not differ between genotypes, eight days after infection (Figure S5H-I). Thus, the higher expression of Hmox1 may have contributed to the hepatoprotective effect in TfrcY20H/Y20H mice.”
A relevant sentence was also added to the discussion (line 313-318):
“For example, HO-1 plays an important role in detoxifying free haem that occurs as a result of haemolysis during malaria infection, thus preventing liver damage due to tissue iron overload, ROS and inflammation (62). Interestingly, infected TfrcY20H/Y20H mice had higher expression of Hmox1, but levels of liver iron and ROS comparable to that of wild-type mice. Consequently, this may be indicative of increased haem processing that could have a tissue protective effect”
Significance (Required):
Important and intersting study highlighting the central role of iron homeostasis for immune repsonse to infection. General interest because iron deficiency has high prevalence in areas with high enedemic burden of infection
Reviewer's expertise: infectious disease, immunity, iron homeostasis-- both basic science and clincal expertise (more than 300 peer reviewed publications on these topcis)
-
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Herein Wideman provide novel and important evidence on the role of iron availability for mounting an efficient immune response in a malaria infection model. They employed TfRC Y201H/Y201H mice which develop iron deficiency due to impaired cellular ingestion of transferrin bound iron. They found that those mice develop higher peak parasitemia after vector borne exposure to Pl. chabaudi chabaudi which was paralleled by an impaired immune response as reflected by altered CD4 cell activation, reduced IFN-g formation or reduced B-cell responsiveness. Those deficiencies could be re-covered upon ex vivo iron supplementation pointing to the importance of iron availability for mounting-CD4+ and B-cell specific anti-plasmodial immune responses at the initial phase of infection. However, TFRC mutated mice were able to clear infection over time in a comparable fashion to wt mice. This excellent study is important in convincingly showing (by employing high quality immunological analyses) the importance of cellular iron deficiency on immune responses in an infection model of general interest. It also indicates that overwhelming immune response as seen in wt mice is associated with organ damage over time.
Minor points:
The authors should discuss why and how TFRC mutated mice were able to control infection over time in a comparable fashion as wt mice although peak parasitemia was significantly higher? The authors and others have previously shown (Frost J et al. Sci Adv 2022, Hoffmann et al. EBioMedicine 2021) that iron deficiency results in reduced neutrophil numbers in different infection models. This could also have contributed to the observed effect in initial infection control but may have also been linked altered histopathology seen in Figure 7. However, no mention of neutrophil numbers in this model is made. It would be important if the authors could provide information on neutrophil numbers (only if this analysis has been already performed) and discuss this issue in association with their observation. In addition, alternative mechanism leading to immune tolerance and reduced tissue damage such as induction of heme oxygenase-1, which is also affected by systemic iron availability, should be discussed.
Significance
Important and intersting study highlighting the central role of iron homeostasis for immune response to infection General interest because iron deficiency has high prevalence in areas with high enedemic burden of infection
Reviewer's expertise: infectious disease, immunity, iron homeostasis-- both basic science and clincal expertise (more than 300 peer reviewed publications on these topics)
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
In this manuscript, the authors have studied the role of iron deficiency in the host response to Plasmodium infection using a transgenic mouse model that carries a mutation in the transferrin receptor. They show that restricted cellular iron acquisition attenuated P. chabaudi infection- induced splenic and hepatic immune responses which in turn mitigated the immunopathology, even though the peak parasitemia was significantly high in the mutant mice. Interestingly, the course of parasite infection doesn't seem to be affected in the mutant mice compared to the wildtype mice despite the induction of poor immune responses. The authors show that the decreased cellular iron uptake broadly impact both innate and adaptive components of the immune system. Conversely, free iron supplementation restored the immune cell functions.
- The study is well performed, and the manuscript is well written. However, the authors should show how conserved the role of cellular iron is across other rodent malaria parasite species at least with P. yoelii or P. berghei blood stage infection models. This question becomes critical to address in order to understand broad relevance to human malaria infections where both the host and parasites are genetically diverse.
- Since, restricted cellular iron uptake mitigates the immunopathology, the authors should explore whether this could also relieve the cerebral malaria condition that is caused by the hyper inflammation in the brain. They should use the P. berghei ANKA parasite strain which causes t cerebral malaria in mice. I think would increase impact of the paper.
Minor comments:
- Line 222: repeating word, "iron iron-supplemented...."
- Figure 3C, S4C & S5F: Why Mann-Whitney test is performed in these particular graphs, whereas rest of the two groups comparison were done using Welch's test? The authors should clearly mention this in the methods section.
- Have authors explored whether gamma-delta T cell responses are affected in the mutant mouse strain compared to wildtype mice as they are one of the early responders and the key cytokine producing cells against the Plasmodium blood stage infection.
Significance
Overall, the study provides novel insights into the role of iron in the immune response to Plasmodium blood stage infection using a rodent malaria model and the interplay of infection, immunity and the development of pathology. As such it is an important study.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
In this paper by Wideman et al, the authors seek to determine the role of cellular iron homeostasis in the pathogenesis of murine malaria.
The authors to attempt to disentangle the effects of anemia from that of cellular iron deficiency. The authors elegantly make use of a murine model of a rare human mutation in the transferrin receptor. This mutation leads to decreased receptor internalization and decreased cellular iron, but otherwise healthy mice. Using this model, the authors use a P. chabaudi infection model and show an increase in pathogen burden and a decrease in pathology. They show in some detail that the immune response to P. chabaudi infection is blunted, both T and B-cell responses are attenuated in the TfRY20H/Y20H model, and the block in proliferation can be rescued by exogenous iron supplementation. They also show that decreased cellular iron attenuates liver pathology through potentially multiple mechanisms.
Minor comments:
- The peak of parasitemia is relatively low (approx..3%) compared to other published studies (e.g. PMID: 22100995, 16714546, 31110285) where the peak in C57BL/6 mice reached 25 - 40%. Can the authors account for this low parasitemia?
- Figure 1K - At homeostasis, serum iron is low in TfR mice however increases to significantly higher than the WT mice at 8 days post infection. Do the authors have an explanation on why these dramatic changes in serum iron are seen?
- Figure S3 - Is it surprising that no effects on splenic neutrophils are seen? Were neutrophils quantified at any other point? These would also be expected to have a role in both the control of malaria infection and on any pathology
Changes to the text
- Fig S1EandF - Please add to the figure legend that these were measured at homeostasis
- Figure 3 - In the legend, H and I are the wrong way around.
- Figure 4 - please add the units of concentration of FeSO4 to all panels
- Line 246 - The authors state: "there was some evidence of decreased malaria-induced hepatomegaly" however there is no significant difference between WT and TfR mice and both show significant hepatomegaly. I feel that this line should be reworded.
Significance
This work is one of the first to attempt to define the requirements for cellular iron in malaria infection. This is a difficult topic, as infection and associated inflammation and the red blood cell destruction caused by malaria all have complex effects on iron within the body. This study fits well with previous observations showing that anemia can be protective as it both prevents parasite growth and limit immunopathology. This work advances the field by demonstrating a cell intrinsic role for iron in malaria infection. There is a broad possible audience for this work, including malaria researchers, immunologists and people interested in the role or iron, both at a cellular level and systemically.
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We thank the reviewers for their comments and insights, we feel the manuscript is now greatly improved. Please find below our answers to the reviewer’s queries
Reviewer #1 (Evidence, reproducibility and clarity):
The manuscript by Niccoli et al. describes the identification of a novel modifier of C9orf72-derived toxicity based on the manipulation of the brain metabolic pathways. The premise for this work is supported by strong literature describing the aberrant glucose metabolism in FTD, AD and other degenerative disorders. The idea tested here is whether increasing the import of pyruvate produced in glia into neurons. They test three different types of importers and find that one of them, Bumpel, the orthologue of human SLC5A12, suppresses toxicity and reduces the accumulation of arginine-containing repeats, GP and PR. The authors investigate several potential mechanisms mediating this reduction of toxic DPRs, but do not find strong evidence linking pyruvate import and increase autophagy or mitochondria metabolism.
Overall, this is an interesting discovery based on a candidate approach that shows the power of Drosophila to efficiently identify novel mediators of neurodegeneration. The article is well written, although more detailed explanations of some experiments would be helpful. The weaknesses of the manuscript are the lack of a clear mechanism mediating the protective activity of pyruvate, the incomplete experiments lacking relevant controls, and the presentation of western blots.
Specific comments:
- The reduced levels of DPRs require that the expression of C9 mRNA or the GR and PR constructs is examined by qPCR. In figure 3E, GP is not even detectable_
We agree with the reviewer, ideally we would have measured the RNA by qPCR. However, the C9 repeats and the DPR constructs are highly repetitive, it is therefore impossible to do a qPCR for them. The upstream and downstream sequence is identical for the C9 and the bumpel constructs, there isn’t, to our knowledge any unique sequence we can use to measure levels of expression in the presence of bumpel.
We did run a GFP control (Fig 2D) and did not see any difference and we have now carried out a qPCR for Gal4-GeneSwitch (Fig S3) to show that the levels of the driver do not change.
- I wonder if there are constructs available to silence Bumpel or overexpress the human orthologues of bumpel. These would be nice controls for the effects observed with the Bumpel overexpression
This would be an extremely interesting experiment, however bumpel is normally only expressed in glia, therefore we can’t down-regulated it in glia whilst upregulating 36R in neurons, as we are limited to one driver (since everything is driven by the Gal4/UAS system). Expression of C9 in glia does not have a clear phenotype (our observation), so we can’t drive both in glia. We tried over-expressing the human homologue SLC5A12 , but it did not rescue the C9 phenotype (data not shown), possibly because it requires (like other human SLC5A type transporters) PDZK1 as extra co-factor (Srivastava S. et al, 2019), and this is not present in flies.
- The argument about bumpel modulating autophagy downstream of Atg1 is not supported by the experimental data
We now have imaging data showing that bumpel modulates the formation of lysosomes, downstream of Atg1 (Fig 5). We also show that bumpel and Atg1 can act synergistically, leading to a much stronger rescue of C9 expression (See Fig 5I.), which also suggests that the two are acting at different points in the same pathway. We also show that bumpel rescues the downregulation of TFEB targets (Fig 5J)
- Western blots throughout show no control lanes and in several occasions are created with cutout bands. The standard for this type of experiments should be more stringent, with entire gels showing all experimental conditions, which requires consistent methods and results vs selecting the best bands from different gels.
We apologise if this was mis-understood, the lanes shows are all from the same blot, where other samples were run too, and it would be confusing for the reader to include them. We have re-run samples where we had remaining sample from our quantifications, so that the lanes are now contiguous and we provide original blot images in the supplemental information for those we could not re-run. The control for all experiments are the C9 expressing line without bumpel, and this is always present, if the reviewer means we are missing -RU controls, these do not produce any DPRs so are not included in western blot or ELISA quantifications as the signal is not above back-ground.
- For figures 2B and 5C, please, show representative WBs
These are ELISA quantifications, not western blots, we choose to run these when possible, as they are more quantitative.
- Figure 5D describes the survival curve as significantly rescued. Statistical tests can indicate differences, but that is in no way convincing. The test may show the curves are different, but the abeta Atg1 flies also seem to start falling early, so an argument could be made in both directions, as a suppressor or an enhancer.
We agree the rescue is not strong enough, we have now removed this lifespan.
- It is unclear why several results are placed in the supplemental materials. In general, all this material seems highly relevant and related to what is shown in the main figures
We are happy to include them in the main manuscript if this would help the reader, and we have now placed all mitochondrial data in Fig 4.
Minor comments:
Please, define several abbreviations throughout
We apologise for this over-sight, we have now does this.
A couple of sections could be improved by carefully sequencing human vs Drosophila background to advance the argument rather than going in circles. There is also a section on mitophagy in between two sections related to autophagy that could be sequenced better.
We have re-structured the sections, we think this has improved the flow.
There is a sentence at the end of page 6 that seems misplaced
We apologise for the over-sight, and we have removed this
Reviewer #1 (Significance):
Overall, this is an interesting discovery based on a candidate approach that shows the power of Drosophila to efficiently identify novel mediators of neurodegeneration. The article is well written, although more detailed explanations of some experiments would be helpful. The weaknesses of the manuscript are the lack of a clear mechanism mediating the protective activity of pyruvate, the incomplete experiments lacking relevant controls, and the presentation of western blots.
We thank the reviewer for the helpful comments, we have added some details in the methods section, we apologise for not having made it clear that the westerns were all derived from the same blot (we have now placed the originals in the supplemental materials). Regarding mechanism, we now show that bumpel over-expression increases clearance of late stage autolysosomes, possibly by increasing transcription of TFEB target lysosomal genes.
Reviewer #2 (Evidence, reproducibility and clarity):
Summary:<br /> Project investigates the role in dementias of glial glucose uptake, conversion to lactate and shuttling via transporters to neurons to produce pyruvate to fuel TCA cycle production of ATG. The experiments are conducted in Drosophila melanogaster, which have become a powerful model system for understanding neurodegeneration mechanisms associated with ALS/FTD associated C9orf72 pathology. Bumple misexpression is shown to rescue early death phenotype in flies expressing a C9orf72 expansion and flies expressing arginine containing di-peptide repeat proteins. The report describes novel insight into the function of bumpel, demonstrating that this conserved orthologue of human SLC14A functions as a sodium exchange transporter for monocarboxylates pyruvate and lactate. These findings conclude that increased neuronal pyruvate, but not its metabolites, rescues C9orf72 associated pathology.<br /> The authors next set out to describe the mechanism by which increase pyruvate rescues survival in C9orf72 expressing flies. Levels of autolysosomes were increased in C9orf72 expressing flies, and stimulation of autophagy by overexpression of atg1 shown to decrease levels of DPRs (though not to same extent as bumple expression). Expression of bumple in C9orf72 flies led to a modest increase in LC3-II, indicating increased autophagy. Co-overexpression of bumple and atg1 did not have an additive effect, suggesting bumple activates autophagy downstream or independent of atg1 activity. Finally the author extend their findings to amyloid models, suggest a common protective mechanism for elevating neuronal pyruvate levels in neurodegenerative disease.
Major comments
Prior data suggests that bumpel is expressed in glia (for example Yildirim et al 2022). In their study the authors do not present any data to demonstrate that the transporter is normally expressed in neurons in flies. This calls into questions the physiological relevance of their findings, that neuronal upregulation of bumpel is protective against C9orf72 associated pathology in neurons, from which it is reasonable for a reader to conclude that bumpel may be a neuronal target for therapeutic intervention. However, the report well demonstrates that regardless of whether the transporter in native to neurons, the increase in monocarboxylates it facilitates is projective against C9orf72 pathology and thus the overall conclusion of the project is supported by experimental evidence. The point of upregulation of a natively expressed gene versus misexpression of a glial enriched transporter should be considered in a bit more detail in the discussion text. The authors may consider speculating the identify of members of the sodium coupled monocarboxylate transporters that are enriched in neurons. Are any of the bumple human orthologues expressed in neurons?_
We thank the reviewer for this comment and suggestion. The reviewer correctly points out that we do not show whether there is a defect in pyruvate import in C9 expressing flies. We could not identify a validated sodium coupled pyruvate transporter in flies with a strong neuronal expression, we have added a comment in the discussion about this. There are a number of human homologues, some, such as SLC5A8, are expressed in neurons, thus providing a possible therapeutic target. We have added a sentence to this regard in the discussion.
[_OPTIONAL] cDNA overexpression of neuron specific sodium coupled monocarboxylate transporters in C9orf72 fly models would strengthen the conclusion their physiological relevance for ALS/FTD. Fly lines for these are not available in repositories, but could be generated and tested at reasonable cost (<£700, ~3 month duration).
This would be an ideal experiment, however, we could not find a neuronal sodium coupled transporter which is known to import monocarboxylates. There are a number of sodium coupled neuronal transporters, but they are mostly homologous to SLC5A6, which is a glucose coupled transporter. Going forward, we will screen a number of transporters to identify if there are any which import pyruvate.
The role of bumple expression in survival (Figure 1) could be a technical artifact due to dilution of Gal4 between C9orf72 and bumple-ORF transgenes. No expression control is shown (for example GFP, LacZ etc). This theory is unlikely as no improvement in survival was seen for the SLC14A class of transporters which have a matching site directed transgene insertion. For clarity this point relating to controls should be commented on in the text.
The reviewer is correct, there could be a dilution of the Gal4. We don’t like using GFP as a control as we have often seen a worsening when expressing other highly stable proteins at high levels. We have generated an “empty” flyORF line (generated by injecting the empty plasmid into the identical attP site), and used it as a control to check for dilution effects, bumpel still rescued relative to this control, we now include this is the supplementary (Fig S1B).
Reduced Mito-GFP levels are used to support a role for bumple in increasing mitophagy. As mito-GFP is a marker for mitochondria but not specifically mitophagy, an alternative explanation for decreased levels could be reduced mitochondria biogenesis. The text should be amended to clarify this point.<br /> The role of Pink1 RNAi in modifying mitophagy is a bit overstated. Whilst Pink1 is involved in stress associated mitophagy, its role in basal mitochondria turnover is less well defined. Text should be adapted.
We have added qualifying statements regarding the possibility of reduced mitochondrial biogenesis, and the fact that Pink1’s role in basal mitophagy is not very clear. The use of the mitophagy inducer drug, Kaempferol, however, suggests that mitophagy is unlikely to be a cause of the DRP reduction.
Minor comments
Introduction well describes current state of C9orf72 fly models. Introduction would benefit from a few comparable lines for AD models. The first paragraph of reports may also be better placed in the introduction._
We thank the reviewer for the suggestion, and have added a more in depth introduction to Aß and have moved the first paragraph of the results section to the introduction
Figure 1 presents survival for three SLC16A transporters and bumple. The C9 control curve appears to be consistent between charts, likely indicating the same control used across experiments, rather than independent controls for each chart. The authors should considered showing either all SLC16A and bumple data on a single chart, or clarify in the figure legend that a common control dataset is used. GFP control is used in later experiments (Figure 2).
We have now indicated that the SLC16A transporters were run together in the figure legend.
Choice of amyloid model needs a line of explanation, particularly with regard to extra/intracellular deposition of amyloid in this model.
We have now added a few sentences describing this when the model is introduced
Fruit Fly Injection method section needs a bit more detail to describe site of injection (head, body etc). This is not clear in the result section either.
We have now added this, the injection was done in the abdomen.
How were bumple orthologues identified? What degree of conservation (sequence homology etc?)
The bumpel orthologues are those identified as most similar by flybase. We have now added the degree of conservation in the text
The speculative mechanism for C9 pathology modification involves interaction of neurons and glia, monocarboxylate transporters and changes in autophagy activity. For clarity a diagram showing the model may be a helpful addition.
We have now added a diagram explaining how we think the rescue is achieved
Typos:<br /> Figure 1 Legend - "p values of ona way ANOVA "
We apologise for the error, and have now corrected it
Figure S2 Legend - Atg1 RNAi genotypes from S2 legend are mentioned erroneously
We apologise for the error, and have now corrected it
Repetition of text in results: "Bumpel, together with its paralogues kumpel and rumpel, is expressed in glia in flies, where it is thought to promote transport of substrates across the brain (31)."
We apologise and have rectified this
"Modulation of Atg1 when bumpel was co-overexpressed, however, did not affect GP<br /> levels (Fig 4E, F)" - Should be refering to Fig 4D, E)
We apologise and have rectified this
Reviewer #2 (Significance):
The study will be of broadly of interest to researcher working in the fields of neurodegeneration and metabolism, providing evidence for a protective role of elevated pyruvate in neuron that provide new understand relating to pathology in C9orf72 associated motor neuron disease and frontotemporal dementia.
Strengths:<br /> The study presents novel data to demonstrate that overexpression of fly monocarboxylate transporter bumple rescues an early death phenotype associate with ALS/FTD gene C9orf72. Any novel therapeutic strategies of ALS are of interest to the field, and the strategy demonstrated here may be readily translated to human cell culture systems for proof of principle translational studies to a more physiologically relevant system. This study further demonstrates the utility of invertebrate models to generate novel understanding of C9orf72 pathology.
Limitations:<br /> The study speculates that there is a link between pyruvate levels and increased autophagy, however the mechanisms by which this occurs is not defined in present study. This is a limitation of the experiment, though opens up an interesting question for future studies._
We thank the reviewer for their comments, and we have now added experiments characterising the role of bumpel in autophagy, particularly showing its rescue of a late autolysosomal block.
Reviewer expertise: The reviewer researches ALS and dementia associated neurodegeneration, utilising Drosophila, rodent and stem cell derived model systems.
Reviewer #3 (Evidence, reproducibility and clarity):
This is an interesting manuscript in which the authors provide evidence that elevated neuronal expression of the pyruvate transporter bumpel can partially rescue shortened lifespan in fly models of frontotemporal dementia and Alzheimer's disease. In addition, elevated neuronal bumpel expression can reduce accumulation of arginine containing FTD-linked dipeptide repeat proteins. Some evidence is presented that elevated neuronal bumpel expression may activate autophagy. These findings are novel and may have implications for therapeutic interventions based on pyruvate import/metabolism to treat neurodegenerative disorders. However, I have several concerns as follows:
Major Comments:
- The authors provide no explanation as to why they targeted bumpel overexpression in neurons. Endogenous bumpel appears to be predominately expressed in glia cells so why not target these cells instead?
We wanted to increase pyruvate import in neurons, so we over-expressed a number of pyruvate transporter that were available in the fly ORF stock centre (so that they would all be inserted into the same site and therefore directly comparable), we were mainly interested in cell autonomous effects of importing glycolytic metabolites. Over-expressing bumpel in glia would be indeed an extremely interesting experiment, unfortunately we do not have the ability to express C9 in neurons while over-expressing bumpel in glia as we only have one over-expression system that works. We are working towards generating a new C9 model so we can then use the Gal 4 system to over-express bumpel in glia, but this is currently not available yet. Over-expression of C9 in glia is not toxic and not a good model of disease.
- Data is shown that overexpressed bumpel can suppress GR and PR dipeptide repeat toxicity when these peptides are translated using an ATG start codon (Fig 2D,E). Does bumpel mediated neuroprotection also correlate with a reduction in DPR levels driven with an ATG start codon?
This would be a very interesting question, unfortunately, whist the Isaacs lab kindly made available the GR antibody for the initial ELISA experiment, we no longer have that antibody available and we do not have a working PR antibody. GR and PR westerns are not possible to carry out as the proteins are too positively charged to run. We do show that bumpel can down-regulate Aß from a UAS promoter, so its effect is not specific to RAN translation.
- The authors provide some evidence suggesting that overexpression of bumpel increases autophagy in the fly brain. However, knockdown of Atg1 while co-expressing bumpel (Fig 4E) did not result in increased GP protein levels. In addition, Atg1 knockdown did not attenuate the protective effects of bumpel overexpression (Fig 4I), suggesting that bumpel is working through a pathway independent of autophagy to promote DPR clearance and protection against toxic peptide accumulation. The authors need to modify the interpretation of their data and temper their claim that autophagy contributes to bumpel-mediated protective effects in the CNS.
We apologise the data was not strong enough. We have now added evidence that bumpel acts downstream of Atg1, on late stage autolysosomal clearance. We also show that bumpel and Atg1 can act synergistically to improve the C9 phenotype when over-expressed, this is now described in Fig 5.
- Although the authors present evidence that increased bumpel expression can activate autophagy, the data is not convincing that the neuroprotective effects associated with bumpel are mediated through autophagy. Pyruvate, in some circumstances, can non-enzymatically scavenge hydrogen peroxide or in other cases trigger oxidative stress resistance through hormetic ROS signaling. The authors should consider these alternative possibilities.
These are indeed possibilities, we have added a sentence to that effect in the discussion, we have now also showed that bumpel is affecting late clearance of autolysosomes, and is leading to an increase in TFEB targets.
- The authors rely on overexpressing bumpel to attenuate C9 toxicity in flies. They should perform the opposite experiment and knockdown bumpel to demonstrate that reduced bumpel expression results in potentiation of C9 and amyloid beta neurotoxicity. In addition, then should show that knockdown of bumpel expression has some effect on autophagy.
This would be a very interesting experiment, unfortunately bumpel is expressed only in a few glia subtypes in a wild type fly, and we can’t downregulate it in glia while over-expressing toxic proteins in neurons, because of limitations of our expression system, both genes need to be over-expressed in the same cell type. We have tried downregulating bumpel in neurons, and don’t get an effect on phenotype, and no effect on DPR levels, but bumpel expression in neurons is extremely low. Moreover, bumpel has 2 paralogs, rumpel and kumpel,(also only present in glia) and all three need to be knocked out for phenotypes to become visible in glia (Yildirim et al, 2022). These experiments would be interesting but outside out scope.
We are in the process of generating new C9 models to be able to do these experiments, but these are currently outside the scope of this work.
Minor Comments:
- Neuronal overexpression of bumpel appears to shorten lifespan of wild type flies (Fig 2A). It is possible that neuronal import of pyruvate may drive mitochondrial oxidative phosphorylation and ROS formation. The authors should comment on this possibility in the discussion._
This is a very good point, we have added a point to that effect.
- In Fig 3 the authors used a mixture of sodium pyruvate and ethyl pyruvate to demonstrate the import properties of bumpel. The rationale for using ethyl pyruvate is unclear as this membrane-permeable metabolite can by-pass any transporters.
The ethyl pyruvate was only used in the injection of flies, not for the FRET experiments looking at the import properties of bumpel. Since we were not over-expressing bumpel, we needed the pyruvate to by-pass the requirement for a transporter. We were showing that delivery of pyruvate by another methods (other than by a transporter) was able to phenocopy the over-expression of bumpel, thus showing the effect is mediated by pyruvate entrance into the cell.
- In the introduction several acronyms are used (i.e. GRN, MAPT, TREM2) that are not defined.
We apologise and have now rectified this.
Reviewer #3 (Significance):
To my knowledge, this is the first study to identify that bumpel can permit the import of pyruvate and lactate into neurons when ectopically expressed in the fly brain. The fact that increased neuronal pyruvate import can partially protect against toxic peptide accumulation is unexpected and quite novel. Although some evidence is presented that bumpel can trigger autophagy, it is not clear if autophagy is mediating bumpel neuroprotective effects. Alternative mechanisms related to pyruvate effects on ROS and oxidative stress resistance should be considered.
We thank the reviewer for their comments, and have added clarifying statements regarding the potential role of ROS.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
This is an interesting manuscript in which the authors provide evidence that elevated neuronal expression of the pyruvate transporter bumpel can partially rescue shortened lifespan in fly models of frontotemporal dementia and Alzheimer's disease. In addition, elevated neuronal bumpel expression can reduce accumulation of arginine containing FTD-linked dipeptide repeat proteins. Some evidence is presented that elevated neuronal bumpel expression may activate autophagy. These findings are novel and may have implications for therapeutic interventions based on pyruvate import/metabolism to treat neurodegenerative disorders. However, I have several concerns as follows:
Major Comments:
- The authors provide no explanation as to why they targeted bumpel overexpression in neurons. Endogenous bumpel appears to be predominately expressed in glia cells so why not target these cells instead?
- Data is shown that overexpressed bumpel can suppress GR and PR dipeptide repeat toxicity when these peptides are translated using an ATG start codon (Fig 2D,E). Does bumpel mediated neuroprotection also correlate with a reduction in DPR levels driven with an ATG start codon?
- The authors provide some evidence suggesting that overexpression of bumpel increases autophagy in the fly brain. However, knockdown of Atg1 while co-expressing bumpel (Fig 4E) did not result in increased GP protein levels. In addition, Atg1 knockdown did not attenuate the protective effects of bumpel overexpression (Fig 4I), suggesting that bumpel is working through a pathway independent of autophagy to promote DPR clearance and protection against toxic peptide accumulation. The authors need to modify the interpretation of their data and temper their claim that autophagy contributes to bumpel-mediated protective effects in the CNS.
- Although the authors present evidence that increased bumpel expression can activate autophagy, the data is not convincing that the neuroprotective effects associated with bumpel are mediated through autophagy. Pyruvate, in some circumstances, can non-enzymatically scavenge hydrogen peroxide or in other cases trigger oxidative stress resistance through hormetic ROS signaling. The authors should consider these alternative possibilities.
- The authors rely on overexpressing bumpel to attenuate C9 toxicity in flies. They should perform the opposite experiment and knockdown bumpel to demonstrate that reduced bumpel expression results in potentiation of C9 and amyloid beta neurotoxicity. In addition, then should show that knockdown of bumpel expression has some effect on autophagy.
Minor Comments:
- Neuronal overexpression of bumpel appears to shorten lifespan of wild type flies (Fig 2A). It is possible that neuronal import of pyruvate may drive mitochondrial oxidative phosphorylation and ROS formation. The authors should comment on this possibility in the discussion.
- In Fig 3 the authors used a mixture of sodium pyruvate and ethyl pyruvate to demonstrate the import properties of bumpel. The rationale for using ethyl pyruvate is unclear as this membrane-permeable metabolite can by-pass any transporters.
- In the introduction several acronyms are used (i.e. GRN, MAPT, TREM2) that are not defined.
Significance
To my knowledge, this is the first study to identify that bumpel can permit the import of pyruvate and lactate into neurons when ectopically expressed in the fly brain. The fact that increased neuronal pyruvate import can partially protect against toxic peptide accumulation is unexpected and quite novel. Although some evidence is presented that bumpel can trigger autophagy, it is not clear if autophagy is mediating bumpel neuroprotective effects. Alternative mechanisms related to pyruvate effects on ROS and oxidative stress resistance should be considered.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary:
Project investigates the role in dementias of glial glucose uptake, conversion to lactate and shuttling via transporters to neurons to produce pyruvate to fuel TCA cycle production of ATG. The experiments are conducted in Drosophila melanogaster, which have become a powerful model system for understanding neurodegeneration mechanisms associated with ALS/FTD associated C9orf72 pathology. Bumple misexpression is shown to rescue early death phenotype in flies expressing a C9orf72 expansion and flies expressing arginine containing di-peptide repeat proteins. The report describes novel insight into the function of bumpel, demonstrating that this conserved orthologue of human SLC14A functions as a sodium exchange transporter for monocarboxylates pyruvate and lactate. These findings conclude that increased neuronal pyruvate, but not its metabolites, rescues C9orf72 associated pathology.
The authors next set out to describe the mechanism by which increase pyruvate rescues survival in C9orf72 expressing flies. Levels of autolysosomes were increased in C9orf72 expressing flies, and stimulation of autophagy by overexpression of atg1 shown to decrease levels of DPRs (though not to same extent as bumple expression). Expression of bumple in C9orf72 flies led to a modest increase in LC3-II, indicating increased autophagy. Co-overexpression of bumple and atg1 did not have an additive effect, suggesting bumple activates autophagy downstream or independent of atg1 activity. Finally the author extend their findings to amyloid models, suggest a common protective mechanism for elevating neuronal pyruvate levels in neurodegenerative disease.
Major comments
Prior data suggests that bumpel is expressed in glia (for example Yildirim et al 2022). In their study the authors do not present any data to demonstrate that the transporter is normally expressed in neurons in flies. This calls into questions the physiological relevance of their findings, that neuronal upregulation of bumpel is protective against C9orf72 associated pathology in neurons, from which it is reasonable for a reader to conclude that bumpel may be a neuronal target for therapeutic intervention. However, the report well demonstrates that regardless of whether the transporter in native to neurons, the increase in monocarboxylates it facilitates is projective against C9orf72 pathology and thus the overall conclusion of the project is supported by experimental evidence. The point of upregulation of a natively expressed gene versus misexpression of a glial enriched transporter should be considered in a bit more detail in the discussion text. The authors may consider speculating the identify of members of the sodium coupled monocarboxylate transporters that are enriched in neurons. Are any of the bumple human orthologues expressed in neurons?<br /> [OPTIONAL] cDNA overexpression of neuron specific sodium coupled monocarboxylate transporters in C9orf72 fly models would strengthen the conclusion their physiological relevance for ALS/FTD. Fly lines for these are not available in repositories, but could be generated and tested at reasonable cost (<£700, ~3 month duration).<br /> The role of bumple expression in survival (Figure 1) could be a technical artifact due to dilution of Gal4 between C9orf72 and bumple-ORF transgenes. No expression control is shown (for example GFP, LacZ etc). This theory is unlikely as no improvement in survival was seen for the SLC14A class of transporters which have a matching site directed transgene insertion. For clarity this point relating to controls should be commented on in the text.<br /> Reduced Mito-GFP levels are used to support a role for bumple in increasing mitophagy. As mito-GFP is a marker for mitochondria but not specifically mitophagy, an alternative explanation for decreased levels could be reduced mitochondria biogenesis. The text should be amended to clarify this point.<br /> The role of Pink1 RNAi in modifying mitophagy is a bit overstated. Whilst Pink1 is involved in stress associated mitophagy, its role in basal mitochondria turnover is less well defined. Text should be adapted.
Minor comments
Introduction well describes current state of C9orf72 fly models. Introduction would benefit from a few comparable lines for AD models. The first paragraph of reports may also be better placed in the introduction.
Figure 1 presents survival for three SLC16A transporters and bumple. The C9 control curve appears to be consistent between charts, likely indicating the same control used across experiments, rather than independent controls for each chart. The authors should considered showing either all SLC16A and bumple data on a single chart, or clarify in the figure legend that a common control dataset is used. GFP control is used in later experiments (Figure 2).
Choice of amyloid model needs a line of explanation, particularly with regard to extra/intracellular deposition of amyloid in this model.
Fruit Fly Injection method section needs a bit more detail to describe site of injection (head, body etc). This is not clear in the result section either.
How were bumple orthologues identified? What degree of conservation (sequence homology etc?)
The speculative mechanism for C9 pathology modification involves interaction of neurons and glia, monocarboxylate transporters and changes in autophagy activity. For clarity a diagram showing the model may be a helpful addition.
Typos:
Figure 1 Legend - "p values of ona way ANOVA "
Figure S2 Legend - Atg1 RNAi genotypes from S2 legend are mentioned erroneously
Repetition of text in results: "Bumpel, together with its paralogues kumpel and rumpel, is expressed in glia in flies, where it is thought to promote transport of substrates across the brain (31)."
"Modulation of Atg1 when bumpel was co-overexpressed, however, did not affect GP<br /> levels (Fig 4E, F)" - Should be refering to Fig 4D, E)
Significance
The study will be of broadly of interest to researcher working in the fields of neurodegeneration and metabolism, providing evidence for a protective role of elevated pyruvate in neuron that provide new understand relating to pathology in C9orf72 associated motor neuron disease and frontotemporal dementia.
Strengths:
The study presents novel data to demonstrate that overexpression of fly monocarboxylate transporter bumple rescues an early death phenotype associate with ALS/FTD gene C9orf72. Any novel therapeutic strategies of ALS are of interest to the field, and the strategy demonstrated here may be readily translated to human cell culture systems for proof of principle translational studies to a more physiologically relevant system. This study further demonstrates the utility of invertebrate models to generate novel understanding of C9orf72 pathology.
Limitations:
The study speculates that there is a link between pyruvate levels and increased autophagy, however the mechanisms by which this occurs is not defined in present study. This is a limitation of the experiment, though opens up an interesting question for future studies.
Reviewer expertise: The reviewer researches ALS and dementia associated neurodegeneration, utilising Drosophila, rodent and stem cell derived model systems.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
The manuscript by Niccoli et al. describes the identification of a novel modifier of C9orf72-derived toxicity based on the manipulation of the brain metabolic pathways. The premise for this work is supported by strong literature describing the aberrant glucose metabolism in FTD, AD and other degenerative disorders. The idea tested here is whether increasing the import of pyruvate produced in glia into neurons. They test three different types of importers and find that one of them, Bumpel, the orthologue of human SLC5A12, suppresses toxicity and reduces the accumulation of arginine-containing repeats, GP and PR. The authors investigate several potential mechanisms mediating this reduction of toxic DPRs, but do not find strong evidence linking pyruvate import and increase autophagy or mitochondria metabolism.
Overall, this is an interesting discovery based on a candidate approach that shows the power of Drosophila to efficiently identify novel mediators of neurodegeneration. The article is well written, although more detailed explanations of some experiments would be helpful. The weaknesses of the manuscript are the lack of a clear mechanism mediating the protective activity of pyruvate, the incomplete experiments lacking relevant controls, and the presentation of western blots.
Specific comments:
- The reduced levels of DPRs require that the expression of C9 mRNA or the GR and PR constructs is examined by qPCR. In figure 3E, GP is not even detectable
- I wonder if there are constructs available to silence Bumpel or overexpress the human orthologues of bumpel. These would be nice controls for the effects observed with the Bumpel overexpression
- The argument about bumpel modulating autophagy downstream of Atg1 is not supported by the experimental data
- Western blots throughout show no control lanes and in several occasions are created with cutout bands. The standard for this type of experiments should be more stringent, with entire gels showing all experimental conditions, which requires consistent methods and results vs selecting the best bands from different gels.
- For figures 2B and 5C, please, show representative WBs
- Figure 5D describes the survival curve as significantly rescued. Statistical tests can indicate differences, but that is in no way convincing. The test may show the curves are different, but the abeta Atg1 flies also seem to start falling early, so an argument could be made in both directions, as a suppressor or an enhancer.
- It is unclear why several results are placed in the supplemental materials. In general, all this material seems highly relevant and related to what is shown in the main figures
Minor comments:
Please, define several abbreviations throughout
A couple of sections could be improved by carefully sequencing human vs Drosophila background to advance the argument rather than going in circles. There is also a section on mitophagy in between two sections related to autophagy that could be sequenced better.
There is a sentence at the end of page 6 that seems misplaced
Significance
Overall, this is an interesting discovery based on a candidate approach that shows the power of Drosophila to efficiently identify novel mediators of neurodegeneration. The article is well written, although more detailed explanations of some experiments would be helpful. The weaknesses of the manuscript are the lack of a clear mechanism mediating the protective activity of pyruvate, the incomplete experiments lacking relevant controls, and the presentation of western blots.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We would like to thank the reviewers for their insightful comments. We believe that the changes that have been suggested will add greatly to this paper, and we will endeavor to incorporate as many of these suggestions as we can.
Reviewer #1
This is an interesting study, which presents yet another mechanism involved in the regulation of tumour associated paraneoplastic syndromes, such as muscle wasting. It suggest the intriguing possibility of using a hight fat diet and modulating mitochondrial metabolism as a means of alleviating cachectic muscle wasting. However, as it stands, these aspects of the study remains rather preliminary. This is particularly the case regarding the role of dietary interventions in the model and understanding of the type of metabolic reprogramming in wasting muscles, which lack direct experimental evidence. If the authors were able to further develop this aspects of the study with robust experimental work, it will make it a very valuable and impactful report.
1- All the mitochondrial phenotypes presented should be compared in the two different tumour models (Gal4/UAS and the QF/QUAS driven), which are indistinctively used throughout the study.
We will ensure that mitochondrial size and TMRE staining are performed in the two different tumour models so that they can be compared.
2- The mitochondrial phenotype of wasting muscles is only evident towards the late stages of tumourigenesis (7 day old larvae). Mitochondria of 5 day old tumour bearing animals is indistinct from the control ones. Given that 5 days is the oldest wild type larvae available, the authors need to assess the mitochondrial size and function in muscles form developmentally delayed, no-tumour bearing larvae to discard a trivial contribution of failed metamorphosis in such phenotype.
We will examine mitochondrial size and TMRE in pmhGal4 > torsoRNAi animals (which undergo delayed metamorphosis) compared with control animals.
4- TMRE staining presented in Figure 1 is not convincing. If available, a biochemical and/or more quantitative method to address mitochondrial function should be used.
We will perform ATP synthesis and O2 consumption assays to provide a biochemical method to accompany the TMRE assays.
5- Related to the point above. The extent of the mitochondrial phenotype following genetic manipulations in the tumour or muscle is not consistently analysed. In some cases, mitochondrial size and activity is assessed but in multiple cases, only mitochondrial size is measured. Mitochondrial activity should be assessed in all cases also.
We will assess mitochondrial activity in a time course of RasV12DlgRNAi vs w1118, as well as tumor-bearing animals treated with nicotinamide, QF-QUAS RasV12scribRNAi, MHC> foxoRNAi, and RasV12DlgRNAi > Impl2RNAi.
6- Are mitochondrial fusion proteins such as Marf upregulated in muscles undergoing wasting in Rasv12dlg RNAi animals?
Regulation of neither Opa1 nor Marf are altered in our proteomics study.
7- Is overexpression of mitochondrial fusion proteins alone sufficient to induce muscle wasting?
No, overexpression of Marf was not sufficient to induce muscle wasting, however overexpression of Marf caused worsened muscle wasting in tumour-bearing animals. We will include this data in our revised manuscript.
8- Is there a change in the expression of ATP5A in the muscles of bearing animals RasV12dlgRNAi, which has dysfunctional mitochondria compared to the control?
There is no change in ATP5A expression in our proteomics study.
9- Regarding measures of insulin signaling activity in muscle (Figure 2): the data provide on FOXO staining is not very convincing. Improved staining and robust and more quantitative measure of insulin signaling activity, such as western blot analysis of pAkt should be provided. Apart from the nucleus, there is an overall increase in FOXO expression in the muscle cells of RasV12dlgRNAi compared to the control. In control animals, there is no signal of FOXO. How do you explain this?
We have attempted western blots of pAkt in tumour-bearing muscle previously and found that tumour metastases caused unreliable results, making immuno-staining a more reliable option. However, pAkt antibody staining also does not work well in the muscles. The control image we displayed was an extreme example, so we will choose more representative images that show more consistent FOXO staining.
12- In S3 J-L, Since MHC expression is also dependent upon muscle health and integrity, it would be better to use another, and more universal, readout for protein translation/synthesis. For example, labelling the tissue with Puromycin or staining for translation initiation factors.
We will perform O-propargyl-puromycin (OPP) staining for a w1118 vs RasV12DlgRNAi time course to provide another translation readout to accompany the MHC staining.
13- How does lipid/high fat diet restore muscle wasting? What happens to the tumours of high fat and Nicotinamide feed animals? In all cases, the impact on tumour size upon genetic manipulations of the muscle should be shown.
We will measure tumour size in tumour-bearing animals on both nicotinamide and high-fat diets, as well as QF-QUAS RasV12scribRNAi MHC> foxoRNAi, marfRNAi and whdRNAi animals. Impl2RNAi in tumour-bearing animals has been shown already (Lodge et al., 2021).
14- Does NAM feeding or High-fat diet restore whd transcript levels??
We will perform qPCR to examine whd transcript levels in tumour-bearing animals on nicotinamide diets as well as high-fat diets.
15- Do these feeding regimes restore insulin signaling in RasV12dlgRNAi animals?
We have demonstrated that for RasV12dlgRNAi animals fed a nicotinamide diet, FOXO levels are decreased (Fig 5D). We will do the same experiment for tumour-bearing animals fed a high fat diet.
17- Related to the point above, DAPI and phalloidin should be included when showing lipid staining to understand better the cellular structures present in the field of view along with the lipid droplets.
DAPI and phalloidin staining is not compatible with lipid staining, as they require the use of PBST (detergent) which breaks down extracellular lipids. We will include more representative, raw images in which the details of the muscle can be seen.
Minor comments<br /> 1. The order of panels in the figures and the main text should be the same for better readability.
We will revisit the figures to ensure readability is improved.
- Figure S3 G-H: The image looks out of focus. Is Atg8 expression high near to the nucleus?
Atg8a expression is highest near the nucleus, and is decreased in RasV12dlgRNAi > Impl2RNAi animals. We will provide more representative images to make this clearer.
Reviewer #2
This manuscript proposes and interesting new mechanism how tumours non-autonomously induce muscle mass loss (cachexia) in a genetic Drosophila model. These effects can be modified by diet. Hence results are interesting for both basic and more clinically interested audience.<br /> The weak point of the paper is the limited quantification of mitochondria sizes/morphologies, which is an important point that asks for significant improvement of either the imaging conditions or the image analysis.
- The authors provide evidence that eye or imaginal disc tumours induce larger mitochondria in muscles. The authors try to quantify mitochondrial sizes using an automated analysis. This is a tricky task from their light microscopy images that appear to be limited in resolution. By looking at the Suppl. Figure 1, I wonder how relevant an increase of a "large" mitochondria fraction from 7 to 12 % is in the tumour larvae, considering that a significant fraction of the mitochondria are currently not counted, as they are too large to be investigated (white colours in S1F, G). Can the authors increase resolution to resolve these large clumps that likely consist of individual mitochondria to reliably segment all of them, and not only a sub fraction. It would be useful to display the size profiles of all mitochondria in various conditions and not only of a very selected subset of "large" mitochondria. This comment applies to all figures in which mitochondria size was quantified and hence is critical for the entire manuscript.
We will utilise a newly developed segmentation and centroid tracking-based analysis pipeline based in MATLAB, that may be able to separate the large clumps of mitochondria, to ensure that as many mitochondria can be quantified as possible. We will also provide size profiles of all mitochondria sizes from all conditions in which we performed mitochondria size analysis.
- Comparing MitoTracker to TMRE is a valid approach to estimate mitochondria activity/health. The images shown in 1H,I are overview images that seem to show large regional differences in the muscles of unclear origin. High resolution images of representative regions as shown for the ATP5A stains would be more convincing as these can resolve individual mitochondria to hopefully see damaged ones next to normal ones. Would "active" mitochondria not be expected to be the ones that oxidise a lot of fatty acid break down products?
We will take representative zoomed in images for 1H & I to better demonstrate mitochondria morphology.
- The authors find that co-overexpressing FOXO in muscles results in a more severe muscle degeneration phenotype in tumour bearing animals than tumour alone. However, it seems the important control of FOXO overexpression in an otherwise wildtype animal is missing. In order to judge if the muscles really detach in these genotypes, instead of shrink and finally rupture, high resolution images of muscle attachment sites would be needed.
We will assess if MHCGal4 > UAS dFOXO causes loss of muscle integrity. In addition, in both wildtype and tumour-bearing animals, we will overexpress FOXO in the muscles and stain for muscle attachment proteins such as tiggrin to determine if the phenotype seen is caused by a mislocalisation of proteins at attachment sites.
- The strongly reduced lipid droplets in the tumour bearing animals is interesting. To better normalise for the reduced size of the muscles, a counter staining for muscle and a following normalisation would make the statement stronger and thus better support the conclusion.
As mentioned above we will provide more representative images to help visualize muscle structures in LipidTOX experiments. In addition, we will normalize the amount of lipid droplets detected to a set area, as opposed to just measuring total lipid droplets.
Reviewer #3
The strength of the study is the use of suitable in vivo model systems, combined with genetic manipulations to study the mechanisms behind cancer cachexia. The weak points of the study is the lack of functional assays such as quantitative measurements of oxidative phosphorylation and metabolites.
1, Throughout the manuscript the authors use TMRE staining to evaluate mitochondrial function. To me it is not clear what function they are actually referring to. I assume they mean respiration/respiratory chain function, as this generates the proton motif force measured, but neither oxygen consumption nor aerobic ATP synthesis is ever mentioned or measured. Especially considering that the authors suggest that an increased flux through beta oxidation, which is a mitochondrial function, results in muscle wasting, the authors might want to consider measuring respiration with different substrates, using either a seahorse or Oroboros or equivalent.
We do not have the necessary equipment or resources to perform Seahorse or Oroboros experiments. Therefore, we will perform O2 consumption and ATP synthesis assays for RasV12dlgRNAi and QF-QUAS RasV12scribRNAi vs w1118, RasV12dlgRNAi > Impl2RNAi, QF-QUAS RasV12scribRNAi > marfRNAi, whdRNAi, and tumour-bearing animals fed high fat diets to provide more insights into mitochondria function.
3, It is difficult to understand that it is even possible for beta oxidation to exceed the capacity of the OXPHOS system. In that case one would have excess of acetyl CoA and NADH, inevitably inhibiting further beta oxidation and the TCA cycle due to lack of NAD, as well as numerous regulatory mechanisms. Additionally, one would expect increased ketone body production. The authors might want to clarify how the excess redox potential, due to increased beta oxidation is utilised.
We will perform acetyl-CoA and NAD/NADH assays in RasV12dlgRNAi and QF-QUAS RasV12scribRNAi vs w1118 to determine if beta-oxidation is occurring in excess. In addition, we will clarify in the text that we hypothesize that increased beta-oxidation is utilizing the muscle’s resources to the point that there is none left to continue energy production.
Minor:
Line 223 "Together, this data suggests that FOXO lies upstream of beta-oxidation, and mitochondria function lies downstream of beta-oxidation".<br /> I would suggest to rephrase. Of course beta-oxidation and the TCA takes place inside mitochondria, so what mitochondrial functions do the authors refer to?
As mentioned earlier, we will perform O2 consumption and ATP synthesis assays to strengthen this claim. In addition, we will rephrase this sentence to avoid confusion.
Line 238 "Overall, this data suggests that the depletion of muscle lipid stores via beta oxidation affects mitochondrial function and is negatively correlated with muscle health in cachectic flies, mice and patients" - The mechanism is not fully clear to me as other energy sources are still available to the fly. The authors might want to expand here.
We will clarify that there may be other energy sources available that were not investigated in this paper.
Line 93 : "To test whether this increase in mitochondrial size could lead to compromised mitochondrial function, we performed live staining with tetramethylrhodamine ethyl ester (TMRE), a compound used to measure the membrane potential of mitochondria." - I am not sure that size on its own correlates with mitochondrial function, but rather the energetic and metabolic state of the cell. Increased biogenesis is a common response to dysfunction, but often reflected in increased mass.
We will clarify the that the increase in size may be a reflection of increased metabolic need of the muscle.
1. Description of the revisions that have already been incorporated in the transferred manuscript
Please insert a point-by-point reply describing the revisions that were already carried out and included in the transferred manuscript. If no revisions have been carried out yet, please leave this section empty.
Reviewer 1:
3- In all cases, the age of experimental animals must be clearly indicated in figures and/or figure legends.
We have already put the ages of the experimental animals in the bottom of the figure legends.
11- Does insulin signaling influence Lipid metabolism in muscle?
We demonstrate in the manuscript that FoxoRNAi in the muscle of tumour-bearing animals reduces whd transcript levels (Fig 4C), and Impl2RNAi in the tumour restores muscle lipid droplet levels (Fig 3G-I).
2. Description of analyses that authors prefer not to carry out
Please include a point-by-point response explaining why some of the requested data or additional analyses might not be necessary or cannot be provided within the scope of a revision. This can be due to time or resource limitations or in case of disagreement about the necessity of such additional data given the scope of the study. Please leave empty if not applicable.
Reviewer 1:
10- The phenotype of increased fatty acid oxidation in wasting muscles is inferred as per the proteomic signature but not directly demonstrated. TCA metabolite tracing using 13C-Palmitate should be used to demonstrate this, which is a central point of the manuscript.
The examination of 13C-palmitate would require metabolomic approaches, for which we do not have the necessary equipment and is beyond our timeframe. Thus, we will aim to examine changes in mitochondria metabolism through other measures mentioned above.
16- The lipid phenotype in cachectic fly muscles is not consistent with that reported in humans and shown by the authors in their xenograft model. While loss of lipid droplets is observed in the fly muscle cells, there is increase in the lipid content within the mouse muscle and only extramyocellular lipid is decreased. The relevance of the extracellular lipid is unclear.
We hypothesize that this is due to a transport of lipids from extracellular lipid droplets to mitochondria for utilization, as has been suggested previously (Rambold et al., 2015). Examining in detail if this is the case in our models is beyond the scope of this paper.
Reviewer 3:
2, The authors suggest that an increase in beta oxidation exceeds mitochondrial function (?), which in turn induces a change in mitochondrial morphology, further contributing to the muscle wasting. The authors may want to demonstrate that there is indeed excess beta oxidation, by measuring a toxic accumulation of different lengths of acylcarnitines. For instance, it is well known that patients with beta oxidation defects accumulate toxic intermediates of beta oxidation that can ultimately affect mitochondrial function.<br /> The manuscript would be much improved if oxygen consumption is measured and combined with analysis of acylcarnitines.
The examination of acylcarnitines would require lipidomic approaches, and is beyond our timeframe for these revisions. To try to address the need for investigations if beta-oxidation is in excess, we will perform oxygen consumption assays as mentioned and alter the manuscript to de-emphasize excess beta-oxidation.
4, Unfortunately the supplementary information is in a format I can't open, thus I can't evaluate the method for identifying large mitochondria and other results in these files. This makes part of the reviewing process difficult.
N/A
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
In this manuscript the authors study the mechanisms behind cancer cachexia, using drosophila cancer models. They find that muscle wasting in cachexia is mediated via two different mechanisms: either via insulin signalling and FOXO activation or beta oxidation via mitochondrial fusion.<br /> It is well known that many cancers can induce a catabolic state, compatible with a decrease in insulin signalling and one of the mechanisms proposed. Additionally, the authors suggest that an imbalance between mitochondrial capacity and beta oxidation flux leads to muscle wasting.
Major comments:
- Throughout the manuscript the authors use TMRE staining to evaluate mitochondrial function. To me it is not clear what function they are actually referring to. I assume they mean respiration/respiratory chain function, as this generates the proton motif force measured, but neither oxygen consumption nor aerobic ATP synthesis is ever mentioned or measured. Especially considering that the authors suggest that an increased flux through beta oxidation, which is a mitochondrial function, results in muscle wasting, the authors might want to consider measuring respiration with different substrates, using either a seahorse or Oroboros or equivalent.
- The authors suggest that an increase in beta oxidation exceeds mitochondrial function (?), which in turn induces a change in mitochondrial morphology, further contributing to the muscle wasting. The authors may want to demonstrate that there is indeed excess beta oxidation, by measuring a toxic accumulation of different lengths of acylcarnitines. For instance, it is well known that patients with beta oxidation defects accumulate toxic intermediates of beta oxidation that can ultimately affect mitochondrial function.<br /> The manuscript would be much improved if oxygen consumption is measured and combined with analysis of acylcarnitines.
- It is difficult to understand that it is even possible for beta oxidation to exceed the capacity of the OXPHOS system. In that case one would have excess of acetyl CoA and NADH, inevitably inhibiting further beta oxidation and the TCA cycle due to lack of NAD, as well as numerous regulatory mechanisms. Additionally, one would expect increased ketone body production. The authors might want to clarify how the excess redox potential, due to increased beta oxidation is utilised.
- Unfortunately the supplementary information is in a format I can't open, thus I can't evaluate the method for identifying large mitochondria and other results in these files. This makes part of the reviewing process difficult.
Minor:
Line 223 "Together, this data suggests that FOXO lies upstream of beta-oxidation, and mitochondria function lies downstream of beta-oxidation".<br /> I would suggest to rephrase. Of course beta-oxidation and the TCA takes place inside mitochondria, so what mitochondrial functions do the authors refer to?
Line 238 "Overall, this data suggests that the depletion of muscle lipid stores via beta oxidation affects mitochondrial function and is negatively correlated with muscle health in cachectic flies, mice and patients" - The mechanism is not fully clear to me as other energy sources are still available to the fly. The authors might want to expand here.
Line 93 : "To test whether this increase in mitochondrial size could lead to compromised mitochondrial function, we performed live staining with tetramethylrhodamine ethyl ester (TMRE), a compound used to measure the membrane potential of mitochondria." - I am not sure that size on its own correlates with mitochondrial function, but rather the energetic and metabolic state of the cell. Increased biogenesis is a common response to dysfunction, but often reflected in increased mass.
Significance
General assessment: The strength of the study is the use of suitable in vivo modelsystems, combined with genetic manipulations to study the mechanisms behind cancer cachexia. The weak points of the study is the lack of functional assays such as quantitative measurements of oxidative phosphorylation and metabolites.
Advance: The main advance of this study is attributed to mechanistic insights behind cancer cachexia and the role of mitochondria in more conditions as opposed to the its involvement in inherited mitochondria disease.
Audience: This report should be of interest to a broad audience since it's studying a condition connected to cancer and cancer metabolism.
Reviewers field of expertise: Mitochondrial disease/dysfunction, in vivo modelling, molecular biology, bioenergetics and metabolism
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Chen and colleagues are using the Drosophila larval muscles model to investigate how a tumour can non-autonomously induce muscle mass loss, a known phenomenon called cancer cachexia. They report that tumours change muscle mitochondria morphologies, specifically their size and their chemistry. These changes correlate with increase in fat metabolism and a depletion of fat and glycogen reserves. Regarding the molecular mechanism, the authors propose that tumour cells secrete IGF binding protein that reduces the level of insulin and thus insulin signalling in muscle. They test this hypothesis by reducing FOXO activity, a negative regulator of insulin signalling, or mitochondrial fusion in muscles of tumour carrying larvae, which indeed appears to result in muscle improvements. These insights from Drosophila muscles suggest that tumour-caused reduced insulin signalling in muscles can be responsible for tumour induced muscle loss. A similar mechanism may apply to mammals and hence these findings are of clinical interest.
Major comments
- The authors provide evidence that eye or imaginal disc tumours induce larger mitochondria in muscles. The authors try to quantify mitochondrial sizes using an automated analysis. This is a tricky task from their light microscopy images that appear to be limited in resolution. By looking at the Suppl. Figure 1, I wonder how relevant an increase of a "large" mitochondria fraction from 7 to 12 % is in the tumour larvae, considering that a significant fraction of the mitochondria are currently not counted, as they are too large to be investigated (white colours in S1F, G). Can the authors increase resolution to resolve these large clumps that likely consist of individual mitochondria to reliably segment all of them, and not only a sub fraction. It would be useful to display the size profiles of all mitochondria in various conditions and not only of a very selected subset of "large" mitochondria.<br /> This comment applies to all figures in which mitochondria size was quantified and hence is critical for the entire manuscript.
- Comparing MitoTracker to TMRE is a valid approach to estimate mitochondria activity/health. The images shown in 1H,I are overview images that seem to show large regional differences in the muscles of unclear origin. High resolution images of representative regions as shown for the ATP5A stains would be more convincing as these can resolve individual mitochondria to hopefully see damaged ones next to normal ones. Would "active" mitochondria not be expected to be the ones that oxidise a lot of fatty acid break down products?
- The authors find that co-overexpressing FOXO in muscles results in a more severe muscle degeneration phenotype in tumour bearing animals than tumour alone. However, it seems the important control of FOXO overexpression in an otherwise wildtype animal is missing. In order to judge if the muscles really detach in these genotypes, instead of shrink and finally rupture, high resolution images of muscle attachment sites would be needed.
- The strongly reduced lipid droplets in the tumour bearing animals is interesting. To better normalise for the reduced size of the muscles, a counter staining for muscle and a following normalisation would make the statement stronger and thus better support the conclusion.
Significance
This manuscript proposes and interesting new mechanism how tumours non-autonomously induce muscle mass loss (cachexia) in a genetic Drosophila model. These effects can be modified by diet. Hence results are interesting for both basic and more clinically interested audience.<br /> The weak point of the paper is the limited quantification of mitochondria sizes/morphologies, which is an important point that asks for significant improvement of either the imaging conditions or the image analysis.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary
Larvae bearing RasV12; dlgRNAi eye tumours recapitulate aspects of cachexia, such as muscle wasting. In this manuscript, the authors use their previously characterized RasV12; dlgRNAi larval model of cancer cachexia to show that tumour induced cachectic muscle wasting is associated with excessive mitochondrial fusion, resulting in the formation of enlarged dysfunctional mitochondria in wasted muscle cells. Muscle specific blockade of mitochondrial fusion prevents muscle wasting and restores mitochondrial potential in tumour bearing animals. The authors also link increased mitochondrial size to decreased insulin signaling (increased foxo) caused by the tumour induced pro-cachexia factor and insulin inhibitor Impl2. Consistently, downregulation of ImpL2 from the tumour decreases foxo levels in muscle and reduces mitochondrial size. Finally, the authors show that wasting muscles in flies show decrease lipid droplets and a molecular and proteomic signature indicative of increased fatty acid oxidation. Muscle wasting, loss of lipids and mitochondrial integrity can be restored upon inhibition of Impl2 in the tumour, downregulation of the mitochondrial lipid transporter CPT1 or feeding animals with a high fat diet.
Major comments
- All the mitochondrial phenotypes presented should be compared in the two different tumour models (Gal4/UAS and the QF/QUAS driven), which are indistinctively used throughout the study.
- The mitochondrial phenotype of wasting muscles is only evident towards the late stages of tumourigenesis (7 day old larvae). Mitochondria of 5 day old tumour bearing animals is indistinct from the control ones. Given that 5 days is the oldest wild type larvae available, the authors need to assess the mitochondrial size and function in muscles form developmentally delayed, no-tumour bearing larvae to discard a trivial contribution of failed metamorphosis in such phenotype.
- In all cases, the age of experimental animals must be clearly indicated in figures and/or figure legends.
- TMRE staining presented in Figure 1 is not convincing. If available, a biochemical and/or more quantitative method to address mitochondrial function should be used.
- Related to the point above. The extent of the mitochondrial phenotype following genetic manipulations in the tumour or muscle is not consistently analysed. In some cases, mitochondrial size and activity is assessed but in multiple cases, only mitochondrial size is measured. Mitochondrial activity should be assessed in all cases also.
- Are mitochondrial fusion proteins such as Marf upregulated in muscles undergoing wasting in Rasv12dlg RNAi animals?
- Is overexpression of mitochondrial fusion proteins alone sufficient to induce muscle wasting?
- Is there a change in the expression of ATP5A in the muscles of bearing animals RasV12dlgRNAi, which has dysfunctional mitochondria compared to the control?
- Regarding measures of insulin signaling activity in muscle (Figure 2): the data provide on FOXO staining is not very convincing. Improved staining and robust and more quantitative measure of insulin signaling activity, such as western blot analysis of pAkt should be provided. Apart from the nucleus, there is an overall increase in FOXO expression in the muscle cells of RasV12dlgRNAi compared to the control. In control animals, there is no signal of FOXO. How do you explain this?
- The phenotype of increased fatty acid oxidation in wasting muscles is inferred as per the proteomic signature but not directly demonstrated. TCA metabolite tracing using 13C-Palmitate should be used to demonstrate this, which is a central point of the manuscript.
- Does insulin signaling influence Lipid metabolism in muscle?
- In S3 J-L, Since MHC expression is also dependent upon muscle health and integrity, it would be better to use another, and more universal, readout for protein translation/synthesis. For example, labelling the tissue with Puromycin or staining for translation initiation factors.
- How does lipid/high fat diet restore muscle wasting? What happens to the tumours of high fat and Nicotinamide feed animals? In all cases, the impact on tumour size upon genetic manipulations of the muscle should be shown.
- Does NAM feeding or High-fat diet restore whd transcript levels??
- Do these feeding regimes restore insulin signaling in RasV12dlgRNAi animals?
- The lipid phenotype in cachectic fly muscles is not consistent with that reported in humans and shown by the authors in their xenograft model. While loss of lipid droplets is observed in the fly muscle cells, there is increase in the lipid content within the mouse muscle and only extramyocellular lipid is decreased. The relevance of the extracellular lipid is unclear.
- Related to the point above, DAPI and phalloidin should be included when showing lipid staining to understand better the cellular structures present in the field of view along with the lipid droplets.
Minor comments
- The order of panels in the figures and the main text should be the same for better readability.
- Figure S3 G-H: The image looks out of focus. Is Atg8 expression high near to the nucleus?
Significance
This is an interesting study, which presents yet another mechanism involved in the regulation of tumour associated paraneoplastic syndromes, such as muscle wasting. It suggest the intriguing possibility of using a hight fat diet and modulating mitochondrial metabolism as a means of alleviating cachectic muscle wasting. However, as it stands, these aspects of the study remains rather preliminary. This is particularly the case regarding the role of dietary interventions in the model and understanding of the type of metabolic reprogramming in wasting muscles, which lack direct experimental evidence. If the authors were able to further develop this aspects of the study with robust experimental work, it will make it a very valuable and impactful report.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We would like to thank the reviewers for their comments and suggestions, which were very helpful to improve our manuscript. The revised manuscript notably includes the following improvements:
- To evaluate the relevance of identified candidate targets genes, we integrated an additional screening step in our method, corresponding to the analysis of RNAseq datasets specific of blood or brain cells. RNAseq data from irradiated hematopoietic stem cells or splenic cells were analyzed and included in the new Table S19, and RNAseq data from zika virus-infected neural progenitors were analyzed and included in the new Table S28. In addition, we also verified that the expression of a subset of blood related genes was decreased in the bone marrow cells of p53Δ31/Δ31 mice, known to exhibit increased p53 activity and to phenocopy dyskeratosis congenita (new Figure S8).
- Luciferase data were expanded to show that, for promoters exhibiting a significant p53-mediated repression in luciferase assays, the p53-dependent regulation was abrogated after mutation of the putative DREAM binding site (new Figures 2e and 2i).
- We found putative DREAM binding sites for 151 targets, and the predicted binding sites were precisely mapped relative to the position of ChIP peaks of DREAM subunits (E2F4 and LIN9) and to transcription start sites of target genes. These additional analyses, shown in the new Figures 3a and 3b, further suggest the reliability of our predicted binding sites. Notably, hypergeometric tests of the distribution of DREAM binding sites relative to E2F4/LIN9 ChIP peaks reveal a significant >1300-fold enrichment of these sites at ChIP peaks.
- We now present a detailed comparison of our results with those reported in other studies, notably the predicted E2F and CHR sites from the Target gene regulation database (new Figure S11), or the list of candidate DREAM targets suggested from Lin37 KO cells (new Figure S10 and new Table S35). This also leads us to discuss the different types of DREAM binding sites (bipartite sites (e.g. CDE/CHR or E2F/CLE) vs sites composed of a single E2F or a single CHR motif).
- We integrated updates of the Human phenotype ontology website to include the latest lists of genes related to blood or brain ontology terms in our analysis. In the previous version of the manuscript we had analyzed a total of 811 genes downregulated ≥ 1.5 fold upon bone marrow cell differentiation. Our revised manuscript now includes the analysis of 883 genes.
- Several improvements were made to present our results more clearly and with more details : 1) additional evidence that the differentiation of Hoxa9ER cells correlates with p53 activation is now provided in the new Figure S1; 2) the precise values for gene expression after bone marrow cell differentiation, as well as p53 regulation scores from the Target gene regulation databases are included in the new Tables S1, S5, S8, S11, S14, S20 and S23; 3) A Venn-like diagram was included to summarize the different steps of our approach in the new Figure 3c, with detailed lists of genes selected at each step in new Tables S17 and S26; 4) for genes associated with blood or brain genetic disorders, bibliographic references describing gene mutations and clinical traits were included in a new Table S36; 5) Figure 4a and Table S37 were improved to include evidence that increased BRD8 in glioblastoma cells leads to a decreased expression of several genes transactivated by p53.
Reviewer #1 (Evidence, reproducibility and clarity):
Summary<br /> In this paper the authors describe a data driven approach to identify and prioritise p53-DREAM targets whose repression might contribute to abnormal haematopoiesis and brain abnormalities observed in p53-CTD deleted mice. The premise is that in these mice, (where they have previously demonstrated p53 to be hyperactive in at least a subset of tissues), that the p53-p21-E2F/DREAM axis is at least in part responsible for observed phenotypes due to the repression of E2F and CDE/CHE element containing genes. Their approach to home in on relevant genes is based on transcriptomic gene ontology analysis of genes repressed in these disease settings where they primarily use publicly available data from HOXA9-ER regulated model of HSC expansion wherein they observe increases on p53-p21 expression upon differentiation where they demonstrate that p53-p21 DREAM target genes are suppressed as we would expect in this scenario where p53-p21 is activating withdrawal from cell cycle. They then spend a lot of effort analysing this datasets combining "gene-ontology", "disease phenotype" and "meta-ChIP-seq" analysis of public data to support the observation that mutations of genes suppressed in this manner are disproportionately linked to heritable haematopoetic and brain disorders. While these results are interesting in terms of framing a hypothesis about how mutations in p53-p21-DREAM regulated targets contribute to such conditions, they are to be expected given the now very well described impact of p53-p21 on both E2F4/DREAM targets.
We agree with the referee that the impact of p53-p21 on both E2F4/DREAM targets is well described. However, discussions with many scientists or clinicians specialized in bone marrow failure syndromes or microcephaly diseases led us to realize that most were not familiarized with the p53-DREAM pathway, so that a study that would bridge the gap between DREAM experts and bone marrow or microcephaly specialists would be particularly useful. In addition, we thought that strategies that would rely on disease-based ontology terms were likely to identify new targets, compared to previous studies that considered cell cycle regulation instead of disease phenotypes. Consistent with this, many genes we identified as candidate DREAM targets were not reported in previous studies. In addition, as detailed below, our positional frequency matrices led to identify DREAM binding sites that had not been predicted by previous approaches.
The natural progression of this work would be to go on to show this occurs in relevant cells or tissues derived from the p53-CTD mice as well as look at modulating target genes to understand underlying mechanisms and consequences.<br /> Rather than this, they focus on validating that a sub-set of these targets are indeed suppressed by specific p53 activation by MDM2 inhibitor Nutlin-3A in MEFs by qPCR and that mutation of predicted CDE CHR elements in luciferase constructs leads to increase luciferase activity. While these findings support their predictions, the results are entirely expected based on what is known about such targets and demonstrating that this occurs in MEFs does not closely relate to haematopoietic and brain cells they suggest this regulation is important. In fact, in the discussion, the authors comment on the importance of cell type context specificity in terms of discordance between predictions of TF binding sites and public datasets.
We agree that additional data from relevant cells or tissues were required to strengthen our conclusions. In the revised manuscript, we evaluated the relevance of candidate target genes related to blood ontology terms by integrating an additional screening step in our method, corresponding to the analysis of RNAseq datasets specific of blood cells. We analyzed dataset GSE171697, with RNAseq data from hematopoietic stem cells of unirradiated p53 KO, or unirradiated or irradiated WT mice, as well as dataset GSE204924, with RNAseq data from splenic cells of irradiated p53Δ24/- or p53+/- mice. The latter dataset appeared interesting because p53Δ24 is a mouse model prone to bone marrow failure and the spleen is a hematopoietic organ in mice. The analysis of these datasets is included in the new Table S19. In the datasets,increased p53 activity correlated with the downregulation of most of the 269 candidate DREAM targets. However, 56 genes which appeared upregulated in cells with increased p53 activity were considered poor candidate p53-DREAM targets and removed from further analyses, leading to a list of 213 genes that appeared as better candidate p53-DREAM targets related to blood abnormalities. Furthermore, we also verified that the expression of a subset of blood-related candidate genes was decreased in the bone marrow cells of p53Δ31/Δ31 mice (prone to bone marrow failure) compared to bone marrow cells from WT mice. This result is presented in the new Figure S8.
As for genes related to brain development, we discussed in the previous version of the manuscript that most genes mutated in syndromes of microcephaly or cerebellar hypoplasia are involved in ubiquitous cellular functions (chromosome condensation, mitotic spindle activity, tRNA splicing…), which suggested that our analysis of transcriptomic changes associated with bone marrow cell differentiation might also be used to identify brain specific targets. However, we agree with the referee that confirmation of these brain specific targets in a more relevant cellular context was preferable. In the revised manuscript, we included the analysis of datasets GSE78711 and GSE80434, containing RNAseq data from human cortical neural progenitors infected by the Zika virus (ZIKV) or mock-infected, because ZIKV was shown to cause p53 activation in cortical neural progenitors and microcephaly. This analysis is detailed in the new supplementary Table S28. In both datasets, increased p53 activity correlated with the downregulation of most of the 226 candidate DREAM targets. Sixty-four genes which appeared more expressed in ZIKV-infected cells were considered poor candidate p53-DREAM targets and removed from further analyses, leading to a list of 162 candidate p53-DREAM targets related to brain abnormalities. We think this significantly increases the relevance of our analysis of brain-specific targets.
Finally, they try and contextualise effects in glioblastoma data by correlating target gene expression with levels of BRD8 since it has recently been shown to attenuate p53 function in glioblastoma and show that some of the brain disease associated genes are expressed at higher levels in BRD8 high patient samples. It seems strange here that they do not also look at expression of p21 or other p53 targets that would help ascertain if p53 activity is indeed suppressed. Moreover, much more elegant methods for predicting transcription factor activity could be applied to this data.
We agree with the referee. Indeed, when we had performed the analysis of glioblastoma cells, we first verified that increased BRD8 levels correlated with decreased p21 levels in these cells. However, we had not included this verification in the previous version of the manuscript. In this revision, we improved the Figure 4 (and Table S37) reporting the analysis of glioblastoma cells to address this point. In Figure 4a, we now show the variations in mRNA levels between BRD8Low and BRD8High tumors, for BRD8 itself, as well as 5 genes well-known to be transactivated by p53 (p21, MDM2, BAX, GADD45A and PLK3) and the 77 p53-DREAM targets associated with microcephaly or cerebellar hypoplasia. The data clearly show that tumors with high BRD8 exhibit a decrease in the expression of p53 transactivated targets, and an increase in p53-DREAM repressed targets.
Major Comments<br /> The major result of this paper as it stands is the prioritisation of candidate genes in the p53-DREAM pathway involved in these conditions, and their refined approach used to identify and prioritise these genes and is such more of a starting point for further investigation. They fall short of demonstrating the relevance of their predictions physiologically in tissues from the mice and do not demonstrate functional importance of regulation of targets they put forward. Given that these genes will be co-ordinately regulated, without a mechanistic experiment in physiologically relevant model it is impossible to infer causality. For example, depleting individual targets in the HOXA9 model and evaluating impact on survival, proliferation and differentiation may be a (relatively) simple way to explore this, perhaps comparing to effects of p53 activating agents such as Nutlin-3A. Of note the authors (Jaber 2016 PMID: 27033104) and several other groups had (Fischer 2014 PMID: 25486564 McDade 2014 PMID: 24823795) previously demonstrated the link between p53-p21 and suppression of DNA-repair/Damage related genes (as is also observed here in particular FA-related genes that they discuss briefly here. I would have thought that this would be an obvious starting point for some mechanistic experiments and in fact I note this has been demonstrated before (Li et al 2018 PMID: 29307578)
The starting point of our study is not the prioritization of DREAM target genes, but rather the detailed phenotyping of p53Δ31/Δ31 mice that we performed in previous publications (Simeonova et al. Cell Rep 2013, Toufektchan et al. Nat. Commun. 2016), in which we mentioned phenotypical traits typical of dyskeratosis congenita and Fanconi anemia, including notably bone marrow failure and cerebellar hypoplasia.
We understand that depleting individual targets in the Hoxa9 system and evaluating impact on survival, proliferation and differentiation might seem appropriate to explore their potential causality. However, our previous work on Fanc genes leads us to think that this might not be informative. Regarding this, we now clearly discuss in the revised version of the manuscript : “Finding a functionally relevant [DREAM binding site] for Fanca, mutated in 60% of patients with Fanconi anemia [59,60], may help to understand how a germline increase in p53 activity can cause defects in DNA repair. Importantly however, we previously showed that p53Δ31/Δ31 cells exhibited defects in DNA interstrand cross-link repair, a typical property of Fanconi anemia cells, that correlated with a subtle but significant decrease in expression for several genes of the Fanconi anemia DNA repair pathway, rather than the complete repression of a single gene in this pathway [25]. Thus, the Fanconi-like phenotype of p53Δ31/Δ31 cells most likely results from a decreased expression of not only Fanca, but also of additional p53-DREAM targets mutated in Fanconi anemia such as Fancb, Fancd2, Fanci, Brip1, Rad51, Palb2, Ube2t or Xrcc2, for which functional or putative [DREAM binding sites] were also found with our systematic approach.” We further discuss in the manuscript how this may also apply to telomere-, ribosome-, of microcephaly-related genes.
The analysis of brain specific targets and the link to BRD8 sits largely as an aside and the analysis of patient data from glioblastomas is underdeveloped as noted above.
As we previously mentioned, the revised manuscript includes the analysis of RNAseq datasets from human cortical neural progenitors infected by the Zika virus (ZIKV) or mock-infected, which significantly increases the relevance of our analysis of brain-specific targets. Furthermore, we improved Figure 4 to present more clearly the impact of BRD8 levels on the expression of genes transactivated by p53 or repressed by p53-DREAM.
The computational methods applied are robust, albeit predominantly coorelative, in terms of identifying regulation of potential causative target genes, validated across human and mouse cell lines, and this indicates a role of these genes in the relevant conditions. However, further validation through application in a bulk or single cell RNAseq patient cohort, or at least an in vivo model would strengthen these conclusions and complement the work presented here which is based on in vitro mouse and human cells. This is pertinent as this study improves upon previously published approaches by focusing on "clinically relevant target genes". Additionally, this would exhibit the potential applications of the findings presented.
We thank the referee for this comment. As mentioned above, in the revised manuscript we analyzed RNAseq data from hematopoietic stem cells of unirradiated WT or p53 KO mice, or irradiated WT mice, and from splenic cells of irradiated p53D24/- or p53+/- mice, and quantified the expression of a subset of blood-related candidate genes in the bone marrow cells of p53Δ31/Δ31 mice (prone to bone marrow failure) and WT mice (new Figure S8 and Table S19). For genes related to brain development, we included the analysis of RNAseq data from human cortical neural progenitors infected by the Zika virus (ZIKV) or mock-infected (Table S28). These RNAseq analyses were added as an additional screening criterion in our approach, which significantly increased the relevance of the target genes identified.
In terms of statistical analysis, the hypergeometric test should be applied to assess significant enrichment of genes for example with CDE/CHR regions within the previously identified lists.
In the revised manuscript, we precisely mapped the DREAM binding sites in 50 bp windows within regions bound by E2F4 and/or LIN9, an analysis included in new Figure 3a. We then compared the distribution of DREAM binding sites at the level of ChIP peaks compared to their distribution over the entire genome and found a > 1300-fold enrichment of these sites at ChIP peaks. This significant enrichment (f=3 10-239 in a hypergeometric test) is most likely underestimated because mouse-human DNA sequence conservations were not determined for putative DBS over the full genome. These new analyses clearly reinforce our previous conclusions.
Minor Comments<br /> References are required for the genes listed which play a role in the diseases of interest.
In the revised manuscript, references are provided for genes which play a role in the diseases of interest. Due to the large number of added references, these were included in a new supplementary table, Table S36.
This paper would benefit from the inclusion of summary schematics and tables throughout (rather than relying only on somewhat unwieldy heatmaps which show little other than all these genes are co-ordinately regulated), this could include summaries of the methods applied, gene or CDE/CHR inclusion criteria, and Venn diagrams indicating the subsets of final genes identified through this approach.
We thank the referee for this suggestion. In the revised manuscript we provide a Venn-like diagram of the different steps of our approach (new Figure 3c), as well as tables listing the genes retained after each step of the selection (new Tables S17 and S26) and these additions improve the clarity of our manuscript.
Reviewer #1 (Significance):
In its current form this is a very limited study that would require significant additional work to move conclusions beyond correlation and hypothesis generation.<br /> Overall, while limited largely to target prioritisation, this research nicely exemplifies how genes affected by the p53-DREAM pathway can be robustly identified, providing a potential resource for individuals working on this pathway or on abnormal haematopoiesis and brain abnormalities. These results are complementary to work previously published by Fischer et al, which has been referenced throughout the analysis (highlighting Target Gene Regulation Database p53 and DREAM target genes) and discussion.
This paper will be of interest to researchers of blood/neurological diseases who can assess if these genes are dysregulated in their datasets, or those investigating the p53-DREAM pathway. This work represents a useful resource detailing genes affected by this pathway in these disease settings, however researchers of the p53-DREAM pathway may find this paper useful when planning an approach to identify and prioritise genes of interest.
We thank the reviewer for considering that our study represents a useful resource for researchers working on the p53-DREAM pathway, abnormal haematopoiesis and brain abnormalities, because it was exactly the purpose of our work. As mentioned above, we think that a study bridging the gap between DREAM experts and bone marrow or microcephaly specialists should be particularly useful.
We also agree with the referee that our approach could be used to identify DREAM targets relevant to other disease settings, and we now mentioned this clearly in the revised manuscript.
While our results are complementary to work previously published by Fischer et al and included in the Target gene regulation database, in the revised manuscript we discuss the novelty of our results in more details, notably by performing additional analyses. For example, our method identified bipartite DREAM binding sites for 151 candidate DREAM targets (of which 56 genes were not previously mentioned by Fischer et al.) and we now provide a detailed mapping (using 50 bp windows) of the bipartite DREAM binding sites we identified relative to ChIP peaks for DREAM subunits, then performed a similar mapping of the E2F and CHR sites included in the Target gene regulation database. Our predicted DREAM binding sites coincided with ChIP peaks more frequently (Figure 3a) than the predicted E2F or CHR from the Target gene regulation database (Figure S11), which further indicates the usefulness of our study as a resource.
Reviewer #2 (Evidence, reproducibility and clarity):
The authors used various systems including Hoxa9-indubible BMCs, human and mouse cells, WT and p53 knockout MEF, glioblastoma cells to screen p53-DREAM targets and observed distinct finding for each system. Since different cell types have various p53 activation and p53 target genes expression, the authors might want to select proper cell type(s) to screen p53-DREAM target genes and design experiments to confirm that these genes are really p53-DREAM target genes.
We agree that additional data from relevant cells or tissues were required to strengthen our conclusions. As mentioned in response to referee #1, in the revised manuscript we evaluated the relevance of candidate target genes related to blood ontology terms by integrating an additional screening step in our method, corresponding to the analysis of RNAseq dataset GSE171697, with data from hematopoietic stem cells of unirradiated or irradiated WT mice and unirradiated p53 KO mice , as well as RNAseq dataset GSE204924, with data from splenic cells of irradiated p53D24/- or p53+/- mice. As for genes related to brain development, we included the analysis of RNAseq datasets GSE78711 and GSE80434 for validation, two datasets from human cortical neural progenitors infected by the Zika virus or mock-infected. Together, the 4 datasets provide evidence for a p53-dependent downregulation in blood- and brain- relevant settings (new Tables S19 and S28).
Importantly, in the revision we also compared our list of 151 genes appearing as the best p53-DREAM candidates with the results of Magès et al., who analyzed, in murine cells with a CRISPR-mediated KO of Lin37 (a subunit of DREAM), the transcriptomic changes that follow a reintroduction of Lin37. This comparison is detailed in the discussion section, with the new Figure S10 and Table S35. We mention: “Our list of 151 genes overlaps only partially with the list of candidate DREAM targets obtained with this approach, with 51/151 genes reported to be downregulated in Lin37-rescued cells [17]. To better evaluate the reasons for this partial overlap, we extracted the RNAseq data from Lin37 KO and Lin37-rescued cells and focused on the 151 genes in our list. For the 51 genes that Mages et al. reported as downregulated in Lin37-rescued cells, an average downregulation of 14.8-fold was observed (Figure S10, Table S35). Furthermore, when each gene was tested individually, a downregulation was observed in all cases, statistically significant for 47 genes, and with a P value between 0.05 and 0.08 for the remnant 4 genes (Table S35). By contrast, for the 100 genes not previously reported to be downregulated in Lin37-rescued cells, an average downregulation of 4.7-fold was observed (Figure S10, Table S35), and each gene appeared downregulated, but this downregulation was statistically significant for only 35/100 genes, and P values between 0.05 and 0.08 were found for 23/100 other genes (Table S35). These comparisons suggest that, for the additional 100 genes, a more subtle decrease in expression, together with experimental variations, might have prevented the report of their DREAM-mediated regulation in Lin37-rescued cells.”
This comparison provides additional evidence that the 151 candidate target genes we identified are bona fide DREAM targets.
Specific comments:<br /> The authors need to describe and define HSC and Diff in Figure 1.
This has been corrected in the revised manuscript. “HSC” was replaced by “Hematopoietic Stem / Progenitor cells (+OHT)” and “Diff” was replaced by “Differentiated cells (5 days – OHT).
Are Figure 1B and 1D list genes p53 targets in bone marrow cells?
In the revised manuscript, we now analyzed RNAseq data to address this point. The question refers to lists of telomere-related genes (Figure 1b in both versions of the manuscript) and Fanconi-related genes (Figure 1d in the previous version, now Figure S2a), but could also apply to other lists of genes related to blood ontology terms (Figures S3-S5 in the revised manuscript). As mentioned in response to referee #1, in the revised manuscript we integrated an additional screening step in our method, corresponding to the analysis of RNAseq datasets specific of blood cells. We analyzed dataset GSE171697, with RNAseq data from hematopoietic stem cells of unirradiated WT or p53 KO mice, or irradiated WT mice, as well as dataset GSE204924, with RNAseq data from splenic cells of irradiated p53D24/- or p53+/- mice. The latter dataset appeared interesting because p53D24 is a mouse model prone to bone marrow failure and the spleen is a hematopoietic organ in mice. Furthermore, we also verified that the expression of a subset of blood-related candidate genes was decreased in the bone marrow cells of p53Δ31/Δ31 mice (prone to bone marrow failure) compared to bone marrow cells from WT mice, a result presented in the new Figure S8.
Where is the detailed information for mouse and human cells in Figure 1 and Figure 2?
In the first draft of the manuscript, supplementary tables provided precise values for ChIP binding. In the revised manuscript, we also provide the precise values for gene expression after bone marrow cell differentiation, as well as p53 regulation scores from the Target gene regulation databases. This additional information is included in the new Tables S1, S5, S8, S11, S14, S20 and S23.
Are Figure 3B list genes also p53 target genes in other cell types such as bone marrow cells and glioblastoma?
For genes in the Figure 3B of the previous version of the manuscript (now Figure 2B in the revised version), we now provide evidence that the blood-related genes are less expressed in the bone marrow cells of p53Δ31/Δ31 mice (mice with increased p53 activity and prone to bone marrow failure) compared to bone marrow cells from WT mice. This result is presented in the new Figure S8. For the brain-related genes of the same Figure, evidence of their p53-mediated regulation is provided by the RNAseq datasets GSE78711 and GSE80434, from human cortical neural progenitors infected by the Zika virus or mock-infected (analyzed in the new Table S28). Evidence of that a decreased p53 activity in glioblastomas correlates with increased expression of the brain-related genes of the same Figure is provided in supplementary Table S37.
Does BRD8high has high p53 and p21?
We now clearly show, in both Figure 4a and Table S37, that glioblastoma cells with high BRD8 exhibit a decreased expression of CDKN1A/p21 and other genes known to be transactivated by p53 (BAX, GADD45A, MDM2, PLK3), consistent with the fact that BRD8 attenuates p53 activity.
Are genes listed in Figure 4B all p53 target genes? can some validation be done?
For genes in Figure 4B, in the revision we focused on the genes that appeared more relevant, i.e. the 77 genes mutated in diseases with microcephaly or cerebellar hypoplasia. All the genes in Figure 4B are repressed in neural progenitors upon infection by the Zika virus, a virus known to cause p53 activation in those cells. This is reported in the new Table S28.
Reviewer #2 (Significance):
This is a potentially interesting study. The major limitation is the absence of validation from the screening. This study would definitely benefit the research community as long as some of the key findings are validated.
We thank the referee for this comment. We hope the new evidence in this revision provide the validation requested by the referee.
Reviewer #3 (Evidence, reproducibility and clarity):
In their work submitted to Review Commons, Rakotopare et al. aim to identify p53-DREAM target genes associated with blood or brain abnormalities. To this end, they utilize published data generated with a cellular model that results in cell-cycle exit and differentiation of murine bone marrow progenitor cells upon inducible expression of Hoxa9. By analyzing this gene expression data set published by Muntean et al., they find that multiple of the 3631 genes which are downregulated more than 1.5-fold in differentiated BMCs are also mutated in several disorders connected to proliferation and differentiation defects during hematopoiesis and brain development. By screening ChIP-seq data sets available at ChIP-Atlas, they find that the promoters of many of these genes are bound by DREAM complex components, and most of them were identified as genes indirectly repressed by p53 before (Fischer et al. 2016, targetgenereg.org). They then use a computational approach to identify putative CDE/CHR DREAM-binding sites in the promoters of 372 genes associated with blood/brain abnormalities which are downregulated in differentiated BMCs and bound by DREAM components. Out of the 173 candidate genes, they select twelve to analyze whether mutation of the putative DREAM binding sites results in increased activity of the promoters in luciferase reporter assays. The authors conclude that their findings suggest a general role for the p53-DREAM pathway in regulating hematopoiesis and brain development.<br /> While the study supports a large body of publications proving that repression of cell cycle genes by the DREAM complex is crucial for cell cycle arrest and exit, it is noted that none of the main conclusions here are unexpected or particularly exciting. All the analyses are based on data sets that compare gene expression in highly proliferative cells with cells that underwent terminal cell cycle exit. Thus, a large portion of the genes that are downregulated in differentiated BMCs are cell cycle genes and well-established targets of DREAM and E2F:RB complexes. Furthermore, it is not surprising that some of these pro-proliferative genes are mutated in diseases connected to proliferation defects like anemias or microcephaly.
We agree with the referee that the DREAM complex is well known to regulate cell cycle genes – in fact, this is what we mention in the first sentence of our introduction in both versions of our manuscript. However, as we already pointed out in response to Referee #1, many scientists or clinicians specialized in bone marrow failure syndromes or microcephaly diseases are not familiarized with the p53-DREAM pathway, and we think our study will be particularly useful to them. Furthermore, our strategy relying on disease-based ontology terms rather than cell cycle regulation led to identify many DREAM targets that were not reported in previous studies, and our positional frequency matrices led to identify DREAM binding sites not predicted by previous approaches. As discussed below, our revised manuscript provides a more detailed comparison of our findings with those from previous studies.
Additionally, I am not very enthusiastic about this manuscript because of several major concerns:
- The authors draw conclusions about the p53-DREAM pathway based on data that was generated in a cellular differentiation model without convincingly showing that p53 plays a central role in gene repression in this experimental setup.<br /> (A) Rakotopare et al. define p53-DREAM target genes based on RNA expression data from proliferating precursor cells and non-proliferating, differentiated BMCs (Muntean et al., 2010). This paper has not studied whether p53 gets activated in the particular experimental setup during Hox9a-induced BMC differentiation. On page 4 of their manuscript, the authors state: "Consistent with the fact that BMC differentiation strongly correlates with p53 activation..." without citing any literature or explaining why this is supposed to be a fact. Furthermore, they imply that cell cycle gene repression in this model system depends on p53 because mRNA expression of the p53 targets p21 and Mdm2 was found to be increased in the differentiated cells (Fig. 1A, 5-fold and 2-fold, respectively). However, defining a large set of "p53-DREAM target genes" based on the moderate increase in mRNA levels of two genes that are known to be activated by p53 without showing any evidence that p53 is even involved in this effect during BMC differentiation is not appropriate.
We agree that Muntean et al. did not study whether p53 gets activated when BMCs differentiate in the Hox9a-ER system. We previously mentioned: “We observed that p53 activation correlated with cell differentiation in this system, because genes known to be transactivated by p53 (e.g. Cdkn1a, Mdm2) were induced, whereas genes repressed by p53 (e.g. Rtel1, Fancd2) were downregulated after tamoxifen withdrawal (Figure 1a)”. We had provided examples for 2 genes transactivated and 2 genes repressed, but clearly mentioned that they were given as examples. In the revised manuscript, we provide additional evidence with a new supplementary Figure that includes changes in expression for 15 additional genes known to be transactivated by p53, and 5 additional genes known to be repressed by p53 (Figure S1). In total, we now correlate HSC differentiation with p53 activation based on the expression of 24 well-known p53-regulated genes, which we hope is more convincing.
In addition, we changed our phrasing and mention “Consistent with the notion that BMC differentiation strongly correlates with p53 activation in this system, 72 of these 76 genes have negative score(s) in the Target gene regulation (TGR) database”.
(B) Interestingly, p53 is among the genes that get repressed on mRNA level in differentiated BMCs (Fig. 1B; Trp53), and the authors also identify the DREAM components E2F4 and LIN9 as bound to the p53 promoter by screening ChIP-Atlas data (Fig. 1C). Given that p53 has never been described as a DREAM target, I find this rather surprising and it makes me wonder whether appropriate parameters were selected for analyzing the ChIP data, particularly since the authors do not provide binding data for sets of non-cell cycle genes as a negative control.
We retrieved ChIP data from the ChIP Atlas database without any specific parameters, thus in a completely unbiased manner. Importantly however, for reasons detailed in the manuscript, we clearly mentioned that total ChIP scores <979/4000 were considered too low to reflect significant DREAM binding. The ChIP score for Trp53 was 630, which rapidly led us to eliminate this gene from our screen.
This ChIP score criterion was already mentioned in the previous version of our manuscript, but we think the addition of a Venn-like diagram (Figure 3c) and summary tables (S17 and S26) in the revised manuscript will probably make it easier to understand.
(C) Finally, the authors utilize the targetgenereg.org database to show that many of the genes they describe as p53-repressed were already identified as p53 targets. This database (Fischer et al. 2016) was created by performing a meta-analysis integrating a plethora of RNA-seq and ChIP-seq datasets with the aim to identify whether a particular gene gets up- or downregulated by p53, shows cell-cycle-dependent expression, is a DREAM/MuvB or E2F:RB target, etc. For example, 57 datasets analyzing p53-dependent RNA expression in human and 15 datasets generated with mouse cells were included, and a positive or negative score shows in how many of these experiments the gene was found to be up (positive score) or downregulated (negative score). Combining a large number of datasets in such a study is very helpful to get an idea if a gene is indeed generally regulated by a transcription factor, or if it just showed up in a few experiments - either as a false positive or because the regulation depends on a particular biological setting. The authors find most of the genes they identify as repressed in differentiated BMCs also as downregulated by p53 in targetgenereg.org, however, it remains unclear what parameters they used to define a gene as p53-repressed. For example, in the caption of Fig. 1C, they state: "According to the Target gene regulation database, 72/76 genes are downregulated upon mouse and/or human p53 activation." The four exemptions are SLX1B (human score: 0, mouse score : na), PML (+41, +9), RAD50 (0, na), and TNKS2 (+17, +4). However, there are several other genes that do not appear to be generally repressed by p53, e.g. HMBOX1 (+4, -2); UPF1 (+1, -2), SMG6 (+18, -2), CTC1 (-5, +11), etc. Thus, without providing details regarding the parameters they use to define p53-target genes, such statements are rather misleading. An easy way to solve this problem would be to show the p53 scores in the tables together with the E2F4/LIN9 ChIP data.
All the genes mentioned as downregulated by p53 had a negative TGR score in human and/or mouse cells. In the revised manuscript, we mention clearly what a negative TGR score means, by stating: “Consistent with the notion that BMC differentiation strongly correlates with p53 activation in this system, 72 of these 76 genes have negative p53 expression score(s) in the Target gene regulation (TGR) database [23], which indicates that they were downregulated upon p53 activation in most experiments carried out in mouse and/or human cells (Figure 1b, Table S1).” We agree with the referee that adding precise TGR scores is informative. In the revised manuscript, we provide the TGR scores for all the genes analyzed, as part of the new supplementary Tables S1, S5, S8, S11, S14, S20 and S23, together with their expression levels in undifferentiated or differentiated cells (as requested by Referee #2). The ChIP data are provided in separate tables (Tables S2, S3, S6, S7, S9, S10, S12, S13, S15, S16, S21, S22, S24 and S25).
- The authors define a large set of genes containing "CDE-CHR" promoter elements and thereby ignore how these elements are defined and what properties they have.<br /> (A) At the beginning of the introduction, the authors state: "The DREAM complex typically represses the transcription of genes whose promoter contain a bipartite CDE/CHR binding site, with a cell cycle-dependent element (CDE) bound by E2F4 or E2F5, and a cell cycle gene homology region (CHR) bound by LIN54, the DNA binding subunit of MuvB (Zwicker et al., 1995; Müller and Engeland, 2010)."<br /> This statement is incorrect. The authors ignore that the CDE/CHR tandem site is just one of four promoter elements that have been shown to recruit DREAM for the transcriptional repression of several hundred genes. It has been studied in detail that DREAM can bind to the following promoter sites:<br /> (I) CHR elements - bound by DREAM via LIN54; also bound by the activator MuvB complexes B-MYB-MuvB and FOXM1-MuvB which results in maximum gene expression in G2/M<br /> (II) CDE-CHR tandem elements - like (I) but binding of DREAM can be stabilized via E2F4/DP interacting with a truncated E2F binding site. Since CDE elements do not represent functional E2F sites, E2F:RB complexes do not bind.<br /> (III) E2F binding sites - bound by DREAM via E2F4/DP; also bound by E2F:RB complexes and activator E2Fs which results in maximum gene expression in G1/S<br /> (IV) E2F-CLE tandem elements - like (III) but binding of DREAM can be stabilized via LIN54 interacting with a non-canonical CHR-like element. Since CLE elements do not represent functional CHR sites, B-MYB-MuvB and FOXM1-MuvB do not bind.<br /> Thus, these promoter sites have different functions and can be clearly distinguished from each other based on their properties - a fact that is completely ignored by the authors. Since the authors do not differentiate between G1/S and G2/M expressed genes and (CDE)-CHR and E2F-(CLE) sites, they identify CDE-CHR elements in G1/S genes that are functional E2F-(CLE) sites. A good example of this is the Rad51ap1 gene (and also the Rad51 gene that the Toledo lab described before as a CDE-CHR gene (Jaber et al. 2016)): these genes get expressed in G1/S and the promoters contain highly conserved E2F sites (parts of which the authors define as CDEs), and CLEs (which the authors define as CHRs). Furthermore, E2F:RB complexes bind to the promoters. Again: even though (CDE)-CHR and E2F-(CLE) sites both bind DREAM, they are otherwise functionally different in their ability to recruit non-DREAM complexes.
We agree that in the previous version of our manuscript we should have presented in more details the different types of DREAM binding sites and have corrected this in the revised manuscript. We now mention in the introduction that “The DREAM complex was initially reported to repress the transcription of genes whose promoter sequences contain a bipartite binding motif called CDE/CHR [19,20] (or E2F/CHR [21]), with a GC-rich cell cycle dependent element (CDE) that may be bound by E2F4 or E2F5, and an AT-rich cell cycle gene homology region (CHR) that may be bound by LIN54, the DNA-binding subunit of MuvB [19,20]. Later studies indicated that DREAM may also bind promoters with a single E2F binding site, a single CHR element, or a bipartite E2F/CHR-like element (CLE), and concluded that E2F and CHR elements are required for the regulation of G1/S and G2/M cell cycle genes, respectively [14,22].”
We hope that the referee will agree with this complete yet concise way of presenting DREAM binding sites. Importantly, we agree that CDE/CHR and E2F/CLE are sites bound by different non-DREAM complexes, but both sites are bound by DREAM, so it makes perfect sense to use them together to define positional frequency matrices for DREAM binding predictions. We would also like to point out that terms used to define DREAM binding sites may vary in the literature. For example, to our knowledge Müller et al. were the first to propose a clear distinction between “CDE/CHR” and “E2F/CLE” sites (Müller et al. (2017) Oncotarget 8, 97737-97748), yet Müller recently co-authored a review in which these two distinct terms were not used, but were replaced by a single, apparently more generic term of “E2F/CHR” (Fischer et al., (2022) Trends Biochem. Sci. 47, 1009-1022). In the revised manuscript we now clearly mention that we designed our positional frequency matrices to search for “bipartite DREAM binding sites”, i.e. sites that might be referred to as CDE/CHR, E2F/CLE or E2F/CHR sites in various publications.
(B) The authors identified putative CDE-CHR in the promoters of genes by building two position weight matrices (PWMs) based on 10 or 22 "validated CDE-CHR elements". However, since they include several genes that are clearly expressed in G1/S and contain E2F-(CLE) sites (e.g. Mybl2/B-myb, Rad51, Fanca, Fen1), it is not surprising that they identify a lot of putative CDE-CHR sites in genes that do not contain such elements.
As discussed above, both CDE/CHR and E2F/CLE are bipartite DREAM binding sites, and we now clearly state that we used bipartite DREAM binding sites to generate our positional frequency matrices and predict DREAM binding.
(C) Finally, in the discussion, the authors state: "A recent update (2.0) of the Target gene regulation database of p53 and cell cycle genes (www.targetgenereg.org) was recently reported to include putative DREAM binding sites for human genes (Fischer et al., 2022). However, this update only suggests potential E2F or CHR binding sites independently, a feature of little help to identify CDE/CHR elements. For example, targetgenereg 2.0 suggests several potential E2F sites, but no CHR site close to the transcription start site of FANCD2, despite the fact that we previously identified a functionally CDE/CHR element near the transcription start site of this gene (Jaber et al., 2016)." This statement highlights again that the authors don't seem to be aware of what specific properties distinct DREAM binding sites have, and that analyzing promoters for CHR and E2F sites separately generates much more meaningful results than the approach they chose. Also, the FANCD2 promoter binds DREAM as well as E2F:RB complexes and contains a highly conserved E2F binding site - which Jaber et al. mutated together with a potential downstream CLE element and named it "CDE/CHR".
In the revised manuscript, we provide a more detailed comparison between the bipartite DREAM binding sites predicted with our positional frequency matrices for 151 genes and the separate E2F and CHR predicted sites reported in the Target gene regulation database for the same set of genes. We now mention: “The Target gene regulation (TGR) database of p53 and cell-cycle genes was reported to include putative DREAM binding sites for human genes, based on separate genome-wide searches for 7 bp-long E2F or 5 bp-long CHR motifs [23]. We analyzed the predictions of the TGR database for the 151 genes for which we had found putative bipartite DBS. A total of 342 E2F binding sites were reported at the promoters of these genes, but only 64 CHR motifs. The similarities between the predicted E2F or CHR sites from the TGR database and our predicted bipartite DBS appeared rather limited: only 14/342 E2F sites overlapped at least partially with the GC-rich motif of our bipartite DBS, while 27/64 CHR motifs from the TGR database exhibited a partial overlap with the AT-rich motif. Importantly, most E2F and CHR sites from the TGR database mapped close to E2F4 and LIN9 ChIP peaks, but only 16% of E2Fs (54/342), and 33% of CHRs (21/64) mapped precisely at the level of these peaks (Figure S11), compared to 55% (83/151) of our bipartite DBS (Figure 3a). Thus, at least for genes with bipartite DREAM binding sites, our method relying on PFM22 appeared to provide more reliable predictions of DREAM binding than the E2F and CHR sites reported separately in the TGR database. Importantly however, predictions of the TGR database may include genes regulated by a single E2F or a single CHR that would most likely remain undetected with PFM22, suggesting that both approaches provide complementary results.”
- The experimental approach chosen to validate CDE-CHR elements in a set of twelve promoters by luciferase reporter assays is not adequate.<br /> (A) Since the authors introduce point mutations in putative CDE and CHR elements in parallel, it is impossible to identify functional CDE elements. As explained above, a functional CDE is not required for binding of MuvB complexes and gene repression, and mutating the CHR alone would already lead to a loss of DREAM binding and to de-repression of a promoter. Thus, without mutating both sites of CDE-CHR elements separately, it is impossible to provide evidence that a putative CDE is functional.<br /> (B) As the putative CDE-CHR elements identified by the authors with a computational approach can overlap with functional E2F-(CLE) elements, the authors inactivate such sites by introducing mutations which leads to loss of DREAM binding and upregulation of the promoters, however, because of the problems described above, this experimental approach in the best case identifies DREAM binding sites, but does not differentiate between (CDE)-CHR and E2F-(CLE) elements.
Yes, we agree with this comment. As discussed above, our goal was to identify DREAM-binding sites, not to differentiate between CDE/CHR and E2F/CLE elements. In other words, we wanted to identify genes regulated by p53 and DREAM, but not distinguish between genes regulated by p53, DREAM and E2F/Rb versus those regulated by p53, DREAM and BMyb-MuvB or FoxM1-MuvB.
(C) The authors analyze the activities of wild-type and mutant promoters in proliferating NIH3T3 cells. Since the mutated promoters showed increased activity (about 2-3 fold), which would be expected when binding of DREAM gets abolished, they conclude: "...these experiments indicated that we could identify functional CDE/CHRs for 12/12 tested genes." In addition to the problems described above, a slight upregulation of promoter activities caused by the introduction of multiple point mutations close to the TSS is not sufficient to verify these elements. The increase in activity could occur independent of DREAM-binding by unrelated mechanisms. The authors should at least analyze the activities of the promoters with and without induction of p53. A loss of p53-dependent repression of the mutated promoters would prove that the elements are essential for p53-dependent repression. Furthermore, there are several experimental approaches to analyze whether DREAM binds to the putative promoter element and whether the introduced mutations disrupt binding (ChIP, DNA affinity purification, etc.).
In the revised manuscript, we show that the promoters of 7 of the tested genes, when cloned in luciferase reporter plasmids and transfected into NIH3T3 cells, exhibited a significant (> 1.4 fold) repression upon p53 activation by cell treatment with Nutlin, the Mdm2 antagonist. For these promoters, we showed that the p53-dependent repression was abrogated by mutating the identified DREAM binding site, which provided direct evidence that our positional frequency matrices can identify functionally relevant DREAM binding sites essential for p53-mediated repression. These experiments were added in Figures 2e and 2i.
Furthermore, as previously mentioned in response to referee #1, in the revised manuscript we precisely mapped the predicted DREAM binding sites for 151 genes in 50 bp windows within regions bound by E2F4 and/or LIN9, an analysis included in new Figure 3a. The distribution of these peaks clearly indicates that most predicted DREAM binding sites map precisely within a 50 bp-window encompassing the ChIP peaks, which represents an enrichment of at least a 1300-fold compared to the rest of the genome. This mapping strongly suggests that our predicted DREAM binding sites are functionally relevant.
Importantly, as shown in the new Figure S11, we carried out a similar mapping of the predicted E2F and CHR sites reported in the Target gene regulation (TGR) database and found that our predicted DREAM binding sites co-mapped with E2F4/LIN9 ChIP peaks more frequently than the E2F and CHR sites of the TGR database, which supports the conclusion that our positional frequency matrices bring new and improved predictions for DREAM binding.
- Taken together, while over-simplifying mechanisms of cell cycle gene regulation, the authors largely ignore recent findings and publications regarding gene regulation by p53, E2F:RB, and DREAM/MuvB complexes:<br /> (A) Publications that show how DREAM binds to (CDE)-CHR sites and that experimentally defined a consensus motif for CHR elements (e.g. PMID: 27465258, PMID: 25106871).<br /> (B) Publications that identify p53-DREAM target genes by activating p53 in cells with or without functional DREAM complex (e.g. PMID: 31667499, PMID: 31400114).<br /> (C) Identification and comparison of (CDE)-CHR and E2F-(CLE) DREAM binding sites that have distinct functions in the activation of cell-cycle expression in G1/S and G2/M (e.g. PMID: 29228647, PMID: 25106871).<br /> These findings have been summarized in several review articles (e.g. PMID: 29125603, PMID: 28799433, PMID: 35835684). All of them describe the mechanisms I have mentioned above in detail, and since Rakotopare et al. cite one of the papers (Engeland 2018), I wonder even more why they did not design their experiments based on current knowledge.
The points (A) and (C) of this comment were largely discussed in our response to points 2 and 3 of the same referee. Briefly, in the revised manuscript we clearly mention CDE/CHR, E2F/CLE and E2F/CHR sites, as well as the functional differences between E2F and CHR sites with regards to cell cycle regulation, but all these sites were considered together in our positional frequency matrices because our goal was to identify genes regulated by p53 and DREAM, not to distinguish between genes regulated by p53, DREAM and E2F/Rb versus those regulated by p53, DREAM and BMyb-MuvB or FoxM1-MuvB.
Regarding point (B) of this comment, in the revised manuscript we performed a detailed comparison of our results with those of Mages et al. who analyzed, in murine cells with a CRISPR-mediated KO of Lin37 (a subunit of DREAM), the transcriptomic changes that follow a reintroduction of Lin37 (Mages et al. (2017) elife 6, e26876). This comparison is detailed in the discussion section, with New Figure S10 and Table S35. As mentioned in response to referee #2, this comparison is perfectly consistent with DREAM regulating the 151 genes for which we identified DREAM binding sites.
Minor concerns:
- The authors state: "Importantly however, the relative importance of the p53-p21-DREAM pathway (called below p53-DREAM) remains controversial, because multiple mechanisms were proposed to account for p53-mediated gene repression (Peuget and Selivanova, 2021)." Even though Peuget & Selivanova do not agree that genes get repressed in response to p53 activation exclusively by the p21-DREAM pathway, they do not question that this mechanism is essential for the p53-dependent repression of a core set of cell cycle genes. Since I am also not aware of any publications that challenge the importance of the p53-p21-DREAM pathway, I do not agree with this statement.
As the referee pointed out, in the first version of the manuscript we wrote that “the relative importance of the p53-p21-DREAM pathway (called below p53-DREAM) remains controversial, because multiple mechanisms were proposed to account for p53-mediated gene repression (Peuget and Selivanova, 2021)”. The term “relative” was crucial in this sentence, because we wanted to say that the relative proportion of genes regulated by DREAM remained controversial. It seems to us that the title of the review by Peuget & Selivanova (“p53-dependent repression: DREAM or reality?”) emphasizes this controversy. Nevertheless, in the revised manuscript, we now mention : “The relative importance of this pathway remains to be fully appreciated, because multiple mechanisms were proposed to account for p53-mediated gene repression [18]”. We hope the referee will find this phrasing more acceptable.
- Some parts of the manuscript are tiring to read - for example, pages 6, 7, and 8 which contain long listings and numbers of genes that are downregulated in differentiated BMC, found to be mutated in various disorders, bind DREAM components, were identified as downregulated by p53, etc. The authors may consider combining central parts of these data in a table that they show in the main manuscript which would make it easier to digest the information and at the same time significantly shorten the manuscript.
We apologize if some parts of the article were tiring to read. We hope that the addition of Tables S17 and S26, as well as the Venn-like diagram in Figure 3c, will improve the reading of the manuscript.
- The supplementary tables (S1-S26) are combined in one Excel file with multiple tabs. The authors should label the tabs accordingly to make it easier for the reader to find a particular table.
We labelled the Excel tabs in the revised manuscript, as suggested.
- At the end of page 6, the authors show that 17 genes found to be downregulated in differentiated BMCs are mutated in multiple bone marrow disorders, however, since they don't include references, it remains unclear where these mutations were originally described.
In the revised manuscript, we included a supplementary table (Table S36) with appropriate references for blood and/or brain related phenotypes for the 106 genes associated with blood or brain abnormalities.
- On page 9, the authors state: "As a prerequisite to luciferase assays, we first verified that the expression of these genes, as well as their p53-mediated repression, can be observedin mouse embryonic fibroblasts (MEFs), because luciferase assays rely on transfections into MEFs (Figure 3b)." The authors don't explain why luciferase assays rely on transfections into MEFs and based on the caption of Fig. 3C, the luciferase assays were not performed in MEFs, but in NIH3T3 cells: "WT or mutant luciferase reporter plasmids were transfected into NIH3T3 cells..."
According to the American Type Culture Collection (ATCC), the NIH3T3 cell line is a mouse embryonic fibroblastic (MEF) cell line, which explains why we had tested the expressions of candidate target genes in MEFs. However, as we now clearly mention in the manuscript, this cell line exhibits an attenuated p53 pathway, which improves cell survival after transfection but leads to decreased p53-mediated repression. These points are now clearly mentioned in the text and in a new supplemental Figure (Figure S9).
Reviewer #3 (Significance):
While the study supports a large body of publications proving that repression of cell cycle genes by the DREAM complex is crucial for cell cycle arrest and exit, it is noted that none of the main conclusions here are unexpected or particularly exciting. All the analyses are based on data sets that compare gene expression in highly proliferative cells with cells that underwent terminal cell cycle exit. Thus, a large portion of the genes that are downregulated in differentiated BMCs are cell cycle genes and well-established targets of DREAM and E2F:RB complexes. Furthermore, it is not surprising that some of these pro-proliferative genes are mutated in diseases connected to proliferation defects like anemias or microcephaly.
Again, we agree with the referee that the DREAM complex is well known to regulate cell cycle genes, but many scientists or clinicians specialized in bone marrow failure syndromes or microcephaly diseases are not familiarized with the p53-DREAM pathway, and we think our study will be particularly useful to them. As for DREAM specialists, our strategy relying on disease-based ontology terms rather than cell cycle regulation led to identify many DREAM targets that were not reported in previous studies, and our positional frequency matrices led to identify DREAM binding sites not predicted by previous approaches. We hope that, by considering all these points together, the referee will acknowledge that our study provides a valuable resource for different types of readerships.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
In their work submitted to Review Commons, Rakotopare et al. aim to identify p53-DREAM target genes associated with blood or brain abnormalities. To this end, they utilize published data generated with a cellular model that results in cell-cycle exit and differentiation of murine bone marrow progenitor cells upon inducible expression of Hoxa9. By analyzing this gene expression data set published by Muntean et al., they find that multiple of the 3631 genes which are downregulated more than 1.5-fold in differentiated BMCs are also mutated in several disorders connected to proliferation and differentiation defects during hematopoiesis and brain development. By screening ChIP-seq data sets available at ChIP-Atlas, they find that the promoters of many of these genes are bound by DREAM complex components, and most of them were identified as genes indirectly repressed by p53 before (Fischer et al. 2016, targetgenereg.org). They then use a computational approach to identify putative CDE/CHR DREAM-binding sites in the promoters of 372 genes associated with blood/brain abnormalities which are downregulated in differentiated BMCs and bound by DREAM components. Out of the 173 candidate genes, they select twelve to analyze whether mutation of the putative DREAM binding sites results in increased activity of the promoters in luciferase reporter assays. The authors conclude that their findings suggest a general role for the p53-DREAM pathway in regulating hematopoiesis and brain development.
While the study supports a large body of publications proving that repression of cell cycle genes by the DREAM complex is crucial for cell cycle arrest and exit, it is noted that none of the main conclusions here are unexpected or particularly exciting. All the analyses are based on data sets that compare gene expression in highly proliferative cells with cells that underwent terminal cell cycle exit. Thus, a large portion of the genes that are downregulated in differentiated BMCs are cell cycle genes and well-established targets of DREAM and E2F:RB complexes. Furthermore, it is not surprising that some of these pro-proliferative genes are mutated in diseases connected to proliferation defects like anemias or microcephaly.
Additionally, I am not very enthusiastic about this manuscript because of several major concerns:
- The authors draw conclusions about the p53-DREAM pathway based on data that was generated in a cellular differentiation model without convincingly showing that p53 plays a central role in gene repression in this experimental setup.
(A) Rakotopare et al. define p53-DREAM target genes based on RNA expression data from proliferating precursor cells and non-proliferating, differentiated BMCs (Muntean et al., 2010). This paper has not studied whether p53 gets activated in the particular experimental setup during Hox9a-induced BMC differentiation. On page 4 of their manuscript, the authors state: "Consistent with the fact that BMC differentiation strongly correlates with p53 activation..." without citing any literature or explaining why this is supposed to be a fact. Furthermore, they imply that cell cycle gene repression in this model system depends on p53 because mRNA expression of the p53 targets p21 and Mdm2 was found to be increased in the differentiated cells (Fig. 1A, 5-fold and 2-fold, respectively). However, defining a large set of "p53-DREAM target genes" based on the moderate increase in mRNA levels of two genes that are known to be activated by p53 without showing any evidence that p53 is even involved in this effect during BMC differentiation is not appropriate.
(B) Interestingly, p53 is among the genes that get repressed on mRNA level in differentiated BMCs (Fig. 1B; Trp53), and the authors also identify the DREAM components E2F4 and LIN9 as bound to the p53 promoter by screening ChIP-Atlas data (Fig. 1C). Given that p53 has never been described as a DREAM target, I find this rather surprising and it makes me wonder whether appropriate parameters were selected for analyzing the ChIP data, particularly since the authors do not provide binding data for sets of non-cell cycle genes as a negative control.
(C) Finally, the authors utilize the targetgenereg.org database to show that many of the genes they describe as p53-repressed were already identified as p53 targets. This database (Fischer et al. 2016) was created by performing a meta-analysis integrating a plethora of RNA-seq and ChIP-seq datasets with the aim to identify whether a particular gene gets up- or downregulated by p53, shows cell-cycle-dependent expression, is a DREAM/MuvB or E2F:RB target, etc. For example, 57 datasets analyzing p53-dependent RNA expression in human and 15 datasets generated with mouse cells were included, and a positive or negative score shows in how many of these experiments the gene was found to be up (positive score) or downregulated (negative score). Combining a large number of datasets in such a study is very helpful to get an idea if a gene is indeed generally regulated by a transcription factor, or if it just showed up in a few experiments - either as a false positive or because the regulation depends on a particular biological setting. The authors find most of the genes they identify as repressed in differentiated BMCs also as downregulated by p53 in targetgenereg.org, however, it remains unclear what parameters they used to define a gene as p53-repressed. For example, in the caption of Fig. 1C, they state: "According to the Target gene regulation database, 72/76 genes are downregulated upon mouse and/or human p53 activation." The four exemptions are SLX1B (human score: 0, mouse score : na), PML (+41, +9), RAD50 (0, na), and TNKS2 (+17, +4). However, there are several other genes that do not appear to be generally repressed by p53, e.g. HMBOX1 (+4, -2); UPF1 (+1, -2), SMG6 (+18, -2), CTC1 (-5, +11), etc. Thus, without providing details regarding the parameters they use to define p53-target genes, such statements are rather misleading. An easy way to solve this problem would be to show the p53 scores in the tables together with the E2F4/LIN9 ChIP data.<br /> 2. The authors define a large set of genes containing "CDE-CHR" promoter elements and thereby ignore how these elements are defined and what properties they have.
(A) At the beginning of the introduction, the authors state: "The DREAM complex typically represses the transcription of genes whose promoter contain a bipartite CDE/CHR binding site, with a cell cycle-dependent element (CDE) bound by E2F4 or E2F5, and a cell cycle gene homology region (CHR) bound by LIN54, the DNA binding subunit of MuvB (Zwicker et al., 1995; Müller and Engeland, 2010)."
This statement is incorrect. The authors ignore that the CDE/CHR tandem site is just one of four promoter elements that have been shown to recruit DREAM for the transcriptional repression of several hundred genes. It has been studied in detail that DREAM can bind to the following promoter sites:
(I) CHR elements - bound by DREAM via LIN54; also bound by the activator MuvB complexes B-MYB-MuvB and FOXM1-MuvB which results in maximum gene expression in G2/M
(II) CDE-CHR tandem elements - like (I) but binding of DREAM can be stabilized via E2F4/DP interacting with a truncated E2F binding site. Since CDE elements do not represent functional E2F sites, E2F:RB complexes do not bind.
(III) E2F binding sites - bound by DREAM via E2F4/DP; also bound by E2F:RB complexes and activator E2Fs which results in maximum gene expression in G1/S
(IV) E2F-CLE tandem elements - like (III) but binding of DREAM can be stabilized via LIN54 interacting with a non-canonical CHR-like element. Since CLE elements do not represent functional CHR sites, B-MYB-MuvB and FOXM1-MuvB do not bind.
Thus, these promoter sites have different functions and can be clearly distinguished from each other based on their properties - a fact that is completely ignored by the authors. Since the authors do not differentiate between G1/S and G2/M expressed genes and (CDE)-CHR and E2F-(CLE) sites, they identify CDE-CHR elements in G1/S genes that are functional E2F-(CLE) sites. A good example of this is the Rad51ap1 gene (and also the Rad51 gene that the Toledo lab described before as a CDE-CHR gene (Jaber et al. 2016)): these genes get expressed in G1/S and the promoters contain highly conserved E2F sites (parts of which the authors define as CDEs), and CLEs (which the authors define as CHRs). Furthermore, E2F:RB complexes bind to the promoters. Again: even though (CDE)-CHR and E2F-(CLE) sites both bind DREAM, they are otherwise functionally different in their ability to recruit non-DREAM complexes.
(B) The authors identified putative CDE-CHR in the promoters of genes by building two position weight matrices (PWMs) based on 10 or 22 "validated CDE-CHR elements". However, since they include several genes that are clearly expressed in G1/S and contain E2F-(CLE) sites (e.g. Mybl2/B-myb, Rad51, Fanca, Fen1), it is not surprising that they identify a lot of putative CDE-CHR sites in genes that do not contain such elements.
(C) Finally, in the discussion, the authors state: "A recent update (2.0) of the Target gene regulation database of p53 and cell cycle genes (www.targetgenereg.org) was recently reported to include putative DREAM binding sites for human genes (Fischer et al., 2022). However, this update only suggests potential E2F or CHR binding sites independently, a feature of little help to identify CDE/CHR elements. For example, targetgenereg 2.0 suggests several potential E2F sites, but no CHR site close to the transcription start site of FANCD2, despite the fact that we previously identified a functionally CDE/CHR element near the transcription start site of this gene (Jaber et al., 2016)." This statement highlights again that the authors don't seem to be aware of what specific properties distinct DREAM binding sites have, and that analyzing promoters for CHR and E2F sites separately generates much more meaningful results than the approach they chose. Also, the FANCD2 promoter binds DREAM as well as E2F:RB complexes and contains a highly conserved E2F binding site - which Jaber et al. mutated together with a potential downstream CLE element and named it "CDE/CHR".<br /> 3. The experimental approach chosen to validate CDE-CHR elements in a set of twelve promoters by luciferase reporter assays is not adequate.
(A) Since the authors introduce point mutations in putative CDE and CHR elements in parallel, it is impossible to identify functional CDE elements. As explained above, a functional CDE is not required for binding of MuvB complexes and gene repression, and mutating the CHR alone would already lead to a loss of DREAM binding and to de-repression of a promoter. Thus, without mutating both sites of CDE-CHR elements separately, it is impossible to provide evidence that a putative CDE is functional.
(B) As the putative CDE-CHR elements identified by the authors with a computational approach can overlap with functional E2F-(CLE) elements, the authors inactivate such sites by introducing mutations which leads to loss of DREAM binding and upregulation of the promoters, however, because of the problems described above, this experimental approach in the best case identifies DREAM binding sites, but does not differentiate between (CDE)-CHR and E2F-(CLE) elements.
(C) The authors analyze the activities of wild-type and mutant promoters in proliferating NIH3T3 cells. Since the mutated promoters showed increased activity (about 2-3 fold), which would be expected when binding of DREAM gets abolished, they conclude: "...these experiments indicated that we could identify functional CDE/CHRs for 12/12 tested genes." In addition to the problems described above, a slight upregulation of promoter activities caused by the introduction of multiple point mutations close to the TSS is not sufficient to verify these elements. The increase in activity could occur independent of DREAM-binding by unrelated mechanisms. The authors should at least analyze the activities of the promoters with and without induction of p53. A loss of p53-dependent repression of the mutated promoters would prove that the elements are essential for p53-dependent repression. Furthermore, there are several experimental approaches to analyze whether DREAM binds to the putative promoter element and whether the introduced mutations disrupt binding (ChIP, DNA affinity purification, etc.).<br /> 4. Taken together, while over-simplifying mechanisms of cell cycle gene regulation, the authors largely ignore recent findings and publications regarding gene regulation by p53, E2F:RB, and DREAM/MuvB complexes:
(A) Publications that show how DREAM binds to (CDE)-CHR sites and that experimentally defined a consensus motif for CHR elements (e.g. PMID: 27465258, PMID: 25106871).
(B) Publications that identify p53-DREAM target genes by activating p53 in cells with or without functional DREAM complex (e.g. PMID: 31667499, PMID: 31400114).
(C) Identification and comparison of (CDE)-CHR and E2F-(CLE) DREAM binding sites that have distinct functions in the activation of cell-cycle expression in G1/S and G2/M (e.g. PMID: 29228647, PMID: 25106871).
These findings have been summarized in several review articles (e.g. PMID: 29125603, PMID: 28799433, PMID: 35835684). All of them describe the mechanisms I have mentioned above in detail, and since Rakotopare et al. cite one of the papers (Engeland 2018), I wonder even more why they did not design their experiments based on current knowledge.
Minor concerns:
- The authors state: "Importantly however, the relative importance of the p53-p21-DREAM pathway (called below p53-DREAM) remains controversial, because multiple mechanisms were proposed to account for p53-mediated gene repression (Peuget and Selivanova, 2021)." Even though Peuget & Selivanova do not agree that genes get repressed in response to p53 activation exclusively by the p21-DREAM pathway, they do not question that this mechanism is essential for the p53-dependent repression of a core set of cell cycle genes. Since I am also not aware of any publications that challenge the importance of the p53-p21-DREAM pathway, I do not agree with this statement.
- Some parts of the manuscript are tiring to read - for example, pages 6, 7, and 8 which contain long listings and numbers of genes that are downregulated in differentiated BMC, found to be mutated in various disorders, bind DREAM components, were identified as downregulated by p53, etc. The authors may consider combining central parts of these data in a table that they show in the main manuscript which would make it easier to digest the information and at the same time significantly shorten the manuscript.
- The supplementary tables (S1-S26) are combined in one Excel file with multiple tabs. The authors should label the tabs accordingly to make it easier for the reader to find a particular table.
- At the end of page 6, the authors show that 17 genes found to be downregulated in differentiated BMCs are mutated in multiple bone marrow disorders, however, since they don't include references, it remains unclear where these mutations were originally described.
- On page 9, the authors state: "As a prerequisite to luciferase assays, we first verified that the expression of these genes, as well as their p53-mediated repression, can be observed<br /> in mouse embryonic fibroblasts (MEFs), because luciferase assays rely on transfections into MEFs (Figure 3b)." The authors don't explain why luciferase assays rely on transfections into MEFs and based on the caption of Fig. 3C, the luciferase assays were not performed in MEFs, but in NIH3T3 cells: "WT or mutant luciferase reporter plasmids were transfected into NIH3T3 cells..."
Significance
While the study supports a large body of publications proving that repression of cell cycle genes by the DREAM complex is crucial for cell cycle arrest and exit, it is noted that none of the main conclusions here are unexpected or particularly exciting. All the analyses are based on data sets that compare gene expression in highly proliferative cells with cells that underwent terminal cell cycle exit. Thus, a large portion of the genes that are downregulated in differentiated BMCs are cell cycle genes and well-established targets of DREAM and E2F:RB complexes. Furthermore, it is not surprising that some of these pro-proliferative genes are mutated in diseases connected to proliferation defects like anemias or microcephaly.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
The authors used various systems including Hoxa9-indubible BMCs, human and mouse cells, WT and p53 knockout MEF, glioblastoma cells to screen p53-DREAM targets and observed distinct finding for each system. Since different cell types have various p53 activation and p53 target genes expression, the authors might want to select proper cell type(s) to screen p53-DREAM target genes and design experiments to confirm that these genes are really p53-DREAM target genes.
Specific comments:
The authors need to describe and define HSC and Diff in Figure 1.
Are Figure 1B and 1D list genes p53 targets in bone marrow cells?
Where is the detailed information for mouse and human cells in Figure 1 and Figure 2?
Are Figure 3B list genes also p53 target genes in other cell types such as bone marrow cells and glioblastoma?
Does BRD8high has high p53 and p21?
Are genes listed in Figure 4B all p53 target genes? can some validation be done?
Significance
This is a potentially interesting study. The major limitation is the absence of validation from the screening. This study would definitely benefit the research community as long as some of the key findings are validated.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary
In this paper the authors describe a data driven approach to identify and prioritise p53-DREAM targets whose repression might contribute to abnormal haematopoiesis and brain abnormalities observed in p53-CTD deleted mice. The premise is that in these mice, (where they have previously demonstrated p53 to be hyperactive in at least a subset of tissues), that the p53-p21-E2F/DREAM axis is at least in part responsible for observed phenotypes due to the repression of E2F and CDE/CHE element containing genes. Their approach to home in on relevant genes is based on transcriptomic gene ontology analysis of genes repressed in these disease settings where they primarily use publicly available data from HOXA9-ER regulated model of HSC expansion wherein they observe increases on p53-p21 expression upon differentiation where they demonstrate that p53-p21 DREAM target genes are suppressed as we would expect in this scenario where p53-p21 is activating withdrawal from cell cycle. They then spend a lot of effort analysing this datasets combining "gene-ontology", "disease phenotype" and "meta-ChIP-seq" analysis of public data to support the observation that mutations of genes suppressed in this manner are disproportionately linked to heritable haematopoetic and brain disorders. While these results are interesting in terms of framing a hypothesis about how mutations in p53-p21-DREAM regulated targets contribute to such conditions, they are to be expected given the now very well described impact of p53-p21 on both E2F4/DREAM targets. The natural progression of this work would be to go on to show this occurs in relevant cells or tissues derived from the p53-CTD mice as well as look at modulating target genes to understand underlying mechanisms and consequences.<br /> Rather than this, they focus on validating that a sub-set of these targets are indeed suppressed by specific p53 activation by MDM2 inhibitor Nutlin-3A in MEFs by qPCR and that mutation of predicted CDE CHR elements in luciferase constructs leads to increase luciferase activity. While these findings support their predictions, the results are entirely expected based on what is known about such targets and demonstrating that this occurs in MEFs does not closely relate to haematopoietic and brain cells they suggest this regulation is important. In fact, in the discussion, the authors comment on the importance of cell type context specificity in terms of discordance between predictions of TF binding sites and public datasets.<br /> Finally, they try and contextualise effects in glioblastoma data by correlating target gene expression with levels of BRD8 since it has recently been shown to attenuate p53 function in glioblastoma and show that some of the brain disease associated genes are expressed at higher levels in BRD8 high patient samples. It seems strange here that they do not also look at expression of p21 or other p53 targets that would help ascertain if p53 activity is indeed suppressed. Moreover, much more elegant methods for predicting transcription factor activity could be applied to this data.
Major Comments
The major result of this paper as it stands is the prioritisation of candidate genes in the p53-DREAM pathway involved in these conditions, and their refined approach used to identify and prioritise these genes and is such more of a starting point for further investigation. They fall short of demonstrating the relevance of their predictions physiologically in tissues from the mice and do not demonstrate functional importance of regulation of targets they put forward. Given that these genes will be co-ordinately regulated, without a mechanistic experiment in physiologically relevant model it is impossible to infer causality. For example, depleting individual targets in the HOXA9 model and evaluating impact on survival, proliferation and differentiation may be a (relatively) simple way to explore this, perhaps comparing to effects of p53 activating agents such as Nutlin-3A. Of note the authors (Jaber 2016 PMID: 27033104) and several other groups had (Fischer 2014 PMID: 25486564 McDade 2014 PMID: 24823795) previously demonstrated the link between p53-p21 and suppression of DNA-repair/Damage related genes (as is also observed here in particular FA-related genes that they discuss briefly here. I would have thought that this would be an obvious starting point for some mechanistic experiments and in fact I note this has been demonstrated before (Li et al 2018 PMID: 29307578)<br /> The analysis of brain specific targets and the link to BRD8 sits largely as an aside and the analysis of patient data from glioblastomas is underdeveloped as noted above.<br /> The computational methods applied are robust, albeit predominantly coorelative, in terms of identifying regulation of potential causative target genes, validated across human and mouse cell lines, and this indicates a role of these genes in the relevant conditions. However, further validation through application in a bulk or single cell RNAseq patient cohort, or at least an in vivo model would strengthen these conclusions and complement the work presented here which is based on in vitro mouse and human cells. This is pertinent as this study improves upon previously published approaches by focusing on "clinically relevant target genes". Additionally, this would exhibit the potential applications of the findings presented.<br /> In terms of statistical analysis, the hypergeometric test should be applied to assess significant enrichment of genes for example with CDE/CHR regions within the previously identified lists.
Minor Comments
References are required for the genes listed which play a role in the diseases of interest. This paper would benefit from the inclusion of summary schematics and tables throughout (rather than relying only on somewhat unwieldy heatmaps which show little other than all these genes are co-ordinately regulated), this could include summaries of the methods applied, gene or CDE/CHR inclusion criteria, and Venn diagrams indicating the subsets of final genes identified through this approach.
Significance
In its current form this is a very limited study that would require significant additional work to move conclusions beyond correlation and hypothesis generation.
Overall, while limited largely to target prioritisation, this research nicely exemplifies how genes affected by the p53-DREAM pathway can be robustly identified, providing a potential resource for individuals working on this pathway or on abnormal haematopoiesis and brain abnormalities. These results are complementary to work previously published by Fischer et al, which has been referenced throughout the analysis (highlighting Target Gene Regulation Database p53 and DREAM target genes) and discussion.
This paper will be of interest to researchers of blood/neurological diseases who can assess if these genes are dysregulated in their datasets, or those investigating the p53-DREAM pathway. This work represents a useful resource detailing genes affected by this pathway in these disease settings, however researchers of the p53-DREAM pathway may find this paper useful when planning an approach to identify and prioritise genes of interest.
My expertise is in the field of transcription factor and p53 family biology in cancer and disease. Our group utilises functional genomics and computational approaches to harness this information to identify causal regulators of downstream effects or indeed novel ways to exploit p53 family
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We thank the referees for their interest, comments and advice on our manuscprit. The reply to the reviewers follows the revision plan proposed Review Commons.
1. Description of the planned revisions
R#1 major comments :
R#1 raised three major points relative to quantitative data. For the two first, we have optimized our quantification methods, as explained in the next section, which clearly improved the results, but some data still have to be re-analyzed for figures 5,6,7.
For the third one, here is the comment and our proposed additional experiments to answer it :
c) Quantifications of lateral fraction Col IV in mosaic experiments do not support decreased lateral secretion in Rab8 OE (3G) or Dys- (S5C), which are central tenets of the study. “
We have endeavoured to detect such differences in Dys mutants and Rab8 OE and do not see any possible improvement in the quantification method and therefore propose, instead, additional experiments.
With respect to Rab8 OE, we suspect that this gain of function is not sufficiently effective under the specific conditions of the experimental setup described in Figure 3, as its effect appears to be more subtle than that of Rab10 OE in Figure 2. We therefore propose to repeat this experiment on a sensitised background in which Rab10 function is partially affected. Unpublished data indicate that this downregulation of Rab10 is not sufficient to induce significant differences in this experimental setup. However, based on the genetic interactions described in the other figures, an additive/synergistic effect between rab8 OE and Rab10 KD can be expected, which would allow to confirm the involvement of Rab8 in basal secretion.
With regard to Dys mutant, we considered another possible explanation for this observation, namely that DAPC could affect the secretion of other BM proteins but not that of collagen IV. It should be noted that Perlecan and LamininA, which are also found in BM fibrils, are ligands for Dystroglycan, which is not the case for collagen IV. Unfortunately, there is no existing transgene with a UAS promoter and a tagged version of these proteins that would allow this hypothesis to be tested within a reasonable timeframe using the same method as that described in Fig.3. Therefore, we propose an alternative approach that would determine whether the secretion of endogenous laminin and/or perlecan is affected by Dystroglycan overexpression (i.e. secreted more laterally) and test whether this effect is Dys-dependent. It should be noted that this hypothesis would be fully consistent with all our data and in particular with that shown in Fig. 5.
R#2 major comments
From the data presented in Figure S1B, the authors state that the basement membrane mislocalization observed in Rab8/10KD has no major impact on polarity maintenance. They based this statement only on the localization of the apical marker aPKC. Although the aPKC data are convincing, it would be more compelling if the authors observe the distribution of other polarity proteins such as Dlg, E-Cadherin, and armadillo to better assess if the overall epithelial polarity is maintained in this condition.
We will complete fig S1 and perform ECad and Dlg staining to provide a better description of apical-basal polarity in the different Rab knock-down conditions.
R#3 comments
Results Figure 4
The authors suggest basal Rab10 expression domain near the Golgi exit point. Can the authors use a Trans-Golgi marker in order to confirm this statement other than the references stated?
Such a staining will be included in the final version with for instance golgin245 staining.
2. Description of the revisions that have already been incorporated in the transferred manuscript
R#1 major comments :
a) Rab8 KD does not significantly increase apical fraction of Collagen IV with respect to control (Fig. 1H). The image in 1C clearly shows that Col IV is present apically, something that has been shown by others and that never occurs in the wild type. Failure of the quantifying method to detect a difference can only mean the quantifying method is not adequate. A 10% average in the control when it's clear that no Col IV at all is found apically in the wild type suggests that the authors are quantifying background signal that they should not be acquiring, and, if acquired, they should be subtracting Rab8/Rab10 double knock down is said to show a synergistic effect, when an additive effect would be more consistent with alternative routes. Other problematic deductions drawn from apical fraction quantifications are found in Fig. 5J (Dys- enhancing Rab8 KD but not Rab10 KD) and Fig. 7D (Exo70- enhancing Rab10 KD but not Rab8 KD)
We agree that this quantification was not optimal. We improved it by quantifying a narrower and more precise region for each domain. The new results are shown in Figure 1H. This improvement reduces the apical signal in the control from 10% to 6% and allows us to detect a significant increase between the control and Rab8 KD, thus resolving the problem raised. After verification, we did not subtract the background because there was no electronic background in our images (i.e. black is really black and equal to zero). Thus, the remaining signal is the true cytoplasmic GFP signal and it may not be appropriate to subtract it. Other data (fig 5J and 7D, now named fig 5L and 7H) were also re-analyzed with no major change.
b) Similar to apical fraction, measurements of planar polarization (trailing/lateral ratio) show average ratios near 1 for Dg, Rab10 and Dys, which is striking given that the localization of these proteins is so clearly polarized. Ratios lower than 1, which are reported for many individual cells in these graphs, should mean reversed polarity. In light of this, I would not be too confident on the effects reported in 5O-Q. In fact, on two occasions, the authors obtain significant differences in these planar polarization measurements that they themselves disregard: Fig. 6J (Rab10 in Exo70-) and Fig. 7I (Dys in Rab8 KD).
We agree that this quantification could be improved. Our initial quantification of the planar polarised proteins, Rab10 and Dys, found at the trailing edge, was confounded by their lateral spread. We have now reported with only the front half of the lateral side. By doing this in Figure 5, we increase the ratio in the control conditions, with almost no points below the value of 1, while the conditions in which polarity is visually affected are unchanged and still close to 1. We did not have time to re-analyze all the data (Figures 6 and 7), but will do so in the final revised version.
R#1 minor comments :
All the minor points raised by R#1 have been addressed by changes in the main text and/or the figures with the exception of the following :
- Fig. S1B does not seem to make a significant point in the context of this study.
Although we understand this comment, we followed suggestion of R#2 who asked in its major comments for more details with other cell polarity markers. These data are not yet included but will be generated for the fully revised version.
- I suggest drawing a summary scheme to aid readers better assess interpretations alternative to the ones given in the text.
While we will be happy to provide such a scheme in the final version, we prefer to wait for the results of the proposed complementary experiments to be as accurate as possible.
R#2 major comments
In the text for Figure 1G-H (page 4), the authors stated that the basal secretion was not restored in Rab8, 10, and 11 triple KD, in our opinion, it is unclear how the authors came to this strong conclusion from the presented data. It would be good if the authors explicitly explain how they come to this conclusion. Is it only based on the weak Coll-IV-GFP signal in the Rab8, 10, and 11 triple KD data compare to the control? If so, the authors should statistically quantify the difference with the control. In Figure 1H, no statistical analysis is provided between the control and triple KD conditions.
We agree that it was not entirely appropriate to give such conclusions on the basis of the quantifications available. A new graph showing basal fluorescence intensity (new Figure 1H) (and not just the ratio of apical to apical plus basal as in Figure 1I) has been added to better support the text. A relevant statistical comparison has been added to Figure 1H (old Figure 1I). We apologize for this oversight.
R#2 minor comments :
We took in account all these comments and changed accordingly the text and the figures
R#3 comments :
Results figure 1
The authors use RNAi lines to arrive at their conclusions, however, the extent of inhibition of gene expression achieved by the RNAi, has not been justified. Also observations from only one RNAi stock may not be completely conclusive:
i) Efficiency of RNAi has not been tested or shown. No supporting data. Rab10-RNAi stock is 26289 BDSC which is in Valium10, which is a weak RNAi line and needs a Dicer.
ii) Can same observations be made using classic alleles or generate somatic clones on follicular epithelial cells?<br />
R#3 raised several questions regarding the efficiency of RNAi, the use of different lines and/or the use of classical mutants as an alternative method.
For Rab10, we tested three different lines with similar results as shown now in Figure S1A-B. These data are also consistent with those obtained by overexpression of a dominant-negative form of Rab10 (Lerner et al, 2013). Unfortunately, Rab10 is located extremely close to the X chromosome centromere and is even more proximal than the FRT transgenes. It is therefore impossible to generate somatic mutant clones.
Regarding Rab8, it is already published that Rab8 RNAi, expression of a dominant-negative form of Rab8 and Rab8 mutant cells obtained by somatic clones give similar defects (Devergne et al, 2017). The text has been modified to better illustrate the available data validating our approach.
In addition, mutant clones would not allow analysis of genetic interactions in complex genetic contexts such as double and triple KDs. Similarly, the choice of the Rab10 line was motivated by the ease of obtaining the appropriate genetic combination according to their genomic location.
iii) Intensity of Collagen IV in the basement membrane in Rab11 knock-down mutants seems to be significantly low as compared to the Rab8 and Rab10 knock downs in supplementary Fig 1B. Are the authors very sure that Rab11 has no functions in basement membrane basal organization?
Good catch! Indeed, Rab11 RNAi significantly reduces basal secretion as now shown on fig 1H. Rab11 has pleiotropic functions in epithelial cells notably for their polarity (Choubey and Roy, 2017, Fletcher et al, 2012…) and, accordingly aPKC is partially disrupted in Rab11 RNAi conditions (Fig S1). Thus, the reason for such a decrease is unclear and could be an indirect consequence of an overall abnormal epithelial structure. Thus, we now report this observation but have not taken its interpretation too far.
iv) Authors need to show where and how fluorescence intensities have been measured.
Magenta rectangles with dashed lines on figure 1A illustrate the ROIs used for this analysis and more details have been added in the ‘experimental procedures’ section.
Results Figures 2 and 3:
Texts and figures have been modified as suggested.
Results Figure 4 :
The authors suggest a UAS-Rab10-RFP transgene show same results as endogenous Rab10-YFP as compared to spatial expression pattern. This is worrisome as expression of full length functional gene tagged with a fluorophore may be an overexpression. A control experiment would be helpful in suggesting/comparing with the Rab10 OE phenotype and that will be more convincing.
We are not sure that we fully understand the reviewer's comment. However, we initially compared endogenous Rab10 and UAS-RAB10 at 25°C, a temperature at which the latter has no visible impact on BM structure (Cerqueira-Campos et al, 2020). Furthermore, even when higher expression was induced (by increasing the temperature and therefore Gal4 activity) and this had an impact on BM structure, this did not change the subcellular localization of Rab10, i.e. it was still planarly polarized, as shown in Fig 5S. The text has been modified to emphasize this point.
Result Figure 5
The authors may provide a Rab10 expression profile in DAPC null or KD mutants which would make their claims more comprehensive.
Data showing Rab10 localization in Dys mutant cells were already shown on Figure S5A-B. Of notice, we also tried similar experiments using RAB10 knock-in line. However, for unexpected reason, having one copy of the chromosome with YFP insertion in Rab10 strongly enhanced DAPC mutant phenotypes in terms of F-actin orientation and follicle elongation ((as described in Cerqueira-Campos et al, 2020). We therefore considered these data as inappropriate.
General comment
In general some immunostainings should be carried out if not in all at least in some experiments with some cell domain specific markers, more specifically PCP markers such as Flamingo/Vangl and basolateral markers such as Lgl/Dlg. This makes the positions specific claims of the authors more valid in the eyes of the reader.
We agree that this may help the reader but the pcp markers mentioned are not expressed in this tissue. However, the tissue planar orientation is now systematically indicated and consistent in all figures. We did not generally perform immunostaining for lateral markers but routinely included F-actin staining to detect cellular cortex. Our quantifications or cortical segmentations were based on the cell outline provided by this stain. On the basis of this staining, the outline of the cells was added on certain figures to facilitate understanding of the images.
3. Description of analyses that authors prefer not to carry out
R#3 comments :
Result Figure 6 :
Exo 70 is a versatile molecule and Rho kinases such as Cdc42 can direct Polarised exocytosis through interaction of Rab effectors with Exo 70. Have the authors considered this?
We agree that it is an interesting prospect, but we consider it as beyond the scope of this article.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
In the present work the authors have elucidated a novel mechanistic model of basement membrane morphogenesis using Drosophila ovarian follicle cells as a model. The authors have employed extensive quantification approaches to justify the spatio-temporal expression of the molecules under study such as Collagen IV, Rab8, Rab10, DAPC, etc. The authors suggest distinct exit domains of BM protein Collagen IV facilitated by Rab8 and Rab10 via distinct routes as they interact with each other. The authors further show that DAPC plays an essential role in Rab10 mediated baso-lateral fibrillar BM synthesis whereas Rab8 functions are more Exocyst (Exo-70 dependent).
Major comments:
Result 1:
The authors use RNAi lines to arrive at their conclusions, however, the extent of inhibition of gene expression achieved by the RNAi, has not been justified. Also observations from only one RNAi stock may not be completely conclusive:
- Efficiency of RNAi has not been tested or shown. No supporting data.<br /> Rab10-RNAi stock is 26289 BDSC which is in Valium10, which is a weak RNAi line and needs a Dicer.
- Can same observations be made using classic alleles or generate somatic clones on follicular epithelial cells?
- Intensity of Collagen IV in the basement membrane in Rab11 knock-down mutants seems to be significantly low as compared to the Rab8 and Rab10 knock downs in supplementary Fig 1B. Are the authors very sure that Rab11 has no functions in basement membrane basal organization?
- Authors need to show where and how fluorescence intensities have been measured.
Result 2:
Confusing diagram. The authors should clarify whether the BM fibrils indicate lateral or planar BM components which they show to be more prominently expressed in Rab10 over-expression mutants.
A short note or an accompanying explanatory diagram on the source of the BM fibrils in the cellular context should make things less confusing.
FF calculation is an ingenious way of trying to look into functions.
The term Opposite effects/functions may be reconsidered as Rab8 and Rab10 compete with each other to deposit Collagen at spatially distinct domains. Opposite functions may give an impression that Rab8 actually represses Rab10 activity or vice versa, which may not be the case here.
Result 3:
Why was anti-GFP Ab detected with Cy3-Cy5 secondary Ab. GFP itself is green so why detect it with a Red secondary? Logic? How clone Collagen GFP and ECM collagen GFP was differentiated? Please justify
A panel with a dotted line joining the peripheral or lateral Collagen as shown in panels D' E' of Fig 3 would support the cartoon provided and link the cartoon to the actual microscopic images.
Result 4:
The authors suggest a UAS-Rab10-RFP transgene show same results as endogenous Rab10-YFP as compared to spatial expression pattern. This is worrisome as expression of full length functional gene tagged with a fluorophore may be an overexpression. A control experiment would be helpful in suggesting/comparing with the Rab10 OE phenotype and that will be more convincing.
When the authors mention back of cells, where do the authors exactly mean? A cartoon of "the back of follicle cells", wrt the entire ovarian follicle would be helpful.
The authors suggest basal Rab10 expression domain near the Golgi exit point. Can the authors use a Trans-Golgi marker in order to confirm this statement other than the references stated?
Result 5:
The authors may provide a Rab10 expression profile in DAPC null or KD mutants which would make their claims more comprehensive.
Result 6:
Exo 70 is a versatile molecule and Rho kinases such as Cdc42 can direct Polarised exocytosis through interaction of Rab effectors with Exo 70. Have the authors considered this?
In general some immunostainings should be carried out if not in all at least in some experiments with some cell domain specific markers, more specifically PCP markers such as Flamingo/Vangl and basolateral markers such as Lgl/Dlg. This makes the positions specific claims of the authors more valid in the eyes of the reader.
Significance
The findings impinge on a critical cellular process of Rab protein interactions in the genesis of the basement membrane which is of potential interest.
This falls under basic research. Since Rab molecules have emerged as molecules governing membrane morphogenesis, Cell and Molecular Biologists as well as a wide audience including clinicians will be interested on this.
Our group works on the roles of Rab11 in membrane morphogenesis in Drosophila model and we are now trying to venture with Rab11 in mammalian wound healing.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary:
In this manuscript, Dennis et al. identify different secretory routes and cell exit sites involved in basement membrane secretion and diversification in epithelial cells. Using the follicular epithelium of the Drosophila ovary as their model system coupled with genetics, imaging, and image analysis approaches, they show that two previously identified RabGTPases, Rab8 and Rab10, work in parallel routes for basement membrane secretion. These two small GTPases work in a partially redundant manner, where Rab8 promotes basal secretion leading to a homogenous basement membrane, while Rab10 promotes lateral and planer-polarized secretion, leading to the formation of fibrils. The authors also show that Rab10 and the dystrophin-associated protein act together to regulate lateral secretion, and dystrophin (Dys) is necessary for dystroglycan (Dg) to recruit Rab10. Furthermore, DAPC is shown to be essential for fibril formation and is sufficient to reorient Collagen IV to the Rab10-dependent secretory route. Dys was also shown to interact directly with exocyst subunit Exo70. Using overexpression and loss of function approaches the authors claim that Exo70 limits the planer polarization of Dys, and as a result, Rab10, hence limiting basement membrane fibril formation. Finally, the authors state that the Exocyst (Exo70) is also required for the Rab8-dependent basement membrane route. Overall, the data described in this manuscript are convincing and the authors' claims are supported by the presented data. We have mainly minor comments and only a few major comments that need to be addressed.
Major Comments:
- In the text for Figure 1G-H (page 4), the authors stated that the basal secretion was not restored in Rab8, 10, and 11 triple KD, in our opinion, it is unclear how the authors came to this strong conclusion from the presented data. It would be good if the authors explicitly explain how they come to this conclusion. Is it only based on the weak Coll-IV-GFP signal in the Rab8, 10, and 11 triple KD data compare to the control? If so, the authors should statistically quantify the difference with the control. In Figure 1H, no statistical analysis is provided between the control and triple KD conditions.
- From the data presented in Figure S1B, the authors state that the basement membrane mislocalization observed in Rab8/10KD has no major impact on polarity maintenance. They based this statement only on the localization of the apical marker aPKC. Although the aPKC data are convincing, it would be more compelling if the authors observe the distribution of other polarity proteins such as Dlg, E-Cadherin, and armadillo to better assess if the overall epithelial polarity is maintained in this condition.
Minor Comments:
General comments:
- In the text describing their data, we recommend that the authors clearly indicate which panel(s) they are referring to.
- The authors should also be consistent with the diction throughout the manuscript when referring to the cortical domain or region of the cell (back/rear/trailing edge/leading edge).
- Several references are missing in the manuscript.
The following specific comments are in order of appearance in the manuscript.
Introduction Section:
The following statements in the introduction should be supported by specific references:
- "BM is critical for tissue development, homeostasis and regeneration, as exemplified in humans by its implication in many congenital and chronic disorders."
- "BM is assembled from core components conserved throughout evolution: type IV collagen (Col IV), the heparan sulfate proteoglycan perlecan, and the glycoproteins laminin and nidogen."
- "During development, the dynamic interplay between cells and BM participates in sculpting organs and maintaining their shape."
- "BM protein secretion shows some specificities, mainly because of the large size of the protein complexes (e.g., procollagen) that must transit from the endoplasmic reticulum to the cell surface". This statement could be supported with references including specific Drosophila references. Additionally, the authors need to clarify what they mean by "some specifies".
Results section:
- In the text describing Fig. 2 (page 5), the authors describe two different basement membrane types: fibrils and homogenous. Moreover, the manuscript focuses on the role of Rab8 and Rab10 in the formation of these two structures. Thus, the authors must better describe the two different types of basement membrane structures and their known roles. This will be helpful for the readers to analyze the presented data, especially for those that are not familiar with the system. In Figure 2A, the authors describe stage 3 basement membrane as uniform BM, do they mean homogenous?
- In the text describing the data for Fig. 3 (page 6), the authors should clearly explain the reason to use anti-GFP antibodies in a non-permeabilized condition (i.e., to detect specifically the extracellular secretion of BM proteins). This will help the readers to interpret the data presented.
- On page 9, the authors stated that the precise localization of Dg in follicle cells is unknown. This statement is incorrect. It has been shown, using a Dg antibody, that Dg localizes at a high level at the basal side of the follicle cells and at a lower level at the apical side (Deng et al, 2003 and Denef et al. 2008).
Discussion Section:
- The following statement is not clear: "Thus, three different Rab proteins are targeted towards the three distinct domains of epithelial cells defined by apical basal polarity, and at least of them is also planar polarized". The authors should rephrase and describe specifically which Rabs they are talking about.
- This statement is vague: "These three Rab GTPases have been jointly involved in different processes (Knödler et al, 2010; Sato et al, 2014; Vogel et al, 2015; Eguchi et al, 2018; Häsler et al, 2020)". The authors could also mention the processes in which Rab8, 10, and 11 are involved.
- The following statements need to be supported by references. "Therefore, more investigations are required to define exactly how the DAPC allows the formation of BM fibrils. Nonetheless, given the importance of the DAPC and BM proteins in muscular dystrophies, our results will pave the way to determine whether a similar function is present also in muscle cells. Interestingly, the extracellular matrix is different between the myotendinous junction and the interjunctional sarcolemmal basement membrane and may provide another developmental context where several routes targeted to different subcellular domains may be implicated".
Experimental Procedure Section:
- In the dissection and immunostaining section (p14), there is a typo: it should be for "20 min" instead of "2for 0 min"
- For the GST pulldown experiments, the authors mention that they use a standard protocol to produce S35 Exo 70 and the GST pulldown experiments. The authors should provide references.
Figure and Figure Legend:
- General comment: The orientation of the images showing the rotation and leading and trailing edges need to be consistent in the different figures (e.g., In Figures 3 and 7, the leading edge is oriented to the top while in Figures 4, S4, 5, 6, the leading edge is oriented to the bottom). This will help the readers to analyze the data.
- In Figure 1 C-G the scale bars are missing and should be added as Fig. 1B.
- Figure S1A: The data presented in Figure S1A is convincing. However, a control panel should be added showing the absence of apical Coll IV for comparison. This information will help with the interpretation of the data.
- In Figure 3 legend: it should be "immunostained" for GFP instead of stain for f-actin and GFP.
- In Figure 4, some scale bars are missing.
- In Figure 4 legend: it should be "(A, E)" after (i.e 0.8 µm above the basal surface) instead of "(C, G)"
- In Figure 5A-E, the authors show quantification of the fibril fraction for Dys-, Rab10 OE, and Rab10OE+Dys, Rab8KD, and Rab8KD+Dys-, and images of the collagen fibril for all the conditions except Dys-, it will be informative that the authors present a representative image of the Coll IV fibril in Dys- condition for comparison. The above comment also applies to Figure 5F-J, and it will be also informative to have a representative image of Dys- condition.
- In Figure 5 legend (p23), it should be "plane" and not "plan".
- Overall, the legend for Fig. S5 is not clear and we recommend the authors to clearly described the different panels. (e.g., it should be "(D)" instead of "(H-J)")
- In Figure 6, some scale bars are missing.
Significance
Despite the important roles of the basement membrane for mechanical support, tissue and organ development, and function, the mechanisms that control the polarized deposition of basement membrane proteins are largely unknown. The contribution of Rab 8 and Rab 10 in the polarized deposition of the basement membrane was previously shown. However, by identifying two competitive secretory routes for the basal secretion of the basement membrane proteins that required these two different RabGTPases, controlled by the DAPC and the exocyst complexes, the authors make a novel contribution to our understanding of the mechanism that leads to the polarized secretion of basement membrane proteins (in that case Collagen IV). Since the basement membrane has critical roles in tissue and organ morphogenesis and functions, and its misregulation has been associated with developmental defects and pathological conditions, this research sheds light on the mechanisms important in these morphogenetic processes and will give insights into their deregulations in pathological conditions.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
This manuscript by Dennis et al. reports a study of the polarized secretion of basement membrane Collagen IV in the Drosophila (fruit fly) follicular epithelium. Using genetic manipulations and confocal imaging, the authors show that Rab-GTPases Rab8 and Rab10, both known to be required for proper basal secretion of Collagen IV (work by the labs of Sally Horne-Badovinac and Trudi Schupbach, respectively), mediate two alternative secretion routes: Rab8 mediates basal-most secretion of soluble Collagen IV that is incorporated homogenously into the basement membrane, whereas Rab10 mediates basal-lateral secretion of Collagen IV that produces insoluble fibers. The authors additionally study the relation between Rab10 and Dystroglycan/Dystrophin (Dystrophin-associated protein complex, DAPC), which they previously showed to be essential for fibril formation (Cerqueira-Campos et al., 2020). They show here that Dystrophin and Rab10 colocalize at the basal trailing side of follicle cells and that overexpressed Dystroglycan can recruit Rab10 to the plasma membrane; however, they also show that Dystrophin mutants fail to display an effect on Rab10 localization, leaving the significance of the proposed Rab10-DAPC interaction unresolved. Finally, the authors present convincing evidence that the exocyst complex opposes fibril formation, and suggestive but comparatively weaker results pointing that this opposition is due to two independent separate exocyst roles: an inhibitory interaction exocyst-Dystrophin (Dystrophin being required for fibril formation), and a positive role in the alternative Rab8 non-fibril route.
Major comment:
- There are several instances throughout the study in which the authors seem to have problems quantifying results. This affects some assertions central to the message of the paper that are not supported by the quantifications presented. It also casts doubts on accessory points deduced from quantitative differences (or lack of difference) that do not seem fully reliable. I would urge the authors to reevaluate their quantification methods.
a) Rab8 KD does not significantly increase apical fraction of Collagen IV with respect to control (Fig. 1H). The image in 1C clearly shows that Col IV is present apically, something that has been shown by others and that never occurs in the wild type. Failure of the quantifying method to detect a difference can only mean the quantifying method is not adequate. A 10% average in the control when it's clear that no Col IV at all is found apically in the wild type suggests that the authors are quantifying background signal that they should not be acquiring, and, if acquired, they should be subtracting. Rab8/Rab10 double knock down is said to show a synergistic effect, when an additive effect would be more consistent with alternative routes. Other problematic deductions drawn from apical fraction quantifications are found in Fig. 5J (Dys- enhancing Rab8 KD but not Rab10 KD) and Fig. 7D (Exo70- enhancing Rab10 KD but not Rab8 KD).
b) Similar to apical fraction, measurements of planar polarization (trailing/lateral ratio) show average ratios near 1 for Dg, Rab10 and Dys, which is striking given that the localization of these proteins is so clearly polarized. Ratios lower than 1, which are reported for many individual cells in these graphs, should mean reversed polarity. In light of this, I would not be too confident on the effects reported in 5O-Q. In fact, on two occasions, the authors obtain significant differences in these planar polarization measurements that they themselves disregard: Fig. 6J (Rab10 in Exo70-) and Fig. 7I (Dys in Rab8 KD).
c) Quantifications of lateral fraction Col IV in mosaic experiments do not support decreased lateral secretion in Rab8 OE (3G) or Dys- (S5C), which are central tenets of the study.
Minor comments:
-
It is stated that Rab10 and Dys associate with tubular endosomes, but no data here support identification as endosomes of these tubular structures, to my understanding.
-
The authors call sup-basal the cell region immediately apical to the most basal. Is there sufficient reason to not call this lateral? If a new term is needed, shouldn't it be supra-basal?
-
In Fig. S1A and B, Col IV is labeled as green but represented in cyan.
-
Fig. S1A should present a wild type control.
-
Fig. S1B does not seem to make a significant point in the context of this study.
-
Fig. 3C'-E' label suggests a gradient made from multiple images, but it looks like just two images and two colors.
-
Graphs in Fig. 3H-J, S5D and 7B are not legible.
-
It is not clear where Y2H results in Fig 6A come from.
-
I suggest drawing a summary scheme to aid readers better assess interpretations alternative to the ones given in the text.
Significance
This study reports important new information on the secretion of Collagen IV by polarized cells of the Drosophila follicular epithelium. It complements previous studies on the roles of Rab8, Rab10 and Dystroglycan/Dystrophin, additionally uncovering a role for the exocyst complex. Addressing some issues with quantitative imaging should increase confidence in its most critical conclusions.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1 (Evidence, reproducibility and clarity):
1) It is interesting MxDnaK1 seems to prefer cytosolic proteins while Mx-DnaK2 prefers inner membrane proteins. The domain-swapping experiments seem to suggest that the NBD is important for this difference. How NBD is important is not addressed. Is it due to ATP hydrolysis, NBD-SBD interaction, or co-chaperone interactions?
Answer: Thanks for your comments. We speculate that the co-chaperone interaction might be the key factor contributing to substrate differences. According to the working principle of Hsp70, its functional diversity is largely determined by substrate differences. Co-chaperones, such as JDPs, play a crucial role in this process as they possess the ability to bind substrates and facilitate their targeted delivery. Therefore, much of the functional diversity of the HSP70s is driven by a diverse class of JDPs 1,2. We found that NBD played important roles in cochaperone recognition of MxDnaKs. Additionally, it is generally accepted that the efficiency of ATP hydrolysis does not significantly impact the substrate recognition of Hsp70. Furthermore, if the NBD-SBD interaction is crucial, the substitution of either the NBD or SBDβ domain might result in similar cell phenotypes, as both alterations disrupt the original NBD-SBDβ interaction. We believe the DnaK proteins and their cochaperones both determine the substrate spectrums. We made corresponding modifications in the revised manuscript. (Page22; Line 488-494 in the marked-up manuscript)
2) About the interactome analysis, since apyrase was added to remove ATP, it's surprising multiple Hsp40s were found in their analysis. Hsp70-Hsp40 interaction is known to require ATP. This may suggest some of the proteins found in their interactome analysis are artifacts. The authors should perform negative controls for their interactome analysis, such as using a control antibody for their CO-IP and analyze any non-specific binding to their resin.
In addition, since JDPs were pull-down, is it possible some of the substrates identified are actually substrates for JDPs, not binding directly to DnaKs?
Answer: This is an interesting question. As you correctly noted, the interaction between Hsp70 and Hsp40 requires ATP. In our experiment, we used apyrase to remove ATP in order to promote tight binding of substrate by DnaK. This methodology was initially described by Calloni, G. et al in 20123, and the authors also identified the co-chaperone protein DnaJ, but with a concentration higher than 77% of the interactors. In our opinions, the incomplete removal of ATP could be the underlying cause of this phenomenon.
We apologize for the undetailed description in Methods. Actually, we implemented negative controls for each MxDnaK in order to eliminate the potential non-specific interactions with Protein A/G beads or antibodies. Specifically, we conducted a CO-IP experiment without the presence of antibodies to assess any non-specific binding to the Protein A/G beads. To further investigate non-specific binding to the antibodies of MxDnaK2 and MxDnaK1, we utilized the mxdnak2-deleted mutant (strain YL2216) and the MxDnaK1 swapping strain with the MxDnaK2 SBDα (strain YL2204), respectively. As the SBDα of MxDnaK1 was employed as antigen to generate antibodies, and YL2204 can’t be recognized by anti-MxDnaK1 (Figure S5). We believe these controls allowed us to evaluate and exclude the non-specific interactions in our CO-IP. We have improved our description in methods. (Page 27; Line 596-607)
While one of the main functions of JDPs is to interact with unfolded substrates and facilitate their delivery to Hsp70, there may still be substrates that do not directly bind to Hsp70. It’s thus possible that some of the substrates identified only bind to JDPs. We made corresponding modifications in the revised manuscript. (Page 14; Line 290-292)
3) For Figure S7, the pull-down assay used His6-tagged JDPs. Ni resin is known to bind Hsp70s non-specifically. It's not surprising DnaK showed up in all the pull-down lanes, especially considering how much DnaK was over-expressed. For some pull-down lanes, the amount of DnaK is much more than that of JDPs, further indicating artifact. The author should include negative controls such as JDPs without His6-tag or any irrelevant protein with His6 tag.
Answer: Thanks for your suggestion. As you and another reviewer pointed out, there were some flaws in the experimental design of the pulldown assay. These include the non-specific binding of Hsp70 proteins to nickel resin, the absence of a negative control without a tag, and the inappropriate selection of the MBP tag. Thus, we employed the nLuc assay as an alternative to the pulldown experiment to validate the interaction between DnaK and JDP (Figure S9). While our manuscript employed nLuc to confirm protein dimerization, it is worth noting that nLuc assay was originally devised for investigating protein interactions 4.
4) For the proposed dimer formation in Fig. 4C, there are multiple bands above the monomer bands. What are these forms? It seems the majority of the Cys residues that could form disulfide bonds are in the NBD of MxDnaK2 since constructs with MxDnaK2-NBD form some sort of high-MW bands above the monomer. Does MxDnaK1-NBD also contain Cys at the analogous positions? The fact that MxDnaK1 didn't show disulfide-bonded bands doesn't mean it doesn't form dimer. It depends on where the Cys residues are.
It's nice the authors did Fig. 4D. However, the authors should include a positive control to show how strong the signal is for a true interaction before interpreting their results.
Answer: Thank you very much for your comments. In at least three independent experiments, we consistently observed two unidentified bands within the molecular weight range of 70-100 kDa during the purification process of His6-MxDnaK2. These bands appeared to be intermediate in size between the monomeric and dimeric forms of His6-MxDnaK2, and disappeared upon DTT treatment. the unidentified band compositions have been confirmed by LC/MS. The upper band included MxDnaK2 (65.3 kDa) and anti-FlhDC factor of E. coli (WP_001300634.1, 27 kDa). In the lower band, we detected the presence of MxDnaK2 and the 50S ribosomal protein L28 of E. coli (WP_000091955.1, 9 kDa). Based on these findings, we conclude that these two additional bands are the result of the interaction between His6-MxDnaK2 and these two E. coli proteins. The related explanations have been added in the legend of Figure 5. (Page 42; Line 938-942)
We analyzed the presence of Cys in MxDnaK1 and MxDnaK2. The NBD region of MxDnaK2 contains two Cys, located at positions 15 and 319. MxDnaK1-NBD contain a Cys at position of 316, which is the analogous position of 319-Cys of MxDnaK2. The analogous position of 15-Cys of MxDnaK2 is a Val in MxDnaK1, which might be an important factor contributing to the inability of MxDnaK1 to form oligomers.
Thanks for your suggestion to add the positive control. We re-performed the nLuc assays including a positive control(αSyn). According to the working principle of the nLuc assay, the amount of fluorescent substrate is limited. Therefore, even for proteins that interact with each other, the fluorescence value gradually decreases and reaches a plateau, similar to the negative control. This gradual decline in fluorescence is a significant indicator of protein interaction. In Figure 4D (Figure 5D in the revision version), we only presented the results of the first 20 minutes of detection. The complete two-hour detection results have been added in the supplementary figure (Figure S14).
5) line 48: "human HSC70 and HSP70 are 85% identical, and the phenotypes of their knockout mutants are different, which is consistent with their largely nonoverlapping substrates" The authors completely ignored that the promoters of HSC70 and HSP70 are very different.
Answer: This is our carelessness. Yes, HSC70 and HSP70 exhibit distinct expression patterns, which play important roles in their functional diversity. We modified the sentence in the new version (Page 5; Line 58)
6) Line 69: "The two PRK00290 proteins, not the other Myxococcus Hsp70s, could alternatively compensate the functions of EcDnaK (DnaK of E. coli) for growth." Please add references for this statement.
Answer: Added, thanks.
7) line 191: What's the mechanism for DnaK's role in oxidative stress? Is the disulfide bond formation in Fig. 4 related? Does disulfide-bond change the activity of DnaK?
Answer: Thanks for your pertinent comments. Honestly, we have no idea about the mechanism for MxDnaK2's role in oxidative stress. In our previous studies, we determined that the deletion of mxdnaK2 resulted in a longer lag phase after H2O2 treatment. Here, our aim was to investigate the impact of region swapping on the cellular function of MxDnaK2. In other bacteria, the critical role that DnaK plays in resistance to oxidative stress stems from the pleotropic functions of this chaperone. By shortening the dwelling time that proteins spend in the unfolded state, the DnaK/DnaJ chaperone system minimizes the risk of metal-catalyzed carbonylation of the side chains of proline, lysine, arginine, and threonine residues, but none of them linked to the dimerization characteristic of DnaK 5-7.
8) Fig. S9 seems redundant.
Answer: Deleted, thanks.
9) line 263, "but the NBD exchange was almost equal to the deletion of the gene with respect to phenotypes." But, the mutant has >50% activity in Fig. 3F.
Answer: We apologize for the confusing description. The “phenotypes” here indicates “cell phenotypes”. What we really tried to say with this sentence is that the NBD swapping strain of either MxDnaK1 or MxDnaK2 presented identical cell phenotypes with the gene-deleted strain. As we have already provided a detailed description of this result earlier, now we consider this sentence to be redundant and have therefore deleted it. (Page 17; Line 355-356)
10) line 221-226: the logic is not quite clear.
Answer: We apologize for the confusing description. In M. xanthus DK1622, MxDnaK1 is essential for cell survival, and an insertion of a second copy of mxdnaK1 in the genome is required for deletion of the in-situ gene. Thus, To verify whether the NBD region is required for the essentiality of MxDnaK1, we performed the region swapping of the in situ MxDnaK1 gene in the att::mxdnaK1 mutant (a DK1622 mutant containing a second copy of mxdnaK1 at attB site), and successfully obtained the MxDnaK1 mutant swapped with the MxDnaK2 NBD region. The experiment indicated that the NBD of MxDnaK1 is essential for the cellular functions of the chaperone. We have added the information and modified the sentences in the manuscript. (Page 15; Line 308-319)
Minor concerns:
Please check spelling. There are some typos such as "HPPES" in the Methods.
Answer: Corrected. Many thanks.
My areas of expertise are protein biochemistry, genetics, and structural biology on heat shock proteins.
Reviewer #2 (Evidence, reproducibility and clarity):
Major comments:
The manuscript is very nice and interesting, although some of the authors' conclusions are perhaps not well supported by their data. For example:
1) In the pulldown experiments the lack of interaction between 2747-MxDnaK2, 3015-MxDnaK2 and 1145-MxDnaK1 should be shown in order to support the conclusion made in line 197-198,
Answer: This is our carelessness. As you and another reviewer pointed out, there are some flaws in the experimental design of the pulldown assay. These include the non-specific binding of Hsp70 proteins to nickel resin, the absence of a negative control without a tag, and the inappropriate selection of the MBP tag. Thus, we employed the nLuc assay as an alternative to the pulldown experiment to validate the interaction between DnaK and JDP (including 2747-MxDnaK2, 3015-MxDnaK2 and 1145-MxDnaK1 interaction) (Figure S9). While our manuscript employed nLuc to confirm protein dimerization, it is worth noting that nLuc assay was originally devised for investigating protein interactions 4.
2) The only evidence that the NBD of MxDnaK1 is essential for bacterial growth is that this mutation couldn´t be obtained in M. xanthus. However, it could be purified in E. coli. Could the authors do some experiments with the M. xanthus strain without the chromosomal MxDnaK1 and then introduce a plasmid with the mutated gene?
Answer: We apologize for the confusing description. Actually, we determined the NBD is essential not only from the mutation couldn’t be obtained. In M. xanthus DK1622, MxDnaK1 is essential for cell survival, and in-situ deletion of the gene could be obtained after an insertion of a second copy of mxdnaK1 in the genome at the attB site. To verify whether the NBD region is required for the essentiality of MxDnaK1, we performed the region swapping of the in situ MxDnaK1 gene in the att::_mxdnaK_1 mutant (a DK1622 mutant containing a second copy of _mxdnaK_1), and successfully obtained the MxDnaK1 mutant swapped with the MxDnaK2 NBD region. The experiment indicated that the NBD of MxDnaK1 is essential for the cellular functions of the chaperone. We have added the information and modified the sentences in the manuscript. (Page 15; Line 308-319)
3) All the experiments with purified proteins were done with MxDnaKs bearing His-tags. It doesn't say explicitly its position, but as they employed a pET28A it is likely that the tag is at the N-terminus, which is close to the linker region. As this tag might interfere, it should be removed for the experiments, or at least a control done with the tag removed.
Answer: We apologize for the lack of detailed description. As you pointed out, the His-tags are located at the N-terminus of DnaKs. The full lengths of MxDnaK1 and MxDnaK2 are 638 and 607 amino acids. The linker regions are located at amino acid positions 381-386 for MxDnaK1 and 387-392 for MxDnaK2. Therefore, we believe that the His-tag is not close to the linker regions. We have included the information in new manuscript. (Page 24; Line 544-546)
The purified His6-DnaK proteins were employed for holdase activity assays and in vitro dimerization assays. Several previous studies have utilized the same holdase activity assay method with His-tagged DnaK 8,9. We suggested that the His-tag did not interfere with the holdase activity of DnaK. To exclude the influence of His-tag on oligomerization, we conducted a control with the tag removed in the in vitro dimerization assay and the result show no difference (Figure S13).
4) The authors state that MxDnaK dimerized in vitro with the NBD, and to disrupt the dimer they used 100 mM DTT, which is a very high concentration. As the protein has the His-tag, it should be removed to corroborate that it is not interfering with the dimerization.
Answer: Thanks for your suggestion. As mentioned above, to exclude the influence of the His-tag on oligomerization, we conducted a control with the tag removed in the in vitro dimerization assay and the result show no difference (Figure S13).
5) Why were the pulldown experiments done with MBP-MxDnaKs? Can you show a negative control between the MBP and the JDPs to rule out this interaction? It will be more suitable to do the pulldown assays with the purified MxDnaK´s without the His-tags (and the His-tags JDP that were employed).
Answer: Thanks for your suggestion. As mentioned above, there are some flaws in the experimental design of the pulldown assay. Thus, we employed the nLuc assay as an alternative to the pulldown experiment to validate the interaction between MxDnaKs and JDPs (Figure S9).
Minor comments:
- E. coli´s DnaK is only essential in heat shock conditions and for lambda phage cycle. If MxDnaK1 is similar to this Hsp70, why the substitution of its NBD for the NBD MxDnaK2 would be lethal for bacterial growth?
Answer: Thanks for the comments. As you correctly point out, DnaK is nonessential in E. coli. But in some other bacteria, DnaK also plays an essential role in cell growth for different reasons 10-12. In our previous studies, we determined that MxDnaK1 is essential in M. xanthus DK1622, and the MxDnaK2 is nonessential. In this study, we performed region swapping and found that only the NBD of MxDnaK1 was unreplaceable. In our opinions, the result indicated that NBD play important roles in the functional diversity between MxDnaK1 and MxDnaK2.
- I think that the writing should be revised and in the supporting information the captions of the figures should include more information.
Answer: Thanks a lot for the suggestion. We revised the manuscript and added more information in the legends of supplementary figures.
Reviewer #2 (Significance):
-General assessment: This is a nice piece of work which would benefit from revision to address the comments above. The authors showed the roles and differences between two DnaK in the same organism. They track these differences to the subdomains of the MxDnaK´s and co-chaperones. It will be interesting for future works to explore more deeply the co-chaperones and their interactions.
-Advance: I think that this manuscript fills a gap regarding the role of DnaK duplicated in bacterial strains. -Audience: I would say that the audience is broad and includes scientists interested in protein folding and chaperones, as well as myxobacteria.
- Rosenzweig, R., Nillegoda, N. B., Mayer, M. P. & Bukau, B. The Hsp70 chaperone network. Nat Rev Mol Cell Biol 20, 665-680, doi:10.1038/s41580-019-0133-3 (2019).
- Kampinga, H. H. & Craig, E. A. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol 11, 579-592, doi:10.1038/nrm2941 (2010).
- Calloni, G. et al. DnaK functions as a central hub in the E. coli chaperone network. Cell Rep 1, 251-264, doi:10.1016/j.celrep.2011.12.007 (2012).
- Dixon, A. S. et al. NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. ACS Chem Biol 11, 400-408, doi:10.1021/acschembio.5b00753 (2016).
- Fredriksson, A., Ballesteros, M., Dukan, S. & Nystrom, T. Defense against protein carbonylation by DnaK/DnaJ and proteases of the heat shock regulon. J Bacteriol 187, 4207-4213, doi:10.1128/JB.187.12.4207-4213.2005 (2005).
- Santra, M., Dill, K. A. & de Graff, A. M. R. How Do Chaperones Protect a Cell's Proteins from Oxidative Damage? Cell Syst 6, 743-751 e743, doi:10.1016/j.cels.2018.05.001 (2018).
- Fredriksson, A., Ballesteros, M., Dukan, S. & Nystrom, T. Induction of the heat shock regulon in response to increased mistranslation requires oxidative modification of the malformed proteins. Mol Microbiol 59, 350-359, doi:10.1111/j.1365-2958.2005.04947.x (2006).
- Chang, L., Thompson, A. D., Ung, P., Carlson, H. A. & Gestwicki, J. E. Mutagenesis reveals the complex relationships between ATPase rate and the chaperone activities of Escherichia coli heat shock protein 70 (Hsp70/DnaK). J Biol Chem 285, 21282-21291, doi:10.1074/jbc.M110.124149 (2010).
- Thompson, A. D., Bernard, S. M., Skiniotis, G. & Gestwicki, J. E. Visualization and functional analysis of the oligomeric states of Escherichia coli heat shock protein 70 (Hsp70/DnaK). Cell Stress Chaperones 17, 313-327, doi:10.1007/s12192-011-0307-1 (2012).
- Shonhai, A., Boshoff, A. & Blatch, G. L. The structural and functional diversity of Hsp70 proteins from Plasmodium falciparum. Protein Sci 16, 1803-1818, doi:10.1110/ps.072918107 (2007).
- Vermeersch, L. et al. On the duration of the microbial lag phase. Curr Genet 65, 721-727, doi:10.1007/s00294-019-00938-2 (2019).
- Burkholder, W. F. et al. Mutations in the C-terminal fragment of DnaK affecting peptide binding. Proc Natl Acad Sci U S A 93, 10632-10637, doi:10.1073/pnas.93.20.10632 (1996).
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary: This manuscript describes interesting studies of two paralogues of the E. coli Hsp70, DnaK, from of M. xanthus: MxDnaK1 and MxDnaK2. MxDnaK1 is similar to E. coli DnaK in terms of heat shock response, subcellular localization, etc. while MxDnaK2 is involved with membrane proteins and does not participate in the heat shock response. The interactome of the Mx DnaK´s are larger than that of E. coli DnaK, and their subcellular localization is also different. Regarding the differences between M. xanthus DnaK´s, MxDnaK2 prefers proteins with a higher hydrophobicity score, consistent with its role associated with membrane proteins. The phenotype of diverse mutants with domain swapping showed that the substitution of the NBD of MxDnaK2 for the NBD of MxDnaK1 led to similar phenotypes as the deletion of MxDnaK2 in terms of sporulation and S motility. Consistently, the interactomes of these variants were reduced in number of substrates in comparison with the wild type enzymes. No obvious effect was observed when the SBD´s subdomains were swept. Both MxDnaK interact with JDPs and NEF cochaperones. However, MxDnaK2 interacts only with one of the NEFs, and it depends on the NBD, and has one specific JDP, whichdepends on the beta-subdomain of the SBD (no information provided regarding NBD). MxDnaK1 interacts with both NEFs and has two specific JDPs, which also seems to depend on the beta subdomain of the SBD. Finally, a phylogenetic analysis reveals that the duplication of the dnak gene in Mx is correlated with the complexity of the proteome.
Major comments:
- The manuscript is very nice and interesting, although some of the authors' conclusions are perhaps not well supported by their data. For example: 1) In the pulldown experiments the lack of interaction between 2747-MxDnaK2, 3015-MxDnaK2 and 1145-MxDnaK1 should be shown in order to support the conclusion made in line 197-198, 2) The only evidence that the NBD of MxDnaK1 is essential for bacterial growth is that this mutation couldn´t be obtained in M. xanthus. However, it could be purified in E. coli. Could the authors do some experiments with the M. xanthus strain without the chromosomal MxDnaK1 and then introduce a plasmid with the mutated gene?
- All the experiments with purified proteins were done with MxDnaKs bearing His-tags. It doesn't say explicitly its position, but as they employed a pET28A it is likely that the tag is at the N-terminus, which is close to the linker region. As this tag might interfere, it should be removed for the experiments, or at least a control done with the tag removed.
- The authors state that MxDnaK dimerized in vitro with the NBD, and to disrupt the dimer they used 100 mM DTT, which is a very high concentration. As the protein has the His-tag, it should be removed to corroborate that it is not interfering with the dimerization.
- Why were the pulldown experiments done with MBP-MxDnaKs? Can you show a negative control between the MBP and the JDPs to rule out this interaction? It will be more suitable to do the pulldown assays with the purified MxDnaK´s without the His-tags (and the His-tags JDP that were employed).
Minor comments:
- E. coli´s DnaK is only essential in heat shock conditions and for lambda phage cycle. If MxDnaK1 is similar to this Hsp70, why the substitution of its NBD for the NBD MxDnaK2 would be lethal for bacterial growth?
- I think that the writing should be revised and in the supporting information the captions of the figures should include more information.
Significance
General assessment: This is a nice piece of work which would benefit from revision to address the comments above. The authors showed the roles and differences between two DnaK in the same organism. They track these differences to the subdomains of the MxDnaK´s and co-chaperones. It will be interesting for future works to explore more deeply the co-chaperones and their interactions.
Advance: I think that this manuscript fills a gap regarding the role of DnaK duplicated in bacterial strains.
Audience: I would say that the audience is broad and includes scientists interested in protein folding and chaperones, as well as myxobacteria.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
In this study, Pan et al. characterized two Hsp70 DnaKs from Myxococcus xanthus DK1622. Through determining interactomes, the authors defined the differences and similarities between these two DnaKs in interacting with co-chaperones and substrates. Using domain-swapping, the authors analyzed the domain requirements for their functions. Lastly, their bioinformatics analyses seem to suggest the presence of these two DnaKs (i.e., DnaK duplication) is due to the increase of proteomic complexity. Overall, the results are interesting although not surprising. As the authors pointed out, many organisms have multiple Hsp70s with different but overlapping functions. Although multiple experimental approaches were used, the manuscript is generally descriptive without revealing any major mechanistic insights.
- It is interesting MxDnaK1 seems to prefer cytosolic proteins while Mx-DnaK2 prefers inner membrane proteins. The domain-swapping experiments seem to suggest that the NBD is important for this difference. How NBD is important is not addressed. Is it due to ATP hydrolysis, NBD-SBD interaction, or co-chaperone interactions?
- About the interactome analysis, since apyrase was added to remove ATP, it's surprising multiple Hsp40s were found in their analysis. Hsp70-Hsp40 interaction is known to require ATP. This may suggest some of the proteins found in their interactome analysis are artifacts. The authors should perform negative controls for their interactome analysis, such as using a control antibody for their CO-IP and analyze any non-specific binding to their resin.<br /> In addition, since JDPs were pull-down, is it possible some of the substrates identified are actually substrates for JDPs, not binding directly to DnaKs?
- For Figure S7, the pull-down assay used His6-tagged JDPs. Ni resin is known to bind Hsp70s non-specifically. It's not surprising DnaK showed up in all the pull-down lanes, especially considering how much DnaK was over-expressed. For some pull-down lanes, the amount of DnaK is much more than that of JDPs, further indicating artifact. The author should include negative controls such as JDPs without His6-tag or any irrelevant protein with His6 tag.
- For the proposed dimer formation in Fig. 4C, there are multiple bands above the monomer bands. What are these forms? It seems the majority of the Cys residues that could form disulfide bonds are in the NBD of MxDnaK2 since constructs with MxDnaK2-NBD form some sort of high-MW bands above the monomer. Does MxDnaK1-NBD also contain Cys at the analogous positions? The fact that MxDnaK1 didn't show disulfide-bonded bands doesn't mean it doesn't form dimer. It depends on where the Cys residues are.<br /> It's nice the authors did Fig. 4D. However, the authors should include a positive control to show how strong the signal is for a true interaction before interpreting their results.
- line 48: "human HSC70 and HSP70 are 85% identical, and the phenotypes of their knockout mutants are different, which is consistent with their largely nonoverlapping substrates." The authors completely ignored that the promoters of HSC70 and HSP70 are very different.
- Line 69: "The two PRK00290 proteins, not the other Myxococcus Hsp70s, could alternatively compensate the functions of EcDnaK (DnaK of E. coli) for growth." Please add references for this statement.
- line 191: What's the mechanism for DnaK's role in oxidative stress? Is the disulfide bond formation in Fig. 4 related? Does disulfide-bond change the activity of DnaK?
- Fig. S9 seems redundant.
- line 263, "but the NBD exchange was almost equal to the deletion of the gene with respect to phenotypes." But, the mutant has >50% activity in Fig. 3F.
- line 221-226: the logic is not quite clear.
Minor concerns:
Please check spelling. There are some typos such as "HPPES" in the Methods.
Significance
In this study, Pan et al. characterized two Hsp70 DnaKs from Myxococcus xanthus DK1622. Through determining interactomes, the authors defined the differences and similarities between these two DnaKs in interacting with co-chaperones and substrates. Using domain-swapping, the authors analyzed the domain requirements for their functions. Lastly, their bioinformatics analyses seem to suggest the presence of these two DnaKs (i.e., DnaK duplication) is due to the increase of proteomic complexity. Overall, the results are interesting although not surprising. As the authors pointed out, many organisms have multiple Hsp70s with different but overlapping functions. Although multiple experimental approaches were used, the manuscript is generally descriptive without revealing any major mechanistic insights.
My areas of expertise are protein biochemistry, genetics, and structural biology on heat shock proteins.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1 (Evidence, reproducibility and clarity (Required)):
Summary: Kellner and Berlin present their research findings pertaining to the effect of GRIN2B variants that modify NMDA receptor function and pharmacology. While these mutations were published previously, the new manuscript provides a more thorough investigation into the effects that these variants pose when incorporated into heteromeric complexes with either wildtype GluN2B or GluN2A - NMDA receptors containing only a single mutated GluN2B subunits is more relevant to the disease cases because the associated patients are heterozygous for the variant. The authors achieved selective expression of receptor heteromeric complexes by utilising an established trafficking control system. The authors found that while a single variant subunit in the receptor complex is largely dominant in its effect on reducing glutamate potency of the NMDA receptor, it 's effect on receptor pharmacology varied. Unlike diheteromeric receptors containing mutated subunits, polyamine spermine potentiated GluN1/2B (but not GluN1/2A/2B) receptors that contained a single mutated GluN2B. In contrast, the neurosteroid, pregnenolone-sulfate (PS), was effective at potentiating the NMDA receptor currents (to varying degrees) regardless of the subunit composition. The potentiation of NMDA receptor currents by PS was also observed in neurons overexpressing the variants.
The techniques used in this study were appropriate to address the objectives and the overall effects are large, and generally convincing. I like the way the results are presented, although have a few (easily addressable) comments.
We thank the reviewer for the positive remarks on our manuscript.
Major comments:
#1 When incrementally adding drugs (e.g. traces in figures 5 and 6), it doesn't always appear like the response has plateaued before changing the solutions/drugs. Therefore, I am curious to what extent the effects observed are underestimated.
The reviewer is correct to note that some responses do not necessarily reach a plateau, despite our efforts reach steady-state (as shown in most figures, e.g., Figs. 1-4, 6b, etc.), in particular when applying pregnenolone-sulfate (PS) (Fig. 5a, all traces in middle and bottom rows). However, in several instances, this was unobtainable due the very slow effect of the neurosteroid (its mode of action is from within the membrane) and the very large size of the cell (~1 mm). For these reasons, these experiments mandated excessively long exposures (~minutes) of oocytes to glutamate and PS (see scale bar- 20 secs) to try to reach steady-state, however this also caused deterioration to some cells (which did not return to baseline- and were therefore discarded). Thus, we eventually converged on settings whereby we did not expose oocytes to more than 4 minutes of the drug. Nevertheless, to try to estimate the extent of the underestimation (if any), we fitted the currents (standard mono-exponential fit, as previously reported1–3 (Suppl. 5a). We found that our application times of PS were, on average, three time the response’s time constants (tau) (Suppl. 5b), and we found a very weak relationship (R2 = 0.09) between the response to PS and time of its application (Suppl. 5c). These are now explicitly mentioned in the text (line #203), and in the legend of Suppl. 5. These thereby suggest that the reaction reached approximately 95% (1 - 1/e^3) of the steady-state value, and we are therefore confident that we have very small, if any, underestimation the extent of PS potentiation.
2 Also, in relation to figure 6, to what extent does agonist application cause desensitization here? Looking at traces in Figure 6b it appears that there is some desensitization and it isn’t clear to what extent this persists during the solution changes.
Agonist desensitization of NMDARs-currents is a well-known phenomenon, but it is very well established that it is not always observed in cells, including neurons (e.g., 4–7). In general, we did not observe very frequent desensitization’s (we provide a larger variety of traces of desensitizing and non-desensitizing currents (Fig. 6b Suppl. 7e and Suppl. 8a). Nevertheless, we explicitly note that in neurons, currents that didn’t reach steady-state after application of 100 mM NMDA were excluded from analysis (Methods - Patch clamping of cultured neurons, line #474), and in most cases desensitization was minor (or absent) following application of 100 mM NMDA and 100 mM PS (Fig. 6b).
3 Could the authors conduct/show the controls where NMDA alone (for 50-60s), or NMDA followed by PE-S (without ifenprodil).
These recordings are now shown in Fig. 6b and Suppl. 8a, (as opposed to Suppl. 7e).
#4 Finally, figure 5 shows the effect of the neurosteroid (and ifenprodil) on NMDA-evoked currents in neurons overexpressing the GluN2B variants in neurons. However, there currents probably reflect a mixture of extrasynaptic and synaptic receptors. To what extent are synaptic NMDA receptors affected by the variants?
To show the extent of the effect of the variants over synaptic receptors, we recorded miniature NMDA-dependent EPSCs; mEPSCNMDA), as described in our previous report8. We find that the varinats completely eliminate the appearance of mEPSCs (Suppl. 7a, b). Change in minis’ frequency is not the result of a presynaptic change or a change in synapse number9, as we have shown that AMPAR-mEPSC frequency was unaffected by the variants (i.e., synapse number and probability of presynaptic release are unchanged by the variants).
To further address this, we also explored the relative synaptic vs. extrasynaptic distribution of the variants by using the established MK-801-protocol (to block all synaptic receptors during spontaneous activity, leaving extrasynaptic receptors unblocked)10,11. In neurons overexpressing the GluN2B-*wt* subunit, we obtained an extrasynaptic fraction of 38%, highly consistent with previous reports12,13. Overexpression of the variants, however, yielded a significantly and higher fraction (~50%) of the remaining current, supposedly suggesting more variant receptors at extrasynaptic loci (__Suppl. 8b, c__). However, due to the experimental settings we have chosen, the results from this experiment represent quite the inverse when involving extreme LoF variants. Firstly, 100 mM NMDA does not saturate variant receptors (whether pure, mixed di- or tri-heteromers, see __Table 1__). Secondly, normal neurotransmission does not open synaptic receptors containing mutant GluN2B-subunits, attested by the complete absence of mEPSCs (see __Suppl. 7a, b and __8,9). Thus, during the 10 minutes exposure to MK-801, only (mostly) purely *wt* receptors are blocked by spontaneous synaptic activity, and thus the second bout of 100 mM NMDA solely exposes the remaining *wt*-receptors. An increase in the number reflects more *wt*-receptors at the extrasynapse than the synapse. Thus, the observed increase in the fraction of extrasynaptic receptors in neurons overexpressing the variants, implies that the number of *wt*-receptors is necessarily decreased from the synapse and increases at the extrasynapse. We deem this to ensue due to the incorporation of the variants at the synapse. This increase cannot be explained by an overall increase in membrane expression of *wt*-receptors in neurons overexpressing the variants, as these cells show a strong reduction in Imax (see __Fig. 6c and Suppl. 7e__). This is now detailed in the text (lines #270-290).
Minor comments:
5 Looking at the fits in the graph of Figure 2b it appears that the slope on the concentration response curves is less steep for the mixed 2B-diheteromeric NMDA receptors. How much are the Hill coefficients changing and can this be interpreted to provide more mechanistic insight? Wouldn't it make sense to include the Hill coefficients in Table 1?
We agree with the reviewer’s observation. Actually, the mixed di-heteromers have a similar Hill coefficient (nH) as the purely di-heteromeric GluN2Bwt receptors (see Table 1), and these show the typical near nH ~1 (e.g., 14–16). The only diverging groups are the purely di-heteromeric variant-containing channels (G689C/S only containing receptors; nH~2). Although these may suggest positive cooperation between the subunits, we are less inclined to infer insights from the latter owing to the fact that we limited our examination to 10 mM glutamate (we limit exposure of oocytes to 10 mM glutamate due to artifacts arising past this concentration, as discussed in Kellner et al.8: Fig. 2—figure supplement 1). (this description is now mentioned in page lines #149, 318, 319).
6 The authors illustrate the changes in potency by the shift in the concentration response curves, but is there any change in efficacy? A simple way to illustrate this would be also present a simple graph showing the maximum current amplitudes (i.e. to 10 mM glutamate) for each of the receptor complexes.
We now provide these data in (Suppl. 2a, b). We would like to note however that the expression pattern of the tailed-receptors (i.e., subunits with carboxy-termini tagged with C1/C2 tails, see Fig. 1a) are less expressive in general when compared with the native subunits (Suppl. 2c). This description is detailed in lines# 162-166.
#7 The authors characterize the 'apparent' affinity (or potency) of the receptor using concentration-response curves, but numerous points in the manuscript refer to changes in affinity. None of the experiments shown directly measure affinity (which would require ligand-binding assays) and so the use of the word affinity is inaccurate/misleading. I suggest the authors replace the instances of the word 'affinity' with 'potency'.
We apologize for the confusion surrounding our use of the term affinity. In fact, we do initially define this term in introduction (page #4): “apparent glutamate affinity (EC50)” to differentiate from affinity (KD). Regardless, and to avoid confusion, we replaced all terms, as suggested by reviewer to potency.
#8 In the third line of the abstract, the authors wrote, 'for which there are no treatments' in relation to GRINopathies. My understanding is that there are symptomatic treatments but that there are no disease-modifying treatments.
Indeed, all current treatments are supportive, rather than provide a bona fide cure or disease-modifying. These are now better defined in the abstract.
#9 The authors have interchangeably used the terms NMDAR or GluNRs throughout the manuscript. I suggest sticking to one of these terms. I would suggest NMDARs since this is less likely to be misread as a a specific NMDA receptor subunit.
Agreed and corrected throughout manuscript.
#10 Typos: 1) Results paragraph 2 sentence one: 'We thereby produced GluN2B-wt, GluN2B-G689C and GluN2B-G689S subunits tagged with C1 or C2, co-expressed these along with the GluN1a-wt subunits in...') Results paragraph 2: '...but these were mainly noticeable when oocytes are were exposed to high (saturating) glutamate concentrations...' 3) Last sentence in the second to last paragraph of the results section entitled 'Mixed di-and tri-heteromeric channels...': 'This , PS may serve to rescue...' 4) Last sentence in last paragraph of the results section entitled 'Mixed di-and tri-heteromeric channels...': 'Despite the latter, we found no evidence for any direct effect of three different physiologically relevant concentrations of the drug on di- or tri-heteromeric receptors'
All typos corrected.
#11 Figures 1e, 2b, 3b: it would be helpful to add a legend to the graph so that the curves can be interpreted without having to read through the figure legend.
Corrected.
#12 The bar graphs in Figure 6 show individual data points but those in figures 4b and 5b don't. Can the authors please add the data points to these graph.
Individual data points have been added.
#13 It would be helpful to reviewers that future manuscripts by the authors include page numbers and line numbers.
Included.
**Referees cross-commenting**
#14 Reviewers 2 and 3 highlight an important issue concerning figure 6 and the extent to which the overexpressed variants subunits can compete and assemble with endogenous NMDA receptors (unlike the system where the surface expression of specific receptor complexes is controlled). Indeed in the recent paper by the same authors, the two variants differed in their surface expression (in HEK cells), with G689C expressing particularly poorly. With reference to the second minor comment of Reviewer 1, the maximum current amplitudes would of course need to be normalized to cell surface expression of the receptor to gain any insight into efficacy.
We provide maximal current amplitudes (Imax) as a proxy for expression level as typically done (e.g.,8,17). These are now shown in Suppl. 2a, b (and see our response to comment #6, above). We would like to emphasize that we find it challenging to gain insights about efficacy of the variants in neuronal synapses, as we purposefully express non-C1/C2 tagged subunits in neurons (as we covet assembly of the variants with endogenous subunits). Moreover, the C1/C2-tagged subunits (whether wt or variants) are less expressive compared to their non-tagged NMDAR-counterparts. For instance, tagged GluN2B-wt subunits express at ~50% compared to non-tagged GluN2B wt subunits (Suppl. 2c). Thus, we find that efficacy of the C1/C2 tagged-subunits is less relatable to the non-tagged subunits (which are used in neurons and likely more relevant to the disease).
Despite the latter, we deem that we have specifically addressed this issue by measuring miniature EPSCs (mEPSCs) (see our reply to comment #4, Suppl. 7a, b). Briefly, even though the non-tagged G689C expresses at ~40% compared to other subunits (in oocytes and mammalian cells8), in neurons it engenders a robust (and highly significant) negative effect over synaptic currents (mEPSCs), as strong as the G689S-variant which expresses much more robustly (non-tagged G689S expresses to same extent as wt subunits). This demonstrates that the reduced efficacy the tagged subunits is less relatable to the non-tagged subunits and, importantly, it does not hinder the variants’ ability to incorporate within the synapse and affect function (i.e., exert a dominant negative effect). Here, we extend these observations towards the major postnatal channel subtype, namely tri-heteromers (2A/2B*), and therefore demonstrate that the robust dominant negative effect of G689C and G689S variants is likely due to their ability to incorporate within the predominant receptor subtype at the synapse (Suppl. 8).
Reviewer #1 (Significance (Required)):
This study emphasizes the complex pattern of effects that variants can have on glutamate receptor function and pharmacology, especially considering the context of receptor subunit composition. The authors have followed up their previous findings on the same mutants (Kellner et al, 2021, Elife), but used a trafficking control system here to characterize properties of mutated receptor complexes that are most likely to exist in neurons. The authors show that the defective currents mediated by NMDA receptors containing a loss-of-function GluN2B variant can be enhanced by neurosteroids (and in the case of GluN1/2B receptors, polyamines also). Development and approval of neurosteroids for the clinic would be required for the findings to translate to a therapy for patients. Readers should also be aware that neurosteroids act on other receptors too (e.g. GABA receptors), which could complicate the outcome. The expertise of the reviewer is in glutamate receptors and synaptic transmission.
We agree with the reviewer’s comment pertaining to challenges in translating PS to the clinic. Indeed, we explicitly mentioned its inhibitory effect on GABAA receptors (see line #366-367 and reference 18), as well as note its potential negative effect over GluN2C/D-containing receptors (line #365 and reference 19). We further describe alternative neurosteroids and means to bypass the limitations of PS, for instance by use of 24(S)-hydroxycholesterol6,18 or synthetic analogues (SGE-201, SGE-301)6. Lastly, we also propose a novel therapeutic approach, for which we did not find any mentions in the literature with regard to GRINopathies, consisting of the use of the FDA-approved Efavirenz (anti-retroviral compound20) to promote activity of cytochrome P450 46A1 (CYP46A1) to increase amounts of 24-S in the brain (discussion, lines #370-383).
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
#1 The objective of this paper is to assess whether a single mutated subunit of GRIN can affect the function of various forms of NMDA receptors. In particular, this study investigates the functional consequences of a GRIN variant when assembled within tri-heteromers, containing 2 GluN1, 1 GluN2A and 1 GluN2B subunits, the major postnatal receptor type. For this purpose, the authors artificially forced the subunits to associate in predefined complexes, using chimeras of GRIN subunits fused to GABAb receptor retention control sites at the endoplasmic reticulum. This trick allows to control the stoichiometry of the channels at the membrane and thus to focus on the function of a single type of NMDA receptor.The take home message of the paper is that a single GluN2B‐variant, whether assembled with a GluN2B‐wt subunit to form mixed di‐heteromer or with a GluN2A‐wt‐subunit (tri‐heteromer), strongly impairs the receptor functioning, as reported by a decrease of the apparent glutamate affinity of the receptor.
Altogether, this is a straightforward study of great interest for the GRIN community.
We greatly appreciate the reviewer’s comment about the relevance of our work towards the GRIN-community.
2 However, the way the background and purpose of the study (title and abstract) are presented is a bit confusing for non-specialists and could be easily improved. Technical information, which is crucial to validate the conclusions drawn from data analysis, should be added to the article. Some additional experiments are suggested to consolidate the work. Finally, additional discussion points are strongly encouraged.
We apologize for not making the paper more accessible to a broader readership. We did so for the sake of brevity. Nevertheless, we have re-written major parts of the manuscript to address this issue and retitled the report: “Rescuing Tri-Heteromeric NMDA Receptor Function: The potential of Pregnenolone-Sulfate in Loss-of-Function GRIN2B Mutations”.
Specific comments
Abstract / Title:
3 This work shows that a single GRIN variant impairs the function of various forms of NMDA receptors. Several sentences in the title and the abstract are confusing for a non-specialized audience. "Two extreme Loss‐of‐Function GRIN2B‐mutations are detrimental to triheteromeric NMDAR‐function, but rescued by pregnanolone‐sulfate." "Here, we have systematically examined how two de novo GRIN2B variants (G689C and G689S) affect the function of di‐ and tri‐heteromers." The number of variants tested is not of capital importance in the title, especially because one could believe that both are tested at the same time; similarly, when variants are named in the abstract, the fact that only 1 variant is studied at a time should be clarified (G689C OR G689S). Indeed, the problem is obvious to those familiar with GRIN disorders, but if this paper is to be published in a journal reaching a large audience rather than a specialized audience, the title of the paper should be modified.
As noted in our reply to comment #1 of this reviewer, we apologize for not making the paper more accessible and have therefore changed the title and re-written major parts of the manuscript to address this issue. We would like to note that we appreciate the reviewer’s comment and intent to increase the readership of our manuscript.
#4 "We find that the inclusion of a single GluN2B‐variant within mixed di‐ or tri‐heteromeric channels is sufficient to prompt a strong reduction in the receptors' glutamate affinity, but these reductions are not as drastic as in purely di‐heterometric receptors containing two copies of the variants. This observation is supported by the ability of a GluN2B‐selective potentiator (spermine) to potentiate mixed diheteromeric channels." Please, clarify the link between the two sentences. How do spermin potentiation of mixed diheteromeric channels supports the observation that the inclusion of a single GluN2B‐variant has less effect than the inclusion of two variants?
Our intention was to highlight that mixed di-heteromeric channels (2B/2B*) are less “damaged” (this is the link) than purely di-heteromeric channels (2B*/2B*).Explicitly mixed di-heteromers show less reduction in glutamate potency AND are also spermine-responsive, whereas purely mutant di-heteromers (2B*/2B*) show reduced potency, BUT do not respond to spermine at all. We have rephrased the sentences in our current manuscript to be clearer:
For instance: The positive responses of mixed di-heteromers, compared to the null effect over pure di-heteromers, is likely the result of the restored pH-sensitivity of mixed di-heteromers (Suppl. 3). This was surprising as the minimal and essential rules of engagement for potentiation by spermine are not well established, particularly in the case of tri-heteromers21,22 (see discussion, lines #341-353).
Methods
#5 All this study is based on the use of a unique ER‐retention technique to limit expression of a desired receptor‐population at the membrane of cells. According to the ER system retention of GABAb receptor, used in this study, while C1/C1-fused subunits are retained in the ER, C2/C2 reach the cell surface and the association of C1/C2 in the ER enables cell-surface targeting of the heterodimer. However, GB2 does not contain any retention signal and can reach the cell surface in the absence of GB1, as a functionally inactive homo-dimer (doi: 10.1042/BJ20041435). If there is an experimental trick that prevents the addressing of C2/C2 to the cell membrane, it should be specified and explained. This is critically important for understanding which receptor populations the data are derived from: receptors containing C1/C2 fused subunits only as stated by the authors, or C1/C2 and C2/C2 fused subunits?
We base our experiments on two seminal reports—23,24—that have developed this unique method (which we also refer to in the text, lines# 112-116). Briefly, the method employs the binding motifs of GABAB1 (GB1) and GB2 subunits and ER-retention motifs (these are now better detailed in Methods section, line # 448). Previous reports explicitly demonstrate that C1/C1- OR C2/C2-containing receptors do not reach the plasma (or very minimally) and we have reproduced these data with our variants (C1/C1: Suppl. 1a-d; C2/C2: Fig. 1a-c).
Figures #6 NMDA-receptor current amplitude should be normalized by the membrane expression of the receptors. A preliminary experiment should measure the effective cell surface expression of each of the subunits in the different transfection conditions.
To address the effective cell surface expression, we employed Imax as a proxy for functional expression (e.g.,8,17). These are now shown in Suppl. 2a, b (and see our response to reviewer 1, comments #6 and 14). Expectedly, we find significantly reduced efficacy by the varinats compared to wt-receptors, and the purely mutant di-heteromeric receptors exhibit the weakest efficacy. We have also addressed this issue by measuring miniature EPSCs (mEPSCs) (see our reply to reviewer 1, comment #4,). We find the variants to abolish mEPSCNMDA frequency (Suppl. 7a, b). This shows that the variants’ reduced efficacy translates to elimination of synaptic activity (dominant negative effect) (also seen in Suppl. 8).
#7 Fig.1a
The scheme should include C2-C2 complexes and mention whether these complexes are expressed at the cell surface (see previous and following comments).
As noted in our reply to comment #5 of this reviewer (above), C2/C2-containing receptors do not reach the plasma membrane (Fig. 1a-c). To avoid confusion, we have now added this scheme to the cartoon presented in Fig. 1a and have provided a more detailed description of the method and clones produced in the Methods section (line # 448).
#8 Fig.1b and c
Current from cells transfected with GluN2B‐wt‐C1 and GluN2B‐wt‐C2 should be compared to current expressed in cells expressing untagged receptor subunits: GluN2B‐wt Current from cells transfected with GluN2B‐wt‐C1 alone should be shown as well (although expected to be retained in the ER) (as performed for GluN2A‐wt‐C1 GluN2B‐wt‐C1 in suppl Fig. 1a)
Current comparisons of oocytes expressing tagged GluN2B‐wt‐C1 and GluN2B‐wt‐C2 and non-tagged GluN2B‐wt are now demonstrated in Suppl. 2c. The results indicate that the “tags” (C1 and C2) affect the expression of the subunits. We have also added a sample trace of current from a cell expressing the GluN2B‐wt‐C1 alone (Fig. 1b).
9 How could you explain the null current from cells transfected with GluN2B‐wt‐C2 alone (Fig.1b middle, and 1c)? since GB2 does not contain any retention signal and can reach the cell surface in the absence of GB1, GluN2B‐wt‐C2 is supposed to reach the cell surface. This is a very important point to clarify (I am probably missing a technical detail) because if the sub-unit tagged with C2 does reach the cell surface, then all the results and conclusions drawn from the C1-C2 conditions are wrong and could be attributed to a mix of complexes containing either C1-C2 or C2-C2.
We now realize that the reviewer was missing a crucial technical detail, namely how the clones are designed. Briefly, all clones have ER retention motifs and cannot reach plasma membrane unless they necessarily assemble as C1/C223,24. Also, please see our replies to comments #5, 7 to this reviewer (and Methods section, line # 448).
My following comments are based on the assumption that only receptors containing C1-C2 tagged subunits reach the membrane (as assumed by the authors and suggested in Figure 1b middle), but explanations should absolutely be provided to convince the reader. Fig. 4a and 5a (see our above replies to comments #5, 7 and 9; and references 23,24).
#10 Please, keep the current scale constant between all current illustrations within the same figure (4a and 5a). Indeed, not only the Spermin- or SP- induced potentiation is an important data (which is presently quantified on the histograms of fig. 4b and 5b) but also knowing whether the amount of current recorded in cells expressing one mutant subunit in presence of SP (for example GluN2A‐wt‐C1 GluN2B‐G689S‐C2) is comparable to the current recorded in wt receptor-expressing cells (GluN2A‐wt‐C1 GluN2B‐wt‐C2) in absence of SP would be an excellent added value for the paper. A special figure could quantify this rescue effect of SP, measuring and comparing the mean currents recorded in these conditions (one current illustration is not sufficient given variations between similar samples). By the way 5mM glutamate might be an excessive concentration. At 1mM, the expected synaptic concentration of glutamate following action potential, according to figures 3 and Suppl1 the response of the mutated receptor is much lower than that of the WT which is already almost maximal. In these conditions, SP-induced potentiation by a factor of two of GluN2A‐wt‐C1 GluN2B‐G689S‐C2 current could be equivalent to control currents recorded in GluN2A‐wt‐C1 GluN2B‐wt‐C2 cells.
We have rescaled all current amplitudes in Figs. 4 and 5 to be identical in size for easier comparison.
We have added all current amplitudes to try to examine the rescue effect of the two drugs in cell overexpressing a specific channel subtype, as requested (Suppl. 4). We find that; indeed, the potentiated currents of the mutant receptors reach (or even surpass) the basal Imax (i.e., current before potentiation) of the non-mutated receptors (Suppl. 4, dashed statistics bar).
In neurons, we address this in two ways. First, we show that the total NMDA-current is reduced by expression of the variants, and this current is “normalized” by PS (Fig. 6a-c). Similar reductions in Imax (by the variants) are shown in Suppl. 7e (to provide more examples). Secondly, neurotransmission (i.e., 1 mM glutamate25,26) is not sufficient for activating mutant receptors, certainly not pre-di-heteromers (see Table1, EC50 and Suppl. 7a, b- no mEPSCs)27–29. Therefore, 5 mM was required. Together, these strongly suggest that PS may normalize the currents of different receptors that respond to PS (under physiological settings and not 1- or 5mM NMDA). As suggested by the reviewer, there are many subtypes, and some may be activated by ambient glutamate (as suggested by application of PS onto neurons without opening the receptors by NMDA; see Suppl. 7c, d).
#11 Fig. 6
Figure 6 is not convincing because cultured hippocampal neurons do express endogenous NMDA receptors. To what extent the recording currents are affected by endogenous, non-mutated GluN2B subunits? Western Blots showing an extinction of endogenous subunits expression when transfected tagged subunits are competitively expressed would be required.
We have previously shown that the two variants incorporate very efficiently within synapses, causing a very robust elimination of synaptic currents (by measuring miniature NMDA-dependent EPSCs; minis) [see Fig. 8 in Kellner et al. eLIFE, 202127, and see review by Sabo et al.9 ). Change in minis’ frequency can be interpreted as either a presynaptic change or a change in synapse number, however we observed that AMPAR-mEPSC frequency was unaffected by these variants. These imply that synapse number and probability of release are unchanged by the variants. As the experiments are performed in wild-type neurons, (which express wild-type GluN2A and -2B), the dramatic effects we observed on minis suggests a dominant-negative effect of these disease-associated GluN2B variants. These are consistent with our observations that mutant subunits can co-assemble with wild-type GluN2B and/or GluN2A subunits. We have now reproduced this experiment (in fact, we employ this strategy prior each experiment to ensure expression of the variants) (Suppl. 7a, b). This thereby shows that there are no available wt-receptors at the synapse.
As there are various pools of NMDARs at synaptic and extrasynaptic sites, we did not think that a western blot would sufficiently differentiate between the latter, and thereby would not provide insight about extinction of wt-receptors (which could be simply pushed to other sites compared to synapse). Moreover, the intracellular pool of receptors is much larger than the amount of NMDARs that can be detected at the membrane (e.g., 30,31), and therefore electrophysiology seemed to be a better means to monitor membrane receptors only:
Thus, to examine the distribution of the variants between synaptic- and extrasynaptic loci, we employed a standard procedure consisting of the use of the activity-dependent blocker MK-801 (Methods). Briefly, neurons were persistently bathed in TTX during which they were probed for Imax using 100 mM NMDA (to refrain from activating other GluRs), followed by application of MK-801 for 10 minutes to exclusively blocks synaptic receptors (that open following action-potential independent miniature neurotransmission). This thereby spares all extrasynaptic receptors from being blocked by MK-801, which are subsequently revealed by a second application of 100 mM NMDA (Suppl. 8a, inset)12. In neurons overexpressing the GluN2B-wt subunit, we obtained an extrasynaptic fraction of 38%, highly consistent with previous reports12,13. Overexpression of the variants, however, yielded a significantly and higher fraction (~50%) of remaining current (Suppl. 8b, c), but instead of reflecting a larger pool of extrasynaptic receptors, the experiment represents quite the inverse when involving LoF variants. Firstly, 100 mM NMDA does not saturate variant receptors (whether pure, mixed di- or tri-heteromers, see Table 1). Secondly, normal neurotransmission does not open synaptic receptors containing mutant GluN2B-subunits, attested by the complete absence of mEPSCs (see Suppl. 7). Thus, during the 10 minutes exposure to MK-801, only wt receptors are blocked by spontaneous synaptic activity, and thus the second bout of 100 mM NMDA solely exposes the remaining wt-receptors at the extrasynapse. Thus, the observed increase in the fraction of extrasynaptic receptors, in neurons overexpressing the variants, implies that the number of wt-receptors is necessarily decreased from the synapse and increases at the extrasynapse, most likely due to the incorporation of the variants at the synapse. This increase cannot be explained by an overall increase in membrane expression of wt-receptors in neurons overexpressing the variants, as these cells show, yet again, a strong reduction in Imax as seen above (see Fig. 6c and Suppl. 7e) (lLines #270-291). These thereby suggest that purely wt-receptors are not necessarily eliminated from the membrane (extinct), rather pushed outside of the synapse.
12 Fig.6b “PE-S” on the graph should be replaced by “PS”
Typo corrected.
Discussion #13 The authors are surprised by the fact (Fig.2) that 1 variant reduces the apparent glutamate affinity of the receptor, but not as much as 2 variants, despite the fact that "NMDARs opening requires all four subunits to be liganded (i.e., occupied by a ligand) which implies that the least affine subunit should have dominated the final affinity of the receptor". I agree that the difference is noticeable, however the glutamate affinity for receptors containing 1 variant is much closer to that of receptors containing 2 variants than that of wild-type receptors. Hence, the results obtained do not seem so surprising and could result, as rightly explained by the authors from a possible cooperativity between the subunits.
We agree with the reviewer that glutamate potency of receptors containing 1 variant subunit is much closer to that of receptors containing 2 variant subunits. However, we maintain our surprise because we expected it to equal (not just close) to the potency of the least affine subunit (the limiting factor). This is based on the notion that all four subunits need to be liganded for channel opening4,32–34. We gently raise the possibility of potential cooperativity (Table 1, see Hill-coefficient and 33,35,36), as well as mention that this may also stem from the variants’ lower proton sensitivity (Suppl. 3), which has also been shown to promote motions of the ATD (amino terminal domain) and increase open probability (positive cooperativity)36. Nevertheless, we are very careful with interpreting the Hill coefficient , as we limited exposure of oocytes to 10 mM glutamate due to artifacts arising past this concentration (see Kellner et al.8: Fig. 2—figure supplement 1). This description is now mentioned in page lines #149, 318, 319. Thus, even the slightest underestimation of the maximal reposnse would surely affect the slope.
#14 On the other hand, the data in Figure 6 are much more difficult to interpret and reconcile with the nature of the expressed receptor subunits (which this time is not controlled) nor their association within the same receptor. However, this aspect, which is essential to the understanding of the consequences of 1 variant on neuronal signalling, is not discussed: Whatever the stoichiometry of the complexes in the heterozygous disease, the mutated and wild type GluN2B subunits coexist in the same cell: Either within the same di-heteromeric complexes GluN2B-wt + GluN2B-mutant, or in separate complexes but nevertheless expressed in the same cell, in di heteromeric (GluN2B-wt + GluN2B-wt and GluN2B-mutant + GluN2B-mutant); or tri-heteromeric (GluN2A-wt + GluN2B-wt and GluN2A-wt + GluN2B-mutant) complexes. Assuming that half of the complexes remain wild-type, e.g. (GluN2A-wt + GluN2B-wt and GluN2A-wt + GluN2B-mutant) we would expect (Fig. 6) a small decrease in NMDA current (carried only by the half that expresses the mutated subunit, and whose function is not zero but only decreased by about 20% in response to 5 mM Glutamate, Fig. 3b). The same reasoning applies to the di-heteromeric conditions (GluN2B-wt + GluN2B-wt; GluN2B-mutant + GluN2B-mutant), here again the decrease observed Fig. 6b is difficult to reconcile with the responses measured Fig. 2b.
In other words, how to explain a 50% decrease of the currents, instead of the 10% expected by the previous reasoning. In this experiment we do not know which subunits are expressed, their proportions, nor how they are associated in functional complexes, which makes the interpretation of the data impossible. The only explanation, far-fetched, for 50 % decrease would be that the complexes were to contain all (or the vast majority) 1 wild-type subunits associated with 1 variant, then a homogeneous 50% reduction in current could be expected. But this extreme condition could only be possible in the case of di-heteromers, which is unlikely the case in Fig.6 as GluN2A currents are measured in presence of Ifenprodil. To conclude
1) the comparison of the currents in transfected and non-transfected neurons does not make sense in figure 6b which is not convincing because we do not know the nature of the currents actually measured. A comparison in controlled condition would make more sense (as I suggested in the criticism of figures 4, 5).
2) The reality of the combinations of expression and association between subunits within different complexes expressed in the same cell must be considered and taken into account in the interpretation of the data. Undoubtedly, the means of restoring the NMDA current will be different depending on the presence of mutated subunits in all functional channels or not.
Indeed, neurons express a variety of different combinations of channel stoichiometry, including following transfection with the variants. We do find find that the effect on whole-cell current is indeed ~50% (Fig. 6b, c), thereby safe to assume that 50% remain “wt”, but we do not know how they distribute between synaptic and extrasynaptic loci. Our results however argue against 50% remaining receptors at the synapse. First, mEPSCNMDA disappear (Suppl. 7a, b and see reply to comment #11 of this reviewer), but wt-receptors are still at the membrane, and they seem to be moving out of synapse (Suppl. 8). Thus, we can only state with higher certainty that the variant subunits are very efficient in incorporating within mixed or pure receptors, especially at the synapse.
We also consider that the reduction in the whole-cell current observed in __Fig. 6b, c__ is not due to the remaining 50% GluN2B-*wt*-containing receptors, rather likely due to other variants, notably GluN2A, which are more prominent at postnatal stages37, such as in our case. In support, we see a large remaining current after saturating ifenprodil application (__Suppl. 7 e, f__)38. Thus, the variants incorporate within all 2A/2B membrane receptors, at the synapse and outside it (i.e., extrasynaptic) (see __Suppl. 8, c__).
**Referees cross-commenting**
The referees' comments are highly relevant. In particular, referee 3's comment 1 seems very interesting because it may help to better understand the discrepancy in the results observed in neurons, i.e. a 50% decrease in the currents induced by the expression of the mutant and wild type subunits in the same cells, whereas theoretically one would expect a 10% decrease of this current (cf. referee 2's 2nd comment in the discussion section). This comment 1 of referee 3 indeed stresses the fact that the control (non-transfected neurons) to which the heterozygous condition is compared is not the correct control, which should rather be neurons transfected with wild type receptor subunits. More generally, this comment underlines the importance of monitoring the effective membrane expression of the different subunits in each of the experimental conditions in order to be able to compare conditions and draw conclusions.
We initially did not perform this control as the literature paints a clear picture whereby expression of the GluN2B-subunit (without adding excess of the GluN1 subunit) does not instigate a robust increase in surface expression of NMDARs (and thus current remains the ~same) 4,39–43, and see our reply to comment #14 (above), and reviewer 3 comment 1 (below). Nevertheless, we have now performed this test by overexpressing GluN2B-wt. In support of previous reports, we do not find any statistical difference in current size between non-transfected neurons and neurons solely overexpressing the GluN2B-wt subunit (Fig. 6a, b). Furthermore, application of PS onto naïve or GluN2Bwt expressing neurons yields identical currents (Imax) and potentiation (Fig. 6c, d). These argue that we did not obtain “overexpression”.
We suggest that the 50% reduction in current size between neurons expressing the mutant and wt expressing neurons stems from the integration of mutant subunits and their dominant negative effect. Evidence for this incorporation is provided by the very strong reduction in synaptic currents (suppl 7a, b), and the supposedly higher abundance of wt-containing receptors in extrasynaptic regions (see reviewer 1 comment 4 and suppl 8). This is
Reviewer #2 (Significance required):
The novelty of the study, is to evaluate the consequences of a single mutated subunit within NMDA receptors affected by GRIN variant, to mimic the heterozygous condition of GRIN encephalopathies, this is of potential value for the field and the interest could also be extended to other genetic diseases (at least the experimental way to study the functioning of only one desired stoichiometric configuration). The strength of this paper is precisely to isolate technically and to study the functioning of a desired stoichiometric configuration only. The main limitation of the paper is the interpretation that the authors make of their data in a physio-pathological context. This work could be of interest for general audience, providing the title and summary are slightly modified. My area of expertise could not be closer to the topic of the article: Glutamate receptors; GRIN; molecular tinkering, cell culture, electrophysiology, receptor stoichiometry...
We thank the reviewer for noting the value in our work and its potential contribution and interest to the field and other diseases. Per reviewer’s suggestion, we have modified the title and text to suit a larger audience.
Reviewer #3 (Evidence, reproducibility and clarity (Required):
This paper is a follow up of an earlier paper published by the group (Kellner et al., eLife 2021), which aimed at characterizing the functional properties of two de novo GluN2B mutations in patients suffering from severe pediatric diseases, GluN2B-G689C and -G689S. NMDA receptors (NMDARs) are tetramers composed of two GluN1 and two GluN2 subunits. A single receptor can incorporate either two identical GluN2 subunits (di-heteromers) or two different GluN2 subunits (tri-heteromers), leading to a large diversity of NMDAR subtypes. The main NMDAR subtypes in the adult forebrain are GluN1/GluN2A and GluN1/GluN2B di-heteromers, as well as GluN1/GluN2A/GluN2B tri-heteromers. While the exact proportions of these three subtypes are still contentious, there are evidence that in the adult N1/2A/2B tri-heteromers form the major population of synaptic NMDARs in the adult forebrain. In addition, patients bearing pathogenic mutations are often heterozygous for the mutation, giving rise to mixed NMDARs incorporating one mutated and one intact GluN2 subunit. In their previous paper, Kellner et al. had shown that purely di-heteromeric GluN1/GluN2B-G689C and -G689S mutants display a drastic (> 1,000-fold) decrease of glutamate sensitivity and a decrease of surface expression. In the current paper, the authors characterize the effects of the -G689C and -G689S mutations on N1/2A/2B tri-heteromeric receptors, as well as on mixed di-heteromeric GluN1/GluN2B receptors containing one copy of the wild-type GluN2B subunit and one copy of the mutated GluN2B subunit. They show that one copy of the mutant subunit, either within mixed diheteromeric or tri-heteromeric receptors, is sufficient to decrease drastically glutamate sensitivity, although the shift in glutamate EC50 is not as strong as in pure di-heteromeric receptors (≈ 500-fold). They furthermore explore strategies to counteract the hypofunction induced by these mutations by testing the effect of positive allosteric modulators (PAMs). They show that spermine, a GluN2B-specific PAM, can potentiate the activity of mixed diheteromeric N1/2B but not N1/2A/2B tri-heteromers. However pregnenolone sulfate (a 2A/2B-specific PAM) can potentiate both the activity of mixed diheteromeric and tri-heteromeric NMDAR populations, either in oocytes or cultured neurons.I have very few major comments to make. The experiments are straightforward and the adequate controls have been made. Here are my two only major comments:
We thank the reviewer for the very detailed overview of our work and for appreciating our controls and methods.
#1 About the experiment on cultured neurons. The authors compare the currents of cultured neurons transfected with GluN2B-G689C and -G689S to non transfected neurons. The adequate control is rather neurons transfected with the wild-type GluN2B subunit to even out any phenomenon linked to transfection of the neuron. Given the overexpression that can occur after transfection, the effect of the mutations on the size of NMDAR currents might be even stronger than what the authors show. However in that case PS might not completely rescue mutant NMDAR currents to wild-type levels.
We initially did not perform this control as the literature paints a clear picture whereby expression of the GluN2B-subunit (without adding excess of the GluN1 subunit) does not instigate a robust increase in surface expression of NMDARs (and thus current remains the ~same) 4,39–43, and see our reply to comment #14 (above), and reviewer 3 comment 1 (below). Nevertheless, we have now performed this test by overexpressing GluN2B-wt. In support of previous reports, we do not find any statistical difference in current size between non-transfected neurons and neurons solely overexpressing the GluN2B-wt subunit (Fig. 6a, b). Furthermore, application of PS onto naïve or GluN2Bwt expressing neurons yields identical currents (Imax) and potentiation (Fig. 6c, d). These argue that we did not obtain “overexpression”. Thus, our results and interpretations hold true, and are therefore not underestimation of the effects of PS in neurons.
2 How come high concentrations of glutamate (>100µM) produce additional current on wt GluN1/GluN2B (with retention signals) compared to 100 µM glutamate, which is supposed to be saturating? It does not seem to stem from an osmotic effect since 10 mM glutamate does not produce any current on uninjected oocytes. Knowing that this "artefactual" effect might also occur in the mutant receptors, how do you take this effect into account when calculating the glutamate EC50s of the mutants? Given the drastic shift in EC50 produced by the mutant, taking into account this artefact is not going to change the conclusion, but the actual EC50s will be affected.
GluN1/GluN2B-wt receptors (with or without retention signals) are indeed saturated at 100 mM glutamate. However, excessively large concentrations of glutamate (>100 mM) may yield artefacts even in non-injected oocytes (in 10 mM, this occurs in ~20% of the cells, see Kellner et al 20218—Fig. 2 and Suppl. 1c, d) as well as in GluN2B-wt injected oocytes (supplementary Table 1 in 44). This is not due to osmolarity, as rightly mentioned by the reviewer (and below), rather possibly by endogenous glutamate receptors and transporters that do not readily contribute to current amplitude (these are extremely small currents), but can cause deterioration of the cell (and enhance ‘leak’) when activated for prolonged times by very large concentrations (e.g.,45). In fact, we explicitly report these to highlight potential artefacts, as these are often overlooked in the field. Regardless, most reports do no go past 100 mM glutamate, not even when describing GRIN2 mutations since most mutations do not cause such drastic shifts in potency as we observed (to the best of our knowledge only one report describes such an extreme LoF mutation for a GluN2A variant46). Of note, these effects are not seen when glycine is applied at high concentrations (supporting lack of effect by osmolarity)47. Thus, we refrained from testing concentrations past 10 mM, aware that it may yield a slight underestimation of glutamate potency (and perhaps the reason for the larger Hill coefficient, nH; see our reply to reviewer #1, comment #5). Importantly, despite the potential underestimation of the EC50, it does not change our conclusions as all groups are measured side-by-side (thus, the same underestimation equally applies to all other groups as well). We now mention this more in detail in the methods under the section – “Two Electrode Voltage Clamp recordings in Xenopus Laevis oocytes”.
Minor comments:
3 In the first paragraph of the "Results" section, when describing the design of the constructs used to force a heteromeric stoichiometry in recombinant systems, the authors do as if they had designed the constructs themselves "Briefly, we tagged...are retained in the ER (Fig. 1a)". Please rewrite this paragraph to show that you used constructs that had been previously designed by another group (Hansen et al., 2014).
We apologize. We did not mean to express that we have developed the method and indeed refer readers to the seminal works of those who did (Stroebel et al., 2014 and Hansen et al. 2014, lines #109-116). We did not go into details for the sake of brevity. We have rewritten this part to give proper acknowledgement to the method’s developers (also see Methods, line# 448).
4 I do not see any evidence of "positive cooperativity" between subunits in ref. 32. Ref. 32, to the best of my knowledge, states that in N1/2A/2B tri-heteromers, the 2A subunit sets the biophysical properties of the tri-heteromer. But there is no account of mixed di-heteromers. In addition, the cooperativity between the glutamate and glycine binding sites is negative.
The reviewer is correct, and we apologize for the mis-citation. Indeed, the cooperativity between glutamate- and glycine-binding is typically reported as negative48,49, and our intention was to highlight the strong cooperativity (whether positive or negative) observed between NMDAR-subunits and meant to cite the works of: 33,35,50 (lines . We have now rephrased the sentence: The divergence from this scenario suggests that the slight amelioration in potency could stem from positive cooperativity between the subunits50 (but see Hill coefficients in Table 1). Indeed, mixed receptors show restored proton sensitivity (Suppl. 3), which has been suggested to be coupled to other receptor features, notably increase in open probability.
5 Interpretation of spermine action within the Results section: it is striking indeed to observe that the mutations in the context of a mixed di-heteromer still allow spermine potentiation, while they abolish this potentiation in pure di-heteromers. As rightly said in the discussion, the regain of spermine potentiation in the mixed compared to the pure diheteromers is likely due to a more favorable transduction of spermine signaling to the pore, likely via a higher pH sensitivity of mixed di-heteromers compared to di-heteromers. I would thus avoid the terms of "one single intact interface" for the mixed di-heteromer, since both spermine binding sites are likely intact in this NMDAR configuration. How is pH sensitivity affected in the mixed di-heteromers?
We have performed a detailed pH dose-responses for the various channel types (Suppl 3). We find that GluN2B mixed di-heteromers exhibit similar IC50 as pure GluN2B-wt di-heteromers, thus explaining their ability to undergo potentiation by spermine via alleviation of proton inhibition. We therefore further suggest that mixed di-heteromers’ have higher pH-sensitivity compared to pure mutant di-heteromers and this mat also contributes to their higher spermine sensitivity. Lastly, we observed that all GluN2A-wt-containing tri-heteromeric receptors were non-responsive to spermine (Fig. 4a). In fact, under our experimental conditions tri-heteromers underwent slight inhibition by spermine, regardless the identity of the GluN2B subunit (whether wt or variant) (Fig. 4b). Thus, as the tri-heteromers used here exhibit identical pH-sensitivity as 2B-di-heteromers, the only diverging aspect is the missing interface between the GluN1a and GluN2B subunits, demonstrating that potentiation by spermine requires at least one GluN2B-subunit with an intact proton sensitivity, and mandates two intact interfaces between GluN1-wt and GluN2B-wt subunits (Table 1)21.
6 In the methods section, the oocyte recording solution (likely Ringer and not Barth) does not contain any potassium. This is probably a typo. Could you correct the composition of your Ringer?
Corrected. We record NMDARs currents by use of a Barth solution containing (in mM): 100 NaCl, 0.3 BaCl2, 5 HEPES, pH 7.3 (adjusted with KOH, at ~2.5 mM) (as in 4,51).
7 There are several typos, especially in the Discussion.
We have corrected the typos throughout the publication.
**Referees cross-commenting**
I overall agree with the comments of reviewers 1 and 2. In particular, I agree that it is pointless to compare the absolute currents of non transfected neurons vs mutant-transfected neurons without an idea of receptor cell-surface expression.
We have performed this experiment (Fig. 6) and please see our reply to this reviewer’s comment #1.
I would like however to give some precisions about some comments of Reviewer 2. About the ER retention technique to express tri-heteromers: I didn't know that the C2 signal could be addressed to the membrane on its own. The lack of leak current stemming from C1-C1 or C2-C2 combinations has been demonstrated in the paper establishing the technique (Hansen et al, 2014), as well as in another paper that developed an analog technique based on GABAB retention signals (Stroebel et al., J Neurosci 2014). So it is fair to consider that the authors were not surprised by the lack of current when co-expressing two GluN2B subunits carrying the C2 signal.
We thank you for this addition and support for our observations.
About the comparison about absolute currents wt vs mutants, +/- spermine (Fig. 4a and 5a). I agree with reviewer 2 that being able to compare absolute currents of wt without spermine to mutant + spermine would be very interesting to see if spermine can actually rescue mutant hypofunction. However, to the defense of the authors, comparing absolute current values of recordings from Xenopus oocytes is meaningless. Indeed the variability of currents for the same construct and same day of experiment is too high (there can be up to a ten-fold difference between the lowest and the highest current of oocytes expressing the same construct the same experimental day). A way to investigate this aspect would be to estimate the open probability of the different constructs with or without spermine via the inhibition kinetics of an open channel blocker (e.g. MK801) and measure surface expression by Western blot, but I am not sure these experiments are worth it for the spermine experiment.
We agree with this reviewer about current size. It is quite variable among cells and would therefore introduce an additional variable and variability: the expression of these modified (C1/C2-tagged) subunits is dually affected by the mutation itself (Kellner et al. 2021) and by the introduction of the tagging (which really hampers there trafficking to membrane, Suppl. 2c); with unknown contribution of each variable. We thereby do not think these provide an added value to our conclusions, yet to grant reviewers’ no 2 request we have added __Suppl. 4 __which shows the rescue effect of the different drugs.
Reviewer #3 (Significance (Required)):
This paper is not of high significance since most of the characterization of the 2B-G689C and -G689S de novo mutants found in patients has already been published (Kellner et al., eLife 2021). However, this paper is worth publishing since it brings new data on the effect of the mutations on tri-heteromeric and mixed di-heteromeric NMDAR populations, which are likely the most abundant NMDAR populations in the patient's brain at adult stage. Tri-heteromeric and mixed NMDAR populations have often been overlooked when studying pathogenic NMDAR mutations due to the difficulty to express them specifically in recombinant systems. This paper (in addition to other papers in the field, see for instance Elmasri et al., Brain Sci. 2022; Li et al., Hum. Mutat. 2019) shows that the effect of the mutations on the receptor biophysical and pharmacological properties (but also on trafficking) differ whether the receptor contains one or two copies of the mutant subunit. This paper is of interest to scientists interested in NMDA receptor structure-function and pharmacology, as well as clinicians interested in GRINopathies (pathologies linked to NMDAR mutations).
I, the reviewer, am an expert in NMDAR structure-function and pharmacology. I believe I have sufficient expertise to evaluate the entirety of the paper.
We thank the reviewer for appreciating and acknowledging the merits of our work for publication.
References:
- Berlin, S. et al. Gαi and Gβγ Jointly Regulate the Conformations of a Gβγ Effector, the Neuronal G Protein-activated K+ Channel (GIRK). J. Biol. Chem. 285, 6179–6185 (2010).
- Kahanovitch, U., Berlin, S. & Dascal, N. Collision coupling in the GABAB receptor–G protein–GIRK signaling cascade. FEBS Lett. 591, 2816–2825 (2017).
- Berlin, S. et al. A Collision Coupling Model Governs the Activation of Neuronal GIRK1/2 Channels by Muscarinic-2 Receptors. Front. Pharmacol. 11, (2020).
- Berlin, S. et al. A family of photoswitchable NMDA receptors. eLife 5, e12040 (2016).
- Reyes-Guzman, E. A., Vega-Castro, N., Reyes-Montaño, E. A. & Recio-Pinto, E. Antagonistic action on NMDA/GluN2B mediated currents of two peptides that were conantokin-G structure-based designed. BMC Neurosci. 18, 44 (2017).
- Paul, S. M. et al. The Major Brain Cholesterol Metabolite 24(S)-Hydroxycholesterol Is a Potent Allosteric Modulator of N-Methyl-D-Aspartate Receptors. J. Neurosci. 33, 17290–17300 (2013).
- Yakovlev, A. V., Kurmasheva, E. D., Ishchenko, Y., Giniatullin, R. & Sitdikova, G. F. Age-Dependent, Subunit Specific Action of Hydrogen Sulfide on GluN1/2A and GluN1/2B NMDA Receptors. Front. Cell. Neurosci. 11, 375 (2017).
- Kellner, S. et al. Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy. eLife 10, e67555 (2021).
- Sabo, S. L., Lahr, J. M., Offer, M., Weekes, A. L. & Sceniak, M. P. GRIN2B-related neurodevelopmental disorder: current understanding of pathophysiological mechanisms. Front. Synaptic Neurosci. 14, (2023).
- Martel, M.-A. et al. The Subtype of GluN2 C-terminal Domain Determines the Response to Excitotoxic Insults. Neuron 74, 543–556 (2012).
- Papouin, T. et al. Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists. Cell 150, 633–646 (2012).
- Harris, A. Z. & Pettit, D. L. Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. J. Physiol. 584, 509–519 (2007).
- Moldavski, A., Behr, J., Bading, H. & Bengtson, C. P. A novel method using ambient glutamate for the electrophysiological quantification of extrasynaptic NMDA receptor function in acute brain slices. J. Physiol. 598, 633–650 (2020).
- Curras, M. C. & Dingledine, R. Selectivity of amino acid transmitters acting at N-methyl-D-aspartate and amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors. Mol. Pharmacol. 41, 520–526 (1992).
- Laube, B., Hirai, H., Sturgess, M., Betz, H. & Kuhse, J. Molecular Determinants of Agonist Discrimination by NMDA Receptor Subunits: Analysis of the Glutamate Binding Site on the NR2B Subunit. Neuron 18, 493–503 (1997).
- Esmenjaud, J. et al. An inter‐dimer allosteric switch controls NMDA receptor activity. EMBO J. 38, (2019).
- Liu, S. et al. A Rare Variant Identified Within the GluN2B C-Terminus in a Patient with Autism Affects NMDA Receptor Surface Expression and Spine Density. J. Neurosci. 37, 4093–4102 (2017).
- Geoffroy, C., Paoletti, P. & Mony, L. Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential. J. Physiol. 600, 233–259 (2022).
- Malayev, A., Gibbs, T. T. & Farb, D. H. Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br. J. Pharmacol. 135, 901–909 (2002).
- Petrov, A. M. et al. CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice. Neurotherapeutics 16, 710–724 (2019).
- Mony, L., Zhu, S., Carvalho, S. & Paoletti, P. Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines. EMBO J. 30, 3134–3146 (2011).
- Stroebel, D., Casado, M. & Paoletti, P. Triheteromeric NMDA receptors: from structure to synaptic physiology. Curr. Opin. Physiol. 2, 1–12 (2018).
- Hansen, K. B., Ogden, K. K., Yuan, H. & Traynelis, S. F. Distinct Functional and Pharmacological Properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA Receptors. Neuron 81, 1084–1096 (2014).
- Stroebel, D., Carvalho, S., Grand, T., Zhu, S. & Paoletti, P. Controlling NMDA Receptor Subunit Composition Using Ectopic Retention Signals. J. Neurosci. 34, 16630–16636 (2014).
- Clements, J. D., Lester, R. A. J., Tong, G., Jahr, C. E. & Westbrook, G. L. The Time Course of Glutamate in the Synaptic Cleft. Science 258, 1498–1501 (1992).
- Budisantoso, T. et al. Evaluation of glutamate concentration transient in the synaptic cleft of the rat calyx of Held: Glutamate concentration in synapse. J. Physiol. 591, 219–239 (2013).
- Kellner, S. et al. Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy. eLife 10, e67555 (2021).
- McAllister, A. K. & Stevens, C. F. Nonsaturation of AMPA and NMDA receptors at hippocampal synapses. Proc. Natl. Acad. Sci. 97, 6173–6178 (2000).
- Ishikawa, T., Sahara, Y. & Takahashi, T. A Single Packet of Transmitter Does Not Saturate Postsynaptic Glutamate Receptors. Neuron 34, 613–621 (2002).
- Washbourne, P., Liu, X.-B., Jones, E. G. & McAllister, A. K. Cycling of NMDA Receptors during Trafficking in Neurons before Synapse Formation. J. Neurosci. 24, 8253–8264 (2004).
- Yan, Y.-G. et al. Clustering of surface NMDA receptors is mainly mediated by the C-terminus of GluN2A in cultured rat hippocampal neurons. Neurosci. Bull. 30, 655–666 (2014).
- Kussius, C. L. & Popescu, G. K. Kinetic basis of partial agonism at NMDA receptors. Nat. Neurosci. 12, 1114–1120 (2009).
- Sun, W., Hansen, K. B. & Jahr, C. E. Allosteric interactions between NMDA receptor subunits shape the developmental shift in channel properties. Neuron 94, 58-64.e3 (2017).
- Benveniste, M. & Mayer, M. L. Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine. Biophys. J. 59, 560–573 (1991).
- Lü, W., Du, J., Goehring, A. & Gouaux, E. Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation. Science 355, eaal3729 (2017).
- Vyklicky, V., Stanley, C., Habrian, C. & Isacoff, E. Y. Conformational rearrangement of the NMDA receptor amino-terminal domain during activation and allosteric modulation. Nat. Commun. 12, 2694 (2021).
- Stroebel, D., Casado, M. & Paoletti, P. Triheteromeric NMDA receptors: from structure to synaptic physiology. Curr. Opin. Physiol. 2, 1–12 (2018).
- Borza, I. & Domany, G. NR2B Selective NMDA Antagonists: The Evolution of the Ifenprodil-Type Pharmacophore. Curr. Top. Med. Chem. 6, 687–695 (2006).
- Tang, Y. P. et al. Genetic enhancement of learning and memory in mice. Nature 401, 63–69 (1999).
- Gonda, S. et al. GluN2B but Not GluN2A for Basal Dendritic Growth of Cortical Pyramidal Neurons. Front. Neuroanat. 14, (2020).
- Sceniak, M. P. et al. A GluN2B mutation identified in Autism prevents NMDA receptor trafficking and interferes with dendrite growth. J. Cell Sci. jcs.232892 (2019) doi:10.1242/jcs.232892.
- Philpot, B. D. et al. Effect of transgenic overexpression of NR2B on NMDA receptor function and synaptic plasticity in visual cortex. Neuropharmacology 41, 762–770 (2001).
- Barria, A. & Malinow, R. Subunit-Specific NMDA Receptor Trafficking to Synapses. Neuron 35, 345–353 (2002).
- Platzer, K. et al. GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. J. Med. Genet. 54, 460–470 (2017).
- Green, T., Rogers, C. A., Contractor, A. & Heinemann, S. F. NMDA Receptors Formed by NR1 in Xenopus laevis Oocytes Do Not Contain the Endogenous Subunit XenU1. Mol. Pharmacol. 61, 326–333 (2002).
- Swanger, S. A. et al. Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains. Am. J. Hum. Genet. 99, 1261–1280 (2016).
- Madry, C., Betz, H., Geiger, J. R. P. & Laube, B. Supralinear potentiation of NR1/NR3A excitatory glycine receptors by Zn2+ and NR1 antagonist. Proc. Natl. Acad. Sci. 105, 12563–12568 (2008).
- Regalado, M. P., Villarroel, A. & Lerma, J. Intersubunit Cooperativity in the NMDA Receptor. Neuron 32, 1085–1096 (2001).
- Durham, R. J. et al. Conformational spread and dynamics in allostery of NMDA receptors. Proc. Natl. Acad. Sci. 117, 3839–3847 (2020).
- Vyklicky, V., Stanley, C., Habrian, C. & Isacoff, E. Y. Conformational rearrangement of the NMDA receptor amino-terminal domain during activation and allosteric modulation. Nat. Commun. 12, 2694 (2021).
- Kellner, S. et al. Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy. eLife 10, e67555 (2021).
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
This paper is a follow up of an earlier paper published by the group (Kellner et al., eLife 2021), which aimed at characterizing the functional properties of two de novo GluN2B mutations in patients suffering from severe pediatric diseases, GluN2B-G689C and -G689S. NMDA receptors (NMDARs) are tetramers composed of two GluN1 and two GluN2 subunits. A single receptor can incorporate either two identical GluN2 subunits (di-heteromers) or two different GluN2 subunits (tri-heteromers), leading to a large diversity of NMDAR subtypes. The main NMDAR subtypes in the adult forebrain are GluN1/GluN2A and GluN1/GluN2B di-heteromers, as well as GluN1/GluN2A/GluN2B tri-heteromers. While the exact proportions of these three subtypes are still contentious, there are evidence that in the adult N1/2A/2B tri-heteromers form the major population of synaptic NMDARs in the adult forebrain. In addition, patients bearing pathogenic mutations are often heterozygous for the mutation, giving rise to mixed NMDARs incorporating one mutated and one intact GluN2 subunit. In their previous paper, Kellner et al. had shown that purely di-heteromeric GluN1/GluN2B-G689C and -G689S mutants display a drastic (> 1,000-fold) decrease of glutamate sensitivity and a decrease of surface expression. In the current paper, the authors characterize the effects of the -G689C and -G689S mutations on N1/2A/2B tri-heteromeric receptors, as well as on mixed di-heteromeric GluN1/GluN2B receptors containing one copy of the wild-type GluN2B subunit and one copy of the mutated GluN2B subunit. They show that one copy of the mutant subunit, either within mixed diheteromeric or tri-heteromeric receptors, is sufficient to decrease drastically glutamate sensitivity, although the shift in glutamate EC50 is not as strong as in pure di-heteromeric receptors (≈ 500-fold). They furthermore explore strategies to counteract the hypofunction induced by these mutations by testing the effect of positive allosteric modulators (PAMs). They show that spermine, a GluN2B-specific PAM, can potentiate the activity of mixed diheteromeric N1/2B but not N1/2A/2B tri-heteromers. However pregnenolone sulfate (a 2A/2B-specific PAM) can potentiate both the activity of mixed diheteromeric and tri-heteromeric NMDAR populations, either in oocytes or cultured neurons.
I have very few major comments to make. The experiments are straightforward and the adequate controls have been made. Here are my two only major comments:
- About the experiment on cultured neurons. The authors compare the currents of cultured neurons transfected with GluN2B-G689C and -G689S to non transfected neurons. The adequate control is rather neurons transfected with the wild-type GluN2B subunit to even out any phenomenon linked to transfection of the neuron. Given the overexpression that can occur after transfection, the effect of the mutations on the size of NMDAR currents might be even stronger than what the authors show. However in that case PS might not completely rescue mutant NMDAR currents to wild-type levels.
- How come high concentrations of glutamate (>100µM) produce additional current on wt GluN1/GluN2B (with retention signals) compared to 100 µM glutamate, which is supposed to be saturating? It does not seem to stem from an osmotic effect since 10 mM glutamate does not produce any current on uninjected oocytes. Knowing that this "artefactual" effect might also occur in the mutant receptors, how do you take this effect into account when calculating the glutamate EC50s of the mutants? Given the drastic shift in EC50 produced by the mutant, taking into account this artefact is not going to change the conclusion, but the actual EC50s will be affected.
Minor comments:
- In the first paragraph of the "Results" section, when describing the design of the constructs used to force a heteromeric stoichiometry in recombinant systems, the authors do as if they had designed the constructs themselves "Briefly, we tagged...are retained in the ER (Fig. 1a)". Please rewrite this paragraph to show that you used constructs that had been previously designed by another group (Hansen et al., 2014).
- I do not see any evidence of "positive cooperativity" between subunits in ref. 32. Ref. 32, to the best of my knowledge, states that in N1/2A/2B tri-heteromers, the 2A subunit sets the biophysical properties of the tri-heteromer. But there is no account of mixed di-heteromers. In addition, the cooperativity between the glutamate and glycine binding sites is negative.
- Interpretation of spermine action within the Results section: it is striking indeed to observe that the mutations in the context of a mixed di-heteromer still allow spermine potentiation, while they abolish this potentiation in pure di-heteromers. As rightly said in the discussion, the regain of spermine potentiation in the mixed compared to the pure diheteromers is likely due to a more favorable transduction of spermine signaling to the pore, likely via a higher pH sensitivity of mixed di-heteromers compared to di-heteromers. I would thus avoid the terms of "one single intact interface" for the mixed di-heteromer, since both spermine binding sites are likely intact in this NMDAR configuration. How is pH sensitivity affected in the mixed di-heteromers?
- In the methods section, the oocyte recording solution (likely Ringer and not Barth) does not contain any potassium. This is probably a typo. Could you correct the composition of your Ringer?
- There are several typos, especially in the Discussion.
Referees cross-commenting
I overall agree with the comments of reviewers 1 and 2. In particular, I agree that it is pointless to compare the absolute currents of non transfected neurons vs mutant-transfected neurons without an idea of receptor cell-surface expression.
I would like however to give some precisions about some comments of Reviewer 2. About the ER retention technique to express tri-heteromers: I didn't know that the C2 signal could be addressed to the membrane on its own. The lack of leak current stemming from C1-C1 or C2-C2 combinations has been demonstrated in the paper establishing the technique (Hansen et al, 2014), as well as in another paper that developed an analog technique based on GABAB retention signals (Stroebel et al., J Neurosci 2014). So it is fair to consider that the authors were not surprised by the lack of current when co-expressing two GluN2B subunits carrying the C2 signal. About the comparison about absolute currents wt vs mutants, +/- spermine (Fig. 4a and 5a). I agree with reviewer 2 that being able to compare absolute currents of wt without spermine to mutant + spermine would be very interesting to see if spermine can actually rescue mutant hypofunction. However, to the defense of the authors, comparing absolute current values of recordings from Xenopus oocytes is meaningless. Indeed the variability of currents for the same construct and same day of experiment is too high (there can be up to a ten-fold difference between the lowest and the highest current of oocytes expressing the same construct the same experimental day). A way to investigate this aspect would be to estimate the open probability of the different constructs with or without spermine via the inhibition kinetics of an open channel blocker (e.g. MK801) and measure surface expression by Western blot, but I am not sure these experiments are worth it for the spermine experiment.
Significance
This paper is not of high significance since most of the characterization of the 2B-G689C and -G689S de novo mutants found in patients has already been published (Kellner et al., eLife 2021). However, this paper is worth publishing since it brings new data on the effect of the mutations on tri-heteromeric and mixed di-heteromeric NMDAR populations, which are likely the most abundant NMDAR populations in the patient's brain at adult stage. Tri-heteromeric and mixed NMDAR populations have often been overlooked when studying pathogenic NMDAR mutations due to the difficulty to express them specifically in recombinant systems. This paper (in addition to other papers in the field, see for instance Elmasri et al., Brain Sci. 2022; Li et al., Hum. Mutat. 2019) shows that the effect of the mutations on the receptor biophysical and pharmacological properties (but also on trafficking) differ whether the receptor contains one or two copies of the mutant subunit. This paper is of interest to scientists interested in NMDA receptor structure-function and pharmacology, as well as clinicians interested in GRINopathies (pathologies linked to NMDAR mutations). I, the reviewer, am an expert in NMDAR structure-function and pharmacology. I believe I have sufficient expertise to evaluate the entirety of the paper.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
The objective of this paper is to assess whether a single mutated subunit of GRIN can affect the function of various forms of NMDA receptors. In particular, this study investigates the functional consequences of a GRIN variant when assembled within tri-heteromers, containing 2 GluN1, 1 GluN2A and 1 GluN2B subunits, the major postnatal receptor type. For this purpose, the authors artificially forced the subunits to associate in predefined complexes, using chimeras of GRIN subunits fused to GABAb receptor retention control sites at the endoplasmic reticulum. This trick allows to control the stoichiometry of the channels at the membrane and thus to focus on the function of a single type of NMDA receptor. The take home message of the paper is that a single GluN2B‐variant, whether assembled with a GluN2B‐wt subunit to form mixed di‐heteromer or with a GluN2A‐wt‐subunit (tri‐heteromer), strongly impairs the receptor functioning, as reported by a decrease of the apparent glutamate affinity of the receptor.
Altogether, this is a straightforward study of great interest for the GRIN community. However, the way the background and purpose of the study (title and abstract) are presented is a bit confusing for non-specialists and could be easily improved. Technical information, which is crucial to validate the conclusions drawn from data analysis, should be added to the article. Some additional experiments are suggested to consolidate the work. Finally, additional discussion points are strongly encouraged.
Specific comments
Abstract / Title:
This work shows that a single GRIN variant impairs the function of various forms of NMDA receptors. Several sentences in the title and the abstract are confusing for a non-specialized audience. "Two extreme Loss‐of‐Function GRIN2B‐mutations are detrimental to triheteromeric NMDAR‐function, but rescued by pregnanolone‐sulfate." "Here, we have systematically examined how two de novo GRIN2B variants (G689C and G689S) affect the function of di‐ and tri‐heteromers." The number of variants tested is not of capital importance in the title, especially because one could believe that both are tested at the same time; similarly, when variants are named in the abstract, the fact that only 1 variant is studied at a time should be clarified (G689C OR G689S). Indeed, the problem is obvious to those familiar with GRIN disorders, but if this paper is to be published in a journal reaching a large audience rather than a specialized audience, the title of the paper should be modified.
Introduction:
"We find that the inclusion of a single GluN2B‐variant within mixed di‐ or tri‐heteromeric channels is sufficient to prompt a strong reduction in the receptors' glutamate affinity, but these reductions are not as drastic as in purely di‐heterometric receptors containing two copies of the variants. This observation is supported by the ability of a GluN2B‐selective potentiator (spermine) to potentiate mixed diheteromeric channels." Please, clarify the link between the two sentences. How do spermin potentiation of mixed diheteromeric channels supports the observation that the inclusion of a single GluN2B‐variant has less effect than the inclusion of two variants?
Methods
All this study is based on the use of a unique ER‐retention technique to limit expression of a desired receptor‐population at the membrane of cells. According to the ER system retention of GABAb receptor, used in this study, while C1/C1-fused subunits are retained in the ER, C2/C2 reach the cell surface and the association of C1/C2 in the ER enables cell-surface targeting of the heterodimer. However, GB2 does not contain any retention signal and can reach the cell surface in the absence of GB1, as a functionally inactive homo-dimer (doi: 10.1042/BJ20041435). If there is an experimental trick that prevents the addressing of C2/C2 to the cell membrane, it should be specified and explained. This is critically important for understanding which receptor populations the data are derived from: receptors containing C1/C2 fused subunits only as stated by the authors, or C1/C2 and C2/C2 fused subunits?
Figures
NMDA-receptor current amplitude should be normalized by the membrane expression of the receptors. A preliminary experiment should measure the effective cell surface expression of each of the subunits in the different transfection conditions.
Fig.1a - The scheme should include C2-C2 complexes and mention whether these complexes are expressed at the cell surface (see previous and following comments).
Fig.1b and c - Current from cells transfected with GluN2B‐wt‐C1 and GluN2B‐wt‐C2 should be compared to current expressed in cells expressing untagged receptor subunits: GluN2B‐wt - Current from cells transfected with GluN2B‐wt‐C1 alone should be shown as well (although expected to be retained in the ER) (as performed for GluN2A‐wt‐C1 GluN2B‐wt‐C1 in suppl Fig. 1a) - How could you explain the null current from cells transfected with GluN2B‐wt‐C2 alone (Fig.1b middle, and 1c)? since GB2 does not contain any retention signal and can reach the cell surface in the absence of GB1, GluN2B‐wt‐C2 is supposed to reach the cell surface. This is a very important point to clarify (I am probably missing a technical detail) because if the sub-unit tagged with C2 does reach the cell surface, then all the results and conclusions drawn from the C1-C2 conditions are wrong and could be attributed to a mix of complexes containing either C1-C2 or C2-C2. My following comments are based on the assumption that only receptors containing C1-C2 tagged subunits reach the membrane (as assumed by the authors and suggested in Figure 1b middle), but explanations should absolutely be provided to convince the reader.
Fig. 4a and 5a - Please, keep the current scale constant between all current illustrations within the same figure (4a and 5a). Indeed, not only the Spermin- or SP- induced potentiation is an important data (which is presently quantified on the histograms of fig. 4b and 5b) but also knowing whether the amount of current recorded in cells expressing one mutant subunit in presence of SP (for example GluN2A‐wt‐C1 GluN2B‐G689S‐C2) is comparable to the current recorded in wt receptor-expressing cells (GluN2A‐wt‐C1 GluN2B‐wt‐C2) in absence of SP would be an excellent added value for the paper. A special figure could quantify this rescue effect of SP, measuring and comparing the mean currents recorded in these conditions (one current illustration is not sufficient given variations between similar samples). By the way 5mM glutamate might be an excessive concentration. At 1mM, the expected synaptic concentration of glutamate following action potential, according to figures 3 and Suppl1 the response of the mutated receptor is much lower than that of the WT which is already almost maximal. In these conditions, SP-induced potentiation by a factor of two of GluN2A‐wt‐C1 GluN2B‐G689S‐C2 current could be equivalent to control currents recorded in GluN2A‐wt‐C1 GluN2B‐wt‐C2 cells.
Fig. 6 - Figure 6 is not convincing because cultured hippocampal neurons do express endogenous NMDA receptors. To what extent the recording currents are affected by endogenous, non-mutated GluN2B subunits? Western Blots showing an extinction of endogenous subunits expression when transfected tagged subunits are competitively expressed would be required. - Fig.6b "PE-S" on the graph should be replaced by "PS"
Discussion
The authors are surprised by the fact (Fig.2) that 1 variant reduces the apparent glutamate affinity of the receptor, but not as much as 2 variants, despite the fact that "NMDARs opening requires all four subunits to be liganded (i.e., occupied by a ligand) which implies that the least affine subunit should have dominated the final affinity of the receptor". I agree that the difference is noticeable, however the glutamate affinity for receptors containing 1 variant is much closer to that of receptors containing 2 variants than that of wild-type receptors. Hence, the results obtained do not seem so surprising and could result, as rightly explained by the authors from a possible cooperativity between the subunits.
On the other hand, the data in Figure 6 are much more difficult to interpret and reconcile with the nature of the expressed receptor subunits (which this time is not controlled) nor their association within the same receptor. However, this aspect, which is essential to the understanding of the consequences of 1 variant on neuronal signalling, is not discussed: Whatever the stoichiometry of the complexes in the heterozygous disease, the mutated and wild type GluN2B subunits coexist in the same cell: Either within the same di-heteromeric complexes GluN2B-wt + GluN2B-mutant, or in separate complexes but nevertheless expressed in the same cell, in di heteromeric (GluN2B-wt + GluN2B-wt and GluN2B-mutant + GluN2B-mutant); or tri-heteromeric (GluN2A-wt + GluN2B-wt and GluN2A-wt + GluN2B-mutant) complexes. Assuming that half of the complexes remain wild-type, e.g. (GluN2A-wt + GluN2B-wt and GluN2A-wt + GluN2B-mutant) we would expect (Fig. 6) a small decrease in NMDA current (carried only by the half that expresses the mutated subunit, and whose function is not zero but only decreased by about 20% in response to 5mM Glutamate, Fig. 3b). The same reasoning applies to the di-heteromeric conditions (GluN2B-wt + GluN2B-wt; GluN2B-mutant + GluN2B-mutant), here again the decrease observed Fig. 6b is difficult to reconcile with the responses measured Fig. 2b. In other words, how to explain a 50% decrease of the currents, instead of the 10% expected by the previous reasoning. In this experiment we do not know which subunits are expressed, their proportions, nor how they are associated in functional complexes, which makes the interpretation of the data impossible. The only explanation, far-fetched, for 50 % decrease would be that the complexes were to contain all (or the vast majority) 1 wild-type subunits associated with 1 variant, then a homogeneous 50% reduction in current could be expected. But this extreme condition could only be possible in the case of di-heteromers, which is unlikely the case in Fig.6 as GluN2A currents are measured in presence of Ifenprodil. To conclude 1) the comparison of the currents in transfected and non-transfected neurons does not make sense in figure 6b which is not convincing because we do not know the nature of the currents actually measured. A comparison in controlled condition would make more sense (as I suggested in the criticism of figures 4, 5). 2) The reality of the combinations of expression and association between subunits within different complexes expressed in the same cell must be considered and taken into account in the interpretation of the data. Undoubtedly, the means of restoring the NMDA current will be different depending on the presence of mutated subunits in all functional channels or not.
Referees cross-commenting
The referees' comments are highly relevant. In particular, referee 3's comment 1 seems very interesting because it may help to better understand the discrepancy in the results observed in neurons, i.e. a 50% decrease in the currents induced by the expression of the mutant and wild type subunits in the same cells, whereas theoretically one would expect a 10% decrease of this current (cf. referee 2's 2nd comment in the discussion section). This comment 1 of referee 3 indeed stresses the fact that the control (non-transfected neurons) to which the heterozygous condition is compared is not the correct control, which should rather be neurons transfected with wild type receptor subunits. More generally, this comment underlines the importance of monitoring the effective membrane expression of the different subunits in each of the experimental conditions in order to be able to compare conditions and draw conclusions.
Significance
The novelty of the study, is to evaluate the consequences of a single mutated subunit within NMDA receptors affected by GRIN variant, to mimic the heterozygous condition of GRIN encephalopathies, this is of potential value for the field and the interest could also be extended to other genetic diseases (at least the experimental way to study the functioning of only one desired stoichiometric configuration).
The strength of this paper is precisely to isolate technically and to study the functioning of a desired stoichiometric configuration only. The main limitation of the paper is the interpretation that the authors make of their data in a physio-pathological context
This work could be of interest for general audience, providing the title and summary are slightly modified My area of expertise could not be closer to the topic of the article: Glutamate receptors; GRIN; molecular tinkering, cell culture, electrophysiology, receptor stoichiometry...
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary:
Kelner and Berlin present their research findings pertaining to the effect of GRIN2B variants that modify NMDA receptor function and pharmacology. While these mutations were published previously, the new manuscript provides a more thorough investigation into the effects that these variants pose when incorporated into heteromeric complexes with either wildtype GluN2B or GluN2A - NMDA receptors containing only a single mutated GluN2B subunits is more relevant to the disease cases because the associated patients are heterozygous for the variant. The authors achieved selective expression of receptor heteromeric complexes by utilising an established trafficking control system. The authors found that while a single variant subunit in the receptor complex is largely dominant in its effect on reducing glutamate potency of the NMDA receptor, it 's effect on receptor pharmacology varied. Unlike diheteromeric receptors containing mutated subunits, polyamine spermine potentiated GluN1/2B (but not GluN1/2A/2B) receptors that contained a single mutated GluN2B. In contrast, the neurosteroid, pregnenolone-sulfate (PS), was effective at potentiating the NMDA receptor currents (to varying degrees) regardless of the subunit composition. The potentiation of NMDA receptor currents by PS was also observed in neurons overexpressing the variants.
The techniques used in this study were appropriate to address the objectives and the overall effects are large, and generally convincing. I like the way the results are presented, although have a few (easily addressable) comments.
Major comments:
- When incrementally adding drugs (e.g. traces in figures 5 and 6), it doesn't always appear like the response has plateaued before changing the solutions/drugs. Therefore, I am curious to what extent the effects observed are underestimated.
- Also, in relation to figure 6, to what extent does agonist application cause desensitization here? Looking at traces in Figure 6b it appears that there is some desensitization and it isn't clear to what extent this persists during the solution changes. Could the authors conduct/show the controls where NMDA alone (for 50-60s), or NMDA followed by PE-S (without ifenprodil).
- Finally, figure 5 shows the effect of the neurosteroid (and ifenprodil) on NMDA-evoked currents in neurons overexpressing the GluN2B variants in neurons. However, there currents probably reflect a mixture of extrasynaptic and synaptic receptors. To what extent are synaptic NMDA receptors affected by the variants?
Minor comments:
- Looking at the fits in the graph of Figure 2b it appears that the slope on the concentration response curves is less steep for the mixed 2B-diheteromeric NMDA receptors. How much are the Hill coefficients changing and can this be interpreted to provide more mechanistic insight? Wouldn't it make sense to include the Hill coefficients in Table 1?
- The authors illustrate the changes in potency by the shift in the concentration response curves, but is there any change in efficacy? A simple way to illustrate this would be also present a simple graph showing the maximum current amplitudes (i.e. to 10 mM glutamate) for each of the receptor complexes.
- The authors characterize the 'apparent' affinity (or potency) of the receptor using concentration-response curves, but numerous points in the manuscript refer to changes in affinity. None of the experiments shown directly measure affinity (which would require ligand-binding assays) and so the use of the word affinity is inaccurate/misleading. I suggest the authors replace the instances of the word 'affinity' with 'potency'.
- In the third line of the abstract, the authors wrote, 'for which there are no treatments' in relation to GRINopathies. My understanding is that there are symptomatic treatments but that there are no disease-modifying treatments.
- The authors have interchangeably used the terms NMDAR or GluNRs throughout the manuscript. I suggest sticking to one of these terms. I would suggest NMDARs since this is less likely to be misread as a a specific NMDA receptor subunit..
- Typos: 1) Results paragraph 2 sentence one: 'We thereby produced GluN2B-wt, GluN2B-G689C and GluN2B-G689S subunits tagged with C1 or C2, co-expressed these along with the GluN1a-wt subunits in...' 2) Results paragraph 2: '...but these were mainly noticeable when oocytes are were exposed to high (saturating) glutamate concentrations...' 3) Last sentence in the second to last paragraph of the results section entitled 'Mixed di-and tri-heteromeric channels...': 'This , PS may serve to rescue...' 4) Last sentence in last paragraph of the results section entitled 'Mixed di-and tri-heteromeric channels...': 'Despite the latter, we found no evidence for any direct effect of three different physiologically relevant concentrations of the drug on di- or tri-heteromeric receptors'
- Figures 1e, 2b, 3b: it would be helpful to add a legend to the graph so that the curves can be interpreted without having to read through the figure legend.
- The bar graphs in Figure 6 show individual data points but those in figures 4b and 5b don't. Can the authors please add the data points to these graph.
- It would be helpful to reviewers that future manuscripts by the authors include page numbers and line numbers
Referees cross-commenting
Reviewers 2 and 3 highlight an important issue concerning figure 6 and the extent to which the overexpressed variants subunits can compete and assemble with endogenous NMDA receptors (unlike the system where the surface expression of specific receptor complexes is controlled). Indeed in the recent paper by the same authors, the two variants differed in their surface expression (in HEK cells), with G689C expressing particularly poorly. With reference to the second minor comment of Reviewer 1, the maximum current amplitudes would of course need to be normalized to cell surface expression of the receptor to gain any insight into efficacy.
Significance
This study emphasizes the complex pattern of effects that variants can have on glutamate receptor function and pharmacology, especially considering the context of receptor subunit composition. The authors have followed up their previous findings on the same mutants (Kellner et al, 2021, Elife), but used a trafficking control system here to characterize properties of mutated receptor complexes that are most likely to exist in neurons. The authors show that the defective currents mediated by NMDA receptors containing a loss-of-function GluN2B variant can be enhanced by neurosteroids (and in the case of GluN1/2B receptors, polyamines also). Development and approval of neurosteroids for the clinic would be required for the findings to translate to a therapy for patients. Readers should also be aware that neurosteroids act on other receptors too (e.g. GABA receptors), which could complicate the outcome. The expertise of the reviewer is in glutamate receptors and synaptic transmission.
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1
Major:
- The statement (line 149'Together, our data suggest that systemic ecdysone levels are unlikely to be involved in modulating tumour-induced muscle detachment or to mediate the role of fatbody Insulin signalling in regulating muscle detachment.') is derived from an experiment with sterol free diet (in which 20HE is genetically addressed) and a pleiotropic experiment (PG>RasG12V). In neither paper nor the current manuscript, 20HE levels have been directly addressed.
Therefore, this statement needs further experimental support and discussion. Ecdysone is a critical hormone during development and especially growth-related effects central to this study. The authors should consider doing pharmacology or augment their claims here with genetic manipulation experiments of 20HE related genes in larvae (Leopold, Rewitz, Rideout, Drummond-Barbosa, Schuldiner labs) and adult animals using genetics, pharmacology or direct assessment of 20HE levels (RIPA, Edgar and Reiff labs).
The main point we were trying to convey is that we do not think global ecdysone levels plays a role in modulating fatbody insulin or tgfb signalling, which in turn affects muscle detachment. We are not claiming that edysone levels is not changing in control vs. tumour bearing animals. In fact, we predict that 20HE levels will be different in tumour bearing vs. control animals (as tumour bearing animals undergo developmental delay), but this is not the main point of our conclusions. We believe that our conclusions are supported by the experiment demonstrating global ecdysone alterations (via feeding sterol-free food) did not affect how fatbody Akt activation altered tgfb signalling and enhanced muscle integrity (Figure S1). Therefore, we don’t think measuring 20HE helps to support our conclusions. Pharmacological inhibition via feeding ecdysone inhibitors effectively demonstrate a similar point to feeding sterol-free food which we have already performed. We are happy to try direct manipulation of 20HE related genes (eip75B-RNAi) in the fatbody to see if this affects muscle detachment or pAkt and pMad levels in tumour bearing animals.
- In Fig.7 the authors used a sog-LacZ stock to show transcriptional activation in fatbody cells. This stock is based on P-element insertion in the according regulatory regions and supposed to express lacZ with an nls. I can clearly see lacZ in nuclei in Fig. 7H, whereas this is very hard to see in nuclei in Fig7i in the tumour model. In addition, lacZ is known for its high stability and not the best option. As this finding is vital for central claims of this study, it should be complemented by either qPCR for sog on fat body cells or using another readout by converting one of the two Mimic lines (BL42189/44958) into GFP sensors for sog.
We will add a counterstain to these images. We will also perform qPCR in the fatbody of control and cachectic animals to assess whether Sog transcription is altered. We agree converting one of the Mimic lines to a GFP sensor would be a good option, but this experiment would require getting new fly lines into Australia, which takes at least 2 months because of quarantine laws. We don’t believe this experiment would change the general conclusions of the paper, therefore would prefer not to do this experiment.
- I have similar problems with Fig.7B-F, as phosphorylated Mad should be translocated to the nucleus. In 7F the authors measure pMad over Dapi, which is the right way but it is hard to see pMad in the nucleaus apart from Fig7B, wheras in D and E, where the authors measure higher levels, I cannot identify clear pMad in nuclei. These images either need to show the Dapi channel or more representative images should be chosen like in Fig.4 with arrows pointing to measured nuclei. Fig.7C something went wrong with the compression of this image.
We will show more representative examples and fix Fig 7C.
- The proper function of RNAi stocks targeting genes like sog, mad, etc. is vital for this study as these lines are used throughout the study. Functional evidence of specific knockdown efficiency should be provided or references given in which these stocks were shown to provide functional knockdown on transcript or protein level.
We agree with the reviewer that this is an important point. We will demonstrate the knockdown of sog and mad (and other RNAis) used in the study by either referring to published data or demonstrate knockdown ourselves.
- Fig.S7 discusses appearance of gbb/Bmp7 and Sog/CHRD in human patients. The analysis the authors performed shows a correlation between both factors, but is hampered by the fact that datasets for peripheral tissues of cachexia patients are unavailable. The authors may consider sorting these after tumor entities in which cachexia occurs frequently vs. low occurrence and then check for both genes.
We will try this analysis.
Fig.5 M-P pMAd is not indicated in the Panels only the legend.
We will fix this error.
- Please follow FlyBase nomenclature, e.g. dlg1 for discs large 1 and unify in the whole manuscript and figure for all genes.
We will fix this error.
- For endogenous fusion proteins like Viking-GFP (e.g. vkg::GFP) choose a format to clearly decipher them from transcriptional readout stocks like sog-lacZ.
We will fix this error.
- The quantifications in most figures are quite small with tiny lettering and XY axis are difficult to read in letter/A4 size.
We will enlarge font size.
Minor:
-
Adjust in-figure caption alignments
-
Line 104: add comma RasV12, dlgRNAi
-
Line 114: replace little not significant (n.s.)
-
Line 334: 'sogRNAi overexpression' to my knowledge, RNAi are expressed, not overexpressed.
-
Line 454: italicize r4>
-
Fig S4E: remove frame
-
Figures 6: It would be better to number and explain the pathway presented in the figure in text and fig legend.
-
Just a personal preference. Lettering of images in images is commonly done horizontally, here it appears like a mix between vertical and horizontal.
We will fix these minor errors.
Reviewer #2
Major comment
Their genetic experiments clearly showed that the reduction of insulin signaling activity in the fatbody induces upregulation of TGF-β signaling and Collagen accumulation. Then, how does TGF-β signaling induce Collagen accumulation?
From the experiments we have carried out, we do not have insights into how TGF-B signalling induce Collagen accumulation.
They showed that Rab10 knockdown and SPARC overexpression reduced the accumulation of fatbody ECM. Are Rab10 and SPARC expression regulated by TGF-β signaling?
We can address this point by assessing if Rab10 and SPARC expression is altered in cachectic fatbody.
Minor comments
Line 90: "Disc Large (Dlg) RNAi in the eye" must be "Discs Large (Dlg1) RNAi in the eye imaginal discs".
we will fix this error.
Figures 1D and 1L are from the same image. Also, Figures 1C and 1M are from the same image. Are both of them necessary to be shown in the different panels?
The duplication of 1C and 1M, was an error, we thank the reviewer for picking this up. We will fix this error. We will use different images for 1D and 1L.
Why are the staining patterns of anti-pAkt shown in Figures 1L and 1U so different? pAkt is not detected in the nuclei in Fig. 1L but its nuclear signal is clear in Fig. 1U.
We will show more representative images of these staining.
Figure 1: Images of counter staining for nuclei like DAPI should be also included for all these fatbody images.
We will show counter staining for DAPI.
Line 101: "Tumour specific ImpL2 inhibition was sufficient to reduce fatbody pAkt levels." Is this correct? ImpL2 inhibition in tumors should elevate the pAKT level in fatbody.
This was a mistake, we will fix this error.
Figure S1~S4: These figures and their legends do not correspond to each other. We thank the reviewer in picking up this error, there was an error in inserting the images into the text. S2 and S3 were swapped.
We will fix this error.
Line 189: The pAkt level in the muscle of tumour-bearing animals should be examined to confirm the activity of the insulin signaling is downregulated.
We will include this data.
Line 189: If the authors conclude that muscle insulin signaling predominantly regulates translation and atrophy, OPP assay for the muscle cells should be examined in the same experimental settings.
We will carry out OPP assay upon Akt overexpression in the muscle.
Line 247: The expression level of Rab10 and SPARC should be examined in the fatbody of tumour-bearing animals to see whether Rab10 is upregulated and SPARC is downregulated.
Line 247: If Rab10 upregulation and SPARC downregulation are the causes of the accumulation of ECM proteins in the fatbody of tumour-bearing animals, how the overexpressed Collagen proteins can be secreted from the fatbody cells?
We are not sure, but the overexpression of Collagen proteins is at an extremely high level, therefore, it is possible that some of it can be processed and secreted despite Rab10 upregulation and SPARC downregulation. We have carried out an experiment to overexpress Collagen proteins in the muscle, in this case, this manipulation did not rescue. This indicates that processing of Collagen in the fatbody is important, however, we do not know how the processing is regulated.
Line 347: Sog is a secreted BMP antagonist. Thus, it can be expected that the Sog overexpression downregulates TGF-β signaling in fatbody and muscle tissues. If the rescued phenotypes with Sog overexpression can be explained by this logic, pMad level should be examined in these experiments.
We have shown this data in Figure R-T. We will refer back to this data in Line 347.
Reviewer #3
Major comments:
- Are the key conclusions convincing?
Most of the conclusions are convincing. It is not clear however whether the ECM accumulation in the fat body of tumor animals is fibrotic and whether it is extracellular or in the cell cortex.
- Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?
-The authors state in line 71 'This deposition of disorganized ECM leads to fibrotic ECM
accumulation.' The authors haven't really provided evidence for the ECM being fibrotic. The authors could either rephrase this or provide additional experimental evidence of fibrosis in the fat body.
We will tone down the claim that the ECM accumulation is fibrotic.
- Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.
-The authors state in line 147" Finally, in tumor-bearing animals fed a sterol-free diet, that underwent a prolonged 3rd instar stage due to reduced ecdysone levels (Parkin and Burnet, 1986), we activated insulin signalling in the fatbody via Akt overexpression (QRasV12, scribRNAi). We found that this manipulation caused a significant decrease in pMad levels in the fatbody and a rescue of muscle detachment (Figure S1 D-I), similar to animals fed a standard diet (Figure 1 O-Q, Figure 2 F-H)." Since it's not already known what the extent of muscle integrity defect there is in tumors with additional sterol free diet, it would be important to show a non-tumor control for comparison in FigS1F. This would also then make it clear to what extent the defect is rescued by Akt overexpression.
We will include a non-tumour control for Fig S1F.
-The authors state in line 158 'Upon the knockdown of Impl2, we found that tumor gbb was not significantly altered (Figure S3A).' Even though this shows an indication that Gbb levels are not reduced, the n number is too low to state that it is non-significant. The authors should increase the n number here.
N=3 is generally enough to see a difference, we will include data done in parallel which shows Impl2 RNAi is sufficient to induce a reduction in Impl2 RNA levels. This will demonstrate that n=3 is sufficient to demonstrate a reduction in transcript levels if there is a reduction.
-The authors state in line 171 'Conversely, knockdown of gbb alone or knockdown of gbb together with ImpL2 significantly rescued the Nidogen overaccumulation defects observed at the plasma membrane of fatbody from tumor-bearing animals, while ImpL2RNAi alone did not (Figure S2 Q-U).' This is a somewhat misleading representation, since again no non-tumor control was used, so the extent of the rescue by gbb knowdown is not obvious. In FigS2P Nidogen levels in the tumor seem ~100% higher than in control. But in FigS2U, in which no control was included, the tumor+gbb knowdown seems ~ 20% lower than tumor. So it is probably a more moderate rescue, but that's only possible to assess by including a non-tumor control in FigS2U. Also the images in FigS2Q-T don't seem representative since they appear to show a much bigger difference in fluorescence intensity than ~20%. Please show more representative images.
We will include a non-tumour control for S2Q-T and show more representative pictures.
-The authors state in line 174 'Finally, co-knockdown of gbb and ImpL2 in the tumor significantly rescued the reduction in OPP and Nidogen levels observed in the muscles of tumor-bearing animals (Figure S3 B-I).'
Again, the single knockdowns and the non-tumor control are not shown in FigS3E and I and should be included for comparison and to see the contribution of each knockdown and to be able to judge the extent of the rescue.
We will include the single knockdowns and a wildtype control
-Regarding Fig3O: Is there a significant tumor muscle attachment defect here? In this graph the tumor only looks about 10% lower than the WT (rather than 40% in Fig2E). The other issue is the extremely low n number for WT. I would recommend increasing the n number for WT here and to indicate in the graph whether the tumor is significantly different to WT (or non-significant, in which case RabRNAi wouldn't actually 'rescue' the defect). In the present form, this graph is not very convincing.
We will increase the n number for WT for this experiment. The reduction in muscle detachment is 10% rather than 40% here is because this experiment was done at day 6, which we will indicate in the figure legend. The 40% reduction in Fig2E is because these samples were processed at day7. Rab10RNAi experiment was carried out at day 6, because by day7, the Rab10RNAi rescue is so good, most of the tumour bearing animals have pupated, thus the experiment could only be carried out at day6.
- Regarding Fig3W: A non-tumor control would be important to include to be able to judge the extent of muscle attachment defects and the extent of the rescue for UAS-Sparc. This will allow to assess the severity of muscle integrity defect in this particular experiment (since it appears to vary in different experiments e.g. muscle defect in tumor 40% in Fig2E and ~10% in Fig3O) and to assess the extent of rescue for the various genotypes.
We will include a non-tumour control for 3W.
-The authors show an accumulation of ECM in the fat body of tumors. It is not clear, whether this ECM accumulates intracellularly near the cell surface or extracellularly. The authors should assess this, maybe by doing electron microscopy.
We do not have an EM facility that can accommodate this experiment, thus doing EM is not an option for us. However, we can address whether the accumulation of ECM is intracellular or extracellular by performing an experiment, where we try perform antibody staining against Viking-GFP without permeabilizing the cells. If Viking is detected without permeabilization, it would indicate the accumulations are extracellular. This approach has been previously used to address this question in Zang et al., elife, 2015.
- Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.
-These suggested experiments should be quite straightforward since they are mostly just repeating previous experiments with the appropriate controls and n numbers. I would think that they can be done within a few months. The electron microscopy should not take more than a few weeks and not be costly.
- Are the data and the methods presented in such a way that they can be reproduced?
-The details on how old animals used in each experiment were, are not easy to find and not written very clearly. They should be included in the each figure legend rather than summarising those details in the methods.
We will add the number of days in the figure legend.
-Also, in line 788 in the methods, several stocks are indicated as coming from particular labs (e.g. UAS-FOXO (Kieran Harvey), UAS-GFP (Kieran Harvey), UAS-lacZRNAi (Kieran Harvey), UAS-RasV12 (Helena Richardson), UAS-cg25C;UAS-Vkg (Brian Stramer)).
However, it is not clear whether these labs actually made these stocks and if so whether it has already been described in their papers how the lines were made. If the lines are unpublished, the detailed information should be given on how the lines were made. Or if the lines are published, the authors should provide the reference.
We will fix these references.
- Are the experiments adequately replicated and statistical analysis adequate?
In general, the n number is rather low in several experiments, especially n of 3 for many controls. And as I mentioned before, rescues of tumor phenotypes are often shown without including a non-tumor control, making it hard to judge the extent of the rescue. Sometimes this information can be found in other figures, but the reader should not have to search for it. And also the severity of the phenotype can vary from experiment to experiment.
We will include a non-tumour control when appropriate to address this.
Minor comments:
- Specific experimental issues that are easily addressable.
- Are prior studies referenced appropriately?
Yes, as far as I can tell.
- Are the text and figures clear and accurate?
-In the literature, people usually call it 'fat body' rather than 'fatbody'.
We will fix this error.
-The authors state in line 265 "Vkg accumulated in the membranes of fatbody where p60 was overexpressed using r4-GAL4 (Figure 5 A-C)."
This must be a typo. I think it is shown in Fig5E-G. Unless it's labelled wrongly in the figure and B, C and D show p60 rather than TorDN.
We will fix this error.
-The authors state in line 188 'This manipulation significantly rescued muscle integrity (Figure S4 A-C) and muscle atrophy (Figure S4 D-F), without affecting muscle ECM levels (Figure S4 G-H).' According to the graph in FigS4H this does actually 'affect muscle ECM levels' significantly, as in that it reduced Nidogen levels further. The authors could rephrase this.
We will reword this statement.
-
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary:
Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate).
This paper uses a Drosophila tumor model induced by the expression of RasV12+Scrib-IR or RasV12+Dlg-IR in the eye imaginal disc to understand how inter-organ communication affects cachexia in the fat body and muscle. The tumor has previously been shown to secrete the factors ImpL2 and Gbb which decreases insulin signalling and increases TGF-beta signalling in the fat body, respectively, and results in fat body and muscle defects. Here they dissect the role of insulin and TGF-beta signalling in the fat body in regulating muscle integrity further. They show that these two pathways converge via Sog in the fat body of tumor-bearing animals and result in aberrant ECM accumulation in the fat body which hinders ECM secretion. This then results in the muscle receiving less fat body-derived ECM which causes muscle attachment defects. Interestingly, these muscle defects can be ameliorated by activating insulin signalling or inhibiting TGF-beta signalling or even by increasing ECM secretion in the fat body. The authors also provide some evidence that the insulin and TGF-beta signalling pathways can converge in non-tumor settings.
Major comments:
- Are the key conclusions convincing?
Most of the conclusions are convincing. It is not clear however whether the ECM accumulation in the fat body of tumor animals is fibrotic and whether it is extracellular or in the cell cortex.<br /> - Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?<br /> - The authors state in line 71 'This deposition of disorganized ECM leads to fibrotic ECM<br /> accumulation.' The authors haven't really provided evidence for the ECM being fibrotic. The authors could either rephrase this or provide additional experimental evidence of fibrosis in the fat body.<br /> - Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.<br /> - The authors state in line 147" Finally, in tumor-bearing animals fed a sterol-free diet, that underwent a prolonged 3rd instar stage due to reduced ecdysone levels (Parkin and Burnet, 1986), we activated insulin signalling in the fatbody via Akt overexpression (QRasV12, scribRNAi). We found that this manipulation caused a significant decrease in pMad levels in the fatbody and a rescue of muscle detachment (Figure S1 D-I), similar to animals fed a standard diet (Figure 1 O-Q, Figure 2 F-H)." Since it's not already known what the extent of muscle integrity defect there is in tumors with additional sterol free diet, it would be important to show a non-tumor control for comparison in FigS1F. This would also then make it clear to what extent the defect is rescued by Akt overexpression.<br /> - The authors state in line 158 'Upon the knockdown of Impl2, we found that tumor gbb was not significantly altered (Figure S3A).' Even though this shows an indication that Gbb levels are not reduced, the n number is too low to state that it is non-significant. The authors should increase the n number here.<br /> - The authors state in line 171 'Conversely, knockdown of gbb alone or knockdown of gbb together with ImpL2 significantly rescued the Nidogen overaccumulation defects observed at the plasma membrane of fatbody from tumor-bearing animals, while ImpL2RNAi alone did not (Figure S2 Q-U).' This is a somewhat misleading representation, since again no non-tumor control was used, so the extent of the rescue by gbb knowdown is not obvious. In FigS2P Nidogen levels in the tumor seem ~100% higher than in control. But in FigS2U, in which no control was included, the tumor+gbb knowdown seems ~ 20% lower than tumor. So it is probably a more moderate rescue, but that's only possible to assess by including a non-tumor control in FigS2U. Also the images in FigS2Q-T don't seem representative since they appear to show a much bigger difference in fluorescence intensity than ~20%. Please show more representative images.<br /> - The authors state in line 174 'Finally, co-knockdown of gbb and ImpL2 in the tumor significantly rescued the reduction in OPP and Nidogen levels observed in the muscles of tumor-bearing animals (Figure S3 B-I).'<br /> Again, the single knockdowns and the non-tumor control are not shown here in Fig3E and I and should be included for comparison and to see the contribution of each knockdown and to be able to judge the extent of the rescue.<br /> - Regarding Fig3O: Is there a significant tumor muscle attachment defect here? In this graph the tumor only looks about 10% lower than the WT (rather than 40% in Fig2E). The other issue is the extremely low n number for WT. I would recommend increasing the n number for WT here and to indicate in the graph whether the tumor is significantly different to WT (or non-significant, in which case RabRNAi wouldn't actually 'rescue' the defect). In the present form, this graph is not very convincing.<br /> - Regarding Fig3W: A non-tumor control would be important to include to be able to judge the extent of muscle attachment defects and the extent of the rescue for UAS-Sparc. This will allow to assess the severity of muscle integrity defect in this particular experiment (since it appears to vary in different experiments e.g. muscle defect in tumor 40% in Fig2E and ~10% in Fig3O) and to assess the extent of rescue for the various genotypes.<br /> - The authors show an accumulation of ECM in the fat body of tumors. It is not clear, whether this ECM accumulates intracellularly near the cell surface or extracellularly. The authors should assess this, maybe by doing electron microscopy.<br /> - Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.<br /> - These suggested experiments should be quite straightforward since they are mostly just repeating previous experiments with the appropriate controls and n numbers. I would think that they can be done within a few months. The electron microscopy should not take more than a few weeks and not be costly.<br /> - Are the data and the methods presented in such a way that they can be reproduced?<br /> - The details on how old animals used in each experiment were, are not easy to find and not written very clearly. They should be included in the each figure legend rather than summarising those details in the methods.<br /> - Also, in line 788 in the methods, several stocks are indicated as coming from particular labs (e.g. UAS-FOXO (Kieran Harvey), UAS-GFP (Kieran Harvey), UAS-lacZRNAi (Kieran Harvey), UAS-RasV12 (Helena Richardson), UAS-cg25C;UAS-Vkg (Brian Stramer)).<br /> However, it is not clear whether these labs actually made these stocks and if so whether it has already been described in their papers how the lines were made. If the lines are unpublished, the detailed information should be given on how the lines were made. Or if the lines are published, the authors should provide the reference.<br /> - Are the experiments adequately replicated and statistical analysis adequate?<br /> In general, the n number is rather low in several experiments, especially n of 3 for many controls. And as I mentioned before, rescues of tumor phenotypes are often shown without including a non-tumor control, making it hard to judge the extent of the rescue. Sometimes this information can be found in other figures, but the reader should not have to search for it. And also the severity of the phenotype can vary from experiment to experiment.
Minor comments:
Specific experimental issues that are easily addressable.
- Are prior studies referenced appropriately?
Yes, as far as I can tell.<br /> - Are the text and figures clear and accurate?<br /> - In the literature, people usually call it 'fat body' rather than 'fatbody'.<br /> - The authors state in line 265 "Vkg accumulated in the membranes of fatbody where p60 was overexpressed using r4-GAL4 (Figure 5 A-C)."<br /> This must be a typo. I think it is shown in Fig5E-G. Unless it's labelled wrongly in the figure and B, C and D show p60 rather than TorDN.<br /> - The authors state in line 188 'This manipulation significantly rescued muscle integrity (Figure S4 A-C) and muscle atrophy (Figure S4 D-F), without affecting muscle ECM levels (Figure S4 G-H).' According to the graph in FigS4H this does actually 'affect muscle ECM levels' significantly, as in that it reduced Nidogen levels further. The authors could rephrase this.<br /> - Do you have suggestions that would help the authors improve the presentation of their data and conclusions?
Significance
- Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.
The field of inter-organ communication in cancer is a very interesting and trending research field. Several labs including this one have provided new insights into how the tumor, the fat body and the muscle communicate and affect each other and how this can cause cachexia. Previous work from the Chen lab already showed that the tumor secretes the factors ImpL2 and Gbb which decreases insulin signalling and increases TGF-beta signalling in the fat body, respectively and results in fat body and muscle defects. Here they dissect this role of insulin and TGF-beta signalling in the fat body in regulating muscle integrity during cachexia further. They show that these two pathways converge via Sog in the fat body of tumor-bearing animals and result in aberrant ECM accumulation in the fat body which hinders ECM secretion. As a result of this, the muscle receives less fat body-derived ECM and displays muscle attachment defects. Interestingly, the authors show that these muscle defects can be ameliorated by activating insulin signalling or inhibiting TGF-beta signalling or even by increasing ECM secretion in the fat body. This has potentially important implications for the clinic since it suggests that targeting ECM secretion or ECM remodeling in the fat tissue could be a promising treatment for cachexia.<br /> Moreover, the authors also provide some evidence that the insulin and TGF-beta signalling pathways can converge in tumor and non-tumor settings. This might also reveal new drug targets to treat cachexia.<br /> - Place the work in the context of the existing literature (provide references, where appropriate).
The Chen lab showed previously that MMP1 secreted from the tumor induces ECM disruption in the fat body as well as muscle, ultimately causing fat body remodeling and muscle wasting (Lodge et al. 2021). They showed that this is via TGF-beta activation in the fat body. Another contributing factor is tumor-secreted Impl2 which decreases Insulin signalling in the fat body and tumor. However, it remained unknown, how ECM accumulation in the fat body might cause muscle wasting. In this paper, the authors look into this.<br /> - State what audience might be interested in and influenced by the reported findings.
This paper would be of interest for scientists and clinicians interested in inter-organ communication in cancer, particularly in the context of cachexia.<br /> - Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.
My expertise lies in the field of Drosophila fat body and ECM, and to some extent tumors but less so signalling pathways.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary
In this paper, the authors show how the interaction of two signaling pathways, insulin/PI3K and TGF-β signaling, in the fatbody plays an important role in cachectic muscle detachment in tumor-bearing animals. The Drosophila tumor models and the genetic experimental tools are sophisticated and the conclusion is well supported by the data from these genetic experiments. They found that the TGF-β signaling activation (phosphorylation of Mad) is negatively regulated by insulin/PI3K signaling in the fatbody. They also identified the functional involvements of two molecules secreted from tumour tissues, Impl2 (a negative regulator of insulin signaling) and Gbb (one of the TGF-β ligands), in protein synthesis and ECM accumulation in the fatbody, respectively. They also showed that the cachectic fatbody traps ECM proteins and prevents ECM secretion to the muscle, causing muscle degradation. Finally, they identified a secreted BMP antagonist, Sog, as an important player in this process. They found that Sog is reduced in the hemolymph of tumour-bearing animals and that Sog expression is regulated by insulin signaling. Furthermore, Sog overexpression in the tumours, fatbody, and muscle rescues cachectic muscle detachment.
Major comment
Their genetic experiments clearly showed that the reduction of insulin signaling activity in the fatbody induces upregulation of TGF-β signaling and Collagen accumulation. Then, how does TGF-β signaling induce Collagen accumulation? They showed that Rab10 knockdown and SPARC overexpression reduced the accumulation of fatbody ECM. Are Rab10 and SPARC expression regulated by TGF-β signaling?
Minor comments
- Line 90: "Disc Large (Dlg) RNAi in the eye" must be "Discs Large (Dlg1) RNAi in the eye imaginal discs".
- Figures 1D and 1L are from the same image. Also, Figures 1C and 1M are from the same image. Are both of them necessary to be shown in the different panels?
- Why are the staining patterns of anti-pAkt shown in Figures 1L and 1U so different? pAkt is not detected in the nuclei in Fig. 1L but its nuclear signal is clear in Fig. 1U.
- Figure 1: Images of counter staining for nuclei like DAPI should be also included for all these fatbody images.
- Line 101: "Tumour specific ImpL2 inhibition was sufficient to reduce fatbody pAkt levels." Is this correct? ImpL2 inhibition in tumors should elevate the pAKT level in fatbody.
- Figure S1~S4: These figures and their legends do not correspond to each other.
- Line 189: The pAkt level in the muscle of tumour-bearing animals should be examined to confirm the activity of the insulin signaling is downregulated.
- Line 189: If the authors conclude that muscle insulin signaling predominantly regulates translation and atrophy, OPP assay for the muscle cells should be examined in the same experimental settings.
- Line 247: The expression level of Rab10 and SPARC should be examined in the fatbody of tumour-bearing animals to see whether Rab10 is upregulated and SPARC is downregulated.
- Line 247: If Rab10 upregulation and SPARC downregulation are the causes of the accumulation of ECM proteins in the fatbody of tumour-bearing animals, how the overexpressed Collagen proteins can be secreted from the fatbody cells?
- Line 347: Sog is a secreted BMP antagonist. Thus, it can be expected that the Sog overexpression downregulates TGF-β signaling in fatbody and muscle tissues. If the rescued phenotypes with Sog overexpression can be explained by this logic, pMad level should be examined in these experiments.
Significance
I found these results from their genetic experiments described here very interesting and of high quality. Although the mechanism by which the TGF-β signaling induces ECM accumulation in fatbody is not clear, this study represents several important advances to understand the key processes in tumor-induced muscle degradation. These data will attract broad audiences not only from cancer biology but also from the research fields including interorgan interactions, systemic signaling in homeostasis, and developmental biology.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
In this manuscript, Bakopolous et al. investigated on the function of Insulin and TGF beta signaling in the converging regulation of sog (BMP antagonist) and how it controls ECM remodeling. Therefore, the authors used a Drosophila model of cachexia established in Lodge et al., 2021. The authors have shown that the tumors increase Impl2 and Gbb in the fatbody leading to the inhibition of insulin signaling and activation of TGF-β signaling respectively. This lead to the accumulation of ECM proteins that contributes to muscle ECM deficit and muscle detachment. These findings are a major advance in the field of cachexia and of broad interest. The authors demonstrate that state-of-the-art genetics in flies allows acquisition of genetically precise data along with important and complex discoveries on signaling pathways with relevance not only for basic, but for biomedical research as well.
The manuscript is concise and very well written. The experiments overt a clear logical order and are comprehensively described. The authors provide exhaustive data to support their novel claims of broad interest to the scientific community. Please find below some minor recommendations and experiments that could shed further light on some aspects of this manuscript.
Major:
- The statement (line 149'Together, our data suggest that systemic ecdysone levels are unlikely to be involved in modulating tumour-induced muscle detachment or to mediate the role of fatbody Insulin signalling in regulating muscle detachment.') is derived from an experiment with sterol free diet (in which 20HE is genetically addressed) and a pleiotropic experiment (PG>RasG12V). In neither paper nor the current manuscript, 20HE levels have been directly addressed.<br /> Therefore, this statement needs further experimental support and discussion. Ecdysone is a critical hormone during development and especially growth-related effects central to this study. The authors should consider doing pharmacology or augment their claims here with genetic manipulation experiments of 20HE related genes in larvae (Leopold, Rewitz, Rideout, Drummond-Barbosa, Schuldiner labs) and adult animals using genetics, pharmacology or direct assessment of 20HE levels (RIPA, Edgar and Reiff labs).
- In Fig.7 the authors used a sog-LacZ stock to show transcriptional activation in fatbody cells. This stock is based on P-element insertion in the according regulatory regions and supposed to express lacZ with an nls. I can clearly see lacZ in nuclei in Fig. 7H, whereas this is very hard to see in nuclei in Fig7i in the tumour model. In addition, lacZ is known for its high stability and not the best option. As this finding is vital for central claims of this study, it should be complemented by either qPCR for sog on fat body cells or using another readout by converting one of the two Mimic lines (BL42189/44958) into GFP sensors for sog.
- I have similar problems with Fig.7B-F, as phosphorylated Mad should be translocated to the nucleus. In 7F the authors measure pMad over Dapi, which is the right way but it is hard to see pMad in the nucleaus apart from Fig7B, wheras in D and E, where the authors measure higher levels, I cannot identify clear pMad in nuclei. These images either need to show the Dapi channel or more representative images should be chosen like in Fig.4 with arrows pointing to measured nuclei. Fig.7C something went wrong with the compression of this image.
- The proper function of RNAi stocks targeting genes like sog, mad, etc. is vital for this study as these lines are used throughout the study. Functional evidence of specific knockdown efficiency should be provided or references given in which these stocks were shown to provide functional knockdown on transcript or protein level.
- Fig.S7 discusses appearance of gbb/Bmp7 and Sog/CHRD in human patients. The analysis the authors performed shows a correlation between both factors, but is hampered by the fact that datasets for peripheral tissues of cachexia patients are unavailable. The authors may consider sorting these after tumor entities in which cachexia occurs frequently vs. low occurrence and then check for both genes.
- Fig.5 M-P pMAd is not indicated in the Panels only the legend.
- Please follow FlyBase nomenclature, e.g. dlg1 for discs large 1 and unify in the whole manuscript and figure for all genes.
- For endogenous fusion proteins like Viking-GFP (e.g. vkg::GFP) choose a format to clearly decipher them from transcriptional readout stocks like sog-lacZ.
- The quantifications in most figures are quite small with tiny lettering and XY axis are difficult to read in letter/A4 size.
Minor:
- Adjust in-figure caption alignments
- Line 104: add comma RasV12, dlgRNAi
- Line 114: replace little not significant (n.s.)
- Line 334: 'sogRNAi overexpression' to my knowledge, RNAi are expressed, not overexpressed.
- Line 454: italicize r4>
- Fig S4E: remove frame
- Figures 6: It would be better to number and explain the pathway presented in the figure in text and fig legend.
- Just a personal preference. Lettering of images in images is commonly done horizontally, here it appears like a mix between vertical and horizontal.
Significance
In this manuscript, Bakopolous et al. investigated on the function of Insulin and TGF beta signaling in the converging regulation of sog (BMP antagonist) and how it controls ECM remodeling. Therefore, the authors used a Drosophila model of cachexia established in Lodge et al., 2021. The authors have shown that the tumors increase Impl2 and Gbb in the fatbody leading to the inhibition of insulin signaling and activation of TGF-β signaling respectively. This lead to the accumulation of ECM proteins that contributes to muscle ECM deficit and muscle detachment. These findings are a major advance in the field of cachexia and of broad interest. The authors demonstrate that state-of-the-art genetics in flies allows acquisition of genetically precise data along with important and complex discoveries on signaling pathways with relevance not only for basic, but for biomedical research as well.
The manuscript is concise and very well written. The experiments overt a clear logical order and are comprehensively described. The authors provide exhaustive data to support their novel claims of broad interest to the scientific community
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
The authors do not wish to provide a response at this time.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #4
Evidence, reproducibility and clarity
Summary
The authors in this manuscript create in vitro degron models of DNMT1 as tools to investigate the roles and functions of DNA methylation in molecular and cellular processes. Degron models can directly target the tagged protein of interest leading to its degradation. When it comes to DNMT1, this system can bypass the use DNMT inhibitors, like DAC and GSK3685032 that can have secondary cytotoxic effects. More specifically, the authors create DNMT1 degron tagged models of two cell lines (DLD-1 and RPE1), as well as a DNMT1 degron tagged model of a DNMT3BKO DLD-1 cell line. These systems allowed the authors to investigate the passive demethylation occurring over consecutive cell divisions, and particularly the role of DNMT1 and DNMT3B and their cooperativity in maintaining DNA methylation levels and how this differs among different genomic regions. The authors characterise the cell fitness of the models they established when DNMT1 is degraded, and methylation levels are lost, and observe a reduction of fitness due to G1 arrest. Finally, the authors show that the loss of DNA methylation observed in these cells leads to reduced levels of heterochromatin (H3K9me3) as well as changes in chromatin and nuclear compartmentalization. Overall, the authors, show an appealing in vitro model that can directly target DNMT1, allowing for more delicate experiments that address the impact of DNA methylation levels in somatic cells, to de-convolute their exact roles from other epigenetic marks and cellular processes that are often correlated with.
Major comments
- The auxin degron system relies on the ectopic expression of OsTir1, which is described in materials and methods under 'Plasmids and Cell line generation'. However, OsTir1 expression is never addressed during the manuscript. Quantification of OsTir1 expression levels across the different cell lines is very important in order to more comprehensively characterise this system. This is especially when considering one of the key points of the authors is to establish these new in vitro models as a new tool to study DNA methylation dynamics in the field.
- The degron system requires an endogenous tag of the protein of interest. Specifically in this work, a tag including the mNGreen and the AID sequence are incorporated at the N-terminus of DNMT1. It is unlikely that there is major interference of the tag to protein function as the tagged cells for DLD-1 and RPE1 are both viable and demonstrate high methylation levels. However, the authors do not consider or discuss that the tag might interfere with the function of the protein at all. It would be useful if the authors compared the tagged cell lines (untreated) with wildtype controls for their methylation levels and/or DNMT1 expression and/or DNMT1 localisation with imaging. These experiments would better substantiate the use of untreated cells as 'wildtype' equivalents and contribute to the better characterisation of these systems as in vitro models.
Furthermore, DNMT1 can have different transcripts that begin from different sites. Do the authors consider whether the tag is included in all/most isoforms of DNMT1, or if there are any expressed without it? - The authors observe that DNMT1 is important for maintaining methylation levels as well as proper cell proliferation. They also observe that DNMT1 depletion does not lead to complete lethality as previously observed (Rhee et al., 2000 Nature, Chen et al., 2007 Nature Genetics). They hypothesise that this might be due to non-specific toxic effects (from CRE) and suggest that the degron system is better suited to bypass such toxicity effects. While this might be true and degron systems do provide a direct and acute protein depletion without non-specific toxicity, the authors do not discuss the implications p53 activity might have on the lack of lethality they observe. Omitting the role of p53 in hypomethylation models and drawing conclusions about toxicity effects between different systems can be misleading and should be corrected. Specifically, it has been shown that hypomethylation triggers p53 dependent apoptosis (Jackson-Grusby et al., 2001 Nature Genetics). The authors do acknowledge the difference in p53 activity when comparing between DLD-1 and RPE-1 DNMT1 depleted cells. The reduced proliferation of RPE-1 cells would suggest that irrespective to the degron system, viability depends on tolerance of each cell line to hypomethylation (whether this is p53 dependent or not). DLD-1 cells seem to have a single nucleotide variant in p53 (p.Ser241Phe (c.722C>T)) (Liu et al., 2006 PNAS), that could potentially explain their viability upon hypomethylation, although further work is required to conclusively suggest such interaction. Furthermore, DNA methylation levels and chromatin organisation of RPE-1 NADNMT1 cells are not characterised in the manuscript and is unclear why. - Figure 1D, 1E: The authors provide a Western blot of DNMT (1/3A/3B) across the established cell lines. While some effects like the degradation of DNMT1 based on the degron system or the KO of DNMT3B are convincing (and work well to validate the cell lines), the observation about upregulation of DNMT3B when DNMT1 is degraded, or levels of DNMT1 after wash out, are not as convincing when only showing one blot. This is especially when considering that the DNMTs might have cell cycle expression differences. Additional replicas of the western blot and quantification of bands across replicas, or qPCR to show upregulation of DNMT transcripts, or imaging (like figure S1E), would help make the claim of DNMT3B upregulation and DNMT1 recovery more convincing. - The authors show that during wash out (after stopping the IAA treatment), DNMT1 levels can recover slightly and show the methylation levels of specific sites (figure 2B). However, the authors do not make any characterisation of the global levels of methylation levels and their potential recovery (?) after wash out. This could be either done by imaging (like in figure 1F and 1G) or dot blot (like figure S2A) or mass-spec.
The authors note that recovery of DNMT1 after wash out is to a lesser extent in the NADNMT1/DNMT3B-/- background. The authors do not speculate why would this be. Past reports of degron tagged proteins show that after treatment endogenous protein levels can recover. Does this hint towards a viability issue of the line due to excessive hypomethylation? While difficult to prove it would be useful to speculate why this effect occurs. - The authors employ DNAme arrays to assess the DNA methylation loss after degradation of DNMT1 and study where in the genome this occurs. Specifically, the authors look on differentially methylated probes between treated/non treated samples and demonstrate their abundance over different genomic regions (figure 2E and S2 H, I, J, K). However, this way of visualising the data is a bit difficult to interpret as differences can be small. Furthermore, number of probes across the genome is not uniformly distributed, so it would be useful to include these numbers. It would be helpful if authors can provide genome browser snapshots with methylation levels and accompanying histone marks (from available data, Rokavec et al., 2017?) like done in figure 4F, S4B and S5C to show representative regions that showcase their observations. Coverage of the EPIC array will mean that these tracks will not have high coverage and thus gaps, and ideally one would need whole genome bisulfite data, however hopefully some snapshots can demonstrate locus specific changes better.
Considering the function of DNMT1 in remethylating the DNA after replication, one would assume that methylation is lost equally across the genome as a simplistic model. Of course, there are many reasons like secondary functions of DNMT1, DNMT3A/3B and TET activity etc that could alter this and provide biases over regions of the genome. The authors discuss this and note most probes show such loss (106,647 of 178,529). It would be useful for the authors to better describe where the rest of the probes (that do not lose the expected methylation, annotated as 'late') are located and speculate what mechanisms might be involved. This is partly addressed in figures S2H and J, but it is not immediately clear what distinguishes late regions from early. Genome tracks with methylation levels and histone tracks as mentioned above could provide examples of regions.
The authors briefly discuss the role of DNMT1 and DNMT3B in methylating specific regions and their cooperativity as well as the underexplored de novo activity of DNMT1. Based on their findings, can the authors draw any new mechanistic conclusions/observations about the activity of DNMT1 and/or DNMT3B and how it is directed? Are there any sequence signatures or histone mark profiles that could explain the hypomethylation or remethylation (after wash out) of specific loci? - The authors observe that 70% of DMPs display an increased methylation in the DNMT3BKO cell line compares to NADNMT1. The authors speculate that this is due to an 'uncontrolled activity' of DNMT1 in the absence of DNMT3B. The increased levels observed could be a clonal effect when generating the KO line. While including additional clonal lines can be a significant amount of work, the authors should acknowledge the effects of clonality in their findings when comparing between the cell lines used (that do not relate to the IAA treatments). - In figures 3D and S3D, the authors compare the viability between IAA treated cells as well as DAC and GSK3685032 and observe increased toxicity/lethality in the case of DAC and GSK3685032. It would be helpful for the authors to discuss the dosage and concentration they used for each drug and why. In order to compare the viability of cells between treatment of different drugs, one would expect dosages that lead to equivalent extents of hypomethylation. - The authors show in figure 3 that the cell lines used have major cell cycle defects, with pronounce G1 arrest, when treated with IAA. Then the authors proceed to perform HiC in treated and untreated sample in figure 4. Can cell cycle differences be cofounding in chromatin compartments and thus affect the data observed in HiC? - For figure 4F and G the authors note a global reduction of H3K9me3 levels after treatment. It would be helpful if the authors include assessment of global levels of H3K9me3 (for e.g. by WB) or ChIP qPCR on loci of interest or specify the use of spike-in in methods, as alterations in global levels of a mark can lead to skewed normalisation/quantifications between samples. Alternatively, comparing the peaks/domains of a mark (and whether they are conserved across cell lines) but not directly compare levels can provide a safer interpretation of the data. - For figures 4F and S5C different days of treatment are provided, with HiC and H3K9me3 being done after 10d of IAA and CpG methylation after 4d of IAA. It is not explained why this discrepancy in days of treatment has occurred, which can be misleading as 10d treated cells should have lower methylation levels from 4d treated cells.
Minor comments:
- Typo in introduction: germiline
- Introduction has some sentences that might need rewording. For example: 'Somatic DNAme domains are erased right after fertilization to establish a totipotent germiline epigenotype, deposited de novo during early development and undergo massive re-shaping during differentiation, lineage specification, and in response to external cues; then, they are maintained and inherited through cell divisions'. It would be good if this is broken into smaller sections as it is hard to follow.
- Introduction does not include the degron technologies and their advancement in the last couple of years. Considering the main point of the paper is to establish an in vitro tool to study DNA methylation based on degrons, it would be helpful to include some information about the technology in the introduction.
- Introduction does not include HiC technologies and the different compartments (A/B, and further subcategories) that the genome can be divided in by them. As the authors then proceed to use HiC data and perform such genome compartmentalisation, it would be helpful if this is addressed briefly at the introduction.
- The authors do not mention the DNMT3BKO strategy they employed. Specifically, the exact strategy should be listed under 'Plasmids and Cell line generation'. A genotyping PCR at supplementary (like figure S1B) could be added. A schematic like Supplementary Figure S1A would also be helpful, but not necessary.
- The duration and concentration of DAC and GSK368503 are not always indicated in figure legends.
- Figure 1C. Homozygous intensity of GFP is much more heterogeneous than the heterozygous levels. It would be interesting if authors could speculate why this is.
- Figure S1D, S1E: Quantification of imaging experiments is shown, however there is no representative images of the staining performed. Incorporate an example image of each staining would be helpful to accompany the quantifications.
- Typo: 106,647 ("early") of 178,529 probes
- Figure 2D: DNA methylation levels in somatic cell lines usually have a bimodal distribution with highly and lowly methylated regions, thus the representation of the data with a boxplot can be misleading.
- Figure 3E: The no. of colonies after IAA removal (from figure 3D) is not included, as suggested from the text.
- Figure S3E: Aneuploidy will be dependent on number of cell divisions so it would be helpful if authors specified how long after treatment the experiment was performed.
- Figure S4B typo: On top track blue compartment is annotated as DLD1-H, while I think it should be DLD1-B2/B3?
- It would be helpful if the authors include an example image of how the segmentation and quantifications for figure 4A and 4B-C were performed as a supplementary figure, demonstrating the area they consider as periphery.
- Figure 3B-C have no error bars and figure legend mentions N>15643 cells per condition. It would be helpful if the number of cells per condition is included in the legend and error bars are included in the figure.
- The authors note that there must be a cooperative effect of DNMT1 and DNMT3B in maintaining DNA methylation and that they observe a strong additive effect in cell survival in double DNMT1/3B depleted cells. These observations have already been observed in the past in HCT116 cells, so it would be useful to cite these papers along with their observations. For e.g. Rhee et al., 2002 Nature, Cai et al., 2017 Genome Research
- A degron tagged DNMT1 in HCT116 cells has already been shown at Onoda et al 2022 bioRxiv that would be good to reference. While the authors in this preprint do not perform any characterisation of methylation levels of the tagged line as in this work, it provides a similar in vitro model that is helpful to include.
- The effects of extensive hypomethylation due to the lack of DNMT activity and its effect in 3D genome integrity has also been shown in the best and would be helpful to mention. For e.g. Du et al., 2021 Cell Reports
Significance
The authors in this work generate and characterise an untransformed (DLD-1) and cancer (RPE-1) cell line model of DNMT1 with a degron tag, as well as DNMT3BKO line of DLD-1 with the degron tagged DNMT1. These in vitro degron models allow for acute deletion of DNMT1 and induced hypomethylation and can be valuable tools to study the effect of DNA methylation in other epigenetic marks and cellular processes. The authors demonstrate the role of DNMT1 and DNMT3B and their cooperativity in maintaining DNA methylation levels in these cells, as previously demonstrated in similar somatic cell models. They also characterise the fitness of these cell lines after DNMT1 degradation and note their viability over DAC and GSK3685032 treatments that can have secondary cytotoxic effects. However, the viability of the cells and the reasons of observed lethality in some systems is underexplored, with the extent of hypomethylation in each system not specified. Finally, the authors show that DNMT1 and DNMT3B impact heterochromatin and the loss of DNA methylation leads to changes in chromatin compartmentalization (with HiC), which have been observed before. While the DNA methylation levels and chromatin organisation of DLD-1 cells was investigated, the authors do not provide any characterisation of these in RPE-1 cells. Furthermore, it appears that RPE-1 cells show more pronounced cell cycle defects and reduced viability hinting towards p53 dependent apoptosis due to loss of methylation, something which is not extensively explored. These observations suggest that the viability of the DLD-1 cells is 'DLD-1 specific'/p53 dependent and not due to the degron system overall. Nevertheless, these in vitro tools will be highly valuable in the epigenetics and specifically DNA methylation fields and their more comprehensive characterisation and will be of high significance.
My field of expertise lies within DNA methylation mechanisms and have limited expertise in HiC experiments.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
The manuscript by Scelfo et al. describes the establishment of an auxin-inducible degron system for depleting DNMT1 in human cancer and immortalized cell lines. Using this system, the authors show that lack of DNMT1 leads to a profound passive loss in 5mC that is enhanced in the context of DNMT3B knock-out. The decrease in 5mC is further associated with cell-cycle arrest in G1. In addition, they demonstrate through microscopy that the peripheral distribution of heterochromatin in the nucleus depends on DNA methylation. By running Hi-C analysis, the authors further show that specific chromatin domain interactions depend on DNMT1 levels while others depend on DNMT3B. Finally, restoring DNMT1 levels through auxin wash out, although with different kinetics, partially alleviates the above-mentioned effects of DNMT1 loss.
This is a well-designed study and in general the data support the conclusions that are drawn by the authors. I have one concern though regarding the description of the genomic distribution of DMPs (Page 11 of the text and Fig. S2H and S2I). Indeed, the authors indicate that "DNAme at active promoters was unaffected" but Fig. S2H and S2I show that, if I understood correctly how data are represented, 2.5 % (S2H) to 5 % (S2I) of DMPs are falling within the active promoter category. I agree that these are under-represented when compared to the % of CpGs falling in this category in the Epic array but one cannot say that no DNAme change is targeting these regions. A similar concern applies to the description of Fig. S2J,K. In addition, I found the authors could describe and justify in a more detailed way their choice of the two cell lines used in the present study (DLD1 and RPE cells). Also, it would be useful to have information on the cell cycle duration in these cells in order to be able to fully interpret the impact of DNMT1 loss on cell cycle in the time frame used here. Finally, information regarding the cell lines used to acquire data is missing in a number of figure legends. This is the case for instance for Fig. 1B,D,E,F,G, Fig. 3A and Fig. S3E in which it is not specified whether the authors used RPE or DLD1 cells.
Significance
The novel system described here will certainly be of interest to researcher in the field of DNA methylation and chromatin organization. This article presents convincing and original data showing that DNMT1 levels can be reversibly down-regulated through the auxin-inducible degron thus providing opportunities to study the effects of DNA methylation loss on chromatin organization without the drawbacks usually observed in long-term KO experiments or treatment with toxic DNMT inhibitors. Example of such data obtained with the degron system are convincingly showing that peripheral heterochromatin relies on DNA methylation by DNMT1 and that interaction of heterochromatic domains also depend on DNMT1 activity. Another original finding is that the spatial organization of different silent chromatin domains can also depend on DNMT3B activity, independently of DNMT1. The fact that DNMT1 levels can be restored after wash out of auxin medium is probably one of the most interesting aspects of this study since it allows to run assays that are not possible in the context of DNMT KO experiments. Using this strategy, the authors demonstrated that, concomitant to an increase in DNA methylation, heterochromatin relocates to the periphery of the nucleus and that DLD1-BA compartmentalization is restored. In this respect, the authors observed that compartmentalization of B4 is rapid and near complete at a time when DNA methylation recovery is still partial, suggesting that DNMT1 could have catalytic-independent roles in this process. Although this is possible, another explanation could be that a partial re-methylation of DNA is sufficient for recovering homotypic interactions.
Regarding Hi-C data, similar results obtained with DNMT1/DNMT3B DKO and 5-aza-deoxycytidine-treated HCT116 cells were already described in a previous study from the authors (Spracklin et al. Nat Struct Mol Biol, 2023). However, differences in the reorganization of chromatin contacts after auxin treatment of DLD1 cells compared to 5-aza-dC or DKO HCT116 cells can be evidenced and are possibly linked to a difference in the organization of heterochromatin between DLD1 cells and HCT116, highlighting the usefulness of running these analyses in different cell types.
Although not really crucial in the context of the present study, information on the transcriptomic changes induced by DNMT1 loss could add some insights into the cellular state induced by auxin treatment. Indeed, cells are arrested in G1 and peripheral heterochromatin seems to undergo spatial rearrangement. This is reminiscent of senescence-associated processes and a loss of DNA methylation during replicative aging has already been documented. Especially, knock-down of DNMT1 is known to trigger premature senescence entry (Cruickshanks et al., Nat Cell Biol, 2013). Hence, a further characterization of the G1-arrested cells upon auxin treatment would clearly add some value to the manuscript.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary:
In this paper, Scelfo, A. et al. investigated the mechanisms underlying the cooperative maintenance of DNA methylation by DNMT1 and DNMT3B. Using a rapid degradation of DNMT1 by the auxin-inducible Degron system, which allows the assessment of reversible and time-dependent effects of DNMT1 loss with low cytotoxicity, the authors revealed a cooperative activity between DNMT1 and DNMT3B to maintain DNA methylation. Furthermore, they showed that gradual loss of DNA methylation is accompanied by progressive and reversible changes in heterochromatin abundance, compartmentalization, and peripheral localization. Collectively, this study provides a new cellular model to investigate the fundamental and biological role of DNA methylation and the molecular mechanism underlying its establishment and maintenance.
Important comments:
- Are there any data showing no change in DNA methylation level of WT DLD-1 and DNMT NA DLD-1 cells?
- In Fig. S2A and S2D, differences in global DNA methylation between NA-DNMT1-IAA-Day4 and DAC-treated cannot be determined from these images alone because the blot intensities appear similar. It is better to present the results in a more quantitative manner with appropriate statistical analysis.
- In Figure 2D, it is better to present the results in a more quantitative manner with appropriate statistical analysis.
- In Figures 3A and S3B, the authors show that DNMT1 depletion decreases the percentage of cells in S phase and increases the percentage of cells in G1 phase and sub-G1 phase in NA-DNMT1/DNMT3B KO. The authors postulate that the decrease in cell proliferation after DNMT1 depletion is due to activation of p53. Data demonstrating activation of the p53 pathway are needed.
Minor comments:
- Regarding IAA-induced DNMT1 degradation, the authors should provide complete DNMT1 blots to show that no additional isoforms are present.
- In Fig. S1C. Molecular weight was not labeled in the immunoblot.
- In Fig. S2B. NeonGreen-IAA 10days images appear to be exposed for different lengths of time.
- In Fig. 4B-C, S1E, S2E. It is better to present the results in a more quantitative manner with appropriate statistical analysis.
- Contrary to Fig. S2A, the PCA analysis does not seem to show any difference between NA-DNMT1-IAA Day2 and Day4.
Significance
Collectively, this study provides a new cellular model to investigate the fundamental and biological role of DNA methylation and the molecular mechanism underlying its establishment and maintenance.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
In this manuscript, Scelfo et al. describe how different DNMTs cooperate to maintain DNA methylation and the impact of decreased DNA methylation on chromatin structure. Toward this, they established an inducible degradation system for DNMT1 in untransformed and cancer cell models. The experiments revealed that DNMT1 and DNMT3B are required to maintain and control DNA methylation patterns throughout the genome. The authors also demonstrate that heterochromatic regions are highly susceptible to DNA demethylation, with loss of their localization to the nuclear periphery and disappearance of their compartmentalization patterns. Together, this work will allow better temporal resolution analysis of DNA methylation abnormalities and will be useful for clarifying the role of DNA methylation and its regulatory mechanism.
Major comments:
- In Figure 2G, the authors report increased DNA methylation at selected loci in the absence of DNMT3B and suggest a compensatory role for DNMT1 in de novo methylation, as this increased DNA methylation is lost upon DNMT1 depletion. However, how do the authors rule out the possibility that this methylation is catalyzed by DNMT3A and maintained by DNMT1?
- In Figure 3, the authors demonstrate that DNMT1 depletion leads to cell cycle arrest at G1. Since p53-proficient RPE-1 cells showed faster G1 arrest (Figure S3B), the authors suggest that DNMT1 depletion activates the cell cycle checkpoint. The authors might want to check p53, p16, and p21 levels in line with their suggestion.
- Figure 4F and 4G demonstrate a global reduction of H3K9me3 levels upon DNMT1 depletion. Is a similar effect seen with H3K27me3?
Significance
Understanding how DNMTs regulate chromatin structure and cell fitness is critical to understand better how DNA methylation impact cell fate and function.
Strength: This work established an inducible DNMT1-degradation system with reversibility, temporal control, and low toxicity.
Weakness: this work is merely descriptive and preliminary to understand the observed phenotypes clearly.
Advance: Although the presented experiments are accurate and well-designed, it has already been reported that DNMT1 and DNMT3A/3B cooperate to maintain DNA methylation patterns and that reduced DNA methylation leads to the disruption of H3K9me3/HP1-enriched heterochromatin structure. In addition, the molecular understanding underlying these phonotypes remains unexplored. In its current form, the contributions of this study to the field will be limited.
-
-
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
The authors do not wish to provide a response at this time
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Rios-Szwed and co-authors show that the depletion of FAM111A results in faster replication speed, longer intra-origin distances, and less chromatin-bound RPA even without induction of replication stress in U2OS cells. Induction of replication stress in FAM111A-depleted cells results in blunted response with less DNA damage, decreased checkpoint activation and resistance to the replication-stress inducing agent, HU. They show that cells without FAM111A display lower levels of single stranded DNA after treatment.
In the second part, the authors show that FAM111A and FAM111B form a complex, although the similarities and differences of their functions are not explored in detail. From the little data shown, it looks like they might be working together in controlling amount of ssDNA. They find that both proteins are expected to have two conserved UBL domains, with one of them overlapping with ssDNA binding domain. Finally, the authors use overexpression of WT and mutant proteins to show that expression of WT and patient-derived mutant has increased level of DNA damage, increased levels of ssDNA, with and without DNA damage, and that the peptidase domain is necessary for the phenotypes.
The data from the first two figures are consistent with FAM111A being involved in regulation of single stranded DNA formation during normal replication and during replication stress. Unfortunately, the work gives no indication of the mechanism of such regulation. I am not convinced that the function has much to do with controlling origin activation (see below). The data from the last two figures is also descriptive. Until the substrates of FAM111A are identified, there will be no understanding of its true function and the data will continue to be descriptive.
Specific points:
Figure 1: The siFAM11A-2 has a stronger phenotype in growth assay but has very little change in levels of cells in G1. No complementation of the phenotype is given.
1D- there is no total RPA so it is unclear if there is no change in pRPA in relation to total RPA. Small differences will be missed without DNA damage and it would be helpful to use more sensitive assays to identify the reduction in ssDNA under unperturbed conditions.
1E- what does the data look like if the lengths of IdU are plotted? This would be a measure of speed of the ongoing forks. Generally, this would be better than the CldU measurement.
1F- the Inter-CldU distance increase could be secondary (indirect effect) of the increased replication speed
1G- It looks like there are many more data points in the siFAM11A-1 and many fewer in the siFAM111A-2. The increase in the MCM quantified in H is bigger with si2 even though the G1 distribution has less change than with si1. Consequently, these data are incolclusive.
1I- no plot is shown for si2 but it is quantified. It would be informative to see the plots for easy comparison.
Figure 2: This is the most interesting part of the paper and generally is well done. As mentioned above, I believe that the phenotype the authors see in Figure 1 is the same phenotype as seen here- less production of ssDNA but it is hard to see this under unperturbed conditions, thus more data should be gathered to test that.
Figure 3: shows novel findings but it is unclear how it relates to the rest of the paper except that it suggests that the paralogs may work together in the pathway that has been explored in Figure 1 and 2. The authors perform computational and predictive analysis that identifies two UBL domains in the FAM111A/B paralogs. The FAM111A UBL2 domain is known to bind ssDNA. The authors might test if the domain can also bind ssDNA in FAM111B and if FAM111B has similar ability to promote ssDNA formation
Figure 4: The human mutations provide some insight as to the requirement for functional peptidase activity for the function of the protein. The work would also be strengthened if a ssDNA binding mutant was made and tested given the authors interest in defining the UBL domains.
Not sure why they use a term "ssDNA exposure"? It implies a removal of something that was covering it which they certainly do not show. I would use ssDNA levels, maybe ssDNA production, formation?
Other points:
As QIBC is used throughout the paper, it would be nice to have a brief explanation of the technique when it is first introduced.
The authors write that the function of FAM111A in promoting ssDNA formation is "distinct from overcoming protein-DNA complexes ahead of the replisome by Top1 or PARP1". It is not clear to this reader how they have determined that they are not the result of the same mechanism as the phenotypes seem very related. I would clarify this point.
Since the authors are including patient mutations, more introduction to the diseases would be useful.
Referee cross-commenting
I have no further comments.
Significance
The findings add to the growing literature on the FAM111 proteins and will be of interest to scientists who are studying them and those interested in replication and replication stress response.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
The manuscript by Rios-Szwed et al have investigated the role of FAM111A in DNA replication. Previous studies had identified that FAM111A suppresses DNA replication via an interaction with RFC and that hyperactive mutants induce apoptosis. Now, Rios-Szwed et al discovered that FAM111A knockdown affects inter origin distance without checkpoint induction. In particular, the firing of dormant origins when dNTPs are limiting is supressed and less ssDNA is produced. Although FAM111B is a strong interactor of FAM111A, no additive effect on DNA replication was detected when both proteins were depleted. On the other hand, overexpression or hyperactive mutants promote more gammaH2AX and ssDNA even in the presence of a caspase inhibitor, suggesting that the protease functions in ssDNA production prior to apoptosis.
Major comments:
Dormant origins are frequently inhibited by phosphatases - is there any evidence that phosphatases are the target of FAM111A. In this context I would suggest to blot for Treslin, as it is one of the first factors being recruited in a kinase dependent manner to the MCM2-7 complex.
Minor comments:
Abstract: Unclear why too much FAM111A causes cell death
Introduction: the R569H point mutant needs to be better introduced - e.g. explain where the mutation is localised or what it affects e.g. it is localised in the predicted peptidase domain
Figure 1A and 1D - are all the lanes shown originating from the same gel - if not please repeat.
Page 3 - I am not sure that in FAM111A depleted cells the DNA synthesis rate is reduced. Could it be, that just fewer cells are in S-phase.
Page 3 - It is stated: "In contrast, the inter-fork distance was slightly increased in FAM111A depleted cells (Fig. S1E)", however, the data but the data do not fully support this statement.
Figure 4C - the quantification of the last lane looks wrong. Is the average or the median? Please find information in the figure and methods section.
Question: If both FAM111A and FAM111B are overexpressed - is this better tolerated?
Is there a homologue in other species?
Referee cross-commenting
I agree with the other reviewers that the study has a descriptive nature. I guess this could be acceptable dependent on the journal choice.
Significance
In general, I really like the study as it establishes how initiation of DNA replication is affected by inhibition and activation of FAM111A. The work is done well and deserves to be seen in a good journal.
The study helps the field to move forward and will allow a more targeted search for specific protease targets. In this way it will help clinicians and also researchers.
My expertise is in initiation of DNA replication.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Rios-Szwed and colleagues investigate functions of FAM111A, a protease that Dr. Alabert has previously shown to localize at nascent DNA and promote PCNA loading. In this manuscript, the authors first describe that FAM111A facilitates efficient activation of replication origins by using DNA combing experiments and by analyzing chromatin loading of DNA replication proteins. Next, they show that FAM111A KO cells show reduced levels of ssDNA exposure after replication stress. Then the authors move on to show that the major FAM111A interactor is FAM111B, which they show to localize at nascent DNA and is epistatic to FAM111A in promoting DNA replication as well as RPA loading after replication stress. Finally, the authors show that unregulated FAM111A activity, either by overexpression of WT FAM111A or disease-associated mutants, causes extensive exposure of ssDNA.
Major comments
- Fig. S1G: Actual inter-origin distances (distance between replication tracks in which a CldU track is flanked by IdU tracks on both sides) should be plotted to estimate the changes in origin firing frequencies. The results should be presented as inter-origin distances, not ratios between UCN-01-treated and untreated. The revised experiment should be included in the main figures as this is central to the conclusion, and statistics should be included.
- The claim "FAM111A ... promotes DNA replication initiation of active and dormant origins" (page 4, line 4) is not fully supported by experiments. Does FAM111A localize at replication origins? Without direct evidence of FAM111A being present at replication origins, it remains possible that the changes in origin activity is secondary to the loss of FAM111A function at forks or something else.
- Fig. S1G: If FAM111A's function to promote activation of dormant origins in response to UCN-01 is unrelated to the function of FAM111A at forks, it is expected to be independent of the PIP motif. Is it the case?
- Fig. 2B: Increased survival after HU treatment might be secondary to reduced S-phase populations in FAM111A-depleted cells (Fig. 1C) as HU would affect only S-phase cells.
- Fig. 2B-I: Similarly, the blunted response to replication stress in FAM111A depleted cells could be simply explained by reduced number of forks per cell as indicated by increased inter-fork distance (Fig. 1F). Similarly, the authors' group has previously reported reduced PCNA levels on chromatin (Alabert et al, 2014), suggesting that there are reduced number of active forks per nucleus.
- Fig. 2H "FAM111A depletion reduced ssDNA exposure upon HU treatment (Fig. 2H, 2I)": The figure in Fig. 2H does not appear to be treated with FAM111A RNAi. If this is FAM111A RNAi cells, siControl cells need to be shown as a comparison.
- Fig. 3B,C: The interaction between FAM111A and FAM111B needs to be validated by coimmunoprecipitation-WB of endogenous proteins.
- Fig. 4A-C: Induction of DNA damage and apoptosis by FAM111A WT and disease mutants (including T338A that the authors claim unstudied) has been reported by Hoffman et al. and therefore not novel.
- Fig. 4E: The increase in ssDNA intensities is mild and might not be biologically significant.
- Fig. 4G: Cell cycle status needs to be assessed by FACS after treatment with each drug. Bleomycin might induce G1/S arrest if G1/S checkpoint is intact.
- ssDNA exposure after FAM111A OE might not be because FAM111A has a function in promoting ssDNA exposure, but could be simply explained by replication fork stalling, for example, due to degradation of essential proteins as proposed before (Hoffman et al, 2020).
- Page 8, line 17, "Altogether, these data revealed that unrestrained FAM111A peptidase activity leads to ssDNA exposure upstream of apoptosis.": Just because the caspase inhibitor did not block the ssDNA exposure, it does not mean ssDNA exposure is upstream of apoptosis - it could be happening in parallel and might be unrelated. A similar unsupported conclusion "ssDNA exposure is upstream of apoptosis" appears in other places: page 8, line 30; page 9, line 22.
- Whether protease activity is necessary for the FAM111A function in regulation of origin activation and in ssDNA exposure is not addressed. Can the phenotypes of FAM111A KO cells be rescued by FAM111A WT but not an active site mutant?
- Similarly, the authors need to test whether the PIP motif of FAM111A is required for the function of FAM111A at forks, such as promoting ssDNA exposure.
Minor comments
- Page 2, Line 8, "FAM111A catalytic activity has not been shown in vitro": Protease activity of FAM111A has been shown using recombinant proteins in vitro by Hoffman et al, 2020.
- Page 7, line 26, "T338A is a previously unstudied GCLEB patient mutation.": The T338A mutant was studied by Hoffman et al. and shown to have hyperactivity in vitro and to cause DNA damage when overexpressed in cells.
Referee cross-commenting
I feel that this study has problems even as a descriptive study. As I mentioned in my review, there are alternative explanations for their observations that the authors have not ruled out. If the authors remove all unsupported claims, then there is not much to conclude from this study. I am not saying their conclusions are wrong - I think this study is just premature.
Significance
This study could be of interest to the audience in DNA replication/DNA repair field and could be unveiling a new function of FAM111A in DNA replication. However, in the current form, this study appears to be a collection of loosely connected observations of FAM111A-manipulated cells without a clear message of what FAM111A does at replication forks and origins. Each observation appears to be loosely tied together with a keyword of ssDNA exposure, but how FAM111A regulates or changes ssDNA exposure is not addressed. The described phenotypes are potentially interesting, but for each observation there is an alternative explanation that could affect authors' interpretation. As outlined in my comments, lack of mechanism, lack of clear conclusion, and misinterpretation of some of the data led to this less enthusiastic review.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
The authors do not wish to provide a response at this time.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
In this manuscript entitled "A population instrinsic timer controls Hox gene expression and cell dispersion during progenitor addition to the body axis", Busby and colleagues investigate the topic of "cell type identity" in the context of body axis elongation in chick embryos. To this end, they performed heterochronic grafts from HH8 stage embryos to HH4 stage embryos and compared these to HH4 homochronic grafts. They found that HH8 grafts ingressed but were then delayed at a stage they termed cell dispersion. By scRNAseq this new cell state was characterized further. While HH8 cells adjusted their expression pattern to their surroundings, Hox gene expression was maintained as in the host developmental stage. Hox gene expression and collinearity of expression changes were also maintained when HH4 cells were grafted into HH8 embryos or cells were cultured ex vivo. Finally, the authors found differences in migration properties between HH4 and HH8 cells, when cultured ex vivo, with HH4 cells migrating faster than HH8.
This constitutes an elegant work to describe the existence of a "cell-intrinsic timer" that regulates cell identity and progressive body axis extension. Experiments and analysis have been performed adequately and conclusions have been drawn appropriately.
There are a rather minor comments I would suggest for further analysis, discussion and potentially experiments to further support this paper:
- A major finding is that grafted cells keep their Hox expression pattern, independent of whether it is from HH4 to HH8 or vice versa. Moreover, grafted HH8 cells pause at the cell dispersion stage and do not mix, unless grafted in very low cell populations. The authors conclude that Hox gene expression seems to be cell intrinsically regulated. However, for pausing of cells after ingression, I wonder if it is rather the difference to the neighbors than a cell-intrinsic effect that prevents the cells from dispersing. One possibility is that differences in adhesion could account for this, since sorting of cell populations based on differential expression of adhesion molecules has been observed in various model systems. This possibility is excluded here, since adhesion-related genes were not differentially expressed in their expression data. However, I would not exclude this possibility at this stage for the following reasons: 1. The authors detect different migration speeds for HH4 and HH8 cell clusters with HH4 cells migrating faster. Differential migration rate could indeed hint at differential adhesion and mechanical properties of the cells. 2. Hox genes have been shown to be upstream of and modulate adhesion molecules, which might be an interesting link. 3. So far, the authors have only analyzed expression of adhesion molecules at mRNA levels. However, the functional components are the adhesion proteins themselves. It might therefore be useful to stain embryos for some "obvious" candidate adhesion molecules, such as cadherins. If no further experiments are performed, then this should at least be discussed.
- The authors describe a new, intermediate stage, namely cell dispersion, in which HH8 MSP pause when grafted into HH4 embryos. They perform scRNAseq and GO term analyses to analyze these cells in more detail. The also perform gene set enrichment analysis. However, I am still wondering about the exact identity of these cells. What are they? What markers do they express? Do they upregulate certain signalling pathways? Etc. I would for instance be interested if there are differences in FGF or Wnt levels/ activities. It would be useful if the authors could analyze their scRNAseq data further in this regard.
- At several points in the manuscript, expression levels and patterns of HH4 and HH8 grafts are compared to each other. It does not become clear what the differences and similarities to the non-grafted cells of the same clusters are. Does grafting itself change the expression patterns?
- The authors found differences in cell cycle stages of HH4 and HH8 grafts. A more detailed discussion of this aspect would be useful rather than just excluding any cell cycle-related genes from the comparisons. Why could there be this difference? What effect could this have? Etc.
Optional: Other experiments that could increase the relevance of the work:
- As discussed by the authors, they specifically compare HH4 stage to HH8, which represents primitive streak stage and 4-somite stage, respectively. It would therefore be interesting to perform grafts from HH8 to later stages, such as HH10, or vice versa, when the process of somitogenesis is more similar. This could reveal if their findings are specific for pre to post node development or more general. However, this might be outside of the scope of this study.
Significance
General assessment: This study provides a systematic analysis of the interaction of embryonic cell clusters from different developmental stages. To this end, "classical" developmental biology techniques, i.e. grafting (complicated techniques that probably less and less people can perform nowadays), is combined with more modern ways of analysis, i.e. scRNAseq. This allows the authors to dissect the differential behaviour of hetero- and homochonic grafts. In the longer term this data can provide the basis for further in-depth mechanistic analyses, some of which could be added here already. The involvement of Hox genes in the control of developmental time is interesting and should be placed into context of our current knowledge. Here, Hox genes are rather used as readout of developmental time rather than active players.
Advance: How developmental time is maintained during embryonic development is a long-standing question in the field. This study provides conceptual advance in this question by describing a cell-intrinsic timer.
Audience: This study is relevant for developmental biologists in general, since it describes how developmental time can be kept by a cell-intrinsic timer, at least in early stages of somite formation in chick embryos.
My expertise: developmental biology, somitogenesis
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
In this manuscript, the authors investigate the importance of intrinsic and extrinsic factors in the timing of progenitor addition to the elongating primary body axis. During development, progenitor populations have to combine their self-renewal with the gradual contribution to the full length of the body axis. The mechanisms underlying the population dynamics that ensure the formation of a proportioned body plan remain poorly understood. By combining heterochronic (HH8 to HH4) and homochronic grafting (HH4 to HH4) of somitic progenitors with next generation sequencing and imaging, the authors observe that the older HH8 tissue shows intrinsic delays in migration and does not disperse within the surrounding mesodermal tissue after ingression through the primitive streak. This behavior correlates with intrinsic and tissue-specific differences in the expression of Hox genes but not with differences in the expression of cell adhesion/migration genes.
Overall, this study provides new data exploring how progenitors control their contribution to the body axis. By combining classic embryology techniques with single-cell sequencing, the authors describe novel cell states that might help understand the progenitor population dynamics. There are however a number of further analyses and experiments that should be performed to support the main claims of the manuscript.
Major comments:
- The authors claim that grafted HH8 cells are paused after the ingression stage and before the dispersion stage. The grafted cells ingress through the primitive streak and then remain as a distinct cluster of cells that does not disperse throughout the mesoderm. This is in contrast with other observations where overexpression of late hox genes delays the cells at the point of ingression. The authors should better demonstrate that their grafts are actually ingressing and then stopping once in the mesoderm compartment. Figure 3B' shows grafted HH8 cells (GFP positive) present in the mesoderm (ME) compartment 3 h after grafting. It is surprising that a cluster of cells can ingress through the primitive streak in a short period of time and then remain paused. It would be helpful to have the equivalent figure right after grafting to assess the differences in the location of the HH8 GFP+ cells and potentially observe them while ingressing.
- The authors describe a novel transcription state, namely clusters 6, 12 and 8 in Figure 2B, populated by HH8 cells 3 h after grafting. It is surprising that the UMAP looks very different between 0 h and 3 h in the HH8-HH4 grafts (Figure 2E and F). The authors should clarify where the HH4 (GFP negative) cells are present in Figure F, I. In the current figures, it looks as if both HH8 and HH4 cells changed completely their transcription profile in only 3 h and populated the central clusters (6, 12, 8). The authors claim that these central clusters are present in normal development and that cells rapidly transit through them. However, it is not clear whether this state happens before or after HH4. For example, the cells may be moving from right to left in UMAP_1 according to time (HH4 in the right, HH8 in the left and a central transient cluster). This would mean that in Figure 2F HH8 grafted cells are regressing to an earlier development state and not a new one. Including RNA velocity analysis could help clarify how the cells are changing their expression profiles.
- Related to the previous point, the striking changes between 0 h and 3 h in the HH8-HH4 grafts (Figure 2E and F) may suggest an effect of the grafting procedure on the transcription profile of the cells. The authors should demonstrate that the grafting of cells does not have a huge impact on the transcriptome and that these changes are specific to the previously undescribed delayed state of HH8 cells. For this, they should include scRNA data of HH4-HH4 3 h. If grafting does not have a significant effect on the transcriptome, they should see GFP positive and negative cells in HH4-HH4 3 h remain intermixed.
- The authors observe that when doing smaller heterochronic grafts, cells can disperse throughout the mesoderm. Nevertheless, the Hox gene expression does not change depending on the size of the grafts. This is in sharp contrast with their observations and claims done for big heterochronic grafts. The result is interesting as it demonstrates that the expression of Hox genes, but not dispersion, is cell intrinsic. However, the uncoupling of hox gene expression and cell dispersion requires further investigation. The authors should repeat the heterochronic grafting of Figure 1 using smaller grafts and check the contribution of grafted cells to the somites. If cells can readily disperse without delay, they might be able to contribute to all somites as observed with homochronic grafts. Similarly, the authors should repeat the explant spreading assay using smaller HH8 grafts and quantify whether differences in the migratory dynamics are observed. The authors already discuss the possibility that other factors apart from Hox expression might affect dispersion. Nevertheless, they should assess the importance of graft size in their experimental system. If smaller grafts maintain the expression profile but have a different capacity to contribute to the body axis, the initial observations might have been influenced by extrinsic factors of the graft (size, cell-to-cell contact, ECM...) and not by cell intrinsic properties (gene expression). This would change the conclusion of the work.
Minor comments:
- It would be informative to have a better time-resolved description of the heterochronic graft behavior in Figure 1. For homochronic grafts, several timepoints are provided allowing the visualization of cells travelling through the body axis. For heterochronic grafts, by contrast, only an early and final timepoint are provided.
- In Figure 4, the authors show that explants of HH4 and HH8 embryos have different migratory dynamics, with HH4 cells migrating faster than HH8. In Figure 4E, HH8 explants seem not to change their area for about 15 h and then start spreading. This indicates that there is a great delay in migration compared to HH4 explants. However, once they start spreading, it seems that the area starts to increase exponentially in a similar manner to what is observed for HH4 at earlier time points. It would be interesting to monitor the HH8 for a longer time to see the behaviors at later time points. HH8 explants may be just delayed, and once they start fully spreading, the speed may not be so different from the one of HH4 explants.
- The authors conclude in Supp. Table 2 that HH8 and HH4 do not have different expressions of adhesion-related genes upon grafting. This observation is very important to understand the potential mechanism behind the different dispersion behaviors, and thus it should be included in the main figure.
Significance
The authors combine classic embryology with single-cell RNA-seq and imaging techniques to explore progenitor population dynamics during addition to the body axis. They conclude that the delayed contribution of older cells to axis formation correlates with the intrinsic expression of posterior hox genes. While the idea of intrinsic regulation of hox genes during axial specification is not conceptually new, the authors use modern techniques to describe with finer detail the progenitor population states. For this reason, this manuscript will be of interest to researchers in the development field who want to better understand the hox control and influence during axial elongation.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
This manuscript describes the differential behavior of the epiblast region of chicken embryos containing the progenitor cells for the medial half of the somites (MSP) at HH4 (building the first 4-5 somites) and HH8 (building more caudal somites). Their approach combines grafting experiments with imaging, single cell and whole mount expression analyses of the grafts. The basic experiment involves the comparison of HH4 to HH4 homochronic grafts with HH8 to HH4 heterochronic grafts. They show that homochronic grafts undergo a dispersion stage after ingression through the primitive streak before they contribute to somites. The same region of HH8 embryos, when grafted into the MSP region of HH4 embryos, however, fail to undergo this dispersion and do not contribute to the first 4-5 somites. They also show that Hox gene expression follows the patterns observed in the grafted tissue, failing to acquire the expression profiles of the receiving host. The authors conclude that the MSP cells contain an internal timer involved in the regulation of their changing behavior as development proceeds.
The general findings reported in this manuscript are novel and can provide insights to further our understanding of the differences between formation of the first 4-5 somites and more caudal somites. However, I think that ADDITIONAL EXPERIMENTS are important to properly evaluate the data and the conclusions of this manuscript.
- A control HH8 to HH8 homochronic graft to check the behavior of the grafted cells: do they disperse in their natural environment after ingression through the primitive streak or they are also paused as a distinctive cell cluster?
- The reverse heterochronic grafting experiment, namely HH4 cells into HH8. Do HH4 cells maintain their dispersal behavior at the ectopic position, or they behave differently?
While the authors assessed the intrinsic properties of HH4 and HH8 tissue by incubating it on fibronectin, this experiment does not properly reproduce the environment of the embryonic region receiving the graft, which might be different at HH4 and HH8. The experiments I am suggesting take this variable into consideration and will therefore help assessing the possible involvement of the host tissue in the behavior of the grafts.
In addition to those experiments, a MORE EXTENSIVE ANALYSES of the already reported experiments could also improve the manuscript.
- When the cells staying in the MSP region after homochronic HH4 grafts reach later stages (e.g. approaching HH8), do they keep dispersing as at earlier stages after ingression through the primitive streak or they remain as a distinct cluster? And does Hox gene expression within those grafts follow the same activation profile observed in the host cells as development proceeds?
- In the experiment reported on fig. 5I, HH4 MSP grafted into HH8 embryos fail to activate Hox genes like Hoxa2, even after 6 hours of incubation. When these grafted embryos develop even further (for the period of time required for a HH4 embryo to reach the HH8 stage), do they activate Hoxa2 or Hoxa3 or they remain negative for these genes?
- The differential GO terms between HH4 and HH8 tissue in cluster 6 include chromatin organization, DNA methylation and C5-methylation of cytosine. This suggests that epigenetic changes might be involved in the behavioral differences between the MSP of the two stages, which can affect many different processes involved in cell activity, including the activation of Hox genes.
SOME COMMENTS ON DATA INTERPRETATION.
- It is clear that Hox gene expression in the grafts matches the profile of the donor tissue, indicating the existence of a Hox "timer". However, in my opinion, the authors place too much emphasis on the possible meaning of these observations in what concerns the differential behavior of the grafted cells. If they want to focus on Hox genes they should include some experiment testing their involvement in cell dispersal, either by misexpression or downregulation of specific genes (although there is plenty of information arguing against this possibility, maybe with the exception of that of Iimura and Pourquie, 2006; in this regard, the authors' own data already indicate that dispersion is independent of Hox gene expression).
- The authors disregard the involvement of differential patterns of cell adhesion molecules as the origin of the differential behavior of HH4 and HH8 grafts in the HH4 context. However, in their data on supplementary fig. 2A there are several genes differentially expressed between the HH8 and HH4 cells (e.g. Ptk7, Spon1 or Nfasc) that could indeed play a role in the differential interaction between cells from the two embryonic stages. It might be interesting to perform HCR experiments with some of these factors to see if they are differentially expressed at the two embryonic stages. Also, although it might be somewhat far reaching, if differential expression is observed by HCR, it might be interesting to experimentally manipulate expression of the relevant gene (s) (misexpression or down-regulation, depending on the stage) to evaluate its/their potential functional relevance.
Minor points
- The authors write that the HH8 specific clusters are 0, 4 and 6. However, I think that it is #7 and not #6 the one belonging to this group. I guess that this is typo, but becomes confusing, as a large part of the analysis of the single cell data is centered on cluster #6.
- In the introduction the authors state that the first 4-5 somites do not develop ganglia, citing Lim et al 1987. I think that the way this is written is imprecise, as it sort of implies that more caudal somites develop ganglia (which would mean that the dorsal root ganglia are somite derivatives). However, somites at any level do not develop ganglia; the anterior half of their sclerotomes are permissive to migration of the neural crest that will eventually build the ganglia, something that seems not to happen in the more anterior somites.
A side note
Different alternative transcripts have been reported at least for Ptk7 and Nfasc. This might be relevant considering that another of the prominent differential GO terms identified in supplementary fig 2C is related to RNA splicing. Would different alternative transcripts for some of these genes be specifically associated with the cells from one of the embryonic stages?
Significance
It has been known for many decades that the first 4-5 somites of amniotes are different to the rest of the somites in several ways, from the structures they generate to the way they are generated or the gene regulatory networks controlling their morphogenesis. Much is known about how the posterior somites are generated and the mechanisms of their differentiation. Conversely, relatively little is known about the same processes in the most anterior somites. The work described in this manuscript shows that the progenitor cells from the epiblast that will contribute to the 4-5 first somites already behave different than those generating more caudal somites. Also, they show that progenitors generating more caudal somites are unable to contribute to the rostral somites. These two sets of observations show that the differences in the rostral and caudal somites are already present in their progenitors and that those features are quite stable within the cells, at least when they are kept as a group.
So far, the single cell analyses shown in this manuscript failed to provide clear hints to explain the different behavior of the two sets of progenitors. However, they represent an important resource to further explore this important biological question. The authors focus on Hox genes as potential regulators of the differential behavior of the HH4 and HH8 MSPs, I guess that prompted by the report by Iimura and Pourquie (2006) indicating the involvement of Hox genes in the migratory properties of the somite progenitors. However, there is plenty of information, mostly genetic studies in mice, indicating that Hox genes might have very little influence in the differential behavior of rostral and caudal somites. In this regard, expression does not mean causation. I think that this manuscript is interesting, most particularly for developmental biologists involved in understanding the mechanisms governing the basic layout of the vertebrate body plan.
Research in my laboratory also explores this type of biological questions, although using more genetic approaches and in a different model system, namely the mouse. I therefore consider myself in a position that allows a knowledgeable evaluation of this manuscript.
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
We thank the four reviewers for their generally positive feedback on the manuscript. Below, we provide a point-by-point response to each reviewer.
We are performing new FCS and gradient measurements as suggested by the reviewers. We are confident we can have these completed within three months (accounting for the summer break).
Reviewer #1 (Evidence, reproducibility and clarity (Required)):
*This manuscript reports a very thorough and careful study of the mobility of Bicoid in the early embryo, explored with single-point fluorescence correlation spectroscopy. Although previous groups have looked into this question in the past, the work presented here is novel and interesting because of the different Bicoid mutants and constructs the authors have examined, in particular with the goal of understanding the role of the protein DNA-binding homeodomain. The authors convincingly show that there is a significant increase in Bicoid dynamics from the anterior to the posterior region of the embryo, and that the homeodomain plays an important role in regulating the protein's dynamics. Their experiments are very well designed and carefully analyzed. The authors also modelled gradient formation to see whether this change in dynamics might play a role in setting the shape of the gradient. I am not sure I fully agree with their conclusion that it does, as mentioned in my comment below. However, it is an interesting discussion to have, and I think this paper makes a significant advance in our understanding of Bicoid's behavior in the early embryo. *
We thank the Reviewer for their positive comments and their suggestions for improving the manuscript. We will resolve the concerns raised by the reviewer with clarity in the revision. We will also add additional comment in the Discussion regarding the interpretation of our results.
*Major comments: *
- 1) Gradient profile quantification: Some of the conclusions made by the authors rely on the comparison between their model of gradient formation (as captured in the equations in lines 232 and 233) and the Bcd intensity profile measured in the embryos. Since the differences in gradient shape predicted by the different models are very small (see Fig. 3B, which is on a log scale and therefore emphasize small differences, and Fig. 3C), it is very important to understand how reliable the experimental concentration profiles are.*
This is a fair comment. It is worth noting that the key differences between the 1- and 2-component models are only apparent at large distances (and hence low concentrations) from the source.
We performed the quantification of the gradients in a manner similar to the Gregor lab, whereby the midsagittal plane is analysed. We used 488nm illumination (rather than 2-photon, as the Gregor lab does) so our measurements are likely noisier. However, we are not investigating the variability in the gradient here, but the mean extent. We currently correct background with a uniform subtraction, but we appreciate that is not the optimal method.
In the revised manuscript, we will repeat the above experiments using a 2-photon microscope. Further, we will image lines expressing His::mcherry without eGFP under the same imaging conditions to more accurately estimate the background signal. While we expect this to improve the data quality, we do not envisage significant change to the observed profiles based on prior experience.
At the moment, I do not find the evidence that [Bcd] concentration profile is more consistent with a 2-component diffusion model than a 1-component model very strong. A few comments related to this: * * 1a. Line 249, it is mentioned that: "observations ... incompatible with the SDD model". Which observations exactly are incompatible with the SDD model?
The key points are in the preceding paragraph. We will improve the model presentation in the Results and also include further contextualisation in the Discussion.
1b. In Fig. 3D, only the prediction of the 2-component model is shown. What would the simple 1-component diffusion model look like? Is it really incompatible with the data?
We agree with this comment and will provide the 1-component fit to the gradient profiles. We expect it to fit well for the anterior half of the embryo but fail at larger distances (as has been previously shown).
Regarding the FCS data, we also show one and two component fits. We will show the alternative fits – a 2 particle fit is clearly an improvement (see also related response to reviewer 2).
1c. Line 243: "The increased fraction in the fast form ... consistent with experimental observation of Bcd in the most posterior" (Mir et al.)". I am not sure how this is significant, since the simple model also predicts there will be Bcd in the posterior - the only difference is how much is there (as shown in Fig. 3C), and it's a very small difference.
The absolute differences are not large between the two models, but due to the observed clustering (Mir et al. 2018), even small differences can have very large effects. In the revision we will provide estimates of the actual concentration differences.
We are performing new experiments with the Fritzsche lab at Oxford to estimate if there is clustering of Bcd. We will also repeat our FCS experiments to validate our key conclusion of AP differences in diffusion of Bcd. These should be completed by the end of the summer.
1d. Since the difference between models is in the posterior region where Bcd concentration is very low, when comparing the models to the data the question of background subtraction is essential. How was the subtracted background (mentioned line 612) estimated?
See above response to the first comment.
1e. Along the same line, were the detectors on the Zeiss LSM analog or photon counting detectors, and how confident can we be that signal is exactly proportional to concentration?
We used PMTs and did not directly do photon counting. But the intensity is still proportional to the concentration. It is possible to estimate the absolute concentration value, e.g., Zhang et al., 2021 (https://doi.org/10.1016/j.bpj.2021.06.035). However, our main conclusions – especially regarding the spatially varying Bcd dynamics – are not dependent on this.
1f. Can the gradients created by the two Bcd mutants (FIg. 4B) be quantified as well, and are they any different from the original Bcd gradient?
We agree this would be useful. We will provide the gradient quantifications of the bcd mutants in the revision.
1e. What is the pink line in Figure 5C (I am assuming the green one is the same as in Fig. 3D)? It could be better to not use normalization here, or normalize everything respective to the eGFP::Bcd data to make comparison in relative concentrations in the posterior for different constructs more evident (also maybe different colors for the three different data sets would help clarity).
This is a fair comment, and we will create graphs with new data for better visualisation.
1f. Discussion, lines 402-403: Does the detailed shape of the Bcd in the posterior region matter at all, since the posterior is not a region where Bicoid is active, as far as we know? Could a varying Bcd dynamics have other consequences that would be more biologically relevant?
Bcd is now known to act at 70% EL (Singh et al., Cell Reports 2022). So, the gradient is relevant for a large extent of the embryo length, though it is not known if there is any effect in the most posterior region.
2) Model for gradient formation (lines 231-238): * * 2a. Whether the molecules of Bcd can change from their fast to slow form is never questioned. How do we know (or why might we suspect) they do exchange?
This is a good point. Within the nucleus, and based on our mutant data, we suspect the fast/slow forms correspond to unbound/bound DNA states.
In the cytoplasm, the dynamics are less clear. Bcd can bind to cytoskeletal elements (Cai et al., PLoS One 2017) as well as to Caudal mRNA. Therefore, it seems reasonable to have different effective dynamic modes – yet, how such switching occurs remains unclear.
Ultimately, our model approximates multiple dynamic modes that are integrated to drive Bcd motion. Including switching between states is a reasonable assumption based on what is known about cytoskeletal and protein dynamics, but we do not have a specific mechanism.
It is challenging to estimate a specific kon / koff rate, as the dynamic changes also depend on the diffusion – which itself is changing. For now, we believe our level of abstraction is appropriate given what is known about the system. It will be very interesting to explore the specific interactions underlying such behaviour in the future, but that is beyond this current manuscript.
2b. The values used in the model for alpha, beta_0 and rho_0 should be mentioned. Maybe having a table with all the parameters in the method section, or even in the supplementary section, would help. The exact values of alpha and beta matter, because if they are large (fast exchange) a single exponential gradient is to be expected, if they are 0 (no exchange) a double exponential gradient is to be expected, with intermediate behavior in between. Which case are we in here?
We agree and will add a more complete table in the revision.
3) Discussion about anomalous diffusion (lines 386-388): The 2-component model used by the authors to interpret their FCS data seems very well justified here (excellent fits with very small residuals). I agree with the authors' conclusion that "the dynamics of Bcd within the nucleus are more complicated than a simple model of bound versus unbound Bcd", but I don't see how that can lead to a diagnostic of anomalous diffusion instead. Maybe it is just a matter of exactly explaining what is meant by anomalous diffusion here (since this term is often used to mean different things). A more likely scenario I think, is that there are more than just two Bcd components in the system.
This is a good point, and we can’t easily differentiate two/multi- component fits from anomalous diffusion ones. This is a known problem. But we have recently shown in a collaboration with the Laurent Heliot lab (Furlan et al, Biophys J 2019), that anomalous diffusion is a good stable indicator of changes, even if it might not be the right model. We use anomalous diffusion as it stably predicts changes. We do not claim, however, that diffusion is anomalous. We will improve the discussion of these points in the revised manuscript.
4) Line 440 and after: What is the evidence that the transition between the two forms might vary non-linearly with Bcd concentration? How would that help adapt to different embryo sizes? It would be good to be more explicit here instead of just referring to another paper.
We will improve this discussion. The central point is that the action of Bicoid is unlikely to simply depend linearly on concentration as in that case the ratio of fast to slow forms would be constant across the embryo. Related to the above comment, it is important to emphasise that we are using a phenomenological model, not one based on a specific mechanism.
5) Since an important aspect of this work is the study of different Bcd constructs in vivo, it is important that these constructs are very clearly described, so the section on the generation of the fly lines (Methods) should be expanded. In particular: * * 5a. It seems that the eGFP:: NLS control used here was different from that first described in Ref. 64 (and used for FCS experiments in Ref. 30 and 36)? If so, what NLS sequence was used here, and precisely what type of eGFP was used (in particular, was the A206K mutation that prevents dimerization present in the eGFP used)? If it is the same construct as in Ref. 64, it should be mentioned explicitly. * * 5b. Were the mutant N51A and R54A lines gifts as well, or have they been described before? If so, previous publications should be referenced. If not, how the plasmid was introduced in the embryo should be briefly explained.
We agree and will expand on the fly lines in the revision.
6) Concentration calibration measurements (Methods Fig. 2, line 568 and on). It is well known that background noise is going to interfere with the measurement of N when the signal becomes equivalent to the background noise (Koppel 197, Phys Rev A 10:1938-1945, and for a recent discussion of this effect for morphogens in fly embryos: Zhang et al., 2021, Biophysical Journal 120,4230-4241). It is almost certain that in the low signal regions of the embryo (e.g. posterior cytoplasm) this is affecting the reported concentration, and should be at least acknowledged.
We agree with the reviewer. We will provide the SBR. We will also correct the N values based on the method followed in Zhang et al., 2021, Biophysical Journal 120,4230-4241.
*7) Reference 3 is mis-characterized in two different ways in the manuscript: * * 7a. Line 50: The conclusion in Ref. 3 was not that the gradient was due to a diffusive process, on the contrary Gregor et al. argued that Bcd was too slow to form such a long-range gradient by diffusion. Studies that do present data consistent with a morphogen gradient formation mechanism driven by diffusion are reference 5, reference 30, Zhou et al., Curr. Biol. 2012;22(8):668-75 and Müller et al., Science 336 (2012) 721-724. *
Gregor et al., do not argue against a diffusion process – indeed, they utilise a SDD model in their paper. However, they do extensively discuss how the predicted dynamics from the SDD model are not compatible with gradient formation as observed after n.c. 13. This problem was resolved to some degree by FCS measurements of Bcd (e.g., Dostatni lab, Development 2011) and the use of a Bcd tandem reporter which showed that production and degradation change during n.c. 14 (Durrieu et al., MSB 2018). We will improve the framing of these results in the revision.
7b. The diffusion coefficient estimated from FRAP measurements and reported in Ref. 3 (D = 0.4 micron^2/s) is mentioned a couple of times in the manuscript (line 66, line 395, line 411). However, this number is simply incorrect. When fast components (such as the ones clearly detected here by FCS) are present, they diffuse out of the photobleached area during the photobleaching step. If that is not corrected for during the analysis (and it wasn't in Ref. 3), then the recovery time measured is just equal to the photobleaching time, and has nothing to do with either the fast or slow fraction of the studied molecule - it has no other meaning than to give a lower bound on the value of the actual effective diffusion coefficient of the molecule. This effect (called the halo effect) is well known in the FRAP community (see e.g. Weiss 2004, Traffic 5:662-671), it has been experimental demonstrated to occur for Bcd-eGFP in the conditions used in Ref. 3 (Reference 30), and the actual diffusion coefficient that should have been extracted from the data presented in Ref. 3 has been recalculated by another group to be instead D = 0.9 micron^2/s (Castle et al., 2011, Cell. Mol. Bioeng. 4:116-121). It would therefore be better to report the corrected value from Castle et al. to help the field converge towards an accurate description of Bcd mobility.
We fully agree and will use the improved FRAP estimated value for Bcd.
*Minor comments and suggestions: *
- 8) Figure 1: From panel A, it seems that what is called "Anterior" and "Posterior" is about 150 micron away from the embryo mid-section, i.e. about 100 micron from either the anterior pole or the posterior pole (so not the tip of the embryo, but somewhere in the anterior half or posterior half). Maybe this should be made clear in the text. *
We have made changes in Figure 1A to indicate the region within which the FCS measurements are carried out. We have added the relevant details in the legend of figure 1 lines 137-138.
*9) Fig. 2A; It might be good to put this graph on a log scale, so that cytoplasmic values are seen more clearly. Also, what about reporting on nuclear to cytoplasmic ratios? *
We will rework on this graph and make necessary changes.
*10) Fig. 2: It could be interesting to plot D_effective as a function of the measured concentration of Bicoid in different locations, since the (interesting) suggestion is made several time that [Bcd] could the a determinant of the protein mobility. *
Our work provides an indication that Bcd concentration is connected to the diffusion. We did this by measuring at two locations. To extend this to a rigorous model would require substantial new measurement along the whole length of the embryo. While interesting, this represents a very large investment of time and lies beyond the current manuscript.
*11) Figure 3B&C: Is the curve for 2-component diffusion (without concentration dependence) for steady-state missing? *
We will clarify in the revision.
*12) Lines 78 and 471: What do the authors mean by "new reagents"? The word reagent evokes a chemical reaction, but there are none here. Do the authors mean new constructs? or new mutants? *
We have changed lines 78 and 479 from “new reagents” to new Bcd mutant eGFP lines”.
*13) Lines 57-59: Another good reference for FCS measurements performed to study the dynamics of a morphogen (in this case Dpp) is Zhou et al., Curr. Biol. 2012;22(8):668-75 *
We added this reference in no.70.
*14) Lines 109-111: A word must be missing. Precisely determined what? *
Precisely measure within cytoplasm, and nuclear compartments and also during interphase stages. We have changed to “precisely measure in the cytoplasmic and nuclear regions during the interphase stages of nuclear cycles (n.c.)12-14.” in line no.111-112.
*15) Line 278: The increase in the slow mode is expected. Maybe explicitly mention why. *
In line 286, we have added “due to the loss of Bcd binding to the DNA”.
*16) Line 282: "with the fast component increasing", maybe replace with "with the diffusion coefficient of the fast component increasing" or "with the fraction of the fast component increasing". *
We have changed line 289 “with the diffusion component of fast component increasing towards the posterior”.
*17) Line 517: Is there a reason why the dorsal surface is always placed in the coverslip? *
We have added these details in line 528-529 in Methods.
*18) Line 524 and on: FCS measurements: What was the duration of each individual FCS measurement? It is great that the exact number of measurements are reported in the supplementary! *
Thank you for the complement. Typically, cytoplasmic measurements are 60secs and nuclear measurements are 20-40s. We have added this in line no.528-529. We also added a column to indicate the duration of each of the measurements in the supplementary tables.
*19) An Airy unit of 120 um seems large in combination with an objective with a NA of 1.2, is there a reason for that? What was the radius of the resulting detection volume? *
Olympus microscopes have a 3x magnification stage in their confocals. This leads to the change in the Airy unit. Otherwise, it would be 40 mm.
*20) Thank you for detailing the reasons behind the choice of excitation power, an important and often omitted details. Where in the excitation path were the values of the laser power measured (before or after the objective?)? *
Thank you for the complement. The laser power is measured before the objective. We removed the objective and measured the laser power in the objective path.
*21) Line 585: "since the brightness of eGFP::Bcd..." do the authors mean the molecular brightness of a single eGFP::Bcd molecule, or the total fluorescence signal? *
It is the total fluorescence signal. We have edited line no.592.
*22) It would be good for reference to mention the approximate value of the molecular brightness recorded for these eGFP constructs at the laser power used. *
We will measure and tabulate in the revised manuscript.
*23) Reference 766: The year (and maybe other things) is missing. *
We have corrected this reference.
24) Figure 2 (Methods): The concentrations shown on the figure should be in nM not uM. * * Thanks for noticing – we have changed.
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
MAJOR POINTS
- 1) FCS measurements and fits *
- a) Please state the duration of each individual FCS measurement. *
In the cytoplasm, the measurements were carried out for 60 secs and in nuclei it is between 20-40s. We could not measure for 60s in the nuclei as the nuclear position fluctuates from its initial position. We will add another column to indicate the duration of FCS measurements in the supplementary tables.
b) The authors acknowledge potential issues with fluorophore photophysics and use different lag time ranges for the calibration dye Atto-488 (0.001 ms in Method Fig. 2) and eGFP (0.1 ms in the main figures). Given the strong influence of different parameters on data interpretation and conclusions, Method Fig. 2 should be repeated with purified eGFP. This is particularly relevant for the noisy FCS measurements in posterior regions.
Performing the experiment with purified eGFP will be a volume calibration. We routinely performed this before each imaging session, and that should be fluorophore independent. As noted by Reviewer 1, it is also important to be clear about background correction. We will provide brightness data for eGFP and background values in the revised manuscript. We can then use this to estimate the corrected concentrations.
We use 0.1 ms to start, as at that point any contribution from the photo-physics should have decayed (0.1 ms is about 3-5 times the day rate of the photophysical process, Sun et al., Analytical Chem 2015).
c) Please explain why no data is shown for "AN" around 0.1 ms lag time in Fig. 1B in contrast to all other figures.
We will add the data for AN from 0.01 in the revised figures.
d) Please state what the estimated diffusion coefficients with one-component model fits are. Please also explain why the fits in Fig. S1E do not reach a value of 1 and why they plateau higher than the experimental data at long lag times. Please constrain the fits to G=1 at 0.1 ms tau and G=0 at 1 s tau to make a fair comparison.
The experimental ACF curves reach 0 at long lag times as would be expected. The one-component fits, however, don’t describe the data well and as a result they do not reach 1 and 0 at short and long lag times, respectively. The fitting is done using a mean-squared estimation of the best approximation of the particular model function to the data. Fixing the parameters can be done, but it will further reduce fit accuracy and deviations will be larger. We will perform this analysis and tabulate the one component fits in supplementary 1 with necessary corrections.
e) Please assess the validity of all multi-component fits by comparing the relative quality of the models to the number of estimated parameters using the Akaike information criterion or similar approaches.
We will provide the values denoting the quality of the fits in the revision. We will provide the 3D 1 particle fit, the 3D 1 particle fit with triplet, the 3D 2 particle fit and the 3D 2 particle fit with triple and will provide appropriate measures of fit quality.
f) Please also present the Bcd-GFP fits with 0.001 ms that are mentioned in line 590, and present the results for the data that did not give comparable tau_D1 and tau_D2 values mentioned in line 593.
We will provide all the curves from 0.001ms in the supplementary. We did not provide these details as we have followed the methods from Abu Arish et al., 2010. As our cytoplasmic and nuclear TauD values match with Abu Arish et al., 2010 and Porcher et al., 2010, we thought the excess data would be redundant.
3) Bicoid gradient and modeling * a) Little et al. 2011 observed that the Bcd gradient decreases around n.c. 13. Can the authors of the present work observe a similar concentration decrease using FCS? This is important to i) validate the FCS concentration measurements, and ii) to resolve the controversy regarding "previous claims based on imaging the Bcd profile within nuclei, which predicted decrease in Bcd diffusion in later stages".*
This is a good point regarding conclusions from the previous literature. The Little et al. paper inferred that diffusion had to decrease from fitting to the gradient profiles. However, subsequent analysis from our lab (Durrieu et al., MSB 2018 [which uses a different method involving a tandem reporter for Bicoid] and this manuscript) strongly suggest that Bicoid remains dynamic, at least through n.c. 13 and early n.c. 14. One way to test this is to use SPIM-FCS, where longer time courses can be taken (though with slower time resolution in the FCS). We have performed preliminary experiments with SPIM-FCS and we will revisit this data to see if we can find evidence for changes in the diffusion.
We will also extend the Discussion to make the results clearer in terms of previous models and literature.
b) Please explain why the experimental Bcd-GFP gradient data does not reach a value of 1 (e.g. in Fig. 3D) despite normalization. Please also explain why the fits become flatter in Fig. 5B compared to the steep fit in Fig. 3D.
Both lines were measured under identical conditions. Therefore, we normalised to the maximum value of both experiments. We will redo, normalising to each individual experiment. Regarding Fig. 5C, the Bcd::eGFP curve is identical to Fig. 3D. The flatter curve is the line with eGFP tagged to a NLS alone.
c) For modeling, please take into account observations that the Bcd source is graded with a wide distribution (30-40% EL, see Spirov et al. 2009, Little et al. 2011, Cai et al. 2017 etc.). The extent of the source used in the present work (x_s=20 um, line 620) is at least five times too small.
Care must be taken in defining the source extent. The most careful measurements are reported in Little et al., PLoS Biology 2011 who performed single molecule FISH. They conclude “We demonstrate that all but a few mRNA particles are confined to the anterior 20% of the egg”. Further, the peak in the particle density is around 20-30um from the anterior (Figure 3, Little et al., PLoS Biology 2011), with the vast majority of counts being with 10% of the anterior pole. Further, Durrieu et al. MSB 2018, showed using a Bcd tandem reporter that there was unlikely to be an extended gradient of bcd mRNA (maximum extent of around 50um). Here, we used a simple source domain, which was arguable a little narrow, but not significantly so. We will increase the value in the revision, but the claim that there is an extended bcd mRNA gradient (Spirov et al., Development 2009) has not been substantiated by later experiments.
- d) Please discuss in the paper how well the simulations in Fig. 3B agree with the experimental data.*
We will provide these details in the revision.
- e) Please provide a precise estimate for the statement "Even with an effective diffusion coefficient of 7 μm2s-1, few molecules would be expected at the posterior given the estimated Bcd lifetime (30-50 minutes)" to turn this into a quantitative argument. How many molecules are expected to reach posterior in which model, and how does it compare to experimental observations?*
This can be estimated based on the root-mean-square distance for diffusive processes. We will provide this in the revision.
- f) The sentence "we find that a model of Bcd dynamics that explicitly incorporates fast and slow forms of Bcd (rather than a single "effective" dynamic mode) is consistent with a range of observations that are otherwise incompatible with the standard SDD model" needs to be toned down and corrected since a simple SDD appears to be sufficient to account for the observed gradients. If the authors disagree, please specifically point out in the paragraph around line 249 what observations exactly are incompatible with a standard SDD model.*
This is similar to the point raised by Reviewer 1. While the standard SDD model can explain the overall gradient shape, it is not compatible with the observed time scales and Bcd puncta tracked in the posterior pole. We will improve the Discussion around this point to make the distinctions between the models clearer.
- 5) Data presentation *
- a) In line 27 and 122 it would be better to rephrase the wording "find/found" and give credit to previous papers that first made these observations. *
We will edit in the revision.
- b) For the statement "This suggests that the dynamics of the fast fraction were not captured by previous FRAP measurements", please explain why this should not be the case even though the fast fraction is shown to be larger than the slow fraction in the current work.*
We will edit in the revision.
- c) Similarly, the sentence "The dynamics of the slower mode correspond closely to measured Bcd dynamics from FRAP" likely needs to be corrected since it neglects the contribution of the faster mode, which is fluorescent as well and should also contribute to the dynamics from FRAP.*
This is similar to the point raised by Reviewer 1 and we will edit in the revision.
d) In the absence of further evidence (see above), the sentences "We establish that such spatially varying differences in the Bcd dynamics are sufficient to explain how Bcd can have a steep exponential gradient in the anterior half of the embryo and yet still have an observable fraction of Bcd near the posterior pole" and "These results explain how a long- ranged gradient can form while retaining a steep profile through much of its range" in the abstract need to be toned down.
We are not sure here what needs to be toned down. Our results show that there are (at least) two dynamic forms of Bcd and, combined, they are capable of forming a long-ranged gradient while also ensuring the gradient remains steep in the anterior (because the diffusion coefficient itself varies across the embryo). We will go through these statements and make sure the meaning is clear.
e) The authors state that "However, we show that eGFP::Bcd in its fastest form can move quickly (~18 μm2s-1), and the fraction of eGFP::Bcd in this form increases at lower concentrations", but this has not been directly shown. Please tone down this statement or directly test the prediction that Bcd has a higher fraction of the fast form in earlier nuclear cycles when Bcd concentration is smaller.
This is a good suggestion, and we will test whether early nuclear cycles of the anterior domain show faster dynamics.
*MINOR POINTS * * 1) Introduction * * a) Please explain explicitly what exactly the contention in Bcd, Nodal and Wingless dynamics is in the cited references. *
We will add in the revision. b) In line 95, it would be better to state that this is a variation of the SDD model rather than "a new model". * We changed from “a new model” to “an improved version of SDD model” in the current version of the manuscript. 2) Methods * * a) The authors state that "The same software was also used to calculate the cross-correlation function", but I couldn't find any cross-correlation analyses. Please clarify. *
It is line 538. There is no cross correlation. We changed this to the autocorrelation function.
b) Please correct the "uM" typo to "nM" in the legend of Method Fig. 2A.
We have changed this in the current version.
- c) In the sentence "Further, since the brightness eGFP:Bcd in the anterior and posterior cytoplasm is lower compared to the nuclei", "brightness" probably needs to be changed to "concentration" since the molecular brightness is unlikely to change. *
We edited the line no.591.
- d) Please explain the background-correction method mentioned in line 612. Please also state at what temperature the experiments were performed.*
We will add a better background correction in the revision. Currently, it is the non-embryo background as background noise. The measurements are carried out at 25oC.
*3) Results * * a) Please provide labels for anterior, posterior, dorsal and ventral in Fig. 1A. * * b) Please explain the colors in Fig. 5C. * * c) Please explain the dashed lines in Fig. 3C. * We have edited Figure 1A and Figure 5C. We will edit Figure 3C in further revision.
*OPTIONAL * * 1) If possible, it would be helpful to mention whether the transgenic animals have any abnormal phenotypes or whether they can rescue the bcd mutant. * We will update in the revision.
*2) To validate the concentration measurements, it would be ideal if the authors could determine the Bcd concentration gradient using FCS along the anterior-posterior axis. This would also address whether there are further unexpected changes in diffusivity in medial regions and along the anterior-posterior axis that would have to be considered for modeling. * To measure the Bcd concentration using FCS along the whole axis would be a very challenging undertaking. To get the data for the two positions analysed already represents a significant amount of work. We have done SPIM-FCS measurements, and we will be repeating our FCS measurements in the Fritzsche lab at Oxford. Combined, we believe this provides sufficient corroboration of our results.
*3) Local photoconversion experiments, e.g. in Bcd-Dendra2 embryos if available, would provide compelling support for the relevance of the measurements in the current work. * This is a nice idea, but this would represent a substantial project in its own right and lies beyond the current work.
Reviewer #3 (Evidence, reproducibility and clarity (Required)):
*In my estimation the experimental work is rigorous and the results fully support the conclusions of the authors. I was surprised, however, that the HD-only form localizes via very different and simpler dynamics than does full-length Bcd, but nevertheless forms at least a qualitatively similar gradient. That leads to the question as to whether the existence of the fast and slow forms and their different ratios in different parts of the embryo actually are physiologically relevant. I don't see a straightforward way to test this experimentally, because the mutations that effect Bcd gradient formation also affect essential functions of the protein that if abrogated produce severe downstream effects on embryonic development and lethality. However I would like to see this point at least addressed in the discussion. The data and the methods are presented in such a manner that they can be reproduced, and the number of replicates and statistical analysis is overall robust. * We thank the Reviewer for the positive and constructive review. They, like both previous reviewers, raise the issue of the model and how it fits with the data. As outlined above, we will improve this part of the data presentation and also the Discussion to make sure the main results are clear.
We agree that the underlying importance of the different dynamic forms of Bicoid – and why they change across the embryo – remains unknown. We believe that our careful characterisation of such behaviour is important nonetheless, as it reveals that: (1) morphogen dynamics are more complicated than typically modelled, and this may be just as relevant for ligands moving through extracellular space; and (2) dynamics can vary in space/time, providing an additional possible mechanism of control for regulating morphogen gradient profiles.
Of course, we would like to explore potential physiological relevance. Further exploration of the homeodomain and its role in regulating dynamics is a potential route, but that belongs in future work.
*Minor comments: *
- The presentation of the graphical data measuring Bcd levels along the a-p axis (Fig 1C, 1D, 4C-F and others) needs to be improved, because the grey lines that represent ACF curves are essentially invisible. This is partly because there is usually extensive overlap between the grey lines and other lines. This may be solved by using a more vivid colour than grey for the ACF curves, or perhaps the ACF lines could be made thicker but with some transparency so that overlapping data can be seen. In any event this aspect of the presentation needs to be improved. * We have made the ACF lines thicker to distinguish from the model fit.
*In Figs 2D and 2I measurements of statistical significance between the proportion of protein in fast and slow modes need to be added. * We will add in the revision.
*Relevant to line 174 and Fig 2, NLS should be defined when first used, the source of the NLS should be given (is it from Bcd?) and the rationale for looking at eGFP::NLS should be made explicit. *
We have added details on how the eGFP::NLS is generated in the methods.
*In Fig 3D the dashed lines need to be defined. I assume these are experimental error bars but this is not stated. *
We now state this in the legends.
*On lines 344-5, shouldn't this conclusion concern the HD rather than the NLS? * Yes, thanks for pointing it out it is related to only NLS not NLSHD. We removed this statement from line 351.
*On line 432, CAP is not an acronym, the correct term is 5' 'cap' or 'cap structure'. Also Cho et al. PMID 15882623 should be added to the references here. * We changed the corresponding section and added the references.
*On lines 446, 456, 469, and throughout: replace 'blastocyst' with 'blastoderm'. The former term is generally used for embryos that undergo full cellular divisions and cleavage in early embryogenesis, not for syncytial embryos such as Drosophila. * We have changed blastocyst to blastoderm throughout the manuscript.
Reviewer #4 (Evidence, reproducibility and clarity (Required)):
Major comments: The averaged autocorrelation curves were fitted to models of diffusion with one and two components. The one-component model was insufficient to reproduce the data and the two-component model seems to fit the data. Have the authors tested models with more than two components? Could it be possible to distinguish more Bcd populations?
While it is possible to fit with further components, it rarely provides useful further insight. In particular, the error in measuring three tau_D’s is typically very large. In addition, the improvement in the fit will be marginal, and thus the extra components cannot be justified statistically. Of course, we cannot exclude a third (or more) possible dynamic modes, but within the resolution of our FCS measurements two components with triplets are in general the maximum that can be accommodated without overfitting. We will provide evidence for this claim in the supplement of the revised manuscript.
In Figure 2E, the same concentration of eGFP::NLS is estimated to exist in the cytoplasm and nucleus. Since the NLS should target eGFP to the nucleus, what is the explanation for this observation? Is it possible that the method used to estimate the concentration of molecules is underestimating the concentration in the nucleus or the opposite in the cytoplasm?
This is a good observation. There are two possible explanations. First, the regular division cycles “reset” the nuclear levels. Therefore, differences may not be so large. Second, FCS measurements of concentration can be noisy, as they depend on the very short time scales in the measurement. We will double check our measurements and clarify this in our revision.
*In the simulation of the SDD model (Figure 3B), simulations at 10 min, 25 min and 120 min are shown. Assuming that 120 min corresponds to early nc14, are simulations at earlier timepoints corresponding to nc12 and nc13 indistinguishable from the profile at 120 min? This demonstration would further support the option to merge the data from all nuclear cycles. *
This is a good point. Here, we were primarily focused on showing the time evolution of the model, rather than directly mapping onto experiment. We will clarify in the revision.
*The results obtained with the BcdN51A mutant show an increase in diffusion speed, while retaining similar proportions of fast and slow populations. In the slow fraction, a new population is found. Assuming that the BcdN51A molecules cannot bind specifically to DNA due to the mutation, what would this newly found population correspond to? Could the authors explore the possibility of nonspecific binding to DNA? The article would also win by discussing more on this aspect or other options. *
This is an interesting question. Dslow for anterior nuclei of N51A mutants increases (Dslow from ~0.2um2/s to ~1.5 um2/s), and the proportion is similar to the slow fraction of WT Bcd in the anterior nuclei (F=50%). The Dslow values of bcdWT suggest that 0.2um2/s is a result of DNA binding. For bcdN51A, Dslow of 1.5 um2/s is suggestive of nonspecific interaction of bcdN51A to the DNA. Such a nonspecific interaction is also noticed in the case of NLS::eGFP, where we see a significant amount (Dslow~ 1-1.5 um2/s , F=20%) of slow form in the anterior nuclei, likely due to non-specific interaction with the DNA.
It is worth noting that the inactive homeodomain of transcription factor sex comb reduced (scr) also interacts non-specifically with DNA at high concentration (Vukojevic et al., PNAS 2010). Non-specific interaction of eGFP fluorophore is also noted to be higher in the nuclei of AT-1 cells that suggest “obstacle-free accessible space” is low in the nuclei (Wachsmuth et al., JMB 2000). Therefore, though we do not understand the specific mechanism, our results for N51 mutants are aligned with previous observations of intra-nuclei dynamics.
The experimental rational behind the BcdMM reporter needs to be better explained as it is not clear. It was previously shown that the N51A mutation disturbs zygotic hb activation and Caudal gradient formation (see Figure 3 in Niessing et al., 2000). Since N51A already causes a strong phenotype by disturbing hb expression and Cad gradient formation, what is the reasoning being adding extra mutations to this background? Since the mutations in the PEST domain and YIRPYL motif are involved in cad translational repression, it would be more interesting to add them to the R54A mutation and further study the repression of cad? It would also shed light on the unexpected no difference or even decrease in diffusion in the cytoplasm of the R54A mutant which should increase if indeed the cad mRNA binding is being repressed.
Our rationale was to remove more elements of Bcd to see if there was some degree of redundancy – at least in terms of the dynamics.
The Bicoid homeodomain N51A mutation is physiologically known to cause de-repression of caudal and inhibit hunchback expression. Mechanistically, nuclear Bcd activates hb transcription. However, in the cytoplasm Bcd interacts with other proteins and forms a complex to de-repress caudal. Bcd binds to caudal mRNA through its HD at one end of the complex. However, in the other end, other proteins in the complex are bound to the 5’cap region caudal mRNA. Our rationale for generating the MM mutation was that the N51A mutation may not be sufficient for Bcd to be released from the protein complex. Therefore, additional mutations to N51A may release Bcd from interactions with either DNA or with other proteins through PEST domain and YIRPYL motif.
*Have the authors confirmed that their BcdR54A indeed inhibits cad translation? *
We have not tested the eGFP:bcdR54A to inhibit cad translation. We will add the data in the revision.
*How many embryos of BcdMM were analysed? The authors should also provide a table with all the values in SI as they have done for all the other reporters. *
We will add this data with the revision.
*The claims with eGFP::NLSBcdHD need to be supported by data from multiple embryos. Even if multiple ACF curves are obtained from one embryo, analysing only one embryo is not sufficient. This would clarify the fact that this reporter seems to be able to reproduce the mobility of Bcd in the nucleus. *
We agree and we are arranging to collect more data. This should be completed by the end of the summer.
*According to the methods, all reporters were expressed in a bcd null background, made with the bcd1 allele. This allele is also known as bcd085 and according to Driever and Nusslein-Volhard, 1988 (PMID: 3383244), this allele only causes an intermediate phenotype. This indicates that a truncated version of the protein probably still exists on the embryo. Do the conclusions obtained here still hold if a truncated version of the Bcd protein exists in addition to their reporters? *
We used the bcdE1 mutant, a null mutant of bcd. This was used by Gregor et al., Cell 2007 in their generation of the original Bcd::eGFP. We have also recently generated a more complete bcdKO mutation (Huang et al., eLife 2017). Our embryos do not have a clear phenotype that we can relate to the specific bcd- background used. Nonetheless, we agree it is an important point to be clear about the genetic background and we will clarify in the revised manuscript.
Minor comments: * * In line 45: "Morphogens are signalling molecules", the authors should consider removing the word "signalling" since not all morphogens are, especially the one being studied, Bicoid. * * In lines 80-81 (and also throughout the text): "We measure the Bcd dynamics at multiple locations along the embryo AP-axis", should be more accurate and changed to anterior and posterior of the embryo. Using "multiple locations along the AP axis" is ambiguous and not exact for what was done.
Yes, this is a fair comment. We have edited these sections in the current manuscript.
*Throughout the article, the authors refer multiple times to "modes for/of Bcd transport". Since they or others have not proven that Bcd is being transported, which would involve at least another factor, the authors should replace transport by movement, diffusion or a similar word with which they are comfortable. *
We have changed transport to movement wherever relevant in the text.
*Suggestion: The authors claim that the Bcd gradient is exponential up to 60% of embryo length. Would this information allow a more precise calculation of the gradient decay length in the exponential region than the 80-100µm stated on line 202? *
This is an interesting point, but our results suggest that the idea of the decay length is not so applicable in the posterior region. There, the Bcd dynamics are generally quicker, thereby increasing l. Of course, we cannot discount possible spatial variation in degradation. However, in previous work, our Bcd tandem reporter (which is sensitive to changes in degradation) did not reveal spatial variation in degradation.
In lines 258-259, the sentence "Further, Bcd binds to caudal mRNA, repressing its expression in the cytoplasm" should be improved to clarify the role of Bcd in caudal mRNA translation repression and references should be added. This should also be corrected in the following paragraph.
We will add the necessary corrections in the revision.
*In line 262, "mutations" should be singular since it corresponds to only one amino acid mutation. *
We have corrected this.
*Figure 4J needs to be corrected as the fractions of the slow and fast populations do not correspond to what is shown in Table 3. For example, Fslow fraction of AC is ~45% in the figure while it is 36% in Table 3. The problem occurs in all fractions. *
We are sorry there is a mislabelling in the corresponding figure. AN is in the place of AC. We have edited figure 4J and removed the mislabelling.
*In the discussion, in lines 379-380, "Given the changing fractions of the fast and slow populations in space, the interactions between the populations are likely non-linear". What is the reasoning for non-linearity and not interchangeability? *
If the interactions between the two populations were linear, then the fraction in each form would be constant across the embryo. Some degree of nonlinearity is required in order to have spatially varying relative populations.
*In line 432 caudal should be italicized. *
We have edited this.
*In the discussion, the authors conclude that "In the nucleus, the two populations can be largely (though not completely) explained by Bcd binding to DNA". The discussion would win by explaining all the possible options. * We will add the necessary changes in the discussion. This is also related to above reviewer comments.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #4
Evidence, reproducibility and clarity
Summary:
Athilingam et al. are interested in understanding how the Bicoid (Bcd) morphogen gradient is formed in the early stages of Drosophila embryonic development. Using fluorescence correlation spectroscopy (FCS), the authors quantify the dynamics of Bcd in nuclei and cytoplasm at anterior and posterior regions of the embryo. First, they characterize the dynamics of eGFP::Bcd in space and time. Analysing FCS autocorrelation curves at the anterior and posterior regions of the embryo during the interphases of nuclear cycles 12 to 14, they detect differences in Bcd diffusion and are able to infer and distinguish two Bcd populations with slow and fast diffusions. Moreover, these dynamics do not vary between nuclear cycles. Using the different diffusions of the slow and fast populations, they find a model capable of explaining the formation of the gradient at larger distances and the existence of the Bcd molecules in the posterior, compatible with the SDD model widely accepted in the community. Lastly, given that Bcd has multiple roles binding to DNA and also to RNA through its homeodomain, mutations affecting DNA/RNA and RNA only binding are used. Using a mutant without the ability to bind to DNA, their determine that the slower diffusion in the nuclei are due to DNA binding. They further confirm this by fusing the homeodomain of Bcd to eGFP::NLS.
Major comments:
The averaged autocorrelation curves were fitted to models of diffusion with one and two components. The one-component model was insufficient to reproduce the data and the two-component model seems to fit the data. Have the authors tested models with more than two components? Could it be possible to distinguish more Bcd populations? In Figure 2E, the same concentration of eGFP::NLS is estimated to exist in the cytoplasm and nucleus. Since the NLS should target eGFP to the nucleus, what is the explanation for this observation? Is it possible that the method used to estimate the concentration of molecules is underestimating the concentration in the nucleus or the opposite in the cytoplasm? In the simulation of the SDD model (Figure 3B), simulations at 10 min, 25 min and 120 min are shown. Assuming that 120 min corresponds to early nc14, are simulations at earlier timepoints corresponding to nc12 and nc13 indistinguishable from the profile at 120 min? This demonstration would further support the option to merge the data from all nuclear cycles. The results obtained with the BcdN51A mutant show an increase in diffusion speed, while retaining similar proportions of fast and slow populations. In the slow fraction, a new population is found. Assuming that the BcdN51A molecules cannot bind specifically to DNA due to the mutation, what would this newly found population correspond to? Could the authors explore the possibility of nonspecific binding to DNA? The article would also win by discussing more on this aspect or other options. The experimental rational behind the BcdMM reporter needs to be better explained as it is not clear. It was previously shown that the N51A mutation disturbs zygotic hb activation and Caudal gradient formation (see Figure 3 in Niessing et al., 2000). Since N51A already causes a strong phenotype by disturbing hb expression and Cad gradient formation, what is the reasoning being adding extra mutations to this background? Since the mutations in the PEST domain and YIRPYL motif are involved in cad translational repression, it would be more interesting to add them to the R54A mutation and further study the repression of cad? It would also shed light on the unexpected no difference or even decrease in diffusion in the cytoplasm of the R54A mutant which should increase if indeed the cad mRNA binding is being repressed. Have the authors confirmed that their BcdR54A indeed inhibits cad translation? How many embryos of BcdMM were analysed? The authors should also provide a table with all the values in SI as they have done for all the other reporters. The claims with eGFP::NLSBcdHD need to be supported by data from multiple embryos. Even if multiple ACF curves are obtained from one embryo, analysing only one embryo is not sufficient. This would clarify the fact that this reporter seems to be able to reproduce the mobility of Bcd in the nucleus. According to the methods, all reporters were expressed in a bcd null background, made with the bcd1 allele. This allele is also known as bcd085 and according to Driever and Nusslein-Volhard, 1988 (PMID: 3383244), this allele only causes an intermediate phenotype. This indicates that a truncated version of the protein probably still exists on the embryo. Do the conclusions obtained here still hold if a truncated version of the Bcd protein exists in addition to their reporters?
Minor comments:
In line 45: "Morphogens are signalling molecules", the authors should consider removing the word "signalling" since not all morphogens are, especially the one being studied, Bicoid. In lines 80-81 (and also throughout the text): "We measure the Bcd dynamics at multiple locations along the embryo AP-axis", should be more accurate and changed to anterior and posterior of the embryo. Using "multiple locations along the AP axis" is ambiguous and not exact for what was done. Throughout the article, the authors refer multiple times to "modes for/of Bcd transport". Since they or others have not proven that Bcd is being transported, which would involve at least another factor, the authors should replace transport by movement, diffusion or a similar word with which they are comfortable. Suggestion: The authors claim that the Bcd gradient is exponential up to 60% of embryo length. Would this information allow a more precise calculation of the gradient decay length in the exponential region than the 80-100µm stated on line 202? In lines 258-259, the sentence "Further, Bcd binds to caudal mRNA, repressing its expression in the cytoplasm" should be improved to clarify the role of Bcd in caudal mRNA translation repression and references should be added. This should also be corrected in the following paragraph. In line 262, "mutations" should be singular since it corresponds to only one amino acid mutation. Figure 4J needs to be corrected as the fractions of the slow and fast populations do not correspond to what is shown in Table 3. For example, Fslow fraction of AC is ~45% in the figure while it is 36% in Table 3. The problem occurs in all fractions. In the discussion, in lines 379-380, "Given the changing fractions of the fast and slow populations in space, the interactions between the populations are likely non-linear". What is the reasoning for non-linearity and not interchangeability? In line 432 caudal should be italicized. In the discussion, the authors conclude that "In the nucleus, the two populations can be largely (though not completely) explained by Bcd binding to DNA". The discussion would win by explaining all the possible options.
Significance
The results presented in this article advance the knowledge of the field by adding data and quantifications of Bcd mobility at four locations: anterior nucleus, posterior nucleus, anterior cytoplasm and posterior cytoplasm. Until now, FCS studies have focused mostly on measuring the dynamics of Bcd in nuclei at the anterior (Abu-Arish et al. 2010; Porcher et al. 2010) of the embryo. The results are also consistent with what was previously found for eGFP:Bcd in the anterior nucleus. Still, this is not surprising as they use the same reporter as the previous studies.
This article will be interesting to an audience comprising biologists and biophysicists interested in protein diffusion.
As a biologist, I do not have sufficient expertise to completely evaluate if the modelling is performed flawlessly. However, in my understanding, the FCS analysis is crucial for the results and their conclusions, hence the comment on the certainty of the existence of only two Bcd populations, though these populations being previously described with FCS. Comments from a physicist with experience in analysing FCS data are thus necessary.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
The manuscript presents experiments that combine a number of techniques to produce an extremely detailed view of Bcd gradient formation in the early Drosophila embryo. The authors provide both empirical and theoretical evidence that support a conclusion that Bcd has both slow and fast moving forms, that the proportion of fast vs slow Bcd is higher at the posterior of the embryo, and that a theoretical model involving both fast and slow moving components fits empirical observations substantially better than a simple diffusion model. Next, they extend the work by investigating what functional motifs of Bcd are required for gradient formation. They demonstrate that a missense mutation N51A in the homeodomain (HD) that affects both DNA binding and cad regulation has major effects on Bcd gradient formation, while the R54A mutation that only affects cad regulation does not. They further show that a protein composed of only an NLS and the Bcd HD can form a gradient that is similar to full-length Bcd, although the two-component dynamics are not recapitulated by the HD-only form.
In my estimation the experimental work is rigorous and the results fully support the conclusions of the authors. I was surprised, however, that the HD-only form localizes via very different and simpler dynamics than does full-length Bcd, but nevertheless forms at least a qualitatively similar gradient. That leads to the question as to whether the existence of the fast and slow forms and their different ratios in different parts of the embryo actually are physiologically relevant. I don't see a straightforward way to test this experimentally, because the mutations that effect Bcd gradient formation also affect essential functions of the protein that if abrogated produce severe downstream effects on embryonic development and lethality. However I would like to see this point at least addressed in the discussion. The data and the methods are presented in such a manner that they can be reproduced, and the number of replicates and statistical analysis is overall robust.
Minor comments:
The presentation of the graphical data measuring Bcd levels along the a-p axis (Fig 1C, 1D, 4C-F and others) needs to be improved, because the grey lines that represent ACF curves are essentially invisible. This is partly because there is usually extensive overlap between the grey lines and other lines. This may be solved by using a more vivid colour than grey for the ACF curves, or perhaps the ACF lines could be made thicker but with some transparency so that overlapping data can be seen. In any event this aspect of the presentation needs to be improved.
In Figs 2D and 2I measurements of statistical significance between the proportion of protein in fast and slow modes need to be added.
Relevant to line 174 and Fig 2, NLS should be defined when first used, the source of the NLS should be given (is it from Bcd?) and the rationale for looking at eGFP::NLS should be made explicit.
In Fig 3D the dashed lines need to be defined. I assume these are experimental error bars but this is not stated.
On lines 344-5, shouldn't this conclusion concern the HD rather than the NLS?
On line 432, CAP is not an acronym, the correct term is 5' 'cap' or 'cap structure'. Also Cho et al. PMID 15882623 should be added to the references here.
On lines 446, 456, 469, and throughout: replace 'blastocyst' with 'blastoderm'. The former term is generally used for embryos that undergo full cellular divisions and cleavage in early embryogenesis, not for syncytial embryos such as Drosophila.
Significance
General assessment: The main strength of the paper is that it extends our knowledge about the dynamics of Bcd gradient formation, and by so doing it advances our understanding of the physical parameters underlying morphological gradients and patterning. The authors are admirably open about questions that were unanswered by the study, which include identifying molecular interactions that affect Bcd dynamics in the cytoplasm, whether Bcd diffusion is dependent on its concentration, and whether other morphogens form gradients in a similar manner. Answering any of these questions would involve substantial experimental work and it is appropriate to leave these questions for subsequent manuscripts.
Advance: A number of high-profile papers were published on this topic in the late 2000s and early 2010s that reached difficult conclusions, so the nature of the mechanisms underlying Bcd gradient formation have remained controversial and somewhat opaque. While this paper does not provide a definitive answer to all relevant open questions, it nevertheless represents a significant advance toward their resolution.
Audience: This paper will be of interest both to developmental biologists interested in gradients and pattern formation, and to biophysicists interested in physical parameters affect molecular movements. It is fundamental research that does not have an obvious clinical or translational component.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary
In this study, Athilingam et al. investigated Bicoid (Bcd) protein dynamics along the anterior-posterior axis of Drosophila embryos. They performed Fluorescence Correlation Spectroscopy (FCS) experiments to analyze Bcd protein diffusion and found that Bcd had a 1.7-fold higher mobility in the posterior compared to the anterior. The authors also generated Bcd homeodomain mutations and analyzed their impact on gradient formation. They found that the BcdN51A mutation exhibited altered nuclear dynamics with faster diffusion, while cytoplasmic dynamics remained unchanged. BcdR54A embryos showed dynamics more similar to the wild-type Bcd, with a minor decrease in slow diffusion in the posterior region. Interestingly, the Bcd homeodomain alone, when fused to eGFP-NLS, was able to replicate the observed Bcd protein dynamics, particularly in the slower diffusive mode. The paper provides evidence that the Bcd homeodomain has a significant influence on protein dynamics and suggests a complex interplay of interactions between Bcd, nuclear DNA, and cytoplasmic RNA that regulate Bcd diffusion and function.
Overall, the data and methods presented in the paper are clearly described. The experiments are adequately replicated, and the statistical analysis appears sufficient. Prior studies are referenced appropriately, and the claims and conclusions are mostly supported by the data. However, the following points should be addressed to corroborate the conclusions:
Major points
- FCS measurements and fits
- a) Please state the duration of each individual FCS measurement.
- b) The authors acknowledge potential issues with fluorophore photophysics and use different lag time ranges for the calibration dye Atto-488 (0.001 ms in Method Fig. 2) and eGFP (0.1 ms in the main figures). Given the strong influence of different parameters on data interpretation and conclusions, Method Fig. 2 should be repeated with purified eGFP. This is particularly relevant for the noisy FCS measurements in posterior regions.
- c) Please explain why no data is shown for "AN" around 0.1 ms lag time in Fig. 1B in contrast to all other figures.
- d) Please state what the estimated diffusion coefficients with one-component model fits are. Please also explain why the fits in Fig. S1E do not reach a value of 1 and why they plateau higher than the experimental data at long lag times. Please constrain the fits to G=1 at 0.1 ms tau and G=0 at 1 s tau to make a fair comparison.
- e) Please assess the validity of all multi-component fits by comparing the relative quality of the models to the number of estimated parameters using the Akaike information criterion or similar approaches.
- f) Please also present the Bcd-GFP fits with 0.001 ms that are mentioned in line 590, and present the results for the data that did not give comparable tau_D1 and tau_D2 values mentioned in line 593.
- Bicoid gradient and modeling
- a) Little et al. 2011 observed that the Bcd gradient decreases around n.c. 13. Can the authors of the present work observe a similar concentration decrease using FCS? This is important to i) validate the FCS concentration measurements, and ii) to resolve the controversy regarding "previous claims based on imaging the Bcd profile within nuclei, which predicted decrease in Bcd diffusion in later stages".
- b) Please explain why the experimental Bcd-GFP gradient data does not reach a value of 1 (e.g. in Fig. 3D) despite normalization. Please also explain why the fits become flatter in Fig. 5B compared to the steep fit in Fig. 3D.
- c) For modeling, please take into account observations that the Bcd source is graded with a wide distribution (30-40% EL, see Spirov et al. 2009, Little et al. 2011, Cai et al. 2017 etc.). The extent of the source used in the present work (x_s=20 um, line 620) is at least five times too small.
- d) Please discuss in the paper how well the simulations in Fig. 3B agree with the experimental data.
- e) Please provide a precise estimate for the statement "Even with an effective diffusion coefficient of 7 μm2s-1, few molecules would be expected at the posterior given the estimated Bcd lifetime (30-50 minutes)" to turn this into a quantitative argument. How many molecules are expected to reach posterior in which model, and how does it compare to experimental observations?
- f) The sentence "we find that a model of Bcd dynamics that explicitly incorporates fast and slow forms of Bcd (rather than a single "effective" dynamic mode) is consistent with a range of observations that are otherwise incompatible with the standard SDD model" needs to be toned down and corrected since a simple SDD appears to be sufficient to account for the observed gradients. If the authors disagree, please specifically point out in the paragraph around line 249 what observations exactly are incompatible with a standard SDD model.
- Data presentation
- a) In line 27 and 122 it would be better to rephrase the wording "find/found" and give credit to previous papers that first made these observations.
- b) For the statement "This suggests that the dynamics of the fast fraction were not captured by previous FRAP measurements", please explain why this should not be the case even though the fast fraction is shown to be larger than the slow fraction in the current work.
- c) Similarly, the sentence "The dynamics of the slower mode correspond closely to measured Bcd dynamics from FRAP" likely needs to be corrected since it neglects the contribution of the faster mode, which is fluorescent as well and should also contribute to the dynamics from FRAP.
- d) In the absence of further evidence (see above), the sentences "We establish that such spatially varying differences in the Bcd dynamics are sufficient to explain how Bcd can have a steep exponential gradient in the anterior half of the embryo and yet still have an observable fraction of Bcd near the posterior pole" and "These results explain how a long- ranged gradient can form while retaining a steep profile through much of its range" in the abstract need to be toned down.
- e) The authors state that "However, we show that eGFP::Bcd in its fastest form can move quickly (~18 μm2s-1), and the fraction of eGFP::Bcd in this form increases at lower concentrations", but this has not been directly shown. Please tone down this statement or directly test the prediction that Bcd has a higher fraction of the fast form in earlier nuclear cycles when Bcd concentration is smaller.
Minor points
- Introduction
- a) Please explain explicitly what exactly the contention in Bcd, Nodal and Wingless dynamics is in the cited references.
- b) In line 95, it would be better to state that this is a variation of the SDD model rather than "a new model".
- Methods
- a) The authors state that "The same software was also used to calculate the cross-correlation function", but I couldn't find any cross-correlation analyses. Please clarify.
- b) Please correct the "uM" typo to "nM" in the legend of Method Fig. 2A.
- c) In the sentence "Further, since the brightness eGFP:Bcd in the anterior and posterior cytoplasm is lower compared to the nuclei", "brightness" probably needs to be changed to "concentration" since the molecular brightness is unlikely to change.
- d) Please explain the background-correction method mentioned in line 612. Please also state at what temperature the experiments were performed.
- Results
- a) Please provide labels for anterior, posterior, dorsal and ventral in Fig. 1A.
- b) Please explain the colors in Fig. 5C.
- c) Please explain the dashed lines in Fig. 3C.
Optional
- If possible, it would be helpful to mention whether the transgenic animals have any abnormal phenotypes or whether they can rescue the bcd mutant.
- To validate the concentration measurements, it would be ideal if the authors could determine the Bcd concentration gradient using FCS along the anterior-posterior axis. This would also address whether there are further unexpected changes in diffusivity in medial regions and along the anterior-posterior axis that would have to be considered for modeling.
- Local photoconversion experiments, e.g. in Bcd-Dendra2 embryos if available, would provide compelling support for the relevance of the measurements in the current work.
Significance
The paper investigates the diffusion dynamics of Bicoid (Bcd), a transcription factor crucial for establishing the anterior-posterior axis during Drosophila embryogenesis. The authors utilize Fluorescence Correlation Spectroscopy (FCS) and various Bcd mutants fused with eGFP to understand the role of Bcd's homeodomain and other domains in its nuclear and cytoplasmic diffusion dynamics. They performed elegant experiments using insightful transgenic lines, showcasing well-designed and well-executed methodology. The paper is very nice to read, with a clear and engaging writing style and excellent presentation of the data, making it easy to follow and understand their findings.
However, there are a few limitations to consider. First, the paper does not provide evidence for the switching between slow and fast populations central for their modeling, leaving an important aspect of the dynamics unexplained. Second, there are doubts regarding the accuracy of the model used to fit the FCS data (see detailed comments in the section "Evidence, reproducibility and clarity"), underscored by the statement "While the increase in the slow mode was expected, the reason for the change in the fast mode is less clear". Third, the relevance of a potentially higher Bcd mobility for gradient formation remains unclear. For example, the fit in Fig. 3D deviates substantially from the data around 0 um embryo length, which is likely even larger than the error expected from a "simple diffusion" fit at the posterior end of the embryo. In addition, in Fig. 3C the lines for the different models appear to be indistinguishable given the noisy measurements, calling the relevance of the findings into question.
Overall, the paper extends our knowledge by providing new insights into the role of the Bcd homeodomain in determining Bcd gradient formation. The paper highlights that homeodomain interactions in the cytoplasm and nuclei are significant contributors to determining Bcd dynamics. Additionally, the paper suggests that additional components within Bcd itself or other proteins in the cytoplasm affect Bcd dynamics at different Bcd concentrations. The paper will be of interest to a broad audience in developmental biology, molecular biology, and biophysics. Researchers studying transcription factor dynamics, morphogen gradients, and Drosophila embryogenesis will find this study particularly valuable. While the study is primarily focused on basic research, the insights gained on Bcd diffusion dynamics and the role of the homeodomain may contribute to a broader understanding of transcription factor regulation and function in other systems.
- FCS measurements and fits
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
This manuscript reports a very thorough and careful study of the mobility of Bicoid in the early embryo, explored with single-point fluorescence correlation spectroscopy. Although previous groups have looked into this question in the past, the work presented here is novel and interesting because of the different Bicoid mutants and constructs the authors have examined, in particular with the goal of understanding the role of the protein DNA-binding homeodomain. The authors convincingly show that there is a significant increase in Bicoid dynamics from the anterior to the posterior region of the embryo, and that the homeodomain plays an important role in regulating the protein's dynamics. Their experiments are very well designed and carefully analyzed. The authors also modelled gradient formation to see whether this change in dynamics might play a role in setting the shape of the gradient. I am not sure I fully agree with their conclusion that it does, as mentioned in my comment below. However, it is an interesting discussion to have, and I think this paper makes a significant advance in our understanding of Bicoid's behavior in the early embryo.
Major comments:
- Gradient profile quantification: Some of the conclusions made by the authors rely on the comparison between their model of gradient formation (as captured in the equations in lines 232 and 233) and the Bcd intensity profile measured in the embryos. Since the differences in gradient shape predicted by the different models are very small (see Fig. 3B, which is on a log scale and therefore emphasize small differences, and Fig. 3C), it is very important to understand how reliable the experimental concentration profiles are. At the moment, I do not find the evidence that [Bcd] concentration profile is more consistent with a 2-component diffusion model than a 1-component model very strong. A few comments related to this:
- 1a. Line 249, it is mentioned that: "observations ... incompatible with the SDD model". Which observations exactly are incompatible with the SDD model?
- 1b. In Fig. 3D, only the prediction of the 2-component model is shown. What would the simple 1-component diffusion model look like? Is it really incompatible with the data?
- 1c. Line 243: "The increased fraction in the fast form ... consistent with experimental observation of Bcd in the most posterior" (Mir et al.)". I am not sure how this is significant, since the simple model also predicts there will be Bcd in the posterior - the only difference is how much is there (as shown in Fig. 3C), and it's a very small difference.
- 1d. Since the difference between models is in the posterior region where Bcd concentration is very low, when comparing the models to the data the question of background subtraction is essential. How was the subtracted background (mentioned line 612) estimated?
- 1e. Along the same line, were the detectors on the Zeiss LSM analog or photon counting detectors, and how confident can we be that signal is exactly proportional to concentration?
- 1f. Can the gradients created by the two Bcd mutants (FIg. 4B) be quantified as well, and are they any different from the original Bcd gradient?
- 1e. What is the pink line in Figure 5C (I am assuming the green one is the same as in Fig. 3D)? It could be better to not use normalization here, or normalize everything respective to the eFP::Bcd data to make comparison in relative concentrations in the posterior for different constructs more evident (also maybe different colors for the three different data sets would help clarity).
- 1f. Discussion, lines 402-403: Does the detailed shape of the Bcd in the posterior region matter at all, since the posterior is not a region where Bicoid is active, as far as we know? Could a varying Bcd dynamics have other consequences that would be more biologically relevant?
- Model for gradient formation (lines 231-238):
- 2a. Whether the molecules of Bcd can change from their fast to slow form is never questioned. How do we know (or why might we suspect) they do exchange?
- 2b. The values used in the model for alpha, beta_0 and rho_0 should be mentioned. Maybe having a table with all the parameters in the method section, or even in the supplementary section, would help. The exact values of alpha and beta matter, because if they are large (fast exchange) a single exponential gradient is to be expected, if they are 0 (no exchange) a double exponential gradient is to be expected, with intermediate behavior in between. Which case are we in here?
- Discussion about anomalous diffusion (lines 386-388): The 2-component model used by the authors to interpret their FCS data seems very well justified here (excellent fits with very small residuals). I agree with the authors' conclusion that "the dynamics of Bcd within the nucleus are more complicated than a simple model of bound versus unbound Bcd", but I don't see how that can lead to a diagnostic of anomalous diffusion instead. Maybe it is just a matter of exactly explaining what is meant by anomalous diffusion here (since this term is often used to mean different things). A more likely scenario I think, is that there are more than just two Bcd components in the system.
- Line 440 and after: What is the evidence that the transition between the two forms might vary non-linearly with Bcd concentration? How would that help adapt to different embryo sizes? It would be good to be more explicit here instead of just referring to another paper.
- Since an important aspect of this work is the study of different Bcd constructs in vivo, it is important that these constructs are very clearly described, so the section on the generation of the fly lines (Methods) should be expanded. In particular:
- 5a. It seems that the eGFP:: NLS control used here was different from that first described in Ref. 64 (and used for FCS experiments in Ref. 30 and 36)? If so, what NLS sequence was used here, and precisely what type of eGFP was used (in particular, was the A206K mutation that prevents dimerization present in the eGFP used)? If it is the same construct as in Ref. 64, it should be mentioned explicitly.
- 5b. Were the mutant N51A and R54A lines gifts as well, or have they been described before? If so, previous publications should be referenced. If not, how the plasmid was introduced in the embryo should be briefly explained.
- Concentration calibration measurements (Methods Fig. 2, line 568 and on). It is well known that background noise is going to interfere with the measurement of N when the signal becomes equivalent to the background noise (Koppel 197, Phys Rev A 10:1938-1945, and for a recent discussion of this effect for morphogens in fly embryos: Zhang et al., 2021, Biophysical Journal 120,4230-4241). It is almost certain that in the low signal regions of the embryo (e.g. posterior cytoplasm) this is affecting the reported concentration, and should be at least acknowledged.
- Reference 3 is mis-characterized in two different ways in the manuscript:
- 7a. Line 50: The conclusion in Ref. 3 was not that the gradient was due to a diffusive process, on the contrary Gregor et al. argued that Bcd was too slow to form such a long-range gradient by diffusion. Studies that do present data consistent with a morphogen gradient formation mechanism driven by diffusion are reference 5, reference 30, Zhou et al., Curr. Biol. 2012;22(8):668-75 and Müller et al., Science 336 (2012) 721-724.
- 7b. The diffusion coefficient estimated from FRAP measurements and reported in Ref. 3 (D = 0.4 micron^2/s) is mentioned a couple of times in the manuscript (line 66, line 395, line 411). However, this number is simply incorrect. When fast components (such as the ones clearly detected here by FCS) are present, they diffuse out of the photobleached area during the photobleaching step. If that is not corrected for during the analysis (and it wasn't in Ref. 3), then the recovery time measured is just equal to the photobleaching time, and has nothing to do with either the fast or slow fraction of the studied molecule - it has no other meaning than to give a lower bound on the value of the actual effective diffusion coefficient of the molecule. This effect (called the halo effect) is well known in the FRAP community (see e.g. Weiss 2004, Traffic 5:662-671), it has been experimental demonstrated to occur for Bcd-eGFP in the conditions used in Ref. 3 (Reference 30), and the actual diffusion coefficient that should have been extracted from the data presented in Ref. 3 has been recalculated by another group to be instead D = 0.9 micron^2/s (Castle et al., 2011, Cell. Mol. Bioeng. 4:116-121). It would therefore be better to report the corrected value from Castle et al. to help the field converge towards an accurate description of Bcd mobility.
Minor comments and suggestions:
- Figure 1: From panel A, it seems that what is called "Anterior" and "Posterior" is about 150 micron away from the embryo mid-section, i.e. about 100 micron from either the anterior pole or the posterior pole (so not the tip of the embryo, but somewhere in the anterior half or posterior half). Maybe this should be made clear in the text.
- Fig. 2A; It might be good to put this graph on a log scale, so that cytoplasmic values are seen more clearly. Also, what about reporting on nuclear to cytoplasmic ratios?
- Fig. 2: It could be interesting to plot D_effective as a function of the measured concentration of Bicoid in different locations, since the (interesting) suggestion is made several time that [Bcd] could the a determinant of the protein mobility.
- Figure 3B&C: Is the curve for 2-component diffusion (without concentration dependence) for steady-state missing?
- Lines 78 and 471: What do the authors mean by "new reagents"? The word reagent evokes a chemical reaction, but there are none here. Do the authors mean new constructs? or new mutants?
- Lines 57-59: Another good reference for FCS measurements performed to study the dynamics of a morphogen (in this case Dpp) is Zhou et al., Curr. Biol. 2012;22(8):668-75
- Lines 109-111: A word must be missing. Precisely determined what?
- Line 278: The increase in the slow mode is expected. Maybe explicitly mention why.
- Line 282: "with the fast component increasing", maybe replace with "with the diffusion coefficient of the fast component increasing" or "with the fraction of the fast component increasing".
- Line 517: Is there a reason why the dorsal surface is always placed in the coverslip?
- Line 524 and on: FCS measurements: What was the duration of each individual FCS measurement? It is great that the exact number of measurements are reported in the supplementary!
- An Airy unit of 120 um seems large in combination with an objective with a NA of 1.2, is there a reason for that? What was the radius of the resulting detection volume?
- Thank you for detailing the reasons behind the choice of excitation power, an important and often omitted details. Where in the excitation path were the values of the laser power measured (before or after the objective?)?
- Line 585: "since the brightness of eGFP::Bcd..." do the authors mean the molecular brightness of a single eGFP::Bcd molecule, or the total fluorescence signal?
- It would be good for reference to mention the approximate value of the molecular brightness recorded for these eGFP constructs at the laser power used.
- Reference 766: The year (and maybe other things) is missing.
- Figure 2 (Methods): The concentrations shown on the figure should be in nM not uM.
Significance
Strengths:
Very careful and systematic study of Bcd's dynamics in the early embryo Use of several mutant and truncated forms of Bcd to pinpoint the importance of the DNA binding domain in setting this dynamics Uncovers a previously unknown change in Bcd dynamics from the anterior to the posterior of the embryo Modelling of the Bcd concentration gradient shape taking into account the measured dynamics
Limitations:
The quantitative comparison between modelled and measured gradient could be improved. The discussion of the biological implications of the work is limited
Advance:
Uncovers a previously unknown change in Bcd dynamics from the anterior to the posterior of the embryo. This raises very interesting questions about molecular mechanisms involving Bicoid. Other studies (cited in this manuscript) reported on Bcd dynamics, but the present study represents a very welcome expansion of these earlier studies, by looking at spatial dependence and by examining several Bcd constructs.
Audience:
Somewhat specialized, as this work should firstly be of interest to scientists studying morphogen gradients. However, it is also a beautiful example dynamical studies in vivo, so it will also be of interest to experimental physicists studying protein motions in vivo (a rather large community).
- Gradient profile quantification: Some of the conclusions made by the authors rely on the comparison between their model of gradient formation (as captured in the equations in lines 232 and 233) and the Bcd intensity profile measured in the embryos. Since the differences in gradient shape predicted by the different models are very small (see Fig. 3B, which is on a log scale and therefore emphasize small differences, and Fig. 3C), it is very important to understand how reliable the experimental concentration profiles are. At the moment, I do not find the evidence that [Bcd] concentration profile is more consistent with a 2-component diffusion model than a 1-component model very strong. A few comments related to this:
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
This manuscript characterizes the ULD mouse model as a new platform for pre-clinical TB vaccine testing. Using the current tuberculosis (TB) vaccine, BCG, the manuscripts shows that three distinct parameters of protective immunity can be assessed in this model: 1) reduction of bacterial burden (which is shown to be more durable in this model than in the conventional model); 2) prevention of dissemination to the contralateral lung; and 3) prevention of detectable infection. The last parameter of protection is notable because vaccines have not been previously shown to be capable of preventing Mycobacterium tuberculosis (Mtb) infection in the mouse model, and in fact, it has been widely believed that mice lack the immune effector mechanisms necessary to prevent detectable infection. We show here that this is not true. When mice are challenged with a physiologic infectious dose of Mtb, vaccine-induced immunity can indeed prevent detectable infection. Thus, we believe this physiologic dose challenge model, provides potential for an improved platform for preclinical vaccine testing, as it allows for measurement of protective parameters that could not previously be assessed and may provide a window to assess meaningful differences between vaccine candidates. We were happy that both reviewers recognized the significance of this work, noting that the study “offers a new avenue for evaluation of TB vaccines, especially vaccines to prevent establishment of long-term infection” and “is clinically useful to test new TB vaccine candidates by improving the conventional TB vaccine model.”
We thank the reviewers for their time and excellent comments. We have addressed the Reviewer’s comments as outlined below. Most could be fully addressed by minor modifications to the manuscript’s texts or figures. Reviewer 2 requested additional studies to further assess the model’s durability at timepoints later than day 125 post-infection. In response to this comment, we have modified the manuscript to soften our conclusions about the model’s durability. However, we do not believe that performing additional experiments (which would take up to a year to perform) to further examine BCG’s durability in this model is necessary to support the manuscript’s conclusions. Changes made to the manuscript in response to the reviewers’ comments are underlined.
This report provides evidence that the ULD infection model of M. tuberculosis provides the capacity to detect 3 types of protection by BCG: 1) durable reductions in Mtb burden, 2) inhibition of Mtb dissemination, 3) prevention of detectable bacteria. In general, this is well-reasoned, well-written, transparently presented and easy to follow. A few points.
Major issues:
In Figure 2A, 2B, 3A - the authors have a highly skewed distribution with a bimodal distribution between detected bacterial counts and zero bacterial counts. This type of distribution does not lend itself to a t-test. What is the mean of two exclusive categories? For these graphs, the authors should consider plotting the median and interquartile range, then applying a non-parametric test. I suspect the p-values will be as significant, if not more, and there will be some comparisons where the median of the BCG group will be 0 CFU.
We completely agree that a t-test would not be appropriate for data with bimodal distribution, such as if the mice with detected bacterial counts and those with zero bacterial counts were both included in this analysis. We apologize that we did not sufficiently explain that only mice with detectable bacterial counts were included in our analysis of BCG’s ability to reduce bacterial burdens; those with zero bacterial counts were excluded. We recognize that doing this may underestimate the ability of a vaccine to reduce bacterial burdens as a handful of mice that might have had detectable bacterial burdens in the absence of vaccination are not included in the analysis. However, including mice all mice with undetectable bacterial burdens would be confounded by the fact that some mice in the ULD model are never infected at all, at least measurably, even in the unvaccinated group. We decided that the best way to disentangle these issues would be to analyze reduction of bacterial burdens and proportion of mice with zero detectable CFUs separately. Thus, for the former, only those with detectable CFUs are considered, and separately, we compare the proportion of mice with mice with undetectable bacterial burdens in the vaccinated mice compared to the unvaccinated controls (Figure 5). For these reasons, we believe the t-test is an appropriate test for this analysis. However, in response to this comment we have made changes to the text, figure legend, and Methods, to clearly state how and why the analysis was done this way. We thank the reviewer for these comments, as we believe the original manuscript was not sufficiently clear in this respect, and it is very important to convey how the analysis is being performed.
In 3B, instead of presenting a model of the data, can the authors present the raw data across all experiments as datapoints with violin plots, or some other form of data visualization? They could present the fixed effect model as a supplementary figure. The fixed effect model works better for plotting proportions in 4A.
We thank the reviewer for this comment. In Figure 3B of the revised manuscript, the raw data across all experiments is now shown as datapoints with violin plots.
Minor points:
Abstract, line 35. The authors state that BCG does A, B, C in a small percentage of mice. It is not clear whether this means all of A, ,B and C happen in a small percentage. Or rather whether the small percentage refers to C alone. Perhaps this can be rewritten for clarity.
We thank the reviewer for this comment. The small percentage was meant to refer to C alone, but we agree this was not clear as it was written. In the revised manuscript, this sentence in the abstract is written as follows, “We show that BCG confers a reduction in lung bacterial burdens that is more durable than that observed after conventional dose challenge, curbs Mtb dissemination to the contralateral lung, and, in a small percentage of mice, prevents detectable infection.”
Line 123. 12/20 vs 10/20. Hard to say it appeared to prevent based on these numbers. Perhaps may prevent?
In the revised manuscript we have changed “appeared to prevent” to “may prevent”, as suggested.
Line 128. The authors use the word colonized here but don't use this term elsewhere. What is the difference between colonized and infected, and why is colonized used only here?
In the revised manuscript we have changed “colonized” to “infected”, as suggested.
The power calculations could be a supplementary table if space is tight.
We are amenable to moving the power calculations to a supplementary table if this is the preference of the editor.
Reviewer #2
Manuscript "Assessing vaccine-mediated protection in an ULD mycobacterium tuberculosis murine model" is an interesting, well-documented and comprehensive study to develop new TB murine model used to assess new TB vaccine candidates. Although TB vaccine are urgently needed, many TB vaccine candidates remain in the development pipeline mainly because the conventional vaccine evaluation strategy is hindered by the lack of reliable animal models that mimic human TB pathogenic cycle. This manuscript used the ULD mouse infection model to resembles human Mtb infection to test the ability of the ULD model as a TB vaccine testing strategy by assessing the BCG vaccination in I. durability in lung bacterial burden, II. the capacity to protect Mtb dissemination to other organs, and III. levels to protect Mtb infection. Overall, this study is quite extensive and potential interest as the result can be readily used for clinical settings.
Major This study started based upon one of the biggest problems of conventional TB infection model, in which the protection efficacy can be misinterpreted as CFU burden dissipates at later time points due to relatively high burden of initial infection load. To propose that vaccine efficacy test outcomes could be better in ULD murine model compared to that of conventional TB infection model as initial infection burden in ULD model is pathogenetically similar to human infection case. This reviewer is concerned about the authors' interpretation of the results as authors monitored all experimental outcomes at maximum day 125 when lung CFU was ~ 50 fold lower than conventional TB model. Because authors didn't monitor longer period of time, it is not clear if the ULD murine model is optimal to prevent lung CFU dissipation or dissemination to other lung lobes or organs. Authors need to provide additional evidence if the ULD model results are still positive to support authors' hypothesis or the BCG vaccine efficacy in the ULD model was attributed simply to yet lower bacterial burden.
We thank the reviewer for these comments. While we agree that it would be interesting to see if the protective effects of BCG immunization were durable even beyond 125 days post-infection, we don’t believe that defining the durability further is necessary to complete the study or to support our conclusions. In many ways, we believe we have been quite comprehensive and rigorous in this study, examining over 1,000 mice at timepoints ranging from 14 to 125 days post-infection. We believe we have conclusively shown that BCG’s reduction of lung bacterial burdens is more durable in the ULD model than with a conventional dose challenge (50-100 CFU); while the difference is maintained out to days 90-125 in the former, it wanes in the latter. Similarly, BCG’s ability to prevent dissemination to the contralateral lung, a parameter that cannot be assessed in the conventional dose model, is also durable to days 90-125. Finally, because we used a large number of mice, we showed for the first time that BCG can prevent detectable infection in mice challenged with physiologic Mtb dose (pIn response to the reviewer’s comments, we have softened our statements regarding showing that BCG confers durable reductions in lung bacterial burdens in the ULD model. Now, throughout the abstract and manuscript, we say that we show that BCG confers a reduction in lung bacterial burdens that is more durable than observed with conventional dose challenge.
Minor Fig. 1 - 10 out of 20 mouse in BCG vaccinated condition didn't show bacterial burden in the lung at any time. It is not clear that this even is attributed to the failed infection or BCG vaccination mediated protection.
We agree. In this same experiment, 7 out of 20 of the unvaccinated control mice also didn’t show bacterial burden in the lung. One of the features of the ULD model is that we use such a low dose that we intentionally leave some of the mice uninfected, even in the unvaccinated controls. We believe that it is necessary to do this to achieve many of the advantages of the model (e.g., assess dissemination to the contralateral lung and prevention of detectable infection), however, an inherent challenge of the model is that in a single experiment you cannot discern whether an individual mouse with no detectable lung bacteria had infection prevented or whether it would never have been infected in the first place. In the manuscript, we do not claim the difference observed in Figure 1 (7/10 vs. 10/20 with zero CFU) is meaningful. We state in lines 123-125 that “we also observed that 7/20 of the unimmunized mice and 10/20 of the BCG-immunized mice had no detectable infection in either lung (Figure 2A), a difference that was not statistically significant in this single experiment (p=0.53).” We go on to show (Figure 5), that if results from several experiments are pooled, the difference becomes highly significant (p
As shown in Fig. 1 and 2A, at 42 day post infection, conventional TB infection model reached 5 X 106 CFU in an unimmunized condition and 5 X 105 CFU in a BCG vaccinated condition. In this ULD model, the CFU was 1 X 105 CFU in an unimmunized condition and 1 X 104 CFU in an BCG vaccinated model even at 63 day post infection. If we directly compare the CFU between ULD and conventional TB infection model, the difference was ~ 50 folds. Authors may need to show the bacterial CFU burden is still plateaued and stable bacterial dissemination even after a longer period of infection.
We have shown that differences in lung bacterial burdens and bacterial dissemination are durable as long as we’ve looked, which is to days 90-125. As discussed above, we believe this is sufficient to support our conclusions and the goals of the study.
Fig. 2 - The conventional TB model may be included as a negative control.
We show results of BCG efficacy in the conventional TB model in Figure 1. Because conventional dose and ULD infections are different doses, they cannot be in the same infection chamber at the same time and therefore they need to be shown as separate experiments. Nevertheless, the results shown in Figure 1 are highly reproducible, as shown by us and by several other groups (as referenced).
Fig. 5A - Why total challenged mouse number gets increased ?
We presume the reviewer is asking why there are more mice challenged at later timepoints than at early timepoints. Our early experiments suggested that there might be relatively more vaccinated mice with undetectable infection at late timepoints than at earlier ones. As a result, we assessed more experiments at late timepoints than at earlier ones.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Manuscript "Assessing vaccine-mediated protection in an ULD mycobacterium tuberculosis murine model" is an interesting, well-documented and comprehensive study to develop new TB murine model used to assess new TB vaccine candidates.
Although TB vaccine are urgently needed, many TB vaccine candidates remain in the development pipeline mainly because the conventional vaccine evaluation strategy is hindered by the lack of reliable animal models that mimic human TB pathogenic cycle. This manuscript used the ULD mouse infection model to resembles human Mtb infection to test the ability of the ULD model as a TB vaccine testing strategy by assessing the BCG vaccination in I. durability in lung bacterial burden, II. the capacity to protect Mtb dissemination to other organs, and III. levels to protect Mtb infection. Overall, this study is quite extensive and potential interest as the result can be readily used for clinical settings.
Major
This study started based upon one of the biggest problems of conventional TB infection model, in which the protection efficacy can be misinterpreted as CFU burden dissipates at later time points due to relatively high burden of initial infection load. To propose that vaccine efficacy test outcomes could be better in ULD murine model compared to that of conventional TB infection model as initial infection burden in ULD model is pathogenetically similar to human infection case. This reviewer is concerned about the authors' interpretation of the results as authors monitored all experimental outcomes at maximum day 125 when lung CFU was ~ 50 fold lower than conventional TB model. Because authors didn't monitor longer period of time, it is not clear if the ULD murine model is optimal to prevent lung CFU dissipation or dissemination to other lung lobes or organs. Authors need to provide additional evidence if the ULD model results are still positive to support authors' hypothesis or the BCG vaccine efficacy in the ULD model was attributed simply to yet lower bacterial burden.
Minor
Fig. 1 - 10 out of 20 mouse in BCG vaccinated condition didn't show bacterial burden in the lung at any time. It is not clear that this even is attributed to the failed infection or BCG vaccination mediated protection. As shown in Fig. 1 and 2A, at 42 day post infection, conventional TB infection model reached 5 X 106 CFU in an unimmunized condition and 5 X 105 CFU in a BCG vaccinated condition. In this ULD model, the CFU was 1 X 105 CFU in an unimmunized condition and 1 X 104 CFU in an BCG vaccinated model even at 63 day post infection. If we directly compare the CFU between ULD and conventional TB infection model, the difference was ~ 50 folds. Authors may need to show the bacterial CFU burden is still plateaued and stable bacterial dissemination even after a longer period of infection.
Fig. 2 - The conventional TB model may be included as a negative control.
Fig. 5A - Why total challenged mouse number gets increased ?
Significance
This study is clinically useful to test new TB vaccine candidates by improving the conventional TB vaccine model.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
This report provides evidence that the ULD infection model of M. tuberculosis provides the capacity to detect 3 types of protection by BCG: 1) durable reductions in Mtb burden, 2) inhibition of Mtb dissemination, 3) prevention of detectable bacteria. In general, this is well-reasoned, well-written, transparently presented and easy to follow. A few points.
Major issues:
In Figure 2A, 2B, 3A - the authors have a highly skewed distribution with a bimodal distribution between detected bacterial counts and zero bacterial counts. This type of distribution does not lend itself to a t-test. What is the mean of two exclusive categories? For these graphs, the authors should consider plotting the median and interquartile range, then applying a non-parametric test. I suspect the p-values will be as significant, if not more, and there will be some comparisons where the median of the BCG group will be 0 CFU.
In 3B, instead of presenting a model of the data, can the authors present the raw data across all experiments as datapoints with violin plots, or some other form of data visualization? They could present the fixed effect model as a supplementary figure. The fixed effect model works better for plotting proportions in 4A.
Minor points:
Abstract, line 35. The authors state that BCG does A, B, C in a small percentage of mice. It is not clear whether this means all of A, ,B and C happen in a small percentage. Or rather whether the small percentage refers to C alone. Perhaps this can be rewritten for clarity.
Line 123. 12/20 vs 10/20. Hard to say it appeared to prevent based on these numbers. Perhaps may prevent?
Line 128. The authors use the word colonized here but don't use this term elsewhere. What is the difference between colonized and infected, and why is colonized used only here?
The power calculations could be a supplementary table if space is tight.
Significance
This is a strong paper and the data are compelling.<br /> The significance is that this offers a new avenue for evaluation of TB vaccines, especially vaccines to prevent establishment of long-term infection.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1: Major comments: The key point of the manuscript is to provide resources for the plant community. The motivation for selecting these specific promoters, how they were obtained and cloned, what they are in detail and how they will be made publically available is all clearly described. The infection experiments presented in it are an added bonus and a proof of concept of the applicability of the system.
Thank you very much.
Minor comments: The promotor sequences will probably be included in the AddGene submission, however, it might be helpful to also deposit the promoter sequences at e.g. GenBank.
Indeed, we have sent all sequence files to AddGene and they will be available for download there. We will look into transferring them to GenBank as well. We have not done this before, but are generally always supportive of maintaining data in open repositories.
Line 133: "There are few exceptions to this rule...". It would probably helpful to list/mark these exceptions in Table 1
We agree. We have now marked them in the table, and included the sentence “There are a few exceptions to this rule (marked with a * in the ‘Bases’ column in table 2), where we used a defined stretch of DNA that has previously been described to complement a mutant” in lines 135-137.
Line 138: "A overhangs". In the GreenGate system, A-modules (promoters) are flanked by A- (5') and B- (3') overhangs (applies to line 144, too). Also, the B-overhang listed here (TTGT) is the reverse complement, which might be confusing for readers.
A very good point. We have modified these lines to “standard four base pair GreenGate promoter module overhangs (5´-ACCT and TTGT-3´) were added via primers during amplification of the promoter sequences (see Supplementary Table 1 for a list of primer sequences. Note that TTGT is the complementary sequence of the A-to-B-module overhang, as this is added via the reverse primer)” in lines 141-144.
Line 149 ff.: How many lines have been established per promoter tested? Did they all yield a similar expression pattern?
This is indeed a very important point which was somehow lost along the way during manuscript preparations, after being moved around between results and methods section. We have put it back in in lines 162-165 as “We recovered several independent transgenic lines for the PEP1 and 2, PEPR1 and 2, as well as BIK1 and RBOHD reporters. Out of those, a minimum of three (RBOHD) and up to seven (PEPR2) independent lines showed fluorescence, and out of those, all individual lines for each reporter showed the same expression patterns.”
Line 163: As someone not being familiar with microscoping Arabidopsis roots, I'm wondering how the authors can be sure that the tissue in question is the vasculature. Is this obvious for experts in the field?
Of course, we can’t give a totally objective answer here, but we believe that by including the transmitted light image next to the fluorescence image, it is indeed visible that the fluorescence is limited to the center of the root, not the complete circumference. At the same time, it is important to note that all images are stereomicroscopic images, not confocal images. Thus, it is indeed not possible to, e.g., conclude if pericycle cells are included or excluded in the region with expression. So, while it is, we believe, safe to assume that it is vascular cells, we can’t determine which cell types in the vascular cylinder are expressing the reporters. This would require confocal imaging, which would increase the resolution, but at the expense of a good overview, which we think is more valuable for such a proof-of-principle.
Discussion: Is there by any chance prior (cell-resolution) knowledge about the expression behaviour of any of the investigated promoters? E. g. by in-situ hybridizations? If so, do the expression patterns match?
No, the expression of these reporters in direct response to fungal infection have so far only been studied by transcriptomics.
Presentation and quality of the images need be improved. Scale bars are missing in all confocal images. In Figure 3 and 4, the name of genes examined can be labeled on the image, which will make it easier for readers. In addition, key information such as the inoculum and sampling time point after fungal inoculation should be described in the legend or the main text.
We have added the scale bars and gene names into the images. We agree that the gene names make it easier for the reader. Further, we have added the inoculum and sampling time to the legend.
More importantly, a "mock" inoculation or "before fungal inoculation" should be performed to reveal the expression changes of the marker genes after fungal inoculation.
This is information was provided in the text and via the supplemental figures, but I assume we didn’t make it clear that these results and images were indeed specific control/mock experiments, and not some ‘general’ expression analysis. We have now tried to make this clearer, specifically in lines 192-194.
Lines 172-174, the pictures are too small to see these details. The same for BIK1 (line 187).
We have split up figure 3 into two separate figures (figures 3 and 4), to allow for them to be displayed larger, so that more details can be observed. Of course, it would also be helpful to do some confocal microscopy on specific regions of interest of these stereomicroscopic images to obtain high-resolution images of these regions, but, unfortunately, we did not reach this point in this project, before our team was disbanded, and we therefore only have the overview images to get a general idea of the responsiveness of the different reporters.
Line 174-176, which results are these referring to? The same for line 200-203.
We assume that this was not clear because we previously failed to make it clear that the control supplementary figures are from experimental controls/mock. We have reworded both paragraphs to, hopefully, explain it a bit better, and included the supplementary figure number that refers to. It’s now in lines 212-215 and 237-242.
This study provides a valuable collection of vectors/constructs for investigation of transcriptional dynamics of plant immunity genes and should attract broad interest of the plant immunity field.
Thank you very much.
The current study by Calabria et al., entitled "pGG-PIP: A GreenGate (GG) entry vector collection with Plant Immune system Promoters (PIP)," reported the development of a set of GreenGate-compatible entry plasmids that contain promoter sequences of a series of immunity-related genes. This tool enables live-cell observation of immune responses at a cellular resolution. Being compatible with many other GreenGate tools, it opens up a door toward simultaneous visualization of different but overlapping immune pathways and ultimately describes the 4D dynamics of plant immunity. It is more than expected that these constructs will be used by a wide range of researchers and contribute to the ultimate understanding of plant innate immunity.
Thank you very much.
It is exciting that the authors observed the marker expression by a fluorescent stereomicroscope. This allows for non-destructive observation of response over time, keeping the system gnotobiotic. However, it was partly disappointing that the author did not take full advantage of this. It would have been much nicer if the authors observed the infection process over time, such that one could tell when and where the response starts, and whether local and systemic reactions occur simultaneously or instead require local-to-systemic signal transduction. They indeed seem to have done such time-course observation (line 378) however did not provide the results. I am curious to know what the authors could have found from those experiments. It would also be a strong appealing point of this method and is therefore highly encouraged
We absolutely agree that this temporal data would be valuable and interesting. So far, we always imaged the colonization sites in the root tips from the first day when they become visible, until the day when the entire root was colonized/dying. However, we only recorded the infection sites directly, and did not image the entire plants, and local as well as systemic responses. This is, of course, something that we would have liked to do, and planned to do in the future, but, so far, we have not gotten to that point. We also attempted to use the images of the infection sites that we have recorded over time to obtain information about disease progression, e.g., colonization speed of the fungus, but this data is not (yet) at a point, where we feel confident that we have enough information to draw solid conclusions. So, while we absolutely agree that this kind of whole-plant imaging with both, high spatial and temporal resolution, must be the aim, at this point, unfortunately, we simply are not at that place yet.
Immune responses are not always induction of expression but sometimes reduction. Some genes up-regulated in the first phase will also be down-regulated afterward in order to go back to the initial non-responding state. During such down-regulation, the expression of a fluorescence marker gene might not accurately reflect the real expression levels, because the translated proteins might stay longer even while its transcription is suppressed. To address this point, it is suggested that the authors observe the marker lines in the presence of a translation inhibitor, such as cycloheximide, and quantitatively analyze the dynamics of protein degradation when no new protein is synthesized.
This is indeed an excellent point. Unfortunately, we have to first say that due to funding issues we are currently unable to do this experiment. However, we did include two things in the revised manuscript: First, we have put in a note that this is indeed a caveat of the system that must be acknowledged (lines 334-337). Second, we have included some information from a different study, which at least addresses this point to some degree. We have imaged the transcriptional response of the WRKY11 transcription factor in response to colonization by Fo5176, and in this case, we not only see a local upregulation next to the colonization site, but we see a complete switch in expression pattern. As part of this switch, WRKY11 expression, which was expressed in all root tissues and cells in uninfected control experiments, switches expression off in all tissues and cells except the vascular cells close to the infection site. So here, we indeed have a downregulation of the reporter. In these experiments, signal from the fluorescent WRKY11 reporter disappears from the cells within a day. As we imaged once per day, we can, unfortunately not get more specific than this one-day window. The day before colonization of the tip, signal is seen in all tissues, one day later, if/when the vasculature if colonized in the tip, there is no weak/residual fluorescence left in the cells of the outer tissues. So we can at least state that we would probably also detect downregulation of expression, despite the protein lifetime. Importantly, all our imaging is done on a regular stereomicroscope, and thus, camera sensitivity is moderate. I could imagine that we may be able to detect some residual fluorescence with ultra-sensitive cameras at a spinning disc, or a sensitive detector at a laser-scanning microscope, but we have not tested this. We have added this information in lines 337-347. I apologize that we can’t add more information than this.
It is remarkable that the authors managed to clone 75 promoter sequences. However, whether all promoters work as expected was not clearly assessed in the present study. Did the authors only transform plants with PEP1, PEP2, PEPR1, and PEPR2 marker constructs? How would they know that the other promoters also work appropriately? In terms of providing these constructs to the research community, it is needed to disclose to which extent the expression has been validated in planta and which promoter has not been assessed.
This is indeed important information. We have not used the promoters in mutant complementation assays, and have added this caveat in lines 348-350.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
The current study by Calabria et al., entitled "pGG-PIP: A GreenGate (GG) entry vector collection with Plant Immune system Promoters (PIP)," reported the development of a set of GreenGate-compatible entry plasmids that contain promoter sequences of a series of immunity-related genes. This tool enables live-cell observation of immune responses at a cellular resolution. Being compatible with many other GreenGate tools, it opens up a door toward simultaneous visualization of different but overlapping immune pathways and ultimately describes the 4D dynamics of plant immunity. It is more than expected that these constructs will be used by a wide range of researchers and contribute to the ultimate understanding of plant innate immunity.
It is exciting that the authors observed the marker expression by a fluorescent stereomicroscope. This allows for non-destructive observation of response over time, keeping the system gnotobiotic. However, it was partly disappointing that the author did not take full advantage of this. It would have been much nicer if the authors observed the infection process over time, such that one could tell when and where the response starts, and whether local and systemic reactions occur simultaneously or instead require local-to-systemic signal transduction. They indeed seem to have done such time-course observation (line 378) however did not provide the results. I am curious to know what the authors could have found from those experiments. It would also be a strong appealing point of this method and is therefore highly encouraged.
Immune responses are not always induction of expression but sometimes reduction. Some genes up-regulated in the first phase will also be down-regulated afterward in order to go back to the initial non-responding state. During such down-regulation, the expression of a fluorescence marker gene might not accurately reflect the real expression levels, because the translated proteins might stay longer even while its transcription is suppressed. To address this point, it is suggested that the authors observe the marker lines in the presence of a translation inhibitor, such as cycloheximide, and quantitatively analyze the dynamics of protein degradation when no new protein is synthesized.
It is remarkable that the authors managed to clone 75 promoter sequences. However, whether all promoters work as expected was not clearly assessed in the present study. Did the authors only transform plants with PEP1, PEP2, PEPR1, and PEPR2 marker constructs? How would they know that the other promoters also work appropriately? In terms of providing these constructs to the research community, it is needed to disclose to which extent the expression has been validated in planta and which promoter has not been assessed.
Referee cross-commenting
I agree with reviewer #1 that the authors need to disclose how many independent lines were established and assessed for each construct.
I also agree with reviewer #2 that the figure and data presentation needs to be improved.
Significance
Overall, the current study already provides a widely useful set of tools for plant researchers, and some additional work would further increase its strength and value.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
This study provides a useful toolkit of reporter/marker constructs for investigating the gene expression of many immune-associated genes. The authors further used this toolkit to examine the expression pattern of several immune elicitor/receptor/downstream component genes after the inoculation of a fungal vascular pathogen Fusarium oxysporum. The study provides valuable tools for plant immunity study. I have some comments regarding the experiment design and data presentation as shown below.
Presentation and quality of the images need be improved. Scale bars are missing in all confocal images. In Figure 3 and 4, the name of genes examined can be labeled on the image, which will make it easier for readers. In addition, key information such as the inoculum and sampling time point after fungal inoculation should be described in the legend or the main text. More importantly, a "mock" inoculation or "before fungal inoculation" should be performed to reveal the expression changes of the marker genes after fungal inoculation.
Lines 172-174, the pictures are too small to see these details. The same for BIK1 (line 187). Line 174-176, which results are these referring to? The same for line 200-203.
Significance
This study provides a valuable collection of vectors/constructs for investigation of transcriptional dynamics of plant immunity genes and should attract broad interest of the plant immunity field.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary:
In their manuscript, Calabria et al. primarily present a collection of 75 plant (Arabidopsis thaliana) promoters cloned by them into the GreenGate system. These promoters represent different pathways of the plant immune system. Exemplarily they used this compilation to check the involvement of several components of the PLANT ELICITOR PEPTIDE (PEP)-pathway in the response of A. thaliana roots to infection with Fusarium oxysporum strain Fo5176 via transcriptional reporters.
Major comments:
The key point of the manuscript is to provide resources for the plant community. The motivation for selecting these specific promoters, how they were obtained and cloned, what they are in detail and how they will be made publically available is all clearly described. The infection experiments presented in it are an added bonus and a proof of concept of the applicability of the system.
Minor comments:
The promotor sequences will probably be included in the AddGene submission, however, it might be helpful to also deposit the promoter sequences at e.g. GenBank.
Line 133: "There are few exceptions to this rule...". It would probably helpful to list/mark these exceptions in Table 1.
Line 138: "A overhangs". In the GreenGate system, A-modules (promoters) are flanked by A- (5') and B- (3') overhangs (applies to line 144, too). Also, the B-overhang listed here (TTGT) is the reverse complement, which might be confusing for readers.
Line 149 ff.: How many lines have been established per promoter tested? Did they all yield a similar expression pattern?
Line 163: As someone not being familiar with microscoping Arabidopsis roots, I'm wondering how the authors can be sure that the tissue in question is the vasculature. Is this obvious for experts in the field?
Discussion: Is there by any chance prior (cell-resolution) knowledge about the expression behaviour of any of the investigated promoters? E. g. by in-situ hybridizations? If so, do the expression patterns match?
Significance
As stated above, this manuscript primarily describes a technical resource useful for the plant science community.
It is GreenGate-based and therefore easily compatible with other GreenGate-based resource collections. Its primary focus is in the area of plant immune research.
The key audience is plant immunologists. However, also researchers requiring e.g. tissue-specific and/or pathogen-inducible expression might find it helpful.
My own field of expertise is plant transformation and cloning systems, thus I went over the part dealing with the proof-of-principle only as a non-expert.
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
The authors do not wish to provide a response at this time.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary: Yeh et al., present novel findings that Bitesize (Btsz) a Synaptotagmin-like protein, helps organize actin during the syncytial blastoderm stages of Drosophila embryo development. Depleting Btsz leads to phenotypes in the syncytial cycles that mimic Drosophila mutants where actin or membrane trafficking is disrupted. Perhaps most interestingly, the authors show that a non-Moesin Binding Domain-containing isoform of Btsz is important for cytoskeletal regulation during syncytial cycles. The authors generated a BtszB-C terminal recombinant protein and showed using imaging and biochemistry that this conserved segment of Btsz (which is present in all isoforms) can bind to and bundle F-actin in vitro. Lastly, the authors show that Btsz localizes to the apical region of pseudocleavage furrows and cell interfaces at gastrulation, which is consistent with previous literature regarding its role in regulating adherens junctions.
Major Concern: Both the imaging data, image analysis and biochemistry, are compelling. The findings regarding expression of alternative isoforms of Btsz are interesting within this developmental context. However, the final model is very simple and may benefit from the addition of experiments or at least further attention in the discussion. For example, it is not entirely clear what the division of labor may be between isoforms that do or do not bind Moesin. Do these isoforms work to accomplish a single function; or do they perform unique functions? Are the isoforms subject to similar or different regulation? At a minimum, the authors thoughts should be included in the Discussion, and a more integrated model presented. Relatedly, the authors mention the possibility that membrane trafficking may be impacted but end abruptly there. Additional experiments would obviously increase impact. If no experiments are added, the existing text should nonetheless be edited to include a more complete Discussion of the results.
Specific Concerns:
- While the authors claim there is an actin defect, that defect is not readily revealed by a change in actin levels. Is the change perhaps in actin stability or in mechanical properties of the actin filaments (for example, if filaments can assemble but not be bundled or appropriately tethered to the plasma membrane in the mutant)? Have the authors tried either FRAP or laser cutting of furrows in mutant embryos?
- While prior publications mention the role for Btsz in building adherens junctions, it would still be useful to see an analysis of junction phenotypes in the hands of these authors. Also, where do junction components concentrate and what do they do, if known, in syncytial embryos? It would be helpful to include this information in the text.
- Does imaging of golgi or endosome markers reveal any differences in membrane compartments in Btsz mutant embryos? Even negative results would be interesting.
- In describing the Myosin network phenotype during cellularization, it is not clear what is meant by the statement that the network has "constricted" over the positions where nuclei were lost. That sounds like an active process. It seems equally possible that the Myosin is just coating the membrane that now fills the gaps where nuclei should be.
- Some aspects of Btsz gene expression are discussed and equated with a small number of previously described genes for cellularization. Are those genes only expressed during cellularization or beyond? It appears that Btsz is expressed beyond cellularization. Do those genes also have complex splicing patterns/multiple isoforms?
- Could the authors comment on why they chose to describe the syncytial phenotypes in Cycle 12 but not other syncytial cycles?
Significance
For strengths and limitations, see above.
Advance: The authors advance the field of regarding Synaptotagmin-like proteins (Slps) by studying alternative isoforms of the proteins which lack a Moesin-binding domain (MBD). They find a novel function for Btsz isoforms that do not contain an MBD and show that a variant of these isoforms can directly bind to and bundle F-actin to regulate actin during syncytial nuclear divisions. Since the domain(s) they tested are conserved in all isoforms, this likely means that the actin binding function of Btsz could be conserved for most Slps, including Btsz isoforms which contain MBD.
Audience: This work is of interest to cell and developmental biologists who study the regulation of actin cytoskeleton. The work as presented also has some relevance to those who study adherens junctions, membrane trafficking, and Synaptotagmin-like proteins. More broadly, this work may be of interest to those who study alternatively-spliced proteins in the context of development.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
This manuscript by Yeh and colleagues examines the function of the Slp-family protein Bitesize in Drosophila. Btsz has been previously studied in the fly embryo and appreciated to regulate F-actin and adhesion-related properties in the formation of the epithelium, but in this manuscript Yeh et al. look at an earlier point of development (division in the early embryonic syncytium) and also examine the role of bitesize transcripts that lack the moesin-binding domain (MBD). The authors disrupt Btsz function and observe defects in actin-dependent structures, such as the apical actin cap and the pseudo-cleavage furrows, which leads to defect in the pseudo-cleavage divisions. They also perform actin-bundling assays with a btsz fragment that does not contain the MBD and see that btsz can still bundle actin, implicating the C2 domains in this function. The work appears well-done, with only one major area of concern (the imaging and analysis of actin caps, below). The manuscript is well-written, with a nice Introduction, and the Results are appropriately described and interpreted. The quantitation appears appropriate, and n number and the statistical tests used by the authors are consistently stated throughout the manuscript. A few more detailed comments are below:
- It does not appear that the actin caps are being measured and imaged. None of the usual internal structures of the caps are apparent, and instead it appears that what is presented are the apical margins of the pseudocleavage furrows (or the very edges of the caps).
- Along these lines, the argument that caps are smaller does not make much sense, since it appears that the "caps" are being measured late once the furrows have formed. Since these dimensions are set by the number of nuclei in the embryo, as long as the caps are growing large enough to get collisions between adjacent nuclei/caps, how can the caps be smaller unless there are fewer nuclei? These changes could also be secondary consequences of differences in nuclear distributions around the embryo periphery. For these reasons, and because of the close packing of nuclei together, usually cap growth rates are plotted in periods prior to cap collisions.
- Sorry if this was missed, but are the cycles at which measurements are made listed in each appropriate figure? I saw "cycle 12" listed in one figure legend, but not others.
- How do the authors know that the nuclear density defects in the CRISPR allele are due to the same mechanism? Could be through same mechanism, but could also be due to defect in nuclear anchoring, cortical portioning, etc...
- The schematics and illustrations are nicely done.
Minor notes:
- a) Should there be actin in the top row of 1A?
Significance
This manuscript by Yeh and colleagues examines the function of the Slp-family protein Bitesize in Drosophila. Btsz has been previously studied in the fly embryo and appreciated to regulate F-actin and adhesion-related properties in the formation of the epithelium, but in this manuscript Yeh et al. look at an earlier point of development (division in the early embryonic syncytium) and also examine the role of bitesize transcripts that lack the moesin-binding domain (MBD). The authors disrupt Btsz function and observe defects in actin-dependent structures, such as the apical actin cap and the pseudo-cleavage furrows, which leads to defect in the pseudo-cleavage divisions. They also perform actin-bundling assays with a btsz fragment that does not contain the MBD and see that btsz can still bundle actin, implicating the C2 domains in this function. The work should be of interest to a developmental community and those workers interested in Slp-family function.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary:
Yeh and colleagues report the requirement of the Drosophila Synaptotagmin-like protein, Bitesize, for the proper formation of pseudocleavage furrows of the syncytial embryo (through shRNA affecting all Bitesize isoforms). Reduced sizes of the compartments for mitotic spindles and of the sizes of mitotic spindles are also quantified. Local losses of the furrows also correlated with collisions of neighbouring nuclei, and with loss of nuclei from the syncytial embryo periphery, consistent with the known role of the furrows. Bitesize has nine predicted splice isoforms. Some include a Moesin-binding domain, which has previously been implicated in Bitesize activity at post-syncytial developmental stages, and all include a shared C-terminus, which has been implicated in actin binding in a related vertebrate protein. Results suggest expression and functional involvement of isoforms with either potential links to the actin cortex, although definitive conclusions would require further analyses (below). In vitro assays showed the ability of the purified C-terminus to bind and to bundle F-actin. An isoform encoding the C-terminus, but not the Moesin-binding domain, localized to the pseudocleavage furrows, and displayed an internal punctate distribution. The effect of Btsz shRNA on F-actin was tested at cellularization, and no effect was observed by comparing F-actin levels at the apical end of the cell to that at furrow canals. One Btsz isoform lacking the Moesin-binding domain was shown to localize apically during cellularization.
Major comments:
- The phenotypic analyses of the Btsz shRNA embryos are clear.
- The in vitro analyses of the F-actin binding and bundling of the Btsz C-terminus are clear.
- Quantifications, statistics and explanations of methods are appropriate.
- The analyses of isoform expression are a concern because it seems from Figure 1C that the primers to distinguish isoforms with and without the Moesin-binding domain could both be detecting isoform I. If this is the case, then primers to specifically detect "Non-MBD isoforms" should be used. If not, then the current primers for detecting "Non-MBD isoforms" should be clarified in relation to isoform I.
- In the Abstract, Discussion, and Results it is concluded that isoforms lacking the Moesin-binding domain function in syncytial development, but this conclusion is not clearly supported by the data. An exon 4 deletion generating a premature stop was designed to disrupt a subset of isoforms lacking the Moesin-binding domain, but it also has the potential to disrupt isoform I which contains exon 4 and the Moesin-binding domain. RT-PCR should be able to detect isoform I specifically. If it is not expressed, then the conclusion would be strengthened. If it is expressed, then is seems difficult to make a specific conclusion about the role of the of non-MBD isoforms.
- The authors say that the exon 4 deletion mutants and the Moesin-binding domain exon mutants have a weaker phenotype than Btsz shRNA embryos, but different markers were used and genetically encoded markers could contribute to the difference.
- Additional analyses to pursue a possible defect in F-actin organization in Btsz shRNA embryos could better connect the in vitro and in vivo analyses.
- That caveat that only one isoform was localized should be added to this sentence: "Unlike other actin cross-linkers involved in cellularization, BtszB did not localize to furrow canals, suggesting that the cellularization phenotypes we observed in Btsz mutants and Btsz RNAi (Figure 4D) were the result of prior syncytial division defects." The caveat also applies to this sentence in the Discussion: "Btsz is present uniquely in an apical-lateral compartment."
Minor comments:
- Within Fig 1A, the axes of the top image should be X and Z rather than X and Y.
- The Arp3 RNAi data in Figure S1B isn't mentioned in the Results. I assume it is a positive control.
- The internal punctate distribution BtszF in Fig 6A could be commented on in the Discussion paragraph about the possibility of Btsz also functioning in membrane trafficking.
Significance
- From the perspective of syncytial Drosophila development, a new factor is shown to be required for cortical reorganization.
- From the perspective of Bitesize, an earlier role in development is shown.
- From the perspective of Bitesize, an additional mechanism of action is implicated, F-actin binding and bundling, by which it could affect the cell cortex (although more work is needed to clarify this in vivo).
- From the perspective of related vertebrate proteins, an F-actin binding activity found in one of these proteins seems to be conserved in Btsz.
- The paper will be of interest to those studying Bitesize and orthologs, the cell cortex, the actin cytoskeleton, the morphogenesis of cells and tissues, and/or syncytial Drosophila development.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reply to the reviewers
Manuscript number: RC-2023-01932
Corresponding author(s): Dennis KAPPEI
We would like to thank all reviewers for their recognition of our approach and the quality of our work as well as their constructive criticism.
Reviewer #1
Reviewer #1: The manuscript by Yong et. al. describes a comparison of various chromatin immunoprecipitation-mass spectrometric (ChIP-MS) methods targeting human telomeres in a variety of systems. By comparing antibody-based methods, crosslinkers, dCas9 and sgRNA targeted methods, KO cells and various controls, they provide a useful perspective for readers interested in similar experiments to explore protein-DNA interactions in a locus-specific manner.
Response: We would like to thank the reviewer for the feedback and the appreciation of our work.
Reviewer #1: While interesting, I found it somewhat difficult to extract a clear comparison of the methods from the text. It was also difficult to compare as data and findings from each method was discussed in its own context. Perhaps it is not in their interest to single out a specific method and it is indeed true that there are caveats with each of the methods.
Response: Across our manuscript we have established one single workflow, for which we present some technical comparisons (e.g. using single or double cross-linking in Fig. 2a/b), technical recommendations such as the use of loss-of-function controls (e.g. Fig. 1c v. Fig. 2a and Extended Data Fig. 3g vs. 3i) and an application to unique loci using dCas9 (Fig. 3f). Based on the suggestions below, we believe that we will improve the clarity of communicating our approach.
Reviewer #1: I think the manuscript would be of interest but I believe that there are remaining questions that need to be addressed before publication. In particular, I found it difficult to reconcile the discrepancy in protein IDs between most experiments vs. the WT/KO experiment in Fig 2. The authors make a big deal about the importance of the KO control but I think the fewer proteins identified there may be experiment-specific and not general to the KO system. I ask that this be investigated more carefully by the authors in their revisions.
Response: We thank the reviewer for highlighting this point. We do not think that the ChIP-MS comparison between U2OS WT and ZBTB48 KO clones (Fig. 2a) has experiment-specific caveats. Instead the KO controls as well as the dTAGV-1 degron system for MYB ChIP-MS (Extended Data Fig. 3) reveal antibody-specific off-targets, which are indeed false-positives. Please see below for further details.
Reviewer #1: Ln 57: What is "standard double cross-linking ChIP reactions" in this context? Is it the two different crosslinkers? The two proteins? The reciprocal IPs of one protein, and blotting for another? It's not clear here or from Extended Fig 1A. Upon further reading, it seems to pertain to the two crosslinkers - if so, the authors should briefly describe their workflow to help readers.
Response: As the reviewer correctly concludes, we indeed intended to highlight the use of two separate crosslinkers (formaldehyde/FA and DSP). This combination is important as illustrated in the side-by-side comparison of Fig. 2a and Fig. 2d. Here, we performed ZBTB48 ChIP-MS in five U2OS WT and five U2OS ZBTB48 KO clones. While in both experiments the bait protein ZBTB48 was abundantly enriched in the samples that were fixed with formaldehyde we lose about half of the telomeric proteins that are known to directly bind to telomeric DNA independent of ZBTB48 and all of their interaction partners. For instance, while the FA+DSP reaction in Fig. 2a enriched all six shelterin complex members, the FA only reaction in Fig. 2d only enriches TERF2. These data suggest that the use of a second cross-linker helps to stabilise protein complexes on chromatin fragments. This is a critical message of our manuscript as ChIP-MS only truly lives up its name if we can enrich proteins that genuinely sit on the same chromatin fragment without protein interactions to the bait protein. We will expand on this in both the text and our schematics in Fig. 1a and 3a to make this clearer for the readers.
Reviewer #1: Ln 95: It is surprising and quite unclear to me why it is that the WT ZBTB48 U2OS pulldown in Fig 1B shows 83 hits for the WT vs Ig control experiment but 27 hits for the WT vs KO condition in Fig 2A. The two WT experiments have the same design and reagents, shouldn't they be as close as technical replicates and provide very similar hits?
The authors seem to make the claim that most of the 'extra' proteins in WT vs Ig are abundant and false positives, but if this is so, shouldn't they bind non-specifically to the beads and be enriched equally in Ig control and ZBTB48 WT IPs?
Response: We again thank the reviewer for raising this point and the need to explain in more detail why we interpret the difference between 83 hits (anti-ZBTB48 antibody vs. IgG; Fig. 1c) and 27 hits (anti-ZBTB48 antibody used in both U2OS WT and ZBTB48 KO cells; Fig. 2a) primarily as false-positives. The KO controls in Fig. 2a allow to keep the ZBTB48 antibody as a constant variable while instead comparing the presence (WT) or absence (KO) of the bait protein. Hence, proteins that were enriched in the IgG comparison in Fig. 1c but that are lost in the WT vs. KO comparison in Fig. 2a are likely directly (or indirectly) recognised by the ZBTB48 antibody, akin to off-targets to this particular reagent. In a Western blot this would be equivalent to seeing multiple bands at different molecular weights with only the band belonging to the protein-of-interest disappearing in KO cells. To illustrate this we would like to refer to Extended Data Fig. 2, in which we have replotted the exact same data from Fig. 2a. However, in addition we have here highlighted proteins that were enriched in the IgG comparison in Fig. 1c. 46 proteins (in pink) are indeed quantified in the WT vs. KO comparison, but these proteins are found below the cut-offs (and most of them with very poor fold changes and p-values). In contrast to the other several hundred proteins common between both experiments that can be considered common background non-specifically bound to the protein G beads, these 46 proteins represent antibody-specific false-positives.
The above consideration is not unique to ChIP-MS as illustrated by the Western blot example. We also do not claim novelty on the experimental logic, e.g. pre-CRISPR in 2006 Selbach and Mann demonstrated the usefulness of RNAi controls in immunoprecipitations (IPs) (PMID: 17072306). However, our data suggests that ChIP-MS is particularly vulnerable to this type of false-positives given that the approach requires (double-)cross-linking to sufficiently stabilise true-positives on the same chromatin fragment.
To supplement the WT vs. ZBTB48 KO comparison, we had included a second experiment in the manuscript that illustrates the same point in even more dramatic fashion. First, KO controls are very clean in principle, but they themselves might come with caveats if e.g. the expression levels between WT and KO samples differ greatly. This might create a situation that the reviewer hinted to, i.e. differential expression of abundant proteins that would proportionally to their expression levels stick to the beads, resulting in “fold enrichments”. The resulting false positives could e.g. be controlled by matched expression proteomes. For ZBTB48 we have previously measured this (PMID: 28500257) and demonstrated that only a small number of genes are differentially expressed (~10) and hence we can interpret the WT vs. ZBTB48 KO comparison quite cleanly. However, for other classes of proteins such as transcription factors that regulate a large number of genes, E3 ligases etc. this might present a more serious concern. Therefore, we extended our loss-of-function comparison to such a transcription factor, MYB, by using the dTAGV-1 degron system. Importantly, the MYB antibody has been used in previous work for ChIP-seq applications (e.g. PMID: 25394790). Here, instead of 186 hits in the MYB vs. IgG comparison using the same MYB antibody in control-treated and dTAGV-1-treated cells (upon 30 min of treatment only) we only detect 9 hits. Again, similar to the WT vs. ZBTB48 KO comparison, 180 proteins are quantified in the DMSO vs. dTAGV-1 comparison, but these proteins fall below the cut-offs (Extended Data Fig. 3g vs. 3i). Again, we believe that this quite drastically illustrates how vulnerable ChIP-MS data is to large numbers of false-positives. This is not only a technical consideration as such datasets are frequently used in downstream pathway/gene set enrichment analyses etc. Such large false discovery rates would obviously lead to error-carry-forward and additional (unintended) misinterpretations. We will carefully expand our textual description across the manuscript to make these points much clearer. In addition, we will move the previous Extended Data Fig. 3 into the main manuscript to more clearly highlight this important point.
Reviewer #1: Volcano plots in Figs 1, 2, and Suppl. Tables etc: Are the plotted points the mean of 5 replicates? Was each run normalized between the replicates in each group, for e.g. by median normalization of the log2 MS intensities? This does not appear to be the case upon inspection of the Suppl Tables. Given the variability in pulldown efficiency, gel digest and peptide recovery, this would certainly be necessary.
Response: All volcano plots are indeed based on 4-5 biological replicates (most stringently in the WT vs. KO comparisons in Fig. 2 based on each 5 independent WT and ZBTB48 KO single cell clones). The x-axis of each volcano plot represents the ratio of mean MS1-based intensities between both experimental conditions in log2 scale. However, precisely to account for the variation that the reviewer highlighted we did not base our analysis on raw MS1 intensities but we used the MaxLFQ algorithm (PMID: 24942700) as part of the MaxQuant analysis software (PMID: 19029910) for genuine label-free quantitation across experimental conditions and replicates. In this context, we would also like to refer to a related comment by reviewer #2 based on which we will now addd concordance information for each replicate (heatmaps for Pearson correlations and PCA plots). We will improve this both in the text and methods section accordingly.
Reviewer #1: Ln 125: The authors make the claim that the ChIP-MS experiments are inherently noisy, with examples from WT cells, dTAG system and IgG controls. This is likely the case, yet their experiments with WT vs KO cells do not identify as many proteins overall. I find this inconsistency somewhat unclear and does not seem to match the claim of ChIP-MS experiments and crosslinking adding to non-specificity. Can the authors add the total number of identified proteins in each volcano plot, for easier reference?
Response: The number of identified proteins does not vary majorly between matched IgG and loss-of-function comparisons and for instance the single cross-linking (FA only) experiment in Fig. 2c has the largest number of quantified proteins among all ZBTB48 IPs. But we will of course add the requested information to all plots.
Reviewer #1: I think the manuscript is interest as it provides important benchmarks for ChIP-proteomics experiments. I believe that there are remaining questions that need to be addressed before publication. In particular, I found it difficult to reconcile the discrepancy in protein IDs between most experiments vs. the WT/KO experiment in Fig 2. The authors make a big deal about the importance of the KO control but I think the fewer proteins identified there may be experiment-specific and not general to the KO system. I ask that this be investigated more carefully by the authors in their revisions.
Response: We would like to thank the reviewer for recognising our work as a source for important benchmarks for ChIP-MS experiments. We hope that with a more detailed description and discussion the highlighted aspects will be more clearly communicated. We originally conceived our manuscript as a short report and now realised that some of the information became too condensed and might therefore benefit from more extensive explanations.
Reviewer #2
Reviewer #2: Summary: In this manuscript, Yong and colleagues have introduced a optimized technique for studying actors on chromatin in specific regions with a localized approach thanks to revisited ChIP-mass spectrometry (MS) with label-free quantitative (LFQ). The authors exhibited the utility of their approach by demonstrating its effectiveness at telomeres from cell culture (human U2OS cells) to tissue samples (liver, mouse embryonic stem cells). As a proof of concept, this technique was tested by the authors with proteins from complex shelterin specific to telomeres (TERF2 and ZBTB48), transcription factors (MYB), and through dCas9-driven locus-specific enrichment. Notably, the authors created a U2OS dCas9-GFP clone and then introduced sgRNAs to target either telomeric DNA (sgTELO) or an unrelated control (sgGAL4). The cells expressing sgTELO exhibited a significant localization of telomeres and an enriched amount of telomeric DNA in ChIP with dCas9. They also found the proteins previously identified as known to be enriched at telomeres (for example, the 6 shelterin members).
Moreover, the authors illustrated the importance of double crosslinking (formaldehyde (FA) and dithiobis(succinimidyl propionate) (DSP) in ChIP-MS. Their data demonstrated also that ChIP-MS is inclined towards false-positives, possibly owing to its inherent cross-linking. However, by utilizing loss-of-function conditions specific to the bait, it can be tightly managed.
- Can you show the concordance between biological replicates for each ChIP with LFQ? (heatmap of Pearson correlation and PCA plot). This will confirm the robustness of the use of LFQ.
Response: We will add the requested concordance data for all volcano plots both in the form of heatmaps of Pearson correlation and PCA plots. Across our datasets, the replicates from the same experimental condition clearly cluster with each other and replicates have high concordance values of >0.9. As expected replicates for the target/bait samples have slightly higher concordance values compared to the negative controls (IgG or loss-of-function samples). We thank the reviewer for this suggestion as the new Extended Data panel will strengthen the illustration of our robust LFQ data.
Reviewer #2: You say that your technique is " a simple, robust ChIP-MS workflow based on comparably low input quantities » (line 139). What would be really interesting for a technical paper would be: a schematic and a table illustrating the differences between your method and the previously published methods (amount of material, timeline,...) to really highlight the novelty in your optimized techniques.
Response: We will add a comparison table with previous publications using ChIP-MS and for reference include some complementary approaches as requested by reviewer #3. On this note, we would like to stress that we are not “only” intending to use less material and to have an easy-to-adopt protocol. A cornerstone of our manuscript is to apply rigorous expectations to ChIP-MS experiments, in particular the ability to enrich proteins that independently bind to the same chromatin fragments as the bait protein (regardless of whether this is an endogenous protein or a exogenous, targeted bait such as dCas9). Otherwise, such experiments risk to be regular protein IPs under cross-linking conditions, which as illustrated by our loss-of-function comparisons are prone to yield particularly large fractions of false-positives.
Reviewer #2: It would be interesting to perform the dCas9 ChIP experiment in telomeric regions with and without LFQ. Since the novelty lies in this parameter, at no time does the paper show that LFQ really allows to have as many or more proteins identified but in a simpler way and with less material. A table allowing to compare with and without LFQ would be interesting.
Response: We do not fully understand what the suggestion “without LFQ” refers to exactly. We assume that this reviewer might suggest to use a different quantitative mass spectrometry approach other than LFQ, e.g. SILAC labelling, TMT labelling etc. Please note that we do not claim that LFQ quantification is per se superior to the various quantification methods that had been developed and widely used across the proteomics community especially before instrument setups and analysis pipelines were stable enough for label-free quantification (a name that is strongly owed to this historic order of development). However, a central goal of our workflow is to make robust and rigorous ChIP-MS accessible to the myriad of laboratories using ChIP-qPCR/-seq and that may not be extensively specialised in mass spectrometry. Both metabolic and isobaric labelling come not only at a higher cost but also present an experimental hurdle to non-specialists compared to performing biological replicates without any labelling, essentially the same way as for any ChIP-qPCR etc. experiment. We will further elaborate on these points in the manuscript to more clearly convey these notions.
In general, with the right effort different quantitative methods should and will likely yield qualitatively similar results. However, comparisons between LFQ approaches (MaxLFQ, iBAQ,…) and labelling approaches (SILAC, TMT, iTRAQ) have already been better explored and verbalised elsewhere (e.g. PMID: 31814417 & 29535314). Therefore, we believe that this will add relatively little value to our manuscript.
Reviewer #2: Put a sentence to explain "label free quantification". For a reader who is not at all familiar with this technique, it would be interesting to explain it and to quote the advantages compared to PLEX.
Response: Thanks for highlighting this. In line with the point above as well as a similar comment by reviewer #1 we will improve this both in the main text and manuscript to clearly explain the terminology, the MaxLFQ algorithm (PMID: 24942700) used and to highlight the advantages compared to labelling approaches.
Reviewer #2: what does the ranking on the right of each volcano plot represent (figure 1 b-e, figure 2a,d,e for example)? top of the most enriched proteins in the mentioned categories? Not very clear when we look on the volcano plot. it must be specified in the legend.
Response: The numbering these panels is meant to link protein names to the data points on the volcano plots. The order of hits is ranked based on strongest fold enrichment, i.e. from right to center. We will clarify this in the figure legends.
Reviewer #2: General assessment/Advance: The authors explain in their article that the ChIP exploiting the sequence specificity of nuclease-dead Cas9 (dCas9) to target specific chromatin loci by directly enriching for dCas9 was already published. Here, the novelty of this study lies in the use of LFQ mass spectrometry to optimize the technique and make it easier to handle. Some comparisons with previous papers or data generated by the lab will be interesting to really show the improvement and the advantage to use LFQ and therefore, to highlight better the novelty of the study.
Response: We thank the reviewer for this assessment and as mentioned above we will include such a comparison table. dCas9 has been used previously in a ChIP-MS approach termed CAPTURE (PMID: 28841410). While this is clearly a landmark paper that illustrated the dCas9 enrichment concept across multiple omics applications (i.e. not limited to proteomics) in their application to telomeres, the authors enriched only 3 out of the 6 shelterin proteins with quite moderate fold enrichments (POT1: 0.99, TERF2: 2.13, TERF2IP: 1.06; in log2 scale). Based on this alone, POT1 and TERF2IP would not have qualified for our cut-off criteria. In addition, while the authors had performed three replicates, detection is only reported in 1-2 out of 3 replicates. While it is difficult to reconstruct statistical values based on the publicly accessible data, it is therefore unlikely that even these 3 proteins would have robustly be considered hits in our datasets. Similarly, using recombinant dCas9 with a sgRNA targeting telomeres that was in vitro reconstituted with sonicated chromatin extracts from 500 million HeLa cells (CLASP; PMID: 29507191) the authors identified only up to 3 shelterin subunits (TERF2, TERF2IP and TPP1/ACD) based on 1 unique peptide each only. For comparison, in our dCas9 ChIP-MS dataset all 6 shelterin subunits are identified with 9-19 unique peptides, contributing to our robust quantification. Even when considering cell line-specific differences (HeLa cells have shorter telomeres and hence provide less biochemical material for enrichment per cell), these comparisons illustrate that prior attempts struggled to robustly replicate even the most abundant telomeric complex members.
Based on these findings, others had suggested that dCas9 “might exclude some relevant proteins from telomeres in vivo” (PMID: 32152500), implying that dCas9 ChIP-MS might inherently not be feasible including at repetitive regions such as telomeres. Therefore, we believe that our dCas9 ChIP-MS data is a proof-of-concept that the method has the genuine ability to robustly enrich key proteins at individual loci. In concordance with the comment above we will include a comparison table with previous papers and expand on these points in the discussion.
Reviewer #2: By presenting this technical paper, the authors allow laboratories across different fields to use this technique to gain insights into protein enrichment in specific chromatin regions such as the promoter of a gene of interest or a particular open region in ATACseq in a easier way and with less materials. This paper holds value in enabling researchers to answer many pertinent questions in various fields.
Response: We again thank the reviewer for this encouraging assessment and we do indeed hope that this manuscript makes a contribution to a much wider use of ChIP-MS approaches as a promising complement to existing genome-wide epigenetics analyses.
Reviewer #3
Reviewer #3: Strengths of the study:
The study is well-structured and provides a robust workflow for the application of ChIP-MS to investigate chromatin composition in various contexts.
The use of telomeres as a model locus for testing the developed ChIP-MS approach is appropriate due to its well-characterized protein composition.
The comparison of WT vs KO lines for ZBTB48 is a rigorous way to control for false-positives, providing more confidence in the results.
The direct comparison of double vs only FA-crosslinking provides valuable insights into the benefit of additional protein-protein crosslinking in ChIP-MS workflows.
Response: We thank the reviewer for this assessment and we agree that the above are several of the key features of our manuscript.
Reviewer #3: Areas for improvement: The novelty of the method is more than questionable as both ChIP-MS coupled to LFQ and dCas9 usage for locus-specific proteomics have been previously reported. The fact that the authors directly pulldown dCas9 instead of using a dCas9-fused biotin ligase and subsequent streptavidin pulldown is only a very minor change to previous methods (not even improvement). It would be more accurate for the authors to present their study as an optimization and rigorous validation of existing techniques rather than a novel approach.
Response: While we appreciate where the reviewer is coming from, it occurs to us that most of the reviewer’s comments equate ChIP approaches with other complementary methods, in particular proximity labelling. The latter is indeed a powerful experimental strategy and in fact we are ourselves avid users. As highlighted to reviewer #1 as well, our manuscript was originally conceived as a shorter report and based on the feedback we will now expand our discussion to more broadly incorporate related approaches.
However, we would like to stress that dCas9 ChIP-MS and dCas9-biotin ligase fusions are not the same thing and this is not a minor tweak to an existing protocol. While both approaches have converging aims – to identify proteins that associate with individual genomic loci – the experimental workflows differ fundamentally. Biotin ligases use a “tag and run” approach by promiscuously leaving a biotin tag on encountered proteins. Subsequently, cellular proteins are extracted and in fact proteins can even be denatured prior to enrichment with streptavidin beads. While this is an in vivo workflow that (depending on the biotin ligase used) may provide sensitivity advantages, it does not retain complex information. The latter is inherently part of ChIP workflows due to the use of cross-linkers. One obvious future application would be to maintain (= not to reverse as we have done here) the crosslink during the mass spectrometry sample preparation in order to read out cross-linked peptides to gain insights into interactions and structural features. We will now more clearly incorporate such notions into our discussion.
In addition, we would like to stress that while this reviewer focuses primarily on the dCas9 aspect of our manuscript, we believe that our general ChIP-MS workflow including the combination with label-free quantitation is useful and important already by itself as e.g. recognised by both reviewers #1 and #2.
Reviewer #3: The authors should more thoroughly discuss previous works using ChIP-MS and dCas9 for locus-specific proteomics. This would give readers a better understanding of how the current work builds on and improves these earlier methods. For a paper that aims on presenting an optimized ChIP-MS workflow it is crucial to showcase in which use cases it outperforms previously published methods.
E.g., compare locus-specific dCas9 ChIP-MS to CasID (doi.org/10.1080/19491034.2016.1239000) and C-Berst (doi.org/10.1038/s41592- 018-0006-2); how does your method perform in comparison to these?
Response: Again, while we will now incorporate more extensively comparisons with previous ChIP-MS publications (and the few prior manuscripts that included dCas9) as well as related techniques, we would like to stress that dCas9 ChIP-MS is not the same approach as CasID and C-BERST, which rely on dCas9 fusions to BirA* and APEX2, respectively. dCas9-APEX2 strategies were also published by two additional groups as CASPEX (back-to-back with the C-BERST manuscript; PMID: 29735997) and CAPLOCUS (PMID: 30805613). All of these methods target specific loci with dCas9 and promiscuously biotinylate proteins that are in proximity to the dCas9-biotin ligase fusion protein. As described above, while the application of the BioID principle (PMID: 22412018) to chromatin regions has converging aims with the dCas9 ChIP-MS part of our manuscript, they do not test the same. ChIP carries chromatin complexes through the entire workflow while the CasID approaches are independent of that. This is the same scenario if we were to compare IP-MS reactions (such as the ChIP-MS reactions presented here for endogenous proteins) and BioID-type experiments for proximity partners of the same bait proteins.
Reviewer #3: Compare likewise the described protein interactomes to previously published interactomes.
Response: We will add comparisons in form of Venn diagrams with previously published interactomes. However, we would like to stress that a key aspect of our manuscript is the smaller yet rigorous hit lists based on e.g. loss-of-function controls, higher stringencies and specificity. Simply comparing final interactomes remains reductionist relative to the importance of other variables such as experimental design, number of replicates, data analysis etc.
Reviewer #3: The authors use sgGAL4 as a control for the telomeric targeting of dCas9. The IF results (Fig3b) show that sgGAL4 barely localizes to the nucleus with very faint signals. It would be helpful to use a control with homogenous nuclear localization of dCas9 to further strengthen the author's conclusions.
Response: dCas9-EGFP in the presence of sgGAL4 localises diffusely to the nucleus as expected. We have here used a very widely used non-targeting sgRNA control that has been originally used for imaging purposes (PMID: 24360272) and has since been used in a variety of studies (e.g. PMID: 26082495, 32540968, 28427715) including a previous dCas9 ChIP-MS attempt (PMID: 28841410). In addition, to the diffuse nuclear, non-telomeric localisation we provide complementary validation of clean enrichment of telomeric DNA specifically in the sgTELO samples. Therefore, we do not see how other non-targeting sgRNAs would provide for better controls or improve our data.
Reviewer #3: The extrapolation of results from the use of telomeres as a proof-of-concept to other loci is not a given considering the highly repetitive structure of telomeric DNA. The authors should either be more cautious about generalizing the results to other loci or demonstrate that their method can also capture locus-specific interactomes at non-repetitive regions.
Response: We agree that the adoption of any locus-specific approach to single genomic loci is a steep additional hurdle and warrants rigorous data on well characterised loci with very clear positive controls. We will expand on these challenges in our discussion. However, we would like to stress that we did not make any such statement in our original manuscript apart from simply referring to our telomeric experiment as proof-of-concept evidence that locus-specific approaches are feasible by ChIP.
Reviewer #3: What are concrete biological insights from this optimized ChIP-MS workflow that previous methods failed to show?
Response: We explicitly used telomeres as an extensively studied locus with clear positive controls that at the same time allows us to evaluate likely false positives. As such the intention of the manuscript was not to yield concrete biological insights but to develop a new methodological workflow.
As also highlighted in a response to reviewer #2, based on other prior attempts to enrich telomers in ChIP-like approaches with dCas9 (PMID: 28841410 & 29507191), it had been suggested that dCas9 “might exclude some relevant proteins from telomeres in vivo” (PMID: 32152500), implying that dCas9 ChIP-MS might inherently not be feasible including at repetitive regions such as telomeres. Therefore, recapitulating the set of well-described telomeric proteins was no trivial feat and our ChIP-MS workflow (both targeted and applied to individual proteins) represents a well-validated method to in the future systematically interrogate changes in chromatin composition. As one example at telomeres, this may include chromatin changes upon the induction of telomeric fusions or general DNA damage.
Reviewer #3: For instance, the authors could compare their mouse and human TERF2 interactomes and discuss similarities and differences between both species.
Response: We thank the reviewer for this suggestion, but the comparison between mouse and human TERF2 interactomes is not suitable across the datasets that we generated. U2OS is a human osteosarcoma cell line that relies on the Alternative Lengthening of Telomeres (ALT) pathway while our mouse data is based on embryonic stem cells (mESCs) and mouse liver tissue. Even the latter, in contrast to adult human tissue, expresses telomerase. We can certainly still pinpoint (as already done in our original manuscript) individual differences among known factors, e.g. the fact that proteins such as NR2C2 are more abundantly found at ALT telomeres (PMID: 19135898, 23229897, 25723166) vs. the detection of the CST complex as telomerase terminator (PMID: 22763445) in the mouse samples. However, the TERF2 datasets contain hundreds of proteins as “hits” above our cut-offs and a key message of our manuscript is that the majority of them are likely false positives. Here, differences are likely extending to expression differences between U2OS cells, mESCs and liver samples. So while appealing in theory, this cross data set comparison would remain rather superficial and error prone at this point. As a biology focused follow-up study, this would need to be rigorously conceived based on an appropriate choice of human and murine cell line models. In addition, this would likely require the generation of FKBP12-TERF2 knock-in fusion clones to allow for rapid depletion of TERF2 for a clean loss-of-function control since sustained loss of TERF2 leads to chromosomal fusions and eventually cell death in most cell types.
Reviewer #3: The authors should also describe which interaction partners are novel and try to validate some of these using orthogonal methods.
Response: We will now highlight more explicitly two proteins, POGZ and UBTF, that are most robustly and reproducibly enriched on telomeric chromatin across datasets, including the U2OS WT vs. ZBTB48 KO comparison (Fig. 2a). However, we would like to abstain from a molecular characterization at this point. As mentioned above, the discovery of novel telomeric proteins is not the focus of this manuscript, which is primarily dedicated to method development. In addition, these type of validations in methods papers are often limited to a few assays (e.g. can 1 or 2 proteins be enriched by ChIP? Do you see some localisation by IF? etc.). However, our research group has a history of publishing in-depth mechanistic papers on the characterisation of novel telomeric proteins (e.g. PMID: 23685356, 28500257, 20639181, doi.org/10.1101/2022.11.30.518500). Therefore, a genuine validation of such factors would require functional insights and clearly warrants independent follow-up work.
Reviewer #3: Human Terf2 ChIP-MS (Fig1A) seems to be much more specific than the mouse counterpart (Fig1D) (32 TERF2 interactors out of 176 hits in human vs 12 TERF2 interactors out of 500 hits in mouse). Could the authors explain this notable difference?
Response: As eluded to above, Fig. 1A and 1D cannot be directly compared, starting with the difference in complexity in the input material – cell line vs. tissue. For comparison, the Terf2 ChIP-MS data from mouse embryonic stem cells tallies up to 19 out of 169 hits, which is much closer to the U2OS results. Again, we deem the majority of hits from the TERF2 ChIP-MS data to be false-positives and the more complex input material from mouse livers likely accounts for the difference in these numbers.
Reviewer #3: The authors used much higher cell numbers than previously published ChIP-MS experiments; while this is understandable for dCas9-based pulldowns, the cell number is expected to be down-scalable for the other IPs (TERF2, ZBTB48, MYB). Since this work primarily describes an optimized Chip-MS workflow, the authors should show that they can reasonably downscale to at least 15 Mio cells per replicate; one way of achieving this could be through digesting on the beads and not in-gel.
Response: As we will illustrate in the comparison table that was also requested by reviewer 2, our approach does not use higher cell numbers than previous ChIP-MS approaches – quite the contrary. In addition, we would like to highlight that while we state 50 million cells in Fig. 1a, we only inject 50% of our samples for MS analysis to retain a back-up sample in case of technical issues with the instruments. In other words, our workflow is already effectively based on 25 million cells and thereby pretty close to the requested 15 million cells while simultaneously requiring substantially less reagents.
Importantly, our examples are based on rather lowly expressed bait proteins such as ZBTB48 (not detected within DDA-based proteomes of ~10,000 proteins in U2OS cells). While the workflow can be applied across proteins, exact input numbers might vary depending on the bait protein, e.g. histones and its modifications would likely require less for the same absolute sample enrichment. For instance, PMID 25990348 and 25755260 performed ChIP-MS on common histone modifications but still used 300-800 million cells per replicate. Considering that we worked on substantially less abundant proteins, we here present a workflow with comparably low input samples.
Reviewer #3: It is not clear from the text or figure what the authors are trying to show in Fig2c. They should either explain this further or take the figure out.
Response: We are trying to illustrate the following: As in any IP reaction the bait protein is the most enriched protein with very high relative intensities, e.g. TERF2 in the TERF2 ChIP-MS data. Direct protein interaction partners – here the other shelterin members – follow at about 1 order of magnitude lower signal intensities. In contrast, proteins that are enriched via an interaction with the same DNA molecule (i.e. that do not physically interact with the bait protein) such as NR2C2, HMBOX1 and ZBTB48 further trail by at least 1 more order of magnitude. These are information that are not easily visualised within the volcano plots and mainly “buried” within the Supplementary Tables. However, these relative intensities displayed in Fig. 2c clearly illustrate the dynamic range challenge that ChIP-MS poses for proteins that independently bind to the same chromatin fragment. We have now modified our text to make this point more clear.
Reviewer #3: Was there any benefit in using a Q Exactive HF vs timsTOF flex?
Response: Yes, measuring the same samples (e.g. the 50% backup mentioned above) on both instruments enriches more telomeric proteins/shelterin proteins in e.g. the dCas9 ChIP-MS data set on the timsTOF fleX. However, given the difference in age of these instruments/technologies between a Q Exactive HF and a timsTOF fleX (in the context of these experiments the equivalent of a timsTOF Pro 2), this is not a fair comparison beyond concluding that a more recent instrument like the timsTOF fleX achieves better coverage and is more sensitive with otherwise comparable measurement parameters. As we did not have the opportunity to run matched samples on e.g. an Exploris 480, we would not want to make claims across vendors. As stated in the discussion we are expecting that even newer generation of mass spectrometers, such as the very recently released Orbitrap Astral or timsTOF Ultra would further improve the sensitivity and/or allow to reduce the amount of input material. Therefore, the main conclusion is that improvements in the mass spec generations improve proteomics data quality and our samples are no exception, i.e. this is not specifically pertinent to our approach.
Reviewer #3: How did the authors analyze the PTM data? This is not described in the methods section. In addition, it would be important to validate the novel PTMs described for NR2C2.
Response: We apologise for the oversight and we will add the description of PTMs as variable modifications during our MaxQuant search in the methods section. The originally deposited datasets already include this and we had simply missed this in our methods text.
While we are not 100% sure to understand the request for validation correctly, we would like to point out that the PTMs on NR2C2 have been previously reported in several high-throughput datasets and for S19 in functional work on NR2C2 (PMID: 16887930). However, the relevance in our data set is as follows: While the PTMs on TERF2 as the bait protein could occur both on telomere-bound TERF2 as well as on nucleoplasmic TERF2, NR2C2 is only enriched in the TERF2 ChIP-MS reactions due to its direct interaction with telomeric DNA. The co-detection of its modifications therefore implies that at least some of the telomere-bound NR2C2 carries these modifications. We showcase this example as an additional angle of how such ChIP-MS datasets can be analysed.
While the robust, MS2-based detection of these modified peptides in our data set and several other publicly available datasets provides strong evidence that these modifications are genuine, further functional validation would involve rather labour-intensive experiments and resource generation (e.g. phospho-site specific antibodies). We hope that the reviewer agrees with us that this would require an independent follow-up study and that this goes beyond the scope of our current manuscript.
Reviewer #3: For this kind of methods paper one would expect to see the shearing results of the ChIP-MS experiments since variations in DNA shearing can impact the detection of false-positives in the ChIP-MS experiments
Response: We will include agarose gel pictures of our sonicates, which we indeed routinely quality controlled prior to ChIP experiments as stated in our methods description.
Reviewer #3: Overall, the current state of the manuscript neither provides direct evidence that the "optimized" ChIP-MS workflow is better in certain aspects/use cases than previously published methods nor does it provide novel biological insights. At the current state it even cannot be considered as a validation of previously published methods since it does not discuss them.
Response: We politely disagree with this conclusion. Again, as mentioned above we are under the impression that this reviewer somehow equates our entire manuscript to a comparison with dCas9-biotin ligase fusions.
Instead, we here provide a workflow for ChIP-MS that incorporates label-free quantification as the experimentally easiest, most intuitive quantification method for non-mass spectrometry experts. This offers a particularly low barrier to entry aimed at making ChIP-MS more widely accessible as a complement to commonly used ChIP-seq applications. Furthermore, we showcase that as a gold standard ChIP-MS – to truly live up to its name – should have the ability to enrich proteins independently binding to the same chromatin fragment. We demonstrated that double cross-linking is critical for these assays and in return illustrate how rigorous loss-of-function controls (both KOs and degron systems) can mitigate prevalent false-positives that are exacerbated due to the cross-linking. Finally, we applied this workflow to different types of endogenous proteins (transcription factors, telomeric proteins) in cell lines and tissue and extend our work to dCas9 ChIP-MS as a targeted method.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Strengths of the study:
- The study is well-structured and provides a robust workflow for the application of ChIP-MS to investigate chromatin composition in various contexts.
- The use of telomeres as a model locus for testing the developed ChIP-MS approach is appropriate due to its well-characterized protein composition.
- The comparison of WT vs KO lines for ZBTB48 is a rigorous way to control for false-positives, providing more confidence in the results.
- The direct comparison of double vs only FA-crosslinking provides valuable insights into the benefit of additional protein-protein crosslinking in ChIP-MS workflows.
Areas for improvement:
- The novelty of the method is more than questionable as both ChIP-MS coupled to LFQ and dCas9 usage for locus-specific proteomics have been previously reported. The fact that the authors directly pulldown dCas9 instead of using a dCas9-fused biotin ligase and subsequent streptavidin pulldown is only a very minor change to previous methods (not even improvement). It would be more accurate for the authors to present their study as an optimization and rigorous validation of existing techniques rather than a novel approach.
- The authors should more thoroughly discuss previous works using ChIP-MS and dCas9 for locus-specific proteomics. This would give readers a better understanding of how the current work builds on and improves these earlier methods. For a paper that aims on presenting an optimized ChIP-MS workflow it is crucial to showcase in which use cases it outperforms previously published methods.
- E.g., compare locus-specific dCas9 ChIP-MS to CasID (doi.org/10.1080/19491034.2016.1239000) and C-Berst (doi.org/10.1038/s41592-018-0006-2); how does your method perform in comparison to these?
- Compare likewise the described protein interactomes to previously published interactomes.
- The authors use sgGAL4 as a control for the telomeric targeting of dCas9. The IF results (Fig3b) show that sgGAL4 barely localizes to the nucleus with very faint signals. It would be helpful to use a control with homogenous nuclear localization of dCas9 to further strengthen the author's conclusions.
- The extrapolation of results from the use of telomeres as a proof-of-concept to other loci is not a given considering the highly repetitive structure of telomeric DNA. The authors should either be more cautious about generalizing the results to other loci or demonstrate that their method can also capture locus-specific interactomes at non-repetitive regions.
- What are concrete biological insights from this optimized ChIP-MS workflow that previous methods failed to show?
- For instance, the authors could compare their mouse and human TERF2 interactomes and discuss similarities and differences between both species.
- The authors should also describe which interaction partners are novel and try to validate some of these using orthogonal methods.
- Human Terf2 ChIP-MS (Fig1A) seems to be much more specific than the mouse counterpart (Fig1D) (32 TERF2 interactors out of 176 hits in human vs 12 TERF2 interactors out of 500 hits in mouse). Could the authors explain this notable difference?
- The authors used much higher cell numbers than previously published ChIP-MS experiments; while this is understandable for dCas9-based pulldowns, the cell number is expected to be down-scalable for the other IPs (TERF2, ZBTB48, MYB). Since this work primarily describes an optimized Chip-MS workflow, the authors should show that they can reasonably downscale to at least 15 Mio cells per replicate; one way of achieving this could be through digesting on the beads and not in-gel.
- It is not clear from the text or figure what the authors are trying to show in Fig2c. They should either explain this further or take the figure out.
- Was there any benefit in using a Q Exactive HF vs timsTOF flex?
- How did the authors analyze the PTM data? This is not described in the methods section. In addition, it would be important to validate the novel PTMs described for NR2C2.
- For this kind of methods paper one would expect to see the shearing results of the ChIP-MS experiments since variations in DNA shearing can impact the detection of false-positives in the ChIP-MS experiments
Significance
Overall, the current state of the manuscript neither provides direct evidence that the "optimized" ChIP-MS workflow is better in certain aspects/use cases than previously published methods nor does it provide novel biological insights. At the current state it even cannot be considered as a validation of previously published methods since it does not discuss them.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary: In this manuscript, Yong and colleagues have introduced a optimized technique for studying actors on chromatin in specific regions with a localized approach thanks to revisited ChIP-mass spectrometry (MS) with label-free quantitative (LFQ). The authors exhibited the utility of their approach by demonstrating its effectiveness at telomeres from cell culture (human U2OS cells) to tissue samples (liver, mouse embryonic stem cells). As a proof of concept, this technique was tested by the authors with proteins from complex shelterin specific to telomeres (TERF2 and ZBTB48), transcription factors (MYB), and through dCas9-driven locus-specific enrichment. Notably, the authors created a U2OS dCas9-GFP clone and then introduced sgRNAs to target either telomeric DNA (sgTELO) or an unrelated control (sgGAL4). The cells expressing sgTELO exhibited a significant localization of telomeres and an enriched amount of telomeric DNA in ChIP with dCas9. They also found the proteins previously identified as known to be enriched at telomeres (for example, the 6 shelterin members). Moreover, the authors illustrated the importance of double crosslinking (formaldehyde (FA) and dithiobis(succinimidyl propionate) (DSP) in ChIP-MS. Their data demonstrated also that ChIP-MS is inclined towards false-positives, possibly owing to its inherent cross-linking. However, by utilizing loss-of-function conditions specific to the bait, it can be tightly managed.
Major comments:
- Can you show the concordance between biological replicates for each ChIP with LFQ? (heatmap of Pearson correlation and PCA plot). This will confirm the robustness of the use of LFQ.
- You say that your technique is " a simple, robust ChIP-MS workflow based on comparably low input quantities » (line 139). What would be really interesting for a technical paper would be: a schematic and a table illustrating the differences between your method and the previously published methods (amount of material, timeline,...) to really highlight the novelty in your optimized techniques.
- It would be interesting to perform the dCas9 ChIP experiment in telomeric regions with and without LFQ. Since the novelty lies in this parameter, at no time does the paper show that LFQ really allows to have as many or more proteins identified but in a simpler way and with less material. A table allowing to compare with and without LFQ would be interesting.
Minor comments:
- Put a sentence to explain "label free quantification". For a reader who is not at all familiar with this technique, it would be interesting to explain it and to quote the advantages compared to PLEX.
- what does the ranking on the right of each volcano plot represent (figure 1 b-e, figure 2a,d,e for example)? top of the most enriched proteins in the mentioned categories? Not very clear when we look on the volcano plot. it must be specified in the legend.
Significance
General assessment/Advance: The authors explain in their article that the ChIP exploiting the sequence specificity of nuclease-dead Cas9 (dCas9) to target specific chromatin loci by directly enriching for dCas9 was already published. Here, the novelty of this study lies in the use of LFQ mass spectrometry to optimize the technique and make it easier to handle. Some comparisons with previous papers or data generated by the lab will be interesting to really show the improvement and the advantage to use LFQ and therefore, to highlight better the novelty of the study.
Audience: By presenting this technical paper, the authors allow laboratories across different fields to use this technique to gain insights into protein enrichment in specific chromatin regions such as the promoter of a gene of interest or a particular open region in ATACseq in a easier way and with less materials. This paper holds value in enabling researchers to answer many pertinent questions in various fields.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
The manuscript by Yong et. al. describes a comparison of various chromatin immunoprecipitation-mass spectrometric (ChIP-MS) methods targeting human telomeres in a variety of systems. By comparing antibody-based methods, crosslinkers, dCas9 and sgRNA targeted methods, KO cells and various controls, they provide a useful perspective for readers interested in similar experiments to explore protein-DNA interactions in a locus-specific manner.
While interesting, I found it somewhat difficult to extract a clear comparison of the methods from the text. It was also difficult to compare as data and findings from each method was discussed in its own context. Perhaps it is not in their interest to single out a specific method and it is indeed true that there are caveats with each of the methods.
I think the manuscript would be of interest but I believe that there are remaining questions that need to be addressed before publication. In particular, I found it difficult to reconcile the discrepancy in protein IDs between most experiments vs. the WT/KO experiment in Fig 2. The authors make a big deal about the importance of the KO control but I think the fewer proteins identified there may be experiment-specific and not general to the KO system. I ask that this be investigated more carefully by the authors in their revisions.
Specific comments:
Ln 57: What is "standard double cross-linking ChIP reactions" in this context? Is it the two different crosslinkers? The two proteins? The reciprocal IPs of one protein, and blotting for another? It's not clear here or from Extended Fig 1A. Upon further reading, it seems to pertain to the two crosslinkers - if so, the authors should briefly describe their workflow to help readers.
Ln 95: It is surprising and quite unclear to me why it is that the WT ZBTB48 U2OS pulldown in Fig 1B shows 83 hits for the WT vs Ig control experiment but 27 hits for the WT vs KO condition in Fig 2A. The two WT experiments have the same design and reagents, shouldn't they be as close as technical replicates and provide very similar hits? The authors seem to make the claim that most of the 'extra' proteins in WT vs Ig are abundant and false positives, but if this is so, shouldn't they bind non-specifically to the beads and be enriched equally in Ig control and ZBTB48 WT IPs?
Volcano plots in Figs 1, 2, and Suppl. Tables etc: Are the plotted points the mean of 5 replicates? Was each run normalized between the replicates in each group, for e.g. by median normalization of the log2 MS intensities? This does not appear to be the case upon inspection of the Suppl Tables. Given the variability in pulldown efficiency, gel digest and peptide recovery, this would certainly be necessary.
Ln 125: The authors make the claim that the ChIP-MS experiments are inherently noisy, with examples from WT cells, dTAG system and IgG controls. This is likely the case, yet their experiments with WT vs KO cells do not identify as many proteins overall. I find this inconsistency somewhat unclear and does not seem to match the claim of ChIP-MS experiments and crosslinking adding to non-specificity. Can the authors add the total number of identified proteins in each volcano plot, for easier reference?
Significance
I think the manuscript is interest as it provides important benchmarks for ChIP-proteomics experiments. I believe that there are remaining questions that need to be addressed before publication. In particular, I found it difficult to reconcile the discrepancy in protein IDs between most experiments vs. the WT/KO experiment in Fig 2. The authors make a big deal about the importance of the KO control but I think the fewer proteins identified there may be experiment-specific and not general to the KO system. I ask that this be investigated more carefully by the authors in their revisions.
-
-
www.biorxiv.org www.biorxiv.org
-
Transparent Peer Review
Download the complete Review Process [PDF] including:
- reviews
- authors' reply
- editorial decisions
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
1. General Statements
We thank the Reviewers for their detailed and constructive comments. As we describe below, we have now amended the manuscript to address their concerns and suggestions.
2. Point-by-point description of the revisions
Reviewer #1
__In the first paragraph the reviewer states that our study is well presented and convincing, but that it seems “an incremental advance to the previous ones, which properly accounted for PLK4 symmetry breaking and are based on similar assumptions”. __We apologise for not explaining properly why our work is an important advance on these previous studies. Although both previous models can account for some aspects of PLK4 symmetry breaking, they both have significant issues. For example, Takao et al. perform no analysis of the robustness of their model, and from the small number of simulations shown it is clear that some very odd behaviours emerge—e.g. the oscillation of the dominant PLK4 site around the 6 compartments (Figure 3C, Example 3) and the bizarre manner in which PLK4 overexpression drives the formation of multiple PLK4 peaks (Figure 4B, first two examples). The authors do not comment on, analyse, or explain these strange phenomena. This model also relies on STIL being added to the system only after PLK4 has already broken symmetry; this is not plausible in rapidly dividing systems such as the fly embryo where Ana2/STIL levels remain constant through multiple rounds of centriole duplication (Steinacker et al., JCB, 2022). The Leda et al. model predicts that inhibiting PLK4 kinase activity will deplete PLK4 from the centriole, but it is now clear that PLK4 accumulates at centrioles when its kinase activity is inhibited (e.g. Yamamoto and Kitagawa, Nat. Comms., 2019). Moreover, this model supposes no spatial relationship between PLK4-binding compartments; this has important implications for the system’s behaviour (see point 1 in our response to Reviewer #2), and is biologically highly implausible. Thus, neither of the previous models can properly account for several important aspects of PLK4 symmetry breaking.
Moreover, the two previous studies are not based on similar assumptions. It is only through our analysis that we discover that the underlying biological process driving symmetry breaking in both previous models can be described in the same terms: with short-range activation and long-range inhibition causing diffusion-driven instability. This crucial conclusion was not obvious from, nor claimed by, either of the previous publications. We believe this is an important step in model development for these systems.
__The reviewer raises a number of minor concerns, the first of which is a previous study from Chau et al. (Cell, 2012), which studies how two component systems break symmetry. Differential diffusion is not essential for symmetry breaking in some of the models considered by Chau et al., and so they wonder if it is really essential in our system. __We thank the reviewer for pointing us to this study. It can be proven mathematically that differential diffusion is essential for symmetry breaking in the Turing-type framework. In the systems studied by Chau et al., symmetry can be broken without differential diffusion if one of the two components can be depleted from the cytoplasm. Such cytoplasmic depletion does not occur in traditional Turing-type systems, and it is almost certainly not occurring during PLK4 symmetry breaking—e.g. FRAP experiments show that PLK4 continuously turns over at centrioles (Cizmecioglu et al., JCB, 2010; Yamamoto and Kitagawa, Nat. Comms., 2019). We discuss this point (p8, para.3).
__The reviewer states that it is unclear which term in equations (3-4) and (5-6) correspond to the self-activation and activation/inhibition of the other component that are indicated in the schematic summary of the models shown in Figure 1C. __As we now clarify, in general it is not always possible to pinpoint a single term in an equation that corresponds to activation/inhibition. Mathematically, a positive feedback for means that , and a negative feedback for means that . Hence, activation and inhibition can change depending on the values of these derivatives during the dynamics as these inequalities may be achieved with complex expressions that extend beyond the usual proportional relationships. We have amended the manuscript to make this clearer (p10, para.2).
The reviewer pointed out an error in the arrows in Figure 2 (we believe this is actually Figure 4). We thank the reviewer for pointing this out and have now corrected this mistake.
Reviewer #2
Major Comments:
__ 1. The reviewer points out that in all models of PLK4 symmetry breaking the overexpression of PLK4 should be able to generate multiple PLK4 peaks (as, experimentally, PLK4 overexpression can generate up to 6 procentrioles around the mother centriole). The Reviewer suggests that the two previous models can do this, but we only show examples where PLK4 overexpression generates two peaks, and the reviewer questions whether this is a general limitation that would invalidate our approach. __We are grateful to the reviewer for pointing this out, and we now expand our analysis and discussion of this important issue (p13-15). It is indeed possible to produce more peaks in our model using different parameters—e.g. decreasing diffusivity leads to thinner peaks, allowing more peaks to form (Figure 3B, Figure 5B). Importantly, however, when diffusion is decreased, the region of the parameter space in which only a single peak will form inevitably becomes smaller—as diffusion can no longer efficiently suppress the formation of additional peaks around the rest of the centriole surface. Hence, in both our original models we struggled to find a parameter regime in which PLK4 robustly formed a single peak, but also formed >3 peaks when PLK4 was overexpressed. As we now discuss in detail, we believe that this is a general problem, as any model of PLK4 symmetry breaking must involve information being communicated around the centriole surface. We now show that a possible solution to this problem is to postulate that increasing PLK4 levels leads to a decrease in PLK4 diffusivity (Figure 3C, Figure 5C)—a biologically plausible possibility (p15, para.2).
In addition, it is not correct to say that the previous formulations of these models do not have this problem (or, in the case of Leda et al., the model actually has a related problem). This problem must apply to the Takao et al. model, as it also relies on information travelling around the centriole surface. This problem is far from obvious, however, because Takao et al. do not analyse the robustness of their model. This problem does not apply to the Leda et al. model, but this is because their model supposes no spatial relationship between the individual compartments and instead assumes that communication between compartments is instantaneous. This allows their system to overcome this communication problem and so robustly form a single peak at low PLK4 concentrations, while forming multiple peaks at high concentrations (as shown in Figure 6B). However, this requires that diffusion is sufficiently fast that concentration gradients are negligible between centriolar compartments, but not so fast that the relevant species are diluted in the much larger cytoplasm. It seems implausible that both of these effects may be achieved with a single diffusion rate in the real-world physical system.
__ 2. The reviewer points out that in our modelling any multiple PLK4 peaks formed will tend to be evenly spaced around the centriole surface whereas, in their original formulations, the two previous models predict that any multiple ‘winning’ PLK4 compartments will not have any preferential spatial location with respect to each other. They ask that we address this difference and justify why we think our prediction is a better representation of PLK4 symmetry breaking. __Although it is not obvious, neither of the previous models makes clear predictions about the spacing of multiple PLK4 peaks. As described above, Leda et al. assume no spatial relationship between PLK4-binding compartments, so relative peak-spacing cannot be assessed. Moreover, from the limited analysis shown, it is not clear that Takao et al. predict random spacing. The authors show only two simulations of PLK4 overexpression (Figure 4B, first two simulations) and the behaviour of PLK4 is very odd: the initial noise in the system fades away before PLK4 levels rapidly and near-simultaneously rise at multiple, reasonably well-spaced, peaks, before fading away to low levels—even after STIL addition. At the end of the simulation the “winning” compartments contain very low levels of PLK4 (often lower than the noise initially introduced into the system), but these compartments are reasonably (simulation 1) or very (simulation 2) evenly spaced.
Nevertheless, the reviewer is correct that the even spacing of multiple peaks is a feature of our model. Unfortunately, it is not possible to compare this prediction to reality because the spacing of multiple PLK4 peaks in cells overexpressing PLK4 has not been quantified yet. Thus, one has to interpret published images, some of which support equal spacing while others do not (e.g. Kleylein-Sohn et al, Dev. Cell, 2007). Moreover, this analysis is likely to be complicated because CEP152 can form incomplete rings. This can be appreciated in Figure 2C in Hatch et al., (JCB, 2010) where the extra centrioles induced by PLK4 overexpression do not appear to be evenly spaced around the centriole, but are quite evenly spaced around the partial CEP152 ring. Therefore, equal spacing of peaks in ideal conditions is a feature predicted by our model that still needs to be fully explored experimentally. We believe that part of the power and value of our model is to suggest such hypotheses. We now discuss this important point (p26, para.2).
__ 3. The reviewer questions our attempt to discretise our continuum model (where we convert the continuous centriole surface to a series of discrete compartments on the centriole surface and show that symmetry breaking can still occur). They note that we only show one example (9 compartments), they ask for more information about how the discretisation was done, and they question the independence of the compartments as PLK4 appears to accumulate in compartments adjacent to the dominant compartment. __We apologise for the lack of clarity here. We now state that our models can break symmetry provided that there are at least two compartments, and we now include simulations showing that this happens for 2 – 10 compartments (Figure S2). The discrete model is a finite-difference discretisation of the continuum model (described in Appendix V). We also now clarify that the compartments are ‘independent’ in the sense that all chemical reactions only occur between components that are within the same compartment. The compartments are still spatially linked via a discretized diffusion (as would likely be the case at the centriole), which explains the observed relationship between neighbouring compartments.
__ 4. The reviewer asks whether all the parameter values that satisfy the mathematical constraints we calculate for our models will break symmetry. If so, they suggest we are using a circular argument when demonstrating that the models break symmetry as we use parameter values chosen specifically to satisfy these constraints. __In Turing-systems, one can mathematically calculate parameter constraints that allow symmetry breaking. As we now clarify, all parameters that satisfy these constraints can break symmetry, while any parameters outside these constraints cannot break symmetry. Thus, it was never our intention to claim something new or surprising when we illustrated the symmetry-breaking properties of our models (Figures 2 and 4, and associated parameter space analysis in Figures 3 and 5), so we apologise that our intention on this point was unclear. Rather, these Figures illustrate the detailed behaviour of each system under different conditions—something that is not possible to intuit from the equations alone.
5. The Reviewer requests more information about how we chose the particular parameter values we use to illustrate each model and asks that we convince readers that other sets of values that satisfy the derived mathematical requirements would result in the same qualitative outcomes. As described in point 4 above, and as we now state more clearly, it is a mathematical fact that parameter values that satisfy the derived mathematical requirements can break symmetry. We now discuss our reasons for choosing specific parameters in more detail (see point 6, below).
__ 6. The Reviewer asks whether the dimensionless parameters we use in our models have any biological relevance, and requests a biological interpretation of all of them. They also request that we relate the Diffusivity ratios of the Activator and Inhibitor species (____) to the experimental observations made by Yamamoto and Kitagawa. __Relating our dimensionless parameters to biologically-relevant dimensional parameters is a complex issue. For example, one can see from equations (5) and (6) that simultaneously doubling (A), (I), and (a), and decreasing (b) by a factor of 4 leaves the system unchanged. Since the concentrations of A and I are unknown at the centriole surface, this means that it is not possible to determine the dimensional values of the rate of production of I (a) and its rate of conversion to A (b). This limitation is the root of the mathematical fact that FRAP experiments can reveal “off” rates but not “on” rates. Moreover, to convert the rate of loss of A (c) and I (d) into dimensional parameters it is necessary to know the timescale of symmetry-breaking. This is unknown, but was assumed to be on the order of hours in the previous models. This corresponds to a degradation/loss rate of minutes with our current choice of parameters, which is consistent with FRAP data (e.g. Yamamoto and Kitagawa, Nat. Comms., 2019). Regarding the ratio, the effective diffusion in our model depends on both the bulk diffusion and the binding/unbinding/degradation rates – a complexity also noted by Yamamoto and Kitagawa. This makes it very difficult to relate the “effective” surface diffusivity to the bulk diffusivity. We are currently investigating the form of this dependency, but this is a complex mathematical problem that is beyond the scope of this manuscript. These issues are difficult to discuss succinctly, so we now simply state that we chose specific parameter values based, in part, on the values and ratios used in the previous modelling papers (p10, para.2; p17, para.2).
Unfortunately, we could not find any experimental measurements of diffusivity in the Yamamoto and Kitagawa paper, as the Reviewer suggests. We now clarify, however, that the ratio we use in both models (2500) is chosen to be between the effective diffusivity ratio (as the previous models used binding/unbinding rates rather than diffusivity) used by Takao et al. (10000) and Leda at al. (200). We also include a phase diagram showing how varying the diffusivity of both factors influences symmetry breaking in both models (Figure 3B, Figure 5B), and we state that we have chosen all remaining parameter values to reflect the parameter values in the original models, when adjusted to the same timescale.
__ 7. The Reviewer asks for more information about how we normalised time in our simulations and whether the time in different simulations is comparable. __We now clarify that the simulations run for a single unit of dimensionless time (so they can be compared), and that the reaction/diffusion parameters in the system are sufficiently large by comparison with unity that all simulations achieve steady state within a unit of time (p11, para.2).
8. The Reviewer asks whether concentrations of _and can be compared between simulations, and also questions our description of _ being uniformly accumulated in Figure 4D, rather than uniformly depleted. __We clarify that concentrations can be compared within a model, but not between models. This is because the dimensional values depend on the dimensional reaction rates, which differ between the models. This is not just a theoretical limitation; experimental fluorescence signals are typically compared in relative arbitrary units so the absolute values of different systems cannot be easily compared for the same reason. We agree with the reviewer that it is better to describe Figure 4D as showing uniform depletion of the activator, and we have adjusted the legend accordingly.
The reviewer makes a number of minor points that are not numbered.
__The reviewer asks for clarification of what we mean by “robustness”: does this refer to the ability to produce the same result in multiple simulations, or to the ability to produce the same result when parameter values are varied? If the latter, then the reviewer suggests our models are not very robust. __We apologise for this confusion and now more clearly define what we mean by robust (p13, para.2). As we discuss in point 1 of our response to this Reviewer, our initial models are indeed not very robust at producing a single PLK4 peak over a range of PLK4 concentrations. We now discuss why this lack of robustness is likely to be intrinsic to any PLK4 symmetry breaking system, and how robustness in all such models can be improved by allowing diffusivity to vary with PLK4 expression levels (p13-p15).
__The Reviewer points out that the original models introduce a noise term at every iteration, whereas we only introduce an initial noise term; they ask us to discuss this difference. __We have run simulations introducing a noise term at every iteration and find that this makes negligible difference (Reviewer Figure 1, attached to the end of this letter). We do not take this approach, however, as this would significantly complicate the mathematical analysis that we perform (the additional noise term turns the system of PDEs into a system of SDEs which do not fit the Turing framework as readily). We now mention this in Appendix V.
The Reviewer states that the reaction schemes are unnecessarily repeated in Figures 1, 2 and 4. We would like to keep these schematics, as in Figure 1 we show a generic scheme (illustrating the two possible Turing-type reaction diffusion systems) whereas in Figures 2 and 4 we show specific reaction regimes (specifying the relevant species) that we test in each model. We feel this information will be useful to readers in this visual format.
The Reviewer states that it is confusing that we refer to the specific reaction parameters (k11 and k12) that need to be swapped to convert the Leda et al. model to the Takao et al. model, as this information will not mean anything to readers who are not familiar with the models. We agree and have now removed this information.
The Reviewer suggests several textual amendments and/or corrections. We thank the reviewer for spotting these and have amended them all accordingly.
__Finally, the Reviewer states in their significance summary that although our key conclusions are convincing, they are not new as Takao et al. describe their model as analogous to a “reaction-diffusion system (also known as a Turing model)”. __We were aware that Takao et al. make this statement, but this does not invalidate the novelty or significance of our work. This is because although Takao et al. described their model as being analogous to a “Turing model”, it is not actually a reaction-diffusion system, and it does not exhibit the property of long-range inhibition that is central to all Turing-systems to produce a single PLK4 peak. Instead, they use lateral inhibition (in which the influence of the inhibiting species does not extend beyond the neighbouring compartments) to reduce the number of potential PLK4 binding sites from ~12 to ~6. A single winning site is subsequently selected when STIL is added to the system—with additional positive feedback (not involving reaction-diffusion) ensuring that the compartment with most PLK4 becomes the dominant site. Their analysis of the reaction-diffusion version of their system is limited to a single supplementary figure (Figure S2D), and they do not perform or refer to any of the relevant mathematical analyses of their model that makes these well-studied systems such powerful tools. We believe that the model presented here is simple enough to draw the attention of the applied mathematics community while robust and complete enough to provide a mechanistic explanation of many interesting features and suggest new possible phenomena. We now discuss these points (p22, para.1).
Reviewer #3
__The Reviewer found our manuscript well-written, and judged it of interest to centriole duplication enthusiasts. __We interpret this to mean that the Reviewer did not think it of more general interest. This seems a harsh assessment, as the precise one-for-one duplication of centrioles is generally considered to be one of the great mysteries of cell biology. It is now widely appreciated that robustly breaking PLK4 symmetry to form a single PLK4 peak is crucial to this process. Thus, our discovery that this process can be described using a well-studied mathematical framework that has already been applied to a vast range of biological processes is potentially of significance even to non-centriole enthusiasts.
The Reviewer made a number of specific comments:
Figure 1. The Reviewer felt the graphic in Figure 1A could be improved by combining it with Figure 1B, and noted that the centrioles look strange. We thank the reviewer for these suggestions and we have now rearranged this Figure. We also now clarify that the schematic depicts Drosophila centrioles, which are simpler than human centrioles.
__Figure 2. The Reviewer suggests that to make the system depicted in Figure 2A fit as a Type I Turing system we have to assume that (I) must dissociate from the centriole or be degraded at higher rates than (I) converts (A) to (I). They suggest this assumption is implicit in the model and they request further explanation. __The reviewer is correct that, in Model 1, the degradation/dissociation of () is the root of its self-inhibition. However, we do not need to make any assumption about the relationship between the rate at which converts to (b), and the dissociation/degradation rate of (d) for this system to work (as the Reviewer implies). This is because, whatever these rates are, the system will approach a steady-state where the production and degradation terms balance, and it is the stability/instability of this state that determines whether the system can break symmetry. Since the degradation rate of (the - term in equation 4) increases more rapidly than its production rate (the term in equation 4) as increases, this results in a stable (i.e. self-inhibiting) system regardless of the parameter values. We have rewritten the sections explaining these equations to try to make these points more clearly and to point readers to Appendix II where we explain the form of the equations.
__The Reviewer asks if in Model 1 it is realistic to assume no turnover or loss of PLK4 (A), and will the system still work if this is altered? __This is a good point. In Model 1, we set c=0 as this makes the analysis significantly simpler, enabling us to display the mathematical predictions alongside the numerical simulation. We have now added the (c,d) phase diagram to show the effect of varying these parameters on the symmetry breaking properties of the system (Figure 3D). We find that the value of c has a relatively weak effect on the symmetry breaking properties of the model since it does not affect the function of as an activator.
__The Reviewer asks if our 1D model would work in 2D, and notes the PLK4 peaks in our models are broad, likely limiting the number of peaks formed. They also note that in our Model 1 it is the unphosphorylated form of PLK4 that accumulates in the peak, which seems unlikely as it is widely believed that PLK4 must be active to phosphorylate STIL to promote its interactions with SAS6 and CPAP. __From a mathematical perspective, modelling our system in 2D would produce very similar results. Symmetry breaking is driven by long-range inhibition/short-range activation, and these behaviours will work analogously in 2D. As discussed in our response to Reviewer #2 (point 1), the broad peaks do indeed limit the number of centrioles that can form, but by altering the parameters we can generate more peaks that are less broad (Figures 3 and 5). The Reviewer is correct that Model 1 (based on Takao et al.) predicts that non-phosphorylated PLK4 () accumulates in the peak. This is also true of the original Takao et al. model, although this was not highlighted or commented on by the authors. We now expand our discussion of this point (p25-p26).
The Reviewer asks if our models can form multiple peaks at higher PLK4 levels. This is again related to Reviewer #2, point 1, and we now show that this is indeed possible under the appropriate parameter regime (Figure 3C and Figure 5C).
The Reviewer asks for more description of how lateral diffusion works in our system. For example, do we consider that not every molecule of (I) will diffuse laterally (as some will be lost to the cytoplasm), or that the probability of a molecule leaving the surface will increase as distance/time increases. We apologise for our lack of clarity. We now state that the proportion of molecules not rebinding to the surface is accounted for in the reaction components of all our models (p7, para.1). In reality, and as we now state, the relationship between this loss and the diffusion rates (and their relation to distance/time, for example) is complicated. We are investigating this relationship in more detail, but this is beyond the scope of the current paper.
The Reviewer asks if symmetry breaking might eventually occur if the system in which we reduce the kinase activity of PLK4 (Figure 2D) were given more time. They also ask whether reducing PLK4 levels by half would lead to a failure in site-selection. The kinase inhibited scenario we show here will not break symmetry over any period of time; this can be proven mathematically, and is verified in the numerical simulations (Figure 3A and 5A, bottom left regions of graphs), which we now state more clearly are always run for a long enough period to reach a steady-state (p11, para.2). The effect of reducing PLK4 levels in our models is analysed in the phase diagrams shown in Figure 3 and 5 (and analysed in more detail in Figure S1), where it can be seen that there are multiple PLK4 concentrations that can be halved without a failure in site selection (although, see also our response to Reviewer #2, point 1).
The Reviewer pointed out some errors in our presentation of Figure 3, (and suggested some improvements in presentation in a point further below) and also asked for more information about the parameters used to generate the data in Figures 2B-D and 4B-D. We thank the Reviewer for these suggestions and have made these changes and provided the additional information requested (e.g. marking the specific parameters used in our simulations on the phase diagrams shown in Figure 3 and Figure 5 with coloured dots).
The Reviewer points out that when PLK4 levels and activity are both high no centrioles are produced in Model 2, whereas 1 centriole is produced in Model 1—neither of which are consistent with experimental observation. We now show an expanded parameter space (new Figures 3A and 5A) where it can be seen that this is not a problem for Model 1. For Model 2, the region of high kinase levels and activity (dark blue, top right, Figure 5A) corresponds to the uniform accumulation of the activator species. Thus, while there are no peaks, this region might produce multiple centrioles, as it is equivalent to a compartmental model in which all of the compartments are occupied. We now discuss this point (p19, para.1).
__The Reviewer questions how the biology fits a Type II Turing system, pointing out that current data suggests that active PLK4 turns over more rapidly at centrioles, whereas in the Type II model we describe (based on the Leda et al. model) it is the phosphorylation state of STIL that determines which species of PLK4:STIL turns over rapidly. They also question the logic of the Model 2 Type II circuit (Figure 3A), questioning how A could drive the dephosphorylation of STIL to promote the production of I. __We agree that current data is more consistent with phosphorylated species of PLK4 turning-over more rapidly at centrioles, but this is not what Leda et al. proposed, and so this is not what we implemented in trying to reformulate their model (although this is effectively the change we make that turns the Leda et al. model into the Takao et al. model). As to the second point, the Reviewer has correctly spotted a problem with our model that arises because the direction of the arrows linking and were inadvertently flipped in Figure 4A. This mistake has been corrected, and we now explain more clearly how the biology of this system fits a Type II Turing system in the legend.
__The Reviewer points out that although we can convert the Leda et al. Model (Model 2) to the Takao et al. Model (Model 1) simply by changing the identity of the _ and _ species, the underlying assumption of the Takao et al. model (that non-phosphorylated PLK4 promotes its own accumulation) was not an inherent assumption of the Leda et al. model. __We apologise for this confusion. As we now clarify (p20, para.1) the Reviewer is correct that when we make mathematical changes to the Leda et al. model we must also assume changes in the underlying biology—so that non-phosphorylated species of PLK4 are now slow diffusing, rather than non-phosphorylated species of STIL, as originally proposed). As the Reviewer points out, current data suggests that non-phosphorylated species of PLK4 do turnover more slowly, although it is not clear why—for example, liquid-liquid phase separation driving the formation of PLK4 condensates has been postulated, but is far from proven. This remains an interesting problem that will be further probed mathematically and experimentally.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
This manuscript attempts to address a very important question in the field of centriole biology: how does PLK4 symmetry breaking occur to produce a new procentriole in a specific single site. The work is theoretical in nature and does not offer new experimental support. Furthermore, the authors are forced to make multiple assumptions to fit PLK4 symmetry breaking into a Turing reaction-diffusion system. In some instances, these assumptions are not intuitive and don't have a strong foothold in the known behavior of the molecules involved. That notwithstanding, I found the manuscript to be well-written for a general audience and believe it will be of interest to the centriole duplication enthusiasts.
The following comments should be addressed prior to publication:
Specific comments:
Figure 1:
- The graphic in Figure 1A depicting the centriole duplication process could be more effectively presented. Perhaps combining Figure 1A and 1B with a graphic that places these events in the context of the centriole duplication process coordinated with the cell cycle would provide a better insight to the relevant biology. The centrioles also look very strange, with the procentriole width being equal to the height of the parent centriole.
Figure 2:
- I take (I) to be synonymous with kinase-active PLK4 (phosphorylated PLK4 in the authors parlance). If (I) phosphorylates (A) to make more (I), then (I) doesn't strictly inhibit the accumulation of (I). It seems to make this fit a Turing system the authors are assuming that phosphorylated (I) must dissociate from the centriole or be degraded at higher rates than it converts (A) to (I). This is an assumption implicit in the model and should be further explained.
- Is it realistic to assume no turnover or loss of unphosphorylated PLK4 (A). Will the model still work if this assumption is altered?
- The centriole surface is modeled in 1-dimensional space, when it is, of course, 2-dimensional. How does this change the model? The site selection also appears weak as the distribution of PLK4 localization is very broad. This likely limits the number of PLK4 sites that can be formed. Finally, the model allows for the accumulation of (A) at a single site. Since (A) is unphosphorylated PLK4, I am left wondering how this species could be proficient in initiating procentriole assembly. I find it unlikely that PLK4 kinase activity is only required for symmetry breaking and not procentriole assembly. Multiple PLK4 phosphorylation sites on STIL promote binding interactions with centriole proteins (SAS6 + CPAP) and are required for procentriole assembly.
- In Figure 2C, are three peaks possible at higher PLK4 levels? Figure 3A would suggest not, which is inconsistent with the known biology.
- I think it would benefit the reader to have more description of what lateral diffusion entails and what assumptions are made. When (I) is released from the centriole surface, it can rebind to the centriole at a neighboring site (a PLK4 condensate or CEP152) and thus diffuse laterally or diffuse away from the surface of the centriole. Does the model account for the fact that not all every (I) molecule produced at the centriole will diffuse laterally? Moreover, the probability of (I) leaving the surface of the centriole must increase as distance/time increases.
- In Figure 2D, would a single site of PLK4 form if a longer period of time was given? In other words, are the kinetics of site selection slowed, or will symmetry breaking never occur in this system? I presume that reducing the overall levels of PLK4 levels by half would not lead to a failure of site selection?
Figure 3:
- The figure labels do not match what is described in the text. Figure 3B should be the top right graph and the bottom two graphs for Model 2 should be labelled 3C and 3D.
- The authors should highlight on the graph which parameters were used to generate the data in the experiments in Figure 2B-D and Figure 4B-D.
- Model 2 predicts that at high levels of PLK4 protein and high levels PLK4 activity, no centrioles are produced, while Model 1 predicts one centriole would be produced. Neither is consistent with experimental observations.
- The figure organization could be adjusted to improve clarity. As presented here, the text goes from discussing Figure 3A-B and skipping Figure 3C-3D until after discussing Figure 4. Instead of having the phase diagrams in their own figure, they could be incorporated into the respective figure that they are describing (Figure 3A-B becomes Figure 2E-2F, Figure 3C-D after current Figure 4D). With this adjustment, the figures could follow the order of the text.
Figure 4:
- It is unclear to me how the biology fits with the underlying assumptions of a type II Turning reaction-diffusion system. Both (A) and (I) contain phosphorylated (and active) PLK4. Current data suggests active PLK4 turns over more rapidly at the centriole - how does this fit with these assumptions? More importantly, the (A) species contain phosphorylated STIL and represent the complex that initiates centriole assembly. (A) promotes the accumulation of more (A) through phosphorylation of STIL, but how does A also drive the dephosphorylation of STIL to promote the assembly of (I)?
- In the section 'unifying the models....', the authors propose the Leda et al model can be modified so that phosphorylated PLK4 defines the (I) species and (A) represents unphosphorylated PLK4. This modification now mirrors that of Takeda et al., and it recreates the same issue - inactive PLK4 accumulates at the site of centriole assembly. There also needs to be an assumption for how A (non-phosphorylated PLK4) would promote its own accumulation, and this is not an inherent assumption from the Leda et al. model.
Significance
Centrioles are microtubule-based structures that comprise the centrosome, the major microtubule organizing center. In mitosis, centrosomes serve to maintain the bipolar spindle to promote faithful cell division. To ensure that only two centrosomes exist in a mitotic cell, centriole copy number is tightly regulated so that centrioles duplicate once and only once per cell cycle. Centriole biogenesis is initiated by Polo-like kinase 4 (PLK4) on the wall of an existing parent centriole to produce a single new procentriole. While progress has been made in understanding how centriole copy number is regulated by PLK4, it is still unclear how procentriole formation is strictly restricted to a single site in each preexisting parent centriole. In this paper, the authors use mathematical modelling to shed some light on this critical question in the centriole field.
The prevailing model in the field is that PLK4 is recruited around the circumference of the proximal end of the parent centriole at the beginning of G1 phase, and transitions to accumulate at a single locus that marks the site of procentriole assembly at the beginning of S phase. Two mathematical models have been proposed to explain how this PLK4 symmetry breaking occurs. However, both make predictions that are inconsistent with the current experimental data. In this study, the authors reconceptualize both published mathematical models for symmetry breaking and PLK4 site selection as two-component Turing systems that rely on activator/inhibitor dynamics. The original models were thought to differ in several key assumptions. However, in this study, the authors propose that the essential features of both models can be described by Turing systems. Moreover, the authors assert that the phosphorylation status of PLK4 is the driver for symmetry breaking.
Turing systems are widely understood and have a well-characterized behavior. The central question here is can the biological observations be adequately fit into this simplified reaction scheme.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary
The authors present a reformulation of two existing mathematical models describing PLK4 symmetry breaking around the mother centriole at the onset of centriole duplication. Rather than considering PLK4 binding to, and unbinding from, a discrete representation of the centriolar periphery as a defined number of compartments, the authors consider PLK4 to diffuse on a continuous 1D ring. Furthermore, the reaction scheme of each existing model is reinterpreted here as a two-component reaction-diffusion system. These alternative representations of the existing models are shown to reproduce the dynamics of the original descriptions of the models.
With the two existing models put in a similar framework, the authors describe how a modification of the Leda et al. model can lead to the same dynamics as the Takao et al. model. Moreover, they point out a difference in the prediction of the reformulated versions of the two models (accumulation versus depletion of I in the peak, compare Fg. 2B and 4B). Finally, the authors report that discretization of the 1D continuous line into 9 compartments also predicts the accumulation of PLK4 at a single site, and thus does not alter the predictions of the two existing models qualitatively. From this, the authors conclude that PLK4 symmetry breaking around the mother centriole can be represented as a two-component Turing reaction-diffusion system.
Major comments
1D continuous space coordinate
The key difference between the models in their new formulations and their original descriptions is the representation of the centriole periphery as a continuous 1D representation of the ring, rather than a number of discrete compartments. The authors mention that the binding and unbinding between compartments and cytoplasm effectively act as a one-dimensional diffusion process on a ring, justifying the use of a continuous space coordinate. However, this justification might not be fully warranted. As discussed in the points below, the reformulations of the centriole periphery in a continuum result in strong predictions regarding PLK4 symmetry breaking and accumulation at distinct sites that are fundamentally different from the predictions of the two existing models in their original formalism.
- Although the authors repeatedly mention "multiple" peaks, they do not present simulations of overexpression conditions that give rise to the accumulation of PLK4 at more than two sites. Would these predictions lie outside the parameter space explored by the authors or are the reformulations of the models intrinsically not capable of recapitulating the formation of more than two foci? The latter would be in contrast to the original formulations of the models, in which a gradual increase in protein levels leads to the stepwise increase of the number of compartments PLK4 accumulates in (Figure 4B, Takao et al.; Figure 6B, Leda et al.). More importantly, PLK4 overexpression has been repeatedly observed experimentally to induce the formation of up to 6 procentrioles around the mother centriole (e.g., Vulprecht et al. 10.1242/jcs.104109). Given this, how can a model that is by design limited to the formation of a maximum of two accumulation sites be a valid representation of PLK4 dynamics around the centriole? The authors must carefully evaluate this apparently central conundrum and adapt their models if needed.
- In the case of PLK4 accumulation at two sites (e.g., in the 2xPLK4 condition), two foci always accumulate on opposite sides of the continuous ring. This is in stark contrast to the models in their original formalism, where two 'winning' compartments do not have any preferential location with respect to each other (Leda et al.), or where a second 'winning' compartment should be at least one compartment away, but then could be located anywhere (Takao et al.). The authors should address these differences and justify why their predictions on a continuous ring are a better representation of PLK4 symmetry breaking than the previous discretization of the centriole into compartments.
- When returning from the continuous formalism to a compartmentalized centriole surface (Figure 5), the authors report that the model remains valid if the continuum space is "divided into an arbitrary number of discrete compartments" (p. 17). However, as the authors only present one exemplary simulation of the model for 9 compartments, it is not clear if other compartment numbers indeed reproduce the formation of only one dominant focus. More fundamentally, it is not clear how the model was discretized, what sets of equations are simulated, as well as if and how diffusion between compartments is accounted for. The authors report in the legend of Figure 5 that compartments are independent, but this is unlikely given the slight accumulation of PLK4 levels in the two compartments adjacent to the dominant compartment.
Model parameters
The authors define their reaction-diffusion system of equations starting from the mathematics, leading them to a set of requirements that the parameters in their equations need to fulfill in order for the system to be able to break symmetry and resolve in a steady state with a single site of PLK4 accumulation. 4. It is not clear whether all the parameter values that satisfy the mathematical constraints wil lead to symmetry breaking. In other words, is satisfying these constraints sufficient for symmetry breaking? If yes, then it would seem that the authors use a circular argument when demonstrating that their models break symmetry using certain values for a,b,c and d, since these values were chosen in the first place to satisfy the mathematical requirement that will lead to symmetry breaking. If no, then the authors should investigate and report which parameter values that fulfill the mathematical constraints do not lead to symmetry breaking, and why. Thus, in Figure 3, the authors should clarify if regions of the parameter space where the models predict no symmetry breaking (e.g., Figure 3B, left panel, a=b=250) fulfill the mathematical constraints. If so, how can one end up with a uniform distribution -i.e., without symmetry breaking, if the mathematical constraints require this state to be unstable?
these parameters can have a steady state in the absence of diffusion, at the onset of the simulation, as well as upon diffusion, at the end of the simulation, yet without symmetry breaking.
turns into another steady state that does not involve symmetry break. that turns unstable in presence of diffusion, but not break symmetry.
This is an important point to clarify. 5. Of all the combinations of parameter values that would satisfy the requirements for symmetry breaking, the authors mention that the reason for specifically choosing the values of a,b,c and d presented in the manuscript is their simplicity (p. 11, 15). It remains however unclear why this specific set of parameter values is preferred over other combinations of values. If this set is merely an arbitrary choice, then the authors should discuss this further and convince the reader that indeed any other set of values that satisfies the derived mathematical requirements would result in the same qualitative outcomes. Alternatively, potential empirical reasons why these values are preferred should be mentioned. 6. Related to the previous point, it is unclear if the parameters presented have much biological relevance. A biological interpretation should be made even for dimensionless parameters. Moreover, this comment is not limited to the a,b,c and d parameters. Concretely, in the reformulation of the model by Takao et al.,D_I is chosen to be 200-fold higher than D_A, whereas for the reformulation of the model by Leda et al., D_I is even 1000-fold higher than D_A. As in both models I and A refer to different species of PLK4 depending on their phosphorylation state, the authors should relate the D_I/D_A ratios chosen to experimental observations of the diffusivity of PLK4 as a function of phosphorylation (Yamamoto and Kitagawa 10.1038/s41467-019-09847-x). 7. As all simulations are presented to run from t=0 to t=1, the authors must clarify what stopping criterion they used to determine the simulation time, and if they normalized the time for each simulation. At present, it is not clear if the simulation time can be compared between different simulations of parameter sets. 8. Moreover, it is not clear how the concentrations of A and I are compared between simulations. In both Figure 2D and Figure 4D, the authors report a uniform accumulation of PLK4 on the ring. However, the total level of PLK4 is 30 in Figure 2D and only 2 in Figure 4D. Here, the authors must clarify why in the case of Figure 4D the outcome should not be interpreted as a uniform depletion, rather than a uniform accumulation.
Minor comments
- It is unclear what exactly is meant when the "robustness" of the reformulated model is discussed. Robustness could be interpreted as the ability of the model to reproduce the same result in repeated simulations but with the same model parameters, or else as the ability to reproduce the same result under varying model parameters. If the latter is concluded here, then it is questionable how robust the models are given the parameter regime analyzed in Figure 3, where two-fold changes in parameter values lead the model to fail to predict symmetry breaking.
- The authors mention that an initial stochastic noise in the binding of PLK4, randomly-generated only at the onset of the simulation, will be reinforced and eventually lead to the formation of a single focus. However, in the original descriptions of the models, this noise term is randomly generated and updated every iteration. What would be the consequence of such a continuous noise in the system for symmetry breaking and maintenance of a single site of PLK4 accumulation in the reformulated model simulations presented here? This must be discussed.
- The diagrams of the reaction schemes are unnecessarily repeated in multiple figures (Figure 1, Figure 2 and Figure 4).
- It is confusing that the authors use the original notations k_11 and k_12 to refer to specific rate parameters of the Leda et al. paper (p. 17). For readers not familiar with the Leda et al. paper, this is too detailed and this information should be put in an appendix if not omitted.
- The authors write that PLK4 is recruited in a "poorly understood process" (Introduction). Although the process is indeed incompletely understood, describing the process as "poorly understood" is an overstatement given the ample literature available on this question.
- The authors refer to the existing models as being "recently" proposed (Introduction). This term may be regarded inappropriate for 5-year-old publications.
- 'Takao' is misspelled as 'Takeo' on several occasions (p. 9,10,14,16,19).
- The Takao et al. paper is referenced from the year 2018 instead of 2019 (p. 9 and in the legend of Figure 2).
Significance
Although the key conclusions of the manuscript are convincing, they are not new.
In fact, Takao et al. describe their model explicitly as a "reaction-diffusion system (also known as a Turing model)" (p. 3539, Takao et al. 10.1083/jcb.201904156) and their model already consists of two components, representing an "active" and "inactive" form of PLK4. The conclusion that a two-component Turing reaction-diffusion model can explain how mother centrioles break PLK4 symmetry to generate a single daughter is thus already evident from Takao et al.'s work.
On the other hand, the original description of the model presented by Leda et al. includes more than two components and is not explicitly labeled as a Turing-inspired reaction scheme, although this might be obvious for people familiar with Turing models. For the Leda model, the authors' reformulation in a two-component reaction-diffusion system could be of potential interest, if the reformulated models lead (the authors) to new interpretations of previous data or generate unanticipated predictions that are testable in experiments.
At present, however, the provided material fails to demonstrate the significance of the reformulation of the models, and therefore seems better suited as review or commentary piece on reaction-diffusion systems explaining PLK4 symmetry breaking.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
The study by Wilmott and colleagues is the design and test of a novel model that accounts for the symmetry break of PLK4 around centrioles prior to duplication. Two previous models have been proposed by xx et al and xx et al and both are described in the details in the introduction. According to the authors, the two previous models are similar but differ in some key points. The model by Leda et al is discrete since PLK4 can accumulate on nine competing points, which represent the nine triplets of microtubules. It is based on numerous chemical interactions and notably the positive feedback of PLK4 on itself. But somehow it does not account very well for the effect of the inactivation of PLK4 phosphorylation on the accumulation of PLK4 all around the centriole. The model by Takao et al is more continuous since it relies on the dynamics of a condensate formed by PLK4 which consumes adjacent PLK4 and thus leads to the concentration of PLK4 in the condensate. In addition to a positive feedback of PLK4 on itself it takes into account the negative effect of PLK4 on the adjacent recruitment of PLK4. But this model is not very robust to variations in the initial conditions. Here the authors proposed a continuous model based on the equations of a Turing model. It is claimed to unify the two previous model in a more generic one that is easier to implement and to study. It accounts for all known impacts of the modulation of PLK4 phosphorylation on PLK4 symmetry break. I am not skilled enough in biochemical modeling to assess properly their description of other models, neither their own model. However, the present study is very well presented and convincingly highlights the conditions for the symmetry break to occur. It seems to be an incremental addition to the previous ones, which properly accounted for PLK4 symmetry break and it is based on similar assumptions. However, the continuous description is certainly easier in terms of computation and the Turing-like morphogenesis is an interesting novel way to think about symmetry break around the centriole.
I have few minor concerns:
- A preceding study by Chau and Lim in Cell in 2012 studied all the interactions patterns between two components that could lead to a symmetry break and the polarization of one of the components. They also studied the robustness of the polarizing patterns. It would be relevant to discuss this study and mention which of these patterns are considered here. In addition, Turing morphogenesis is not used in this study by Chau and Lim. I am not a specialist but it might means that the difference of diffusion rates between the two components might not be essential to the polarization. It would be interesting to test how critical it is in this study. It is somehow studied in the two right phase diagram in Figure 3. But it is unclear to me if the conclusion is that a robust polarization could not appear if the system is not driven by a genuine Turing-like mechanism. It is somehow obvious that if the inactivator diffuse faster than the activator, the activator will aggregates more easily, but it is unclear to me whether this is a requirement. It doesn't seem to be the case in the study by Chau and Lim.
- The study by Chau and Lim proposed a way to test the robustness of the polarizing pattern to variations of the interaction parameters and concentrations of the two species. It would be a great addition to this study.
- It is unclear which term of the equations (3-4) and (5-6) correspond to the self-activation and activation/inhibition of the other component. In model1, the positive feedback of the inactivator on itself is drawn in the scheme (Figure 1) but the corresponding term in equation 4 (a positive term depending only on the concentration of the inactivator) seems to lack. In model 2, the positive feedbacks on both the activator and the inactivator, drawn in the scheme (figure 2), are also absent from equations 5 and 6.
- The two arrows between A and I seem to be inverted in the scheme in Figure 2. I understood from the text and the equations that A must act negatively on I, and not positively, and that I must act negatively A, and not positively.
Significance
The study by Wilmott and colleagues is the design and test of a novel model that accounts for the symmetry break of PLK4 around centrioles prior to duplication. Two previous models have been proposed by xx et al and xx et al and both are described in the details in the introduction. According to the authors, the two previous models are similar but differ in some key points. The model by Leda et al is discrete since PLK4 can accumulate on nine competing points, which represent the nine triplets of microtubules. It is based on numerous chemical interactions and notably the positive feedback of PLK4 on itself. But somehow it does not account very well for the effect of the inactivation of PLK4 phosphorylation on the accumulation of PLK4 all around the centriole. The model by Takao et al is more continuous since it relies on the dynamics of a condensate formed by PLK4 which consumes adjacent PLK4 and thus leads to the concentration of PLK4 in the condensate. In addition to a positive feedback of PLK4 on itself it takes into account the negative effect of PLK4 on the adjacent recruitment of PLK4. But this model is not very robust to variations in the initial conditions. Here the authors proposed a continuous model based on the equations of a Turing model. It is claimed to unify the two previous model in a more generic one that is easier to implement and to study. It accounts for all known impacts of the modulation of PLK4 phosphorylation on PLK4 symmetry break. I am not skilled enough in biochemical modeling to assess properly their description of other models, neither their own model. However, the present study is very well presented and convincingly highlights the conditions for the symmetry break to occur. It seems to be an incremental addition to the previous ones, which properly accounted for PLK4 symmetry break and it is based on similar assumptions. However, the continuous description is certainly easier in terms of computation and the Turing-like morphogenesis is an interesting novel way to think about symmetry break around the centriole.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Reviewer #1 (Evidence, reproducibility and clarity (Required)):
Summary
Ge et al. defined the role of Gli1 in M1 macrophage activation and osteoclast differentiation in physiological conditions and inflammatory arthritis. The authors found that Gli1 expression is elevated in human RA synovial tissue relative to that in healthy donor controls. Moreover, the authors showed that the administration of GANT58, a Gli1 inhibitor, ameliorates inflammation and bone erosion in CIA mice. Gli1 expression is suppressed by LPS/IFN-____γ stimulation in Raw264.7 cells while being induced by RANKL stimulation in Raw264.7 cells. However, GANT58 suppressed LPS/IFN-____ɣ -induced expression of inflammatory cytokines and iNOS and osteoclastogenesis. The authors also identified DNMT1 and DNMT3a as downstream effectors of Gli1. Transcriptomic analysis of GANT58 treated Raw264.7 cells identified diminished protein expression of DNMT1 and DNMT3a by GANT58. Gli1 also directly interacts with DNMT1. Intriguingly, DNMT1 overexpression restores the effect of GANT58 on LPS/IFN-____ɣ-mediated activation, while DNMT3a overexpression reverses the effect of GANT58 on RANKL-induced osteoclastogenesis. Since this study defines the role of Gli1 in the function and differentiation of myeloid cells, this is interesting. In addition, GANT58 nearly completely protects mice from arthritis, suggesting a therapeutic potential of Gli1 targeting in RA. However, the details of experiments are not clearly described, and the authors present the mixed data from Raw264.7 cells and BMMs without any explanations.
Reply: Many thanks for your recognition and constructive comments on our research. In this study, used mouse macrophage-like cell line RAW264.7 and primary bone marrow-derived macrophages (BMMs). The RAW264.7 is the most commonly used mouse macrophage cell line in medical research, and it is one of the most commonly used in vitro models for osteoclasts and inflammation research. In addition, compared with cell lines, primary cells have the characteristics of unchanged genetic material and biological characteristics closer to cell physiology in vivo. Therefore, in addition to cell lines, we also extracted primary macrophages from bone marrow for experiments to improve the reliability of this study. According to your comments, we have revised the manuscript, and our point-by-point responses are shown as follows.
Major comments
Comment 1. Figs 1h and i. The author should show the histological score.
Reply: Thanks for the constructive comment. According to your suggestion, we have scored the results of H&E staining histologically and added quantitative results.
Comment 2. Pharmacological inhibitors often show non-specific effects. To complement their findings showing the effect of GANT58 on M1 macrophage activation and osteoclastogenesis, the authors should utilize Gli1-deficient cells that can be obtained by siRNAs-mediated knock down or Gli1 deletion.
Reply: Thanks for the professional and constructive comment. To make the results more reliable, we have synthesized siRNA and supplemented the related experiments to verify the role of GLI1 in M1 macrophage activation and osteoclastogenesis, which showed the same trend as GANT58 intervention. In the revised manuscript, the relevant results were shown in the Response to Reviewer File.
Comment 3. Figure 4d: The authors should measure DNMT1 and DAMT3a RNA expression in LPS/IFN-____ɣ- treated (Fig 2c and d) or RANKL treated Raw264.7 cells.
Reply: Thanks for your constructive comment. According to the suggestion, we have added the RNA expression of DNMT1 and DAMT3a to the revised Figure 4. At the same time, the corresponding contents are also described in the Results part.
__ detailed information of RNA-seq including how many genes are regulated by GANT58 and what is their cutoff (fold induction and FDR). The authors should deposit their RNA seq data in the public databases repository such as GEO.__
Reply: Thanks for the professional and constructive comment. In the revised manuscript, we have made a more detailed analysis of the sequencing results and the detail information of RNA-seq have been added in the supplementary information.
Revised in the manuscript:
2.4. GLI1 regulates the expression of DNMTs in distinct ways during the different fates of macrophages
As a nuclear transcription factor, GLI1 exerts an active effect through nuclear entry. In order to explore the potential downstream regulation mechanism of GLI1, RNA sequencing (RNA-seq) on the macrophages before and after GLI1 intervention was performed then to observe gene expression changes. The seq data showed that more genes were down-regulated (143) than up-regulated (74) in GANT58 treated cells (Fig. S7a, b). Among these differentially altered genes, we revealed through Gene Ontology (GO) analysis that GANT58's intervention in GLI1 affected multiple biological processes including macrophage chemotaxis and macrophage cytokine production (Fig. 4a). What’s more, the results of the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of the pathway team enrichment was then performed and we showed the TOP30 enriched pathway. In these pathways, we classified them into cellular processes (red), human diseases (blue) and organismal systems (green) respectively. It showed that these down-regulated genes were involved in the development of human diseases such as rheumatoid arthritis, as well as organismal systems such as osteoclast differentiation (Fig. S8c; ____Fig. 4b). These evidences confirmed our previous results. Specifically, GANT58 reduced some of the osteoclast and inflammation-related genes in the cell resting state.
Comment 5. Figure 5c. The authors should add non-stimulating condition as a control.
__Reply: __Thanks for your constructive comment. We have re-conducted the experiment and added the control group.
Comment 6. Figure 6C: DNMT3a deficiency regulates limited number of genes such as IRF8. The authors should measure IRF8 RNA or protein expression in RANKL-treated cells.
Reply: Thanks for your constructive comment. It is reported that DNMT3a can affect the activity of IRF8 and regulate the formation of osteoclasts. Thus, according to your suggestion, we have added IRF8 gene expression detection in the revised manuscript. As shown below, the gene expression of Irf8 was decreased after being treated by RANKL. However, the expression of Irf8 was reversed by Dnmt3a knock down.
Comment 7. Although the effects of Gli1 on bone metabolism in the literature are inconclusive, Gli1 is expressed on other cell types in bone. Gli1 haplodeficiency in mice decreased bone mass with reduced bone formation and enhanced bone resorption compared to control mice (PMID:25313900). Gli1 is also used as a marker for osteogenic progenitors which are precursors of chondrocytes and osteoblasts (PMID: 29230039). Thus, the beneficial effect of GANT58 on inflammation and bone erosion in CIA mice may result from the effects of GANT58 on multiple cell types other than F4/80+ cells. The authors should include these references in the discussion on pg.9 and expand their discussion.
__Reply: __Thank you for your constructive comments. Indeed. there have been some divergent conclusions about the function of hedgehog and GLI1 in bone metabolism, which suggests that GLI1 may have multiple roles. According to your suggestion, we have expanded the relevant discussion and added related references in the Discussion part.
Discussion:
… … Although we have demonstrated that the inhibition of GLI1 by GANT58 can reduce the inflammatory response and inhibit osteoclast formation and that this mechanism is achieved through the downregulation of DNMTs, these findings also raise new questions. In the previous research report, Gli1 haplodeficiency in mice decreased bone mass with reduced bone formation compared to control mice, which was due to the osteoblasts with weakened function [44]. In this process, the osteogenic differentiation of mesenchymal stem cells also affected the function of osteoclasts. In addition, GLI1 is also used as a marker for osteogenic progenitors which are precursors of chondrocytes and osteoblasts [45]. These studies suggest that the regulation of GLI1 on bone metabolism is complex, and the therapeutic effect of GANT58 on RA may be more than just affecting the inflammatory reaction mediated by macrophages and the bone destruction mediated by osteoclasts. In addition to macrophages and osteoclasts, the functions of synovial fibroblasts and osteoblasts play essential roles in the RA microenvironment. These cells are also closely linked to each other. Synovial fibroblasts OPG and RANKL secreted by osteoblasts are important factors that regulate osteoclasts. Therefore, in a follow-up study, we will extend the study of GLI1 to its regulatory mechanism in osteoblasts.
Reference:
[44] Y. Kitaura, H. Hojo, Y. Komiyama, T. Takato, U.I. Chung, S. Ohba, Gli1 haploinsufficiency leads to decreased bone mass with an uncoupling of bone metabolism in adult mice, PLoS One 9(10) (2014) e109597.
[45] Y. Shi, G. He, W.C. Lee, J.A. McKenzie, M.J. Silva, F. Long, Gli1 identifies osteogenic progenitors for bone formation and fracture repair, Nat Commun 8(1) (2017) 2043.
Minor comments
Comment 1. CIA model: The experiment design of CIA model is not clearly described. The author should specify the time point of GANT58 injection.
__Reply: __Thank you for your comment and we are sorry for the confusion caused by vague method descriptions about animal experiments. We have added the specific design and method description of related experiments in the revised manuscript.
Revised in the manuscript:
Materials and Methods:
… … An emulsion of bovine type II collagen (Chondrex, Redmond, WA, USA) and an equal amount (1:1, v/v) of complete Freund’s adjuvant (Chondrex) was prepared to establish the CIA mouse model. First, 0.1 ml of the emulsion was injected intradermally into the base of the tail on day 0. On day 21, 0.1 mg of bovine type II collagen mixed with incomplete Freund’s adjuvant (Chondrex) was injected. From the 21st day, mice began to receive injection intervention treatment. For vehicle group, mice were injected with the same volume of placebo daily. For treatment groups, mice were injected with GANT58 or 5-AzaC solution daily. All interventions began the day after the second injection of bovine type II collagen. Arthritis score was given every three days from the second immunization. On day 49, all mice were sacrificed (in accordance with the guidelines of the Animal Welfare and Ethics Committee of the Soochow University) for the collection of specimens. … …
Comment 2. Joint inflammation of RA can be caused by many different cells. Abstract needs to be revised.
Reply: Thanks for your constructive comment. According to the suggestion, we have revised relevant descriptions in the abstract.
Abstract:
Rheumatoid arthritis (RA) is characterized by joint synovitis and bone destruction, the etiology of which remains to be explored. Many types of cells are involved in the progress of RA joint inflammation, among which the overactivation of M1 macrophages and osteoclasts has been thought an essential cause of joint inflammation and bone destruction. Glioma-associated oncogene homolog 1 (GLI1) has been revealed to be closely linked to bone metabolism. In this study, GLI1-expression in synovial tissue of RA patients showed to be positively correlated with RA-related scores and was highly expressed in collagen-induced arthritis (CIA) mouse articular macrophage-like cells. The decreased expression and inhibition of nuclear transfer of GLI1 downregulated macrophage M1 polarization and osteoclast activation, the effect of which was achieved by modulation of DNA methyltransferases (DNMTs) via transcriptional regulation and protein interaction ways. By pharmacological inhibition of GLI1, the proportion of proinflammatory macrophages and the number of osteoclasts were significantly reduced, and the joint inflammatory response and bone destruction in CIA mice were alleviated. This study clarified the mechanism of GLI1 in macrophage phenotypic changes and activation of osteoclasts, suggesting potential applications of GLI1 inhibitor in the clinical treatment of RA.
Comment 3. Figure 4g, h: are these experiments done in the resting states?
Reply: Thank you for your comment. This part of the experiments was carried out during the induction of M1 macrophage or induction of osteoclast. In this work, we found that GANT58 can inhibit GLI1 and at the same time reduce the gene expression of DNMT3a but not DNMT1 in the resting state. However, during M1 macrophage and osteoclast induction, GANT58 seemed to be able to inhibit both DNMT1 and DNMT3a protein expression. In view of the discovery that the expression of DNMT1 increased during the polarization of M1 macrophages, while the expression of DNMT3a increased during the activation of osteoclasts, we performed the binding experiment of GLI1 with DNMT1 in the process of LPS/IFN-γ induction, while the binding experiment with DNMT3a in the process of RANKL induction. We have added a detailed description to the revised manuscript.
Reviewer #1 (Significance (Required)):
Strengths: Hedgehog (hh) signaling has been implicated in the differentiation of osteogenic progenitors. Gli1+ mesenchymal progenitors are responsible for both normal bone formation and fracture repair. This study defines a new role of Gli1 in the function and differentiation of myeloid cells. In addition, GANT58 nearly completely protects mice from arthritis, suggesting a therapeutic potential of Gli1 targeting in RA.
Reply: Thank the reviewer for your recognition of our research work.
Limitations: This study mainly uses a pharmacological inhibitor to study the mechanism underlying Gli1's action. In addition, the details of experiments are not clearly described, and the authors present the mixed data from Raw264.7 cells and BMMs without any explanations. Advance: This study provides conceptual advancement for hh signaling research by demonstrating the function of Gli1 in myeloid cells.
Reply: Thank the reviewer for your constructive comments and help us to further improve the manuscript.
Audience: Basic research
Reviewer #2 (Evidence, reproducibility and clarity (Required)):
Summary:
The paper by Ge et al seeks to identify a role for GLI1 in rheumatoid arthritis, as GLI1 is upregulated in the synovium of patients with rheumatoid arthritis. Inhibition of GLI1 by the GANT58 limited inflammation and destructive bone loss in a murine model of arthritis (Collagen Induced Arthritis). Inhibition of GLI1 increased expression of pro-inflammatory cytokines and M1 macrophage differentiation. Inhibition of GLI1 also blocked osteoclast formation. As has been shown in other settings, the function of GLI1 in M1 and osteoclast differentiation was linked to regulation by DNMTs.
Major comments:
Comment 1. There are several main problems with the text. Overall, the authors show an intriguing set of data implicating the use of GANT58 as a means to limit rheumatoid arthritis inflammation and bone destruction. The authors directly link the functions of GANT58 with loss of GLI1 activity by showing that GLI1 protein is reduced or translation to the nucleus blocked. It would be compelling if the authors would leverage a genetic model (either GLI1 knockout, or a CRISPR/siRNA approach) to see if it recapitulates key findings in vitro and in vivo. These data could further their claims that their findings are in fact directly due to GLI1.
Reply: Thanks for the professional and constructive comment. To make the results more reliable, we have synthesized siRNA and supplemented the related experiments to verify the role of GLI1 in M1 macrophage activation and osteoclastogenesis. Related experiments have been updated in the revised manuscript, which are shown in the Response to Reviewer File.
Comment 2. Overall, the paper lacks methodologic clarity that limits thorough interpretation of the data. Multiple experiments are missing from the Materials and Methods, including descriptions of the definition of trabecular bone and its analysis in micro-CT, the means by which cytoplasmic and nuclear fractions were generated, and the timing and dosing of GANT58 in vitro studies. In addition, key details regarding the reagents include the sources of primary antibodies used in the western blots and immunoprecipitation studies. Important methodologies are not well explained, which include the treatment of the Sham animals (presumably healthy) are not explained, that is, whether they receive injections of vehicle or are truly naïve. Finally, there is no statistical methodology, minimal explanation of the RNA-sequencing analyses, and no statement about how the RNA-sequencing data will be made available. This lack of detail makes a thorough assessment of the quality and interpretations of the data challenging and replication of the results impossible.
Reply: Thanks for your careful reading and constructive comments. We are sorry for the lack of some detailed methodological descriptions in the manuscript. In order to better explain how our experiment is carried out and improve the repeatability of the experiment, we have comprehensively improved the description of the experimental method in the revised manuscript.
Materials and Methods:
4.1. Experimental animals and human synovial tissue. Male DBA mice aged 6-8 weeks and weighing 15-20 g were randomly selected and fed in a specific pathogen-free (SPF) environment at a room temperature of 25℃, a relative humidity of 60%, and 12 hours of alternating light. All animal experiments were approved by the Animal Ethics Committee of the Soochow University (201910A354). The animals were divided randomly into groups (6 per group): sham group (healthy mice not received any treatment), vehicle control group (CIA model mice treated with solvent), and GANT58 (GLI1 specific inhibitor; MedChemExpress, New Jersey, USA) group (mice treated with 20 mg/kg GANT58) or 5-AzaC (DNMTs specific inhibitor; MedChemExpress) group (mice treated with 2 mg/kg 5-AzaC). An emulsion of bovine type II collagen (Chondrex, Redmond, WA, USA) and an equal amount (1:1, v/v) of complete Freund’s adjuvant (Chondrex) was prepared to establish the CIA mouse model. First, 0.1 ml of the emulsion was injected intradermally into the base of the tail on day 0. On day 21, 0.1 mg of bovine type II collagen mixed with incomplete Freund’s adjuvant (Chondrex) was injected. For vehicle group, mice were injected with the same volume of placebo daily. For treatment groups, mice were injected with GANT58 or 5-AzaC solution daily. All interventions began the day after the second injection of bovine type II collagen. Arthritis score was given every three days from the second immunization. On day 49, all mice were sacrificed (in accordance with the guidelines of the Animal Welfare and Ethics Committee of the Soochow University) for the collection of specimens. … …
4.3. Micro-CT analysis. The fixed bone samples of mice were collected. The joint samples were placed in a SkyScan 1174 Micro-CT scanning warehouse (Belgium). The parameters were set as follows: voltage 50 kV, current 800 μA, scanning range 2 cm × 2 cm, and scanning layer thickness 8 μm. The scan data were then entered into computer to conduct three-dimensional reconstruction with NRecon software (Bruker, Germany), and the bone tissue parameters were analysed with CTAn software (Bruker, Germany) after data conversion. During this procedure, we performed an analysis of bone parameters including BMD (Bone Mineral Density), BV/TV (Percentage Trabecular Area), Tb.N (Trabecular Number) and Tb.Sp (Trabecular Separation) by selecting the small joint of paws as the region of interest (ROI) in CTAn software. The three-dimensional reconstruction images were exhibited by Mimics Research software (Version 21.0; Materialise, Belgium).
4.11. Western blotting. Cells were seeded in 6-well plates at a density of 1 × 106/well with stimulation with RANKL (50 ng/ml) or LPS (100 ng/ml) + IFN-γ (20 ng/ml). First, cells were collected to extract total protein, and the BCA (Beyotime) method was used to adjust the protein concentration. Total protein was mixed with 5× loading buffer (Beyotime) and boiled at 95 °C for 10 minutes. For cytoplasmic/nucleus isolation, cells were collected and protein was extracted according to the instructions using the nuclear protein and cytoplasmic protein extraction kit (Beyotime). The proteins were separated by SDS polyacrylamide gel electrophoresis (SDS–PAGE; EpiZyme, Shanghai, China) based on their different molecular weights. Electrophoresis was performed using Bio–Rad (California, USA) equipment at 180 V for 40 minutes. Then, the proteins were transferred to a nitrocellulose membrane at 350 mA for 70 minutes using membrane transfer equipment (Bio–Rad). The membrane was removed and placed into western blot blocking buffer for 1 hour at room temperature. The diluted primary antibodies (GLI1, Abclonal, A14675; β-actin, Beyotime, AF5003; Lamin-B1, Abcam, ab16048; NFATc1, Abclonal, A1539; CTSK, Abclonal, A5871; MMP9, Abclonal, A11147; DNMT1, Abclonal, A16729; DNMT3a, Cell Signaling Technology, D23G1; GAPDH, Abclonal, A19056) were placed on the membrane and incubated at 4 ℃ for 12 hours, and then the corresponding secondary antibody was added and incubated for 1 hour at room temperature. Finally, a chemiluminescence detection system (Bio–Rad) was used to observe the results.
4.12. High-throughput sequencing (RNA-seq). To further screen for differential genes, we first subjected RAW264.7 cells to a 24-hour adaptive culture, followed by the addition of GANT58 at a final concentration of 10 μM to the GANT58 intervention group and cultured for a total of 24 h. After the cell treatment was completed, cells of the control group and GANT58 treated group were collected respectively, and RNA-seq detection and analysis were entrusted to a professional biological company (Azenta Life Sciences, Suzhou, China). Briefly, for differential expression gene analysis, the differential expression conditions were set as fold change (FC) > 1.5 and false discovery rate (FDR) 4.14. Statistical analysis. All data are presented as the mean ± standard deviation (SD). Statistical analysis was performed with an unpaired two-tailed Student’s t test for single comparisons with GraphPad Prism 8 (GraphPad Software, CA, USA). One-way analysis of variance (ANOVA) was used to compare data from more than two groups. p values less than 0.05 were considered statistically significant.
The specific statistical methods are marked in Figure legends as well.
Data Availability: The authors declare that all data supporting the findings of this study are available within this paper and its Supplementary Information and raw data are available on request from the corresponding author.
Comment 3. The authors should expand their introduction and Discussion to include a description of the history of other GLI inhibitors (such as GANT61) in rheumatoid arthritis. Further, the authors failed to cite current studies showing that GLI1 is upregulated in RA patients (DOI: 10.1007/s10753-015-0273-3 amongst others).
Reply: Many thanks to your thoughtful reading and constructive comment. According to your suggestion, we have added some revisions, including the description of GLI1 inhibitors, in the introduction and discussion sections. At the same time, we have also added descriptions and citations of GLI1 and RA-related research in corresponding positions.
Introduction:
… … To date, three mammalian GLI proteins have been identified, among which GLI1 usually acts as a transcriptional activator. On the basis of these studies, small molecular compounds such as GANT58 (selective inhibitor of GLI1) and GANT61 (inhibitor of GLI1 and GLI2) are often used as pharmacological interventions of GLI1, so as to achieve the purpose of inhibiting GLI1 activity and regulating the molecular biological process [13, 14]. Many of the physiopathological processes involved with GLIs are complex and worth discussing. Relevant studies have shown that GLI1-activated transcription promotes the development of inflammatory diseases such as gastritis, and antagonizing GLI1 transcription can alleviate the inflammatory degradation of articular cartilage [15, 16]. … …
Discussion:
… … In previous studies, GLI1 signal transduction and other pathways, including the NF-κB signaling pathway, were usually studied in tumor-associated diseases and are considered a response network that promotes cancer development [21, 22]. Qin. et al. found that the content of SHH in RA patients serum increased significantly by comparing with healthy patients [23]. At the same time, our study also showed that GLI1 was more expressed in the joint tissue of RA patients. These results suggest that HH-GLI signaling pathway may be involved in the regulation of the pathological process of RA. However, the research results of the hedgehog pathway in bone metabolism are complex. … …
Reference:
[13] X. Chen, C. Shi, H. Cao, L. Chen, J. Hou, Z. Xiang, K. Hu, X. Han, The hedgehog and Wnt/beta-catenin system machinery mediate myofibroblast differentiation of LR-MSCs in pulmonary fibrogenesis, Cell Death Dis 9(6) (2018) 639.
[14] R.K. Schneider, A. Mullally, A. Dugourd, F. Peisker, R. Hoogenboezem, P.M.H. Van Strien, E.M. Bindels, D. Heckl, G. Busche, D. Fleck, G. Muller-Newen, J. Wongboonsin, M. Ventura Ferreira, V.G. Puelles, J. Saez-Rodriguez, B.L. Ebert, B.D. Humphreys, R. Kramann, Gli1(+) Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target, Cell Stem Cell 23(2) (2018) 308-309.
[23] S. Qin, D. Sun, H. Li, X. Li, W. Pan, C. Yan, R. Tang, X. Liu, The Effect of SHH-Gli Signaling Pathway on the Synovial Fibroblast Proliferation in Rheumatoid Arthritis, Inflammation 39(2) (2016) 503-12.
Comment 4. The antibody for GLI1 seems poor and inconsistent. Knockdown studies to show its specificity, and an example of the whole membrane stained for GLI1 would provide important validation of the reagent.
Reply: Thanks for your comment and we are sorry for showing the western blot results with poor quality. In the revised manuscript, we used the newly purchased antibody (Abclonal, Catalog: A14675) and rearranged the groupings for better comparison of protein expression and replaced the results with clearer blot images. Original images of all western blot results can be uploaded subsequently.
Comment 5. Regarding Figure S1:
The studies of RA patients are underpowered. With only three RA patients and three healthy synovial the distribution of DAS28 scores is clustered at healthy and active disease, and the correlation study is unconvincing.
Reply: Thanks for your constructive comment. We are sorry that the studies of RA patients might not be convincing enough due to the small sample size. In order to avoid controversial conclusions, we left out the results of correlation analysis between GLI1 expression and DAS28. In the follow-up study, we will collect additional clinical pathology data for statistical analysis and quantified the expression of GLI1 in healthy control patients and RA patients.
Comment 6. Regarding Figure 1 f-g and Figure 4j-k:
However, the information on inflammatory bone loss are incomplete. The methodology for the assessment of BMD and trabecular bone parameters in the hind paw is not explained. The 3D reconstructions are of the whole bone hind paw, but the anatomical region where trabecular bone is assayed not defined. It would be convincing if the authors added erosion scores in the hind paws or knees to show that the erosion in the synovium, which contributes to inflammatory arthritis, mirrors what occurs in the trabeculae.
Reply: Thanks for your constructive comment. We are sorry for incomplete description on in vivo experiments, including the micro-CT analysis and histological analysis. In the revised manuscript, we further supplemented and improved the relevant methods. The Inflammatory cell infiltration score and bone erosion score were also added according to your suggestion.
Materials and Methods:
4.3. Micro-CT analysis. The fixed bone samples of mice were collected. The joint samples were placed in a SkyScan 1174 Micro-CT scanning warehouse (Belgium). The parameters were set as follows: voltage 50 kV, current 800 μA, scanning range 2 cm × 2 cm, and scanning layer thickness 8 μm. The scan data were then entered into computer to conduct three-dimensional reconstruction with NRecon software (Bruker, Germany), and the bone tissue parameters were analysed with CTAn software (Bruker, Germany) after data conversion. During this procedure, we performed an analysis of bone parameters including BMD (Bone Mineral Density), BV/TV (Percentage Trabecular Area), Tb.N (Trabecular Number) and Tb.Sp (Trabecular Separation) by selecting the small joint of paws as the region of interest (ROI, bone tissue from ankle joint to toe) in CTAn software. The three-dimensional reconstruction images were exhibited by Mimics Research software (Version 21.0; Materialise, Belgium).
Comment 7. Regarding Figure 2:
-The methods and text do not state the dose of GANT58 used in these assays. Nor do they specify the timing of the GANT58 application in relationship to LPS and IFNg stimulation.
Reply: Thanks for your thoughtful reading and constructive comment. We apologize for not expressing the detailed dose and intervention time of GANT58 in some experiments in detail. In the revised manuscript, we have added drug dose and intervention time cutoff points in the parts of Methods, Results, and Figure Legends.
-The authors conclude that GLI1 limits the differentiation of M1 macrophages and also directly blocks the production of pro-inflammatory cytokines. The data are difficult to parse in that the directionality is not clear. If GLI1 promotes M1 macrophages, there would be less proinflammatory cytokines due to the reduction of their proliferation. To evaluate the role of GLI1 in regulating the cytokines, additional studies showing a transcriptional regulation of these cytokines is warranted.
Reply: Thank you for your professional and constructive comment. We totally agree with you that the release of inflammatory cytokines is affected not only by gene expression but also by the number of cells that proliferate. Therefore, to exclude this interference, we further examined transcriptional expression of cytokines responsible for cellular inflammation under the same conditions. The results shown in the Response to Reviewer File confirmed the inhibition of GANT58 on the expression of pro-inflammatory cytokine mRNAs, which further supported our conclusion.
-To show that the fractionation of the cytoplasm and nuclear compartments was complete, the westerns for GLI1, lamin-B1 and beta actin should be shown in the same blot.
Reply: Thank you for your professional and constructive comment. According to your suggestion, we have rearranged the groupings to show the westerns for GLI1, lamin-B1 and β-actin in the same blot for better comparison in the revised manuscript.
-In Section 2.3 ("the expression of and intranuclear transport..."), the authors state that their previous studies showed GLI was expressed in macrophages (line 80-81). It is unclear whether the authors are referring to studies in this manuscript or a previously published study and a citation is needed.
Reply: Thank you for your careful reading and helpful comment. We are sorry that the description in this part is confusing. In fact, what we want to refer to is the in vivo results described in the first section of the results part. We have changed this description in the revised manuscript.
2.3. The expression and intranuclear transport of GLI1 is involved in osteoclast activation
The over activation of osteoclast is the direct cause of bone destruction in RA. As described of the in vivo experimental results in the first part, we have found that GLI1 is highly expressed in macrophage-like cells in the subchondral bone of the joints, which raised our concerns about GLI1 and osteoclasts. … …
In response to Figure 3:
-The authors show that GANT58 has a potent impact in limiting osteoclast formation. The text states that GANT58 is a pretreatment, but the timing of this is not stated.
Reply: Thanks for your constructive comment. In order to reach the working concentration of drugs at the beginning of some experiments, we usually pretreated cells for 6-8 hours. We have added the specific time in the parts of Materials and Methods or Figure legends.
-It would be interesting to see whether there is a dose-response effect of GANT58.
Reply: Thanks for your comment. According to your comment, we set the concentration of GANT58 to 0, 1, 5 and 10 μM to intervene the induction of M1 macrophages and osteoclasts respectively. As shown in the Response to Reviewer File, with the increase of GANT58 concentration, the mean fluorescence intensity of iNOS in macrophages seems to decrease gradually, but there is no statistical significance when the concentration is below 5 μM. Similarly, when the concentration reached 10 μM, GANT58 significantly inhibited the formation of osteoclasts.
-It is not stated how long the cells are RANKL treated prior to nuclear/cytoplasmic fractionation? (3a, b, c and i).
Reply: Thanks for your constructive comment. For osteoclast induction and intervention, we treated cells for 48 h as cell transcription regulation usually occurs in the early and middle stages of osteoclast differentiation. According to your comment, we have added the description of specific intervention time information in Figure legends and other parts.
-The "Zoom" images in Figure 3j do not have a box to delineate where the higher magnification images are taken from in the top panes. The images appear to be from serial sections. This should be clarified.
Reply: Thanks for your constructive comment. In the revised Figure, we have boxed the area represented by the Zoom images. We can ensure that these images come from different groups of specimen slices. In order to better observe the number of osteoclasts, we chose a larger shooting multiple, which might make the pictures look similar. The revised images are shown in the Figure 3n, o in the Response to Reviewer File.
In Figure 3 and Figure 6e and 6f:
Although the data in BMM showed that there was no impact on cell survival was limited at low concentrations, showing that the differentiating osteoclasts are not more sensitive to apoptosis by GANT58 would be compelling. The large difference in cellularity in the presence of GANT58 provokes this question.
Reply: Thank you for your careful reading and helpful comment. As shown of the CCK8 result, GANT58 had no significant inhibitory effect neither on BMMs nor RAW264.7 cells until the concentration reached 40 μM. In the process of changing the polarization phenotype of macrophages, the cell morphology will also change to some extent. In our research results, the change of cell morphology after GANT58 intervention might be due to the inhibition of M1 macrophages. In order to observe the effect of GANT58 on BMM cell death and apoptosis, we further performed living/dead staining and apoptosis detection by fluorescence after GANT58 intervention. The results showed that GANT58 did not change the level of apoptosis nor increase the number of dead cells at the concentration of 10 μM. However, when the concentration increased to 30μM, the number of apoptotic cells increased. These results suggest that we should pay strict attention to the control of drug concentration in experimental intervention and transformation application. The supplementary results are shown in the Response to Reviewer File.
In Figure 4:
-The IP studies (4g and 4h) lack showing successful pull-down of GLI1 by western blotting as a critical control for the study.
Reply: Thanks for your constructive comment. During the performance of CO-IP experiment, we simultaneously detected the expression of GLI1 to verify the effectiveness of the antibodies used. In the revised Figure 4g and h, we have updated the corresponding results.
Revised Figure 4:
-Details about the steps involved in RNA-sequencing analyses need to be provided.
__Reply: __Thanks for your constructive comment. According to your suggestion, we have provided the steps involved in RNA-sequencing analyses in the Methods.
4.12. High-throughput sequencing (RNA-seq). To further screen for differential genes, we first subjected RAW264.7 cells to a 24-hour adaptive culture, followed by the addition of GANT58 at a final concentration of 10 μM to the GANT58 intervention group and cultured for a total of 24 h. After the cell treatment was completed, cells of the control group and GANT58 treated group were collected respectively, and RNA-seq detection and analysis were entrusted to a professional biological company (Azenta Life Sciences, Suzhou, China). Briefly, for differential expression gene analysis, the differential expression conditions were set as fold change (FC) > 1.5 and false discovery rate (FDR)
-Studies have previously shown a reduction of inflammatory arthritis by 5'-Azac and should be cited.
__Reply: __Thank you for your careful reading and helpful comment. In the discussion part of the revised manuscript, we have cited the related articles, which is shown as below.
Discussion:
… … In addition to normal physiological development, the abnormal expression of DNMTs causes the development of tumors and other diseases [35]. Through the treatment of DNMTs inhibitors, the inflammatory arthritis in mice was significantly relieved, which was consistent with the previous studies [36]. These results suggested that DNMTs might be involved in the inflammatory reaction and bone destruction of RA. Reports have suggested that the absence of DNMT3a inhibits the formation of osteoclasts, which may be due to the methylation of downstream IRF8 by DNMT3a [37]. In our study, we also verified this finding through pharmacological and genetic intervention. … …
Reference:
[36] D.M. Toth, T. Ocsko, A. Balog, A. Markovics, K. Mikecz, L. Kovacs, M. Jolly, A.A. Bukiej, A.D. Ruthberg, A. Vida, J.A. Block, T.T. Glant, T.A. Rauch, Amelioration of Autoimmune Arthritis in Mice Treated With the DNA Methyltransferase Inhibitor 5'-Azacytidine, Arthritis Rheumatol 71(8) (2019) 1265-1275.
-What is the proposed functional consequence for GLI1 binding to DNMT3a? Does GLI1 inhibition lead to hypomethylation of DNA by DNMT?
Reply: Many thanks for your constructive comment. In this study, it is interesting to find that GLI1 can affect the expression of Dnmt3a at the level of gene transcription, and affect the expression of DNMT3a and DNMT1 both in the process of protein expression. Through the CO-IP experiment, we confirmed that GLI1 protein can bind to DNMT1 instead of DNMT3a protein. These results suggested that GLI1 may regulate the expression of DNMT3a and DNMT1 at genetic level and post-translation proteinic level, respectively. Patricia Gonz á lez Rodr í Guez's latest research showed that during autophagy induction, GLI1 is upregulated, phosphorylated, translocated to the nucleus and recruited to the regions closer to the Transcription Start Site (TSS) of the Dnmt3a gene. This may be the direct mechanism of GLI1 regulating the expression of DNMT3a [1]. Theoretically, the expression of DNMTs affects the degree of methylation of related genes [2]. Thus, in the follow-up study, we will further verify the degree of genomic methylation caused by GLI1's regulation of DNMTs, and further explore more possible ways of GLI1's regulation of DNMTs and its potential role in other cell models.
Reference:
[1] P. Gonzalez-Rodriguez, M. Cheray, L. Keane, P. Engskog-Vlachos, B. Joseph, ULK3-dependent activation of GLI1 promotes DNMT3A expression upon autophagy induction, Autophagy (2022) 1-12.
[2] Dura M, Teissandier A, Armand M, Barau J, Lapoujade C, Fouchet P, Bonneville L, Schulz M, Weber M, Baudrin LG, Lameiras S, Bourc'his D. DNMT3A-dependent DNA methylation is required for spermatogonial stem cells to commit to spermatogenesis, Nat Genet 54(4) (2022) 469-480.
Figure 5:
-The groups in 5g are not well defined.
Reply: Thank you for your careful reading and comment. We're sorry that we didn’t clearly show the grouping information. In the revised Figure 5g, we have added the complete information of the groups.
-DNMT1 and DNMT3a reduction by siRNA, CRISPR or knockout would strengthen the inhibitor studies.
Reply: Thanks for your constructive comment. In the revised manuscript, we knocked down the expression of DNMT1 and DNMT3a by siRNA, and supplemented the related experimental results, which are shown in the Response to Reviewer File.
Regarding Figure 5 and 6:
-What is the impact of DNMT1 and DNMT3a overexpression on their own (not in the presence of GANT58)?
Reply: Thanks for your constructive comment. According to your comment, we observed and compared the differences in the polarization of macrophages M1 and the activation of osteoclasts between the DNMTs overexpression group and the control group. The results showed that overexpression of DNMT1 seemed to have no obvious effect on the formation of M1 macrophages. During the osteoclast activation, at day 4 of RANKL induction, the TRAP positive stained osteoclast number seemed to be no significance between WT group and Dnmt3aOE group. However, at day 3, there was more osteoclast in Dnmt3aOE group, which suggested that overexpression of Dnmt3a might accelerate the activation of osteoclasts to some extent. The results are shown in the Response to Reviewer File.
Minor comments:
Comment 1. The authors do not include a description of DNMTs in the introduction.
Reply: Thanks for your constructive comment. According to your suggestion, we have added a description of DNMTs in the Introduction.
Introduction:
DNA methylation is an important epigenetic marker playing an important role in regulating gene expression, maintaining chromatin structure, gene imprinting, X chromosome inactivation and embryo development an important epigenetic modification way to regulate gene expression, which is activated by DNA methyltransferases (DNMTs) [17]. As reported, DNMT1 and DNMT3a are involved in the progress of many physiological disorders, such as immune response and cell differentiation [18, 19]. In this study, … …
Reference:
[17] E. Li, Y. Zhang, DNA methylation in mammals, Cold Spring Harb Perspect Biol 6(5) (2014) a019133.
[18] Y. Fu, X. Zhang, X. Liu, P. Wang, W. Chu, W. Zhao, Y. Wang, G. Zhou, Y. Yu, H. Zhang, The DNMT1-PAS1-PH20 axis drives breast cancer growth and metastasis, Signal Transduct Target Ther 7(1) (2022) 81.
[19] R. Ramabadran, J.H. Wang, J.M. Reyes, A.G. Guzman, S. Gupta, C. Rosas, L. Brunetti, M.C. Gundry, A. Tovy, H. Long, T. Gu, S.M. Cullen, S. Tyagi, D. Rux, J.J. Kim, S.M. Kornblau, M. Kyba, F. Stossi, R.E. Rau, K. Takahashi, T.F. Westbrook, M.A. Goodell, DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells, Nat Cell Biol 25(4) (2023) 528-539.
Comment 2. The descriptions of the groups are often unclear. In Figure 2, the label "GANT58" (blue bars) is presumably for a group that is treated for LPS+IFNg+GANT58 but this is not clarified.
Reply: Thanks for your careful reading and we are sorry for the ambiguous labeling. We have checked the whole manuscript and changed the related labeling information.
Comment 3. The distinction of Figure 3g as multinuclear giant cells (vs TRAP+ OCs in panel 3d) should be explained.
Reply: Thanks for your comment. Osteoclast is defined as a multinucleated giant cell with bone absorption function, which is composed of multiple monocytes/macrophages [1]. As osteoclasts mature, their cytoskeleton will undergo drastic reorganization. Filamentous actin (F-actin) firstly constitutes a podosomes with a highly dynamic structure, thereby completing the cell adhesion, migration, dissolution of bone minerals and digestion of organic matrix [2]. Therefore, in addition to observing the formation of osteoclasts by TRAP staining, we also carried out immunofluorescence staining to observe the F-actin ring formation to further evaluate the functional maturity of osteoclasts. Osteoclasts usually have 2-50 nuclei, so we mainly regarded multinucleated giant cells with complete F-actin rings as mature osteoclasts during the quantification process.
Reference:
[1] da Costa CE, Annels NE, Faaij CM, Forsyth RG, Hogendoorn PC, Egeler RM, Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med 7;201(5) (2005) 687-93.
[2] Portes M, Mangeat T, Escallier N, Dufrancais O, Raynaud-Messina B, Thibault C, Maridonneau-Parini I, Vérollet C, Poincloux R, Nanoscale architecture and coordination of actin cores within the sealing zone of human osteoclasts, Elife (11) (2022) e75610.
Comment 4. The labels in 4C of "R1, R2, R3" standing for GANT58 is confusing
__Reply: __We are sorry for the confusing labeling. In the revised manuscript, we have added specific grouping information in the Figure legend, as shown below.
*Figure 4. DNA methyltransferases might be a regulatory target downstream of GLI1. a Biological process GO analysis of RNA-seq results for macrophages with or without GANT58 treatment. b KEGG rich analysis of RNA-seq results. c Heat map of parts of the relevant gene transcriptional expressions (C = control group; R = GANT58 treated group; red: increased expression; blue: decreased expression). d Relative mRNA expression of Gli1, Dnmt1 and Dnmt3a in macrophages with or without GANT58 treatment. Statistical analysis was performed using two-way ANOVA test. e RAW264.7 cells were stimulated by LPS and IFN-γ for 24 h, with or without GANT58 co-intervention. Western blot results of DNMT1 and DNMT3a protein expression and grayscale value ratio to β-actin of western blot results. n = 3. f RAW264.7 cells were stimulated by RANKL for 3 days, with or without GANT58 co-intervention. Western blot results of DNMT1 and DNMT3a protein expression and grayscale value ratio to β-actin of western blot results. n = 3. Statistical analysis was performed using two-way ANOVA test. g, h Co-IP detection of protein binding between GLI1 and DNMT1/DNMT3a. n = 3. i Protein–protein interface interaction of GLI1 and DNMT1 with PyMOL. j Micro-CT scanning and 3D reconstruction of mouse paws. k Bone parameters of BV/TV, BMD, Tb.N, Tb.Th. n = 6. Statistical analysis was performed using one-way ANOVA test. Data shown represent the mean ± SD. *p
Comment 5. In Figure S8, the numbers between the western blots are not explained.
__Reply: __Many thanks for your careful reading and comment. The numbers between the blots represent the ratio of the gray value of DNMT1 and DNMT3a immunoblot to the gray value of β-actin immunoblot, so as to reflect the relative expression of proteins. In order to avoid confusion, we made a statistical chart of the results and added it to revised Figure S8.
Comment 6. In Figure S9 there are references to asterisks which do not appear in the figure.
__Reply: __We are sorry for the mistake. We have deleted the relevant information in the revised Supplementary information. Thanks again.
Reviewer #2 (Significance (Required)):
The paper presented by Ge et al present interesting data suggesting that a GLI1 inhibitor (GANT58) has a strong impact on inflammatory arthritis in a murine model. Interesting data are presented whose novelty need better contextualization with other published studies, as previously published studies which are not cited in this manuscript include the finding that GLI1 is upregulated in patients with rheumatoid arthritis, that other GLI inhibitors have been utilized in murine models of rheumatoid arthritis, and that GLI1 has been shown to regulate DNMT expression in cancer settings. The authors connect GLI1 inhibition with DNMT activation in limiting M1 macrophage and osteoclast differentiation. However, several important controls are needed to in the in vitro studies as outlined above.
Reviewer #3 (Evidence, reproducibility and clarity (Required)):
Summary
The manuscript by Ge et al. describes the possible roles of GLI1 in macrophage and osteoclast activation in rheumatoid arthritis via its functional interaction with DNA methyltransferases. The authors found that the GLI1 expression was elevated in RA synovial tissues and GLI1-specific inhibitor, GANT58, ameliorated arthritis in CIA mice. GLI1 expression in F4/80-positive macrophages in CIA synovial tissues led the authors to assess the roles of GLI1 in macrophages and osteoclasts. GANT58 suppressed M1 macrophage polarization by IFNg+LPS and osteoclastogenesis by RANKL. RNA-seq analysis of GANT58-treated macrophages revealed that DNA methyltransferases, DNMT1 and DNMT3a were possible targets of GLI1, and the studies with small inhibitors or overexpression of DNMTs suggest that GLI1 enhanced M1 polarization and osteoclastogenesis through DNMTs. The manuscript is well-written, the methods are accurate, and the results and data interpretation are consistent and clearly presented. This work deserves publication in Research Commons after addressing the following questions:
Major comments
Comment 1. GANT58 may inhibit GLI2 in addition to GLI1 and have off-target effects. Major findings with GANT58 in vitro, the suppressive effects on M1 polarization, osteoclastogenesis, and DNMT3a expression should be assessed with siRNA/shRNA knockdown or CRISPR/Cas9 knockout of GLI1.
Reply: Many thanks for your careful reading and constructive comment. According to your comment, we have constructed Gli1 knock-down cells and carried out related experiments. The results have been added in the revised manuscript, which are shown in the Response to Reviewer File.
Comment 2. In CIA with GANT58, the author performed only preventive treatment, not therapeutic treatment. Does GANT58 suppress adaptive immune responses via inhibiting APC function (ex. anti-CII IgG production)? Alternatively, the inhibitory effects of GANT58 on the effecter phase of RA (M1 macrophage and osteoclast activation) can be assessed using the serum-transfer arthritis models.
__Reply: __Many thanks for your constructive comments. Your question is indeed a direction worthy of attention. In our study, GANT58 was given during the stage of model establishment, showing a good effect of relieving arthritis, which was proved to come from the direct inhibition of inflammatory phenotype macrophages and osteoclasts. However, as autoimmune diseases, the enhancement of antigen presenting function and anti-Col II IgG production can enhance the immune response of the body [1]. The regulatory effect of GANT58 on macrophages suggests that it may have a potential impact on APC function. Despite this, whether GANT58 can regulate the pathological process of RA by influencing this pathway is inconclusive. Therefore, according to your suggestion, we will improve the relevant experiments in our follow-up research, and apply GANT58 to various animal models of RA to further explore the possible mechanism of GANT58 in the treatment of RA and provide more reliable theoretical support for its transformation and application.
Reference:
[1] Tsark EC, Wang W, Teng YC, Arkfeld D, Dodge GR, Kovats S, Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages, J Immunol 1;169(11) (2002) 6625-33.
Minor comments
Comment 1. GANT58 is a water insoluble agent. Can you please include how to dissolve GANT58, administration route, and rationale of 20 mg/kg, for CIA?
__Reply: __Thank you for your professional comment. In this work, GANT58 was ordered from MedChemExpress (MCE; Cat. No.: HY-13282) Company. According to the instructions for use, we prepared 20 mg/ml ethanol solution of GANT58 into 2 mg/ml working solution for injection in vivo according to the following ratio: 10% EtOH + 90% (20% SBE-β-CD in PBS); Clear solution; Need ultrasonic. During the experiment, GANT58 was injected i.p. at a dose of 20 mg/kg daily for 28 days. With regard to the choice of drug injection concentration, according to the previous literature, most studies used a dose of 50 mg/kg for daily injection [1, 2]. Hereby, we set up concentration gradient intervention (0, 10, 20, and 50 mg/kg) in the preliminary experiment and found that 20 and 50 both had good therapeutic effects. Therefore, according to the consideration of economy and safety, we chose 20 mg/kg as our final intervention concentration.
Reference:
[1] Li G, Deng Y, Li K, Liu Y, Wang L, Wu Z, Chen C, Zhang K, Yu B, Hedgehog Signalling Contributes to Trauma-Induced Tendon Heterotopic Ossification and Regulates Osteogenesis through Antioxidant Pathway in Tendon-Derived Stem Cells, Antioxidants (Basel) 16;11(11) (2022) 2265.
[2] Lauth M, Bergström A, Shimokawa T, Toftgård R, Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 15;104(20) (2007) 8455-60.
Comment 2. Zoom photos in Fig 1j are not clear. Is GLI1 exclusively expressed in F4/80+ macrophages in synovial tissues?
__Reply: __Many Thanks for your comment. In the revised manuscript, we have improved the resolution of the image for better observation. According to the results, although GLI1 is more expressed in F4/80 positive cells, not all GLI1 proteins are expressed in macrophages, and we can find that some GLI1 positive staining is expressed in other cells. In the follow-up study, we will continue to explore this phenomenon and study the relationship between GLI1 and cells like synovial fibroblasts in RA.
Comment 3. In Fig 2 and 3, the treatment of macrophages with IFNg+LPS and RANKL enhanced the nuclear translocation of GLI1, suggesting that these stimuli may activate hedgehog signals. Recent studies, however, suggest various non-canonical activation pathways of GLI1. Does hedgehog inhibitor (ex. SMO inhibitor) also suppress M1 polarization and osteoclastogenesis?
__Reply: __Thank you for your constructive comment. We agree with that the activation of GLI1 is regulated by many various pathways. According to your comment, we additionally used Cyclopamine, a selective inhibitor of SMO, to intervene during the polarization of M1 macrophages and the activation of osteoclasts. The results are shown in the Response to Reviewer File: Cyclopamine could also inhibit the proinflammatory polarization of macrophages to a certain extent, and a significant inhibition of the osteoclast formation could be observed as well. These results may further confirm the important role of HH/GLI1 in regulating macrophage caused inflammation and osteoclast activation.
Comment 4. In Fig 6, the overexpression of DNMT3a reversed the inhibitory effects of GANT58 in osteoclastogenesis. This supports the author's conclusion that GLI1 may enhance osteoclastogenesis via DNMT3a upregulation. However, this conclusion should be carefully evaluated by examining effects of the overexpression of DNMT3a without GANT58. Does the overexpression of DNMT3a by itself enhance osteoclastogenesis or just reverse the GANT58-mediated suppression?
Reply: Thanks for your constructive comment. According to your comment, we observed and compared the differences in the activation of osteoclasts between the DNMT3a overexpression group and the control group. The results showed that at day 4 of induction, the TRAP positive stained osteoclast number seemed to be no significance between WT group and Dnmt3aOE group. However, at day 3, there was more osteoclast in Dnmt3aOE group, which suggested that overexpression of Dnmt3a might accelerate the activation of osteoclasts to some extent. The results are shown in the Response to Reviewer File.
Comment 5. Is RNA-seq data with GANT58 compatible with known target genes of GLI1 reported in previous studies?
Reply: Thanks for your constructive comment. By consulting and comparing with other research articles, most of the data trends in RNA sequencing results are the same as those in other studies. In addition, the expression of some genes is different from other studies (MMP13 increased in our data but decreased in other study [1]), which may be caused by different cell lines and different intervention methods.
Reference:
[1] Akhtar N, Makki MS, Haqqi TM, MicroRNA-602 and microRNA-608 regulate sonic hedgehog expression via target sites in the coding region in human chondrocytes, Arthritis Rheumatol 67(2) (2015) 423-34.
Reviewer #3 (Significance (Required)):
Significance
The main limitation of this paper is the lack of siRNA knockdown study of GLI1 and DNMTs. Another limitation of this paper is that the direct in vivo data demonstrating the inhibitory effects of GANT58 on M1 macrophage and osteoclast activation in CIA is lacking. The strength is the promising activity of GLI inhibitor, GANT58 as an anti-rheumatic drug on monocyte/macrophage-associated inflammation and bone destruction. The roles of hedgehog/GLI signals in macrophage function are largely unknown, and the findings of this study may contribute to this research field. This study will be interesting to rheumatologists and immunologists.
Reply: Thanks again for your constructive comments, which helped us to improve the quality of the manuscript.
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Reply to the Reviewers
I thank the Referees for their...
Referee #1
- The authors should provide more information when...
Responses + The typical domed appearance of a hydrocephalus-harboring skull is apparent as early as P4, as shown in a new side-by-side comparison of pups at that age (Fig. 1A). + Though this is not stated in the MS 2. Figure 6: Why has only...
Response: We expanded the comparison
Minor comments:
- The text contains several...
Response: We added...
Referee #2
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary
The manuscript by Ge et al. describes the possible roles of GLI1 in macrophage and osteoclast activation in rheumatoid arthritis via its functional interaction with DNA methyltransferases. The authors found that the GLI1 expression was elevated in RA synovial tissues and GLI1-specific inhibitor, GANT58, ameliorated arthritis in CIA mice. GLI1 expression in F4/80-positive macrophages in CIA synovial tissues led the authors to assess the roles of GLI1 in macrophages and osteoclasts. GANT58 suppressed M1 macrophage polarization by IFNg+LPS and osteoclastogenesis by RANKL. RNA-seq analysis of GANT58-treated macrophages revealed that DNA methyltransferases, DNMT1 and DNMT3a were possible targets of GLI1, and the studies with small inhibitors or overexpression of DNMTs suggest that GLI1 enhanced M1 polarization and osteoclastogenesis through DNMTs. The manuscript is well-written, the methods are accurate, and the results and data interpretation are consistent and clearly presented. This work deserves publication in Research Commons after addressing the following questions:
Major comments
- GANT58 may inhibit GLI2 in addition to GLI1 and have off-target effects. Major findings with GANT58 in vitro, the suppressive effects on M1 polarization, osteoclastogenesis, and DNMT3a expression should be assessed with siRNA/shRNA knockdown or CRISPR/Cas9 knockout of GLI1.
- In CIA with GANT58, the author performed only preventive treatment, not therapeutic treatment. Does GANT58 suppress adaptive immune responses via inhibiting APC function (ex. anti-CII IgG production)? Alternatively, the inhibitory effects of GANT58 on the effecter phase of RA (M1 macrophage and osteoclast activation) can be assessed using the serum-transfer arthritis models.
Minor comments
- GANT58 is a water insoluble agent. Can you please include how to dissolve GANT58, administration route, and rationale of 20 mg/kg, for CIA?
- Zoom photos in Fig 1j are not clear. Is GLI1 exclusively expressed in F4/80+ macrophages in synovial tissues?
- In Fig 2 and 3, the treatment of macrophages with IFNg+LPS and RANKL enhanced the nuclear translocation of GLI1, suggesting that these stimuli may activate hedgehog signals. Recent studies, however, suggest various non-canonical activation pathways of GLI1. Does hedgehog inhibitor (ex. SMO inhibitor) also suppress M1 polarization and osteoclastogenesis?
- In Fig 6, the overexpression of DNMT3a reversed the inhibitory effects of GANT58 in osteoclastogenesis. This supports the author's conclusion that GLI1 may enhance osteoclastogenesis via DNMT3a upregulation. However, this conclusion should be carefully evaluated by examining effects of the overexpression of DNMT3a without GANT58. Does the overexpression of DNMT3a by itself enhance osteoclastogenesis or just reverse the GANT58-mediated suppression?
- Is RNA-seq data with GANT58 compatible with known target genes of GLI1 reported in previous studies?
Significance
The main limitation of this paper is the lack of siRNA knockdown study of GLI1 and DNMTs. Another limitation of this paper is that the direct in vivo data demonstrating the inhibitory effects of GANT58 on M1 macrophage and osteoclast activation in CIA is lacking. The strength is the promising activity of GLI inhibitor, GANT58 as an anti-rheumatic drug on monocyte/macrophage-associated inflammation and bone destruction. The roles of hedgehog/GLI signals in macrophage function are largely unknown, and the findings of this study may contribute to this research field. This study will be interesting to rheumatologists and immunologists.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary:
The paper by Ge et al seeks to identify a role for GLI1 in rheumatoid arthritis, as GLI1 is upregulated in the synovium of patients with rheumatoid arthritis. Inhibition of GLI1 by the GANT58 limited inflammation and destructive bone loss in a murine model of arthritis (Collagen Induced Arthritis). Inhibition of GLI1 increased expression of pro-inflammatory cytokines and M1 macrophage differentiation. Inhibition of GLI1 also blocked osteoclast formation. As has been shown in other settings, the function of GLI1 in M1 and osteoclast differentiation was linked to regulation by DNMTs.
Major comments:
There are several main problems with the text. Overall, the authors show an intriguing set of data implicating the use of GANT58 as a means to limit rheumatoid arthritis inflammation and bone destruction. The authors directly link the functions of GANT58 with loss of GLI1 activity by showing that GLI1 protein is reduced or translation to the nucleus blocked. It would be compelling if the authors would leverage a genetic model (either GLI1 knockout, or a CRISPR/siRNA approach) to see if it recapitulates key findings in vitro and in vivo. These data could further their claims that their findings are in fact directly due to GLI1.
Overall, the paper lacks methodologic clarity that limits thorough interpretation of the data. Multiple experiments are missing from the Materials and Methods, including descriptions of the definition of trabecular bone and its analysis in microCT, the means by which cytoplasmic and nuclear fractions were generated, and the timing and dosing of GANT58 in vitro studies. In addition, key details regarding the reagents include the sources of primary antibodies used in the western blots and immunoprecipitation studies. Important methodologies are not well explained, which include the treatment of the Sham animals (presumably healthy) are not explained, that is, whether they receive injections of vehicle or are truly naïve. Finally there is no statistical methodology, minimal explanation of the RNAsequencing analyses, and no statement about how the RNAsequencing data will be made available. This lack of detail makes a thorough assessment of the quality and interpretations of the data challenging and replication of the results impossible.
The authors should expand their introduction and Discussion to include a description of the history of other GLI inhibitors (such as GANT61) in rheumatoid arthritis. Further, the authors failed to cite current studies showing that GLI1 is upregulated in RA patients (DOI: 10.1007/s10753-015-0273-3 amongst others).
The antibody for GLI1 seems poor and inconsistent. Knockdown studies to show its specificity, and an example of the whole membrane stained for GLI1 would provide important validation of the reagent.
Regarding Figure S1: The studies of RA patients are underpowered. With only three RA patients and three healthy synovial the distribution of DAS28 scores is clustered at healthy and active disease, and the correlation study is unconvincing.
Regarding Figure 1 f-g and Figure 4j-k: However, the information on inflammatory bone loss are incomplete. The methodology for the assessment of BMD and trabecular bone parameters in the hindpaw is not explained. The 3D reconstructions are of the whole bone hindpaw, but the anatomical region where trabecular bone is assayed not defined. It would be convincing if the authors added erosion scores in the hind paws or knees to show that the erosion in the synovium, which contributes to inflammatory arthritis, mirrors what occurs in the trabeculae.
Regarding Figure 2:
- The methods and text do not state the dose of GANT58 used in these assays. Nor do they specify the timing of the GANT58 application in relationship to LPS and IFNg stimulation.
- The authors conclude that GLI1 limits the differentiation of M1 macrophages and also directly blocks the production of pro-inflammatory cytokines. The data are difficult to parse in that the directionality is not clear. If GLI1 promotes M1 macrophages, there would be less proinflammatory cytokines due to the reduction of their proliferation. To evaluate the role of GLI1 in regulating the cytokines, additional studies showing a transcriptional regulation of these cytokines is warranted.
- To show that the fractionation of the cytoplasm and nuclear compartments was complete, the westerns for GLI1, lamin-B1 and beta actin should be shown in the same blot.
- In Section 2.3 ("the expression of and intranuclear transport..."), the authors state that their previous studies showed GLI was expressed in macrophages (line 80-81). It is unclear whether the authors are referring to studies in this manuscript or a previously published study and a citation is needed.
In response to Figure 3:
- The authors show that GANT58 has a potent impact in limiting osteoclast formation. The text states that GANT58 is a pretreatment, but the timing of this is not stated.
- It would be interesting to see whether there is a dose-response effect of GANT58.
- It is not stated how long the cells are RANKL treated prior to nuclear/cytoplasmic fractionation? (3a, b, c and i).
- The "Zoom" images in Figure 3j do not have a box to delineate where the higher magnification images are taken from in the top panes. The images appear to be from serial sections. This should be clarified.
In Figure 3 and Figure 6e and 6f: Although the data in BMM showed that there was no impact on cell survival was limited at low concentrations, showing that the differentiating osteoclasts are not more sensitive to apoptosis by GANT58 would be compelling. The large difference in cellularity in the presence of GANT58 provokes this question.
In Figure 4:
- The IP studies (4g and 4h) lack showing successful pull-down of GLI1 by western blotting as a critical control for the study.
- Details about the steps involved in RNAsequencing analyses need to be provided.
- Studies have previously shown a reduction of inflammatory arthritis by 5'-Azac and should be cited.
- What is the proposed functional consequence for GLI1 binding to DNMT3a? Does GLI1 inhibition lead to hypomethylation of DNA by DNMT?
Figure 5:
- The groups in 5g are not well defined.
- DNMT1 and DNMT3a reduction by siRNA, CRISPR or knockout would strengthen the inhibitor studies.
Regarding Figure 5 and 6:
- What is the impact of DNMT1 and DNMT3a overexpression on their own (not in the presence of GANT58)?
Minor comments:
- The authors do not include a description of DNMTs in the introduction.
- The descriptions of the groups are often unclear. In Figure 2, the label "GANT58" (blue bars) is presumably for a group that is treated for LPS+IFNg+GANT58 but this is not clarified.
- The distinction of Figure 3g as multinuclear giant cells (vs TRAP+ OCs in panel 3d) should be explained.
- The labels in 4C of "R1, R2, R3" standing for GANT58 is confusing
- In Figure S8, the numbers between the western blots are not explained.
- In Figure S9 there are references to asterisks which do not appear in the figure.
Significance
The paper presented by Ge et al present interesting data suggesting that a GLI1 inhibitor (GANT58) has a strong impact on inflammatory arthritis in a murine model. Interesting data are presented whose novelty need better contextualization with other published studies, as previously published studies which are not cited in this manuscript include the finding that GLI1 is upregulated in patients with rheumatoid arthritis, that other GLI inhibitors have been utilized in murine models of rheumatoid arthritis, and that GLI1 has been shown to regulate DNMT expression in cancer settings. The authors connect GLI1 inhibition with DNMT activation in limiting M1 macrophage and osteoclast differentiation. However, several important controls are needed to in the in vitro studies as outlined above.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary
Ge et al. defined the role of Gli1 in M1 macrophage activation and osteoclast differentiation in physiological conditions and inflammatory arthritis. The authors found that Gli1 expression is elevated in human RA synovial tissue relative to that in healthy donor controls. Moreover, the authors showed that the administration of GANT58, a Gli1 inhibitor, ameliorates inflammation and bone erosion in CIA mice. Gli1 expression is suppressed by LPS/IFN-ɣ stimulation in Raw264.7 cells while being induced by RANKL stimulation in Raw264.7 cells. However, GANT58 suppressed LPS/IFN-ɣ -induced expression of inflammatory cytokines and iNOS and osteoclastogenesis. The authors also identified DNMT1 and DNMT3a as downstream effectors of Gli1. Transcriptomic analysis of GANT58 treated Raw264.7 cells identified diminished protein expression of DNMT1 and DNMT3a by GANT58. Gli1 also directly interacts with DNMT1. Intriguingly, DNMT1 overexpression restores the effect of GANT58 on LPS/IFN-ɣ-mediated activation, while DNMT3a overexpression reverses the effect of GANT58 on RANKL-induced osteoclastogenesis. Since this study defines the role of Gli1 in the function and differentiation of myeloid cells, this is interesting. In addition, GANT58 nearly completely protects mice from arthritis, suggesting a therapeutic potential of Gli1 targeting in RA. However, the details of experiments are not clearly described, and the authors present the mixed data from Raw264.7 cells and BMMs without any explanations.
Major comments
- Figs 1h and i. The author should show the histological score.
- Pharmacological inhibitors often show non-specific effects. To complement their findings showing the effect of GANT58 on M1 macrophage activation and osteoclastogenesis, the authors should utilize Gli1-deficient cells that can be obtained by siRNAs-mediated knock down or Gli1 deletion.
- Figure 4d: The authors should measure DNMT1 and DAMT3a RNA expression in LPS/IFN-ɣ- treated (Fig 2c and d) or RANKL treated Raw264.7 cells.
- The authors should provide detailed information of RNA-seq including how many genes are regulated by GANT58 and what is their cutoff (fold induction and FDR). The authors should deposit their RNA seq data in the public databases repository such as GEO.
- Figure 5c. The authors should add non-stimulating condition as a control.
- Figure 6C: DNMT3a deficiency regulates limited number of genes such as IRF8. The authors should measure IRF8 RNA or protein expression in RANKL-treated cells.
- Although the effects of Gli1 on bone metabolism in the literature are inconclusive, Gli1 is expressed on other cell types in bone. Gli1 haplodeficiency in mice decreased bone mass with reduced bone formation and enhanced bone resorption compared to control mice (PMID:25313900). Gli1 is also used as a marker for osteogenic progenitors which are precursors of chondrocytes and osteoblasts (PMID: 29230039). Thus, the beneficial effect of GANT58 on inflammation and bone erosion in CIA mice may result from the effects of GANT58 on multiple cell types other than F4/80+ cells. The authors should include these references in the discussion on pg.9 and expand their discussion.
Minor comments
- CIA model: The experiment design of CIA model is not clearly described. The author should specify the time point of GANT58 injection.
- Joint inflammation of RA can be caused by many different cells. Abstract needs to be revised.
- Figure 4g, h: are these experiments done in the resting states?
Significance
Strengths: Hedgehog (hh) signaling has been implicated in the differentiation of osteogenic progenitors. Gli1+ mesenchymal progenitors are responsible for both normal bone formation and fracture repair. This study defines a new role of Gli1 in the function and differentiation of myeloid cells. In addition, GANT58 nearly completely protects mice from arthritis, suggesting a therapeutic potential of Gli1 targeting in RA.
Limitations: This study mainly uses a pharmacological inhibitor to study the mechanism underlying Gli1's action. In addition, the details of experiments are not clearly described, and the authors present the mixed data from Raw264.7 cells and BMMs without any explanations. Advance: This study provides conceptual advancement for hh signaling research by demonstrating the function of Gli1 in myeloid cells.
Audience: Basic research
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Reply to the reviewers
Manuscript number: RC-2023-01939
Corresponding authors: Jiro Toshima, Junko Y. Toshima
- __ General Statements __ We are grateful for the reviewer’s evaluation of our study. In the new manuscript, we have answered all of the points raised by the two reviewers (the altered or added text is indicated in red in the new manuscript). Reviewer #1 pointed out that definition of "Vps21 activity" is unclear throughout the manuscript. In this study we have developed a novel biochemical method capable of detecting Vps21p activity with high sensitivity (Fig. 2) and utilized this method to measure Vps21p activity, which is clearly stated in the new manuscript. The reviewer #1 also pointed out the issue that we have not clearly explained about difference of two Vps21p-residing structures, small endosome-like puncta and aberrant large structure. To clearly distinguish them, in the new manuscript we have added data showing the size distribution of Vps21p-residing structures (Fig. S2). Regarding comment #2, we think that the reviewer may have misunderstood the data (please see the response to this comment described below). Reviewer #2 did not request any additional experiments but gave us many helpful comments to improve the manuscript. In the new manuscript, we have revised all the places that the reviewer pointed out.
__ Point-by-point description of the revisions__
__Reviewer #1 (Evidence, reproducibility and clarity (Required)): __
(Reviewers’ comments are in italics)
*Summary: *
In the present study Nagano et al. identify an overlapping function of clathrin adaptors in the activation of the yeast Vps21 Rab GTPase. This activation is regulated in a concerted manner by two TGN cargo adaptors, AP-1 and GGA1/2. The basis of this study is derived from the previous work Nagano et al., 2019 where authors reported that Ent3p and Ent5p are important for the formation of the Vps21p-positive endosome. By utilizing a synthetic genetic approach, the authors observed that disruption/loss of the AP-1 complex (apl4 mutant), Ent3p, Ent5p or Pik1 decreased fluorescence intensity for GFP-Vps21p and increased number of Vps21p puncta. They found that these effects for AP-1 disruption are additive, that is, each makes a distinct contribution, at least in ent3∆/ent5∆ mutant cells. They next examined the role of factors required for TGN localization of Ent3p/5p and AP-1 in Vps21p activation. The authors reported that GGA1/2, Pik1p and the Ypt31/32 Rab GTPases make modest contributions to targeting of AP-1 and Ent3/5 to the TGN. The observation that accumulation of GFP-Vps21 next to vacuolar compartments in pik1-1 ent3D mutants similar to that of ent3Dent5Dapl4D, lead authors to conclude that both PI(4)P as well as PI(4)P independent Ent3p recruitment to TGN plays a crucial role in Vps21p activation. Further they found that compared to the pik1-1 ypt31ts mutant (41%), activity of Vps21p (14%) was severely reduced in the pik1-1 ypt31ts gga1D gga2D mutant pointing towards redundancy among these factors in Vps21p activation. Finally using a class E Vps mutant authors found a fall in endosomal population of GFP-Vps9p ~29% in the ent3D ent5D mutant, which was further reduced to 0% in the ent3D ent5D apl4D* mutant. Collectively this study suggests a differential role of TGN adaptors, AP-1 and GGA in early endosome formation. Ent3p/5p and AP-1 are proposed to activate Vps21p by localizing Vps9p on endosomes and thus facilitating its transport whereas GGAs act redundantly along with Pik1p and Ypt31/32 in regulating TGN localization of Ent3p/5p and AP-1. *
Major comments:
There is a considerable amount of data that address the roles of AP-1, Ent3, Ent5, Gga1/2, and Pik1 in targeting of Vps21 and related trafficking pathway components to the TGN/endosome. The experiments are essentially genetic epistasis tests that compare the fluorescence patterns of GFP-Vps21 in a sophisticated set of strains. The genetic data are interpreted in terms of spatiotemporal dynamics of Vps21: proportion Vps21GTP on a compartment and number of GFP-Vps21 positive compartments. *Being genetic in nature, the data are open to wide interpretations in terms of molecular mechanisms that target candidate proteins Vps21p and Vps9 to the TGN/endosome. The authors presentation (Fig. 7) is based on well controlled experiments and is logical, but key questions regarding Vps9 trafficking as it relates to Vps21 endosome formation are not resolved. *
Response:
In this study, in addition to comparison of the fluorescence patterns of GFP-tagged yeast Rab5 (Vps21p), we have developed a novel biochemical method capable of detecting the amount of active Vps21p with high sensitivity. The amount of active Vps21p obtained by this method correlated well with the results obtained by imaging analysis, and we think this approach significantly increased the reliability of our results.
Using this new biochemical method and fluorescence imaging analysis, we have clarified the overall regulatory mechanisms of Vps21p by vesicle transport from the TGN. In particular, we believe that this is an important study that links the activation of Vps21p that mediates endosome formation with numerous previous studies involving vesicle transport from the TGN to the endosome.
Comment #1(a)
-
- Throughout their study the authors conflate measurements of GFP-Vps21 puncta intensity and number of Vps21p puncta as readouts of Vps21 "activity". Figure 7 exemplifies this especially: "Vps21p Activity: 100%; Vps21p Activity: 45%; Vps21p Activity: 10%". *
- *a) Would the authors please explicitly define how they use "activity" in the manuscript? * Response:
We appreciate the reviewer’s pointing out our error. As the reviewer pointed out, since we have used the word “activity” when we explained the result obtained by the fluorescence intensity and the number of Vps21p puncta in lines 312-315 (in the new manuscript), we have revised this sentence “~ a decreased PI(4)P level reduces Vps21p activity and thus inhibits fusion of Vps21p compartments.” to “~a decreased PI(4)P level seems to inhibit fusion of Vps21p compartments.” (lines 314-315).
In other parts of the manuscript, we have used the word “activity” only when we explained the result obtained by measuring the amount of active Vps21p by the biochemical method (Fig. 2). “Vps21p Activity” depicted in Fig. 7A-C are also based on the results obtained by the biochemical assay, and thus we have added explanatory sentences in the Discussion section (lines 432-433, 447) and figure legend (lines 996-998) in the new manuscript.
Comment #1(b)
- *b) The amounts of Vps21-GTP were measured for the ent3D ent5 and ent3D ent5 apl4D mutants (Fig. 2). Other mutant backgrounds should be analyzed in order to address the specific requirements of gga1/2, pik1 and ypt31/32 genes and to challenge the assumption that aspects of GFP-Vps21 localization correlate with the proportion of Vps21GTP. * Response:
We agree with the reviewer’s comment that it is crucial to confirm that aspects of GFP-Vps21 localization correlate with the proportion of Vps21GTP. In the previous manuscript, we have already measured the amount of active Vps21p (GTP-bound form of Vps21p) in the pik1-1, and pik1-1 ent3D mutants (Fig. 4E) and shown that it decreases to ~62% in the pik1-1 mutant, or to ~22% in the pik1-1 ent3D mutant relative to wild-type cells (Fig. 4E). The relative amount of GTP-bound form of Vps21p in these mutants correlated well with the results obtained by imaging analyses of GFP-Vps21p (Fig. 4B and C). To make it clearer, we have added sentences “and the amounts of active Vps21p in these mutants correlate well with the results obtained by imaging analyses of GFP-Vps21p (Fig. 4B, C, and H).” in lines 326-327. We have also demonstrated that the amount of active Vps21p correlated with the fluorescence intensity of GFP-Vps21p at puncta in the pik1-1 ypt31ts or the pik1-1 ypt31ts gga1D2D mutant (Figs 4F-J, S4E), and explained about this in lines 334-341.
Comment #1(c)
- *c) Regarding the measurements of fluorescence intensity of GFP-Vps21 puncta, how were distinct puncta identified, particularly in the large clusters of puncta shown in Figs. 1D, 3A, 4F, 5A, 5C. * Response:
As the reviewer pointed out, in the previous manuscript we have not clearly explained about how we had distinguished two Vps21p-residing structures, small endosome-like puncta and aberrant large structure. To clearly distinguish them, in the new manuscript we examined the size and number of these structures and showed the data in Fig. S2. This result revealed that the ent3D5D apl4D mutant contains single large Vps21p-residing structure with a size of >100 pixels and many small Vps21p-residing puncta with a size of ~50 pixels. To explain about this, we have added sentences in lines 235-239. Regarding Fig. 5A and 5C, since these figures do not show the localization of Vps21p, we have not added explanation about them.
Comment #2
- In the representative micrographs shown in Fig. 1A (Vph1-mCH), 1B (Hse1-tdTom), 1D (Sec7-mCH) and 5A, why do only (roughly) half of the cells in each micrograph express the tagged organelle marker protein? Shouldn't all of the cells? What is especially concerning is that the appearance of GFP-Vps9 in cells that express Sec7-mCH is different than in cells that do not. Specifically, there are fewer GFP-Vps9 puncta in expressing cells and GFP-Vps9 appears to be largely cytosolic in these cells. Have the authors noted the same? *
Response:
In Fig. 1, we expressed mCherry/tdTomato-tagged protein only in wild-type cells (Fig. 1A and B) or in ent3D5D mutants (Fig. 1D) to distinguish the mutant cells from the wild-type cells, as described in the Result section (lines 156-159) and figure legends. As explained in the text (lines 156-159), by labeling only wild-type or mutant cells, we precisely evaluated the differences in the localization of GFP-Vps21p by comparing mutant cells directly alongside wild-type cells.
In Fig. 5A, we expressed Sec7-mCH only in the ent3D5D mutants to distinguish the mutants from wild-type cells (the upper panels) or the ent3D5D apl4D mutants (the lower panels), as described in figure legend. Therefore, the reviewer’s comment that “the appearance of GFP-Vps9 in cells that express Sec7-mCH is different than in cells that do not. Specifically, there are fewer GFP-Vps9 puncta in expressing cells and GFP-Vps9 appears to be largely cytosolic in these cells.” is exactly what we wanted to show in this figure. To show this more clearly, we labeled cells with “WT” or “mutant” in these micrographs (Fig. 1A, 1B, 1D, and 5A).
Comment #3
- Figure 4A: How were the proportional contributions of each factor to the TGN localization of Ent3/5, AP-1 determined? What do the percentiles indicate? *
Response:
As described in the Result section (lines 293-297), we have shown that deletion of the GGA1 and GGA2 genes significantly decreased the localization of Ent3-GFP at the TGN to ~33% of wild-type cell, without changing the localization of Ent5-GFP and Apl2-GFP (Fig. S3A, B). Based on these results, the contribution of Gga1/2p to the localization of Ent3p, Ent5p, or AP-1 was evaluated to be 37%, 0%, or 0%, respectively (Fig. 4A). To make this clearer, we have added sentence “~ and thus, we evaluated the contribution of Gga1p/2p to the localization of Ent3p, Ent5p, or AP-1 to be 37%, 0%, or 0%, respectively (Fig. 4A)” in line 296-297. Similarly, we have determined the contribution of PI(4)P by assessing the localization of Ent3p, Ent5p and Apl2p at the TGN in the pik1-1 (Fig. S3C and D), as described in lines 297-305. Regarding Rab11s (Ypt31p/32p), we have evaluated the contribution based on the data in our previous study, as described in line 305-309.
Comment #4
- In the model presented in Figure 7, the authors proposed that AP-1 is required to target Vps9 from the late TGN to the early TGN. The best characterized function of AP-1 is to concentrate integral membrane proteins to form the inner layer of a clathrin coated vesicle. Vps9 is a soluble protein that fractionates with cytosolic proteins (Burd et al., 1996). Despite measuring intensity and localizing Vps9p with different endosomal markers (Fig. 6), the basis of membrane recruitment of Vps9 by TGN clathrin adaptors is unclear. How do the authors envision AP-1 to function in targeting of Vps9, a soluble protein, between compartments? *
Response:
Like other many Rab-GEFs (e.g., Sec2p, the GEF for Sec4p or Mon1p/Ccz1p, the GEF for Rab7), we think that Vps9p transiently localizes to the donor organelle to activate Rab proteins and load them on the transport vesicle. We have previously demonstrated that Arf1p, a Golgi-resident GTPase, plays an important role in the recruitment of Vps9p to the Golgi (Nagano et al., Comm. Biol., 2019). In this study we have shown that deletion of AP-1 in the ent3D5D mutant increases the localization of Vps9p at the TGN (Fig. 5A and B). These suggest that AP-1, like Ent3p/5p (Nagano et al., Comm Bio, 2019), is dispensable for the recruitment of Vps9p to the TGN but required for the transport of Vps9p from TGN to endosomes.
In a recent study Casler et al. proposed a role of AP-1 function that maintain Golgi-resident proteins by mediating intra-Golgi recycling pathway (Casler et al., JCB, 2021). Based on this model, we have speculated that AP-1 also functions to maintain Vps9p in the TGN by recycling from the late TGN to early TGN and discussed about this in the second paragraph of the Discussion section (lines 434-454 in the new manuscript). However, as the reviewer #2 pointed out (please see comment #6 of the reviewer #2), Casler et al proposed AP-1’s role in transport from the TGN back to earlier Golgi compartment but did not discuss compartmentalization within the TGN, we have modified sentence in the Discussion from “~ the role of AP-1 that recycles Vps9p back to the early TGN might become apparent” to “~ the role of AP-1 that recycles Vps9p back to the earlier Golgi compartment might become apparent” (lines 444-445).
__Minor Comment: __
- The interchangeable terminology used to refer to Rab GTPases throughout the manuscript made it exceptionally difficult for me to focus on the presentation of the experiments. Vps21 and Rab5 are used interchangeably, but this study investigated Vps21, not Rab5. Vps21 does not even appear in the title or abstract. Similarly, Ypt31/32 is used interchangeably with Rab11, but this study investigated Ypt31/32, not Rab11. The accurate names of the yeast proteins should be used. A discussion regarding significance of the yeast proteins for understanding mammalian Rab5 and Rab11 belongs in the Discussion. *
Response:
In accordance with the reviewer’s suggestion, we have replaced Rab5 with yeast Rab5 or Ypt21p. We have also replaced Rab11 with yeast Rab11 or Ypt31p/32p.
__Reviewer #1 (Significance (Required)): __
*General assessment: In general, this is a well-executed and controlled study. The major strengths are the large quantity of data from complementary experiments that provide a rationale for the proposed mechanistic model proposed (Fig. 7). The major weaknesses lie with the genetic approach, which does not lend itself to the mechanistic interpretations that the authors propose, and the narrow scope of the work such that the study will be of interest to a small group of colleagues. The audience will likely include researchers who use yeast to investigate proteins sorting in the endo-lysosome network of organelles and colleagues who investigate signaling by Rab GTPases. *
Response:
We cannot agree with the reviewer’s comment that “the narrow scope of the work such that the study will be of interest to a small group of colleagues”, because the regulation of endosome formation by Rab5 is one of the major topics in the field of membrane traffic, and many mechanisms still remain to be elucidated. Moreover, the model we have proposed in this study is adaptable not only to yeast but to higher organisms, as discussed in the last paragraph of the Discussion section. The endolysosomal pathway is important for the regulation of a wide variety of crucial cellular processes, including mitosis, antigen presentation, cell migration, cholesterol uptake, and many intracellular signaling cascades. Our work thus also has implications for development, immunity, and oncogenesis. We believe that the studies described in our paper represent an advance in our understanding of the cellular biology of endocytic trafficking and therefore would be interesting to researchers in other fields, as well as membrane traffic filed.
__ __
__Reviewer #2 (Evidence, reproducibility and clarity (Required)): __
(Reviewers’ comments are in italics)
*Summary: *
*The manuscript by Nagano et al. describes the results of extensive analysis on the roles of clathrin adaptors for activation of Rab5 during TGN-to-endosome traffic in budding yeast. They examined the localization and activation status of Vps21, a major Rab5 member in yeast, in a variety of mutants and showed that AP-1 had a cooperative role with Epsin-related Ent3/5 in transport of Vps9 (Rab5 GEF) to endosomes. GGAs, PI4 kinase Pik1, and Ypt31/12 (Rab11) had partially overlapping functions in recruitment of AP-1 and Ent3/5 to TGN. *
*It is an indeed extensive study but the interpretation of the results is complicated and somewhat speculative. It is most probably because the differences between mutants are partial (even though the authors tried to show statistics) and the logics to lead conclusions are not always compelling. To be honest, I had a hard time to follow rationales to justify arguments. The conclusions the authors make, that is, multiple clathrin adaptors cooperate in the TGN-to-endosome traffic, are reasonable, but I have several questions as follows, which I would like the authors to address. *
Comment #1
-
- The description about Vps21 fluorescence is often quite confusing. When the authors say fluorescence intensity, is it the total intensity of a whole cell or the average fluorescence intensity of individual puncta? For example, in Fig. 1D, it doesn't look to me at all that the GFP intensity of ent3/ent5 is lower than WT. How did the authors obtain the data of Fig. 1E? If the authors measured the fluorescence of individual puncta, how did they do it? * Response:
We agree that in the previous manuscript explanation about how we measured Vps21p fluorescence intensity was insufficient. In this study, we have measured the whole fluorescence intensity of single GFP-Vps21p punctate structure, which was subtracted the cytoplasmic fluorescence background, and shown it as the fluorescence intensity of Vps21p compartment (the aberrant large GFP-Vps21p structure (Fig. 3A) were excluded). The graphs of fluorescence intensity of GFP-Vps21p show the average of three data (each average of 50 puncta) from three independent experiments. To clarify where and how Vps21 fluorescence was measured, in the new manuscript we have revised text (lines 160-161, 163, 166, 177, 179) and added explanatory sentences in “Materials and Methods” (lines 542-546).
Regarding Fig. 1D and E, since the fluorescence intensity of GFP-Vps21p at the cytosol was increased in the ent3D5D mutant (Fig. 1D), the fluorescence intensity in the mutant may not have appeared lower than that in wild-type cell. To show the decrease of the fluorescence intensities of individual Vps21p puncta in the mutant cells more clearly, we have added the higher magnification view of GFP-Vps21p puncta in Fig. 1D in the new manuscript.
Comment #2
- Related to the previous question, how the images were taken is very important. In the legend to Fig.1, there is no description about the image analysis. Are they epifluorescence images or confocal images, and if the latter, are they ones of 2D confocal images or maximum intensity projections of Z stacks as mentioned in the legend to Fig. 3A? It matters very much. *
Response:
We appreciate the reviewer’s helpful suggestion. In Fig. 1, we have used epifluorescence images for analyzing the fluorescence intensity or number of GFP-Vps21p puncta, because Vps21p puncta have high mobility (please see also the responses to comment #9). In accordance with the reviewer’s suggestion, we have added the description about imaging method in the legend of Fig. 1 (lines 831-832, 837 and 843).
Comment #3
- It is also confusing when the authors say increase or decrease of fluorescence. Is it the intensity or the number of puncta? Please clarify which the authors intend to mention whenever relevant. There are many places that bother readers. *
Response:
We appreciate the reviewer’s helpful suggestion. In accordance with the reviewer’s suggestion, we have revised manuscript (lines 274 and 316).
Comment #4
- The method the authors developed to estimate the activation states of Vps21 is intriguing. It may provide important information without direct measurements of the GTP-binding activity. However, the results should be carefully interpreted because this kind of tricky experiments may not reflect the exact biochemical statuses in the cell. For example, I am concerned about whether release of GTP or spontaneous GTPase activity during the preparation processes is ignored. *
Response:
As the reviewer pointed out, we cannot rule out the possibility that the GTP-bound status might be changed during the preparation processes. However, this problem also occurs in the conventional pull-down assay, which assesses the amount of the GTP-bound form of Rab proteins. To confirm whether the activity of Vps21p assessed by this method reflects in vivo activation level, we have demonstrated that the level of active Vps21p correlated with the in vivo phenotypes, such as fluorescence intensity of GFP-Vps21p at the endosome and number of GFP-Vps21p puncta, that implicate defect of endosomal fusion. Thus, in the new manuscript we have added some sentences to explain about this (lines 221-222).
Comment #5
- In Discussion (p. 20, line 410), the authors describe that "Gga2p is localized predominantly at the Tlg2-residing compartment," but this is wrong. In the BioRxiv paper (2022), the authors showed that "Gga2p appears around the Sec7p-subcompartment and disappears at a similar time as Sec7p." I understand that, to explain the roles of GGAs in endosomal transport, it is reasonable to assume their presence in the Tlg2 compartment (and I agree on that), but the above description is wrong and must be corrected. *
Response:
We appreciate the reviewer’s helpful suggestion. As the reviewer described, we have recently demonstrated that Gga2p localization well overlapped with the Tlg2p-residing TGN sub-compartment that is structurally distinct from the Sec7p-residing sub-compartment (Toshima et al., BioRxiv, 2022). Thus, in accordance with reviewer's suggestion, we have changed this sentence to “Interestingly, Gga2p appears to reside at the Tlg2p sub-compartment, which is distinct from the Sec7p sub-compartment.” in the new manuscript (lines 427-428).
Comment #6
- Hypothesizing the role of AP-1 in the recycling from the late TGN to the early TGN is new. Glick's group proposed its role in transport from the TGN back to earlier compartment (Golgi) but did not discuss compartmentalization within the TGN. The authors' speculation is a fancy idea, but I am afraid there is no direct evidence for that. *
Response:
We appreciate the reviewer’s appropriate and helpful suggestion. As the reviewer pointed out, Glick's group has proposed its role in transport from the TGN back to earlier Golgi compartment, but not discussed compartmentalization within the TGN (Casler et al., 2021, JCB), and thus we modified sentence in the Discussion section from “~ the role of AP-1 that recycles Vps9p back to the early TGN might become apparent.” to “~ the role of AP-1 that recycles Vps9p back to the earlier Golgi compartment might become apparent.” (lines 444-445).
Comment #7
- The role of Ypt31/32 (Rab11) is also puzzling to me. It could be an indirect effect, which might be due to the complex network of GTPases as proposed by Chris Fromme (2014). Am I correct? *
Response:
As the reviewer pointed out, Fromme’s group has shown that Ypt31/32 forms the complex networks with several GTPases and their GEFs (McDonold and Fromme, 2014, Dev Cell; Thomas and Fromme, 2016, JCB, Thomas et al., 2019, Dev Cell), in which Ypt31/32 promotes the activation of Arf1p via its GEF Sec7p. We have previously shown that Arf1p plays an important role in the recruitment of Vps9p to the Golgi (Nagano et al., Comm. Biol., 2019). These findings suggest that disruption of Ypt31p/32p may affect the localization of Vps9p through reduced activity of Arf1p. However, arf1D and ypt31ts mutants exhibit different effects on the Vps9p localization: in arf1D mutant the recruitment of Vps9p to the TGN is impaired and in ypt31ts mutant Vps9p localization at the TGN is increased (Nagano et al., 2019, Comm Biol.). Thus, the role of Ypt31/32 in the Vps9p localization appears to be independent of Arf1p activity. In the new manuscript, we have added a brief discussion about this (lines 466-473).
Comment #8
- In the legend to Fig. 3D, the authors state that the read arrowheads indicate 50 nm vesicles and black arrowheads indicate vesicle clusters. However, the electron micrograph clearly shows that their morphologies are different. Red ones, which I estimate to be a little larger than 50 nm, often appear to have dense material inside, while those in black are even larger (probably around 200 nm) and do not look like a cluster of the same type of vesicles (I do not even think that such large structures should be called vesicles). How do the authors explain these differences? *
Response:
In the previous manuscript explanation about the electron microscopy analysis was insufficient. In the new manuscript, to clearly distinguish two Vps21p-residing structures, small endosome-like puncta and aberrant large structure, observed in ent3D5D apl4D mutant by fluorescence microscopy (Fig. 3A), we examined the size and number of these structures and showed the data in Fig. S2. This result revealed that the ent3D5D apl4D mutant contains single aberrant large aggregate with a size of >100 pixel adjacent to the vacuole and endosome-like structures with a size of Comment #9
- In Fig. 4F, the authors show different sets of images, Focal plane and Z projection. What is the purpose to do it? The results with Z projection should be more informative. Why the authors use only Focal plane data for the analysis in panel G? *
Response:
We measured the fluorescence intensity or number of individual GFP-Vps21p puncta using a single focal plane images (Figs. 1C, 1E, 3I, and 4B), because Vps21p-residing small puncta have high mobility and identical endosome often appears in multiple different planes in the Z-stack image taken by a conventional epifluorescence microscope. In contrast, we analyzed the aberrant large aggregate using Z projection image (Figs. 3B, S3G) because this structure is relatively stable and low motile, and not observed if it is not in the focal plane. In Fig. 4F, since both of small puncta and large aggregate are analyzed, we have shown both of focal plane image and Z-projection image. In new manuscript, we have added about the description about imaging method in each figure legend or text (lines 230-232, 332-334).
__Reviewer #2 (Significance (Required)): __
*It is a complicated story but I find most of the conclusions reasonable. It provides important knowledge to the understanding on the Rab5 GTPase regulation in trafficking from the TGN. *
Response:
We are very grateful for this reviewer’s favorable evaluation of our studies.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
The manuscript by Nagano et al. describes the results of extensive analysis on the roles of clathrin adaptors for activation of Rab5 during TGN-to-endosome traffic in budding yeast. They examined the localization and activation status of Vps21, a major Rab5 member in yeast, in a variety of mutants and showed that AP-1 had a cooperative role with Epsin-related Ent3/5 in transport of Vps9 (Rab5 GEF) to endosomes. GGAs, PI4 kinase Pik1, and Ypt31/12 (Rab11) had partially overlapping functions in recruitment of AP-1 and Ent3/5 to TGN.
It is an indeed extensive study but the interpretation of the results is complicated and somewhat speculative. It is most probably because the differences between mutants are partial (even though the authors tried to show statistics) and the logics to lead conclusions are not always compelling. To be honest, I had a hard time to follow rationales to justify arguments. The conclusions the authors make, that is, multiple clathrin adaptors cooperate in the TGN-to-endosome traffic, are reasonable, but I have several questions as follows, which I would like the authors to address.
- The description about Vps21 fluorescence is often quite confusing. When the authors say fluorescence intensity, is it the total intensity of a whole cell or the average fluorescence intensity of individual puncta? For example, in Fig. 1D, it doesn't look to me at all that the GFP intensity of ent3/ent5 is lower than WT. How did the authors obtain the data of Fig. 1E? If the authors measured the fluorescence of individual puncta, how did they do it?
- Related to the previous question, how the images were taken is very important. In the legend to Fig.1, there is no description about the image analysis. Are they epifluorescence images or confocal images, and if the latter, are they ones of 2D confocal images or maximum intensity projections of Z stacks as mentioned in the legend to Fig. 3A? It matters very much.
- It is also confusing when the authors say increase or decrease of fluorescence. Is it the intensity or the number of puncta? Please clarify which the authors intend to mention whenever relevant. There are many places that bother readers.
- The method the authors developed to estimate the activation states of Vps21 is intriguing. It may provide important information without direct measurements of the GTP-binding activity. However, the results should be carefully interpreted because this kind of tricky experiments may not reflect the exact biochemical statuses in the cell. For example, I am concerned about whether release of GTP or spontaneous GTPase activity during the preparation processes is ignored.
- In Discussion (p. 20, line 410), the authors describe that "Gga2p is localized predominantly at the Tlg2-residing compartment," but this is wrong. In the BioRxiv paper (2022), the authors showed that "Gga2p appears around the Sec7p-subcompartment and disappears at a similar time as Sec7p." I understand that, to explain the roles of GGAs in endosomal transport, it is reasonable to assume their presence in the Tlg2 compartment (and I agree on that), but the above description is wrong and must be corrected.
- Hypothesizing the role of AP-1 in the recycling from the late TGN to the early TGN is new. Glick's group proposed its role in transport from the TGN back to earlier compartment (Golgi) but did not discuss compartmentalization within the TGN. The authors' speculation is a fancy idea, but I am afraid there is no direct evidence for that.
- The role of Ypt31/32 (Rab11) is also puzzling to me. It could be an indirect effect, which might be due to the complex network of GTPases as proposed by Chris Fromme (2014). Am I correct?
- In the legend to Fig. 3D, the authors state that the read arrowheads indicate 50 nm vesicles and black arrowheads indicate vesicle clusters. However, the electron micrograph clearly shows that their morphologies are different. Red ones, which I estimate to be a little larger than 50 nm, often appear to have dense material inside, while those in black are even larger (probably around 200 nm) and do not look like a cluster of the same type of vesicles (I do not even think that such large structures should be called vesicles). How do the authors explain these differences?
- In Fig. 4F, the authors show different sets of images, Focal plane and Z projection. What is the purpose to do it? The results with Z projection should be more informative. Why the authors use only Focal plane data for the analysis in panel G?
Significance
It is a complicated story but I find most of the conclusions reasonable. It provides important knowledge to the understanding on the Rab5 GTPase regulation in trafficking from the TGN.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #1
Evidence, reproducibility and clarity
Summary:
In the present study Nagano et al. identify an overlapping function of clathrin adaptors in the activation of the yeast Vps21 Rab GTPase. This activation is regulated in a concerted manner by two TGN cargo adaptors, AP-1 and GGA1/2. The basis of this study is derived from the previous work Nagano et al., 2019 where authors reported that Ent3p and Ent5p are important for the formation of the Vps21p-positive endosome. By utilizing a synthetic genetic approach, the authors observed that disruption/loss of the AP-1 complex (apl4 mutant), Ent3p, Ent5p or Pik1 decreased fluorescence intensity for GFP-Vps21p and increased number of Vps21p puncta. They found that these effects for AP-1 disruption are additive, that is, each makes a distinct contribution, at least in ent3∆/ent5∆ mutant cells. They next examined the role of factors required for TGN localization of Ent3p/5p and AP-1 in Vps21p activation. The authors reported that GGA1/2, Pik1p and the Ypt31/32 Rab GTPases make modest contributions to targeting of AP-1 and Ent3/5 to the TGN. The observation that accumulation of GFP-Vps21 next to vacuolar compartments in pik1-1 ent3∆ mutants similar to that of ent3∆ent5∆apl4∆, lead authors to conclude that both PI(4)P as well as PI(4)P independent Ent3p recruitment to TGN plays a crucial role in Vps21p activation. Further they found that compared to the pik1-1 ypt31ts mutant (41%), activity of Vps21p (14%) was severely reduced in the pik1-1 ypt31ts gga1∆ gga2∆ mutant pointing towards redundancy among these factors in Vps21p activation. Finally using a class E Vps mutant authors found a fall in endosomal population of GFP-Vps9p ~29% in the ent3∆ ent5∆ mutant, which was further reduced to 0% in the ent3∆ ent5∆ apl4∆ mutant. Collectively this study suggests a differential role of TGN adaptors, AP-1 and GGA in early endosome formation. Ent3p/5p and AP-1 are proposed to activate Vps21p by localizing Vps9p on endosomes and thus facilitating its transport whereas GGAs act redundantly along with Pik1p and Ypt31/32 in regulating TGN localization of Ent3p/5p and AP-1.
Major comments:
There is a considerable amount of data that address the roles of AP-1, Ent3, Ent5, Gga1/2, and Pik1 in targeting of Vps21 and related trafficking pathway components to the TGN/endosome. The experiments are essentially genetic epistasis tests that compare the fluorescence patterns of GFP-Vps21 in a sophisticated set of strains. The genetic data are interpreted in terms of spatiotemporal dynamics of Vps21: proportion Vps21GTP on a compartment and number of GFP-Vps21 positive compartments. Being genetic in nature, the data are open to wide interpretations in terms of molecular mechanisms that target candidate proteins Vps21p and Vps9 to the TGN/endosome. The authors presentation (Fig. 7) is based on well controlled experiments and is logical, but key questions regarding Vps9 trafficking as it relates to Vps21 endosome formation are not resolved. 1. Throughout their study the authors conflate measurements of GFP-Vps21 puncta intensity and number of Vps21p puncta as readouts of Vps21 "activity". Figure 7 exemplifies this especially: "Vps21p Activity: 100%; Vps21p Activity: 45%; Vps21p Activity: 10%". - a) Would the authors please explicitly define how they use "activity" in the manuscript? - b) The amounts of Vps21-GTP were measured for the ent3D ent5 and ent3D ent5 apl4D mutants (Fig. 2). Other mutant backgrounds should be analyzed in order to address the specific requirements of gga1/2, pik1 and ypt31/32 genes and to challenge the assumption that aspects of GFP-Vps21 localization correlate with the proportion of Vps21GTP. - c) Regarding the measurements of fluorescence intensity of GFP-Vps21 puncta, how were distinct puncta identified, particularly in the large clusters of puncta shown in Figs. 1D, 3A, 4F, 5A, 5C. 2. In the representative micrographs shown in Fig. 1A (Vph1-mCH), 1B (Hse1-tdTom), 1D (Sec7-mCH) and 5A, why do only (roughly) half of the cells in each micrograph express the tagged organelle marker protein? Shouldn't all of the cells? What is especially concerning is that the appearance of GFP-Vps9 in cells that express Sec7-mCH is different than in cells that do not. Specifically, there are fewer GFP-Vps9 puncta in expressing cells and GFP-Vps9 appears to be largely cytosolic in these cells. Have the authors noted the same? 3. Figure 4A: How were the proportional contributions of each factor to the TGN localization of Ent3/5, AP-1 determined? What do the percentiles indicate? 4. In the model presented in Figure 7, the authors proposed that AP-1 is required to target Vps9 from the late TGN to the early TGN. The best characterized function of AP-1 is to concentrate integral membrane proteins to form the inner layer of a clathrin coated vesicle. Vps9 is a soluble protein that fractionates with cytosolic proteins (Burd et al., 1996). Despite measuring intensity and localizing Vps9p with different endosomal markers (Fig. 6), the basis of membrane recruitment of Vps9 by TGN clathrin adaptors is unclear. How do the authors envision AP-1 to function in targeting of Vps9, a soluble protein, between compartments?
Minor Comment:
- The interchangeable terminology used to refer to Rab GTPases throughout the manuscript made it exceptionally difficult for me to focus on the presentation of the experiments. Vps21 and Rab5 are used interchangeably, but this study investigated Vps21, not Rab5. Vps21 does not even appear in the title or abstract. Similarly, Ypt31/32 is used interchangeably with Rab11, but this study investigated Ypt31/32, not Rab11. The accurate names of the yeast proteins should be used. A discussion regarding significance of the yeast proteins for understanding mammalian Rab5 and Rab11 belongs in the Discussion.
Significance
General assessment: In general, this is a well-executed and controlled study. The major strengths are the large quantity of data from complementary experiments that provide a rationale for the proposed mechanistic model proposed (Fig. 7).
The major weaknesses lie with the genetic approach, which does not lend itself to the mechanistic interpretations that the authors propose, and the narrow scope of the work such that the study will be of interest to a small group of colleagues. The audience will likely include researchers who use yeast to investigate proteins sorting in the endo-lysosome network of organelles and colleagues who investigate signaling by Rab GTPases.
-
-
www.biorxiv.org www.biorxiv.org
-
Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
1. General Statements [optional]
We would like to thank all reviewers for their constructive feedback and for raising specific points that have helped to improve our manuscript. We accept that the initial submission did not include some quantitative aspects of the observed effects. These are now included together with all the suggested experiments from the reviewers with the use of additional mutants and appropriate protein markers. We believe that the manuscript offers a conceptual advance and a molecular mechanism for the effects of caffeine on cell cycle progression of eukaryotic cells and is of interest to geneticists working on cell cycle, cancer and biogerontology.
Reply to the reviewers
Reviewer #1 (Evidence, reproducibility and clarity):
Summary:
In the manuscript “The AMPK-TORC1 signaling axis regulates caffeine-mediated DNA damage checkpoint override and cell cycle effects in fission yeast,” the authors studied the role of genes that are potentially involved in the caffeine-mediated override of a cell cycle arrest caused by activation of the DNA damage checkpoint. The methylxanthine substance caffeine has been known to override the DNA damage checkpoint arrest and enhance sensitivity to DNA damaging agents. While caffeine was reported to target the ATM ortholog Rad3, the authors previously reported that caffeine targets TORC1 (Rallis et al, Aging Cell, 2013). Inhibition of TORC1, like caffeine, was also reported to override DNA damage checkpoint signaling. Therefore, in the present study, the authors compared the effects of caffeine and torin1 (a potent inhibitor for TORC1 and TORC2) on cell cycle arrest caused by phleomycin, a DNA damaging agent, using various gene deletion S. pombe mutants.
The authors concluded that they identified a novel role of Ssp1 (calcium/calmodulin-dependent protein kinase) and Ssp2 (catalytic subunit of AMP-activated kinase) in the cell cycle effects caused by caffeine, based on the following findings; (1) the caffeine-mediated DNA damage checkpoint override requires Ssp1 and Ssp2; (2) Ssp1 and Ssp2 are required for caffeine-induced hypersensitivity against phleomycin; (3) under normal growth conditions, caffeine leads to a sustained increase of the septation index in a Ssp2-dependent manner; (4) Caffeine activates Ssp2 and partially inhibits TORC1.
Major comments:
I do not think that many of the authors’ claims are supported by the results of the present study. The corresponding parts are detailed below.
- The conclusion of the first paragraph in the Results (top in page 6; Our findings indicate that caffeine and torin1 indirectly and directly inhibit TORC1 activity respectively.) is not supported by the data in Figure 1. The result that caffeine, but not torin1, requires Ssp1 and Ssp2 to override the phleomycin-induced cell cycle arrest does not necessarily indicate that caffeine indirectly inhibits TORC1 via Ssp1 and Ssp2. Rather, the authors should mention that this conclusion is based on the authors’ previous reports by citing them (e.g., Rallis et al, Sci Rep, 2017). To add to Figure 1, an additional experiment using a constitutively active AMPK mutant, a temperature-sensitive TORC1 mutant, and a srk1 deletion mutant will help the authors claim their original conclusion as one possibility.
Torin1 inhibits TORC1 and 2 leading to G2 cell cycle arrest following accelerated mitosis. In contrast, caffeine has been reported to enhance the inhibitory effect of rapamycin on TORC1 signaling but does not inhibit growth. It has not been reported that TORC1 is a direct target of rapamycin. We previously demonstrated that caffeine induces Srk1 in a Sty1 dependent manner (Alao et al., 2014). Furthermore, Ssp1 plays a role in regulating Srk1/ Cdc25 activity. It is therefore possible, that Ssp1 influences the ability of caffeine to promote mitotic progression as part of the stress response while also affecting TORC1 activity via Ssp2. As ssp2∆ cells have higher intrinsic TORC1 activity, this could also attenuate the effect of caffeine on mitosis.
We have modified the first paragraph of the results section to address the reviewer’s concerns.
We have previously reported that Srk1 modulates the ability of caffeine to drive cells into mitosis (Alao et al., 2014).
- The conclusion of the second paragraph in the Results (lower-middle in page 6; Our results indicate that caffeine induces the activation of Ssp2.) is not based on the results of Figure 2. Figure 2 simply illustrates that both caffeine and torin1 cause hypersensitivity to phleomycin dependent on Ssp1 and Ssp2.
We appreciate the reviewer’s contention and have modified the text.
- The conclusion of the fourth paragraph in the Results (middle in page 7) is not clearly supported by the result, due to an insufficient data analysis. As the cell length and the progress through mitosis are the key assay parameters in Figure 3, the average cell length should be shown next to each micrograph of Figure 3A and 3B. In Figure 3C, a mitotic index and the average cell length should be shown next to each micrograph. A statistical analysis is necessary for the authors to compare the measurements and to claim as the headline (Caffeine exacerbates the ssp1D phenotype under environmental stress conditions), as the effect of caffeine was not evident._
We have conducted additional experiments to measure cell length and modified the figure to include this data. We believe our observation that caffeine alone induces increased cell length in ssp1 mutants, confirms a role for the Ssp1 protein in modulating the effects of caffeine. We previously showed that Caffeine activates Srk1 which in turn inhibits Cdc25 activity similar to other environmental stresses (Alao et al., 2014). Ssp1 negatively regulates Srk1 following exposure to stress. In contrast, caffeine advances mitosis in wt cells and thus does not result in increased cell length. We also demonstrate that caffeine greatly enhances cell length in ssp1 mutants exposed to heat stress in marked contrast to rapamycin and torin1. These findings indicate that Ssp1 mediates the effect of caffeine on mitosis.
- In the middle of page 8, the statement “Accordingly, the effect of caffeine and torin1 on DNA damage sensitivity was attenuated in gsk3D mutants (Figure 5C and 5D).” is not supported by the corresponding results. Rather, Figure 5C and 5D look almost the same.
We agree with this and other reviewers that demonstrating enhanced sensitivity to caffeine is problematic. Nonetheless, our cell cycle data clearly indicate a differential role for Gsk3 in mediating the cell cycle effects of caffeine and torin1. In terms of DNA damage sensitivity, we have reproducibly observed a lower degree of DNA damage sensitivity in gsk3 mutants relative to wt cells. Hence, while caffeine is less effective at enhancing DNA damage sensitivity relative to torin1 in wt cells; we observed that caffeine and torin1 increase DNA damage sensitivity to a similar degree in gsk3 mutants.
- The description and the conclusion of the last paragraph in the Results (bottom in page 8 – page 9) are not supported by the results of Figure 6, due to an insufficient data analysis. The extent of phosphorylation must be quantified as a ratio of the phosphorylated species (e.g., pSsp2) to all species of the protein (e.g., Ssp2).
We have carefully repeated our experiments under various conditions. Our results clearly indicate caffeine induced Ssp2 phosphorylation. These observations have not been reported previously.
From Figure 6, the authors claim that caffeine (10 mM) partially inhibits TORC1 signaling. However, the authors previously showed that the same concentration of caffeine inhibited phosphorylation of ribosome S6 kinase as strongly as rapamycin, the potent TOR inhibitor (Rallis et al, Aging Cell, 2013). The authors are advised to assess phosphorylation of S6 kinase again in the present study and compare to the results of the present results in Figure 6, because addition of that data may allow the authors to discuss that caffeine affects TORC1 downstream pathways at different intensities.
While rapamycin is a strong inhibitor of TORC1 in budding yeast, this is not the case in fission yeast. Our previous assessments of p-S6 levels and polysomal profiles as well as cell-cycle progression kinetics have shown this (Rallis et al, Aging Cell, 2013). In addition, gene expression analysis from our previous studies have shown that caffeine treatment results in a gene expression profile similar to that of cells in nitrogen starvation (TORC1 inhibition).
We have now used an Sck1-HA strain to further enhance our study and address the reviewer’s concerns. Previous studies have shown that 100 ng/mL rapamycin does not affect Sck1 phosphorylation. We demonstrate that in contrast to rapamycin (100 ng/ mL) 10 mM caffeine affects Sck1-HA expression and or phosphorylation. This effect was also observed with 5 µM torin1 albeit to a greater degree.
Also, immunoblotting of the same proteins looks somehow different from panel to panel (e.g., pSsp2 in panel A and D; Actin in panel A, C, and D). Therefore, the blotting result before clipping had better be shown as a supplementary material.
We repeated the blots were necessary and used ponceau S as a loading control. The original blots can be made available to all.
Minor comments:
- (Figure 1) The septation index of the phleomycin-treated cells (without any further additional drugs) should be shown, as a baseline.
We have included data for untreated cultures and phleomycin-only treated cultures.
- (Figure 1D, Optional) As a ppk18D cek1D double deletion mutant is reported, the authors are advised to add and test that mutant in this experiment.
We have added the related data for the _ppk18_Δ _cek1_Δ double mutant.
- (Figure 2) The authors need to clarify the number of cell bodies spotted (e.g., in the Figure legend).
We have modified the figure legend accordingly.
- (Figure 3) The different number of cells in micrographs may give an (wrong) impression on the cell proliferation rate. Therefore, it is advisable to use the micrographs in which the similar number of cells are shown for conditions with the similar cell proliferation rates.
We have included data to show the cell lengths under different conditions. We find that different conditions greatly affect proliferation rates. For instance, cells do not proliferate in the presence of torin1. We initially sought to investigate if caffeine induces a phenotype in ssp1 mutants by virtue of its interaction with the DNA damage response. The micrographs were included as representative examples and have been now complemented with cell length data.
- (Figure 4B) ssp2D, not spp2D.
The figure legend has been edited.
- (Figure 4) The septation index of the none-treated cells should be shown as a baseline.
We have included base line data for untreated wt cells in figure 1. We have no reason to suspect any of the mutants would provide different results over the time investigated.
- (Figure 6B, 6E) What do the black arrows indicate? Figure Legend does not seem to explain them.
The legend has been modified to indicate what the arrows refer to.
- (Figure 6C) Indicate which part of the Maf1-PK blot corresponds to the phosphorylated species, because Maf1-PK is probed with an anti-V5 (not a phosphorylation-specific) antibody.
These experiments have been carefully repeated under different conditions and the figure is now modified accordingly.
- (Figure 6D) gsk3Dssp1D, not gs3Dssp1D.
We have deleted this figure and have now replaced it with data we believe is more appropriate.
Reviewer #1 (Significance):
As caffeine is implicated in protective effects against diseases including cancer and improved responses to clinical therapies, the topic of the present study is of interest and importance to the broad audience.
In the present study, the most significant finding is that caffeine- and torin1-induced hypersensitivity to phleomycin is dependent on Ssp1 and Ssp2 (Figure 2). This result may be important in chemotherapy against cancers. On the other hand, caffeine is known to activate AMPK (e.g., Jensen Am J Physiol Endocrinol, 2007). Besides, as detailed in the Major comments, many of the major conclusions are not supported by the present results. Therefore, based on my field of expertise (cell cycle, cell proliferation, and TOR signaling), I conclude that the present study hardly extends the knowledge in the field of "the cell biology of caffeine."_
We thank the reviewer for their helpful comments. We accept the constructive criticisms and have carried out extensive additional experiments to provide further roles for Ssp2 and TORC1, in mediating the cell cycle effects of caffeine. We stress that caffeine has previously been proposed its effects via inhibition of Rad3 activity. Our previous work showed that caffeine did not inhibit Rad3 mediated checkpoint signaling. As later studies suggested caffeine inhibited TORC1 activity, the major goal was to investigate if caffeine is an indirect inhibitor of TORC1 via Ssp2 which is activated by several stresses. It has never been demonstrated that caffeine signals via Ssp2. This study provides the first evidence that caffeine modulates cell cycle progression by at least partially signaling via Ssp2 and TORC1. After nearly 30 years, it is vital that its precise activity, in particular enhancing DNA damage sensitivity is properly characterized. Such work woold open the way for additional studies on how caffeine activates cell physiology. For instance, we show that caffeine at 10 mM is more effective at inhibiting Sck1 activity than Rapamycin at 100 ng/ ml. In contrast, rapamycin at this concentration is more effective at inhibiting Maf1 activity. Hence further studies on how exactly the combination of caffeine and rapamycin influences their effect on ageing and other TORC1 regulated processes.
Reviewer #2 (Evidence, reproducibility and clarity):
Summary: In this paper, Alao and Rallis analyze the role of AMPK and TORC1 pathways, and the respective crosstalk, in regulating cell cycle progression in the presence of DNA damage in S. pombe. The authors show, almost exclusively through chemo-genetic epistasis assays, that caffeine inhibits TORC1 indirectly activating AMPK, in contrast to the specific ATP-competitive TORC1 inhibitor torin1. Specifically, it is shown that in the absence of a functional AMPK pathway caffeine is unable to revert the TORC1-inhibition-dependent override of cell-cycle arrest caused by the DNA-damaging agent phleomycin, henceforth partially suppressing the growth inhibition caused by the co-treatment.
Major comments: The overall story of the paper is convincing. However, the choice of an almost exclusively chemo-genetic approach, lack of controls in some experiments and some discrepancy in data presentation suggest that the manuscript undergoes revision before the authors claim that their conclusions are fully supported by the results. In detail:
In Figure 1, graphs of septation indexes are presented separately for each strain. This presentation prevents the reader from clearly comparing the differences of septation caused by genetic background rather than the treatment, i.e. the septation happening by treatment with torin1. I feel it would be better to group the results by drug rather than by strain/mutant. If the results are presented this way because the experiments on different strains were run separately, I further suggest that they are re-run so to always include at least the wt in every run._
We have included data for untreated and phleomycin only treated wt cells as a reference. Additionally, all experiments were repeated at least 2 times. We have used this assay for over 10 years and have found it to be reproducible and reliable. We are not able to include wt cells in every run as this would be beyond the manpower capacity and time constraints involved. It is also likely that torin1 activity is influenced by the ssp1/ 2 backgrounds due to increased basal TORC1 activity as previously reported. The main goal was to illustrate that caffeine differs from a direct inhibitor such as torin1.
Furthermore, torin1 inhibits both TORC1 and TORC2 and thus cannot be directly compared to caffeine. We do prove however, in this and other figures that in contrast to torin1 and rapamycin that caffeine signals via targets upstream of TORC1. We can therefore deduce that it functions in a manner similar to other environmental and nutrient stresses, which require with the Ssp1 and Sty1 regulated pathways to advance mitosis and other processes such as autophagy induction.
In Figure 2C-D, an inconsistency is observable between the phleo+caffeine sensitivity of ssp1Δ and ssp2Δ, the latter retaining a higher sensitivity. Provided that this is not only due to this specific replicate, how would the authors explain such a difference and fit it into their conclusion of a "cascade" signaling with Ssp1 acting upstream of Ssp2?
We agree that analyzing the different interacting pathways involved, is complex. For instance, Ssp1 is required for suppressing Srk1 following Sty1 activation independently of its effects on Ssp2 and TORC1. Furthermore, basal TORC1 activity is higher in Ssp2 mutants as previously reported. It is likely that Ssp1 exerts a more definitive role as it is required to directly reactivate Cdc25 activity following exposure to stress. In contrast Ssp2 activation eventually results in increased Cdc25 activity via inhibition of PP2A (Figure 8). These experiments are, thus, intended to compliment those in figure1 but the DNA damaging effects of caffeine must also be taken into account.
In Figure 2I, a huge discrepancy is observable compared to panel 2A in terms of phleo+caffeine (no ATP) sensitivity of wt cells. Here, cells seem to cope well with the phleomycin treatment even if co-treated with caffeine. This renders the main finding of the panel (the effect of phelo+caffeine+ATP) rather uninterpretable.
We have noted that relevant assays, at least in fission yeast, are influenced by the culture vessels (e.g., plastic type/ glass) as well as the vessel volume (probably due to different aeration, oxygen availability that affects growth and metabolism parameters). We have corrected figure 1a. In terms of ATP, these experiments are highly reproducible even if the exact mechanism remains unclear.
In Figure 3A, the simple observation of elongation is sometimes hard to assess, for example in the ATP-caused suppression of the effect of torin 1, as also acknowledge by the authors in the text. I feel it would be really necessary to quantify such results on an adequate number of cells.
We have reproducibly observed this uncharacterized effect of ATP. We have analysed the cell length in additional experiments to show that ATP influences average cell length under these conditions. It is important to note that the effects of phleomycin are pleotropic. For instance, it likely induces cell cycle arrest at various cell cycle phases as well as in early and late G2. Additionally, it may influence other cellular processes such as DNA or compete with drug targets such as TORC1 which is influenced by ATP.
In Figure 3B,C wt is missing to compare the results in the presence of the same treatments. I understand the focus on Ssp1, but the authors should show the same treatments on wt cells. Similarly, it would be better to show the drug treatments in panel C also at 30{degree sign}C. For the same reasons as in the previous point, quantifications would greatly enhance the credibility of the claims here.
Previous work by other investigators have shown that wt cells proliferate normally under these conditions. We also show in figure 1 that cell proliferation is not affected under nor cycling conditions in these assays. We have added cell length data that convincingly prove that Ssp1 is required to mediate the mitotic effects of caffeine. It appears that caffeine induces a cell cycle delay that requires Ssp1 to suppress Srk1- mediated Cdc25 inhibition. Furthermore, recent studies have demonstrated that rapamycin (which targets TORC1 downstream of Ssp1) allows cell proliferation at higher temperatures in S. pombe.
A major point is the almost complete absence of molecular data. Except for Figure 6, the data do not include a detection of the relative activation of the relevant pathways. Figure 6 could hardly fill this gap, since the samples therein analyzed are not the ones utilized in most of the other figures, but simple, single time-point treatment with a single drug. The authors usually refer in the text to previous knowledge about how a treatment influences a pathway. However, they should show it here in their experimental conditions.
We have performed extensive additional experiments including those suggested by the reviewer. These experiments conclusively show caffeine induces Ssp2 phosphorylation in an Ssp1- dependent manner. We also demonstrate that caffeine attenuates TORC1 signaling. Together with the cell cycle data, our findings strongly suggest caffeine indirectly inhibits TORC1 signaling a manner analogous to other environmental stresses. We also note that the inhibitory effect of caffeine on TORC1 has been demonstrated in several studies. What have provided further evidence for this but have for the first time demonstrated, that caffeine affects Ssp2.
Minor comments:<br /> • A different grouping of the experiments/panels would help the reader. For example, Fig. 2I would fit better together with Fig. 3A, to match the composition of the various chapters of the results.
We have performed additional experiments as suggested by the other reviewers. We believe the data is now easier to understand.
Torin 1 is sometimes referred to with a capital T or with a lowercase t, especially in the Figures. I suggest to uniform the nomenclature.
We have edited the text.
In the results, the authors state that "ATP may increase TORC1 activity or act as a competitive inhibitor towards both compounds.". It's a little bit odd to refer to ATP as a competitive inhibitor of drugs. I would rather be ATP, the physiological agonist, outcompeting two compounds which are working as ATP-competitive inhibitors.
We have modified the text accordingly.
Reviewer #2 (Significance):
The interplay between TORC1 and AMPK is of great interest in the cell signaling field, basically in every model organism.
The paper provides a conceptual advance in the field showing a genetic interaction between the two pathways using a model organism which has probably been overlooked so far, which is a pity because S. pombe is the best organism to study G2/M cell cycle/size regulation. The story would be of interest especially for an audience working in cell signaling in microorganisms, but not so much (at least at this stage) for the community working on aging, disease and chemo-/radio-sensitization, contrary to what the authors claim. Furthermore, for the above-mentioned reasons, I feel like the authors are a little bit overshooting when claiming (for example in the abstract and in the discussion), that their work provides a clear understanding of the mechanism.<br /> As requested by Review Commons, I specify that my expertise is on TORC1/AMPK/PKA pathways, on their crosstalk and their regulation by metabolic intermediates.
We believe that the additional requested experiments have adequately improved the manuscript and support our presented mechanistic model.
Caffeine is interest in cancer biology and the biogerontology field proven by recent reports on metabolic phenotyping, liver function testing, induction of autophagy and interplay with HIF-1, just to mention a few.
Reviewer #3 (Evidence, reproducibility and clarity):
Summary<br /> This manuscript examines the genetic requirements for checkpoint override by caffeine in the fission yeast model organism. The main outcome is to show that checkpoint override, which has previously been linked to the downregulation of TORC1, is dependent on on the AMPK pathway (Ssp1/Ssp2). Additional analysis of downstream factors and the cross-talking Sty1 pathway implicates Greatwall kinases and Igo1 (PP2A inhibitor - endosulfine analogue) although the pleiotropic nature of these pathways and the rather blunt endpoints of septation index and phleomycin sensitivity makes robust data interpretation difficult.
Major comments<br /> For clarity the manuscript would benefit from some restructuring. In particular it would help the reader if the diagram presented in figure 7 was presented first as this would help orientate the reader with the pathways. The mammalian equivalents should be indicated.
Figure 8 (previously figure 7) summarizes our findings schematically. We believe that it works well at the end as a conclusion to the work and the discussion. Wherever appropriate we have mentioned the mammalian equivalent (e.g., for Rad3).
For scientific accuracy and clarity the manuscript requires significant attention. For example in the abstract where Rad3 is introduced it is not made clear that this is the fission yeast gene. It would be better to introduce ATR at this point? Anther example in the abstract: 'Deletion of ssp1 and ssp2 suppresses...' should read 'Deletion of ssp1 or ssp2 suppresses...' as the two genes are not deleted in the same strain. I would recommend that the authors carefully revise the manuscript paying close attention to each statement. Fore example on page 4: 'Downstream of TORC1, caffeine failed to accelerate ppk18D but not igo1D and partially overrode DNA damage checkpoint signalling'. It is unclear what the authors mean by accelerate. I assume they mean accelerate cell cycle progression, but there is no direct analysis of cell cycle kinetics in the results. Similarly on page 5: '... ppk18D mutant displayed slower cell cycle kinetics than wild type cells exposed to phleomycin and caffeine or torin1 (Figuer 1D)'. However, the figure shows no cell cycle kinetic analysis.
We have modified the wording of the abstract according to the reviewer’s suggestions.
We refer to accelerated progression into mitosis and have edited the text where appropriate. Depending on the type of DNA damage, S. pombe cells transiently or permanently arrest cell cycle progression. It is well known that caffeine overrides these cell cycle DNA damage checkpoints. We previously proved that this was not due to Rad3 inhibition. Additionally, TORC1 (which controls the timing of mitosis) inhibition overrides checkpoint signaling. Our aim was to investigate if caffeine mimics this effect at least partially, via activation of Ssp2. We have demonstrated this is the case, although the basal state of the various mutants can complicate the data analysis in terms of cell cycle progression. Following exposure to phleomycin, this septation index peaks at 60 minutes following exposure to caffeine. In ppk18 mutants this peak was delayed by 30 minutes. Thus, wt and ppk18 mutants proceed through mitosis and cytokinesis at different rates (as determined by measuring the septation index).
The authors appear to make the assumption that 'Inhibition of DNA damage signalling by caffeine and torin1 enhanced phleomycin sensitivity...' (page 6) but then clearly go on to show that the mutants used are sensitive for other unknown reasons. To make this link it would be necessary to artificially impose a G2 delay and show how much and in which circumstances this reverses the effect on sensitivity of caffeine/torin1. The authors should thus be very clear that they cannot equate sensitivity to 'checkpoint over-ride' and adjust their wording and assumptions accordingly. Assumptions on epistasis need to use the same assay and not equate between assays. As an example F1C and F2D do not equate as phleo+caffeine would be expected to be sensitised above phleo+torin1. This is not commented on in the text. Also on page 7 '... ATP also suppressed the ability of torin1 to override DNA damage checkpoint signalling albeit to a lesser degree (Figure 2I).' However, this figure only shows sensitivity, not septation index.
We accept that these results can be difficult to interpret. Firstly, caffeine appears to modulate cell cycle progression by various means. We previously demonstrated that it stabilizes Cdc25 independently of checkpoint signaling. However, it also activates Ssp2 which subsequently affects Cdc25 activity via PP2A. Its effect on mitosis can thus differ depending on the context. For instance, igo1 mutants already have high PP2A activity which would affect the subsequent effect of caffeine on Cdc25 activity. Ssp2 on the other hand appears to regulate cell fate according to the nutritional state. Its sensing of nutritional cues is not limited to ATP/ AMP levels as it also regulates the response to amino acid quality (e.g., glutamate versus torin1).
We have carried out additional experiments on the effect of ATP. While it did affect progression into mitosis, the results were complicated and have not been shown. Instead, we have provided additional data to show that it affects cell length which is an indicator of G2 cell length. In other words, longer cells spend more time in G2 prior to septation.
We also suspect that caffeine is itself a DNA damaging agent as previously reported in the early 1970s. More recent studies have also indicated a role for Rad3 and DNA repair proteins for tolerance to caffeine. In fact, TORC1 itself has been reported to be required for DNA damage repair. Thus, TORC1 inhibition could potentially enhance DNA damage sensitivity independently of mitotic progression as shown in some of our experiments.
While we have clearly identified a role for Ssp2 in mediating the cell cycle effects of caffeine, we accept that these findings will require further studies (beyond the scope of this one); to give more insights on how these caffeine- mediated effects occur. What is clear is that caffeine overrides DNA damage checkpoint signaling by at least partially inhibiting TORC1 signaling.
All the septation index graphs require an untreated (I.e no caffeine or torin1) control.
We now show in figure 1a, that the septation index does not change over the time period studied, when cells were left untreated. These assays have been routinely used for many years now and are very reproducible. The graphs clearly show the differential effects caffeine and torin1 exert on cell cycle progression in wt and mutant strains exposed to phleomycin.
Figure 3 is not quantitative and cannot support the conclusions drawn from it. If, for example, the authors wish to demonstrate ATP can suppress checkpoint override (Figure 3A) they should use the same septation assay used before. If this is not possible, then it should be explained why not and an alternative quantitative assay should be developed. It is unclear why the authors include Figure 3B,C at all.
Ssp2, on the other hand, appears to regulate cell fate according to the nutritional state. Its sensing of nutritional cues is not limited to ATP/AMP levels as it also regulates the response to amino acid quality (e.g., glutamate versus torin1). Additionally, exposure to stress may induce a transient decline in ATP levels. We thus investigated how ATP might affect caffeine or torin1. We could not detect any major changes in the septation index (not shown). Cells exposed to ATP in the presence of caffeine and phleomycin were shorter. We cannot tell how exactly suppresses the effect of caffeine and torin1 on DNA damage sensitivity.
It is unclear to this reviewer what the significance of the data with gsk3D cells is (Figure 5). The authors should introduce the protein, why there is an expectation that it would have a role in the pathway and explain its relevance. Similarly when discussing the resulting data.
Gsk3 lies downstream of TORC2 which is inhibited by torin1 but not caffeine. Gsk3 regulates Pub1 stability which is the E3 ligase for Cdc25. We showed previously that caffeine stabilizes Cdc25, suggesting it might interfere with Pub1 activity. Additionally, we are investigating caffeine as an indirect inhibitor of TORC1 with torin1 that directly inhibits both complexes. Our data provide further evidence for a differential effect of caffeine and torin1 on TORC1 signaling. We have modified the text accordingly.
Figure 5A shows a similar response of wild type cells to phleomycin regarding checkpoint override as was shown in Figure 1A. However Figure 5C is not recognisable as equivalent to Figure 2A, yet both report sensitivity to phleomycin od wild type cells under equivalent circumstances. This is a major concern as to reproducibility of these data. It is also not possible to conclude from either Figure 5C or 5D that caffeine or torin1 treatment is, or is not, sensitising cells to phleomycin treatment, yet this conclusion is made when discussing the data.
We agree with this and other reviewers that demonstrating enhanced sensitivity to caffeine is problematic. Nonetheless, our cell cycle data clearly indicate a differential role for Gsk3 in mediating the cell cycle effects of caffeine and torin1. In terms of DNA damage sensitivity, we have reproducibly observed a lower degree of DNA damage sensitivity in gsk3 mutants relative to wt cells. Hence, while caffeine is less effective at enhancing DNA damage sensitivity relative to torin1 in wt cells; we observed that caffeine and torin1 increase DNA damage sensitivity to a similar degree in gsk3 mutants.
Figure 6A shows that caffeine, but not torin1 results in Ssp2 phosphorylation. Is this experiment reproducible and does the total level of Ssp2 increase reproducibly? This should be doe ae and the results discussed. Ideally, the bands would be quantified against actin intensity and presented as a bar graph with standard deviation.
We have repeated these experiments alone and in combination with phleomycin. This data convincingly show that caffeine but not torin1 induces Ssp2 phosphorylation. In fact, torin1 suppresses Ssp2 phosphorylation, likely due to inhibition of a feedback mechanism resulting from TORC1 inhibition. In contrast, caffeine likely activates Ssp1 via the stress response, which in turn phosphorylates Ssp2.
Figure 6B, when introduced should explain the background as to why eIF2alpha phosphorylation is a readout of TORC1 activity. Importantly, the figure should be supported by an actin control and 3 repeats quantified. Figure 6C purports to establish that caffeine moderately attenuates Maf1 phosphorylation. To be able to state this, it would be essential to quantify the gel and report repeated results relative to actin and the total levels of Maf1. Similarly Figure6D and 6E require an actin control and would benefit from proper quantification.
We have repeated the Maf1 experiments to clarify the data and show that caffeine suppresses Sck1 an additional TORC1 phosphorylation target.
Minor comments<br /> p3 'cigarette smoke and other gases'?
We have edited the statement.
P4 torin1 was dissolved in DMSO (not were)
We have edited the text.
p5 phospho not phosphor Ssp2
We have edited the text.
p6 exlpain why ppk18 deletion results are surprising. Also this result could be discussed.
It had been proposed previously, that Ppk18 is the Greatwall homologue in S. pombe and thus the major regulator of PP2A and mitosis downstream of TOCR1. Later studies suggested a redundant role for Cek1 in this pathway. While deletion of cek1 in a ppk18 background modulated the effect of torin1 on cell cycle progression, it did not interfere with the effects of caffeine. At present we cannot account for this observation. We cannot rule out that caffeine activates an additional kinase that regulates Igo1 activity.
Together our data show that caffeine advances progression into mitosis in a manner that differs from direct inhibition of TORC1 by torin1.
We have now added the relevant comments on this unexpected observation within the discussion.
Explain why Cek1 is not tested
We have now tested a ppk18 cek1 double mutant.
p6 introduce what pap1 is when first mentioned
We have introduced PP2APab1 as requested.
Reviewer #3 (Significance):
The data show that fission yeast Ssp1/2 has a role in inhibiting TORC1 in response to caffeine and this influences checkpoint override. This is an incremental, but potentially interesting, observation contributing to understanding mechanism(s) of caffeine action. The lack of quantification, the pleiotropic nature of the mutants used and the rather blunt endpoints assayed make it hard to establish to what extent the direct TORC1 inhibition by Ssp2 causes the checkpoint override, which limits is potential impact. The core observation may, however, be of interest to the wider caffeine field. The referee has the perspective of a yeast cell cycle geneticist.
We thank the reviewer for identifying the significance of the study in understanding the mechanisms of caffeine effects on the cell cycle. We have added all the suggested experiments with additional mutants and protein markers as well quantitative approaches that have appropriately improved the manuscript. We believe that the mechanism provided is of more general interest and not limited to the caffeine field: manipulating the cell cycle and understanding the interplays between growth and stress are of general interest and importance.
Reviewer #4 (Evidence, reproducibility and clarity):
The authors provide a series of genetic studies identifying a role for Ssp1-Ssp2 signaling in TORC1-dependent responses to DNA damage. The main assays are cell division (i.e. septation index) and cell viability (i.e. serial dilution spot assays) following treatment with the DNA damaging agent phleomycin. The authors perform these assays in a number of genetic mutant backgrounds to determine which genes and pathways are required for the relevant cellular response. Supporting data also include microscopy images and western blots to test protein phosphorylation. In general, the results support a role for Ssp1-Ssp2 acting upstream of TORC1. However, in several cases the data do not support a straightforward relationship, and it is confusing to parse through a number of intermediate effects, which often vary between different assays. I have provided some specific comments below that might be addressed to strengthen the technical aspects of the manuscript.
Major<br /> 1. The authors conclude "that caffeine and torin1 indirectly and directly inhibit TORC1 activity respectively" based on Figure 1. This conclusion seems quite strong given the indirect nature of assays in Figure 1, which test septation in the presence of DNA damage. The conclusion would require experiments that assay TORC1 activity itself.
Both caffeine and torin1 have previously been reported to inhibit TORC1 which controls the timing of mitosis. We sought to investigate if caffeine mediates its effects via the stress response pathway. We have conducted additional experiments which clearly demonstrate that caffeine inhibits TORC1 at least partially via the activation of Ssp2. These observations make sense as we have previously shown that caffeine actives the stress response pathway to activate Srk1 which inhibits Cdc25. More recent studies my others indicate that Ssp1 is required to suppress Srk1 to allow progression into mitosis. This accounts for the failure of ssp1 mutants to advance mitosis under stress conditions. Additionally, Ssp1 activates Ssp2 which leads to the downstream inhibition of TORC1.
- Figure 2 needs some explanation to introduce the idea that cell growth reflects an intact DNA damage response that prevented division in the presence of phleomycin. I also felt that the conclusions were very strong given the data, and the authors should discuss each case more carefully. For example, deletion of ssp1 does not really suppress the ability of torin1 to enhance phleo sensitivity (Figure 2C).
We would not expect the deletion of ssp1 to suppress the effect of torin1 under stress conditions. We have provided further evidence to show that Ssp1 is required to facilitate progression into mitosis at least in the presence of phleomycin or heat stress.
- Microscopy imaging in Figure 3 nicely complements some of the other assays. However, it seems important to know if the cells are actively growing in each of these cases. An example is torin and rapamycin shortening ssp1 mutants at 35 degrees: are these cells actively cycling?
Our aim was to demonstrate that caffeine exacerbates the ssp1 phenotype. This would provide further evidence to show that caffeine exerts its effects at least in part by activating Ssp1. Cells do not cycle in the presence of torin1 as it inhibits both TORC complexes. We have provided additional evidence to show that caffeine does indeed interact with Ssp1. As the primary aim of the study was to determine is caffeine overrides DNA damage via Ssp1 we have not investigated if they are cycling. Their shortened size suggests that rapamycin and torin1 affect cell division in a different manner from caffeine.
- From Figure 6A, the authors conclude that caffeine induces phosphorylation of Ssp2. However, it appears that both Ssp2 protein levels and its phosphorylation levels are both increased, which seems an important distinction.
We have repeated these experiments several times under different conditions. Some proteins become more stable when phosphorylated as has been previously demonstrated for Srk1 for instance.
- In Figure 6D, the authors should show separate gsk3 and ssp1 mutants. It seems likely that all phosphorylation of Ssp2 is due to Ssp1, but this should be shown.
We have replaced the figure with a ssp1 single mutant.
- I am confused about Maf1 phosphorylation in Figure 6C. It is increased upon torin1 treatment, but it is discussed as an indicator or TORC1 activity. Does that mean that loss of its phosphorylation correlates with increased TORC1 activity? As written, I thought it was a TORC1 substrate, which led to confusion about its increased phosphorylation upon torin1 treatment.
Maf1 is phosphorylated by TORC1. Inhibition of TORC1 would thus lead to a loss of phospho-Maf1 moieties and the accumulation of the unphosphorylated form. We have conducted additional experiments and under various conditions to show that caffeine weakly inhibits Maf1 phosphorylation. We note however, that different stresses result in differential outcomes following TORC1 inhibition. As such we have included new data to show that caffeine suppresses the TORC1 target Sck1. In S. pombe Sck1 and Sck2 regulate progression into mitosis.
Minor<br /> 1. An untreated control should be shown for assays in Figure 1.
We have included this data for figure 1a.
- An untreated control should be shown for assays in Figure 4.
We have noted in the results for figure 1, that untreated cells and phleomycin only treated cells do not show any changes in septation index over the time course studied in these experiments.
Reviewer #4 (Significance):
The study has significance in connecting several conserved and central signaling pathways including TORC1, AMPK, and PP2A. Also, the study uses caffeine and torin1 that have effects in many different cell types. The connection between caffeine and torin1 effects on phleomycin-treated cells was previously established by these researchers. The significance of the current study is providing a genetic pathway for this connection. The significance is partly limited by some of the technical points raised in the previous section, such as some inconsistencies in the strength of results from different assays. Also, the role of these pathways in DNA damage response signaling is not new. While the main significance of this work might relate to a more specialized audience, it does add to a broader body of literature regarding these conserved pathways and processes.
My expertise is yeast cell biology.
While the roles of the pathways in DNA damage has been reported usinbg genetic and pharmacological combinations we dissect their relationships and provide mechanistic connections.
We thank the reviewer for identifying the significance of this study. We believe we have now addressed the technical issues raised.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #4
Evidence, reproducibility and clarity
The authors provide a series of genetic studies identifying a role for Ssp1-Ssp2 signaling in TORC1-dependent responses to DNA damage. The main assays are cell division (i.e. septation index) and cell viability (i.e. serial dilution spot assays) following treatment with the DNA damaging agent phleomycin. The authors perform these assays in a number of genetic mutant backgrounds to determine which genes and pathways are required for the relevant cellular response. Supporting data also include microscopy images and western blots to test protein phosphorylation. In general, the results support a role for Ssp1-Ssp2 acting upstream of TORC1. However, in several cases the data do not support a straightforward relationship, and it is confusing to parse through a number of intermediate effects, which often vary between different assays. I have provided some specific comments below that might be addressed to strengthen the technical aspects of the manuscript.
Major
- The authors conclude "that caffeine and torin1 indirectly and directly inhibit TORC1 activity respectively" based on Figure 1. This conclusion seems quite strong given the indirect nature of assays in Figure 1, which test septation in the presence of DNA damage. The conclusion would require experiments that assay TORC1 activity itself.
- Figure 2 needs some explanation to introduce the idea that cell growth reflects an intact DNA damage response that prevented division in the presence of phleomycin. I also felt that the conclusions were very strong given the data, and the authors should discuss each case more carefully. For example, deletion of ssp1 does not really suppress the ability of torin1 to enhance phleo sensitivity (Figure 2C).
- Microscopy imaging in Figure 3 nicely complements some of the other assays. However, it seems important to know if the cells are actively growing in each of these cases. An example is torin and rapamycin shortening ssp1 mutants at 35 degrees: are these cells actively cycling?
- From Figure 6A, the authors conclude that caffeine induces phosphorylation of Ssp2. However, it appears that both Ssp2 protein levels and its phosphorylation levels are both increased, which seems an important distinction.
- In Figure 6D, the authors should show separate gsk3 and ssp1 mutants. It seems likely that all phosphorylation of Ssp2 is due to Ssp1, but this should be shown.
- I am confused about Maf1 phosphorylation in Figure 6C. It is increased upon torin1 treatment, but it is discussed as an indicator or TORC1 activity. Does that mean that loss of its phosphorylation correlates with increased TORC1 activity? As written, I thought it was a TORC1 substrate, which led to confusion about its increased phosphorylation upon torin1 treatment.
Minor
- An untreated control should be shown for assays in Figure 1.
- An untreated control should be shown for assays in Figure 4.
Significance
The study has significance in connecting several conserved and central signaling pathways including TORC1, AMPK, and PP2A. Also, the study uses caffeine and torin1 that have effects in many different cell types. The connection between caffeine and torin1 effects on phleomycin-treated cells was previously established by these researchers. The significance of the current study is providing a genetic pathway for this connection. The significance is partly limited by some of the technical points raised in the previous section, such as some inconsistencies in the strength of results from different assays. Also, the role of these pathways in DNA damage response signaling is not new. While the main significance of this work might relate to a more specialized audience, it does add to a broader body of literature regarding these conserved pathways and processes.
My expertise is yeast cell biology.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #3
Evidence, reproducibility and clarity
Summary
This manuscript examines the genetic requirements for checkpoint override by caffeine in the fission yeast model organism. The main outcome is to show that checkpoint override, which has previously been linked to the downregulation of TORC1, is dependent on on the AMPK pathway (Ssp1/Ssp2). Additional analysis of downstream factors and the cross-talking Sty1 pathway implicates Greatwall kinases and Igo1 (PP2A inhibitor - endosulfine analogue) although the pleiotropic nature of these pathways and the rather blunt endpoints of septation index and phleomycin sensitivity makes robust data interpretation difficult.
Major comments
For clarity the manuscript would benefit from some restructuring. In particular it would help the reader if the diagram presented in figure 7 was presented first as this would help orientate the reader with the pathways. The mammalian equivalents should be indicated.
For scientific accuracy and clarity the manuscript requires significant attention. For example in the abstract where Rad3 is introduced it is not made clear that this is the fission yeast gene. It would be better to introduce ATR at this point? Anther example in the abstract: 'Deletion of ssp1 and ssp2 suppresses...' should read 'Deletion of ssp1 or ssp2 suppresses...' as the two genes are not deleted in the same strain. I would recommend that the authors carefully revise the manuscript paying close attention to each statement. Fore example on page 4: 'Downstream of TORC1, caffeine failed to accelerate ppk18D but not igo1D and partially overrode DNA damage checkpoint signalling'. It is unclear what the authors mean by accelerate. I assume they mean accelerate cell cycle progression, but there is no direct analysis of cell cycle kinetics in the results. Similarly on page 5: '... ppk18D mutant displayed slower cell cycle kinetics than wild type cells exposed to phleomycin and caffeine or torin1 (Figuer 1D)'. However, the figure shows no cell cycle kinetic analysis.
The authors appear to make the assumption that 'Inhibition of DNA damage signalling by caffeine and torin1 enhanced phleomycin sensitivity...' (page 6) but then clearly go on to show that the mutants used are sensitive for other unknown reasons. To make this link it would be necessary to artificially impose a G2 delay and show how much and in which circumstances this reverses the effect on sensitivity of caffeine/torin1. The authors should thus be very clear that they cannot equate sensitivity to 'checkpoint over-ride' and adjust their wording and assumptions accordingly. Assumptions on epistasis need to use the same assay and not equate between assays. As an example F1C and F2D do not equate as phleo+caffeine would be expected to be sensitised above phleo+torin1. This is not commented on in the text. Also on page 7 '... ATP also suppressed the ability of torin1 to override DNA damage checkpoint signalling albeit to a lesser degree (Figure 2I).' However, this figure only shows sensitivity, not septation index.
All the septation index graphs require an untreated (I.e no caffeine or torin1) control.
Figure 3 is not quantitative and cannot support the conclusions drawn from it. If, for example, the authors wish to demonstrate ATP can suppress checkpoint override (Figure 3A) they should use the same septation assay used before. If this is not possible, then it should be explained why not and an alternative quantitative assay should be developed. It is unclear why the authors include Figure 3B,C at all.
It is unclear to this reviewer what the significance of the data with gsk3D cells is (Figure 5). The authors should introduce the protein, why there is an expectation that it would have a role in the pathway and explain its relevance. Similarly when discussing the resulting data.
Figure 5A shows a similar response of wild type cells to phleomycin regarding checkpoint override as was shown in Figure 1A. However Figure 5C is not recognisable as equivalent to Figure 2A, yet both report sensitivity to phleomycin od wild type cells under equivalent circumstances. This is a major concern as to reproducibility of these data. It is also not possible to conclude from either Figure 5C or 5D that caffeine or torin1 treatment is, or is not, sensitising cells to phleomycin treatment, yet this conclusion is made when discussing the data.
Figure 6A shows that caffeine, but not torin1 results in Ssp2 phosphorylation. Is this experiment reproducible and does the total level of Ssp2 increase reproducibly? This should be doe ae and the results discussed. Ideally, the bands would be quantified against actin intensity and presented as a bar graph with standard deviation.
Figure 6B, when introduced should explain the background as to why eIF2alpha phosphorylation is a readout of TORC1 activity. Importantly, the figure should be supported by an actin control and 3 repeats quantified. Figure 6C purports to establish that caffeine moderately attenuates Maf1 phosphorylation. To be able to state this, it would be essential to quantify the gel and report repeated results relative to actin and the total levels of Maf1. Similarly Figure6D and 6E require an actin control and would benefit from proper quantification.
Minor comments
p3 'cigarette smoke and other gases'?
P4 torin1 was dissolved in DMSO (not were)
p5 phospho not phosphor Ssp2
p6 exlain why ppk18 deletion results are surprising. Also this result could be discussed.
Explain why Cek1 is not tested
p6 introduce what pap1 is when first mentioned
Significance
The data show that fission yeast Ssp1/2 has a role in inhibiting TORC1 in response to caffeine and this influences checkpoint override. This is an incremental, but potentially interesting, observation contributing to understanding mechanism(s) of caffeine action. The lack of quantification, the pleiotropic nature of the mutants used and the rather blunt endpoints assayed make it hard to establish to what extent the direct TORC1 inhibition by Ssp2 causes the checkpoint override, which limits is potential impact. The core observation may, however, be of interest to the wider caffeine field. The referee has the perspective of a yeast cell cycle geneticist.
-
Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.
Learn more at Review Commons
Referee #2
Evidence, reproducibility and clarity
Summary: In this paper, Alao and Rallis analyze the role of AMPK and TORC1 pathways, and the respective crosstalk, in regulating cell cycle progression in the presence of DNA damage in S. pombe. The authors show, almost exclusively through chemo-genetic epistasis assays, that caffeine inhibits TORC1 indirectly activating AMPK, in contrast to the specific ATP-competitive TORC1 inhibitor torin 1. Specifically, it is shown that in the absence of a functional AMPK pathway caffeine is unable to revert the TORC1-inhibition-dependent override of cell-cycle arrest caused by the DNA-damaging agent phleomycin, henceforth partially suppressing the growth inhibition caused by the co-treatment.
Major comments: The overall story of the paper is convincing. However, the choice of an almost exclusively chemo-genetic approach, lack of controls in some experiments and some discrepancy in data presentation suggest that the manuscript undergoes revision before the authors claim that their conclusions are fully supported by the results. In detail:
- In Figure 1, graphs of septation indexes are presented separately for each strain. This presentation prevents the reader from clearly comparing the differences of septation caused by genetic background rather than the treatment, i.e. the septation happening by treatment with torin 1. I feel it would be better to group the results by drug rather than by strain/mutant. If the results are presented this way because the experiments on different strains were run separately, I further suggest that they are re-run so to always include at least the wt in every run.
- In Figure 2C-D, an inconsistency is observable between the phleo+caffeine sensitivity of ssp1Δ and ssp2Δ, the latter retaining a higher sensitivity. Provided that this is not only due to this specific replicate, how would the authors explain such a difference and fit it into their conclusion of a "cascade" signaling with Ssp1 acting upstream of Ssp2?
- In Figure 2I, a huge discrepancy is observable compared to panel 2A in terms of phleo+caffeine (no ATP) sensitivity of wt cells. Here, cells seem to cope well with the phleomycin treatment even if co-treated with caffeine. This renders the main finding of the panel (the effect of phelo+caffeine+ATP) rather uninterpretable.
- In Figure 3A, the simple observation of elongation is sometimes hard to assess, for example in the ATP-caused suppression of the effect of torin 1, as also acknowledge by the authors in the text. I feel it would be really necessary to quantify such results on an adequate number of cells.
- In Figure 3B,C wt is missing to compare the results in the presence of the same treatments. I understand the focus on Ssp1, but the authors should show the same treatments on wt cells. Similarly, it would be better to show the drug treatments in panel C also at 30{degree sign}C. For the same reasons as in the previous point, quantifications would greatly enhance the credibility of the claims here.
- A major point is the almost complete absence of molecular data. Except for Figure 6, the data do not include a detection of the relative activation of the relevant pathways. Figure 6 could hardly fill this gap, since the samples therein analyzed are not the ones utilized in most of the other figures, but simple, single time-point treatment with a single drug. The authors usually refer in the text to previous knowledge about how a treatment influences a pathway. However, they should show it here in their experimental conditions.
Minor comments:
- A different grouping of the experiments/panels would help the reader. For example, Fig. 2I would fit better together with Fig. 3A, to match the composition of the various chapters of the results.
- Torin 1 is sometimes referred to with a capital T or with a lowercase t, especially in the Figures. I suggest to uniform the nomenclature.
- In the results, the authors state that "ATP may increase TORC1 activity or act as a competitive inhibitor towards both compounds.". It's a little bit odd to refer to ATP as a competitive inhibitor of drugs. I would rather be ATP, the physiological agonist, outcompeting two compounds which are working as ATP-competitive inhibitors.
Significance
The interplay between TORC1 and AMPK is of great interest in the cell signaling field, basically in every model organism. The paper provides a conceptual advance in the field showing a genetic interaction between the two pathways using a model organism which has probably been overlooked so far, which is a pity because S. pombe is the best organism to study G2/M cell cycle/size regulation. The story would be of interest especially for an audience working in cell signaling in microorganisms, but not so much (at least at this stage) for the community working on aging, disease and chemo-/radio-sensitization, contrary to what the authors claim. Furthermore, for the above-mentioned reasons, I feel like the authors are a little bit overshooting when claiming (for example in the abstract and in the discussion), that their work provides a clear understanding of the mechanism.
As requested by Review Commons, I specify that my expertise is on TORC1/AMPK/PKA pathways, on their crosstalk and their regulation my metabolic intermediates.
-